PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Herrmann, HC; Chang, G; Klugherz, BD; Mahoney, PD				Herrmann, HC; Chang, G; Klugherz, BD; Mahoney, PD			Hemodynamic effects of sildenafil in men with severe coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	72nd Annual Scientific Session of the American-Heart-Association	NOV 07-10, 1999	ATLANTA, GA	Amer Heart Assoc			ACUTE MYOCARDIAL-INFARCTION; ERECTILE DYSFUNCTION; STENOSIS SEVERITY; FLOW VELOCITY; IN-VITRO; CITRATE; RESERVE	Background The cardiovascular effects of sildenafil are important because of the frequent presence of underlying cardiac disease in men with erectile dysfunction and reports indicating serious cardiac events temporally associated with the use of this drug. Methods We assessed the systemic, pulmonary, and coronary hemodynamic effects of oral sildenafil (100 mg) in 14 men (mean [+/-SD] age, 61+/-11 years) with severe stenosis of at least one coronary artery (stenosis of >70 percent of the vessel diameter) who were scheduled to undergo percutaneous coronary revascularization. Blood-flow velocity and flow reserve were assessed with a Doppler guidewire in 25 coronary arteries, including 13 severely diseased arteries (mean degree of stenosis, 78+/-7 percent) and 12 arteries without stenosis, used as a reference; maximal hyperemia was induced (to assess flow reserve) with the intracoronary administration of adenosine both before and after sildenafil. Results Oral sildenafil produced only small decreases (<10 percent) in systemic arterial and pulmonary arterial pressures, and it had no effect on pulmonary-capillary wedge pressure, right atrial pressure, heart rate, or cardiac output. There were no significant changes in average peak coronary flow velocity, coronary-artery diameter, volumetric coronary blood flow, or coronary vascular resistance. Coronary flow reserve at base line was lower in the stenosed arteries (1.26+/-0.26) than in the reference arteries (2.19+/-0.44) and increased about 13 percent in both groups of arteries combined after the administration of sildenafil (from 1.70+/-0.59 to 1.92+/-0.72, P=0.003). The ratio of coronary flow reserve in coronary arteries with stenosis to that in the reference arteries (0.57+/-0.14) was not affected by sildenafil. Conclusions No adverse cardiovascular effects of oral sildenafil were detected in men with severe coronary artery disease. (N Engl J Med 2000;342:1622-6.) (C)2000, Massachusetts Medical Society.	Hosp Univ Penn, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Herrmann, HC (corresponding author), Hosp Univ Penn, Dept Med, Div Cardiovasc, 9 Founders Pavil,3400 Spruce St, Philadelphia, PA 19104 USA.	herrmann@mail.med.upenn.edu						Arora RR, 1999, NEW ENGL J MED, V341, P700, DOI 10.1056/NEJM199908263410915; Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3; Baumgart D, 1998, CIRCULATION, V98, P40, DOI 10.1161/01.CIR.98.1.40; Cheitlin, 1999, CIRCULATION, V100, P2389; Cheitlin MD, 1999, CIRCULATION, V99, P168, DOI 10.1161/01.CIR.99.1.168; DOUCETTE JW, 1992, CIRCULATION, V85, P1899, DOI 10.1161/01.CIR.85.5.1899; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; Feenstra J, 1998, LANCET, V352, P957, DOI 10.1016/S0140-6736(98)00015-4; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; GOULD KL, 1990, J AM COLL CARDIOL, V15, P459, DOI 10.1016/S0735-1097(10)80078-6; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; Jackson G, 1999, AM J CARDIOL, V83, p13C; Kloner RA, 1999, AM J CARDIOL, V83, P576; Matherne GP, 1998, DEV CARDIOVASC MED, V209, P86; MULLER JE, 1996, JAMA-J AM MED ASSOC, V275, P1045; SCOBLIONKO DP, 1984, AM J CARDIOL, V53, P689, DOI 10.1016/0002-9149(84)90387-4; THERON HD, 1990, AM J CARDIOL, V66, P1186, DOI 10.1016/0002-9149(90)91096-O; Traverse JH, 1999, CIRCULATION, V100, P489; Wallis RM, 1999, AM J CARDIOL, V83, p3C; WILSON RF, 1990, CIRCULATION, V82, P1595, DOI 10.1161/01.CIR.82.5.1595; Zusman RM, 1999, AM J CARDIOL, V83, p35C; 1999, VIAGRA SILDENAFIL CI	23	217	228	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2000	342	22					1622	1626		10.1056/NEJM200006013422201	http://dx.doi.org/10.1056/NEJM200006013422201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	319CE	10833207				2022-12-28	WOS:000087321600001
J	Condit, R; Ashton, PS; Baker, P; Bunyavejchewin, S; Gunatilleke, S; Gunatilleke, N; Hubbell, SP; Foster, RB; Itoh, A; LaFrankie, JV; Lee, HS; Losos, E; Manokaran, N; Sukumar, R; Yamakura, T				Condit, R; Ashton, PS; Baker, P; Bunyavejchewin, S; Gunatilleke, S; Gunatilleke, N; Hubbell, SP; Foster, RB; Itoh, A; LaFrankie, JV; Lee, HS; Losos, E; Manokaran, N; Sukumar, R; Yamakura, T			Spatial patterns in the distribution of tropical tree species	SCIENCE			English	Article							RAIN-FOREST; DIVERSITY	Fully mapped tree census plots of large area, 25 to 52 hectares, have now been completed at six different sites in tropical forests, including dry deciduous to wet evergreen forest on two continents. One of the main goals of these plots has been to evaluate spatial patterns in tropical tree populations. Here the degree of aggregation in the distribution of 1768 tree species is examined based on the average density of conspecific trees in circular neighborhoods around each tree. When all individuals larger than 1 centimeter in stem diameter were included, nearly every species was more aggregated than a random distribution. Considering only larger trees (greater than or equal to 10 centimeters in diameter), the pattern persisted, with most species being more aggregated than random. Rare species were more aggregated than common species. All six forests were very similar in all the particulars of these results.	Smithsonian Trop Res Inst, Ctr Trop Forest Sci, Unit 0948, APO, AA 34002 USA; Harvard Univ, Inst Int Dev, Ctr Trop Forest Sci, Cambridge, MA 02138 USA; Univ Washington, Coll Forest Resources, Silviculture Lab, Seattle, WA 98195 USA; Royal Thai Forest Dept, Bangkok 10900, Thailand; Univ Peradeniya, Dept Bot, Peradeniya, Sri Lanka; Univ Georgia, Ctr Trop Forest Sci, Athens, GA 30602 USA; Field Museum Nat Hist, Ctr Trop Forest Sci, Chicago, IL 60605 USA; Osaka City Univ, Osaka 5588585, Japan; Nanyang Technol Univ, Natl Inst Educ, Ctr Trop Forest Sci, Singapore 1025, Singapore; Sarawak Forest Dept, Kuching 93660, Sarawak, Malaysia; Forest Res Inst Malaysia, Kuala Lumpur 52109, Malaysia; Indian Inst Sci, Bangalore 560012, Karnataka, India	Smithsonian Institution; Smithsonian Tropical Research Institute; Harvard University; University of Washington; University of Washington Seattle; Royal Forest Department - Thailand; University of Peradeniya; University System of Georgia; University of Georgia; Field Museum of Natural History (Chicago); Osaka Metropolitan University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National Institute of Education (NIE) Singapore; Jabatan Hutan Sarawak; Institute Penyelidikan Perhutanan Malaysia; Indian Institute of Science (IISC) - Bangalore	Condit, R (corresponding author), Smithsonian Trop Res Inst, Ctr Trop Forest Sci, Unit 0948, APO, AA 34002 USA.	ctfs@tivoli.si.edu	Raman, Sukumar/C-9809-2013	Baker, Patrick/0000-0002-6560-7124				Ashton PS, 1998, MAN BIOSPH, V20, P47; CONDIT R, 1995, TRENDS ECOL EVOL, V10, P18, DOI 10.1016/S0169-5347(00)88955-7; Condit R, 1998, TROPICAL FOREST CENS; CONNELL J H, 1971, P298; Croat T.B., 1978, FLORA BARRO COLORADO; Dale MRT, 1999, SPATIAL PATTERNS ANA; Folt CL, 1999, TRENDS ECOL EVOL, V14, P300, DOI 10.1016/S0169-5347(99)01616-X; GETIS A, 1987, ECOLOGY, V68, P473, DOI 10.2307/1938452; HAASE P, 1995, J VEG SCI, V6, P575, DOI 10.2307/3236356; Harms KE, 2000, NATURE, V404, P493, DOI 10.1038/35006630; Hastings HM, 1993, FRACTALS USERS GUIDE; He FL, 1997, J VEG SCI, V8, P105, DOI 10.2307/3237248; HUBBELL SP, 1979, SCIENCE, V203, P1299, DOI 10.1126/science.203.4387.1299; Itoh A, 1997, PLANT ECOL, V132, P121, DOI 10.1023/A:1009779424279; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; Lieberman Milton, 1994, P106; MANOKARAN N, 1992, STAND TABLE DISTRIBU, V1; Martinez VJ, 1999, SCIENCE, V284, P445, DOI 10.1126/science.284.5413.445; Okuda T, 1997, PLANT ECOL, V131, P155, DOI 10.1023/A:1009727109920; Palmiotto P. A., 1998, THESIS YALE U NEW HA; PENTTINEN A, 1992, FOREST SCI, V38, P806; Wallace AR, 1853, NARRATIVE TRAVELS AM; WHITEMORE TC, 1972, TREE FLORA MALAYA MA; Wills C, 1999, P ROY SOC B-BIOL SCI, V266, P1445, DOI 10.1098/rspb.1999.0799	24	800	1087	5	290	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1414	1418		10.1126/science.288.5470.1414	http://dx.doi.org/10.1126/science.288.5470.1414			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827950				2022-12-28	WOS:000087270900048
J	Petek, H; Weida, MJ; Nagano, H; Ogawa, S				Petek, H; Weida, MJ; Nagano, H; Ogawa, S			Real-time observation of adsorbate atom motion above a metal surface	SCIENCE			English	Article							DYNAMICS; STATES	The dynamics of cesium atom motion above the copper(lll) surface following electronic excitation with light was studied with femtosecond (10(-15) seconds) time resolution. Unusual changes in the surface electronic structure within 160 femtoseconds after excitation, observed by time-resolved two-photon photo-emission spectroscopy, are attributed to atomic motion in a copper-cesium bond-breaking process. Describing the change in energy of the cesium antibonding state with a simple classical model provides information on the mechanical forces acting on cesium atoms that are "turned on" by photoexcitation. Within 160 femtoseconds, the copper-cesium bond extends by 0.35 angstrom from its equilibrium value.	Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan; Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA	Hitachi Limited; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Petek, H (corresponding author), Fritz Haber Inst, Dept Phys Chem, Faradayweg 4-6, D-14195 Berlin, Germany.	petek@pitt.edu	Ogawa, Susumu/Q-4248-2018; Petek, Hrvoje/A-3912-2009	Ogawa, Susumu/0000-0001-7981-010X; Petek, Hrvoje/0000-0001-9605-2590				Bartels L, 1998, PHYS REV LETT, V80, P2004, DOI 10.1103/PhysRevLett.80.2004; Bauer M, 1999, PHYS REV B, V60, P5016, DOI 10.1103/PhysRevB.60.5016; Borisov AG, 1999, SURF SCI, V430, P165, DOI 10.1016/S0039-6028(99)00431-8; BRADSHAW AM, 1989, PHYSICS CHEM ALKALI; DAI HL, 1995, LASER SPECTROSCOPY P, V5; Diehl RD, 1997, J PHYS-CONDENS MAT, V9, P951, DOI 10.1088/0953-8984/9/5/003; EIGLER DM, 1991, NATURE, V352, P600, DOI 10.1038/352600a0; GAO SW, 1992, SOLID STATE COMMUN, V84, P271, DOI 10.1016/0038-1098(92)90119-T; Ge NH, 1998, SCIENCE, V279, P202, DOI 10.1126/science.279.5348.202; Hellsing B, 1997, J CHEM PHYS, V106, P982, DOI 10.1063/1.473177; Hofer U, 1997, SCIENCE, V277, P1480, DOI 10.1126/science.277.5331.1480; ISHIDA H, 1992, PHYS REV B, V45, P6171, DOI 10.1103/PhysRevB.45.6171; MENZEL D, 1964, J CHEM PHYS, V41, P3311, DOI 10.1063/1.1725730; MUSCAT JP, 1979, SURF SCI, V84, P262, DOI 10.1016/0039-6028(79)90137-7; Ogawa S, 1999, SURF SCI, V427-28, P34, DOI 10.1016/S0039-6028(99)00229-0; Ogawa S, 1999, PHYS REV LETT, V82, P1931, DOI 10.1103/PhysRevLett.82.1931; OGAWA S, UNPUB; Petek H, 2000, SURF SCI, V451, P22, DOI 10.1016/S0039-6028(00)00004-2; Petek H, 1997, PROG SURF SCI, V56, P239, DOI 10.1016/S0079-6816(98)00002-1; ZIMMERMANN FM, 1995, SURF SCI REP, V22, P127, DOI 10.1016/0167-5729(96)80001-X	20	221	226	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1402	1404		10.1126/science.288.5470.1402	http://dx.doi.org/10.1126/science.288.5470.1402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827946				2022-12-28	WOS:000087270900044
J	Nagaya, K; Fetters, MD; Ishikawa, M; Kubo, T; Koyanagi, T; Saito, Y; Sameshima, H; Sugimoto, M; Takagi, K; Chiba, Y; Honda, H; Mukubo, M; Kawamura, M; Satoh, S; Neki, R				Nagaya, K; Fetters, MD; Ishikawa, M; Kubo, T; Koyanagi, T; Saito, Y; Sameshima, H; Sugimoto, M; Takagi, K; Chiba, Y; Honda, H; Mukubo, M; Kawamura, M; Satoh, S; Neki, R			Causes of maternal mortality in Japan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; HOSPITALIZED-PATIENTS	Context Japan's maternal mortality rate is higher than that of other developed countries. Objectives To identify causes of maternal mortality in Japan, examine attributes of treating facilities associated with maternal mortality, and assess the preventability of such deaths. Design and Setting Cross-sectional study of maternal deaths occurring in Japan between January 1, 1991, and December 31, 1992, Subjects Of 230 women who died while pregnant or within 42 days of being pregnant, 197 died in a hospital and had medical records available, 22 died outside of a medical facility, and 11 did not have records available. Main Outcome Measures Maternal mortality rates per 100000 live births by cause (identified by death certificate review and information from treating physicians or coroners); resources and staffing patterns of facilities where deaths occurred; and preventability of death, as determined by a 42-member panel of medical specialists. Results Overall maternal mortality was 9.5 per 100000 births. Hemorrhage was the most common cause of death, occurring in 86 (39%) of 219 women. Seventy-two (37%) of 197 deaths occurring in facilities were deemed preventable and another 32 (16%) possibly preventable. Among deaths that occurred in a medical facility with an obstetrician on duty, the highest rate of preventable deaths (4.09/100000 live births) occurred in facilities with 1 obstetrician. Among the 72 preventable deaths, 49 were attributed to 1 physician functioning as the obstetrician and anesthetist. While the unpreventable maternal death rate was highest in referral facilities, the preventable maternal death rate was 14 times lower in referral facilities than in transferring facilities. Conclusions Inadequate obstetric services are associated with maternal mortality in Japan. Reducing single-obstetrician only delivery patterns and establishing regional 24-hour inpatient obstetrics facilities for high-risk cases may reduce maternal mortality in Japan.	Sayama Hlth Ctr, Sayama, Osaka 3501324, Japan; Univ Michigan Hlth Syst, Dept Family Med, Ann Arbor, MI USA; Asahikawa Med Coll, Dept Obstet & Gynecol, Asahikawa, Hokkaido 078, Japan; Kochi Med Sch, Matern & Perinatal Intens Care Unit, Nankoku, Japan; Kyushu Univ Hosp, Matern & Perinatal Care Unit, Fukuoka 812, Japan; Hirosaki Univ, Sch Med, Dept Obstet & Gynecol, Hirosaki, Aomori 036, Japan; Miyazaki Med Coll, Dept Obstet & Gynecol, Miyazaki 88916, Japan; Japanese Red Cross Med Ctr, Dept Obstet & Gynecol, Tokyo, Japan; Tokyo Womens Med Coll, Daini Hosp, Dept Obstet & Gynecol, Tokyo, Japan; Natl Cardiovasc Ctr, Dept Perinatol, Osaka, Japan; Mitsui Mem Hosp, Dept Obstet & Gynecol, Tokyo 101, Japan; Yodogawa Christians Hosp, Dept Obstet & Gynecol, Osaka, Japan	University of Michigan System; University of Michigan; Asahikawa Medical College; Kochi University; Kyushu University; Hirosaki University; University of Miyazaki; Japanese Red Cross Medical Center; University of Tokyo; Tokyo Women's Medical University; National Cerebral & Cardiovascular Center - Japan; Mitsui Memorial Hospital	Nagaya, K (corresponding author), Sayama Hlth Ctr, 2-16-1 Inariyama, Sayama, Osaka 3501324, Japan.	NagayaKen@aol.com		Sameshima, Hiroshi/0000-0001-8898-4857				BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Brennan T A, 1992, Qual Manag Health Care, V1, P29; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; *DEP HLTH ENGL, 1996, REP ENQ MAT DEATHS U; Fischer G, 1997, J FAM PRACTICE, V45, P40; FORTNEY J A, 1990, World Health Statistics Quarterly, V43, P246; GURWITZ JH, 1994, J AM GERIATR SOC, V42, P33, DOI 10.1111/j.1532-5415.1994.tb06070.x; ICHIJYO M, 1991, NIPPON SANKA FUJINHA, V46, P59; *JAP ASS OBST GYN, 1996, NIPP SANK FUJ GAKK M; *JINTS SOK YOR HIG, 1997, ANZENNA OSAN NETTOWA, V54, P17; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; *MAT CHILD HLTH DI, 1993, BOSH EIS NO OM TOUK; *NAT HLTH MRS AUST, 1993, REP MAT DEATHS AUSTR, P90; *PHS, 1988, INT CLASS DIS; *STAT INF DEP, 1993, IR SHIS CHOUS BYOUIN; *STAT INF DEP, 1994, ISH SHIK YAK CHOUS; TADA H, 1994, PERINATAL MED, V24, P17; TAKEDA Y, 1994, NIPPON SANKA FUJINHA, V46, P1279	22	68	71	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2661	2667		10.1001/jama.283.20.2661	http://dx.doi.org/10.1001/jama.283.20.2661			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819948	Bronze			2022-12-28	WOS:000087046000033
J	Davies, G				Davies, G			The ward	LANCET			English	Editorial Material									Reaside Clin, Swift Unit, Birmingham B45 9BE, W Midlands, England		Davies, G (corresponding author), Reaside Clin, Swift Unit, Birmingham Great Pk, Birmingham B45 9BE, W Midlands, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1809	1810		10.1016/S0140-6736(00)02313-8	http://dx.doi.org/10.1016/S0140-6736(00)02313-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832848				2022-12-28	WOS:000087126100046
J	Li, XY; Bhaumik, SR; Green, MR				Li, XY; Bhaumik, SR; Green, MR			Distinct classes of yeast promoters revealed by differential TAF recruitment	SCIENCE			English	Article							IN-VIVO; TRANSCRIPTIONAL ACTIVATION; BINDING; TBP; REQUIREMENT; SELECTIVITY; CELLS	The transcription factor TFIID contains the TATA box binding protein (TBP) and multiple TBP-associated factors (TAFs), Here, the association of TFIID components with promoters that either are dependent on multiple TAFs (TAF(dep)) or have no apparent TAF requirement (TAF(ind)) is analyzed in yeast. At TAF(dep) promoters, TAFs are present at Levels comparable to that of TBP, whereas at TAF(ind) promoters, TAFs are present at Levels that approximate background. After inactivation of several general transcription factors, including TBP, TAFs are still recruited by activators to TAF(dep) promoters. The results reveal two classes of promoters: at TAF(ind) promoters, TBP is recruited in the apparent absence of TAFs, whereas at TAF(dep) promoters, TAFs are co-recruited with TBP in a manner consistent with direct activator-TAF interactions.	Univ Massachusetts, Sch Med, Program Mol Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Howard Hughes Med Inst, Worcester, MA 01605 USA.				NIGMS NIH HHS [GM33977] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033977] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; LEE TI, IN PRESS NATURE; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0	18	154	154	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1242	1244		10.1126/science.288.5469.1242	http://dx.doi.org/10.1126/science.288.5469.1242			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817999				2022-12-28	WOS:000087112600051
J	Oliver, A; Canton, R; Campo, P; Baquero, F; Blazquez, J				Oliver, A; Canton, R; Campo, P; Baquero, F; Blazquez, J			High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection	SCIENCE			English	Article							ESCHERICHIA-COLI; ADAPTIVE EVOLUTION; MUTATION-RATES; BACTERIA; MUTATORS; POPULATIONS; RESISTANCE; VIRULENCE; STRAINS; GENE	The lungs of cystic fibrosis (CF) patients are chronically infected for years by one or a few Lineages of Pseudomonas aeruginosa. These bacterial populations adapt to the highly compartmentalized and anatomically deteriorating Lung environment of CF patients, as well as to the challenges of the immune defenses and antibiotic therapy, These selective conditions are precisely those that recent theoretical studies predict for the evolution of mechanisms that augment the rate of variation. Determination of spontaneous mutation rates in 128 P. aeruginosa isolates from 30 CF patients revealed that 36% of the patients were colonized by a hypermutable (mutator) strain that persisted for years in most patients. Mutator strains were not found in 75 non-CF patients acutely infected with P. aeruginosa. This investigation also reveals a link between high mutation rates in vivo and the evolution of antibiotic resistance.	Hosp Ramon & Cajal, Natl Inst Hlth INSALUD, Dept Microbiol, E-28034 Madrid, Spain; Hosp Ramon & Cajal, Natl Inst Hlth INSALUD, Unit Cyst Fibrosis, E-28034 Madrid, Spain	Hospital Universitario Ramon y Cajal; Hospital Universitario Ramon y Cajal	Baquero, F (corresponding author), Hosp Ramon & Cajal, Natl Inst Hlth INSALUD, Dept Microbiol, E-28034 Madrid, Spain.	fbaquero@hrc.insalud.es; jblazquez@hrc.insalud.es	Oliver, Antonio/V-5541-2019; Cantón, Rafael/AAP-8669-2021; Blazquez, Jesus/T-4680-2017; Oliver, Antonio/E-4048-2012	Oliver, Antonio/0000-0001-9327-1894; Blazquez, Jesus/0000-0003-0495-3848; Oliver, Antonio/0000-0001-9327-1894; Canton, Rafael/0000-0003-1675-3173				BALLESTERO S, 1993, INT CONGR SER, V1034, P55; Baquero F, 1997, TRENDS ECOL EVOL, V12, P482, DOI 10.1016/S0169-5347(97)01223-8; Baquero F, 1997, BIOESSAYS, V19, P731, DOI 10.1002/bies.950190814; Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; DERETIC V, 1994, J BACTERIOL, V176, P2773, DOI 10.1128/JB.176.10.2773-2780.1994; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; GROSS MD, 1981, MUTAT RES, V91, P107, DOI 10.1016/0165-7992(81)90081-6; Kepler TB, 1998, P NATL ACAD SCI USA, V95, P11514, DOI 10.1073/pnas.95.20.11514; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; MAHENTHIRALINGAM E, 1994, INFECT IMMUN, V62, P596, DOI 10.1128/IAI.62.2.596-605.1994; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; MARTIN C, 1995, J CLIN MICROBIOL, V33, P1461, DOI 10.1128/JCM.33.6.1461-1466.1995; Matic I, 1997, SCIENCE, V277, P1833, DOI 10.1126/science.277.5333.1833; Miller JH, 1996, ANNU REV MICROBIOL, V50, P625, DOI 10.1146/annurev.micro.50.1.625; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; National Committee for Clinical Laboratory Standards, 1998, M100S8 NAT COMM CLIN; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Renders N, 1996, J CLIN MICROBIOL, V34, P3190, DOI 10.1128/JCM.34.12.3190-3195.1996; Rosenstein BJ, 1998, LANCET, V351, P277, DOI 10.1016/S0140-6736(97)09174-5; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; SPEERT D, 1994, J INFECT DIS, V169, P134, DOI 10.1093/infdis/169.1.134; Taddei F, 1997, NATURE, V387, P700, DOI 10.1038/42696; Tenaillon O, 1999, GENETICS, V152, P485; TSUI LC, 1995, AM J RESP CRIT CARE, V151, pS47, DOI 10.1164/ajrccm/151.3_Pt_2.S47	27	1082	1118	4	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1251	1253		10.1126/science.288.5469.1251	http://dx.doi.org/10.1126/science.288.5469.1251			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10818002				2022-12-28	WOS:000087112600054
J	Bildirici, L; Smith, P; Tzavelas, C; Horefti, E; Rickwood, D				Bildirici, L; Smith, P; Tzavelas, C; Horefti, E; Rickwood, D			Biotechniques - Transfection of cells by immunoporation	NATURE			English	Article							GENE-TRANSFER; DNA; ELECTROPORATION; EXPRESSION		Univ Essex, Dept Biol, Colchester CO4 3SQ, Essex, England	University of Essex	Bildirici, L (corresponding author), Univ Essex, Dept Biol, Wivenhoe Pk, Colchester CO4 3SQ, Essex, England.	rickd@essex.ac.uk		Horefti, Elina/0000-0002-9527-4420				Ambrosini E, 1999, J NEUROSCI RES, V55, P569; FROMM M, 1987, METHOD ENZYMOL, V153, P351; Hargest R, 1998, ADV EXP MED BIOL, V451, P385; Mack KD, 1998, J IMMUNOL METHODS, V211, P79, DOI 10.1016/S0022-1759(97)00194-4; NIELSEN T, 1994, MOL GEN GENET, V242, P280, DOI 10.1007/BF00280417; PFAU J, 1990, NUCLEIC ACIDS RES, V18, P6165, DOI 10.1093/nar/18.20.6165; WATANABE Y, 1994, J BIOCHEM-TOKYO, V116, P1220, DOI 10.1093/oxfordjournals.jbchem.a124667; Yang YW, 1997, BIOTECHNOL APPL BIOC, V25, P47, DOI 10.1111/j.1470-8744.1997.tb00413.x	8	16	17	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 18	2000	405	6784					298	298		10.1038/35012701	http://dx.doi.org/10.1038/35012701			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830950	Bronze			2022-12-28	WOS:000087085700033
J	Barlow, DH; Gorman, JM; Shear, MK; Woods, SW				Barlow, DH; Gorman, JM; Shear, MK; Woods, SW			Cognitive-behavioral therapy, imipramine, or their combination for panic disorder - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRUE DRUG RESPONSE; ANXIETY DISORDERS; PATTERN-ANALYSIS; DOUBLE-BLIND; HEALTH-CARE; FOLLOW-UP; PLACEBO; AGORAPHOBIA; EXPOSURE; FLUVOXAMINE	Context Panic disorder (PD) may be treated with drugs, psychosocial intervention, or both, but the relative and combined efficacies have not been evaluated in an unbiased fashion. Objective To evaluate whether drug and psychosocial therapies for PD are each more effective than placebo, whether one treatment is more effective than the other, and whether combined therapy is more effective than either therapy alone. Design and Setting Randomized, double-blind, placebo-controlled clinical trial conducted in 4 anxiety research clinics from May 1991 to April 1998. Patients A total of 312 patients with PD were included in the analysis. Interventions Patients were randomly assigned to receive imipramine, up to 300 mg/d, only (n = 83); cognitive-behavioral therapy (CBT) only (n = 77); placebo only (n = 24); CBT plus imipramine (n = 65); or CBT plus placebo (n = 63). Patients were treated weekly for 3 months (acute phase); responders were then seen monthly for 6 months (maintenance phase) and then followed up for 6 months after treatment discontinuation. Main Outcome Measures Treatment response based on the Panic Disorder Severity Scale (PDSS) and the Clinical Global Impression Scale (CGI) by treatment group. Results Both imipramine and CBT were significantly superior to placebo for the acute treatment phase as assessed by the PDSS (response rates for the intent-to-treat [ITT] analysis, 45.8%, 48.7%, and 21.7%; P = .05 and P = .03, respectively), but were not significantly different for the CGI (48.2%, 53.9%, and 37.5%, respectively). After 6 months of maintenance, imipramine and CBT were significantly more effective than placebo for both the PDSS (response rates, 37.8%, 39.5%, and 13.0%, respectively; P=.02 for both) and the CGI (37.8%, 42.1%, and 13.0%, respectively). Among responders, imipramine produced a response of higher quality. The acute response rate for the combined treatment was 60.3% for the PDSS and 64.1% for the CGI; neither was significantly different from the other groups. The 6-month maintenance response rate for combined therapy was 57.1% for the PDSS (P = .04 vs CBT alone and P = .03 vs imipramine alone) and 56.3% for the CGI (P = .03 vs imipramine alone), but not significantly better than CBT plus placebo in either analysis. Six months after treatment discontinuation, in the ITT analysis CGI response rates were 41.0% for CBT plus placebo, 31.9% for CBT alone, 19.7% for imipramine alone, 13% for placebo, and 26.3% for CBT combined with imipramine. Conclusions Combining imipramine and CBT appeared to confer limited advantage acutely but more substantial advantage by the end of maintenance. Each treatment worked well immediately following treatment and during maintenance; CBT appeared durable in follow-up.	Boston Univ, Ctr Anex & Related Disorders, Boston, MA 02215 USA; Boston Univ, Dept Psychol, Boston, MA 02215 USA; Columbia Univ, Dept Psychiat, New York, NY USA; Long Isl Jewish Med Ctr, Glen Oaks, NY USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA	Boston University; Boston University; Columbia University; Northwell Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University	Barlow, DH (corresponding author), Boston Univ, Ctr Anex & Related Disorders, 648 Beacon St,6th Floor, Boston, MA 02215 USA.		Barlow, David/F-8738-2011; /AAF-4811-2020	/0000-0002-3103-5228	NIMH NIH HHS [MH45965, MH45964, MH45966] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R10MH045966, R01MH045966, R10MH045964, R01MH045964, R10MH045965, R01MH045965] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Amer Psychiat Assoc, 1998, AM J PSYCHIAT, V155, P1; Barlow DH, 1996, ARCH GEN PSYCHIAT, V53, P727; BARLOW DH, 1989, BEHAV THER, V20, P261, DOI 10.1016/S0005-7894(89)80073-5; BARLOW DH, 1994, MASTERY YOUR ANXIETY, V2; BEITMAN BD, 1992, BEHAV RES THER, V30, P403, DOI 10.1016/0005-7967(92)90052-I; BLACK DW, 1993, ARCH GEN PSYCHIAT, V50, P44; BYSTRITSKY A, 1994, ANXIETY, V1, P287; CLARK DM, 1994, BRIT J PSYCHIAT, V164, P759, DOI 10.1192/bjp.164.6.759; DINARDO PA, 1993, ARCH GEN PSYCHIAT, V50, P251; DiNardo PA, 1988, ANXIETY DISORDERS IN; Guy W., 1976, DHEW PUBL ADM, P218; Hofmann SG, 1998, AM J PSYCHIAT, V155, P43, DOI 10.1176/ajp.155.1.43; HOFMANN SG, 1999, COST EFFECTIVENESS P, P224; KATERNDAHL DA, 1995, J FAM PRACTICE, V40, P237; KATON W, 1994, TREATMENT PANIC DISO, P4; KELLER MB, 1994, J NERV MENT DIS, V182, P290, DOI 10.1097/00005053-199405000-00007; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KLEIN DF, 1993, NEUROPSYCHOPHARMACOL, V8, P241, DOI 10.1038/npp.1993.27; KLERMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P742, DOI 10.1001/jama.265.6.742; Lecrubier Y, 1997, ACTA PSYCHIAT SCAND, V95, P145, DOI 10.1111/j.1600-0447.1997.tb00388.x; LEON AC, 1995, BRIT J PSYCHIAT, V166, P19, DOI 10.1192/S0007125000293355; Lepola UM, 1998, J CLIN PSYCHIAT, V59, P528, DOI 10.4088/JCP.v59n1006; LIEBOWITZ MR, 1995, J PRACT PSYCHIAT BEH, V1, P10; Lydiard RB, 1996, J CONSULT CLIN PSYCH, V64, P660; MARKS IM, 1983, ARCH GEN PSYCHIAT, V40, P153; MARKS IM, 1993, BRIT J PSYCHIAT, V162, P776, DOI 10.1192/bjp.162.6.776; MAVISSAKALIAN M, 1986, AM J PSYCHIAT, V143, P1106; MAVISSAKALIAN M, 1996, LONG TERM TREATMENTS, P265; MAVISSAKALIAN MR, 1995, AM J PSYCHIAT, V152, P673; Nair NPV, 1996, ANXIETY, V2, P192, DOI 10.1002/(SICI)1522-7154(1996)2:4<192::AID-ANXI6>3.0.CO;2-Q; OEHRBERG S, 1995, BRIT J PSYCHIAT, V167, P374, DOI 10.1192/bjp.167.3.374; QUITKIN FM, 1984, ARCH GEN PSYCHIAT, V41, P782; QUITKIN FM, 1987, ARCH GEN PSYCHIAT, V44, P259; Robins L.N., 1991, PSYCHIAT DISORDERS A; SALVADORCARULLA L, 1995, BRIT J PSYCHIAT, V166, P23, DOI 10.1192/S0007125000293367; Sharp DM, 1996, J ANXIETY DISORD, V10, P219, DOI 10.1016/0887-6185(96)00008-4; Shear MK, 1997, AM J PSYCHIAT, V154, P1571, DOI 10.1176/ajp.154.11.1571; Sherbourne CD, 1996, AM J PSYCHIAT, V153, P213; Stewart JW, 1998, ARCH GEN PSYCHIAT, V55, P334, DOI 10.1001/archpsyc.55.4.334; SWINSON RP, 1992, CAN MED ASSOC J, V147, P878; TELCH MJ, 1993, BEHAV RES THER, V31, P279, DOI 10.1016/0005-7967(93)90026-Q; Uhlenhuth EH, 1997, PSYCHOPHARMACOL BULL, V33, P31; Wade AG, 1997, BRIT J PSYCHIAT, V170, P549, DOI 10.1192/bjp.170.6.549; WALKER EA, 1990, AM J PSYCHIAT, V147, P1656; WOLFE BE, 1994, TREATMENT OF PANIC DISORDER, P3; Woods SW, 1998, AM J PSYCHIAT, V155, P1446, DOI 10.1176/ajp.155.10.1446; ZITRIN CM, 1980, ARCH GEN PSYCHIAT, V37, P63; ZITRIN CM, 1983, ARCH GEN PSYCHIAT, V40, P125	48	658	671	1	94	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2529	2536		10.1001/jama.283.19.2529	http://dx.doi.org/10.1001/jama.283.19.2529			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	312VL	10815116				2022-12-28	WOS:000086964600033
J	Li, K; Li, YC; Shelton, JM; Richardson, JA; Spencer, E; Chen, ZJ; Wang, XD; Williams, RS				Li, K; Li, YC; Shelton, JM; Richardson, JA; Spencer, E; Chen, ZJ; Wang, XD; Williams, RS			Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis	CELL			English	Article							LACKING MITOCHONDRIAL-DNA; CELL-DEATH; TRANSCRIPTION FACTOR; MESSENGER-RNA; ACTIVATION; MICE; RELEASE; CASPASE-3; PATHWAY; MOUSE	Cytochrome c released from mitochondria has been proposed to be an essential component of an apoptotic pathway responsive to DNA damage and other forms of cell stress. Murine embryos devoid of cytochrome c die in utero by midgestation, but cell lines established from early cytochrome c null embryos are viable under conditions that compensate for defective oxidative phosphorylation. As compared to cell lines established from wild-type embryos, cells lacking cytochrome c show reduced caspase-3 activation and are resistant to the proapoptotic effects of UV irradiation, serum withdrawal, or staurosporine. In contrast, cells lacking cytochrome c demonstrate increased sensitivity to cell death signals triggered by TNF alpha. These results define the role of cytochrome c in different apoptotic signaling cascades.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.			Wang, Xiaodong/0000-0001-9885-356X				ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HAKE LE, 1990, DEVELOPMENT, V110, P249; HAKE LE, 1993, J BIOL CHEM, V268, P4788; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI K, 1995, J BIOL CHEM, V270, P25281, DOI 10.1074/jbc.270.42.25281; LIMBACH KJ, 1985, NUCLEIC ACIDS RES, V13, P617, DOI 10.1093/nar/13.2.617; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; SALEMME FR, 1977, ANNU REV BIOCHEM, V46, P299, DOI 10.1146/annurev.bi.46.070177.001503; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	41	404	432	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 12	2000	101	4					389	399		10.1016/S0092-8674(00)80849-1	http://dx.doi.org/10.1016/S0092-8674(00)80849-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830166	Bronze			2022-12-28	WOS:000087010400007
J	Gershon, D				Gershon, D			Partners resolve their differences and unite at the second attempt	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					258	258		10.1038/35012210	http://dx.doi.org/10.1038/35012210			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821289				2022-12-28	WOS:000087080100067
J	Holick, MF				Holick, MF			Microgravity-induced bone loss - will it limit human space exploration?	LANCET			English	Editorial Material							BED REST; WEIGHTLESSNESS; FLIGHT		Boston Univ, Sch Med, Dept Med,Vitamin D Skin & Bone Res Lab, Sect Endocrinol Nutr & Diabet, Boston, MA 02118 USA	Boston University	Holick, MF (corresponding author), Boston Univ, Sch Med, Dept Med,Vitamin D Skin & Bone Res Lab, Sect Endocrinol Nutr & Diabet, Boston, MA 02118 USA.			Holick, Michael/0000-0001-6023-9062				ARNAUD SB, 1991, AVIAT SPACE ENV MED, V52, P1; Holick MF, 1998, BONE, V22, p105S, DOI 10.1016/S8756-3282(98)00014-3; LEBLANC AD, 1990, J BONE MINER RES, V5, P843; LOCKWOOD DR, 1990, J ENDOCRINOL METAB, V41, P533; LUEKEN SA, 1993, J BONE MINER RES, V8, P1433; PARFITT AM, 1981, ACTA ASTRONAUT, V8, P1083, DOI 10.1016/0094-5765(81)90082-5; SCHNEIDER VS, 1984, CALCIFIED TISSUE INT, V36, P151; SLOVIK DM, 1986, J BONE MINER RES, V1, P377; STUPAKOV GP, 1984, KOSM BIOL AVIAK MED+, V18, P33; TILTON FE, 1980, AVIAT SPACE ENVIR MD, V51, P1209; Whedon G D, 1974, Trans Assoc Am Physicians, V87, P95	11	32	37	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 6	2000	355	9215					1569	1570		10.1016/S0140-6736(80)02208-8	http://dx.doi.org/10.1016/S0140-6736(80)02208-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821356				2022-12-28	WOS:000086981200003
J	Wallingford, JB; Rowning, BA; Vogeli, KM; Rothbacher, U; Fraser, SE; Harland, RM				Wallingford, JB; Rowning, BA; Vogeli, KM; Rothbacher, U; Fraser, SE; Harland, RM			Dishevelled controls cell polarity during Xenopus gastrulation	NATURE			English	Article							SIGNALING PATHWAYS; LAEVIS; ORGANIZER; MOVEMENT; MESODERM; MOTILITY; KINASE; AXIS	Although cell movements are vital for establishing the normal architecture of embryos, it is unclear how these movements are regulated during development in vertebrates. Inhibition of Xenopus Dishevelled (Xdsh) function disrupts convergent extension movements of cells during gastrulation, but the mechanism of this effect is unclear, as cell fates are not affected(1). In Drosophila, Dishevelled controls both cell fate and cell polarity(2-4), but whether Dishevelled is involved in controlling cell polarity in vertebrate embryos has not been investigated. Here we show, using time-lapse confocal microscopy, that the failure of cells lacking Xdsh function to undergo convergent extension results from defects in cell polarity. Furthermore, Xdsh mutations that inhibit convergent extension correspond to mutations in Drosophila Dishevelled that selectively perturb planar cell polarity. Finally, the localization of Xdsh at the membrane of normal dorsal mesodermal cells is consistent with Xdsh controlling cell polarity. Our results show that polarized cell behaviour is essential for convergent extension and is controlled by vertebrate Dishevelled. Thus, a vertebrate equivalent of the Drosophila planar cell polarity signalling cascade may be required for normal gastrulation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Life Sci Div MS6 2100, Berkeley, CA 94720 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Beckman Inst, Pasadena, CA 91125 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; California Institute of Technology; California Institute of Technology	Harland, RM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.	harland@socrates.berkeley.edu	Rothbächer, Ute/G-2688-2013; Rothbächer, Ute/AAB-6901-2022; Fraser, Scott/Y-3406-2019	Rothbächer, Ute/0000-0002-9989-6139; Rothbächer, Ute/0000-0002-9989-6139; Fraser, Scott/0000-0002-5377-0223				Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; HOWARD JE, 1993, MECH DEVELOP, V43, P37, DOI 10.1016/0925-4773(93)90021-O; KELLER R, 1992, DEVELOPMENT, P81; KELLER R, 1991, 49 S SOC DEV BIOL CE, P93; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Miller JR, 1999, J CELL BIOL, V146, P427, DOI 10.1083/jcb.146.2.427; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; SHIH J, 1992, DEVELOPMENT, V116, P901; SHIH J, 1992, DEVELOPMENT, V116, P915; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Vogt Walther, 1929, Wilhelm Roux Arch Entwickl Mech Org, V120, P384, DOI 10.1007/BF02109667; Wallingford JB, 1997, DEV BIOL, V187, P224, DOI 10.1006/dbio.1997.8571	17	610	622	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 4	2000	405	6782					81	85		10.1038/35011077	http://dx.doi.org/10.1038/35011077			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811222				2022-12-28	WOS:000086901600055
J	Aly, N; McDonald, K; Leathley, M; Sharma, A; Watkins, C				Aly, N; McDonald, K; Leathley, M; Sharma, A; Watkins, C			Retrospective note case review of acute and inpatient stroke outcomes	BRITISH MEDICAL JOURNAL			English	Article									Univ Hosp Aintree, Dept Med Elderly, Aintree Stroke Unit, Liverpool L9 7AL, Merseyside, England		Sharma, A (corresponding author), Univ Hosp Aintree, Dept Med Elderly, Aintree Stroke Unit, Liverpool L9 7AL, Merseyside, England.		Watkins, Caroline L/E-6898-2013	Watkins, Caroline L/0000-0002-9403-3772				AZZIMONDI G, 1994, STROKE, V25, P1752, DOI 10.1161/01.STR.25.9.1752; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1371; Mahaffey KW, 1998, CIRCULATION, V97, P757, DOI 10.1161/01.CIR.97.8.757	3	18	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1511	1512		10.1136/bmj.320.7248.1511	http://dx.doi.org/10.1136/bmj.320.7248.1511			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834893	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000087471000025
J	Mair, F; Whitten, P				Mair, F; Whitten, P			Systematic review of studies of patient satisfaction with telemedicine	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; TELEDERMATOLOGY; FEASIBILITY	Objective To review research into patient satisfaction with teleconsultation, specifically clinical consultations between healthcare providers and patients involving real time inter active video. Design Systematic review of telemedicine satisfaction studies. Electronic databases searched include Medline, Embase, Science Citation Index, Social Sciences Citation Index, Arts and Humanities Citation Index, and the TIE (Telemedicine Information Exchange) database. Subjects Studies conducted worldwide and published between 1966 and 1998. Main outcome measures Quality of evidence about patient satisfaction. Results 32 studies were identified. Study methods used were simple survey instruments (26 studies), exact methods not specified (5), and qualitative methods (1). Study designs were randomised controlled trial (1 trial); random patient selection (2); case-control (1); and selection criteria not specified or participants represented consecutive referrals, convenience samples, or volunteers (28). Sample sizes were less than or equal to 20 (10 trials), less than or equal to 100 (14), > 100 (7), and not specified (1). All studies reported good levels of patient satisfaction. Qualitative analysis revealed methodological problems with all the published work. Even so, important issues were highlighted that merit further investigation. There is a paucity of data examining patients' perceptions or the effects of this mode of healthcare delivery on the interaction between providers and clients. Conclusions Methodological deficiencies (low sample sizes, context, and study designs) of the published research limit the generalisability of the findings. The studies suggest that teleconsultation is acceptable to patients in a variety of circumstances, but issues relating to patient satisfaction require further exploration from the perspective of both clients and providers.	Dept Primary Care, Liverpool L69 3GB, Merseyside, England; Michigan State Univ, Dept Telecommun, E Lansing, MI 48824 USA	University of Liverpool; Michigan State University	Mair, F (corresponding author), Dept Primary Care, Whelan Bldg,Quandrangle, Liverpool L69 3GB, Merseyside, England.	f.s.mair@liv.ac.uk						Allen A, 1995, Telemed J, V1, P41, DOI 10.1089/tmj.1.1995.1.41; Allen A, 1996, J Telemed Telecare, V2 Suppl 1, P92, DOI 10.1258/1357633961929439; BAER L, 1995, AM J PSYCHIAT, V152, P1383; Baigent M F, 1997, J Telemed Telecare, V3 Suppl 1, P3, DOI 10.1258/1357633971930346; Ball C J, 1995, J Telemed Telecare, V1, P22; Blackmon LA, 1997, PSYCHIATR SERV, V48, P1464; Blakeslee DB, 1998, LARYNGOSCOPE, V108, P1, DOI 10.1097/00005537-199801000-00001; Brecht R M, 1996, Telemed J, V2, P25, DOI 10.1089/tmj.1.1996.2.25; Brennan JA, 1998, J TELEMED TELECARE, V4, P18, DOI 10.1258/1357633981931911; Callahan EJ, 1998, TELEMED J, V4, P363, DOI 10.1089/tmj.1.1998.4.363; Clarke P H, 1997, J Telemed Telecare, V3 Suppl 1, P12, DOI 10.1258/1357633971930788; CONRATH DW, 1975, BEHAV SCI, V20, P296, DOI 10.1002/bs.3830200503; Couturier P, 1998, J TELEMED TELECARE, V4, P85, DOI 10.1258/1357633981931597; DONGIER M, 1986, CAN J PSYCHIAT, V31, P32, DOI 10.1177/070674378603100107; Doolittle CC, 1998, J TELEMED TELECARE, V4, P58, DOI 10.1258/1357633981931470; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Duffy JR, 1997, MAYO CLIN PROC, V72, P1116, DOI 10.4065/72.12.1116; Gilmour E, 1998, BRIT J DERMATOL, V139, P81; Graham MA, 1996, AM BEHAV SCI, V39, P602, DOI 10.1177/0002764296039005007; Harrison R, 1996, BRIT MED J, V313, P1377, DOI 10.1136/bmj.313.7069.1377; HUBBLE JP, 1993, MOVEMENT DISORD, V8, P380, DOI 10.1002/mds.870080326; Huston J L, 1997, J Telemed Telecare, V3, P205, DOI 10.1258/1357633971931174; Itzhak B, 1998, J TELEMED TELECARE, V4, P11, DOI 10.1258/1357633981931759; Jones D H, 1996, J Telemed Telecare, V2 Suppl 1, P7, DOI 10.1258/1357633961929402; Kunkler IH, 1998, J TELEMED TELECARE, V4, P113, DOI 10.1258/1357633981932055; Loane MA, 1998, J TELEMED TELECARE, V4, P36, DOI 10.1258/1357633981931254; Lowitt MH, 1998, ARCH DERMATOL, V134, P471, DOI 10.1001/archderm.134.4.471; Mahmud K, 1995, J Telemed Telecare, V1, P173; McLaren P M, 1996, J Telemed Telecare, V2, P57, DOI 10.1258/1357633961929178; *NHS CTR REV, 1996, 4 NHS CTR REV DISS; Oakley AMM, 1997, NEW ZEAL MED J, V110, P51; Pedersen S, 1995, Telemed J, V1, P47, DOI 10.1089/tmj.1.1995.1.47; PEREDNIA DA, 1995, JAMA-J AM MED ASSOC, V273, P483, DOI 10.1001/jama.273.6.483; TAKANO T, 1995, TELECOMMUN POLICY, V19, P241, DOI 10.1016/0308-5961(94)00024-M; Trott P, 1996, J Telemed Telecare, V2 Suppl 1, P98, DOI 10.1258/1357633961929457; Whitten P, 1997, J Telemed Telecare, V3 Suppl 1, P67, DOI 10.1258/1357633971930436; Wootton R, 1998, J R Soc Med, V91, P614	37	487	487	2	106	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 3	2000	320	7248					1517	1520		10.1136/bmj.320.7248.1517	http://dx.doi.org/10.1136/bmj.320.7248.1517			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	321TP	10834899	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000087471000028
J	Ryan, M; Farrar, S				Ryan, M; Farrar, S			Using conjoint analysis to elicit preferences for health care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOCTOR-PATIENT-RELATIONSHIP; UTILITIES		Univ Aberdeen, Hlth Econ Res Unit, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Ryan, M (corresponding author), Univ Aberdeen, Hlth Econ Res Unit, Aberdeen AB25 2ZD, Scotland.	m.ryan@abdn.ac.uk						ADAMOWICZ W, 1994, J ENVIRON ECON MANAG, V26, P271, DOI 10.1006/jeem.1994.1017; Anderson N., 1977, PSYCHOL REV, V77, P153; BRADLEY M, 1991, USERS MANUAL SPEED V; Bryan S, 1998, HEALTH ECON, V7, P595, DOI 10.1002/(SICI)1099-1050(1998110)7:7<595::AID-HEC381>3.3.CO;2-5; CATTIN P, 1982, J MARKETING, V46, P44, DOI 10.2307/1251701; CAVE M, 1993, VALUATION CHANGES QU; Cleary PD, 1999, BRIT MED J, V319, P720, DOI 10.1136/bmj.319.7212.720; EMERY DR, 1979, PSYCHOMETRIKA, V44, P195, DOI 10.1007/BF02293971; Farrar S, 2000, SOC SCI MED, V50, P63, DOI 10.1016/S0277-9536(99)00268-3; Greene, 2003, ECONOMETRIC ANAL, P1241; GREENE WH, 1995, LIMDEP VERSION 7 0; Hakim Z, 1999, HEALTH ECON, V8, P103; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; Kocur G, 1982, UMTANH110001821 US D; LUCE RD, 1964, J MATH PSYCHOL, V1, P1, DOI 10.1016/0022-2496(64)90015-X; MAAS A, 1992, MED DECIS MAKING, V12, P288, DOI 10.1177/0272989X9201200408; MCFADDEN D, 1973, 199BART10 U CAL BERK; *NHS MAN EX, 1989, LOC VOIC VIEWS LOC P; NHS Management Executive, 1992, LOC VOIC VIEWS LOC P; OPALUCH JJ, 1993, J ENVIRON ECON MANAG, V24, P41, DOI 10.1006/jeem.1993.1003; PROPPER C, 1995, J HUM RESOUR, V30, P677, DOI 10.2307/146227; PROPPER C, 1990, ECON J, V100, P193, DOI 10.2307/2234196; Ratcliffe J, 1999, INT J TECHNOL ASSESS, V15, P340, DOI 10.1017/S0266462399015263; Ryan M, 1999, SOC SCI MED, V48, P535, DOI 10.1016/S0277-9536(98)00374-8; Ryan M, 1997, HEALTH ECON, V6, P261, DOI 10.1002/(SICI)1099-1050(199705)6:3<261::AID-HEC262>3.3.CO;2-E; RYAN M, IN PRESS J PUBLIC HL; Ryan Mandy, 1998, Health Expect, V1, P117, DOI 10.1046/j.1369-6513.1998.00024.x; SANMIGUEL F, IN PRESS APPL EC; Scott A, 1999, SCOT J POLIT ECON, V46, P111, DOI 10.1111/1467-9485.00124; *SECR STAT HLTH, 1989, HLTH NAT; *SECR STAT HLTH WA, 1989, WORK PAT; *SECR STAT HLTH WA, 1989, PROM BETT HLTH; Smith R, 1999, BRIT MED J, V319, P1123, DOI 10.1136/bmj.319.7217.1123; van der Pol M, 1998, J Health Serv Res Policy, V3, P70; VERHOEF CG, 1991, HEALTH POLICY, V17, P39, DOI 10.1016/0168-8510(91)90116-F; Vick S, 1998, J HEALTH ECON, V17, P587, DOI 10.1016/S0167-6296(97)00035-0; 1988, J TRANSPORT EC POLIC, V22	37	616	617	0	50	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 3	2000	320	7248					1530	1533		10.1136/bmj.320.7248.1530	http://dx.doi.org/10.1136/bmj.320.7248.1530			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	321TP	10834905	Green Published			2022-12-28	WOS:000087471000035
J	Clarke, DL; Johansson, CB; Wilbertz, J; Veress, B; Nilsson, E; Karlstrom, H; Lendahl, U; Frisen, J				Clarke, DL; Johansson, CB; Wilbertz, J; Veress, B; Nilsson, E; Karlstrom, H; Lendahl, U; Frisen, J			Generalized potential of adult neural stem cells	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; ASTROCYTES; TRANSPLANTATION; IDENTIFICATION; GENERATION; EXPRESSION; NEURONS; MUSCLE	The differentiation potential of stem ce(Ls in tissues of the adult has been thought to be Limited to cell lineages present in the organ from which they were derived, but there is evidence that some stem cells may have a broader differentiation repertoire. We show here that neural stem cells from the adult mouse brain can contribute to the formation of chimeric chick and mouse embryos and give rise to cells of all germ layers. This demonstrates that an adult neural stem cell has a very broad developmental capacity and may potentially be used to generate a variety of cell types for transplantation in different diseases.	Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden	Karolinska Institutet	Frisen, J (corresponding author), Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden.	jonas.frisen@cmb.ki.se		Lendahl, Urban/0000-0001-9543-8141; Karlstrom, Helena/0000-0002-0498-2473				BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Barres BA, 1999, CELL, V97, P667, DOI 10.1016/S0092-8674(00)80777-1; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; CLARKE DL, UNPUB; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Geiger H, 1998, CELL, V93, P1055, DOI 10.1016/S0092-8674(00)81210-6; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Joyner AL, 1993, GENE TARGETING PRACT; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; LAZARIDES E, 1976, P NATL ACAD SCI USA, V73, P4344, DOI 10.1073/pnas.73.12.4344; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Momma S, 2000, CURR OPIN NEUROBIOL, V10, P45, DOI 10.1016/S0959-4388(99)00056-2; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Shihabuddin LS, 1999, MOL MED TODAY, V5, P474, DOI 10.1016/S1357-4310(99)01596-8; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; VALTZ NLM, 1991, NEW BIOL, V3, P364; Weiss S, 1998, J NEUROBIOL, V36, P307, DOI 10.1002/(SICI)1097-4695(199808)36:2<307::AID-NEU14>3.0.CO;2-A; West JD, 1999, CURR TOP DEV BIOL, V44, P21; White PM, 1999, DEVELOPMENT, V126, P4351	25	809	944	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 2	2000	288	5471					1660	1663		10.1126/science.288.5471.1660	http://dx.doi.org/10.1126/science.288.5471.1660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834848				2022-12-28	WOS:000087382300046
J	Means-Markwell, M; Burgess, T; DeKeratry, D; O'Neil, K; Mascola, J; Fleisher, T; Lucey, D				Means-Markwell, M; Burgess, T; DeKeratry, D; O'Neil, K; Mascola, J; Fleisher, T; Lucey, D			Eosinophilia with aberrant T cells and elevated serum levels of interleukin-2 and interleukin-15	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; KILLER-CELLS; IN-VITRO; IL-15; CYTOKINE; PROLIFERATION; CYTOTOXICITY; ACTIVATION; EXPRESSION; EXPANSION		Washington Hosp Ctr, Infect Dis Serv, Washington, DC 20010 USA; Natl Naval Med Ctr, Dept Med, Bethesda, MD USA; Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD USA; NIH, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA	MedStar Washington Hospital Center; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); National Institutes of Health (NIH) - USA	Lucey, D (corresponding author), Washington Hosp Ctr, Infect Dis Serv, Rm 2A-56,110 Irving St NW, Washington, DC 20010 USA.		Mascola, John/AAI-7193-2021					Brugnoni D, 1996, BLOOD, V87, P1416, DOI 10.1182/blood.V87.4.1416.bloodjournal8741416; Carson DA, 1997, NAT MED, V3, P148, DOI 10.1038/nm0297-148; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; Flamand L, 1996, J CLIN INVEST, V97, P1373, DOI 10.1172/JCI118557; Kirman I, 1996, AM J GASTROENTEROL, V91, P1789; Lucey DR, 1997, CLIN DIAGN LAB IMMUN, V4, P43, DOI 10.1128/CDLI.4.1.43-48.1997; MACDONALD D, 1990, BRIT J HAEMATOL, V76, P168, DOI 10.1111/j.1365-2141.1990.tb07867.x; Mori A, 1996, J IMMUNOL, V156, P2400; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; SCHWARTZ DH, 1991, J ACQ IMMUN DEF SYND, V4, P11; SILBERSTEIN DS, 1989, J IMMUNOL, V142, P2162; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; Zambello R, 1997, BLOOD, V89, P201, DOI 10.1182/blood.V89.1.201.201_201_211	17	20	22	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2000	342	21					1568	1571		10.1056/NEJM200005253422104	http://dx.doi.org/10.1056/NEJM200005253422104			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316XJ	10824075	Bronze			2022-12-28	WOS:000087193100004
J	Landzberg, BR; Jacobson, IM				Landzberg, BR; Jacobson, IM			An unusual case of acute colitis	LANCET			English	Article							MICROSCOPIC POLYANGIITIS; POLYARTERITIS-NODOSA		Cornell Univ, Weill Med Coll, Dept Med, Div Gastroenterol, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital	Landzberg, BR (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Gastroenterol, 525 E 68th St,J-314, New York, NY 10021 USA.							Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003; Guillevin L, 1998, ARTHRITIS RHEUM, V41, P2100, DOI 10.1002/1529-0131(199812)41:12<2100::AID-ART3>3.3.CO;2-A; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Mercado U, 1999, J RHEUMATOL, V26, P2081	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1786	1786		10.1016/S0140-6736(00)02267-4	http://dx.doi.org/10.1016/S0140-6736(00)02267-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832830				2022-12-28	WOS:000087126100014
J	Yoshida, N; Toyoda, S				Yoshida, N; Toyoda, S			Constraining the atmospheric N2O budget from intramolecular site preference in N2O isotopomers	NATURE			English	Article							STRATOSPHERIC NITROUS-OXIDE; O-17/O-16 RATIOS; NORTH PACIFIC; KINETIC NITROGEN; MASS; FRACTIONATION; O-18/O-16; NITRIFICATION; WATERS; OCEAN	Nitrous oxide (N2O) is an important trace gas in the atmosphere. It is an active greenhouse gas in the troposphere and it also controls ozone concentration in the stratosphere through nitric oxide production(1). One way to trace the geochemical cycle of N2O is by measuring the natural abundance of stable isotopes, namely N-15 and O-18 (refs 2-15). Here we report the intramolecular distribution of N-15 within the linear NNO molecule, determined by measuring molecular and fragment ions of N2O on a modified mass spectrometer. This revealed a preference for N-15 at the central N position, or alpha-site, within N2O isotopomers (isotope-containing molecules). Moreover, this preference varied significantly throughout the atmosphere. In the troposphere, low a-site preference indicates local emission of N2O from soils and fossil-fuel combustion, each with distinct isotopomer signatures, which then mixes with background N2O. In the stratosphere, on the other hand, loss of N2O is observed as enhanced a-site preference for N-15, due to fractionation during ultraviolet photolysis of N2O. We have constructed an atmospheric mass balance of N2O, incorporating isotopomer abundance, which shows that the intramolecular distribution of N-15 is a parameter that has the potential to increase significantly the resolution with which sources and sinks of N2O can be identified and quantified in the atmosphere.	Tokyo Inst Technol, Interdisciplinary Grad Sch Sci & Engn, Dept Environm Sci & Technol, Midori Ku, Yokohama, Kanagawa 2268502, Japan; Japan Sci & Technol Corp, CREST Project, Kawaguchi, Saitama 3320012, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Yoshida, N (corresponding author), Tokyo Inst Technol, Interdisciplinary Grad Sch Sci & Engn, Dept Environm Sci & Technol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268502, Japan.		Yoshida, Naohiro/A-8335-2010; Toyoda, Sakae/J-7151-2013	Yoshida, Naohiro/0000-0003-0454-3849; 				BEGUN GM, 1961, J CHEM PHYS, V35, P547, DOI 10.1063/1.1731966; Brenninkmeijer CAM, 1999, RAPID COMMUN MASS SP, V13, P2028, DOI 10.1002/(SICI)1097-0231(19991030)13:20<2028::AID-RCM751>3.0.CO;2-J; CLIFF SS, 1994, ANAL CHEM, V66, P2791, DOI 10.1021/ac00089a031; Cliff SS, 1999, J GEOPHYS RES-ATMOS, V104, P16171, DOI 10.1029/1999JD900152; Cliff SS, 1997, SCIENCE, V278, P1774, DOI 10.1126/science.278.5344.1774; Dore JE, 1998, NATURE, V396, P63, DOI 10.1038/23921; FRIEDMAN L, 1950, J CHEM PHYS, V18, P1325, DOI 10.1063/1.1747471; HOLTON JR, 1990, J ATMOS SCI, V47, P392, DOI 10.1175/1520-0469(1990)047<0392:OTGEOM>2.0.CO;2; INOUE HY, 1994, CHEM GEOL, V113, P135, DOI 10.1016/0009-2541(94)90009-4; JOHNSTON JC, 1995, J GEOPHYS RES-ATMOS, V100, P16801, DOI 10.1029/95JD01646; KIM KR, 1993, SCIENCE, V262, P1855, DOI 10.1126/science.262.5141.1855; KIM KR, 1990, NATURE, V347, P58, DOI 10.1038/347058a0; Kroeze C, 1999, GLOBAL BIOGEOCHEM CY, V13, P1, DOI 10.1029/1998GB900020; Rahn T, 1998, GEOPHYS RES LETT, V25, P4489, DOI 10.1029/1998GL900186; Rahn T, 1997, SCIENCE, V278, P1776, DOI 10.1126/science.278.5344.1776; RICHTSMEIER AJ, 1994, J DEV BEHAV PEDIATR, V15, P14, DOI 10.1097/00004703-199402000-00003; TANAKA N, 1995, INT J MASS SPECTROM, V142, P163, DOI 10.1016/0168-1176(94)04100-L; THIEMENS MH, 1991, SCIENCE, V251, P932, DOI 10.1126/science.251.4996.932; Toyoda S, 1999, ANAL CHEM, V71, P4711, DOI 10.1021/ac9904563; UEDA S, 1991, GEOPHYS RES LETT, V18, P1449, DOI 10.1029/91GL01722; WAHLEN M, 1985, NATURE, V313, P780, DOI 10.1038/313780a0; YAMAZAKI T, 1987, PLANT CELL PHYSIOL, V28, P263; YOSHIDA N, 1988, NATURE, V335, P528, DOI 10.1038/335528a0; YOSHIDA N, 1984, NATURE, V307, P442, DOI 10.1038/307442a0; YOSHIDA N, 1983, GEOCHEM J, V17, P231, DOI 10.2343/geochemj.17.231; YOSHIDA N, 1989, NATURE, V342, P895, DOI 10.1038/342895a0; Yoshinari T, 1997, MAR CHEM, V56, P253, DOI 10.1016/S0304-4203(96)00073-4; Yung YL, 1997, SCIENCE, V278, P1778, DOI 10.1126/science.278.5344.1778; Zipf EC, 1998, GEOPHYS RES LETT, V25, P4333, DOI 10.1029/1998GL900159; [No title captured]	30	259	273	9	159	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					330	334		10.1038/35012558	http://dx.doi.org/10.1038/35012558			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830958				2022-12-28	WOS:000087085700042
J	Lydon-Rochelle, M; Holt, VL; Martin, DP; Easterling, TR				Lydon-Rochelle, M; Holt, VL; Martin, DP; Easterling, TR			Association between method of delivery and maternal rehospitalization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VAGINAL DELIVERY; CESAREAN DELIVERY; VACUUM EXTRACTOR; CHILDBIRTH; EPISIOTOMY; FORCEPS; WOMEN; RISK; CHOLECYSTITIS; METAANALYSIS	Context Despite nearly 4 million deliveries in the United States each year, minimal information exists on unintended health consequences following childbirth, particularly in relation to delivery method. Objective To assess the risk for maternal rehospitalization associated with cesarean or assisted vaginal delivery compared with spontaneous vaginal delivery. Design Retrospective cohort study of data from the Washington State Birth Events Record Database for 1987 through November 1, 1996. Setting and Participants All primiparous women without selected chronic medical conditions who delivered live singleton infants in nonfederal short-stay hospitals in Washington State (N=256 795). Main Outcome Measures Relative risks (RRs) of rehospitalization within 60 days of cesarean or assisted vaginal vs spontaneous vaginal deliveries, Results A total of 3149 women (1.2%) were rehospitalized within 60 days of delivery. In logistic regression analyses adjusting for maternal age, rehospitalization was found to be more likely among women with cesarean delivery (RR, 1.8, 95% confidence interval [CI], 1.6-1.9) or assisted vaginal delivery (RR, 1.3; 95% CI, 1.2-1.4) than among women with spontaneous Vaginal delivery. Cesarean delivery was associated with significantly increased risks of rehospitalization for uterine infection, obstetrical surgical wound complications, and cardiopulmonary and thromboembolic conditions. Among women with assisted vaginal delivery, significant increased risks were seen for rehospitalization with postpartum hemorrhage, obstetrical surgical wound complications, and pelvic injury, Conclusions Women with cesarean and assisted vaginal deliveries were at increased risk for rehospitalization, particularly with infectious morbidities, Effective strategies for preventing and controlling peripartum infection should be an obstetrical priority.	Univ Washington, Ctr Womens Hlth Res, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Sch Nursing, Dept Family & Child Nursing, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lydon-Rochelle, M (corresponding author), Univ Washington, Ctr Womens Hlth Res, Sch Publ Hlth & Community Med, Dept Hlth Serv, Mailstop 357262, Seattle, WA 98195 USA.	minot@u.washington.edu			AHRQ HHS [5 T32 HS00034] Funding Source: Medline; NINR NIH HHS [1 P30 NR0400] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000034] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM COLL OBST GYN, 1998, ACOG ED B, V245, P1; ANDERSSON R, 1995, INT J EPIDEMIOL, V24, P829, DOI 10.1093/ije/24.4.829; Ashton CM, 1997, MED CARE, V35, P1044, DOI 10.1097/00005650-199710000-00006; Atkinson NW, 1996, OBSTET GYNECOL, V87, P99, DOI 10.1016/0029-7844(95)00359-2; Bofill JA, 1996, AM J OBSTET GYNECOL, V175, P1325, DOI 10.1016/S0002-9378(96)70049-2; Boggess KA, 1996, OBSTET GYNECOL, V87, P779, DOI 10.1016/0029-7844(96)00037-3; Cardini F, 1998, JAMA-J AM MED ASSOC, V280, P1580, DOI 10.1001/jama.280.18.1580; CHANG PL, 1992, OBSTET GYNECOL, V80, P117; ELDAR S, 1986, ISRAEL J MED SCI, V22, P892; Feldman DM, 1999, AM J OBSTET GYNECOL, V181, P1185, DOI 10.1016/S0002-9378(99)70105-5; Fernandez CO, 1997, OBSTET GYNECOL, V90, P775, DOI 10.1016/S0029-7844(97)00440-7; Glazener CMA, 1997, BRIT J OBSTET GYNAEC, V104, P330, DOI 10.1111/j.1471-0528.1997.tb11463.x; GLAZENER CMA, 1995, BRIT J OBSTET GYNAEC, V102, P282, DOI 10.1111/j.1471-0528.1995.tb09132.x; GRAVES EJ, 1999, VITAL HLTH STAT 13, V140, P1; HELWIG JT, 1993, OBSTET GYNECOL, V82, P276; HEMMINKI E, 1991, J EPIDEMIOL COMMUN H, V45, P24, DOI 10.1136/jech.45.1.24; HENRIKSEN TB, 1994, BMJ-BRIT MED J, V309, P1255, DOI 10.1136/bmj.309.6964.1255; Hohner V, 1999, BERD CHARS LINKAGE R; JOHANSON RB, 1993, BRIT J OBSTET GYNAEC, V100, P524, DOI 10.1111/j.1471-0528.1993.tb15301.x; JOHANSON RB, 2000, COCHRANE LIB, P1; LEIGH DA, 1990, J HOSP INFECT, V15, P107, DOI 10.1016/0195-6701(90)90119-9; MACARTHUR C, 1991, BRIT J OBSTET GYNAEC, V98, P1193, DOI 10.1111/j.1471-0528.1991.tb15386.x; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; MARTENS MG, 1995, J REPROD MED, V40, P171; MYERS SA, 1988, NEW ENGL J MED, V319, P1511, DOI 10.1056/NEJM198812083192304; Orth K, 1997, CHIRURG, V68, P898, DOI 10.1007/s001040050291; PARRISH KM, 1993, AM J EPIDEMIOL, V138, P119, DOI 10.1093/oxfordjournals.aje.a116834; *PHS, 1988, INT CLASS DIS; Robinson JN, 1999, AM J OBSTET GYNECOL, V181, P1180, DOI 10.1016/S0002-9378(99)70104-3; ROOS NP, 1995, MED CARE, V33, P127; SAS Institute Inc., 1990, SAS PROC GUID; SCHIRREN J, 1990, CHIRURG, V61, P382; Scott KD, 1999, AM J OBSTET GYNECOL, V180, P1054, DOI 10.1016/S0002-9378(99)70594-6; Soreide E, 1996, ACTA ANAESTH SCAND, V40, P14, DOI 10.1111/j.1399-6576.1996.tb04382.x; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; Tetzschner T, 1996, BRIT J OBSTET GYNAEC, V103, P1034, DOI 10.1111/j.1471-0528.1996.tb09557.x; WATTS DH, 1991, OBSTET GYNECOL, V77, P287, DOI 10.1097/00006250-199102000-00026; WATTS DH, 1990, OBSTET GYNECOL, V75, P52; Zetterstrom J, 1999, OBSTET GYNECOL, V94, P21, DOI 10.1016/S0029-7844(99)00248-3; Zhang J, 1999, AM J OBSTET GYNECOL, V180, P970, DOI 10.1016/S0002-9378(99)70669-1	40	208	213	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2411	2416		10.1001/jama.283.18.2411	http://dx.doi.org/10.1001/jama.283.18.2411			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815084				2022-12-28	WOS:000086808200036
J	Kiefer, JR; Pawlitz, JL; Moreland, KT; Stegeman, RA; Hood, WF; Gierse, JK; Stevens, AM; Goodwin, DC; Rowlinson, SW; Marnett, LJ; Stallings, WC; Kurumbail, RG				Kiefer, JR; Pawlitz, JL; Moreland, KT; Stegeman, RA; Hood, WF; Gierse, JK; Stevens, AM; Goodwin, DC; Rowlinson, SW; Marnett, LJ; Stallings, WC; Kurumbail, RG			Structural insights into the stereochemistry of the cyclooxygenase reaction	NATURE			English	Article							PROSTAGLANDIN-H SYNTHASE; HIGHER OXIDATION-STATES; X-RAY-DIFFRACTION; ENDOPEROXIDE SYNTHASE; PEROXIDASE REACTION; ARACHIDONIC-ACID; ACTIVE-SITE; CATALYSIS; ACTIVATION; BINDING	Cyclooxygenases are bifunctional enzymes that catalyse the first committed step in the synthesis of prostaglandins, thromboxanes and other eicosanoids(1-3). The two known cyclooxygenases isoforms share a high degree of amino-acid sequence similarity(1-4), structural topology(5-7) and an identical catalytic mechanism(1-3). Cyclooxygenase enzymes catalyse two sequential reactions in spatially distinct, but mechanistically coupled active sites(8-11). The initial cyclooxygenase reaction converts arachidonic acid (which is achiral) to prostaglandin G(2) (which has five chiral centres). The subsequent peroxidase reaction reduces prostaglandin G(2) to prostaglandin H-2. Here we report the co-crystal structures of murine apo-cyclooxygenase-2 in complex with arachidonic acid and prostaglandin. These structures suggest the molecular basis for the stereospecificity of prostaglandin G(2) synthesis.	Monsanto Co, Searle Discovery Res, St Louis, MO 63198 USA; Vanderbilt Univ, Vanderbilt Sch Med, Dept Biochem, Nashville, TN 37232 USA	Monsanto; Vanderbilt University	Kurumbail, RG (corresponding author), Monsanto Co, Searle Discovery Res, 700 Chesterfield Pkwy N, St Louis, MO 63198 USA.		Moreland, Trent/I-5497-2013	Moreland, Trent/0000-0002-8996-832X; Kiefer, James/0000-0001-6317-0902; Goodwin, Douglas/0000-0002-7869-7704				Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; ELING TE, 1991, J BIOL CHEM, V266, P12348; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; Hamberg M, 1998, ARCH BIOCHEM BIOPHYS, V349, P376, DOI 10.1006/abbi.1997.0443; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HSI LC, 1993, J LIPID MEDIATOR, V6, P131; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; Kurumbail RG, 1997, NATURE, V385, P555, DOI 10.1038/385555b0; Landino LM, 1997, J BIOL CHEM, V272, P21565, DOI 10.1074/jbc.272.34.21565; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Stevens AM, 1999, J CRYST GROWTH, V196, P350, DOI 10.1016/S0022-0248(98)00847-1; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; UENO R, 1982, J BIOL CHEM, V257, P5584; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400	30	171	177	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					97	101		10.1038/35011103	http://dx.doi.org/10.1038/35011103			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811226				2022-12-28	WOS:000086901600059
J	Wheeler, R				Wheeler, R			One person's innovation is another's experiment	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1548	1548		10.1136/bmj.320.7248.1548	http://dx.doi.org/10.1136/bmj.320.7248.1548			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834915				2022-12-28	WOS:000087471000061
J	Merkel, S; Goncharov, AF; Mao, HK; Gillet, P; Hemley, RJ				Merkel, S; Goncharov, AF; Mao, HK; Gillet, P; Hemley, RJ			Raman spectroscopy of iron to 152 gigapascals: Implications for Earth's inner core	SCIENCE			English	Article							HIGH-PRESSURE; GRUNEISEN-PARAMETER; STATIC COMPRESSION; PHASE-TRANSITIONS; LATTICE-DYNAMICS; TEMPERATURES; ELASTICITY; ROTATION; METALS; GPA	Raman spectra of hexagonal close-packed iron (epsilon-Fe) have been measured from 15 to 152 gigapascals by using diamond-anvil cells with ultrapure synthetic diamond anvils. The results give a Gruneisen parameter gamma(o) = 1.68 (+/-0.20) and q = 0.7 (+/-0.5), Phenomenological modeling shows that the Raman-active made can be approximately correlated with an acoustic phonon and thus provides direct information about the high-pressure elastic properties of iron, which have been controversial. In particular, the C-44 elastic modulus is found to be Lower than previous determinations. This Leads to changes of about 35% at core pressures for shear wave anisotropies.	Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Carnegie Inst Washington, Ctr High Pressure Res, Washington, DC 20015 USA; Ecole Normale Super Lyon, CNRS, UMR 5570, Lab Sci Terre, F-69364 Lyon, France	Carnegie Institution for Science; Carnegie Institution for Science; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Merkel, S (corresponding author), Carnegie Inst Washington, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.		Merkel, Sébastien/E-5501-2011; Goncharov, Alexander F./AAX-9943-2020	Merkel, Sébastien/0000-0003-2767-581X; Goncharov, Alexander F./0000-0002-6422-8819				ALFEE D, IN PRESS PHYS REV B; ALTHOFF JD, 1993, PHYS REV B, V48, P13253, DOI 10.1103/PhysRevB.48.13253; Anderson OL, 1998, PHYS EARTH PLANET IN, V109, P179, DOI 10.1016/S0031-9201(98)00123-X; BOEHLER R, 1990, J GEOPHYS RES-SOLID, V95, P21731, DOI 10.1029/JB095iB13p21731; Brandes E.A, 1983, SMITHELLS LIGHT META; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; BUNDY FP, 1965, J APPL PHYS, V36, P616, DOI 10.1063/1.1714038; Dubrovinsky LS, 2000, PHYS REV LETT, V84, P1720, DOI 10.1103/PhysRevLett.84.1720; Dubrovinsky LS, 2000, AM MINERAL, V85, P386, DOI 10.2138/am-2000-2-318; Gillet P, 1998, REV MINERAL, V37, P525; Glatzmaier GA, 1996, SCIENCE, V274, P1887, DOI 10.1126/science.274.5294.1887; Goncharov AF, 1999, PHYS REV LETT, V83, P1998, DOI 10.1103/PhysRevLett.83.1998; Goncharov AF, 1998, PHYS REV LETT, V80, P101, DOI 10.1103/PhysRevLett.80.101; Hemley RJ, 1997, SCIENCE, V276, P1242, DOI 10.1126/science.276.5316.1242; JEANLOZ R, 1979, J GEOPHYS RES, V84, P6059, DOI 10.1029/JB084iB11p06059; JEPHCOAT AP, 1986, J GEOPHYS RES-SOLID, V91, P4677, DOI 10.1029/JB091iB05p04677; JEPHCOAT AP, 1999, EOS, V80, pF929; Kuang WL, 1997, NATURE, V389, P371, DOI 10.1038/38712; Laio A, 2000, SCIENCE, V287, P1027, DOI 10.1126/science.287.5455.1027; Lubbers R, 2000, SCIENCE, V287, P1250, DOI 10.1126/science.287.5456.1250; Mao HK, 1998, NATURE, V396, P741, DOI 10.1038/25506; Mao HK, 1999, NATURE, V399, P280, DOI 10.1038/20472; MAO HK, 1990, J GEOPHYS RES-SOLID, V95, P21737, DOI 10.1029/JB095iB13p21737; MAO HK, 1986, J GEOPHYS RES-SOLID, V91, P4673, DOI 10.1029/JB091iB05p04673; MAO HK, UNPUB; Marinelli F, 1996, PHYS REV B, V54, P6054, DOI 10.1103/PhysRevB.54.6054; McQueen R. G., 1970, HIGH VELOCITY IMPACT, P296; NGUYEN J, COMMUNICATION; OLIJNYK H, 1992, PHYS REV LETT, V68, P2232, DOI 10.1103/PhysRevLett.68.2232; Olijnyk H, 1997, PHYS REV B, V56, P10751, DOI 10.1103/PhysRevB.56.10751; OLIJNYK H, 1999, AIRAPT 17 C, P148; OLIJNYK H, 1992, HIGH PRESSURE RES, V10, P461, DOI DOI 10.1080/08957959208201457; Ostanin SA, 1998, PHYS REV B, V58, P15962, DOI 10.1103/PhysRevB.58.R15962; Shen GY, 1998, REV MINERAL, V37, P369; Shen GY, 1998, GEOPHYS RES LETT, V25, P373, DOI 10.1029/97GL03776; Singh AK, 1998, J APPL PHYS, V83, P7567, DOI 10.1063/1.367872; Singh AK, 1998, PHYS REV LETT, V80, P2157, DOI 10.1103/PhysRevLett.80.2157; Song XD, 1996, NATURE, V382, P221, DOI 10.1038/382221a0; Steinle-Neumann G, 1999, PHYS REV B, V60, P791, DOI 10.1103/PhysRevB.60.791; STIXRUDE L, 1994, PHYS REV B, V50, P6442, DOI 10.1103/PhysRevB.50.6442; Stixrude L, 1997, J GEOPHYS RES-SOL EA, V102, P24729, DOI 10.1029/97JB02125; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; Su WJ, 1996, SCIENCE, V274, P1883, DOI 10.1126/science.274.5294.1883; TAKAHASHI T, 1964, SCIENCE, V145, P483, DOI 10.1126/science.145.3631.483; TAKEMURA K, 1999, AIRAPT 17 C, P150; UPADHYAYA JC, 1994, CAN J PHYS, V72, P61, DOI 10.1139/p94-011; VOCADIO L, COMMUNICATION; Vocadlo L, 2000, PHYS EARTH PLANET IN, V117, P123, DOI 10.1016/S0031-9201(99)00092-8; Wasserman E, 1996, PHYS REV B, V53, P8296, DOI 10.1103/PhysRevB.53.8296; WENK HR, 1988, GEOPHYS RES LETT, V15, P76, DOI 10.1029/GL015i001p00076; WENK HR, UNPUB NATURE	51	119	123	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1626	1629		10.1126/science.288.5471.1626	http://dx.doi.org/10.1126/science.288.5471.1626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834838				2022-12-28	WOS:000087382300036
J	Cheng, YW; Kawachi, I; Coakley, EH; Schwartz, J; Colditz, G				Cheng, YW; Kawachi, I; Coakley, EH; Schwartz, J; Colditz, G			Association between psychosocial work characteristics and health functioning in American women: prospective study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; QUALITY-OF-LIFE; JOB STRAIN; SOCIAL SUPPORT; WHITEHALL-II; CARDIOVASCULAR-DISEASE; UNITED-STATES; RANDOM SAMPLE; RISK; POPULATION	Objective To examine prospectively the relation between psychosocial work characteristics and changes in health related quality of life over four years in a cohort of working women in the United Slates. Design Longitudinal cohort study. Setting United States. Participants 21 290 female registered nurses who completed the Karasek's job content questionnaire and a modified version of the short form 36 questionnaire (SF-36) as used for a survey of health status by the medical outcomes study. Main outcome measures Seven dimensions of health status: physical functioning, role limitations due to physical health problems, bodily pain, vitality, social functioning, role limitations due to emotional problems, and mental health. Results Examined separately low job control, high job demands, and low work related social support were associated with poor health status at baseline as well as greater functional declines over the four year follow up period. Examined in combination, women with low job control, high job demands, and low work related social support ("iso-strain" jobs) had the greatest functional declines. These associations could not be explained by age, body mass index, comorbid disease status, alcohol consumption, smoking status, education level, exercise level, employment status, marital status, or presence of a confidant. Conclusions Adverse psychosocial work conditions arp important predictors of poor functional status and its decline over time.	Harvard Univ, Sch Publ Hlth, Harvard Ctr Soc & Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Kawachi, I (corresponding author), Harvard Univ, Sch Publ Hlth, Harvard Ctr Soc & Hlth, 665 Huntington Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291; CHENG, YAWEN/0000-0001-7112-8835	NATIONAL CANCER INSTITUTE [R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012806] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-40356, R01 CA040356] Funding Source: Medline; NHLBI NIH HHS [HL03453] Funding Source: Medline; NIA NIH HHS [R01-AG-12806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Achat H, 1998, QUAL LIFE RES, V7, P735, DOI 10.1023/A:1008837002431; Amick BC, 1998, SCAND J WORK ENV HEA, V24, P54, DOI 10.5271/sjweh.278; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; CAIN KC, 1992, STAT MED, V11, P783, DOI 10.1002/sim.4780110609; FENSTER L, 1995, AM J EPIDEMIOL, V142, P1176, DOI 10.1093/oxfordjournals.aje.a117576; Hastie TJ., 1990, GEN ADDITIVE MODELS, Vvol. 43, DOI DOI 10.1201/9780203753781; Hellerstedt WL, 1997, INT J EPIDEMIOL, V26, P575, DOI 10.1093/ije/26.3.575; HOMER C, 1990, AM J PUBLIC HEALTH, V135, P173; JOHNSON JV, 1988, AM J PUBLIC HEALTH, V78, P1336, DOI 10.2105/AJPH.78.10.1336; JOHNSON JV, 1989, SCAND J WORK ENV HEA, V15, P271, DOI 10.5271/sjweh.1852; KARASEK R, 1981, AM J PUBLIC HEALTH, V74, P694; Karasek R., 1990, HLTH WORK STRESS PRO; Karasek R., 1985, JOB CONTENT QUESTION; KARASEK RA, 1988, AM J PUBLIC HEALTH, V78, P910, DOI 10.2105/AJPH.78.8.910; LANDSBERGIS PA, 1992, J BEHAV MED, V15, P379, DOI 10.1007/BF00844730; LERNER DJ, 1994, AM J PUBLIC HEALTH, V84, P1580, DOI 10.2105/AJPH.84.10.1580; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; ROSNER B, 1979, J CHRON DIS, V32, P464; SCHNALL PI, 1994, ANNU REV PUBL HEALTH, V45, P381; SCHNALL PL, 1992, HYPERTENSION, V19, P488, DOI 10.1161/01.HYP.19.5.488; Stansfeld SA, 1998, PSYCHOSOM MED, V60, P247, DOI 10.1097/00006842-199805000-00004; THEORELL T, 1988, SCAND J WORK ENV HEA, V14, P189, DOI 10.5271/sjweh.1932; Ware JE, 1993, SF36 HLTH SURVEY MAN; Zapf D, 1996, J Occup Health Psychol, V1, P145, DOI 10.1037/1076-8998.1.2.145	25	224	229	1	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1432	1436		10.1136/bmj.320.7247.1432	http://dx.doi.org/10.1136/bmj.320.7247.1432			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	320RT	10827043	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000087414700021
J	Wente, SR				Wente, SR			Gatekeepers of the nucleus	SCIENCE			English	Editorial Material							MESSENGER-RNA EXPORT; PORE COMPLEX PROTEIN; MOLECULAR ARCHITECTURE; LOCALIZATION SIGNALS; NUCLEOPORIN NUP153; BINDING-PROTEINS; IMPORT SUBSTRATE; TRANSPORT FACTOR; RECEPTOR; IDENTIFICATION	Nuclear pore complexes (NPCs) form the site for entry and exit from the nucleus. A convergence of studies have defined the physical framework for the nuclear transport mechanism. This includes definition of the soluble transport machinery required for protein and RNA movement, x-ray structure analysis of transport factors, definitive compositional analysis of yeast NPCs, and documentation of the relative steady state arrangement of NPC components within the portal. With this information, researchers are now in the exciting position to examine the dynamic interplay between shuttling transport factors and the static pore complex.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Wente, SR (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	swente@cellbio.wustl.edu						ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AFZELIUS BA, 1955, EXP CELL RES, V8, P147, DOI 10.1016/0014-4827(55)90051-3; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; ANDERSON NG, 1953, SCIENCE, V117, P517, DOI 10.1126/science.117.3046.517; CALLAN HG, 1950, PROC R SOC SER B-BIO, V137, P367, DOI 10.1098/rspb.1950.0047; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Cullen BR, 2000, P NATL ACAD SCI USA, V97, P4, DOI 10.1073/pnas.97.1.4; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; GALL JG, 1954, EXP CELL RES, V7, P197, DOI 10.1016/0014-4827(54)90054-3; GALL JG, 1967, J CELL BIOL, V32, P391, DOI 10.1083/jcb.32.2.391; Goldfarb D, 1991, Trends Cell Biol, V1, P20, DOI 10.1016/0962-8924(91)90065-H; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Hetzer M, 2000, J CELL BIOL, V148, P293, DOI 10.1083/jcb.148.2.293; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; IMAMOTO N, 1995, FEBS LETT, V368, P415; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Keminer O, 1999, P NATL ACAD SCI USA, V96, P11842, DOI 10.1073/pnas.96.21.11842; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Rappsilber J, 2000, ANAL CHEM, V72, P267, DOI 10.1021/ac991081o; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63; WATSON ML, 1959, J BIOPHYS BIOCHEM CY, V6, P147, DOI 10.1083/jcb.6.2.147; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; Yaseen NR, 1999, J BIOL CHEM, V274, P26493, DOI 10.1074/jbc.274.37.26493; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	70	208	213	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1374	1377		10.1126/science.288.5470.1374	http://dx.doi.org/10.1126/science.288.5470.1374			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827939				2022-12-28	WOS:000087270900037
J	Berger, A				Berger, A			Cochlear hair cells generated in mammals after birth	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	2000	320	7246					1360	1360						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818018				2022-12-28	WOS:000087232500013
J							Early Breast Canc Trialists Collaborat	Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials	LANCET			English	Article							ADJUVANT RADIOTHERAPY; POSTOPERATIVE RADIOTHERAPY; PREMENOPAUSAL WOMEN; MORTALITY; CHEMOTHERAPY	Background The long-term effects of radiotherapy on mortality from breast cancer and other causes remain uncertain. Methods A meta-analysis was done of 10-year and 20-year results from 40 unconfounded randomised trials of radiotherapy for early breast cancer. It involved central review of individual patients' data on recurrence and cause-specific mortality from 20 000 women, half with "node-positive" disease. Radiotherapy Fields generally included not only chest wall (or breast) but also axillary, supraclavicular, and internal mammary nodes. Findings A reduction of approximately two-thirds in local recurrence was seen in all trials, largely independent of the type of patient or type of radiotherapy (8.8% vs 27.2% local recurrence by year 10). Hence, to assess effects on breast cancer mortality of substantially better local control, results from all trials were combined. Breast cancer mortality was reduced (2p=0.0001) but other, particularly vascular, mortality was increased (2p=0.0003), and overall 20-year survival was 37.1% with radiotherapy versus 35.9% control (2p=0.06). There was little effect on early deaths, but logrank analyses of later deaths indicate that, on average after year 2, radiotherapy reduced annual mortality rates from breast cancer by 13.2% (SE 2.5) but increased those from other causes by 21.2% (SE 5.4). Nodal status, age, and decade of follow-up strongly affected the ratio of breast cancer mortality to other mortality, and hence affected the ratio of absolute benefit to absolute hazard from these proportional changes in mortality. Interpretation Radiotherapy regimens able to produce the two-thirds reduction in local recurrence seen in these trials, but without long-term hazard, would be expected to produce an absolute increase in 20-year survival of about 2-4% (except for women at particularly low risk of local recurrence). The average hazard seen in these trials would, however, reduce this 20-year survival benefit in young women and reverse it in older women.	Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Early Breast Canc Trialists Collaborat (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.		McLaughlin, John R/E-4577-2013					ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; Abe O, 1998, LANCET, V352, P930; [Anonymous], 1996, Lancet, V348, P1189; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; Burdett S, 1998, LANCET, V352, P257; Clarke M, 1998, LANCET, V351, P1451; CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; Hellman S, 1997, NEW ENGL J MED, V337, P996, DOI 10.1056/NEJM199710023371408; Hojris I, 1999, LANCET, V354, P1425, DOI 10.1016/S0140-6736(99)02245-X; Overgaard M, 1999, LANCET, V353, P1641, DOI 10.1016/S0140-6736(98)09201-0; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Paszat LF, 1998, J CLIN ONCOL, V16, P2625, DOI 10.1200/JCO.1998.16.8.2625; Potyka I, 1999, BRIT J CANCER, V80, P11; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; Recht A, 1998, J CLIN ONCOL, V16, P2886, DOI 10.1200/JCO.1998.16.8.2886; RUTQVIST LE, 1990, BRIT J CANCER, V61, P866, DOI 10.1038/bjc.1990.193; Shimizu Y, 1999, RADIAT RES, V152, P374, DOI 10.2307/3580222; Van De Steene J, 1998, 10TH INTERNATIONAL CONGRESS ON SENOLOGY - BREAST DISEASES OF THE SENOLOGIC INTERNATIONAL SOCIETY, P385; Whelan TJ, 2000, J CLIN ONCOL, V18, P1220, DOI 10.1200/JCO.2000.18.6.1220	22	1152	1174	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 20	2000	355	9217					1757	1770		10.1016/S0140-6736(00)02263-7	http://dx.doi.org/10.1016/S0140-6736(00)02263-7			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832826				2022-12-28	WOS:000087126100010
J	Bunge, HP; Grand, SP				Bunge, HP; Grand, SP			Mesozoic plate-motion history below the northeast Pacific Ocean from seismic images of the subducted Farallon slab	NATURE			English	Article							MANTLE CONVECTION; MODELS; TOMOGRAPHY; TECTONICS; LARAMIDE; DYNAMICS; EARTH	The high-resolution seismic imaging of subducted oceanic slabs(1,2) has become a powerful tool for reconstructing palaeogeography(3). The images can now be interpreted quantitatively by comparison with models of the general circulation of the Earth's mantle(4). Here we use a three-dimensional spherical computer model of mantle convection(5,6) to show that seismic images of the subducted Far-allon plate provide strong evidence for a Mesozoic period of low-angle subduction under North America. Such a period of low-angle subduction has been invoked independently to explain Rocky Mountain uplift far inland from the plate boundary during the Laramide orogeny(7). The computer simulations also allow us to locate the largely unknown Kula-Farallon spreading plate boundary, the location of which is important for inferring the trajectories of 'suspect' terrain across the Pacific basin(8).	Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Univ Texas, Dept Geol Sci, Austin, TX 78712 USA	Princeton University; University of Texas System; University of Texas Austin	Bunge, HP (corresponding author), Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA.		bunge, hans-peter/AAA-1860-2021; Grand, Stephen/B-4238-2011					Atwater T., 1970, GEOL SOC AM BULL, V81, P3513, DOI [DOI 10.1130/0016-7606(1970)81[3513:IOPTFT]2.0.CO;2, 10.1130/0016-7606(1970)81[3513:IOPTFT]2.0.CO;2]; BERCOVICI D, 1989, SCIENCE, V244, P893; BIRD P, 1988, SCIENCE, V239, P1501, DOI 10.1126/science.239.4847.1501; Bunge H.-P., 1995, Computers in Physics, V9, P207, DOI 10.1063/1.168525; Bunge HP, 1997, J GEOPHYS RES-SOL EA, V102, P11991, DOI 10.1029/96JB03806; Bunge HP, 1998, SCIENCE, V280, P91, DOI 10.1126/science.280.5360.91; CONEY PJ, 1977, NATURE, V270, P403, DOI 10.1038/270403a0; DAVIES GF, 1992, J GEOL, V100, P151, DOI 10.1086/629582; Debiche M. G., 1987, GEOL SOC AM SPEC PAP, V207, P1; Dickinson W.R., 1978, LARAMIDE FOLDING ASS, V151, P355, DOI DOI 10.1130/MEM151-P355; DUFFY TS, 1995, J GEOPHYS RES-SOL EA, V100, P529, DOI 10.1029/94JB02065; ENGEBRETSON DC, 1984, TECTONICS, V3, P115, DOI 10.1029/TC003i002p00115; ENGEBRETSON DC, 1986, GEOL SOC AM SPEC PAP, V206, P1; Grand SP., 1997, GSA TODAY, V7, P1; HAGER BH, 1989, PHILOS T R SOC A, V328, P309, DOI 10.1098/rsta.1989.0038; Hamilton W.B, 1978, PACIFIC SECTION SOC, P33; JORDAN TE, 1986, AM J SCI, V286, P737, DOI 10.2475/ajs.286.10.737; JORDAN TE, 1983, GEOL SOC AM BULL, V94, P341, DOI 10.1130/0016-7606(1983)94<341:ATRTGO>2.0.CO;2; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; LIVACCARI RF, 1981, NATURE, V289, P276, DOI 10.1038/289276a0; Megnin C, 1997, GEOPHYS RES LETT, V24, P1299, DOI 10.1029/97GL01256; Mitrovica JX, 1996, J GEOPHYS RES-SOL EA, V101, P555, DOI 10.1029/95JB03208; RICARD Y, 1992, J GEOPHYS RES-SOL EA, V97, P14223, DOI 10.1029/92JB00740; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; STOCK J, 1988, TECTONICS, V7, P1339, DOI 10.1029/TC007i006p01339; TACKLEY PJ, 1993, GEOPHYS RES LETT, V20, P2187, DOI 10.1029/93GL02317; TACKLEY PJ, 1994, J GEOPHYS RES-SOL EA, V99, P15877, DOI 10.1029/94JB00853; Van der Voo R, 1999, NATURE, V397, P246, DOI 10.1038/16686; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; vanderLee S, 1997, NATURE, V386, P266, DOI 10.1038/386266a0; WASSERBURG GJ, 1964, SCIENCE, V143, P465, DOI 10.1126/science.143.3605.465; ZHONG SJ, 1995, SCIENCE, V267, P838, DOI 10.1126/science.267.5199.838	32	146	149	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					337	340		10.1038/35012586	http://dx.doi.org/10.1038/35012586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830960				2022-12-28	WOS:000087085700044
J	Kealey, T				Kealey, T			More is less - Economists and government lag decades behind Derek Price's thinking.	NATURE			English	Editorial Material									Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England	Addenbrooke's Hospital; University of Cambridge	Kealey, T (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England.							De Solla Price D. J., 1963, LITTLE SCI BIG SCI, DOI 10.7312/pric91844	1	7	7	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					279	279		10.1038/35012717	http://dx.doi.org/10.1038/35012717			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830939				2022-12-28	WOS:000087085700021
J	Qvarnstrom, A; Part, T; Sheldon, BC				Qvarnstrom, A; Part, T; Sheldon, BC			Adaptive plasticity in mate preference linked to differences in reproductive effort	NATURE			English	Article							FLYCATCHER FICEDULA-ALBICOLLIS; SECONDARY SEXUAL CHARACTER; MALE COLLARED FLYCATCHERS; MATING PREFERENCES; MALE COMPETITION; PARENTAL CARE; BADGE SIZE; CHOICE; CONSEQUENCES; SELECTION	There is abundant evidence for the existence of marked mate preferences in natural populations, but the occurrence of within-population variation in mate preferences has received little attention(1-3) and is often regarded as nonadaptive deviation from the optimal norm(2,3). Here we show experimentally that the preference of female collared flycatchers Ficedula albicollis for male forehead patch size, a sexually selected trait(4-6), varies with the time of breeding, an environmental factor with strong effects on reproductive success. Contrary to expectations based on time-constrained choice models(7,8), only late-breeding females prefer males with a large patch size. The variation in mate preference matches a seasonal change in female reproductive success: longterm data reveal a positive relationship between female reproductive success and male patch size exclusively in late breeders. In addition, female reproductive effort, as assessed by clutch size, appears to be adjusted relative to both timing of breeding and male phenotype. We conclude that not only can mate preferences display adaptive plasticity within populations, but this plasticity can also be linked to differences in reproductive investment.	Uppsala Univ, Evolutionary Biol Ctr, Dept Anim Ecol, SE-75236 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Conservat Biol, SE-75007 Uppsala, Sweden; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	Uppsala University; Swedish University of Agricultural Sciences; University of Oxford	Qvarnstrom, A (corresponding author), Univ Calif San Diego, Dept Biol 0116, La Jolla, CA 92093 USA.	annaq@biomail.ucsd.edu	Sheldon, Ben C/A-8056-2010	Sheldon, Ben C/0000-0002-5240-7828; Qvarnstrom, Anna/0000-0002-1178-4053; Part, Tomas/0000-0001-7388-6672				Andersson Malte, 1994; Bakker TCM, 1999, NATURE, V401, P234, DOI 10.1038/45727; CRICK HQP, 1993, J ANIM ECOL, V62, P263, DOI 10.2307/5357; Gibson RM, 1996, TRENDS ECOL EVOL, V11, P468, DOI 10.1016/0169-5347(96)10050-1; Griffith SC, 1999, P ROY SOC B-BIOL SCI, V266, P765; GUSTAFSSON L, 1988, NATURE, V335, P813, DOI 10.1038/335813a0; GUSTAFSSON L, 1995, NATURE, V375, P311, DOI 10.1038/375311a0; Gustafsson L., 1989, P75; GUSTAFSSON L, 1990, NATURE, V347, P279, DOI 10.1038/347279a0; Jennions MD, 1997, BIOL REV, V72, P283, DOI 10.1017/S0006323196005014; Kokko H, 1998, P ROY SOC B-BIOL SCI, V265, P1871, DOI 10.1098/rspb.1998.0515; Part T, 1997, ANIM BEHAV, V54, P893, DOI 10.1006/anbe.1997.0514; PART T, 1989, J ANIM ECOL, V58, P305, DOI 10.2307/5002; Qvarnstrom A, 1999, EVOLUTION, V53, P1564, DOI 10.1111/j.1558-5646.1999.tb05419.x; Qvarnstrom A, 1999, P ROY SOC B-BIOL SCI, V266, P2089; Qvarnstrom A, 1997, P ROY SOC B-BIOL SCI, V264, P1225, DOI 10.1098/rspb.1997.0169; REAL L, 1990, AM NAT, V136, P376, DOI 10.1086/285103; Sheldon BC, 1997, P ROY SOC B-BIOL SCI, V264, P297, DOI 10.1098/rspb.1997.0042; Sheldon BC, 1999, ANIM BEHAV, V57, P285, DOI 10.1006/anbe.1998.0968; Widemo F, 1999, TRENDS ECOL EVOL, V14, P26, DOI 10.1016/S0169-5347(98)01531-6; WIGGINS DA, 1994, OIKOS, V70, P359, DOI 10.2307/3545773	21	155	155	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 18	2000	405	6784					344	347		10.1038/35012605	http://dx.doi.org/10.1038/35012605			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830962				2022-12-28	WOS:000087085700046
J	Helmlinger, G; Endo, M; Ferrara, N; Hlatky, L; Jain, RK				Helmlinger, G; Endo, M; Ferrara, N; Hlatky, L; Jain, RK			Growth factors - Formation of endothelial cell networks	NATURE			English	Article							TUMOR ANGIOGENESIS; HYPOXIA; PROLIFERATION		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Steele Lab,Dept Radiat Oncol, Boston, MA 02114 USA; Genentech Inc, S San Francisco, CA 94080 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Radiat Oncol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Roche Holding; Genentech; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Helmlinger, G (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Steele Lab,Dept Radiat Oncol, Boston, MA 02114 USA.		Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548				Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FILHO IPT, 1993, AM J PHYSIOL, V265, pH1434; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; HLATKY L, 1994, CANCER RES, V54, P6083; HLATKY L, 1985, CELL TISSUE KINET, V18, P597, DOI 10.1111/j.1365-2184.1985.tb00703.x; Hlatky L, 1996, BRIT J CANCER, V74, pS151; Kimura H, 1996, CANCER RES, V56, P5522; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Patan S, 1996, MICROVASC RES, V51, P260, DOI 10.1006/mvre.1996.0025; SHOLLEY MM, 1984, LAB INVEST, V51, P624	13	128	133	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					139	141		10.1038/35012132	http://dx.doi.org/10.1038/35012132			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821260				2022-12-28	WOS:000087080100037
J	Huigens, ME; Luck, RF; Klaassen, RHG; Maas, MFPM; Timmermans, MJTN; Stouthamer, R				Huigens, ME; Luck, RF; Klaassen, RHG; Maas, MFPM; Timmermans, MJTN; Stouthamer, R			Infectious parthenogenesis	NATURE			English	Article							MICROBE-ASSOCIATED PARTHENOGENESIS; TRICHOGRAMMA HYMENOPTERA; WOLBACHIA; SUPERPARASITISM; ALLOCATION; PRETIOSUM; WASPS; SEX	Parthenogenesis-inducing Wolbachia bacteria are reproductive parasites that cause infected female wasps to produce daughters without mating(1,2). This manipulation of the host's reproduction enhances the transmission of Wolbachia to future generations because the bacteria are passed on vertically only from mothers to daughters. Males are dead ends for cytoplasmically inherited bacteria: they do not pass them on to their offspring. Vertical transmission of Wolbachia has been previously considered to be the main mode of transmission. Here we report frequent horizontal transmission from infected to uninfected wasp larvae sharing a common food source. The transferred Wolbachia are then vertically transmitted to the new host's offspring. This natural and unexpectedly frequent horizontal transfer of parthenogensis-inducing Wolbachia intraspecifically has important implications for the co-evolution of Wolbachia and their host.	Wageningen Univ Agr, Entomol Lab, Dept Plant Sci, NL-6700 EH Wageningen, Netherlands; Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA	Wageningen University & Research; University of California System; University of California Riverside	Stouthamer, R (corresponding author), Wageningen Univ Agr, Entomol Lab, Dept Plant Sci, NL-6700 EH Wageningen, Netherlands.		Klaassen, Raymond/K-3027-2013					Braig HR, 1998, J BACTERIOL, V180, P2373, DOI 10.1128/JB.180.9.2373-2378.1998; Ewald PW, 1994, EVOLUTION INFECT DIS; KAZMER DJ, 1992, EVOLUTION REPROD STR; Moran NA, 1996, P NATL ACAD SCI USA, V93, P2873, DOI 10.1073/pnas.93.7.2873; PAK GA, 1982, ENTOMOL EXP APPL, V32, P68, DOI 10.1111/j.1570-7458.1982.tb03183.x; Pinto JD, 1997, P ENTOMOL SOC WASH, V99, P238; RIGAUD T, 1995, J EVOLUTION BIOL, V8, P249, DOI 10.1046/j.1420-9101.1995.8020249.x; Schilthuizen M, 1998, ANN ENTOMOL SOC AM, V91, P410, DOI 10.1093/aesa/91.4.410; Schilthuizen M, 1997, P ROY SOC B-BIOL SCI, V264, P361, DOI 10.1098/rspb.1997.0052; STOUTHAMER R, 1993, NATURE, V361, P66, DOI 10.1038/361066a0; STOUTHAMER R, 1994, HEREDITY, V73, P317, DOI 10.1038/hdy.1994.139; Stouthamer R, 1997, INFLUENTIAL PASSENGERS, P102; STOUTHAMER R, 1993, ENTOMOL EXP APPL, V67, P183, DOI 10.1007/BF02386524; STOUTHAMER R, 1990, P NATL ACAD SCI USA, V87, P2424, DOI 10.1073/pnas.87.7.2424; SUZUKI Y, 1984, ANIM BEHAV, V32, P478, DOI 10.1016/S0003-3472(84)80284-5; VANALPHEN JJM, 1992, FUNCT ECOL, V6, P528, DOI 10.2307/2390049	16	208	230	1	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					178	179		10.1038/35012066	http://dx.doi.org/10.1038/35012066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821272				2022-12-28	WOS:000087080100049
J	Maurer, SM; Firestone, RB; Scriver, CR				Maurer, SM; Firestone, RB; Scriver, CR			Science's neglected legacy	NATURE			English	Editorial Material									Ernest Orlando Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; McGill Univ, Montreal Childrens Hosp, Res Inst, Montreal, PQ H3H 1P3, Canada	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; McGill University	Maurer, SM (corresponding author), 2632 Hilgard St, Berkeley, CA 94709 USA.	maurer@econ.berkeley.edu		Firestone, Richard/0000-0003-3833-5546				Brazma A, 2000, NATURE, V403, P699, DOI 10.1038/35001676; Butler D, 2000, NATURE, V403, P231, DOI 10.1038/35002145; Campbell EG, 2000, RES POLICY, V29, P303, DOI 10.1016/S0048-7333(99)00068-2; Cotton RGH, 1998, SCIENCE, V279, P10; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Maurer SM, 2000, HUM MUTAT, V15, P22, DOI 10.1002/(SICI)1098-1004(200001)15:1<22::AID-HUMU7>3.0.CO;2-Q; MURTAGH F, VIRTUAL OBSERVATORY; RIDLEY M, 1991, ECONOMIST, V318, P7644; SCOTCHMER S, 1991, J ECON PERSPECT, V5, P29, DOI 10.1257/jep.5.1.29; SZALAY A, 1999, ACCESSING LARGE DIST; Winker K, 1999, NATURE, V401, P524, DOI 10.1038/44002	11	28	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					117	120		10.1038/35012169	http://dx.doi.org/10.1038/35012169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	314WG	10821250				2022-12-28	WOS:000087080100021
J	Koul, PA; Wahid, A				Koul, PA; Wahid, A			Recurrent paralysis in a young man	LANCET			English	Article							RENAL TUBULAR-ACIDOSIS		Sherikashmir Inst Med Sci, Dept Internal Med, Srinagar 19011, Kashmir, India	Sher-i-Kashmir Institute of Medical Sciences	Koul, PA (corresponding author), Sherikashmir Inst Med Sci, Dept Internal Med, Postbag 27, Srinagar 19011, Kashmir, India.		Koul, Parvaiz/AAS-8828-2021; Koul, Parvaiz/AFK-7442-2022; Koul, Parvaiz/B-1666-2017	Koul, Parvaiz/0000-0002-1700-9285; Koul, Parvaiz/0000-0002-1700-9285; Koul, Parvaiz/0000-0002-1700-9285				Dubose TDJ, 1995, METABOLIC MOL BASES, P3655; Jarolim P, 1998, J BIOL CHEM, V273, P6380, DOI 10.1074/jbc.273.11.6380; KOUL PA, 1993, J INTERN MED, V233, P463, DOI 10.1111/j.1365-2796.1993.tb00999.x; LehmannHorn F, 1996, REV PHYSIOL BIOCH P, V128, P195; Nimmannit S, 1996, NEPHRON, V72, P604, DOI 10.1159/000188947	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 6	2000	355	9215					1612	1612		10.1016/S0140-6736(00)02218-2	http://dx.doi.org/10.1016/S0140-6736(00)02218-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821366				2022-12-28	WOS:000086981200013
J	Jurkovich, GJ				Jurkovich, GJ			Strengthening of the case for organised trauma-care systems	LANCET			English	Editorial Material									Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	Jurkovich, GJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA.							[Anonymous], 1976, Bull Am Coll Surg, V61, P15; Mann NC, 1999, J TRAUMA, V47, pS25, DOI 10.1097/00005373-199909001-00007; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; National Academy of Sciences (US) and National Research Council (US) Committee on Trauma National Academy of Sciences (US) and National Research Council (US) Committee on Shock, 1966, ACC DEATH DIS NEGL D; O'Keefe GE, 1999, ANN SURG, V229, P409, DOI 10.1097/00000658-199903000-00015	6	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 20	2000	355	9217					1740	1741		10.1016/S0140-6736(00)02257-1	http://dx.doi.org/10.1016/S0140-6736(00)02257-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832820				2022-12-28	WOS:000087126100004
J	Lecky, F; Woodford, M; Yates, DW				Lecky, F; Woodford, M; Yates, DW		UK Trauma Audit Res Network	Trends in trauma care in England and Wales 1989-97	LANCET			English	Article							INJURY SEVERITY SCORE; REVISION	Background In 1988, the Royal College of Surgeons reported major deficiencies in trauma care in UK hospitals. We investigated whether and how that care has changed in the last decade by use of data collected by the UK Trauma Audit and Research Network. Methods We analysed injury-severity, process, and outcome variables from 91 602 patients' records on the database at the end of 1997, collected from 97 (49% of trauma-receiving) hospitals in England, Wales, and two In Ireland. We did longitudinal analyses of odds of death, process variables, and individual hospitals' performance. We took account of potential selection bias from missing data and recruitment of new hospitals. Findings The severity-adjusted odds of death after trauma declined gradually from 1989 (odds ratio 1997/1989 0.63 [95% CI [0.49-0.82]). In 1997, the reduction in odds of death was significant even after adjustment for missing data (ratio 1997/1989 0.72 [0.55-0.92]) and recruitment of new hospitals (0.64 [0.44-0.93]). There was significant variability in the proportion of survivors (adjusted for severity of injury and age) between the highest and lowest 10% of UK hospitals. The time between the call to the emergency services and arrival at hospital increased from 32 min in 1989 to 45 min in 1997, irrespective of injury severity. The proportion of severely injured patients seen first by senior doctors increased from 32% to 60%. Interpretation Hospital care has made a valuable but variable contribution to reductions in case fatality after injury in the UK in the past 10 years, though further improvement is possible.	Univ Manchester, Hope Hosp, NW Injury Res Collaborat, UK Trauma Audit & Res Network, Salford M6 8HD, Lancs, England	University of Manchester	Lecky, F (corresponding author), Univ Manchester, Hope Hosp, NW Injury Res Collaborat, UK Trauma Audit & Res Network, Salford M6 8HD, Lancs, England.							BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CAMPBELL FA, 1996, RELIABILITY STUDY IN; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; *COMM INF SCAL, 1990, ABBR INJ SCAL; COPES WS, 1995, J TRAUMA, V38, P432, DOI 10.1097/00005373-199503000-00027; HOLLIS S, 1995, J TRAUMA, V38, P763, DOI 10.1097/00005373-199505000-00015; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Roberts I, 1996, BRIT MED J, V313, P1239, DOI 10.1136/bmj.313.7067.1239; *ROYAL COLL SURG E, 1988, REP WORK PART MAN PA; Rutledge R, 1998, J TRAUMA, V44, P41, DOI 10.1097/00005373-199801000-00003; Wang CY, 1997, BIOMETRICS, V53, P131, DOI 10.2307/2533103; YATES DW, 1992, BRIT MED J, V305, P737, DOI 10.1136/bmj.305.6856.737; YATES DW, 1990, ABC MAJOR TRAUMA; 1993, HLTH NATION	16	122	123	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1771	1775		10.1016/S0140-6736(00)02264-9	http://dx.doi.org/10.1016/S0140-6736(00)02264-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832827				2022-12-28	WOS:000087126100011
J	Hattori, M; Fujiyama, A; Taylor, TD; Watanabe, H; Yada, T; Park, HS; Toyoda, A; Ishii, K; Totoki, Y; Choi, DK; Soeda, E; Ohki, M; Takagi, T; Sakaki, Y; Taudien, S; Blechschmidt, K; Polley, A; Menzel, U; Delabar, J; Kumpf, K; Lehmann, R; Patterson, D; Reichwald, K; Rump, A; Schillhabel, M; Schudy, A; Zimmermann, W; Rosenthal, A; Kudoh, J; Shibuya, K; Kawasaki, K; Asakawa, S; Shintani, A; Sasaki, T; Nagamine, K; Mitsuyama, S; Antonarakis, SE; Minoshima, S; Shimizu, N; Nordsiek, G; Hornischer, K; Brandt, P; Scharfe, M; Schon, O; Desario, A; Reichelt, J; Kauer, G; Blocker, H; Ramser, J; Beck, A; Klages, S; Hennig, S; Riesselmann, L; Dagand, E; Haaf, T; Wehrmeyer, S; Borzym, K; Gardiner, K; Nizetic, D; Francis, F; Lehrach, H; Reinhardt, R; Yaspo, ML; Groner, Y				Hattori, M; Fujiyama, A; Taylor, TD; Watanabe, H; Yada, T; Park, HS; Toyoda, A; Ishii, K; Totoki, Y; Choi, DK; Soeda, E; Ohki, M; Takagi, T; Sakaki, Y; Taudien, S; Blechschmidt, K; Polley, A; Menzel, U; Delabar, J; Kumpf, K; Lehmann, R; Patterson, D; Reichwald, K; Rump, A; Schillhabel, M; Schudy, A; Zimmermann, W; Rosenthal, A; Kudoh, J; Shibuya, K; Kawasaki, K; Asakawa, S; Shintani, A; Sasaki, T; Nagamine, K; Mitsuyama, S; Antonarakis, SE; Minoshima, S; Shimizu, N; Nordsiek, G; Hornischer, K; Brandt, P; Scharfe, M; Schon, O; Desario, A; Reichelt, J; Kauer, G; Blocker, H; Ramser, J; Beck, A; Klages, S; Hennig, S; Riesselmann, L; Dagand, E; Haaf, T; Wehrmeyer, S; Borzym, K; Gardiner, K; Nizetic, D; Francis, F; Lehrach, H; Reinhardt, R; Yaspo, ML; Groner, Y		Chromosome 21 mapping sequencing consortium	The DNA sequence of human chromosome 21	NATURE			English	Article							RADIATION HYBRID MAP; HUMAN GENOME; DOWN-SYNDROME; LONG ARM; PHYSICAL MAP; ALLELIC LOSS; GENE; REGION; HUMAN-CHROMOSOME-21; LINKAGE	Chromosome 21 is the smallest human autosome. An extra copy of chromosome 21 causes Down syndrome, the most frequent genetic cause of significant mental retardation, which affects up to 1 in 700 live births. Several anonymous loci for monogenic disorders and predispositions for common complex disorders have also been mapped to this chromosome, and loss of heterozygosity has been observed in regions associated with solid tumours. Here we report the sequence and gene catalogue of the long arm of chromosome 21. We have sequenced 33,546,361 base pairs (bp) of DNA with very high accuracy, the largest contig being 25,491,867 bp. Only three small clone gaps and seven sequencing gaps remain, comprising about 100 kilobases. Thus, we achieved 99.7% coverage of 21q. We also sequenced 281,116 bp from the short arm. The structural features identified include duplications that are probably involved in chromosomal abnormalities and repeat structures in the telomeric and pericentromeric regions. Analysis of the chromosome revealed 127 known genes, 98 predicted genes and 59 pseudogenes.	RIKEN, Genom Sci Ctr, Sagamihara, Kanagawa 2288555, Japan; Inst Mol Biotechnol, D-07745 Jena, Germany; Keio Univ, Sch Med, Dept Mol Biol, Tokyo 1608582, Japan; GBF German Res Ctr Biotechnol, D-38124 Braunschweig, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; RIKEN, Tsukuba Life Sci Res Ctr, Tsukuba, Ibaraki 3050074, Japan; Natl Canc Ctr, Res Inst, Canc Genom Div, Tokyo 1040045, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1088639, Japan; UFR Necker Enfants Malad, CNRS, UMR 8602, F-75730 Paris, France; Eleanor Roosevelt Inst Canc Res, Denver, CO 80206 USA; Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland; Inst Biol, CNRS, UPR 1142, F-34060 Montpellier, France; Univ London, Sch Pharm, London WC1N 1AX, England	RIKEN; Keio University; Helmholtz Association; Helmholtz-Center for Infection Research; Max Planck Society; RIKEN; National Cancer Center - Japan; University of Tokyo; Centre National de la Recherche Scientifique (CNRS); University of Geneva; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of London; University College London; University of London School of Pharmacy	Sakaki, Y (corresponding author), RIKEN, Genom Sci Ctr, Sagamihara, Kanagawa 2288555, Japan.		Nizetic, Dean/F-9509-2015; Hattori, Masahira/AAD-3785-2019; Ishii, Kazuo/N-9946-2019; Francis, Fiona/B-5854-2016; Sasaki, Takashi/AAD-1461-2019; Hattori, Masahira/C-6958-2016; Antonarakis, Stylianos E/N-8866-2014; Taylor, Todd/A-7121-2009; ishii, kazuo/K-7428-2014	Hattori, Masahira/0000-0001-9467-0344; Antonarakis, Stylianos E/0000-0001-8907-5823; Taylor, Todd/0000-0003-4247-6253; Nizetic, Dean/0000-0001-5486-5761; Rump, Andreas/0000-0001-7116-6364; Francis, Fiona/0000-0001-8542-7537; ishii, kazuo/0000-0001-7801-1891; Sasaki, Takashi/0000-0002-6275-046X; DE SARIO, Albertina/0000-0002-9997-1645; Reinhardt, Richard/0000-0001-9376-2132; Choi, Dong-Kug/0000-0001-7041-1524; Ishii, Kazuo/0000-0002-8363-8266				Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Antonarakis SE, 1998, GENOMICS, V51, P1, DOI 10.1006/geno.1998.5335; Bockmuhl U, 1998, HEAD NECK-J SCI SPEC, V20, P145, DOI 10.1002/(SICI)1097-0347(199803)20:2<145::AID-HED8>3.0.CO;2-2; BonneTamir B, 1996, AM J HUM GENET, V58, P1254; Chaib H, 1997, HUM MOL GENET, V6, P27, DOI 10.1093/hmg/6.1.27; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; DUTRIAUX A, 1994, GENOMICS, V22, P472, DOI 10.1006/geno.1994.1414; Epstein C.J., 1995, METABOLIC MOL BASES, P749; ESTABROOKS LL, 1990, AM J MED GENET, V36, P306, DOI 10.1002/ajmg.1320360312; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Gardiner K, 1995, SOMAT CELL MOLEC GEN, V21, P399, DOI 10.1007/BF02310207; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Graw SL, 1995, SOMAT CELL MOLEC GEN, V21, P415, DOI 10.1007/BF02310208; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; Hattori M, 1997, NUCLEIC ACIDS RES, V25, P1802, DOI 10.1093/nar/25.9.1802; Hildmann T, 1999, GENOME RES, V9, P360; ICHIKAWA H, 1993, NAT GENET, V4, P361, DOI 10.1038/ng0893-361; Jackson MS, 1999, HUM MOL GENET, V8, P205, DOI 10.1093/hmg/8.2.205; Kohno T, 1998, GENE CHROMOSOME CANC, V21, P236, DOI 10.1002/(SICI)1098-2264(199803)21:3<236::AID-GCC8>3.0.CO;2-0; Kola I, 1997, HUM MOL GENET, V6, P1713, DOI 10.1093/hmg/6.10.1713; Korenberg JR, 1995, GENOME RES, V5, P427, DOI 10.1101/gr.5.5.427; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LEJEUNE J, 1959, CR HEBD ACAD SCI, V248, P1721; MCINNIS MG, 1993, GENOMICS, V16, P562, DOI 10.1006/geno.1993.1231; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; NIZETIC D, 1994, HUM MOL GENET, V3, P759, DOI 10.1093/hmg/3.5.759; Ohgaki K, 1998, GENE CHROMOSOME CANC, V23, P244, DOI 10.1002/(SICI)1098-2264(199811)23:3<244::AID-GCC6>3.3.CO;2-#; Pajukanta P, 1999, AM J HUM GENET, V64, P1453, DOI 10.1086/302365; Ruault M, 1999, GENE, V239, P55, DOI 10.1016/S0378-1119(99)00381-9; SACCONE S, 1993, P NATL ACAD SCI USA, V90, P11929, DOI 10.1073/pnas.90.24.11929; Sakata K, 1997, GENE CHROMOSOME CANC, V18, P318, DOI 10.1002/(SICI)1098-2264(199704)18:4<318::AID-GCC12>3.3.CO;2-#; Satge D, 1998, CANCER RES, V58, P448; Satge D, 1998, AM J MED GENET, V78, P207, DOI 10.1002/(SICI)1096-8628(19980707)78:3<207::AID-AJMG1>3.3.CO;2-Q; Schwendel A, 1998, BRIT J CANCER, V78, P806, DOI 10.1038/bjc.1998.583; Sertie AL, 1996, HUM MOL GENET, V5, P843, DOI 10.1093/hmg/5.6.843; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; STRATENWERTH G, 1994, PSYCHIAT PRAX, V21, P3; Veske A, 1996, HUM MOL GENET, V5, P165, DOI 10.1093/hmg/5.1.165; Wan TSK, 1999, LEUKEMIA RES, V23, P1079, DOI 10.1016/S0145-2126(99)00117-4; Yamamoto N, 1999, ONCOL REP, V6, P1223; Zoubak S, 1996, GENE, V174, P95, DOI 10.1016/0378-1119(96)00393-9	46	853	1104	1	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					311	319		10.1038/35012518	http://dx.doi.org/10.1038/35012518			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830953	hybrid, Green Published			2022-12-28	WOS:000087085700037
J	Head, JF; Inouye, S; Teranishi, K; Shimomura, O				Head, JF; Inouye, S; Teranishi, K; Shimomura, O			The crystal structure of the photoprotein aequorin at 2.3 angstrom resolution	NATURE			English	Article							CALCIUM-BINDING PROTEIN; RECOMBINANT AEQUORIN; BIOLUMINESCENCE; CRYSTALLOGRAPHY; PURIFICATION; REGENERATION; IONS	Aequorin is a calcium-sensitive photoprotein originally obtained from the jellyfish Aequorea aequorea(1). Because it has a high sensitivity to calcium ions and is biologically harmless, aequorin is widely used as a probe to monitor intracellular levels of free calcium. The aequorin molecule contains four helix-loop-helix 'EF-hand' domains, of which three can bind calcium(2). The molecule also contains coelenterazine as its chromophoric ligand(3). When calcium is added, the protein complex decomposes into apoaequorin, coelenteramide and CO2, accompanied by the emission of light(4). Apoaequorin can be regenerated into active aequorin in the absence of calcium by incubation with coelenterazine, oxygen and a thiol agent(5). Cloning and expression of the complementary DNA for aequorin were first reported in 1985 (refs 2, 6), and growth of crystals of the recombinant protein has been described(7); however, techniques have only recently been developed to prepare recombinant aequorin of the highest purity(8), permitting a full crystallographic study. Here we report the structure of recombinant aequorin determined by X-ray crystallography. Aequorin is found to be a globular molecule containing a hydrophobic core cavity that accommodates the ligand coelenterazine-2-hydroperoxide. The structure shows protein components stabilizing the peroxide and suggests a mechanism by which calcium activation may occur.	Boston Univ, Sch Med, Struct Biol Grp, Dept Physiol, Boston, MA 02118 USA; Chisso Corp, Yokohama Res Ctr, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Mie Univ, Fac Bioresources, Tsu, Mie 514, Japan; Marine Biol Lab, Woods Hole, MA 02543 USA	Boston University; Chisso Corporation; Mie University; Marine Biological Laboratory - Woods Hole	Head, JF (corresponding author), Boston Univ, Sch Med, Struct Biol Grp, Dept Physiol, Boston, MA 02118 USA.	jfh@medxtal.bu.edu	Inouye, Sharon/R-7216-2019	Inouye, Satoshi/0000-0001-8732-7839; Head, James/0000-0002-6226-4146				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COOK WJ, 1993, J MOL BIOL, V229, P461, DOI 10.1006/jmbi.1993.1046; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANNICK LI, 1993, PROTEINS, V15, P103, DOI 10.1002/prot.340150113; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; INOUYE S, 1989, J BIOCHEM-TOKYO, V105, P473, DOI 10.1093/oxfordjournals.jbchem.a122689; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; MUSICKI B, 1986, J CHEM SOC CHEM COMM, V126, P1256; NOMURA M, 1991, FEBS LETT, V295, P63, DOI 10.1016/0014-5793(91)81385-L; OHMIYA Y, 1992, FEBS LETT, V301, P197, DOI 10.1016/0014-5793(92)81247-J; OHMIYA Y, 1993, FEBS LETT, V320, P267, DOI 10.1016/0014-5793(93)80600-Y; OTWINOWSKI Z, 1993, P CCP 4 STUD WEEK DA; PRASHER D, 1985, BIOCHEM BIOPH RES CO, V126, P1259, DOI 10.1016/0006-291X(85)90321-3; SHIMOMUR.O, 1973, TETRAHEDRON LETT, P2963; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; Shimomura O, 1999, PROTEIN EXPRES PURIF, V16, P91, DOI 10.1006/prep.1999.1049; Shimomura O, 1996, BIOCHEM BIOPH RES CO, V221, P77, DOI 10.1006/bbrc.1996.0548; SHIMOMURA O, 1995, BIOCHEM BIOPH RES CO, V211, P359, DOI 10.1006/bbrc.1995.1821; SHIMOMURA O, 1975, NATURE, V256, P236, DOI 10.1038/256236a0; SHIMOMURA O, 1988, BIOCHEM J, V251, P405, DOI 10.1042/bj2510405; SHIMOMURA O, 1989, BIOCHEM J, V261, P913, DOI 10.1042/bj2610913; SHIMOMURA O, 1990, BIOCHEM J, V270, P309, DOI 10.1042/bj2700309; SHIMOMURA O, 1978, P NATL ACAD SCI USA, V75, P2611, DOI 10.1073/pnas.75.6.2611; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TSUJI FI, 1986, P NATL ACAD SCI USA, V83, P8107, DOI 10.1073/pnas.83.21.8107; VIJAYKUMAR S, 1992, J MOL BIOL, V224, P413, DOI 10.1016/0022-2836(92)91004-9	29	252	282	3	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 18	2000	405	6784					372	376		10.1038/35012659	http://dx.doi.org/10.1038/35012659			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830969				2022-12-28	WOS:000087085700053
J	Briscoe, J; Pierani, A; Jessell, TM; Ericson, J				Briscoe, J; Pierani, A; Jessell, TM; Ericson, J			A homeodomain protein code specifies progenitor cell identity and neuronal fate in the ventral neural tube	CELL			English	Article							FLOOR PLATE; SPINAL-CORD; GENE-EXPRESSION; MORPHOGEN GRADIENT; HEDGEHOG; DROSOPHILA; SPECIFICATION; INDUCTION; MESODERM; BRINKER	Distinct classes of neurons are generated at defined positions in the ventral neural tube in response to a gradient of Sonic Hedgehog (Shh) activity. A set of homeodomain transcription factors expressed by neural progenitors act as intermediaries in Shh-dependent neural patterning. These homeodomain factors fall into two classes: class I proteins are repressed by Shh and class II proteins require Shh signaling for their expression. The profile of class I and class II protein expression defines five progenitor domains, each of which generates a distinct class of postmitotic neurons. Cross-repressive interactions between class I and class II proteins appear to refine and maintain these progenitor domains. The combinatorial expression of three of these proteins-Nkx6.1, Nkx2.2, and Irx3-specifies the identity of three classes of neurons generated in the ventral third of the neural tube.	Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Columbia University; Howard Hughes Medical Institute; Karolinska Institutet	Jessell, TM (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA.	tmj1@columbia.edu	Pierani, Alessandra/O-6136-2017	Pierani, Alessandra/0000-0002-4872-4791; Briscoe, James/0000-0002-1020-5240; Ericson, Johan/0000-0002-8019-7127				Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Dasen JS, 1999, CURR OPIN GENET DEV, V9, P566, DOI 10.1016/S0959-437X(99)00015-5; Ding Q, 1998, DEVELOPMENT, V125, P2533; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ericson J, 1997, COLD SPRING HARB SYM, V62, P451; Erskine L, 1998, DEV BIOL, V199, P26, DOI 10.1006/dbio.1998.8912; Funayama N, 1999, DEVELOPMENT, V126, P4129; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Huang AM, 1997, GENE DEV, V11, P1963, DOI 10.1101/gad.11.15.1963; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; KRAUT R, 1991, DEVELOPMENT, V111, P601; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; Lawrence P., 1992, MAKING FLY GENETICS; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LEBER SM, 1995, J NEUROSCI, V15, P1236; Lewis KE, 1999, DEVELOPMENT, V126, P2397; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Mansouri A, 1998, MECH DEVELOP, V78, P171, DOI 10.1016/S0925-4773(98)00168-3; MARTI E, 1995, DEVELOPMENT, V121, P2537; Matise MP, 1998, DEVELOPMENT, V125, P2759; McDowell N, 1999, SEMIN CELL DEV BIOL, V10, P311, DOI 10.1006/scdb.1999.0307; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Muramatsu T, 1997, BIOCHEM BIOPH RES CO, V230, P376, DOI 10.1006/bbrc.1996.5882; Pabst O, 1998, MECH DEVELOP, V73, P85, DOI 10.1016/S0925-4773(98)00035-5; Papin C, 2000, DEV BIOL, V217, P166, DOI 10.1006/dbio.1999.9531; Pierani A, 1999, CELL, V97, P903, DOI 10.1016/S0092-8674(00)80802-8; Qiu MS, 1998, MECH DEVELOP, V72, P77, DOI 10.1016/S0925-4773(98)00018-5; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; SMITH JC, 1995, CURR OPIN CELL BIOL, V7, P856, DOI 10.1016/0955-0674(95)80070-0; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; Wu XL, 1998, DEVELOPMENT, V125, P3765; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	48	883	903	0	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 12	2000	101	4					435	445		10.1016/S0092-8674(00)80853-3	http://dx.doi.org/10.1016/S0092-8674(00)80853-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830170	Bronze			2022-12-28	WOS:000087010400011
J	Verma, R; Deshaies, RJ				Verma, R; Deshaies, RJ			A proteasome howdunit: The case of the missing signal	CELL			English	Review							KAPPA-B-ALPHA; DEGRADATION; PROTEIN; PROTEOLYSIS; DESTRUCTION; CHAPERONE; TURNOVER; SITE		CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Deshaies, RJ (corresponding author), CALTECH, Div Biol, 156-29, Pasadena, CA 91125 USA.		Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354				Becker G, 1999, P NATL ACAD SCI USA, V96, P6439, DOI 10.1073/pnas.96.11.6439; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	19	111	115	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 12	2000	101	4					341	344		10.1016/S0092-8674(00)80843-0	http://dx.doi.org/10.1016/S0092-8674(00)80843-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830160	Bronze			2022-12-28	WOS:000087010400001
J	Alfe, D; Gillan, MJ; Price, GD				Alfe, D; Gillan, MJ; Price, GD			Constraints on the composition of the Earth's core from ab initio calculations	NATURE			English	Article							ORDER PHASE-TRANSITIONS; INNER-CORE; ENERGY CALCULATIONS; FIRST-PRINCIPLES; IRON; DIAMOND; STATE	Knowledge of the composition of the Earth's core(1-3) is important for understanding its melting point and therefore the temperature at the inner-core boundary and the temperature profile of the core and mantle. In addition, the partitioning of light elements between solid and liquid, as the outer core freezes at the inner-core boundary, is believed to drive compositional convection(4), which in turn generates the Earth's magnetic field. It is generally accepted that the liquid outer core and the solid inner core consist mainly of iron(1). The outer core, however, is also thought to contain a significant fraction of light elements, because its density-as deduced from seismological data and other measurements-is 6-10 per cent less than that estimated for pure liquid iron(1-3). Similar evidence indicates a smaller but still appreciable fraction of light elements in the inner core(5,6). The leading candidates for the light elements present in the core are sulphur, oxygen and silicon(3). Here we obtain a constraint on core composition derived from ab initio calculation of the chemical potentials of light elements dissolved in solid and liquid iron. We present results for the case of sulphur, which provide strong evidence against the proposal that the outer core is close to being a binary iron-sulphur mixture(7).	Univ London Birkbeck Coll, Res Sch Geol & Geophys Sci, London WC1E 6BT, England; UCL, Dept Phys & Astron, London WC1E 6BT, England	University of London; Birkbeck University London; University of London; University College London	Alfe, D (corresponding author), Univ London Birkbeck Coll, Res Sch Geol & Geophys Sci, Gower St, London WC1E 6BT, England.	d.alfe@ucl.ac.uk	Alfe`, Dario/C-1521-2008; Price, Geoffrey D/C-1545-2008; Gillan, Michael J/C-2130-2008	Alfe`, Dario/0000-0002-9741-8678; Price, Geoffrey D/0000-0001-8232-6853; 				AHRENS TJ, 1979, J GEOPHYS RES, V84, P985, DOI 10.1029/JB084iB03p00985; Alfe D, 2000, PHYS REV B, V61, P132, DOI 10.1103/PhysRevB.61.132; Alfe D, 1998, PHYS REV B, V58, P8248, DOI 10.1103/PhysRevB.58.8248; Alfe D, 1999, NATURE, V401, P462, DOI 10.1038/46758; Alfe D, 2000, INT J QUANTUM CHEM, V77, P871, DOI 10.1002/(SICI)1097-461X(2000)77:5<871::AID-QUA8>3.0.CO;2-3; Alfe D, 1999, PHYS EARTH PLANET IN, V110, P191, DOI 10.1016/S0031-9201(98)00134-4; ALFE D, UNPUB PHYS REV B; Atkins P. W., 1994, PHYSICAL CHEM; BIRCH F, 1964, J GEOPHYS RES, V69, P4377, DOI 10.1029/JZ069i020p04377; Boehler R, 1996, PHYS EARTH PLANET IN, V96, P181, DOI 10.1016/0031-9201(96)03150-0; Chandler D., 1987, INTRO MODERN STAT ME; de Wijs GA, 1998, PHYS REV B, V57, P8223, DOI 10.1103/PhysRevB.57.8223; FRENKEL D, 1987, UNDERSTANDING MOL SI, pCH4; GIANNOZZI P, 1991, PHYS REV B, V43, P7231, DOI 10.1103/PhysRevB.43.7231; Hammond B.L., 1994, MONTE CARLO METHODS; JEPHCOAT A, 1987, NATURE, V325, P332, DOI 10.1038/325332a0; Kent PRC, 1999, PHYS REV B, V59, P1917, DOI 10.1103/PhysRevB.59.1917; Kilburn MR, 1997, EARTH PLANET SC LETT, V152, P139, DOI 10.1016/S0012-821X(97)00125-8; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; Kresse G, 1995, EUROPHYS LETT, V32, P729, DOI 10.1209/0295-5075/32/9/005; LOPER DE, 1978, GEOPHYS J ROY ASTR S, V54, P389, DOI 10.1111/j.1365-246X.1978.tb04265.x; MASTERS TG, 1990, J GEOPHYS RES-SOLID, V95, P21691, DOI 10.1029/JB095iB13p21691; Murthy V.R., 1970, PHYS EARTH PLANET IN, V2, P276; POIRIER JP, 1994, PHYS EARTH PLANET IN, V85, P319, DOI 10.1016/0031-9201(94)90120-1; RAJAGOPAL G, 1995, PHYS REV B, V51, P10591, DOI 10.1103/PhysRevB.51.10591; RINGWOOD AE, 1977, GEOCHEM J, V11, P111, DOI 10.2343/geochemj.11.111; Stixrude L, 1997, J GEOPHYS RES-SOL EA, V102, P24729, DOI 10.1029/97JB02125; SUGINO O, 1995, PHYS REV LETT, V74, P1823, DOI 10.1103/PhysRevLett.74.1823; USSELMAN TM, 1975, AM J SCI, V275, P278, DOI 10.2475/ajs.275.3.278; Vocadlo L, 1999, GEOPHYS RES LETT, V26, P1231, DOI 10.1029/1999GL900214	30	83	83	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					172	175		10.1038/35012056	http://dx.doi.org/10.1038/35012056			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821270				2022-12-28	WOS:000087080100047
J	Griner, PF; Danoff, D				Griner, PF; Danoff, D			Sustaining change in medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Assoc Amer Med Coll, Ctr Assessment & Management Change Acad Med, Washington, DC 20037 USA; Assoc Amer Med Coll, Div Med Educ, Washington, DC 20037 USA	Association of American Medical Colleges; Association of American Medical Colleges	Griner, PF (corresponding author), Assoc Amer Med Coll, Ctr Assessment & Management Change Acad Med, 2450 N St NW, Washington, DC 20037 USA.	pfgriner@aamc.org						*AC MED MAN CAR, 2000, AC MED MAN CAR FOR J; Anderson MB, 1999, ACAD MED, V74, P561; *ASS AM MED COLL, 1998, WHAT AM SAY NAT ME 2; *ASS AM MED COLL, 1998, 1 ASS AM MED COLL; FRIEDLAND JA, 1998, C GRAD UND MED ED NE; Hunt CE, 1999, ACAD MED, V74, P289, DOI 10.1097/00001888-199903000-00022; Jones RF, 1998, JAMA-J AM MED ASSOC, V280, P813, DOI 10.1001/jama.280.9.813; Nutter DO, 2000, ACAD MED, V75, P200, DOI 10.1097/00001888-200002000-00025; Skeff KM, 1999, AM J MED, V106, P76, DOI 10.1016/S0002-9343(98)00360-X; Wilkerson L, 1998, ACAD MED, V73, P387, DOI 10.1097/00001888-199804000-00011; Wipf JE, 1999, ACAD MED, V74, P938, DOI 10.1097/00001888-199908000-00021	11	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2429	2431		10.1001/jama.283.18.2429	http://dx.doi.org/10.1001/jama.283.18.2429			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815087				2022-12-28	WOS:000086808200039
J	Carr, PL; Ash, AS; Friedman, RH; Szalacha, L; Barnett, RC; Palepu, A; Moskowitz, MM				Carr, PL; Ash, AS; Friedman, RH; Szalacha, L; Barnett, RC; Palepu, A; Moskowitz, MM			Faculty perceptions of gender discrimination and sexual harassment in academic medicine	ANNALS OF INTERNAL MEDICINE			English	Article							WOMEN; SURGERY	Background: Gender-based discrimination and sexual harassment are common in medical practice and may be even more prevalent in academic medicine. Objective: To examine the prevalence of gender-based discrimination and sexual harassment among medical school faculty and the associations of gender-based discrimination with number of publications, career satisfaction, and perceptions of career advancement. Design: A self-administered mailed questionnaire of U.S. medical school faculty that covered a broad range of topics relating to academic life. Setting: 24 randomly selected medical schools in the contiguous United States. Participants: A random sample of 3332 full-time faculty, stratified by specialty, graduation cohort, and sex. Measurements: Prevalence of self-reported experiences of discrimination and harassment, number of peer-reviewed publications, career satisfaction, and perception of career advancement. Results: Female faculty were more than 2.5 times more likely than male faculty to perceive gender-based discrimination in the academic environment (P < 0.001). Among women, rates of reported discrimination ranged from 47% for the youngest faculty to 70% for the oldest faculty. Women who reported experiencing negative gender bias had similar productivity but lower career satisfaction scores than did other women (P ( 0.001). About half of female faculty but few male faculty experienced some form of sexual harassment. These experiences were similarly prevalent across the institutions in the sample and in all regions of the United States. Female faculty who reported being sexually harassed perceived gender-specific bias in the academic environment more often than did other women (80% compared with 61%) and more often reported experiencing gender bias in professional advancement (72% compared with 47%). Publications, career satisfaction, and professional confidence were not affected by sexual harassment, and self-assessed career advancement was only marginally lower for female faculty who had experienced sexual harassment (P = 0.06). Conclusion: Despite substantial increases in the number of female faculty, reports of gender-based discrimination and sexual harassment remain common.	Harvard Univ, Boston, MA 02115 USA; Radcliffe Coll, Murray Res Ctr, Cambridge, MA 02138 USA; Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA; Massachusetts Gen Hosp, Womens Hlth Associates, Boston, MA 02114 USA	Harvard University; Boston Medical Center; Boston University; Harvard University; Massachusetts General Hospital	Carr, PL (corresponding author), Massachusetts Gen Hosp, Womens Hlth Associates, Blake 10,32 Fruit St, Boston, MA 02114 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Palepu, Anita/0000-0002-7881-4800; Friedman, Robert/0000-0002-9440-2443				*ASS AM MED COLL, 1997, FAC ROST SYST; BALDWIN DWC, 1991, WESTERN J MED, V155, P140; Capek L, 1997, PLAST RECONSTR SURG, V99, P289, DOI 10.1097/00006534-199702000-00001; Cole JR, 1991, OUTER CIRCLE WOMEN S; Commission EEO., 1980, FED REGISTER, V45, P25024; CONLEY F, 1994, J COLL SCI TEACH, V24, P17; Conley F K, 1992, JAMA, V267, P740, DOI 10.1001/jama.267.5.740; CONLEY FK, 1993, NEW ENGL J MED, V328, P351, DOI 10.1056/NEJM199302043280513; Dresler CM, 1996, ARCH SURG-CHICAGO, V131, P1128; FITZGERALD LF, 1988, J VOCAT BEHAV, V32, P152, DOI 10.1016/0001-8791(88)90012-7; Fitzgerald LF, 1993, PSYCHOL WOMEN HDB IS, P553; Frank E, 1998, ARCH INTERN MED, V158, P352, DOI 10.1001/archinte.158.4.352; Gilligan C., 1982, DIFFERENT VOICE PSYC; GORDON GH, 1992, J GEN INTERN MED, V7, P443, DOI 10.1007/BF02599165; Hostler S L, 1993, J Am Med Womens Assoc (1972), V48, P51; KOMAROMY M, 1993, NEW ENGL J MED, V328, P322, DOI 10.1056/NEJM199302043280507; LAFONTAINE E, 1986, SEX ROLES, V15, P433, DOI 10.1007/BF00287982; Lenhart S A, 1991, J Am Med Womens Assoc (1972), V46, P77; LILLEMOE KD, 1994, SURGERY, V116, P255; Lubitz R M, 1996, JAMA, V275, P414, DOI 10.1001/jama.275.5.414; Maypole D. E., 1982, J SOCIOLOGY SOCIAL W, V9, P682; MCCANN ND, 1992, HARASSED 100 WOMEN D; MCGLYNN EA, 1989, PHYSICIAN JOB SATISF; McGoldrick K E, 1992, J Am Med Womens Assoc (1972), V47, P4; PADGITT SC, 1986, J COLL STUDENT DEV, V27, P34; PHILLIPS SP, 1993, NEW ENGL J MED, V329, P1936, DOI 10.1056/NEJM199312233292607; RICHMAN JA, 1992, JAMA-J AM MED ASSOC, V267, P692, DOI 10.1001/jama.267.5.692; RIGER S, 1991, AM PSYCHOL, V46, P497, DOI 10.1037/0003-066X.46.5.497; Sandler B., 1990, INITIATIVES, V52, P5; Satterfield AT, 1997, PSYCHOL WOMEN QUART, V21, P395, DOI 10.1111/j.1471-6402.1997.tb00121.x; Schiffman M, 1995, J Am Med Womens Assoc (1972), V50, P207; TILL F, 1980, SEXUAL HARASSMET REP; WOLF TM, 1991, MED EDUC, V25, P182, DOI 10.1111/j.1365-2923.1991.tb00050.x; 1993, LANCET, V342, P627	34	194	200	1	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					889	896		10.7326/0003-4819-132-11-200006060-00007	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	319HF	10836916				2022-12-28	WOS:000087334900006
J	Gleeson, M; Herbert, A; Richards, A				Gleeson, M; Herbert, A; Richards, A			Regular review - Management of lateral neck masses in adults	BRITISH MEDICAL JOURNAL			English	Review							SQUAMOUS-CELL CARCINOMA; FINE-NEEDLE ASPIRATION; CERVICAL LYMPH-NODE; RECURRENT PLEOMORPHIC ADENOMA; COMPUTED-TOMOGRAPHY; HEAD; BIOPSY; RADIOTHERAPY; DISSECTION; SITE		Guys Hosp, Dept Otolaryngol & Skull Base Surg, London SE1 9RT, England; St Thomas Hosp, Dept Cytopathol, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Gleeson, M (corresponding author), Guys Hosp, Dept Otolaryngol & Skull Base Surg, London SE1 9RT, England.							BARAKAT M, 1987, ANN ROY COLL SURG, V69, P181; BIRCHALL MA, 1991, ANN ROY COLL SURG, V73, P91; DAWSON AK, 1989, INT J RADIAT ONCOL, V16, P819, DOI 10.1016/0360-3016(89)90501-4; Dolan RW, 1998, OTOLARYNG HEAD NECK, V119, P463, DOI 10.1016/S0194-5998(98)70102-0; EISELE DW, 1992, LARYNGOSCOPE, V102, P1328, DOI 10.1288/00005537-199212000-00002; ELLIS ER, 1991, HEAD NECK-J SCI SPEC, V13, P177, DOI 10.1002/hed.2880130303; GLUCKMAN JL, 1980, HEAD NECK SURG, V3, P90, DOI 10.1002/hed.2890030203; GOODER P, 1984, J LARYNGOL OTOL, V98, P1031, DOI 10.1017/S0022215100147942; Henriksson G, 1998, CANCER, V82, P617, DOI 10.1002/(SICI)1097-0142(19980215)82:4<617::AID-CNCR1>3.0.CO;2-I; Janot F, 1996, BRIT J CANCER, V73, P531, DOI 10.1038/bjc.1996.92; JONES AS, 1993, CANCER, V72, P1756, DOI 10.1002/1097-0142(19930901)72:5<1756::AID-CNCR2820720540>3.0.CO;2-5; LEFEBVRE JL, 1990, AM J SURG, V160, P443, DOI 10.1016/S0002-9610(05)80562-8; MACK Y, 1993, INT J RADIAT ONCOL, V25, P619, DOI 10.1016/0360-3016(93)90007-I; MAYNARD JD, 1988, BRIT J SURG, V75, P764, DOI 10.1002/bjs.1800750814; McGuirt WF, 1999, MED CLIN N AM, V83, P219, DOI 10.1016/S0025-7125(05)70098-5; MCGUIRT WF, 1978, LARYNGOSCOPE, V88, P594; Mendenhall WM, 1998, HEAD NECK-J SCI SPEC, V20, P739; Ramzy I, 1985, Diagn Cytopathol, V1, P39, DOI 10.1002/dc.2840010110; Righi PD, 1997, HEAD NECK-J SCI SPEC, V19, P604, DOI 10.1002/(SICI)1097-0347(199710)19:7<604::AID-HED7>3.3.CO;2-K; Sack MJ, 1998, ARCH OTOLARYNGOL, V124, P1155, DOI 10.1001/archotol.124.10.1155; SAMSON MJ, 1991, LARYNGOSCOPE, V101, P1060; STELL PM, 1983, CLIN ONCOL, V9, P101; WATKIN GT, 1986, BRIT J SURG, V73, P74, DOI 10.1002/bjs.1800730130; Wong WL, 1996, AM J SURG, V172, P628, DOI 10.1016/S0002-9610(96)00313-3	24	23	23	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1521	1524		10.1136/bmj.320.7248.1521	http://dx.doi.org/10.1136/bmj.320.7248.1521			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834900	Green Published			2022-12-28	WOS:000087471000032
J	Moller, LA; Lose, G; Jorgensen, T				Moller, LA; Lose, G; Jorgensen, T			Incidence and remission rates of lower urinary tract symptoms at one year in women aged 40-60: longitudinal study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INCONTINENCE; PREVALENCE; POPULATION; QUESTIONNAIRE; PATTERNS	Objectives To determine the incidence and rates of remission of lower urinary tract symptoms at one year in women aged 40-60, and to assess factors associated with remission. Design Ongoing longitudinal cohort study. Setting One rural and one urban county in Denmark. Participants 4000 women recruited on a random basis, 2860 of whom were followed up at one year. Measurements Incidence and rates of remission of lower urinary tract symptoms. Results Prevalence, incidence, and rates of remission of lower urinary tract symptoms in 2284 women were respectively 28.5% (95% confidence interval 26.7% to 30.4%), 10.0% (8.5% to 11.4%), and 27.8% (25.6% to 30.0%). Overall, symptoms were not significantly associated with events performed or initiated in the study period: medical consultation (1.6, 0.8 to 2.8), pelvic floor physiotherapy (0.9, 0.5 to 1.8), treatment with antibiotics on suspicion of a lower urinary tract infection (1.3, 0.8 to 2.2), or other treatment (1.7, 0.7 to 4.1). Many of the individual symptoms were, however, associated with seeking professional help. Conclusions Lower urinary tract symptoms constitute dynamic conditions, with women experiencing more or fewer symptoms, and eventually a cessation of symptoms. The distinction between permanent and fluctuating cases may have important clinical and scientific implications.	Univ Copenhagen, Glostrup Cty Hosp, Dept Obstet & Gynaecol, DK-2600 Glostrup, Denmark; Glostrup Cty Hosp, Ctr Prevent Med, Med Dept CF, Glostrup, Denmark	University of Copenhagen; University of Copenhagen	Moller, LA (corresponding author), Univ Copenhagen, Glostrup Cty Hosp, Dept Obstet & Gynaecol, DK-2600 Glostrup, Denmark.	LarsAM@Dadlnet.dk	Jørgensen, Torben/Z-1335-2018	Jorgensen, Torben/0000-0001-9453-2830				[Anonymous], 1990, Br J Obstet Gynaecol, V97 Suppl 6, P1; Bernstein I, 1996, Int Urogynecol J Pelvic Floor Dysfunct, V7, P37, DOI 10.1007/BF01895104; BUMP RC, 1992, AM J OBSTET GYNECOL, V167, P1213, DOI 10.1016/S0002-9378(11)91691-3; BURGIO KL, 1991, J UROLOGY, V146, P1255, DOI 10.1016/S0022-5347(17)38063-1; CAMPBELL AJ, 1985, AGE AGEING, V14, P65, DOI 10.1093/ageing/14.2.65; CREIGHTON SM, 1990, BRIT J UROL, V66, P613, DOI 10.1111/j.1464-410X.1990.tb07192.x; DIOKNO AC, 1990, UROLOGY, V36, P129, DOI 10.1016/0090-4295(90)80211-5; ELVING LB, 1989, SCAND J UROL NEPHROL, P37; HERZOG AR, 1990, J GERONTOL, V45, pM67, DOI 10.1093/geronj/45.2.M67; Holtedahl K, 1998, MATURITAS, V28, P205, DOI 10.1016/S0378-5122(97)00085-6; Holtedahl K, 1998, ACTA OBSTET GYN SCAN, V77, P671, DOI 10.1034/j.1600-0412.1998.770616.x; Jackson S, 1996, BRIT J UROL, V77, P805, DOI 10.1046/j.1464-410X.1996.00186.x; JOZWIK M, 1993, MED HYPOTHESES, V40, P381, DOI 10.1016/0306-9877(93)90225-F; MILSOM I, 1993, J UROLOGY, V149, P1459, DOI 10.1016/S0022-5347(17)36415-7; Moller LA, 2000, ACTA OBSTET GYN SCAN, V79, P298, DOI 10.1080/j.1600-0412.2000.079004298.x; MOMMSEN S, 1994, WORLD J UROL, V12, P319; Nygaard IE, 1996, J AM GERIATR SOC, V44, P1049, DOI 10.1111/j.1532-5415.1996.tb02936.x; NYGAARD IE, 1994, OBSTET GYNECOL, V84, P183; Samuelsson E, 1997, ACTA OBSTET GYN SCAN, V76, P74, DOI 10.3109/00016349709047789; SOMMER P, 1990, BRIT J UROL, V66, P12, DOI 10.1111/j.1464-410X.1990.tb14855.x; THOMAS TM, 1980, BRIT MED J, V281, P1243, DOI 10.1136/bmj.281.6250.1243; YARNELL JWG, 1981, J EPIDEMIOL COMMUN H, V35, P71, DOI 10.1136/jech.35.1.71	22	69	70	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 27	2000	320	7247					1429	1432		10.1136/bmj.320.7247.1429	http://dx.doi.org/10.1136/bmj.320.7247.1429			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827042	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000087414700020
J	Harris, B				Harris, B			Suffer the little children ...	LANCET			English	Editorial Material											Harris, B (corresponding author), Casa Allanza,apartado 1734-2050, San Pedro, Costa Rica.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1805	1805		10.1016/S0140-6736(00)02309-6	http://dx.doi.org/10.1016/S0140-6736(00)02309-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832845				2022-12-28	WOS:000087126100043
J	Collerson, KD; Hapugoda, S; Kamber, BS; Williams, Q				Collerson, KD; Hapugoda, S; Kamber, BS; Williams, Q			Rocks from the mantle transition zone: Majorite-bearing xenoliths from Malaita, southwest Pacific	SCIENCE			English	Article							ONTONG JAVA PLATEAU; EARTHS LOWER MANTLE; HIGH-PRESSURE; SOLOMON-ISLANDS; SYSTEM MGO-AL2O3-SIO2; MINERAL INCLUSIONS; GARNET PERIDOTITE; ALUMINOUS PHASE; SOLID-SOLUTION; DIAMOND	Rocks containing high-pressure mineral assemblages derived from the mantle transition zone between depths of about 400 and 670 kilometers occur as xenoliths and megacrysts on the island of Malaita in the southwest Pacific on the Ontong Java Plateau. Observed ultrahigh pressure mineral chemistries include majorite, calcium- and magnesium-perovskite, aluminous silicate phases, and microdiamond. Based on an empirical barometer, majoritic garnets in these xenoliths record pressures of up to 22 gigapascal. The occurrence of material with perovskite chemistry and several enigmatic aluminous phases indicates pressures of up to 27 gigapascal, Samples were brought to the surface at about 34 million years ago by potassic ultramafic magmas, which evidently originated in the Lower mantle.	Univ Queensland, Dept Earth Sci, Brisbane, Qld 4072, Australia; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA	University of Queensland; University of California System; University of California Santa Cruz	Collerson, KD (corresponding author), Univ Queensland, Dept Earth Sci, Brisbane, Qld 4072, Australia.	k.collerson@mailbox.uq.edu.au	Kamber, Balz S/A-1823-2008	Kamber, Balz S/0000-0002-8720-0608				AKAOGI M, 1977, PHYS EARTH PLANET IN, V15, P90, DOI 10.1016/0031-9201(77)90013-9; Akaogi M, 1999, PHYS EARTH PLANET IN, V115, P67, DOI 10.1016/S0031-9201(99)00076-X; AKAOGI M, 1979, PHYS EARTH PLANET IN, V19, P31, DOI 10.1016/0031-9201(79)90088-8; [Anonymous], 1981, GEO-MAR LETT, DOI DOI 10.1007/BF02463330; [Anonymous], 1975, PHYS CHEM EARTH; [Anonymous], 1979, 2 INT KIMB C AM GEOP; [Anonymous], [No title captured]; BASSETT WA, 1990, ANNU REV EARTH PL SC, V18, P387; BREY GP, 1990, J PETROL, V31, P1313, DOI 10.1093/petrology/31.6.1313; Brucato JR, 1999, ASTRON ASTROPHYS, V348, P1012; CANIL D, 1994, PHYS EARTH PLANET IN, V86, P25, DOI 10.1016/0031-9201(94)05059-7; DAVIES RM, 1998, P 7 INT KIMB C 13 17, V1, P148; DURBEN DJ, 1992, AM MINERAL, V77, P890; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GASPARIK T, 1984, CONTRIB MINERAL PETR, V85, P186, DOI 10.1007/BF00371708; GRAND SP, 1984, GEOPHYS J ROY ASTR S, V76, P399, DOI 10.1111/j.1365-246X.1984.tb05053.x; GURNEY JJ, 1985, T GEOL SOC S AFR, V88, P301; Haggerty SE, 1999, SCIENCE, V285, P851, DOI 10.1126/science.285.5429.851; HAGGERTY SE, 1995, J GEODYN, V20, P331, DOI 10.1016/0264-3707(95)00016-3; HAGGERTY SE, 1990, SCIENCE, V248, P993, DOI 10.1126/science.248.4958.993; HAGGERTY SE, 1994, EARTH PLANET SC LETT, V122, P57, DOI 10.1016/0012-821X(94)90051-5; Heinemann S, 1997, PHYS CHEM MINER, V24, P206, DOI 10.1007/s002690050034; Herzberg C, 1996, J GEOPHYS RES-SOL EA, V101, P8271, DOI 10.1029/96JB00170; Hirose K, 1999, NATURE, V397, P53, DOI 10.1038/16225; Hofmeister AM, 1996, AM MINERAL, V81, P418; IRIFUNE T, 1986, EARTH PLANET SC LETT, V77, P245, DOI 10.1016/0012-821X(86)90165-2; IRIFUNE T, 1993, EARTH PLANET SC LETT, V117, P101, DOI 10.1016/0012-821X(93)90120-X; IRIFUNE T, 1994, NATURE, V370, P131, DOI 10.1038/370131a0; Irifune T, 1996, PHYS EARTH PLANET IN, V96, P147, DOI 10.1016/0031-9201(96)03147-0; IRIFUNE T, 1989, GEOLOGICAL SOC AUSTR, V14, P877; KATO T, 1988, EARTH PLANET SC LETT, V89, P123, DOI 10.1016/0012-821X(88)90038-6; KESSON SE, 1989, CHEM GEOL, V78, P97, DOI 10.1016/0009-2541(89)90110-1; KESSON SE, 1994, EARTH PLANET SC LETT, V121, P261, DOI 10.1016/0012-821X(94)90071-X; KESSON SE, 1989, CHEM GEOL, V78, P83, DOI 10.1016/0009-2541(89)90109-5; Knittle E., 1987, HIGH PRESSURE MINERA, P243; KROENKE LW, 1972, HIG725 HAW I, P119; Liu LG, 1999, CONTRIB MINERAL PETR, V134, P170, DOI 10.1007/s004100050476; LIU LG, 1978, EARTH PLANET SC LETT, V41, P398, DOI 10.1016/0012-821X(78)90171-1; LIU LG, 1977, EARTH PLANET SC LETT, V36, P237, DOI 10.1016/0012-821X(77)90203-5; MADON M, 1989, J GEOPHYS RES-SOLID, V94, P15687, DOI 10.1029/JB094iB11p15687; McCammon C, 1997, SCIENCE, V278, P434, DOI 10.1126/science.278.5337.434; MOORE RO, 1985, NATURE, V318, P553, DOI 10.1038/318553a0; MOORE RO, 1986, GEOL SOC AUST ABSTR, V16, P409; Moore RO., 1989, KIMBERLITES RELATED, P1029; Neal C.R., 1997, GEOPH MONOG SERIES, V100, P183; NEAL CR, 1988, J PETROL, V29, P149, DOI 10.1093/petrology/29.1.149; NEAL CR, 1989, GEOCHIM COSMOCHIM AC, V53, P1975, DOI 10.1016/0016-7037(89)90318-9; NEAL CR, 1985, T GEOL SOC S AFR, V88, P347; Nixon P.H., 1987, MANTLE XENOLITHS; NIXON PH, 1980, MINERAL MAG, V43, P587, DOI 10.1180/minmag.1980.043.329.05; NIXON PH, 1980, NATURE, V287, P718, DOI 10.1038/287718a0; NIXON PH, 1979, MANTLE SAMPLE INCLUS, V2, P400; OMORI K, 1971, AM MINERAL, V56, P1607; Ono S, 1996, PHYS EARTH PLANET IN, V96, P171, DOI 10.1016/0031-9201(96)03149-4; OTTER ML, 1989, GEOL SOC AUSTR SPEC, V14, P1042; PERKINS D, 1981, CONTRIB MINERAL PETR, V78, P99, DOI 10.1007/BF00371147; Petterson MG, 1997, TECTONOPHYSICS, V283, P1, DOI 10.1016/S0040-1951(97)00206-0; Ringwood A.E., 1989, SPEC PUB GEOL SOC AU, V14, P457; RINGWOOD AE, 1970, EARTH PLANET SC LETT, V7, P371, DOI 10.1016/0012-821X(69)90052-1; RINGWOOD AE, 1992, EARTH PLANET SC LETT, V113, P521, DOI 10.1016/0012-821X(92)90129-J; SALISBURY JW, 1991, INFRARED 2 1 25 MICR; SAUTTER V, 1991, SCIENCE, V252, P827, DOI 10.1126/science.252.5007.827; Sharp TG, 1997, SCIENCE, V277, P352, DOI 10.1126/science.277.5324.352; Simons FJ, 1999, LITHOS, V48, P17, DOI 10.1016/S0024-4937(99)00041-9; Sobolev NV, 1997, GEOL GEOFIZ+, V38, P358; Stachel T, 1997, CONTRIB MINERAL PETR, V127, P336, DOI 10.1007/s004100050284; Stachel T, 1998, CONTRIB MINERAL PETR, V132, P34, DOI 10.1007/s004100050403; SUZUKI A, 1995, SCIENCE, V269, P216, DOI 10.1126/science.269.5221.216; van Roermund HLM, 1998, TERRA NOVA, V10, P295; Walter MJ, 1998, J PETROL, V39, P29, DOI 10.1093/petrology/39.1.29	70	82	92	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	2000	288	5469					1215	1223		10.1126/science.288.5469.1215	http://dx.doi.org/10.1126/science.288.5469.1215			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817992				2022-12-28	WOS:000087112600044
J	Kieffer, SW; Lopes-Gautier, R; McEwen, A; Smythe, W; Keszthelyi, L; Carlson, R				Kieffer, SW; Lopes-Gautier, R; McEwen, A; Smythe, W; Keszthelyi, L; Carlson, R			Prometheus: Io's wandering plume	SCIENCE			English	Article								Unlike any volcanic behavior ever observed on Earth, the plume from Prometheus on Io has wandered 75 to 95 kilometers west over the last 20 years since it was first discovered by Voyager and more recently observed by Galileo. Despite the source motion, the geometric and optical properties of the plume have remained constant. We propose that this can be explained by vaporization of a sulfur dioxide and/or sulfur "snowfield" over which a Lava flow is moving. Eruption of a boundary-layer slurry through a rootless conduit with sonic conditions at the intake of the melted snow can account for the constancy of plume properties.	SW Kieffer Sci Consulting Inc, Bolton, ON L7E 5T4, Canada; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Arizona	Kieffer, SW (corresponding author), SW Kieffer Sci Consulting Inc, 6 Queen St,Suite 206,POB 520, Bolton, ON L7E 5T4, Canada.		Lopes, Rosaly M.C./D-1608-2016	Lopes, Rosaly M.C./0000-0002-7928-3167; Kestay, Laszlo/0000-0003-1879-4331				Carslaw H.S., 1959, CONDUCTION HEAT SOLI, P88; Fisher R.V., 1968, GEOL RUNDSCH, V57, P837, DOI DOI 10.1007/BF01845368; FISHER RV, 1984, PYROCLASTIC ROCKS, P263; JAMES MR, 1998, LUNAR PLANET SCI, V29, P1349; JOHNSON TV, 1982, SATELLITES JUPITER, P637; JuradoChichay Z, 1996, B VOLCANOL, V57, P471, DOI 10.1007/BF00304433; KAMB B, 1991, J GEOPHYS RES-SOL EA, V96, P16585, DOI 10.1029/91JB00946; KIEFFER SW, 1982, SATELLITES JUPITER; Lopes-Gautier R, 2000, SCIENCE, V288, P1201, DOI 10.1126/science.288.5469.1201; McEwen AS, 2000, SCIENCE, V288, P1193, DOI 10.1126/science.288.5469.1193; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; MORRISSEY MM, 1991, EOS, V72, P566; Ozisik M.N., 1968, BOUNDARY VALUE PROBL; SMITH BA, 1979, NATURE, V280, P738, DOI 10.1038/280738a0; WILSON L, 1981, J GEOPHYS RES, V86, P2971, DOI 10.1029/JB086iB04p02971; WILSON L, 1981, LUNAR PLANET SCI, V12, P1191; WOHLETZ K, 1984, STUDIES GEOPHYSICS, pCH12; Wohletz K. H., 1986, B VOLCANOL, V48, P245, DOI [10.1007/BF01081754, DOI 10.1007/BF01081754]	18	68	69	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1204	1208		10.1126/science.288.5469.1204	http://dx.doi.org/10.1126/science.288.5469.1204			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817989				2022-12-28	WOS:000087112600041
J	Milan, D; Jeon, JT; Looft, C; Amarger, V; Robic, A; Thelander, M; Rogel-Gaillard, C; Paul, S; Iannuccelli, N; Rask, L; Ronne, H; Lundstrom, K; Reinsch, N; Gellin, J; Kalm, E; Le Roy, P; Chardon, P; Andersson, L				Milan, D; Jeon, JT; Looft, C; Amarger, V; Robic, A; Thelander, M; Rogel-Gaillard, C; Paul, S; Iannuccelli, N; Rask, L; Ronne, H; Lundstrom, K; Reinsch, N; Gellin, J; Kalm, E; Le Roy, P; Chardon, P; Andersson, L			A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; MEAT QUALITY; GENE; CHROMOSOME-15; ALIGNMENT; TOOL	A high proportion of purebred Hampshire pigs carries the dominant RN- mutation, which causes high glycogen content in skeletal muscle. The mutation has beneficial effects on meat content but detrimental effects on processing yield. Here, it is shown that the mutation is a nonconservative substitution (R200Q) in the PRKAG3 gene, which encodes a muscle-specific isoform of the regulatory gamma subunit of adenosine monophosphate-activated protein kinase (AMPK). Loss-of-function mutations in the homologous gene in yeast (SNF4) cause defects in glucose metabolism, including glycogen storage. Further analysis of the PRKAG3 signaling pathway may provide insights into muscle physiology as well as the pathogenesis of noninsulin-dependent diabetes mellitus in humans, a metabolic disorder associated with impaired glycogen synthesis.	Swedish Univ Agr Sci, Dept Anim Breeding & Genet, SE-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Plant Biol, SE-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Food Sci, SE-75124 Uppsala, Sweden; INRA, Lab Genet Cellulaire, F-31326 Castanet Tolosan, France; Univ Kiel, Inst Anim Breeding & Husb, D-24098 Kiel, Germany; INRA, Genet Quantitat & Appl Stn, F-78352 Jouy En Josas, France; Univ Uppsala, Dept Med Biochem & Microbiol, SE-75223 Uppsala, Sweden	Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences; INRAE; University of Kiel; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Uppsala University	Andersson, L (corresponding author), Swedish Univ Agr Sci, Dept Anim Breeding & Genet, Box 597, SE-75124 Uppsala, Sweden.		Rask, Lars B/L-4177-2013; robic, annie/AAM-6932-2021	Ronne, Hans/0000-0002-1645-6091; robic, annie/0000-0003-3071-8614; ROGEL-GAILLARD, Claire/0000-0002-2174-1962; Amarger, Valerie/0000-0001-9258-6675				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Enfalt AC, 1997, LIVEST PROD SCI, V47, P221, DOI 10.1016/S0301-6226(96)01409-1; ESTRADE M, 1993, COMP BIOCHEM PHYS B, V104, P321, DOI 10.1016/0305-0491(93)90375-F; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Green P., 1990, DOCUMENTATION CRIMAP; Greiwe JS, 1999, J APPL PHYSIOL, V87, P222, DOI 10.1152/jappl.1999.87.1.222; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kluijtmans LAJ, 1996, J CLIN INVEST, V98, P285, DOI 10.1172/JCI118791; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; LEROY P, 1990, GENET RES, V55, P33, DOI 10.1017/S0016672300025179; Looft C, 1996, GENET SEL EVOL, V28, P437, DOI 10.1051/gse:19960503; Mariani P, 1996, MAMM GENOME, V7, P52, DOI 10.1007/s003359900012; MILAN D, 1996, MAMM GENOME, V7, P45; Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363; Sun HFS, 1999, CYTOGENET CELL GENET, V85, P273, DOI 10.1159/000015312; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yerle M, 1998, CYTOGENET CELL GENET, V82, P182, DOI 10.1159/000015095	29	578	639	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1248	1251		10.1126/science.288.5469.1248	http://dx.doi.org/10.1126/science.288.5469.1248			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10818001				2022-12-28	WOS:000087112600053
J	Montrasio, F; Frigg, R; Glatzel, M; Klein, MA; Mackay, F; Aguzzi, A; Weissmann, C				Montrasio, F; Frigg, R; Glatzel, M; Klein, MA; Mackay, F; Aguzzi, A; Weissmann, C			Impaired prion replication in spleens of mice lacking functional follicular dendritic cells	SCIENCE			English	Article							CREUTZFELDT-JAKOB-DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; SCRAPIE-INFECTED MICE; BETA-DEFICIENT MICE; LYMPHOTOXIN-BETA; MOUSE SPLEEN; AGENT REPLICATION; INCUBATION PERIOD; DISTINCT ROLES; BONE-MARROW	In scrapie-infected mice, prions are found associated with splenic but not circulating B and T lymphocytes and in the stroma, which contains follicular dendritic cells (FDCs), Formation and maintenance of mature FDCs require the presence of B cells expressing membrane-bound Lymphotoxin-alpha/beta. Treatment of mice with soluble lymphotoxin-beta receptor results in the disappearance of mature FDCs from the spleen. We show that this treatment abolishes splenic prion accumulation and retards neuroinvasion after intraperitoneal scrapie inoculation. These data provide evidence that FDCs are the principal sites for prion replication in the spleen.	Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, MRC, Prion Unit, London W2 1PG, England; Biogen Inc, Cambridge Ctr 14, Cambridge, MA 02142 USA; Univ Zurich, Dept Pathol, Inst Neuropathol, CH-8091 Zurich, Switzerland	Imperial College London; Biogen; University of Zurich	Weissmann, C (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, MRC, Prion Unit, Norfolk Pl, London W2 1PG, England.		Glatzel, Markus/G-3356-2011; Aguzzi, Adriano/A-3351-2008; Mackay, Fabienne/B-7440-2008; Glatzel, Markus/V-8844-2019	Glatzel, Markus/0000-0002-7720-8817; Mackay, Fabienne/0000-0002-6074-2693; Glatzel, Markus/0000-0002-7720-8817; Montrasio, Fabio/0000-0002-6069-1937; Aguzzi, Adriano/0000-0002-0344-6708				Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; Beekes M, 1998, J GEN VIROL, V79, P601, DOI 10.1099/0022-1317-79-3-601; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown KL, 1997, J GEN VIROL, V78, P2707, DOI 10.1099/0022-1317-78-10-2707; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; BRUCE ME, 1985, J GEN VIROL, V66, P2517, DOI 10.1099/0022-1317-66-12-2517; BUELER H, 1994, MOL MED, V1, P19; CLARKE MC, 1971, RES VET SCI, V12, P195; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; FRASER H, 1987, VET MICROBIOL, V13, P211, DOI 10.1016/0378-1135(87)90084-8; FRASER H, 1989, PROG CLIN BIOL RES, V317, P63; Gonzalez M, 1998, J EXP MED, V187, P997, DOI 10.1084/jem.187.7.997; Grathwohl KUD, 1996, ARCH VIROL, V141, P1863, DOI 10.1007/BF01718200; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; KIMBERLIN RH, 1989, VIRUS RES, V12, P213, DOI 10.1016/0168-1702(89)90040-3; KIMBERLIN RH, 1989, VIRUS RES, V12, P201, DOI 10.1016/0168-1702(89)90039-7; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KOSCOVILBOIS M, COMMUNICATION; Lasmezas CI, 1996, J VIROL, V70, P1292; Mackay F, 1997, EUR J IMMUNOL, V27, P2033, DOI 10.1002/eji.1830270830; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Matsumoto M, 1997, J EXP MED, V186, P1997, DOI 10.1084/jem.186.12.1997; MCBRIDE PA, 1992, J PATHOL, V168, P413, DOI 10.1002/path.1711680412; MONTRASIO F, UNPUB; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; OROURKE KI, 1994, J GEN VIROL, V75, P1511, DOI 10.1099/0022-1317-75-6-1511; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; QU W, 1999, J EXP MED, V190, P629; RACE RE, 1992, J GEN VIROL, V73, P3319, DOI 10.1099/0022-1317-73-12-3319; Raeber AJ, 1999, EMBO J, V18, P2702, DOI 10.1093/emboj/18.10.2702; RUBENSTEIN R, 1991, J INFECT DIS, V164, P29, DOI 10.1093/infdis/164.1.29; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H	41	293	299	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1257	1259		10.1126/science.288.5469.1257	http://dx.doi.org/10.1126/science.288.5469.1257			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10818004				2022-12-28	WOS:000087112600056
J	Tilman, D				Tilman, D			Causes, consequences and ethics of biodiversity	NATURE			English	Article							STATISTICAL INEVITABILITY; GRASSLAND ECOSYSTEMS; PLANT DIVERSITY; PRODUCTIVITY; STABILITY	The existence of so great a diversity of species on Earth remains a mystery, the solution to which may also explain why and how biodiversity influences the functioning of ecosystems. The answer may lie in quantifying the trade-offs that organisms face in dealing with the constraints of their environment. Societal responses to the loss of biodiversity also involve trade-offs, and the elaboration of these will be essential in developing wiser environmental ethics and policy.	Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Tilman, D (corresponding author), Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA.	tilman@lter.umn.edu	Tilman, David/ABD-5309-2021					Aarssen LW, 1997, OIKOS, V80, P183, DOI 10.2307/3546531; [Anonymous], 1861, ORIGIN SPECIES MEANS; ARMSTRONG RA, 1980, AM NAT, V115, P151, DOI 10.1086/283553; Daily GC, 1997, NATURES SERVICES SOC, DOI DOI 10.12987/9780300188479-039; Doak DF, 1998, AM NAT, V151, P264, DOI 10.1086/286117; Elton C. S., 1958, ECOLOGY INVASIONS AN; Fehr WR, 1984, GENETIC CONTRIBUTION, V7; HASTINGS A, 1980, THEOR POPUL BIOL, V18, P363, DOI 10.1016/0040-5809(80)90059-3; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; Huisman J, 1999, NATURE, V402, P407, DOI 10.1038/46540; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; Loreau M, 1998, P NATL ACAD SCI USA, V95, P5632, DOI 10.1073/pnas.95.10.5632; Maddison A., 1995, MONITORING WORLD EC; McGradySteed J, 1997, NATURE, V390, P162, DOI 10.1038/36561; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; ROELFS AP, 1988, ANNU REV PHYTOPATHOL, V26, P351, DOI 10.1146/annurev.py.26.090188.002031; Schulze E.D., 1993, BIODIVERSITY ECOSYST; Tilman D, 1998, AM NAT, V151, P277, DOI 10.1086/286118; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Tilman D., 1982, Monographs in Population Biology, pi; Tilman D, 1999, ECOLOGY, V80, P1455, DOI 10.1890/0012-9658(1999)080[1455:TECOCI]2.0.CO;2; Tilman D, 1997, P NATL ACAD SCI USA, V94, P1857, DOI 10.1073/pnas.94.5.1857; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; Tilman D, 1996, ECOLOGY, V77, P350, DOI 10.2307/2265614; TILMAN D, 1994, NATURE, V367, P363, DOI 10.1038/367363a0; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494	26	321	439	11	210	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					208	211		10.1038/35012217	http://dx.doi.org/10.1038/35012217			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821280				2022-12-28	WOS:000087080100057
J	Kasiske, BL; Cohen, D; Lucey, MR; Neylan, JF				Kasiske, BL; Cohen, D; Lucey, MR; Neylan, JF		Amer Soc Transplantation	Payment for immunosuppression after organ transplantation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Conference of the American-Society-of-Transplantation-Immunosuppression	DEC   04, 1998	PHILADELPHIA, PENNSYLVANIA	Amer Soc Transplantat Immunosuppress			RENAL-TRANSPLANT; NONCOMPLIANCE; CYCLOSPORINE; RECIPIENTS; THERAPY	Dramatic improvements in organ transplantation have meant that a growing number of patients must take expensive immunosuppressive medications for the rest of their lives, Currently, Medicare covers most transplantation procedures in the United States, but ends coverage for outpatient immunosuppressive medications after 36 months. Evidence suggests that at least some patients have reduced immunosuppression and their transplants fail because they cannot afford these medication costs, In the years since the advent of effective immunosuppressive therapy, the US Congress has struggled with this issue, and in 1999 temporarily extended medication coverage for eligible patients (based on age and disability) by 8 months, However, a more permanent solution is needed. We advocate that Medicare should cover the cost of all immunosuppressive therapy for all solid organ transplant recipients who cannot afford to pay, A number of potentially cost-effective approaches could be taken, but, in any case, something must be done to ensure that transplants do not fail because recipients cannot pay for immunosuppression.	Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA; Columbia Presbyterian Med Ctr, Dept Med, New York, NY 10032 USA; Univ Penn, Div Gastroenterol, Philadelphia, PA USA; Emory Univ, Sch Med, Div Nephrol, Atlanta, GA USA	Hennepin County Medical Center; Columbia University; NewYork-Presbyterian Hospital; University of Pennsylvania; Emory University	Kasiske, BL (corresponding author), Amer Soc Transplantat, 236 Route 38 W,Suite 100, Moorestown, NJ 08057 USA.		Lucey, Michael/AAR-4571-2020					BERGMANN LS, 1993, TRANSPLANT P, V25, P1340; BUTKUS DE, 1992, NEW ENGL J MED, V327, P840, DOI 10.1056/NEJM199209173271203; DEGEEST S, 1995, TRANSPLANTATION, V59, P340; DIDLAKE RH, 1988, TRANSPLANT P, V20, P63; DUNN J, 1990, TRANSPLANTATION, V49, P349, DOI 10.1097/00007890-199002000-00024; EGGERS P, 1992, SEMIN NEPHROL, V12, P284; FIELD MJ, 1999, EXTENDING MED COVERA; FRAZIER PA, 1994, CLIN TRANSPLANT, V8, P550; Gaston RS, 1999, TRANSPLANT P, V31, p21S, DOI 10.1016/S0041-1345(99)00118-9; Greenstein S, 1998, TRANSPLANTATION, V66, P1718, DOI 10.1097/00007890-199812270-00026; HILBRANDS LB, 1995, TRANSPLANTATION, V60, P914, DOI 10.1097/00007890-199511150-00006; KILEY DJ, 1993, TRANSPLANTATION, V55, P51, DOI 10.1097/00007890-199301000-00010; OWENS ML, 1975, ARCH SURG-CHICAGO, V110, P1450; RETTIG RA, 1991, KIDNEY FAILURE FEDER, P191; ROVELLI M, 1989, TRANSPLANT P, V21, P3979; Sanders CE, 1996, AM J KIDNEY DIS, V28, P572, DOI 10.1016/S0272-6386(96)90469-2; SANDERS CE, 1993, AM J KIDNEY DIS, V21, P9, DOI 10.1016/S0272-6386(12)80713-X; SCHWEIZER RT, 1990, TRANSPLANTATION, V49, P374, DOI 10.1097/00007890-199002000-00029; SKETRIS I, 1994, TRANSPLANT P, V26, P2538; Soumerai SB, 1999, NEW ENGL J MED, V340, P722, DOI 10.1056/NEJM199903043400909; *TASK FORC ORG TRA, 1986, ORG TRANSPL ISS REC, P99; UEHLING DT, 1976, SURGERY, V79, P278; WOODWARD RS, IN PRESS J AM SOC NE; ZOLLER KM, 1980, KIDNEY INT, V18, P110, DOI 10.1038/ki.1980.116	24	77	77	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2445	2450		10.1001/jama.283.18.2445	http://dx.doi.org/10.1001/jama.283.18.2445			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815094				2022-12-28	WOS:000086808200046
J	Pharoah, POD; Adi, Y				Pharoah, POD; Adi, Y			Consequences of in-utero death in a twin pregnancy	LANCET			English	Article							SPASTIC CEREBRAL-PALSY; INTRAUTERINE DEATH; MONOZYGOTIC TWINS; FETUS PAPYRACEUS; MULTIPLE BIRTHS; VANISHING TWIN; BRAIN-DAMAGE; MORTALITY; COTWIN; HYPOTHESIS	Background Twins have a higher mortality and morbidity than singletons and, among twins, the surviving co-twin of a fetus that dies in utero is particularly at risk. We did a cohort study to quantify mortality and serious morbidity in co-twin survivors of fetuses that died in utero. Methods We collected data of all registered twin births in England and Wales between 1993 and 1995 in which one twin was registered as having died in utero. Copies of all death certificates of these fetuses and death certificates of live-born co-twins of fetuses that died in utero were obtained from the Office for National Statistics. A questionnaire was sent to the general practitioners of all surviving co-twins to find out if the child had any disability. Findings There were 434 fetal death/live-birth same-sex twin pairs. Among the live births, there were 59 neonatal deaths, seven postneonatal deaths (first 28 days), and five infant deaths (<1 year). In three of the five deaths, the cause of death was cerebral palsy. Ten of the children who survived infancy were lost. to follow up. Responses were received from general practitioners for 241 of 353 survivors (68% response). Of the 241 respondents, 23 had cerebral palsy and 28 had other cerebral impairment. Among the children who survived to infancy, the prevalence of cerebral palsy was 106 (95% CI 70-150) per 1000 and prevalence of other cerebral impairment was 114 (80-160) per 1000. There were 163 fetal death/live-birth different-sex twin pairs. Of the live births, 13 died in the neonatal period and four were lost to follow up. Of the 146 survivors, responses were received from the general practitioners for 102 (70% response). Three of the 102 had cerebral palsy and 12 had other cerebral impairment. The prevalence of cerebral palsy was 29 (95% CI 6-83) per 1000 and of other cerebral impairment 118 (62-196) per 1000 infant survivors. Interpretation The live-birth cc-twin of a fetus that died in utero is at increased risk of cerebral impairment, the overall risk is 20% (95% CI 16-25). The gestational-age-specific prevalence of cerebral palsy after fetal death of the co-twin is much higher than that reported for the general twin population.	Univ Liverpool, Dept Publ Hlth, Fdn Study Infant Death, Unit Perinatal & Paediat Epidemiol, Liverpool L69 3GB, Merseyside, England	University of Liverpool	Pharoah, POD (corresponding author), Univ Liverpool, Dept Publ Hlth, Fdn Study Infant Death, Unit Perinatal & Paediat Epidemiol, Muspratt Bldg, Liverpool L69 3GB, Merseyside, England.		Adi, Yaser A/S-5100-2016	Adi, Yaser A/0000-0002-3989-2873				ANDERSON RL, 1990, PRENATAL DIAG, V10, P513, DOI 10.1002/pd.1970100806; Baldwin VJ, 1993, PATHOLOGY MULTIPLE P; BEJAR R, 1990, AM J OBSTET GYNECOL, V162, P1230, DOI 10.1016/0002-9378(90)90024-2; BENSON CB, 1994, RADIOLOGY, V192, P765, DOI 10.1148/radiology.192.3.8058944; Blickstein I, 1998, DEV MED CHILD NEUROL, V40, P358; BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; BURN J, 1988, TWINNING TWINS; ELLIS RF, 1979, ACTA GENET MED GEMEL, V28, P347, DOI 10.1017/S0001566000008904; ENBOM JA, 1985, AM J OBSTET GYNECOL, V152, P424, DOI 10.1016/S0002-9378(85)80152-6; FUSI L, 1990, BRIT J OBSTET GYNAEC, V97, P511, DOI 10.1111/j.1471-0528.1990.tb02521.x; GRETHER JK, 1993, PEDIATRICS, V92, P854; HAGAY ZJ, 1986, J REPROD MED, V8, P717; Heys RF, 1996, BRIT MED J, V313, P1004; ISHIMATSU J, 1994, J MATERN-FETAL INVES, V4, P141; JUNG JH, 1984, PEDIATRICS, V73, P467; KELSEY JL, 1986, METHODS OBSERVATIONA; LARROCHE JC, 1990, BIOL NEONATE, V57, P261; MELNICK M, 1977, LANCET, V2, P1287; MOORE CM, 1969, J PEDIATR, V74, P523, DOI 10.1016/S0022-3476(69)80034-X; MYRIANTHOPOULOS N C, 1970, American Journal of Human Genetics, V22, P611; NYLANDER PPS, 1979, ACTA GENET MED GEMEL, V28, P363, DOI 10.1017/S000156600000893X; Pharoah POD, 1997, DEV MED CHILD NEUROL, V39, P292; Pharoah POD, 1998, ARCH DIS CHILD-FETAL, V79, pF21, DOI 10.1136/fn.79.1.F21; Pharoah POD, 1996, ARCH DIS CHILD-FETAL, V75, pF174, DOI 10.1136/fn.75.3.F174; Pharoah POD, 1997, BRIT MED J, V314, P441, DOI 10.1136/bmj.314.7078.441a; POTTER EL, 1963, AM J OBSTET GYNECOL, V87, P566, DOI 10.1016/0002-9378(63)90050-4; RYDHSTROM H, 1993, J REPROD MED, V38, P142; SCHINZEL AAGL, 1979, J PEDIATR-US, V95, P921, DOI 10.1016/S0022-3476(79)80278-4; Sebire NJ, 1997, BRIT J OBSTET GYNAEC, V104, P1203, DOI 10.1111/j.1471-0528.1997.tb10948.x; SZYMONOWICZ W, 1986, ARCH DIS CHILD, V61, P454, DOI 10.1136/adc.61.5.454; VanBogaert P, 1996, DEV MED CHILD NEUROL, V38, P166; Weig SG, 1995, PEDIATR NEUROL, V13, P279, DOI 10.1016/0887-8994(95)00219-7; West CR, 1999, ARCH DIS CHILD-FETAL, V80, pF217, DOI 10.1136/fn.80.3.F217; Williams K, 1996, ARCH DIS CHILD-FETAL, V75, pF178, DOI 10.1136/fn.75.3.F178; YOSHIDA K, 1986, ACTA GENET MED GEMEL, V35, P91, DOI 10.1017/S0001566000006292	35	146	154	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 6	2000	355	9215					1597	1602		10.1016/S0140-6736(00)02215-7	http://dx.doi.org/10.1016/S0140-6736(00)02215-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821363				2022-12-28	WOS:000086981200010
J	James, P; Ellis, CJ; Whitlock, RML; McNeil, AR; Henley, J; Anderson, NE				James, P; Ellis, CJ; Whitlock, RML; McNeil, AR; Henley, J; Anderson, NE			Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study	BRITISH MEDICAL JOURNAL			English	Article							SERUM	Objective To assess whether a raised serum troponin T concentration would be an independent predictor of death in patients with an acute ischaemic stroke. Design Observational study. Setting Auckland Hospital, Auckland, New Zealand. Subjects All 181 patients with an acute ischaemic stroke admitted over nine months in 1997-8, from a total of 8057 patients admitted to the acute medical service. Main outcome measures Blood samples for measuring troponin T concentration were collected 12-72 hours after admission; other variables previously associated with severity of stroke were also recorded and assessed as independent predictors of inpatient mortality: Results Troponin T concentration was raised(>0.1 mu g/l) in 17% (30) of patients admitted with an acute ischaemic stroke. Thirty one patients died in hospital (12/30 (40%,) patients with a raised troponin T concentration v 19/151 (13%) patients with a normal concentration (relative risk 3.2 (95% confidence 1.7 to 5.8: p = 0.0025)). Of 17 possible predictors of death, assessed in a multivariate stepwise model, only a raised troponin T concentration (P = 0.0002), age (P = 0.0008), and an altered let:ei of consciousness at presentation (P = 0.0074) independently predicted an adverse outcome. Conclusions Serum troponin T concentration at hospital admission is a powerful predictor of mortality in patients admitted with an acute ischaemic stroke.	Auckland Hosp, Dept Gen Med, Auckland 1001, New Zealand; Auckland Hosp, Dept Med, Auckland 1001, New Zealand; Green Lane Hosp, Dept Physiol, Auckland 1003, New Zealand; Auckland Hosp, Dept Chem Pathol, Auckland 1001, New Zealand	Auckland City Hospital; Auckland City Hospital; Auckland City Hospital	Ellis, CJ (corresponding author), Auckland Hosp, Dept Med, 4th Floor, Auckland 1001, New Zealand.		James, Paul/G-2943-2014	James, Paul/0000-0002-4361-4657				Anderson NE, 1997, AUST NZ J MED, V27, P561, DOI 10.1111/j.1445-5994.1997.tb00965.x; ASPLUND K, 1985, STROKE, V16, P885; BONITA R, 1993, LANCET, V341, P1510, DOI 10.1016/0140-6736(93)90640-3; Brickner ME, 1996, AM J MED, V100, P465; Christenson RH, 1998, CLIN CHEM, V44, P494; Donnelly R, 1998, LANCET, V351, P537, DOI 10.1016/S0140-6736(05)78549-4; McNeil AR, 1998, CLIN CHEM, V44, P2377; MYERS MG, 1981, STROKE, V12, P200, DOI 10.1161/01.STR.12.2.200; MYERS MG, 1982, STROKE, V13, P838, DOI 10.1161/01.STR.13.6.838; NORRIS JW, 1979, STROKE, V10, P548, DOI 10.1161/01.STR.10.5.548; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; SAMUELS MA, 1993, NEUROL CLIN, V11, P273, DOI 10.1016/S0733-8619(18)30153-1; Saver JL, 1999, STROKE, V30, P293, DOI 10.1161/01.STR.30.2.293; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303	14	156	161	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1502	1504		10.1136/bmj.320.7248.1502	http://dx.doi.org/10.1136/bmj.320.7248.1502			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834890	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000087471000020
J	Ichimura, K; Oh, SK; Nakagawa, M				Ichimura, K; Oh, SK; Nakagawa, M			Light-driven motion of liquids on a photoresponsive surface	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; MACROCYCLIC AMPHIPHILES; ORGANIC-SURFACES; AZOBENZENE; CALIX<4>RESORCINARENES; GRADIENTS; INTERFACE	The macroscopic motion of Liquids an a flat solid surface was manipulated reversibly by photoirradiation of a photoisomerizable monolayer covering the surface. When a liquid droplet several millimeters in diameter was placed on a substrate surface modified with a calix[4]resorcinarene derivative having photochromic azobenzene units, asymmetrical photoirradiation caused a gradient in surface free energy due to the photoisomerization of surface azobenzenes, leading to the directional motion of the droplet. The direction and velocity of the motion were tunable by varying the direction and steepness of the gradient in Light intensity. The light-driven motion of a fluid substance in a surface-modified glass tube suggests potential applicability to microscale chemical process systems.	Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Ichimura, K (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.		Nakagawa, Masaru/AAE-2820-2019					BAIN CD, 1989, ANGEW CHEM INT EDIT, V28, P506, DOI 10.1002/anie.198905061; BROCHARD F, 1989, LANGMUIR, V5, P432, DOI 10.1021/la00086a025; CARTER SB, 1965, NATURE, V208, P1183, DOI 10.1038/2081183a0; CARTER SB, 1967, NATURE, V213, P256, DOI 10.1038/213256a0; CAZABAT AM, 1990, NATURE, V346, P824, DOI 10.1038/346824a0; CHAUDHURY MK, 1992, SCIENCE, V256, P1539, DOI 10.1126/science.256.5063.1539; CHEN YL, 1991, J PHYS CHEM-US, V95, P10736, DOI 10.1021/j100179a041; Fujimaki M, 1998, LANGMUIR, V14, P4495, DOI 10.1021/la971257m; Gallardo BS, 1999, SCIENCE, V283, P57, DOI 10.1126/science.283.5398.57; Grunze M, 1999, SCIENCE, V283, P41, DOI 10.1126/science.283.5398.41; ICHIMURA K, 1988, LANGMUIR, V4, P1214, DOI 10.1021/la00083a030; ICHIMURA K, IN PRESS CHEM REV; Kurita E, 1998, J MATER CHEM, V8, P397, DOI 10.1039/a704163b; Moller G, 1998, LANGMUIR, V14, P4955, DOI 10.1021/la980400o; Oh SK, 1999, CHEM LETT, P349; OH SP, UNPUB; PANAIOTOV I, 1991, MACROMOLECULES, V24, P4250, DOI 10.1021/ma00015a004; Seki T, 1998, J PHYS CHEM B, V102, P5313, DOI 10.1021/jp9812839; Shin JY, 1999, LANGMUIR, V15, P4404, DOI 10.1021/la981477f; Siewierski LM, 1996, LANGMUIR, V12, P5838, DOI 10.1021/la960506o; UEDA M, 1994, J MATER CHEM, V4, P883, DOI 10.1039/jm9940400883; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013	22	1212	1260	29	630	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1624	1626		10.1126/science.288.5471.1624	http://dx.doi.org/10.1126/science.288.5471.1624			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834837				2022-12-28	WOS:000087382300035
J	Kim, TK; Ebright, RH; Reinberg, D				Kim, TK; Ebright, RH; Reinberg, D			Mechanism of ATP-dependent promoter melting by transcription factor IIH	SCIENCE			English	Article							RNA-POLYMERASE-II; MAJOR LATE PROMOTER; TERMINAL-DOMAIN; BASAL TRANSCRIPTION; COMPLEX-FORMATION; CRYSTAL-STRUCTURE; DNA; TFIIH; INITIATION; HELICASE	We show that transcription factor IIH ERCC3 subunit, the DNA helicase responsible for adenosine triphosphate (ATP)-dependent promoter melting during transcription initiation, does not interact with the promoter region that undergoes melting but instead interacts with DNA downstream of this region. We show further that promoter melting does not change protein-DNA interactions upstream of the region that undergoes melting but does change interactions within and downstream of this region. Our results rule out the proposal that IIH functions in promoter melting through a conventional DNA-helicase mechanism. We propose that IIH functions as a molecular wrench: rotating downstream DNA relative to fixed upstream protein-DNA interactions, thereby generating torque on, and melting, the intervening DNA.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Howard Hughes Med Inst,Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA; Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Waksman Inst, Dept Chem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Howard Hughes Med Inst,Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA.		Kim, Tae-Kyung/AAX-4230-2020; Ebright, Richard/O-3321-2019	Kim, Tae-Kyung/0000-0001-5161-9864; Ebright, Richard/0000-0001-8915-7140; Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037120, R01GM037120] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53665, GM37120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Coin F, 1998, COLD SPRING HARB SYM, V63, P105, DOI 10.1101/sqb.1998.63.105; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, J BIOL CHEM, V272, P28175, DOI 10.1074/jbc.272.45.28175; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; JIANG Y, 1995, J BIOL CHEM, V270, P1277, DOI 10.1074/jbc.270.3.1277; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIM TK, IN PRESS PROTEIN DNA; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LeRoy G, 1998, J BIOL CHEM, V273, P7134, DOI 10.1074/jbc.273.12.7134; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MALODONADO E, 1996, METHOD ENZYMOL, V274, P72; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; ROY R, 1994, J BIOL CHEM, V269, P9826; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	35	206	212	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 26	2000	288	5470					1418	1421		10.1126/science.288.5470.1418	http://dx.doi.org/10.1126/science.288.5470.1418			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827951				2022-12-28	WOS:000087270900049
J	Roila, F; Ballatori, E; Ruggeri, B; De Angelis, V; Tonato, M; Bosnjak, S; Del Favero, A; Ciccarese, G; Basurto, C; Ciccarese, G; Palladino, MA; Porozzi, S; Marinkovic, Z; Neskovic-Konstantinovic, Z; Susnjar, S; Vasovic, S; Colakovic, S; Lukic, V; Radosavljevic, D; Fava, S; Grimi, E; Calcagno, A; De Paoli, A; Luoni, M; Tocci, A; Nuzzo, A; Laudadio, L; Di Blasio, A; Sacco, M; Contu, A; Olmeo, N; Pazzola, A; Baldino, G; Picece, V; Nicodemo, M; Cirillo, M; Recaldin, E; Dazzi, C; Cariello, A; Giovanis, P; Zumaglini, F; Rosati, G; Manzione, L; Bilancia, D; Rossi, A; Donati, D; Maccaferri, R; Malacarne, P; Labianca, R; Quadri, A; Pessi, MA; Cortesi, E; Martelli, O; Giuliodori, L; Silva, RR; Mari, D; Massidda, B; Ionta, MT; Alessandroni, P; Baldelli, A; Antimi, M; Minelli, M; Gridelli, C; Rossi, A; Passalacqua, R; Quarta, M; Sassi, M; Pinaglia, D; De Marino, E; Giampaolo, MA; Ciancola, F; Lalli, A; Di Felice, S; Casartelli, C				Roila, F; Ballatori, E; Ruggeri, B; De Angelis, V; Tonato, M; Bosnjak, S; Del Favero, A; Ciccarese, G; Basurto, C; Ciccarese, G; Palladino, MA; Porozzi, S; Marinkovic, Z; Neskovic-Konstantinovic, Z; Susnjar, S; Vasovic, S; Colakovic, S; Lukic, V; Radosavljevic, D; Fava, S; Grimi, E; Calcagno, A; De Paoli, A; Luoni, M; Tocci, A; Nuzzo, A; Laudadio, L; Di Blasio, A; Sacco, M; Contu, A; Olmeo, N; Pazzola, A; Baldino, G; Picece, V; Nicodemo, M; Cirillo, M; Recaldin, E; Dazzi, C; Cariello, A; Giovanis, P; Zumaglini, F; Rosati, G; Manzione, L; Bilancia, D; Rossi, A; Donati, D; Maccaferri, R; Malacarne, P; Labianca, R; Quadri, A; Pessi, MA; Cortesi, E; Martelli, O; Giuliodori, L; Silva, RR; Mari, D; Massidda, B; Ionta, MT; Alessandroni, P; Baldelli, A; Antimi, M; Minelli, M; Gridelli, C; Rossi, A; Passalacqua, R; Quarta, M; Sassi, M; Pinaglia, D; De Marino, E; Giampaolo, MA; Ciancola, F; Lalli, A; Di Felice, S; Casartelli, C		Italian Grp Antimetic Res	Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MODERATELY EMETOGENIC CHEMOTHERAPY; EMESIS; MAINTENANCE	Background: The prevention of delayed nausea and vomiting caused by moderately emetogenic chemotherapy for cancer has not been studied systematically. Methods: We enrolled patients who were scheduled to receive chemotherapy for the first time in a double-blind, randomized, multicenter study. All the patients received ondansetron combined with dexamethasone for prophylaxis against emesis that might occur within 24 hours after the start of chemotherapy (acute emesis). They were then divided into two groups: patients who did not have either vomiting or moderate-to-severe nausea (the low-risk group) and patients who had one or both (the high-risk group). Patients in the low-risk group were then randomly assigned to one of the following regimens, given on days 2 through 5 after the start of chemotherapy: oral placebo, 4 mg of dexamethasone given orally twice daily, or 8 mg of ondansetron in combination with 4 mg of dexamethasone, given orally twice daily. Patients in the high-risk group were randomly assigned to receive oral dexamethasone alone or in combination with ondansetron at the same doses as those used in the low-risk group. Results: Among the 618 patients in the low-risk group, there was a complete absence of both delayed vomiting and moderate-to-severe nausea in 91.8 percent of those who received ondansetron combined with dexamethasone, 87.4 percent of those who received dexamethasone alone, and 76.8 percent of those who received placebo. The proportions of patients who were protected by dexamethasone combined with ondansetron or by dexamethasone alone were significantly greater than the proportion protected by placebo (P<0.001 and P<0.02, respectively). Of the 87 patients in the high-risk group, complete protection was achieved in 40.9 percent of those treated with ondansetron and dexamethasone and in 23.3 percent treated with dexamethasone alone (P not significant). Conclusions: The best way to prevent delayed nausea and vomiting in patients receiving moderately emetogenic chemotherapy is to control these complications within the first 24 hours after the start of chemotherapy. Dexamethasone alone provides adequate protection against delayed emesis in patients at low risk (those who have not had acute emesis). (N Engl J Med 2000;342:1554-9.) (C) 2000, Massachusetts Medical Society.	Policlin Hosp, Div Med Oncol, I-06122 Perugia, Italy; Univ Aquila, Dept Internal Med & Publ Hlth, Med Stat Unit, I-67100 Laquila, Italy; Inst Oncol & Radiol, Belgrade, Yugoslavia; Univ Perugia, Dept Internal Med & Oncol Sci, I-06100 Perugia, Italy; Div Med Oncol, Perugia, Italy; Legnano Hosp, Med Oncol Serv, Legnano, Italy; Hosp Renzetti, Div Med Oncol, Lanciano, Italy; Med Oncol Serv, Sassari, Italy; Negrar Hosp, Div Med Oncol, Verona, Italy; Div Med Oncol, Ravenna, Italy; Div Med Oncol, Potenza, Italy; Arcispedale S Anna, Div Med Oncol, Ferrara, Italy; Div Med Oncol, Bergamo, Italy; Univ La Sapienza, Div Med Oncol, Rome, Italy; Med Oncol Serv, Fabriano, Italy; Univ Cagliari, Dept Med Oncol, Cagliari, Italy; Med Oncol Serv, Pesaro, Italy; Hosp S Eugenio, Med Oncol Serv, Rome, Italy; Natl Canc Inst, Med Oncol Div B, Naples, Italy; Med Oncol Serv, Parma, Italy; Med Oncol Serv, Foligno, Italy; V Fazzi Hosp, Div Internal Med, Dept Med Oncol, Lecce, Italy; Med Oncol Serv, Anagni, Italy; Med Oncol Serv, Giulianova, Italy; Med Oncol Serv, Erba, Italy	University of L'Aquila; University of Perugia; University of Ferrara; Arcispedale Sant'Anna; Sapienza University Rome; University of Cagliari; Sant'Eugenio Hospital; IRCCS Fondazione Pascale	Roila, F (corresponding author), Policlin Hosp, Div Med Oncol, I-06122 Perugia, Italy.		Rosati, Gerardo/AHC-8996-2022; Bilancia, Domenico/AAO-9167-2021; Rosati, Gerardo/AAH-5676-2020; Giovanis, Petros/AAW-5088-2021; Gridelli, Cesare/AAA-8621-2019; Cortesi, Enrico/AAA-2983-2019	Rosati, Gerardo/0000-0001-7004-6862; 				FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; Hosmer D.W., 1989, APPL LOGISTIC REGRES, P1; *IT GROUP ANT RES, 1997, ANN ONCOL, V8, P51; KAIZER L, 1994, J CLIN ONCOL, V12, P1050, DOI 10.1200/JCO.1994.12.5.1050; Koo WH, 1996, ANN ONCOL, V7, P71; Pater JL, 1997, ANN ONCOL, V8, P181, DOI 10.1023/A:1008247830641; Roila F, 1999, NEW ENGL J MED, V340, P1926; Roila F, 1998, ANN ONCOL, V9, P811, DOI 10.1023/A:1008471812316; ROILA F, 1995, NEW ENGL J MED, V332, P1	9	141	143	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2000	342	21					1554	1559						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316XJ	10824073				2022-12-28	WOS:000087193100002
J	Kress, JP; Pohlman, AS; O'Connor, MF; Hall, JB				Kress, JP; Pohlman, AS; O'Connor, MF; Hall, JB			Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE UNIT; PERMISSIVE HYPERCAPNIA; RESPIRATORY-FAILURE; MIDAZOLAM; PROPOFOL; COST; COMPLICATIONS; EXTUBATIONS; MULTICENTER	Background: Continuous infusions of sedative drugs in the intensive care unit may prolong the duration of mechanical ventilation, prolong the length of stay in the intensive care unit and the hospital, impede efforts to perform daily neurologic examinations, and increase the need for tests to assess alterations in mental status. Whether regular interruption of such infusions might accelerate recovery is not known. Methods: We conducted a randomized, controlled trial involving 128 adult patients who were receiving mechanical ventilation and continuous infusions of sedative drugs in a medical intensive care unit. In the intervention group, the sedative infusions were interrupted until the patients were awake, on a daily basis; in the control group, the infusions were interrupted only at the discretion of the clinicians in the intensive care unit. Results: The median duration of mechanical ventilation was 4.9 days in the intervention group, as compared with 7.3 days in the control group (P=0.004), and the median length of stay in the intensive care unit was 6.4 days as compared with 9.9 days, respectively (P=0.02). Six of the patients in the intervention group (9 percent) underwent diagnostic testing to assess changes in mental status, as compared with 16 of the patients in the control group (27 percent, P=0.02). Complications (e.g., removal of the endotracheal tube by the patient) occurred in three of the patients in the intervention group (4 percent) and four of the patients in the control group (7 percent, P=0.88). Conclusions: In patients who are receiving mechanical ventilation, daily interruption of sedative-drug infusions decreases the duration of mechanical ventilation and the length of stay in the intensive care unit. (N Engl J Med 2000;342:1471-7.) (C)2000, Massachusetts Medical Society.	Univ Chicago, Dept Med, Sect Pulm & Crit Care, Chicago, IL 60637 USA; Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Hall, JB (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care, MC 6026, Chicago, IL 60637 USA.							BIDANI A, 1994, JAMA-J AM MED ASSOC, V272, P957, DOI 10.1001/jama.272.12.957; Boulain T, 1998, AM J RESP CRIT CARE, V157, P1131, DOI 10.1164/ajrccm.157.4.9702083; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Chamorro C, 1996, CRIT CARE MED, V24, P932, DOI 10.1097/00003246-199606000-00010; CHENG EY, 1995, CRIT CARE CLIN, V11, P1005, DOI 10.1016/S0749-0704(18)30050-2; Christensen MJ, 1996, AUSTRALAS PLANT PATH, V25, P186, DOI 10.1071/AP96032; COX DR, 1972, J R STAT SOC B, V34, P187; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; GUNDLACH CA, 1991, HOSP FORMUL, V26, P132; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; HANSENFLASCHEN JH, 1991, JAMA-J AM MED ASSOC, V266, P2870, DOI 10.1001/jama.266.20.2870; INDECK M, 1988, J TRAUMA, V28, P1020, DOI 10.1097/00005373-198807000-00018; JACOBS JR, 1991, INT ANESTHESIOL CLIN, V29, P23, DOI 10.1097/00004311-199102940-00004; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 1996, AM J RESP CRIT CARE, V153, P1012, DOI 10.1164/ajrccm.153.3.8630539; MIRSKI MA, 1995, CRIT CARE MED, V23, P2038, DOI 10.1097/00003246-199512000-00013; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; RIKER RR, 1994, CRIT CARE MED, V22, P433, DOI 10.1097/00003246-199403000-00013; RONAN KP, 1995, CRIT CARE MED, V23, P286, DOI 10.1097/00003246-199502000-00014; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; Shelly MP, 1999, INTENS CARE MED, V25, P137, DOI 10.1007/s001340050805; SIVAM SP, 1985, LIFE SCI, V37, P199, DOI 10.1016/0024-3205(85)90645-9; Swart EL, 1999, CRIT CARE MED, V27, P1461, DOI 10.1097/00003246-199908000-00009; VASSAL T, 1993, INTENS CARE MED, V19, P340, DOI 10.1007/BF01694708; WOOD LDH, 1998, PRINCIPLES CRITICAL, P499; 1998, 1999 NY TIMES ALMANA, P316	29	1773	1875	2	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2000	342	20					1471	1477		10.1056/NEJM200005183422002	http://dx.doi.org/10.1056/NEJM200005183422002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314QT	10816184				2022-12-28	WOS:000087068200002
J	Nakamura, Y; Ito, K; Ehrenberg, M				Nakamura, Y; Ito, K; Ehrenberg, M			Mimicry grasps reality in translation termination	CELL			English	Review							CRYSTAL-STRUCTURE; RIBOSOME		Univ Tokyo, Inst Med Sci, Dept Tumor Biol, Minato Ku, Tokyo 1088639, Japan; Uppsala Univ, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden	University of Tokyo; Uppsala University	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Dept Tumor Biol, Minato Ku, Tokyo 1088639, Japan.	nak@ims.u-tokyo.ac.jp		Ito, Koichi/0000-0002-2042-405X				AULD DS, 1995, SCIENCE, V267, P1994, DOI 10.1126/science.7701322; Crawford DJG, 1999, EMBO J, V18, P727, DOI 10.1093/emboj/18.3.727; Eurwilaichitr L, 1999, MOL MICROBIOL, V32, P485, DOI 10.1046/j.1365-2958.1999.01346.x; Freistroffer DV, 2000, P NATL ACAD SCI USA, V97, P2046, DOI 10.1073/pnas.030541097; Frolova LY, 2000, RNA, V6, P381, DOI 10.1017/S135583820099143X; GOLDSTEIN JL, 1970, P NATL ACAD SCI USA, V67, P537, DOI 10.1073/pnas.67.2.537; Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Kurland C.G., 1996, ESCHERICHIA COLI SAL, P979; Nakamura Y, 1998, GENES CELLS, V3, P265, DOI 10.1046/j.1365-2443.1998.00191.x; Nakamura Y, 1996, CELL, V87, P147, DOI 10.1016/S0092-8674(00)81331-8; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Selmer M, 1999, SCIENCE, V286, P2349, DOI 10.1126/science.286.5448.2349; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Tate WP, 1996, PROG NUCLEIC ACID RE, V52, P293, DOI 10.1016/S0079-6603(08)60970-8; Tuite MF, 2000, CELL, V100, P289, DOI 10.1016/S0092-8674(00)80663-7; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Yoshizawa S, 1999, SCIENCE, V285, P1722, DOI 10.1126/science.285.5434.1722	18	83	88	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 12	2000	101	4					349	352		10.1016/S0092-8674(00)80845-4	http://dx.doi.org/10.1016/S0092-8674(00)80845-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830162	Bronze			2022-12-28	WOS:000087010400003
J	DeKoter, RP; Singh, H				DeKoter, RP; Singh, H			Regulation of B lymphocyte and macrophage development by graded expression of PU.1	SCIENCE			English	Article							TRANSCRIPTION FACTOR PU.1; MURINE FETAL LIVER; T-CELL; CHROMOSOMAL POSITION; ETS ONCOGENE; STEM-CELLS; DIFFERENTIATION; LINEAGE; PROGENITORS; PRECURSORS	The ets family transcription factor PU.1 is required for the development of multiple lineages of the immune system. Using retroviral transduction of PU.1 complementary DNA into mutant hematopoietic progenitors, we demonstrate that differing concentrations of the protein regulate the development of B lymphocytes as compared with macrophages. A low concentration of PU.1 protein induces the B cell fate, whereas a high concentration promotes macrophage differentiation and blocks B cell development. Conversely, a transcriptionally weakened mutant protein preferentially induces B cell generation. Our results suggest that graded expression of a transcription factor can be used to specify distinct cell fates in the hematopoietic system.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago	Singh, H (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave, Chicago, IL 60637 USA.	hsingh@midway.uchicago.edu	DeKoter, Rodney/A-9415-2009	DeKoter, Rodney/0000-0002-9201-1983				Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; COLLINS LS, 1987, J IMMUNOL, V138, P1082; CROSS MA, 1994, ONCOGENE, V9, P3013; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DEKOTER RP, UNPUB; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FEINSTEIN SC, 1982, J MOL BIOL, V156, P549, DOI 10.1016/0022-2836(82)90266-2; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; Glimcher LH, 1999, CELL, V96, P13, DOI 10.1016/S0092-8674(00)80955-1; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; HROMAS R, 1993, BLOOD, V82, P2998; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; RAMKUMAR S, UNPUB; ROSS IL, 1994, ONCOGENE, V9, P121; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Singh H, 1999, COLD SPRING HARB SYM, V64, P13, DOI 10.1101/sqb.1999.64.13; Spain LM, 1999, J IMMUNOL, V163, P2681; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; WALSH JC, UNPUB; WINKLER TH, 1995, BLOOD, V85, P2045, DOI 10.1182/blood.V85.8.2045.bloodjournal8582045	33	542	554	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1439	1441		10.1126/science.288.5470.1439	http://dx.doi.org/10.1126/science.288.5470.1439			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827957				2022-12-28	WOS:000087270900055
J	Kassebaum, DG; Cohen, JJ				Kassebaum, DG; Cohen, JJ			Nonaccredited Medical Education in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Assoc Amer Med Coll, Washington, DC 20037 USA	Association of American Medical Colleges	Kassebaum, DG (corresponding author), POB 468, Gleneden Beach, OR 97388 USA.							*AM MED ASS, 1999, 25 AM MED ASS BOARD; Astin A.W., 1993, ASSESSMENT EXCELLENC; Banta T, 1996, ASSESSMENT PRACTICE; BLOOM M, 1999, PHYSICIANS WEEK 0322; Commission on Higher Education, 1996, FRAM OUTC ASS; *ED COMM FOR MED G, 1995, ANN REP 1995 1998; Flexner A., 1910, MEDICAL ED US CANADA; GELMON SB, 1999, STRATGIES CHANGE IMP; *GEN ACC OFF, 1994, GAOHEHS9428; JACOB JA, 1999, AM MED NEWS     0104; Kassebaum D G, 1997, Acad Med, V72, P1127, DOI 10.1097/00001888-199712000-00029; KING SR, 1999, NY TIMES        0630; Liaison Committee on Medical Education, 1998, FUNCT STRUCT MED SCH; MANGAN KS, 1999, CHRONICLE HIGHE 0205; MANGAN KS, 1999, CHRONICLE HIGHE 0709; *WHO, 1996, WORLD DIR MED SCH	16	9	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2000	342	21					1602	1605		10.1056/NEJM200005253422110	http://dx.doi.org/10.1056/NEJM200005253422110			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316XJ	10824081				2022-12-28	WOS:000087193100010
J	Konishi, T				Konishi, T			Cultural aspects of violence against women in Japan	LANCET			English	Editorial Material									Musashino Womens Univ, Fac Human Studies, Hoya, Tokyo 2028585, Japan		Konishi, T (corresponding author), Musashino Womens Univ, Fac Human Studies, 1-1-20 Sinmachi, Hoya, Tokyo 2028585, Japan.							*BUR JUST STAT, 1998, CRIM VICT CHANG 1997; ISHIKAWA Y, 1995, REALITY SEXUAL VICTI; KONISHI T, 1997, JASS P, V8, P28; *OFF GEND EQ, 2000, REP VIOL MEN WOM; SASAGAWA M, 1998, ACTA CRIM JAPON, V64, P202	5	7	7	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1810	1810		10.1016/S0140-6736(00)02314-X	http://dx.doi.org/10.1016/S0140-6736(00)02314-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	315RE	10832849				2022-12-28	WOS:000087126100047
J	Rascol, O; Brooks, DJ; Korczyn, AD; De Deyn, PP; Clarke, CE; Lang, AE				Rascol, O; Brooks, DJ; Korczyn, AD; De Deyn, PP; Clarke, CE; Lang, AE		056 Study Grp	A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	XIIIth International Congress on Parkinsons Disease	JUL 28, 1999	VANCOUVER, CANADA	Smithkline Beecham Pharmaceut, Pharmacia & Upjohn Inc			BROMOCRIPTINE; MULTICENTER; 5-YEAR; THERAPY; 3-YEAR; TRIAL; DOPA	Background: There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist. Methods: In this prospective, randomized, double-blind study, we compared the safety and efficacy of the dopamine D2-receptor agonist ropinirole with that of levodopa over a period of five years in 268 patients with early Parkinson's disease. If symptoms were not adequately controlled by the assigned study medication, patients could receive supplementary levodopa, administered in an open-label fashion. The primary outcome measure was the occurrence of dyskinesia. Results: Eighty-five of the 179 patients in the ropinirole group (47 percent) and 45 of the 89 patients in the levodopa group (51 percent) completed all five years of the study. In the ropinirole group, 29 of the 85 patients (34 percent) received no levodopa supplementation. The analysis of the time to dyskinesia showed a significant difference in favor of ropinirole (hazard ratio for remaining free of dyskinesia, 2.82; 95 percent confidence interval, 1.78 to 4.44; P<0.001). At five years, the cumulative incidence of dyskinesia (excluding the three patients who had dyskinesia at base line), regardless of levodopa supplementation, was 20 percent (36 of 177 patients) in the ropinirole group and 45 percent (40 of 88 patients) in the levodopa group. There was no significant difference between the two groups in the mean change in scores for activities of daily living among those who completed the study. Adverse events led to the early withdrawal from the study of 48 of 179 patients in the ropinirole group (27 percent) and 29 of 89 patients in the levodopa group (33 percent). The mean (+/-SD) daily doses given by the end of the study were 16.5+/-6.6 mg of ropinirole (plus 427+/-221 mg of levodopa in patients who received supplementation) and 753+/-398 mg of levodopa (including supplements). Conclusions: Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary. (N Engl J Med 2000;342:1484-91.) (C) 2000, Massachusetts Medical Society.	Univ Hosp, INSERM, U455, Neuropharmacol Unit,Clin Invest Ctr, Toulouse, France; Hammersmith Hosp, Imperial Coll Sch Med, Div Neurosci, London, England; Tel Aviv Univ, Sch Med, Dept Neurol, Ramat Aviv, Israel; Born Bunge Fdn, Gen Hosp Middelheim, Dept Neurol, Antwerp, Belgium; Univ Antwerp, B-2020 Antwerp, Belgium; Univ Birmingham, Dept Neurol, Birmingham, W Midlands, England; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada; Toronto Western Hosp, Toronto, ON M5T 2S8, Canada	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Imperial College London; Tel Aviv University; University of Antwerp; University of Birmingham; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Rascol, O (corresponding author), Fac Med Toulouse, Serv Pharmacol Med & Clin, 37 Allees Jules Guesde, F-31073 Toulouse, France.	rascol@cict.fr	Korczyn, Amos D/C-3461-2017; Lang, Anthony/ABF-8114-2021	Korczyn, Amos D/0000-0003-0125-2579; Lang, Anthony/0000-0003-1229-3667; Brooks, David/0000-0003-2602-2518				Adler, 1997, NEUROLOGY, V49, P1484; Adler CH, 1997, NEUROLOGY, V49, P393, DOI 10.1212/WNL.49.2.393; Block G, 1997, EUR NEUROL, V37, P23, DOI 10.1159/000117399; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Brooks DJ, 1995, J NEURAL TRANSM-SUPP, P231; CALNE DB, 1974, LANCET, V2, P1355; Chase Thomas N., 1998, Neurology, V50, pS17; COTZIAS GC, 1969, NEW ENGL J MED, V280, P337, DOI 10.1056/NEJM196902132800701; DIAMOND SG, 1987, ANN NEUROL, V22, P8, DOI 10.1002/ana.410220105; DIAMOND SG, 1978, ANN NEUROL, V3, P267, DOI 10.1002/ana.410030314; FACTOR SA, 1993, MOVEMENT DISORD, V8, P257, DOI 10.1002/mds.870080302; Fahn S, 1997, CNS DRUGS, V8, P376, DOI 10.2165/00023210-199708050-00004; Fahn S., 1987, RECENT DEV PARKINSON, P153; Frucht S, 1999, NEUROLOGY, V52, P1908, DOI 10.1212/WNL.52.9.1908; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; HELY MA, 1994, J NEUROL NEUROSUR PS, V57, P903, DOI 10.1136/jnnp.57.8.903; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Hubble JP, 1999, MED CLIN N AM, V83, P525, DOI 10.1016/S0025-7125(05)70118-8; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Korczyn AD, 1998, MOVEMENT DISORD, V13, P46, DOI 10.1002/mds.870130112; Korczyn AD, 1999, NEUROLOGY, V53, P364, DOI 10.1212/WNL.53.2.364; KORCZYN AD, 1999, NEUROLOGY, V53, P1162; KORTEN JJ, 1975, EUR NEUROL, V13, P65, DOI 10.1159/000114663; Lieberman, 1999, NEUROLOGY, V52, P435; Lieberman A, 1998, NEUROLOGY, V51, P1057, DOI 10.1212/WNL.51.4.1057; MONTASTRUC JL, 1994, J NEUROL NEUROSUR PS, V57, P1034, DOI 10.1136/jnnp.57.9.1034; NUTT JG, 1990, NEUROLOGY, V40, P340; Olanow CW, 1998, NEUROLOGY, V50, pS1, DOI 10.1212/WNL.50.3_Suppl_3.S1; Pearce RKB, 1998, MOVEMENT DISORD, V13, P234, DOI 10.1002/mds.870130207; Poewe W, 1998, NEUROLOGY, V51, pS21, DOI 10.1212/WNL.51.2_Suppl_2.S21; Poewe WH, 1998, MOVEMENT DISORD, V13, P39, DOI 10.1002/mds.870130111; RINNE UK, 1985, NEUROLOGY, V35, P1196, DOI 10.1212/WNL.35.8.1196; Rinne UK, 1997, NEUROLOGY, V48, P363, DOI 10.1212/WNL.48.2.363; RINNE UK, 1989, NEUROLOGY, V39, P336, DOI 10.1212/WNL.39.3.336	34	1170	1207	1	102	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2000	342	20					1484	1491		10.1056/NEJM200005183422004	http://dx.doi.org/10.1056/NEJM200005183422004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	314QT	10816186				2022-12-28	WOS:000087068200004
J	Bernard, GR; Sopko, G; Cerra, F; Demling, R; Edmunds, H; Kaplan, S; Kessler, L; Masur, H; Parsons, P; Shure, D; Webb, C; Weidemann, H; Weinmann, G; Williams, D				Bernard, GR; Sopko, G; Cerra, F; Demling, R; Edmunds, H; Kaplan, S; Kessler, L; Masur, H; Parsons, P; Shure, D; Webb, C; Weidemann, H; Weinmann, G; Williams, D			Pulmonary artery catheterization and clinical outcomes - National Heart, Lung, and Blood Institute and Food and Drug Administration workshop report	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CRITICALLY ILL PATIENTS; CARE; KNOWLEDGE; TIME	Objective The efficacy and safety of the pulmonary artery catheter are under scrutiny because of its association with increased morbidity and mortality in observational studies. In response, the National Heart, Lung, and Blood Institute (NHLBI) and the US Food and Drug Administration (FDA) conducted the Pulmonary Artery Catheterization and Clinical Outcomes workshop in Alexandria, Va, on August 25 and 26, 1997, to develop recommendations regarding actions to improve pulmonary artery catheter utility and safety. Participants The NHLBI and FDA planning task force selected a workshop chairperson, subcommittee chairs, and participants. Approximately 85 participants were selected for their collective expertise in critical care, pulmonary medicine, cardiovascular medicine and surgery, pediatrics, nursing, biostatistics,and medical economics. The meeting was open to industry representatives and other government and lay observers. This workshop was funded by the NHLBI an the FDA's Division of Devices. Evidence Published reports relating to the efficacy and safety of the pulmonary artery catheter, especially consensus documents developed by professional societies. Consensus Process The planning task force disseminated materials, held teleconferences, and developed draft position papers prior to the workshop. These were modified during the workshop and thereafter in the course of several teleconferences, and presented to the entire group for final modifications and approval. Conclusions A need exists for collaborative education of physicians and nurses in performing, obtaining, and interpreting information from the use of pulmonary artery catheters. This effort should be led by professional societies, in collaboration with federal agencies, with the purpose of developing and disseminating standardized educational programs. Areas given high priority for clinical trials were pulmonary artery catheter use in persistent/refractory congestive heart failure, acute respiratory distress syndrome, severe sepsis and septic shock, and low-risk coronary artery bypass graft surgery.	Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA; NHLBI, Bethesda, MD 20892 USA; Univ Minnesota, Minneapolis, MN USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Calif Los Angeles, Los Angeles, CA USA; US FDA, Rockville, MD 20857 USA; NIH, Bethesda, MD 20892 USA; Univ Colorado, Denver, CO 80202 USA; Washington Univ, St Louis, MO USA; Cleveland Clin, Cleveland, OH 44106 USA; Brown Univ, Providence, RI 02912 USA	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Brigham & Women's Hospital; University of Pennsylvania; University of California System; University of California Los Angeles; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; University of Colorado System; University of Colorado Denver; Washington University (WUSTL); Cleveland Clinic Foundation; Brown University	Bernard, GR (corresponding author), Vanderbilt Univ, Sch Med, Room T-1219 Med Ctr N, Nashville, TN 37232 USA.			Wiedemann, Herbert/0000-0002-4587-4401				Beale RJ, 1997, JAMA-J AM MED ASSOC, V277, P110, DOI 10.1001/jama.1997.03540260024017; BLUMBERG MS, 1980, INT J EPIDEMIOL, V9, P361; Boyd O, 1997, JAMA-J AM MED ASSOC, V277, P110, DOI 10.1001/jama.1997.03540260024019; BUSH HS, 1989, CRIT CARE MED, V17, pS137; COLLINS R, 1995, LANCET, V345, P669; CONNORS AF, 1983, NEW ENGL J MED, V308, P263, DOI 10.1056/NEJM198302033080508; CONNORS AF, 1985, CHEST, V88, P567, DOI 10.1378/chest.88.4.567; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; COOK DJ, 1994, CRIT CARE MED, V22, P1314, DOI 10.1097/00003246-199408000-00016; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; EISENBERG PR, 1984, CRIT CARE MED, V12, P549, DOI 10.1097/00003246-198407000-00001; Gnaegi A, 1997, CRIT CARE MED, V25, P213, DOI 10.1097/00003246-199702000-00003; GORE JM, 1987, CHEST, V92, P721, DOI 10.1378/chest.92.4.721; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; HOGUE CW, 1995, J THORAC CARDIOV SUR, V110, P517, DOI 10.1016/S0022-5223(95)70249-0; IBERTI TJ, 1994, CRIT CARE MED, V22, P1674; IBERTI TJ, 1990, JAMA-J AM MED ASSOC, V264, P2928, DOI 10.1001/jama.264.22.2928; Jaeschke RZ, 1997, CRIT CARE MED, V25, P1514, DOI 10.1097/00003246-199709000-00018; MERMEL LA, 1991, AM J MED, V91, pS197, DOI 10.1016/0002-9343(91)90369-9; NAYLOR CD, 1993, JAMA-J AM MED ASSOC, V269, P2407, DOI 10.1001/jama.269.18.2407; ROIZEN MF, 1993, ANESTHESIOLOGY, V78, P380; Sandham JD, 1998, CRIT CARE MED, V26, P1288, DOI 10.1097/00003246-199807000-00037; SANDHAM JD, 1996, AM J RESP CRIT CARE, V153, pA601; SHAH KB, 1984, ANESTHESIOLOGY, V61, P271, DOI 10.1097/00000542-198409000-00007; Sibbald WJ, 1997, CRIT CARE MED, V25, P2060, DOI 10.1097/00003246-199712000-00027; SPODICK DH, 1980, AM J CARDIOL, V46, P173, DOI 10.1016/0002-9149(80)90620-7; SWAN HJC, 1970, NEW ENGL J MED, V283, P447, DOI 10.1056/NEJM197008272830902; Taylor RW, 1997, CRIT CARE MED, V25, P910; TUMAN KJ, 1989, ANESTHESIOLOGY, V70, P199, DOI 10.1097/00000542-198902000-00004; Tuman KJ, 1997, ANESTH ANALG, V84, P1; Vincent JL, 1998, CRIT CARE MED, V26, P1283, DOI 10.1097/00003246-199807000-00035; ZION MM, 1990, CHEST, V98, P1331, DOI 10.1378/chest.98.6.1331	33	119	127	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2568	2572		10.1001/jama.283.19.2568	http://dx.doi.org/10.1001/jama.283.19.2568			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312VL	10815121				2022-12-28	WOS:000086964600038
J	Smil, V				Smil, V			Horse power	NATURE			English	Editorial Material									Univ Manitoba, Dept Geog, Winnipeg, MB R3T 2N2, Canada	University of Manitoba	Smil, V (corresponding author), Univ Manitoba, Dept Geog, Winnipeg, MB R3T 2N2, Canada.								0	7	7	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					125	125		10.1038/35012175	http://dx.doi.org/10.1038/35012175			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821251				2022-12-28	WOS:000087080100026
J	Tegmark, M				Tegmark, M			Cosmology - The dark side of distortion	NATURE			English	Editorial Material									Univ Penn, Dept Phys, Philadelphia, PA 19104 USA	University of Pennsylvania	Tegmark, M (corresponding author), Univ Penn, Dept Phys, Philadelphia, PA 19104 USA.							BACON D, ASTROPH0003008; de Bernardis P, 2000, NATURE, V404, P955, DOI 10.1038/35010035; Kaiser N., ASTROPH0003338; VANWAERBEKE L, IN PRESS ASTRON ASTR; Wittman DM, 2000, NATURE, V405, P143, DOI 10.1038/35012001	5	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					133	134		10.1038/35012190	http://dx.doi.org/10.1038/35012190			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821255				2022-12-28	WOS:000087080100030
J	Entwistle, VA; Watt, IS; Johnson, F				Entwistle, VA; Watt, IS; Johnson, F			The case of Norplant as an example of media coverage over the life of a new health technology	LANCET			English	Article								Background The contraceptive implant Norplant (levonorgestrel) had a fairly short life in the UK. This made it a convenient subject for a case study of how media coverage alters over time. We set out to produce a critical description of national newspaper coverage of Norplant over the course of its use in the UK. Methods We searched newspaper databases and press-clippings files for articles about Norplant printed between 1992 and 1996. For those that met our inclusion criteria, we extracted bibliographical data, made a standardised judgment about the "slant" of the article towards Norplant, and used qualitative techniques to analyse the content of the articles. Findings 101 national newspaper articles were included in the study. Norplant attracted media coverage over the course of its career, but the slant of articles shifted dramatically over time from a favourable to a negative presentation. This reflected the use of different story types over the course of time. Early reports presented Norplant very positively as either a clear improvement on existing contraceptive methods or a valuable addition to the range. Any disadvantages were down-played. The positive image of Norplant was reinforced immediately after its official launch by reports that it was in great demand but women might be denied access to it. Less than a year later, however, newspaper reports about Norplant were dominated by the stories of individual women who had had bad experiences with the product. Interpretation Three main reporting themes were seen. At first, Norplant was presented as a positive new development, and one that might be denied to people. In later coverage it became a flawed and damaging product. These themes recur in media reporting of health technologies, and the fact that they occur at different stages in a product's career means that a balanced assessment of the technology is not usually feasible from media reporting at any one time. An appreciation of the forms and implications of these reporting frameworks could help health-care providers and users to appraise media reports more critically.	Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland; Univ York, Dept Hlth Studies, York YO1 5DD, N Yorkshire, England; Univ Coll, Imperial Canc Res Fund, Hlth Behav Unit, London, England	University of Aberdeen; University of York - UK; Cancer Research UK; University of London; University College London	Entwistle, VA (corresponding author), Univ Aberdeen, Hlth Serv Res Unit, Polwarth Bldg, Aberdeen AB25 2ZD, Scotland.		Entwistle, Vikki Ann/I-9266-2019; Johnson, Fiona/F-1305-2014	Entwistle, Vikki Ann/0000-0002-0856-4025; Johnson, Fiona/0000-0002-4271-1834				Anderson P, 1999, BRIT MED J, V318, P1578, DOI 10.1136/bmj.318.7198.1578; Berger A, 1998, BMJ, V317, P824; BOWER H, 1995, DOCTOR          1005, P20; Brindle D., 1999, SOCIAL POLICY MEDIA, P39; Bromham DR, 1996, BRIT MED J, V312, P1555, DOI 10.1136/bmj.312.7046.1555; Draper P., 1977, HLTH MASS MEDIA NATL; Entwhistle V., 1999, SOCIAL POLICY MEDIA, P118; ENTWISTLE V, 1995, BRIT MED J, V310, P920, DOI 10.1136/bmj.310.6984.920; ERIKSON R, 1989, NEGOTIATING CONTROL; FOWLER R, 1991, LANGUAGE NEWS DISCOU, P10; FRANKLIN R, 1999, SOCIAL POLICY MEDIA, P1; Galtung J., 1973, MANUFACTURE NEWS SOC, P62; GRILLI R, 1998, COCHRANE LIB; Karpf Anne, 1988, DOCTORING MEDIA REPO, P4; LAWLER PG, 1998, BRIT MED J, V317, P882; MCCOMBS ME, 1993, J COMMUN, V43, P58, DOI 10.1111/j.1460-2466.1993.tb01262.x; MCQUAIL D, 1987, MASS COMMUNICATION T, P135; Offringa M, 1998, BMJ-BRIT MED J, V317, P223, DOI 10.1136/bmj.317.7153.223; Rogers EM., 1983, DIFFUSION INNOVATION	19	15	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 6	2000	355	9215					1633	1636		10.1016/S0140-6736(00)02226-1	http://dx.doi.org/10.1016/S0140-6736(00)02226-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821380				2022-12-28	WOS:000086981200038
J	Hayreh, SS				Hayreh, SS			Steroid therapy for visual loss In patients with giant-cell arteritis	LANCET			English	Editorial Material							TEMPORAL ARTERITIS; OCULAR MANIFESTATIONS; CRITERIA		Univ Iowa, Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA	University of Iowa	Hayreh, SS (corresponding author), Univ Iowa, Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.		Hayreh, Sohan Singh/AFU-1623-2022	Hayreh, Sohan/0000-0002-0709-886X				BLUMBERG S, 1980, JAMA-J AM MED ASSOC, V244, P1713, DOI 10.1001/jama.244.15.1713; Cohen D N, 1973, Trans Am Acad Ophthalmol Otolaryngol, V77, pOP74; GOUET D, 1986, PRESSE MED, V15, P603; GRAHAM E, 1981, BRIT MED J, V282, P269, DOI 10.1136/bmj.282.6260.269; Hayreh S S, 1962, Br J Ophthalmol, V46, P212, DOI 10.1136/bjo.46.4.212; Hayreh SS, 1997, AM J OPHTHALMOL, V123, P285, DOI 10.1016/S0002-9394(14)70123-0; HAYREH SS, 1980, OPHTHALMOLOGY, V87, P75, DOI 10.1016/s0161-6420(80)35283-4; Hayreh SS, 1998, AM J OPHTHALMOL, V125, P509, DOI 10.1016/S0002-9394(99)80192-5; Hayreh SS, 1998, AM J OPHTHALMOL, V125, P521, DOI 10.1016/S0002-9394(99)80193-7; HAYREH SS, 1996, OPHTHALMOL CLIN N AM, V9, P404; HAYREH SS, 1995, EXP EYE RES, V61, P257; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; Kearns TP, 1975, EYE SYSTEMIC DIS, P105; Kupersmith MJ, 1999, BRIT J OPHTHALMOL, V83, P796, DOI 10.1136/bjo.83.7.796; KYLE V, 1991, BAILLIERE CLIN RHEUM, V5, P485, DOI 10.1016/S0950-3579(05)80067-6; WADMAN B, 1972, ACTA MED SCAND, V192, P377	16	21	21	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 6	2000	355	9215					1572	1573		10.1016/S0140-6736(00)02210-8	http://dx.doi.org/10.1016/S0140-6736(00)02210-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821358				2022-12-28	WOS:000086981200005
J	Beigel, Y; Greenberg, Z; Ostfeld, I				Beigel, Y; Greenberg, Z; Ostfeld, I			Letting the patient off the hook	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Rabin Med Ctr, Dept Internal Med A, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Minist Hlth, Cent Publ Hlth Lab, Jerusalem, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Beigel, Y (corresponding author), Rabin Med Ctr, Dept Internal Med A, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.							FREUDENTHAL AR, 1993, NEW ENGL J MED, V329, P542, DOI 10.1056/NEJM199308193290805; GRACIA LS, 1997, DIAGNOSTIC MED PARAS, P248; GROVE DI, 1995, MANDELL DOUGLAS BENN, V2, P2531; MANDELL GL, 1995, MANDELL DOUGLAS BENN, V2, P1701; Ong RKC, 1998, CHEST, V113, P1673, DOI 10.1378/chest.113.6.1673; REEDER MM, 1980, SEMIN ROENTGENOL, V15, P35, DOI 10.1016/0037-198X(80)90038-3; Sarinas P S, 1997, Semin Respir Infect, V12, P130; SILLIS M, 1990, J MED MICROBIOL, V33, P253, DOI 10.1099/00222615-33-4-253	8	6	6	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2000	342	22					1658	1661		10.1056/NEJM200006013422208	http://dx.doi.org/10.1056/NEJM200006013422208			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319CE	10833213				2022-12-28	WOS:000087321600008
J	Ness, GJ; House, A; Ness, AR				Ness, GJ; House, A; Ness, AR			Aggression and violent behaviour in general practice: population based survey in the north of England	BRITISH MEDICAL JOURNAL			English	Article									Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England; Acad Unit Psychiat & Behav Sci, Leeds LS2 9LT, W Yorkshire, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Sheffield; University of Leeds; University of Bristol	Ness, GJ (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.		Ness, Andy R/M-7612-2013	Ness, Andy R/0000-0003-3548-9523; House, Allan/0000-0001-8721-8026				DURSO P, 1989, BRIT MED J, V298, P97, DOI 10.1136/bmj.298.6666.97; *HLTH SERV ADV COM, 1987, VIOL STAFF HLTH SERV; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; JARMAN B, 1983, BRIT MED J, V286, P1795; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774	5	49	50	3	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1447	1448		10.1136/bmj.320.7247.1447	http://dx.doi.org/10.1136/bmj.320.7247.1447			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827050	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000087414700028
J	Ross, GW; Abbott, RD; Petrovitch, H; Morens, DM; Grandinetti, A; Tung, KH; Tanner, CM; Masaki, KH; Blanchette, PL; Curb, JD; Popper, JS; White, LR				Ross, GW; Abbott, RD; Petrovitch, H; Morens, DM; Grandinetti, A; Tung, KH; Tanner, CM; Masaki, KH; Blanchette, PL; Curb, JD; Popper, JS; White, LR			Association of coffee and caffeine intake with the risk of Parkinson disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; JAPANESE ANCESTRY; MEN; HAWAII; EPIDEMIOLOGY; RECEPTORS; SMOKING; ALCOHOL; SYSTEM	Context The projected expansion in the next several decades of the elderly population at highest risk for Parkinson disease (PD) makes identification of factors that promote or prevent the disease an important goat. Objective To explore the association of coffee and dietary caffeine intake with risk of PD. Design, Setting, and Participants Data were analyzed from 30 years of fallow-up of 8004 Japanese American men (aged 45-68 years) enrolled in the prospective longitudinal Honolulu Heart Program between 1965 and 1968. Main Outcome Measure Incident PD, by amount of coffee intake (measured at study enrollment and 6-year follow-up) and by total dietary caffeine intake (measured at enrollment). Results During follow-up, 102 men were identified as having PD. Age-adjusted incidence of PD declined consistently with increased amounts of coffee intake, from 10.4 per 10000 person-years in men who drank no coffee to 1.9 per 10000 person-years in men who drank at least 28 oz/d (P<.001 for trend). Similar relationships were observed with total caffeine intake (P<.001 for trend) and caffeine from noncoffee sources (P = .03 for trend). Consumption of increasing amounts of coffee was also associated with lower risk of PD in men who were never, past, and current smokers at baseline (P = .049, P = .22, and P = .02, respectively, for trend). Other nutrients in coffee, including niacin, were unrelated to PD incidence. The relationship between caffeine and PD was unaltered by intake of milk and sugar. Conclusions Our findings indicate that higher coffee and caffeine intake is associated with a significantly lower incidence of PD, This effect appears to be independent of smoking. The data suggest that the mechanism is related to caffeine intake and not to other nutrients contained in coffee.	Dept Vet Affairs, Honolulu, HI 96850 USA; Univ Hawaii, John A Burns Sch Med, Dept Med, Honolulu, HI 96822 USA; Univ Hawaii, John A Burns Sch Med, Pacific Biomed Res Ctr, Honolulu, HI 96822 USA; Univ Virginia, Sch Med, Dept Hlth Evaluat Sci, Div Biostat & Epidemiol, Charlottesville, VA 22908 USA; Pacific Hlth Res Inst, Honolulu, HI USA; NIAID, NIH, Bethesda, MD 20892 USA; Parkinsons Inst, Sunnyvale, CA USA; Kuakini Med Ctr Honolulu Asia Aging Study, Honolulu, HI USA; Univ Hawaii, Sch Publ Hlth, Honolulu, HI 96822 USA	University of Hawaii System; University of Hawaii System; University of Virginia; Pacific Health Research & Education Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Hawaii System	Ross, GW (corresponding author), Dept Vet Affairs, Honolulu 151,POB 50188, Honolulu, HI 96850 USA.		Grandinetti, Andrew/P-7436-2015; Abdullah, J/C-2828-2011	Grandinetti, Andrew/0000-0002-7257-5773; Abdullah, J/0000-0002-0258-7410	NHLBI NIH HHS [N01-HC-05102] Funding Source: Medline; NIA NIH HHS [N01-AG-4-2149] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC005102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [N01AG042149] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		COX DR, 1972, J R STAT SOC B, V34, P187; CURB JD, 1986, AM J EPIDEMIOL, V123, P648, DOI 10.1093/oxfordjournals.aje.a114284; Day J. C., 1996, CURRENT POPULATION R; Fall PA, 1999, MOVEMENT DISORD, V14, P28, DOI 10.1002/1531-8257(199901)14:1&lt;28::AID-MDS1007&gt;3.0.CO;2-O; GRANDINETTI A, 1994, AM J EPIDEMIOL, V139, P1129, DOI 10.1093/oxfordjournals.aje.a116960; Heilbrun L K, 1985, Hawaii Med J, V44, P294; Hellenbrand W, 1996, NEUROLOGY, V47, P644, DOI 10.1212/WNL.47.3.644; JIMENEZJIMENEZ FJ, 1992, MOVEMENT DISORD, V7, P339, DOI 10.1002/mds.870070407; Kanda T, 1998, NEUROREPORT, V9, P2857, DOI 10.1097/00001756-199808240-00032; KARTZINEL R, 1976, NEUROLOGY, V26, P741, DOI 10.1212/WNL.26.8.741; LANE PW, 1982, BIOMETRICS, V38, P613, DOI 10.2307/2530043; Lang A. E. T., 1989, QUANTIFICATION NEURO, P285; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Langston JW, 1998, ANN NEUROL, V44, pS45, DOI 10.1002/ana.410440707; MALLY J, 1994, J PHARM PHARMACOL, V46, P515, DOI 10.1111/j.2042-7158.1994.tb03840.x; MCGEE D, 1982, AM J CLIN NUTR, V36, P657, DOI 10.1093/ajcn/36.4.657; Morens DM, 1996, NEUROLOGY, V46, P1044, DOI 10.1212/WNL.46.4.1044; NEFZGER MD, 1968, AM J EPIDEMIOL, V88, P149, DOI 10.1093/oxfordjournals.aje.a120874; NEHLIG A, 1992, BRAIN RES REV, V17, P139, DOI 10.1016/0165-0173(92)90012-B; POPOLI P, 1991, J PHARM PHARMACOL, V43, P280, DOI 10.1111/j.2042-7158.1991.tb06685.x; Richardson PJ, 1997, TRENDS PHARMACOL SCI, V18, P338, DOI 10.1016/S0165-6147(97)01096-1; SHOULSON I, 1975, NEUROLOGY, V25, P722, DOI 10.1212/WNL.25.8.722; TANNER CM, 1992, NEUROL CLIN, V10, P317, DOI 10.1016/S0733-8619(18)30212-3; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; WARD CD, 1990, ADV NEUROL, V53, P245; WATANABE H, 1986, NEUROPHARMACOLOGY, V25, P577, DOI 10.1016/0028-3908(86)90208-X; White L, 1996, JAMA-J AM MED ASSOC, V276, P955, DOI 10.1001/jama.276.12.955; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; ZHANG ZX, 1993, NEUROEPIDEMIOLOGY, V12, P195, DOI 10.1159/000110318	31	509	527	1	80	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2674	2679		10.1001/jama.283.20.2674	http://dx.doi.org/10.1001/jama.283.20.2674			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819950	Bronze			2022-12-28	WOS:000087046000035
J	Ramsey, S				Ramsey, S			Violence	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Ramsey, S (corresponding author), Lancet, London WC1X 8RR, England.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1744	1744		10.1016/S0140-6736(00)02260-1	http://dx.doi.org/10.1016/S0140-6736(00)02260-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832823				2022-12-28	WOS:000087126100007
J	Spencer, JR; Rathbun, JA; Travis, LD; Tamppari, LK; Barnard, L; Martin, TZ; McEwen, AS				Spencer, JR; Rathbun, JA; Travis, LD; Tamppari, LK; Barnard, L; Martin, TZ; McEwen, AS			Io's thermal emission from the Galileo photopolarimeter-radiometer	SCIENCE			English	Article							ACTIVE VOLCANISM; HOT-SPOTS; TEMPERATURE; EUROPA; PHOTOMETRY; SSI	Galileo's photopolarimeter-radiometer instrument mapped to's thermal emission during the 124, 125, and 127 flybys with a spatial resolution of 2.2 to 300 kilometers. Mapping of Loki in 124 shows uniform temperatures for most of Loki Patera and high temperatures in the southwest corner, probably resulting from an eruption that began 1 month before the observation. Most of Loki Patera was resurfaced before 127. Pele's caldera floor has a low temperature of 160 kelvin, whereas flows at Pillan and Zamama have temperatures of up to 200 kelvin, Global maps of nighttime temperatures provide a means for estimating global heat flow.	Lowell Observ, Flagstaff, AZ 86001 USA; NASA, Goddard Space Flight Ctr, Inst Space Studies, New York, NY 10025 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Arizona	Spencer, JR (corresponding author), Lowell Observ, 1400 W Mars Hill Rd, Flagstaff, AZ 86001 USA.							Davies AG, 1997, GEOPHYS RES LETT, V24, P2447, DOI 10.1029/97GL02310; GOGUEN JD, 1988, ICARUS, V76, P465, DOI 10.1016/0019-1035(88)90015-2; GOGUEN JD, 1998, B AM ASTRON SOC, V29, P978; HANSEN OL, 1973, ICARUS, V18, P237, DOI 10.1016/0019-1035(73)90208-X; Howell RR, 1997, ICARUS, V127, P394, DOI 10.1006/icar.1997.5686; HOWELL RR, 2000, LUNAR PLANET SCI, V31, P1974; Lopes-Gautier R, 2000, SCIENCE, V288, P1201, DOI 10.1126/science.288.5469.1201; Lopes-Gautier R, 1999, ICARUS, V140, P243, DOI 10.1006/icar.1999.6129; MACINTOSH B, UNPUB; McEwen A.S., 1992, LUNAR PLANET SCI, VXXIII, P881; McEwen AS, 2000, SCIENCE, V288, P1193, DOI 10.1126/science.288.5469.1193; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; McEwen AS, 1998, SCIENCE, V281, P87, DOI 10.1126/science.281.5373.87; RUSSELL EE, 1992, SPACE SCI REV, V60, P531; SEGATZ M, 1988, ICARUS, V75, P187, DOI 10.1016/0019-1035(88)90001-2; SPENCER J, UNPUB; Spencer JR, 1999, SCIENCE, V284, P1514, DOI 10.1126/science.284.5419.1514; SPENCER JR, 1994, ICARUS, V107, P195, DOI 10.1006/icar.1994.1016; Spencer JR, 2000, SCIENCE, V288, P1208, DOI 10.1126/science.288.5469.1208; Spencer JR, 1997, GEOPHYS RES LETT, V24, P2451, DOI 10.1029/97GL02591; VEEDER GJ, 1994, J GEOPHYS RES-PLANET, V99, P17095, DOI 10.1029/94JE00637; [No title captured]	22	97	98	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1198	1201		10.1126/science.288.5469.1198	http://dx.doi.org/10.1126/science.288.5469.1198			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817987				2022-12-28	WOS:000087112600039
J	Pandya, KJ; Raubertas, RF; Flynn, PJ; Hynes, HE; Rosenbluth, RJ; Kirshner, JJ; Pierce, HI; Dragalin, V; Morrow, GR				Pandya, KJ; Raubertas, RF; Flynn, PJ; Hynes, HE; Rosenbluth, RJ; Kirshner, JJ; Pierce, HI; Dragalin, V; Morrow, GR			Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester cancer center community clinical oncology program study	ANNALS OF INTERNAL MEDICINE			English	Article							DOUBLE-BLIND TRIAL; MENOPAUSAL; FLUSHES; PLACEBO; ACETATE	Background: Hot flashes are the most frequently reported side effect of tamoxifen treatment. Although hormones are an effective treatment, their safety is questionable in women with breast cancer. It is therefore important to evaluate nonhormonal treatments for hot flashes. Objective: To evaluate the effectiveness of oral clonidine for control of hot flashes associated with tamoxifen therapy in postmenopausal women with breast cancer. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: University of Rochester Cancer Center Community Clinical Oncology Program. Patients: 194 postmenopausal women with breast cancer who were receiving adjuvant tamoxifen therapy. Intervention: Oral clonidine hydrochloride, 0.1 mg/d, or placebo for 8 weeks. Measurements: In a daily diary, patients recorded number, duration, and severity of hot flashes and overall quality-of-life score (on a 10-point scale) during a 1-week baseline period and during the 4th, 8th, and 12th weeks of the study. Results: Patients in the placebo and treatment groups were similar in age, duration of tamoxifen use, reported frequency and duration of hot flashes at baseline, and dropout rates. One hundred forty-nine patients completed 12 weeks of follow-up. The mean decrease in hot flash frequency was greater in the clonidine group than in the placebo group after 4 weeks of treatment (37% compared with 20% [95% CI for difference, 7% to 27%]) and 8 weeks of treatment (38% compared with 24% [CI for difference, 3% to 27%]). Patients receiving clonidine were more likely than patients receiving placebo to report difficulty sleeping (41% compared with 21%; P = 0.02). A significant difference was seen in the mean change in quality-of-life scores (0.3 points in the clonidine group compared with -0.2 points in the placebo group; P = 0.02) at 8 weeks, although the median difference was 0 in both groups. Conclusion: Oral clonidine, 0.1 mg/d, is effective against tamoxifen-induced hot flashes in postmenopausal women with breast cancer.	Univ Rochester, Ctr Canc, Community Clin Oncol Program Res Base, Rochester, NY 14642 USA; Metro Minnesota Community Clin Oncol Program, St Louis Pk, MN USA; Wichita Community Clin Oncol Program, Wichita, KS USA; No New Jersey Community Clin Oncol Program, Hackensack, NJ 07601 USA; Syracuse Hematol Oncol Community Clin Oncol Progr, Syracuse, NY USA; NW Community Clin Oncol Program, Tacoma, WA USA	University of Rochester	Pandya, KJ (corresponding author), Univ Rochester, Ctr Canc, Community Clin Oncol Program Res Base, 601 Elmwood Ave,Box 704, Rochester, NY 14642 USA.				NATIONAL CANCER INSTITUTE [U10CA037420] Funding Source: NIH RePORTER; NCI NIH HHS [CA37420] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT BH, 1981, AM J OBSTET GYNECOL, V139, P631, DOI 10.1016/0002-9378(81)90475-0; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; BULLOCK JL, 1975, OBSTET GYNECOL, V46, P165; CASPER RF, 1985, CLIN ENDOCRINOL, V22, P293, DOI 10.1111/j.1365-2265.1985.tb03243.x; CLAYDEN JR, 1974, BRIT MED J, V1, P409, DOI 10.1136/bmj.1.5905.409; EDINGTON RF, 1980, CAN MED ASSOC J, V123, P23; ERLIK Y, 1981, MATURITAS, V3, P167, DOI 10.1016/0378-5122(81)90008-6; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; GOLDBERG RM, 1994, J CLIN ONCOL, V12, P155, DOI 10.1200/JCO.1994.12.1.155; LAUFER LR, 1982, OBSTET GYNECOL, V60, P583; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; MCKINLAY SM, 1974, BRIT J PREV SOC MED, V28, P108; MORROW GR, 1980, CANCER TREAT REP, V64, P451; PANDYA KJ, 1990, P AN M AM SOC CLIN, V9, P340; SWARTZMAN LC, 1990, J BEHAV MED, V13, P15, DOI 10.1007/BF00844897; WREN BG, 1986, MED J AUSTRALIA, V144, P369, DOI 10.5694/j.1326-5377.1986.tb115924.x	16	195	202	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2000	132	10					788	793		10.7326/0003-4819-132-10-200005160-00004	http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313XN	10819701				2022-12-28	WOS:000087025100003
J	Weatherall, D				Weatherall, D			Academia and industry: increasingly uneasy bedfellows	LANCET			English	Editorial Material									John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	University of Oxford	Weatherall, D (corresponding author), John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.							Holden C, 2000, SCIENCE, V287, P1573; Madis S, 2000, NATURE, V403, P818, DOI 10.1038/35002748; Marshall E, 2000, SCIENCE, V287, P1723, DOI 10.1126/science.287.5459.1723; Nathan DG, 1999, LANCET, V353, P771, DOI 10.1016/S0140-6736(99)00072-0; Smaglik P, 2000, NATURE, V403, P820, DOI 10.1038/35002758	5	55	56	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 6	2000	355	9215					1574	1574		10.1016/S0140-6736(00)02211-X	http://dx.doi.org/10.1016/S0140-6736(00)02211-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821359				2022-12-28	WOS:000086981200006
J	Ferner, RE				Ferner, RE			Commentary: Reporting of adverse events is worth the effort	BRITISH MEDICAL JOURNAL			English	Editorial Material							PRACTICE RESEARCH DATABASE		City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Ferner, RE (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England.			Ferner, Robin/0000-0003-3769-1346				FINNEY DJ, 1986, MONITORING DRUG SAFE, P421; Lawson DH, 1998, QJM-MON J ASSOC PHYS, V91, P445, DOI 10.1093/qjmed/91.6.445; Mann RD, 1998, BRIT J CLIN PHARMACO, V46, P195, DOI 10.1046/j.1365-2125.1998.00774.x; RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 29	2000	320	7243					1186	1187						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310MW	10836821				2022-12-28	WOS:000086832800021
J	Heit, JA; Elliott, CG; Trowbridge, AA; Morrey, BF; Gent, M; Hirsh, J				Heit, JA; Elliott, CG; Trowbridge, AA; Morrey, BF; Gent, M; Hirsh, J		Ardeparin Arthroplasty Study Grp	Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						heparin, low-molecular-weight; thromboembolism; venous thrombosis; arthroplasty, replacement, knee; arthroplasty, replacement, hip	PROLONGED THROMBOPROPHYLAXIS; ARTHROPLASTY; ENOXAPARIN; DALTEPARIN; THROMBOSIS; DISCHARGE; EFFICACY; SURGERY; SAFETY; RISK	Background: The optimal duration of prophylaxis against venous thromboembolism after total hip or knee replacement is uncertain. Objective: To determine the efficacy and safety of extended out-of-hospital prophylaxis with low-molecular-weight heparin (ardeparin sodium). Design: Randomized, double-blind, placebo-controlled trial. Setting: 33 community, university, or university-affiliated hospitals. Patients: 1195 adults who had elective total hip or knee replacement and completed 4 to 10 days of postoperative ardeparin prophylaxis. Intervention: Daily subcutaneous ardeparin (100 anti-X-a IU/kg of body weight) or placebo from time of hospital discharge to 6 weeks after surgery. Measurements: Symptomatic, objectively documented venous thromboembolism or death, along with major bleeding, from time of hospital discharge to 12 weeks after surgery. Results: Patients who received ardeparin (n = 607) and those who received placebo (n = 588) did not differ significantly in the cumulative incidence of venous thromboembolism or death (9 cases [1.5%] compared with 12 cases [2.0%]; odds ratio, 0.7 [95% Cl, 0.3 to 1.7]; P > 0.2; absolute difference, -0.56 percentage points [Cl, -2.2 to 1.1 percentage points]) or major bleeding (2 cases [0.3%] compared with 3 cases [0.5%]). Conclusions: Among patients who had total knee or total hip replacement and received 4 to 10 days of postoperative ardeparin prophylaxis, the cumulative incidence of symptomatic venous thromboembolism or death after hospital discharge was not significantly reduced by extended out-of-hospital ardeparin prophylaxis. Extended ardeparin use could provide a maximum 2.2-percentage point true reduction in such events. The benefit of extended ardeparin use is not clinically important for patients. Future research should identify high-risk patients who would benefit most from extended prophylaxis.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Univ Utah, Latter Day St Hosp, Sch Med, Salt Lake City, UT 84143 USA; Texas A&M Univ, Coll Med, Temple, TX 76508 USA; McMaster Univ, Hamilton, ON, Canada	Mayo Clinic; Utah System of Higher Education; University of Utah; Texas A&M University System; McMaster University	Heit, JA (corresponding author), Mayo Clin & Mayo Fdn, Plummer 549,200 1st St SW, Rochester, MN 55905 USA.							Bergqvist D, 1996, NEW ENGL J MED, V335, P696, DOI 10.1056/NEJM199609053351002; Clagett GP, 1998, CHEST, V114, p531S, DOI 10.1378/chest.114.5_Supplement.531S; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Dahl OE, 1997, THROMB HAEMOSTASIS, V77, P26; FRANCIS CW, 1986, CLIN ORTHOP RELAT R, V232, P271; FRIEDMAN RJ, 1994, J BONE JOINT SURG AM, V76A, P1174; Ginsberg JS, 2000, ARCH INTERN MED, V160, P669, DOI 10.1001/archinte.160.5.669; Heit JA, 1997, THROMB HAEMOSTASIS, V77, P32; Lassen MR, 1998, THROMB RES, V89, P281, DOI 10.1016/S0049-3848(98)00018-8; Leclerc JR, 1998, ARCH INTERN MED, V158, P873, DOI 10.1001/archinte.158.8.873; Lindahl TL, 1999, THROMB HAEMOSTASIS, V81, P18; MANTEL N, 1959, J NATL CANCER I, V22, P719; Planes A, 1996, LANCET, V348, P224, DOI 10.1016/S0140-6736(96)01453-5; Prentice CRM, 1999, THROMB HAEMOSTASIS, P193; Robinson KS, 1997, ANN INTERN MED, V127, P439, DOI 10.7326/0003-4819-127-6-199709150-00004; 1990, JAMA, V263, P2753	16	122	125	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					853	+		10.7326/0003-4819-132-11-200006060-00002	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319HF	10836911				2022-12-28	WOS:000087334900001
J	Bennet, G				Bennet, G			Railway signals passed at danger: psychology matters	BRITISH MEDICAL JOURNAL			English	Editorial Material																		Cocks RA, 1999, BMJ-BRIT MED J, V319, P1018, DOI 10.1136/bmj.319.7216.1018	1	1	1	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1549	1549		10.1136/bmj.320.7248.1549	http://dx.doi.org/10.1136/bmj.320.7248.1549			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834917	Green Published			2022-12-28	WOS:000087471000062
J	Murphy, MS; Sibal, A; Mann, JR				Murphy, MS; Sibal, A; Mann, JR			Lesson of the week - Persistent diarrhoea and occult vipomas in children	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VASOACTIVE INTESTINAL PEPTIDE		Birmingham Childrens Hosp, Dept Gastroenterol & Nutr, Birmingham B4 6NH, W Midlands, England; Birmingham Childrens Hosp, Dept Oncol, Birmingham B4 6NH, W Midlands, England	University of Birmingham; University of Birmingham	Murphy, MS (corresponding author), Inst Child Hlth, Clin Res Block,Whittall St, Birmingham B4 6NH, W Midlands, England.	m.s.murphy@bham.ac.uk						ACHESON DWK, 1992, J INFECTION, V24, P225, DOI 10.1016/S0163-4453(05)80028-3; BINDER HJ, 1977, ANNU REV PHARMACOL, V17, P355, DOI 10.1146/annurev.pa.17.040177.002035; BLOOM SR, 1980, GASTROENTEROLOGY, V78, P1143; BLOOM SR, 1973, LANCET, V2, P14; DESJEUX JF, 1996, PEDIAT GASTROINTESTI, P792; IIDA Y, 1980, ARCH DIS CHILD, V55, P929, DOI 10.1136/adc.55.12.929; KAPLAN SJ, 1980, AM J DIS CHILD, V134, P21, DOI 10.1001/archpedi.1980.02130130013005; LEVINE MM, 1987, J INFECT DIS, V155, P377, DOI 10.1093/infdis/155.3.377; LONG RG, 1981, BRIT MED J, V282, P1767, DOI 10.1136/bmj.282.6278.1767; LONG RG, 1983, J PEDIATR GASTR NUTR, V2, P122, DOI 10.1097/00005176-198302010-00013; SCHWARTZ CJ, 1974, J CLIN INVEST, V54, P536, DOI 10.1172/JCI107790; SCULLY RE, 1974, NEW ENGL J MED, V291, P1351; VERNER JV, 1958, AM J MED, V25, P374, DOI 10.1016/0002-9343(58)90075-5; Voorhees ML, 1962, J CLIN ENDOCR METAB, V22, P26	14	11	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 3	2000	320	7248					1524	1526		10.1136/bmj.320.7248.1524	http://dx.doi.org/10.1136/bmj.320.7248.1524			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834901	Green Published			2022-12-28	WOS:000087471000033
J	Moynihan, R; Bero, L; Ross-Degnan, D; Henry, D; Lee, K; Watkins, J; Mah, C; Soumerai, SB				Moynihan, R; Bero, L; Ross-Degnan, D; Henry, D; Lee, K; Watkins, J; Mah, C; Soumerai, SB			Coverage by the news media of the benefits and risks of medications	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CLINICAL-TRIALS; PHYSICIANS; LESSONS; INFORMATION; NEWSPAPERS; PRESCRIBE; MEDICINES; QUALITY; PRESS	Background The news media are an important source of information about new medical treatments, but there is concern that some coverage may be inaccurate and overly enthusiastic. Methods We studied coverage by U.S. news media of the benefits and risks of three medications that are used to prevent major diseases. The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiovascular disease; alendronate, a bisphosphonate for the treatment and prevention of osteoporosis; and aspirin, which is used for the prevention of cardiovascular disease. We analyzed a systematic probability sample of 180 newspaper articles (60 for each drug) and 27 television reports that appeared between 1994 and 1998. Results Of the 207 stories, 83 (40 percent) did not report benefits quantitatively. Of the 124 that did, 103 (83 percent) reported relative benefits only, 3 (2 percent) absolute benefits only, and 18 (15 percent) both absolute and relative benefits. Of the 207 stories, 98 (47 percent) mentioned potential harm to patients, and only 63 (30 percent) mentioned costs. Of the 170 stories citing an expert or a scientific study, 85 (50 percent) cited at least one expert or study with a financial tie to a manufacturer of the drug that had been disclosed in the scientific literature. These ties were disclosed in only 33 (39 percent) of the 85 stories. Conclusions News-media stories about medications may include inadequate or incomplete information about the benefits, risks, and costs of the drugs as well as the financial ties between study groups or experts and pharmaceutical manufacturers. (N Engl J Med 2000;342:1645-50.) (C)2000, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Australian Broadcasting Corp, Sydney, NSW, Australia; Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; Univ Newcastle, Fac Med & Hlth Sci, Sch Populat Hlth Sci, Newcastle, NSW 2308, Australia	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Newcastle	Soumerai, SB (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 200, Boston, MA 02215 USA.		Henry, David/AAU-4650-2020; Moynihan, Ray/ABC-3010-2020; Henry, David/AAJ-4332-2020	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242				ANGELL M, 1994, NEW ENGL J MED, V331, P189, DOI 10.1056/NEJM199407213310309; BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; Brown J, 1996, SOC SCI MED, V43, P1685, DOI 10.1016/0277-9536(95)00402-5; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; DAN BB, 1992, JAMA-J AM MED ASSOC, V268, P1026, DOI 10.1001/jama.268.8.1026; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; DONNER A, 1986, BIOMETRICS, V42, P401, DOI 10.2307/2531060; DONNER A, 1986, BIOMETRICS, V42, P1009; ENTWISTLE V, 1995, BRIT MED J, V310, P920, DOI 10.1136/bmj.310.6984.920; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; GRILLI R, 2000, MASS MEDIA INTERVENT; Guyatt G, 1999, AM MED WRITERS ASS J, V14, P32; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; Kennedy GE, 1999, TOB CONTROL, V8, P254, DOI 10.1136/tc.8.3.254; Krimsky S, 1998, JAMA-J AM MED ASSOC, V280, P225, DOI 10.1001/jama.280.3.225; Lebow MA, 1999, OBSTET GYNECOL, V93, P453, DOI 10.1097/00006250-199903000-00029; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Loo L. K., 1998, JGIM, V13, P60; MCCORMACK JP, 1993, ANN PHARMACOTHER, V27, P1272, DOI 10.1177/106002809302701018; Melzer D, 1998, BMJ-BRIT MED J, V316, P762, DOI 10.1136/bmj.316.7133.762; *MICR, 1999, USP DISP INF, V1, P1647; Myers MG, 1996, CAN MED ASSOC J, V155, P772; *NAT HLTH COUNC, 1997, AM TALK SCI MED NEWS; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; Nelkin D, 1996, LANCET, V347, P1600, DOI 10.1016/S0140-6736(96)91081-8; OXMAN AD, 1993, J CLIN EPIDEMIOL, V46, P987, DOI 10.1016/0895-4356(93)90166-X; Remuzzi G, 1999, LANCET, V353, P1289, DOI 10.1016/S0140-6736(99)90044-2; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Schwartz LM, 1999, NEW ENGL J MED, V341, P279, DOI 10.1056/NEJM199907223410411; Shuchman M, 1997, ANN INTERN MED, V126, P976, DOI 10.7326/0003-4819-126-12-199706150-00008; Sitthi-amorn C, 1998, INT J TECHNOL ASSESS, V14, P71, DOI 10.1017/S0266462300010539; Snedecor GW, 1980, STAT METHODS, V7th; VANTRIGT AM, 1994, SOC SCI MED, V38, P637, DOI 10.1016/0277-9536(94)90261-5; VANTRIGT AM, 1995, SOC SCI MED, V41, P893, DOI 10.1016/0277-9536(94)00389-B; 1995, LOS ANGELES TIM 0311, P4; 1999, JAMA, V281, P12; 1995, SAN DIEGO TRIBU 0315, pA13	40	326	332	1	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2000	342	22					1645	1650		10.1056/NEJM200006013422206	http://dx.doi.org/10.1056/NEJM200006013422206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319CE	10833211	Green Published, Green Submitted			2022-12-28	WOS:000087321600006
J	Jones, J				Jones, J			The private finance initiative: spinning out the defence	BRITISH MEDICAL JOURNAL			English	Article							NHS; PFI											*DEP HLTH, 1999, PFI CAP PFI QUEST AN; Gaffney D, 1999, BMJ-BRIT MED J, V319, P48, DOI 10.1136/bmj.319.7201.48; Gaffney D, 1999, BRIT MED J, V319, P116, DOI 10.1136/bmj.319.7202.116; Gaffney D, 1999, BRIT MED J, V319, P249, DOI 10.1136/bmj.319.7204.249; *HOUS COMM SEL COM, 1999, MIN EV MOND 19 JUL 1; Pitt D, 2000, BRIT MED J, V320, P797; Pollock AM, 1999, BMJ-BRIT MED J, V319, P179, DOI 10.1136/bmj.319.7203.179; Reeves C, 1999, BRIT MED J, V319, P191, DOI 10.1136/bmj.319.7203.191a	8	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1460	1461		10.1136/bmj.320.7247.1460	http://dx.doi.org/10.1136/bmj.320.7247.1460			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827057	Green Published			2022-12-28	WOS:000087414700032
J	Kmietowicz, Z				Kmietowicz, Z			Deaths from breast cancer fall dramatically in UK and US	BRITISH MEDICAL JOURNAL			English	News Item																		2000, LANCET, V355, P1822	1	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1428	1428						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827041				2022-12-28	WOS:000087414700019
J	Sheikh, A; Alves, B				Sheikh, A; Alves, B			Hospital admissions for acute anaphylaxis: time trend study	BRITISH MEDICAL JOURNAL			English	Article									Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England	Imperial College London	Sheikh, A (corresponding author), Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England.		Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056				Dibs S D, 1997, Pediatrics, V99, pE7, DOI 10.1542/peds.99.1.e7; Ewan PW, 1998, BRIT MED J, V316, P1442, DOI 10.1136/bmj.316.7142.1442; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; *NHS CTR COD CLASS, 1995, GUID US TABL EQ ICD; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514	5	138	142	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1441	1441		10.1136/bmj.320.7247.1441	http://dx.doi.org/10.1136/bmj.320.7247.1441			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827045	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000087414700025
J	Zahn, S; Canary, JW				Zahn, S; Canary, JW			Electron-induced inversion of helical chirality in copper complexes of N,N-dialkylmethionines	SCIENCE			English	Article							REDOX; SWITCH; DRIVEN; LIGAND; LIGHT	Stereodynamic complexes of copper were found to undergo inversion of a helical chiral element upon oxidation or reduction. The amino acid methionine was derivatized by the attachment of two chromophores to the nitrogen atom, The resultant ligands formed stable complexes with Cu-1 and Cu-11 salts. For a derivative of a given absolute chirality, the complexes afford nearly mirror image circular dichroism spectra. The spectral changes originate from reorientation of the nitrogen-attached chromophores due to a conformation interconversion driven by the exchange of a carboxylate for a sulfide ligand. The electrically induced chirality inversion coupled with strong interactions with polarized light is unique and may Lead to novel chiral molecular devices.	NYU, Dept Chem, New York, NY 10003 USA	New York University	Canary, JW (corresponding author), NYU, Dept Chem, New York, NY 10003 USA.	james.canary@nyu.edu			NIGMS NIH HHS [GM49170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armaroli N, 1999, J AM CHEM SOC, V121, P4397, DOI 10.1021/ja984051w; Ashton PR, 1999, J AM CHEM SOC, V121, P3951, DOI 10.1021/ja984341c; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; CANARY JW, 1995, J AM CHEM SOC, V117, P8484, DOI 10.1021/ja00137a032; Canary JW, 1998, INORG CHEM, V37, P6255, DOI 10.1021/ic9803098; CANARY JW, IN PRESS ENANTIOMER; Castagnetto JM, 1997, CHIRALITY, V9, P616, DOI 10.1002/(SICI)1520-636X(1997)9:5/6<616::AID-CHIR32>3.3.CO;2-6; DESANTIS G, 1992, J CHEM SOC DALTON, P3283, DOI 10.1039/dt9920003283; GOULLE V, 1993, J CHEM SOC CHEM COMM, P1034, DOI 10.1039/c39930001034; Huck NPM, 1996, SCIENCE, V273, P1686, DOI 10.1126/science.273.5282.1686; JANICKI SZ, 1995, J AM CHEM SOC, V117, P8524, DOI 10.1021/ja00138a005; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Mao CD, 1999, NATURE, V397, P144, DOI 10.1038/16437; MUNOZ S, 1993, J AM CHEM SOC, V115, P4899, DOI 10.1021/ja00064a064; Nakanishi K., 1994, CIRCULAR DICHROISM P, P361; Porsch M, 1997, ADV MATER, V9, P635, DOI 10.1002/adma.19970090809; SHINKAI S, 1985, J AM CHEM SOC, V107, P3950, DOI 10.1021/ja00299a034; SIEGRIST AE, 1980, HELV CHIM ACTA, V63, P1311, DOI 10.1002/hlca.19800630524; SUAREZ M, 1995, J AM CHEM SOC, V117, P6732, DOI 10.1021/ja00130a013; TYEKLAR Z, 1993, BIOINORGANIC CHEM CO, P277; Westermeier C, 1999, CHEM COMMUN, P2427, DOI 10.1039/a907454f; Yang DK, 1997, ANNU REV MATER SCI, V27, P117, DOI 10.1146/annurev.matsci.27.1.117; Zahn S, 1999, ORG LETT, V1, P861, DOI 10.1021/ol990715a; Zahn S, 1998, ANGEW CHEM INT EDIT, V37, P305, DOI 10.1002/(SICI)1521-3773(19980216)37:3<305::AID-ANIE305>3.0.CO;2-T; ZELIKOVICH L, 1995, NATURE, V374, P790, DOI 10.1038/374790a0	25	192	195	3	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1404	1407		10.1126/science.288.5470.1404	http://dx.doi.org/10.1126/science.288.5470.1404			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827947				2022-12-28	WOS:000087270900045
J	Van Vlem, B; Billiouw, JM				Van Vlem, B; Billiouw, JM			Xanthogranulomatous pyelonephritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Onze Lieve Vrouw Hosp, B-9300 Aalst, Belgium		Van Vlem, B (corresponding author), Onze Lieve Vrouw Hosp, B-9300 Aalst, Belgium.								0	1	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2000	342	21					1572	1572		10.1056/NEJM200005253422105	http://dx.doi.org/10.1056/NEJM200005253422105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316XJ	10824076				2022-12-28	WOS:000087193100005
J	Ackers, ML; Puhr, ND; Tauxe, RV; Mintz, ED				Ackers, ML; Puhr, ND; Tauxe, RV; Mintz, ED			Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States - Antimicrobial resistance on the rise	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CA	Infect Dis Soc Amer			DRUG-RESISTANCE; PHAGE TYPES; FEVER; INDIA; TRAVEL	Context Multidrug-resistant Salmonella serotype Typhi infections have been reported worldwide, but data on the incidence of resistant strains in the United States are lacking. Objectives To determine the incidence of antimicrobial-resistant Salmonella Typhi infections and to identify risk factors for infection, Design Cross-sectional laboratory-based surveillance study. Setting and Participants A total of 293 persons with symptomatic typhoid fever who had Salmonella Typhi isolates and epidemiological information submitted to US public health departments and laboratories from June 1, 1996, to May 31, 1997, Main Outcome Measures Proportion of Salmonella Typhi isolates demonstrating resistance to 12 antimicrobial agents; patient epidemiological factors associated with drug-resistant infections. Results Median age was 21 years (range, 3 months to 84 years); 56% were male, Two hundred twenty-eight (80%) were hospitalized; 2 died. In the 6 weeks before illness onset, 81% of patients had traveled abroad. Seventy-four Salmonella Typhi isolates (25%) were resistant to 1 or more antimicrobial agent, and 51 (17%) were resistant to 5 or more agents, including ampicillin, chloramphenicol, and trimethoprimsulfamethoxazole (multidrug-resistant Salmonella Typhi [MDRST]). Although no resistance to ciprofloxacin or ceftriaxone was observed, 20 isolates (7%) were nalidixic acid-resistant (NARST). Patients with MDRST and NARST infections were more likely to report travel outside the United States, particularly to the Indian subcontinent (Bangladesh, India, and Pakistan) (odds ratio [OR], 29.3; 95% confidence interval [CI], 6.8-126.7; P<.001 and OR, 35.9; 95% CI, 3.4-377.3; P<.001, respectively). Conclusions Our data suggest that ciprofloxacin and ceftriaxone are appropriate empirical therapy for suspected typhoid fever; however, resistance may be anticipated. Continued monitoring of antimicrobial resistance among Salmonella Typhi strains will help determine vaccination and treatment policies.	Ctr Dis Control & Prevent, Food & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Mintz, ED (corresponding author), Ctr Dis Control & Prevent, Food & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Mail Stop A-38,1600 Clifton Rd, Atlanta, GA 30333 USA.							AGARWAL V, 1992, INDIAN J MED RES-A, V95, P14; AM NT, 1993, B SOC PATHOL EXOT, V86, P476; Atkins BL, 1998, JAMA-J AM MED ASSOC, V279, P579, DOI 10.1001/jama.279.8.579; Bhatia R S, 1992, J Assoc Physicians India, V40, P705; BHUTTA ZA, 1991, REV INFECT DIS, V13, P832; *CDCP, 1997, HLTH INF INT TRAV 19, P199; CHANDRA R, 1992, J TROP MED HYG, V95, P284; COOVADIA YM, 1992, Q J MED, V82, P91; Daga M K, 1994, J Assoc Physicians India, V42, P599; GULATI S, 1992, ANN TROP PAEDIATR, V12, P137, DOI 10.1080/02724936.1992.11747558; HUANG MB, 1992, J CLIN MICROBIOL, V30, P3243, DOI 10.1128/JCM.30.12.3243-3248.1992; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P419; Mahon BE, 1996, JAMA-J AM MED ASSOC, V276, P307, DOI 10.1001/jama.276.4.307; Mermin JH, 1998, ARCH INTERN MED, V158, P633, DOI 10.1001/archinte.158.6.633; *NAT COMM CLIN LAB, 1995, PUBL NAT COMM CLIN L; PILLAI PK, 1993, INDIAN J MED RES-A, V97, P154; RAO PS, 1993, AM J TROP MED HYG, V48, P108, DOI 10.4269/ajtmh.1993.48.108; RICE PA, 1977, AM J EPIDEMIOL, V106, P160, DOI 10.1093/oxfordjournals.aje.a112446; Rowe B, 1997, CLIN INFECT DIS, V24, pS106, DOI 10.1093/clinids/24.Supplement_1.S106; ROWE B, 1991, LANCET, V337, P1422, DOI 10.1016/0140-6736(91)93116-Q; RYAN CA, 1989, REV INFECT DIS, V11, P1; Saha SK, 1999, PEDIATR INFECT DIS J, V18, P387, DOI 10.1097/00006454-199904000-00018; SUDARSANA J, 1992, INDIAN J MED RES-A, V95, P68; Threlfall EJ, 1999, LANCET, V353, P1590, DOI 10.1016/S0140-6736(99)01001-6; UMASANKAR S, 1992, BUR, V2, pR139; *US TRAV TOUR ADM, 1998, INT TRAV US 1996 US, P4; Wain J, 1997, CLIN INFECT DIS, V25, P1404, DOI 10.1086/516128; Zhang L, 1991, Zhonghua Yi Xue Za Zhi, V71, P314; ZHANG L, 1991, CHUNG HUA HSUEH TSA, V71, P324	29	130	134	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2668	2673		10.1001/jama.283.20.2668	http://dx.doi.org/10.1001/jama.283.20.2668			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	314FP	10819949				2022-12-28	WOS:000087046000034
J	Lopes-Gautier, R; Doute, S; Smythe, WD; Kamp, LW; Carlson, RW; Davies, AG; Leader, FE; McEwen, AS; Geissler, PE; Kieffer, SW; Keszthelyi, L; Barbinis, E; Mehlman, R; Segura, M; Shirley, J; Soderblom, LA				Lopes-Gautier, R; Doute, S; Smythe, WD; Kamp, LW; Carlson, RW; Davies, AG; Leader, FE; McEwen, AS; Geissler, PE; Kieffer, SW; Keszthelyi, L; Barbinis, E; Mehlman, R; Segura, M; Shirley, J; Soderblom, LA			A close-up look at Io from Galileo's near-infrared mapping spectrometer	SCIENCE			English	Article							ACTIVE VOLCANISM; SILICATE	Infrared spectral images of Jupiter's volcanic moon lo, acquired during the October and November 1999 and February 2000 flybys of the Galileo spacecraft, were used to study the thermal structure and sulfur dioxide distribution of active volcanoes. Loki Patera, the solar system's most powerful known volcano, exhibits Large expanses of dark, cooling lava on its caldera floor. Prometheus, the site of long-lived plume activity, has two major areas of thermal emission, which support ideas of plume migration. Sulfur dioxide deposits were mapped at local scales and show a more complex relationship to surface colors than previously thought, indicating the presence of other sulfur compounds.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Calif Los Angeles, IGPP, Los Angeles, CA 90095 USA; SW Kieffer Sci Consulting Inc, Bolton, ON L7E 5T4, Canada; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; US Geol Survey, Flagstaff, AZ 86001 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of California System; University of California Los Angeles; University of Arizona; United States Department of the Interior; United States Geological Survey	Lopes-Gautier, R (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	rlopes@lively.jpl.nasa.gov	Shirley, James/AAR-1264-2020; Lopes, Rosaly M.C./D-1608-2016; Davies, Ashley/S-5588-2018	Lopes, Rosaly M.C./0000-0002-7928-3167; Kestay, Laszlo/0000-0003-1879-4331; Davies, Ashley/0000-0003-1747-8142				Carlson RW, 1997, GEOPHYS RES LETT, V24, P2479, DOI 10.1029/97GL02609; Davies AG, 1996, ICARUS, V124, P45, DOI 10.1006/icar.1996.0189; DAVIES AG, 1999, LUNAR PLANET SCI, V30; DOUTE S, UNPUB; Geissler PE, 1999, ICARUS, V140, P265, DOI 10.1006/icar.1999.6128; HOWELL R, 2000, LUNAR PLANET SCI, V31; Kieffer SW, 2000, SCIENCE, V288, P1204, DOI 10.1126/science.288.5469.1204; Lopes-Gautier R, 1999, ICARUS, V140, P243, DOI 10.1006/icar.1999.6129; McEwen AS, 2000, SCIENCE, V288, P1193, DOI 10.1126/science.288.5469.1193; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; McEwen AS, 1998, SCIENCE, V281, P87, DOI 10.1126/science.281.5373.87; Pearl J.S., 1982, SATELLITES JUPITER, P724; Schmitt B, 1998, ASTROPHYS SPACE SC L, V227, P199, DOI 10.1007/978-94-011-5252-5_9; SCHMITT B, 1994, ICARUS, V111, P79, DOI 10.1006/icar.1994.1135; Spencer JR, 1997, ICARUS, V127, P221, DOI 10.1006/icar.1996.5670; Spencer JR, 2000, SCIENCE, V288, P1208, DOI 10.1126/science.288.5469.1208; Strom R. G., 1982, SATELLITES JUPITER, P598	17	74	74	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	2000	288	5469					1201	1204		10.1126/science.288.5469.1201	http://dx.doi.org/10.1126/science.288.5469.1201			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817988				2022-12-28	WOS:000087112600040
J	Goodman, WG; Goldin, J; Kuizon, BD; Yoon, C; Gales, B; Sider, D; Wang, Y; Chung, J; Emerick, A; Greaser, L; Elashoff, RM; Salusky, IB				Goodman, WG; Goldin, J; Kuizon, BD; Yoon, C; Gales, B; Sider, D; Wang, Y; Chung, J; Emerick, A; Greaser, L; Elashoff, RM; Salusky, IB			Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BEAM COMPUTED-TOMOGRAPHY; NONINVASIVE DETECTION; HEMODIALYSIS-PATIENTS; PEDIATRIC-PATIENTS; CALCIUM; MORTALITY; ATHEROSCLEROSIS; TRANSPLANT; ASSOCIATION; THERAPY	Background: Cardiovascular disease is common in older adults with end-stage renal disease who are undergoing regular dialysis, but little is known about the prevalence and extent of cardiovascular disease in children and young adults with end-stage renal disease. Methods: We used electron-beam computed tomography (CT) to screen for coronary-artery calcification in 39 young patients with end-stage renal disease who were undergoing dialysis (mean [+/-SD] age, 19+/-7 years; range, 7 to 30) and 60 normal subjects 20 to 30 years of age. In those with evidence of calcification on CT scanning, we determined its extent. The results were correlated with the patients' clinical characteristics, serum calcium and phosphorus concentrations, and other biochemical variables. Results: None of the 23 patients who were younger than 20 years of age had evidence of coronary-artery calcification, but it was present in 14 of the 16 patients who were 20 to 30 years old. Among those with calcification, the mean calcification score was 1157+/-1996, and the median score was 297. By contrast, only 3 of the 60 normal subjects had calcification. As compared with the patients without coronary-artery calcification, those with calcification were older (26+/-3 vs. 15+/-5 years, P<0.001) and had been undergoing dialysis for a longer period (14+/-5 vs. 4+/-4 years, P<0.001). The mean serum phosphorus concentration, the mean calcium-phosphorus ion product in serum, and the daily intake of calcium were higher among the patients with coronary-artery calcification. Among 10 patients with calcification who underwent follow-up CT scanning, the calcification score nearly doubled (from 125+/-104 to 249+/-216, P=0.02) over a mean period of 20+/-3 months. Conclusions: Coronary-artery calcification is common and progressive in young adults with end-stage renal disease who are undergoing dialysis. (N Engl J Med 2000;342:1478-83.) (C)2000, Massachusetts Medical Society.	Univ Calif Los Angeles, Med Ctr, Div Nephrol, Sch Med,Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Goodman, WG (corresponding author), Univ Calif Los Angeles, Med Ctr, Div Nephrol, Sch Med,Dept Med, 7-155 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.			Goldin, Jonathan/0000-0003-3007-9947	NCRR NIH HHS [RR-00865] Funding Source: Medline; NIDDK NIH HHS [DK-35423, DK-52905] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052905, R01DK035423] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Achenbach S, 1998, NEW ENGL J MED, V339, P1964, DOI 10.1056/NEJM199812313392702; AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; AVRAM MM, 1992, AM J KIDNEY DIS, V20, P324, DOI 10.1016/S0272-6386(12)70294-9; Bergstrom J, 1998, AM J KIDNEY DIS, V32, P834, DOI 10.1016/S0272-6386(98)70148-9; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; Bostom AG, 1996, ATHEROSCLEROSIS, V125, P91, DOI 10.1016/0021-9150(96)05865-0; Braun J, 1996, AM J KIDNEY DIS, V27, P394, DOI 10.1016/S0272-6386(96)90363-7; Celermajer DS, 1998, NEW ENGL J MED, V339, P2014, DOI 10.1056/NEJM199812313392709; DEFRONZO RA, 1978, METABOLISM, V27, P1866, DOI 10.1016/S0026-0495(78)80005-5; Dixon WJ., 1983, INTRO STAT ANAL; Fiorino AS, 1998, ANN INTERN MED, V128, P839, DOI 10.7326/0003-4819-128-10-199805150-00008; Hsu CH, 1997, AM J KIDNEY DIS, V29, P641, DOI 10.1016/S0272-6386(97)90352-8; KAUFMANN RB, 1995, MAYO CLIN PROC, V70, P223, DOI 10.4065/70.3.223; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; Maher JE, 1999, MAYO CLIN PROC, V74, P347, DOI 10.4065/74.4.347; Mailloux LU, 1998, AM J KIDNEY DIS, V32, P705, DOI 10.1016/S0272-6386(98)70146-5; MAUTNER SL, 1994, RADIOLOGY, V192, P625, DOI 10.1148/radiology.192.3.8058925; MILLINER DS, 1990, KIDNEY INT, V38, P931, DOI 10.1038/ki.1990.293; *NAT I DIAB DIG KI, 1998, REN DAT SYST USRDS 1, V1999, P63; Owen WF, 1996, AM J KIDNEY DIS, V28, P931, DOI 10.1016/S0272-6386(96)90397-2; PENNISI AJ, 1976, AM J DIS CHILD, V130, P957, DOI 10.1001/archpedi.1976.02120100047007; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; Rumberger JA, 1999, MAYO CLIN PROC, V74, P538; RUMBERGER JA, 1995, CIRCULATION, V91, P1363, DOI 10.1161/01.CIR.91.5.1363; RUMBERGER JA, 1994, AM J CARDIOL, V73, P1169, DOI 10.1016/0002-9149(94)90176-7; Rumberger JA, 1999, MAYO CLIN PROC, V74, P243, DOI 10.4065/74.3.243; Salusky IB, 1998, KIDNEY INT, V54, P907, DOI 10.1046/j.1523-1755.1998.00045.x; SALUSKY IB, 1988, KIDNEY INT, V33, P975, DOI 10.1038/ki.1988.96; Warady BA, 1997, PEDIATR NEPHROL, V11, P49, DOI 10.1007/s004670050232; Watson KE, 1997, CIRCULATION, V96, P1755, DOI 10.1161/01.CIR.96.6.1755; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Zager PG, 1998, KIDNEY INT, V54, P1417; Zager PG, 1998, KIDNEY INT, V54, P561, DOI 10.1046/j.1523-1755.1998.00005.x	34	2215	2332	0	74	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2000	342	20					1478	1483		10.1056/NEJM200005183422003	http://dx.doi.org/10.1056/NEJM200005183422003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314QT	10816185	Bronze			2022-12-28	WOS:000087068200003
J	Keller, MB; McCullough, JP; Klein, DN; Arnow, B; Dunner, DL; Gelenberg, AJ; Markowitz, JC; Nemeroff, CB; Russell, JM; Thase, ME; Trivedi, MH; Zajecka, J; Blalock, JA; Borian, FE; Jody, DN; DeBattista, C; Koran, LM; Schatzberg, AF; Fawcett, J; Hirschfeld, RMA; Keitner, G; Miller, I; Kocsis, JH; Kornstein, SG; Manber, R; Ninan, PT; Rothbaum, B; Rush, AJ; Vivian, D; Rothbaum, B				Keller, MB; McCullough, JP; Klein, DN; Arnow, B; Dunner, DL; Gelenberg, AJ; Markowitz, JC; Nemeroff, CB; Russell, JM; Thase, ME; Trivedi, MH; Zajecka, J; Blalock, JA; Borian, FE; Jody, DN; DeBattista, C; Koran, LM; Schatzberg, AF; Fawcett, J; Hirschfeld, RMA; Keitner, G; Miller, I; Kocsis, JH; Kornstein, SG; Manber, R; Ninan, PT; Rothbaum, B; Rush, AJ; Vivian, D; Rothbaum, B			A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DYSTHYMIC DISORDER; MOOD DISORDERS; CLINICAL-TRIAL; DOUBLE-BLIND; IMIPRAMINE; SERTRALINE; CONTINUATION; OUTPATIENTS; OUTCOMES; EFFICACY	Background: Patients with chronic forms of major depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain. Methods: We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both. At base line, all patients had scores of at least 20 on the 24-item Hamilton Rating Scale for Depression (indicating clinically significant depression). Remission was defined as a score of 8 or less at weeks 10 and 12. For patients who did not have remission, a satisfactory response was defined as a reduction in the score by at least 50 percent from base line and a score of 15 or less. Raters were unaware of the patients' treatment assignments. Results: Of the 681 patients, 662 attended at least one treatment session and were included in the analysis of response. The overall rate of response (both remission and satisfactory response) was 48 percent in both the nefazodone group and the psychotherapy group, as compared with 73 percent in the combined-treatment group (P<0.001 for both comparisons). Among the 519 subjects who completed the study, the rates of response were 55 percent in the nefazodone group and 52 percent in the psychotherapy group, as compared with 85 percent in the combined-treatment group (P<0.001 for both comparisons). The rates of withdrawal were similar in the three groups. Adverse events in the nefazodone group were consistent with the known side effects of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness). Conclusions: Although about half of patients with chronic forms of major depression have a response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of psychotherapy, the combination of the two is significantly more efficacious than either treatment alone. (N Engl J Med 2000;342:1462-70.) (C)2000, Massachusetts Medical Society.	Brown Univ, Dept Psychiat, Providence, RI 02906 USA; Virginia Commonwealth Univ, Dept Psychol, Unipolar Mood Disorders Inst, Richmond, VA 23284 USA; SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Arizona, Dept Psychiat, Tucson, AZ USA; Cornell Univ, Coll Med, Dept Psychiat, New York, NY USA; Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA; Univ Texas, Med Branch, Dept Psychiat & Behav Sci, Galveston, TX 77550 USA; Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA; Rush Presbyterian St Lukes Med Ctr, Dept Psychiat, Chicago, IL 60612 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Bristol Myers Squibb Co, Plainsboro, NJ USA	Brown University; Virginia Commonwealth University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stanford University; University of Washington; University of Washington Seattle; University of Arizona; Cornell University; Emory University; University of Texas System; University of Texas Medical Branch Galveston; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Rush University; University of Texas System; UTMD Anderson Cancer Center; Bristol-Myers Squibb	Keller, MB (corresponding author), Brown Univ, Dept Psychiat & Human Behav, 345 Blackstone Blvd, Providence, RI 02906 USA.		Young, Alexander/A-1523-2009; Trivedi, Madhukar/A-9029-2013; Manber, Rachel/GQI-3672-2022	Young, Alexander/0000-0002-9367-9213; Trivedi, Madhukar/0000-0002-2983-1110; Rush, Augustus/0000-0003-2004-2382; Nemeroff, Charles/0000-0001-7867-1160	NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH061590] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AG HLTH CAR POL R, 1993, AHCPR PUBL; [Anonymous], 1993, AM J PSYCHIAT, V150, P1; Beck AT, 1987, COGNITIVE THERAPY DE; CASSANO GB, 1992, J PSYCHIATR RES, V26, P257, DOI 10.1016/0022-3956(92)90032-J; CONTE HR, 1986, ARCH GEN PSYCHIAT, V43, P471; FAWCETT J, 1987, PSYCHOPHARMACOL BULL, V23, P309; Feiger AD, 1999, INT CLIN PSYCHOPHARM, V14, P19, DOI 10.1097/00004850-199901000-00002; GARLOW SJ, 2000, KAPLAN SADOCKS COMPR, V2, P2412; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; Harrison Wilma M., 1995, P124; HAYS RD, 1995, ARCH GEN PSYCHIAT, V52, P11; HOWLAND RH, 1993, HOSP COMMUNITY PSYCH, V44, P633; Judd LL, 1997, J AFFECT DISORDERS, V45, P5, DOI 10.1016/S0165-0327(97)00055-4; Keller MB, 1996, PSYCHIAT CLIN N AM, V19, P1, DOI 10.1016/S0193-953X(05)70270-7; Keller MB, 1998, J CLIN PSYCHIAT, V59, P598, DOI 10.4088/JCP.v59n1107; Keller MB, 1998, JAMA-J AM MED ASSOC, V280, P1665, DOI 10.1001/jama.280.19.1665; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Klein DN, 1998, J ABNORM PSYCHOL, V107, P338, DOI 10.1037/0021-843X.107.2.338; Klerman GL, 1984, INTERPERSONAL PSYCHO; Kocsis JH, 1996, ARCH GEN PSYCHIAT, V53, P769; KOCSIS JH, 1988, ARCH GEN PSYCHIAT, V45, P253; Kocsis JH, 1995, DIAGNOSIS TREATMENT; Lewinsohn P.M., 1974, ESSENTIAL PAPERS DEP, P150; MARKOWITZ JC, 1994, AM J PSYCHIAT, V151, P1114; MCCULLOUGH JP, 1991, J NERV MENT DIS, V179, P734, DOI 10.1097/00005053-199112000-00004; MCCULLOUGH JP, 1984, PSYCHIATRY, V47, P234, DOI 10.1080/00332747.1984.11024245; McCullough JP, 1995, THERAPIST MANUAL COG; McCullough JP, 2000, TREATMENT CHRONIC DE; Miller IW, 1998, J CLIN PSYCHIAT, V59, P608, DOI 10.4088/JCP.v59n1108; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Roth A., 1996, WHAT WORKS WHOM CRIT; Rush AJ, 1999, WPA SER EVID EXPER P, V1, P161; Rush AJ, 1998, J CLIN PSYCHIAT, V59, P589, DOI 10.4088/JCP.v59n1106; SPITZER R. L., 1994, STRUCTURED CLIN INTE; Thase ME, 1996, ARCH GEN PSYCHIAT, V53, P777; WEISSMAN MM, 1988, AM J PSYCHIAT, V145, P815; WELLS KB, 1992, ARCH GEN PSYCHIAT, V49, P788	38	896	911	1	116	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2000	342	20					1462	1470		10.1056/NEJM200005183422001	http://dx.doi.org/10.1056/NEJM200005183422001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	314QT	10816183	Green Published			2022-12-28	WOS:000087068200001
J	Iribarren, C; Sidney, S; Bild, DE; Liu, K; Markovitz, JH; Roseman, JM; Matthews, K				Iribarren, C; Sidney, S; Bild, DE; Liu, K; Markovitz, JH; Roseman, JM; Matthews, K			Association of hostility with coronary artery calcification in young adults - The CARDIA study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Conference on Cardiovascular Disease, Epidemiology, and Prevention	MAR 24-27, 1999	ORLANDO, FLORIDA				DENSITY-LIPOPROTEIN-CHOLESTEROL; ACUTE MYOCARDIAL-INFARCTION; ELECTRON-BEAM CT; HEART-DISEASE; CAROTID ATHEROSCLEROSIS; POSTMENOPAUSAL WOMEN; ADRENALINE INFUSION; TOTAL MORTALITY; RISK-FACTORS; A BEHAVIOR	Context Psychosocial factors, including personality and character traits, may play a role in the development and expression of coronary artery disease. Objective To evaluate whether hostility, a previously reported predictor of clinical coronary artery disease, is associated with coronary calcification, which is a marker of subclinical atherosclerosis. Design Prospective cohort study. Setting and Participants Volunteer subsample from Chicago, ill, and Oakland, Calif, consisting of 374 white and black men and women, aged 18 to 30 years at baseline, who participated in the Coronary Artery Risk Development in You ng Adults (CARDIA) study. Cook-Medley hostility assessment data were collected at baseline from 1985 to 1986 and at year 5 examinations from 1990 to 1992. After the 10-year examinations in the 1995-1996 year, electron-beam computed tomographic scans were performed. Main Outcome Measures Presence of any detectable coronary artery calcification (coronary calcium score >0), and coronary artery calcium scores of 20 or higher. Results In logistic regression analysis adjusting for age, sex, race, and field center comparing those with hostility scores above and below the median of the distribution of the present sample, the odds ratio of having any coronary calcification was 2.57 (95% confidence interval, 1.31-5.22), and the odds ratio of having a calcium score of 20 or higher was 9.56 (95% confidence interval. 2.29-65.9) for calcium scores of 20 or higher. The associations with any coronary artery calcification persisted after adjusting for demographic, lifestyle, and physiological variables. Results using a cynical distrust subscale were somewhat weaker than for those using the global hostility score. Power was inadequate to perform sex- or race-specific analyses. Conclusion These results suggest that a high hostility level may predispose young adults to coronary artery calcification.	Kaiser Permanente Med Care Program, Oakland, CA 94611 USA; NHLBI, Dept Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Northwestern Univ, Sch Med, Dept Family & Community Med, Chicago, IL USA; Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA; Univ Alabama, Div Prevent Med, Birmingham, AL USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA	Kaiser Permanente; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Northwestern University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Iribarren, C (corresponding author), Kaiser Permanente Div Res, 3505 Broadway, Oakland, CA 94611 USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC048048, N01HC048049, N01HC048047] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-48048, N01-HC-48049, N01-HC-48047] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; ALEXANDERSEN P, 1996, ATHEROSCLEROSIS, V125, P11; ARCHER J, 1991, BRIT J PSYCHOL, V82, P12; BAREFOOT JC, 1994, AM J CARDIOL, V74, P439, DOI 10.1016/0002-9149(94)90899-0; BAREFOOT JC, 1995, AM J EPIDEMIOL, V142, P477, DOI 10.1093/oxfordjournals.aje.a117663; BAREFOOT JC, 1983, PSYCHOSOM MED, V45, P59, DOI 10.1097/00006842-198303000-00008; BAREFOOT JC, 1989, PSYCHOSOM MED, V51, P46, DOI 10.1097/00006842-198901000-00005; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BIELAK LF, 1994, RADIOLOGY, V192, P631, DOI 10.1148/radiology.192.3.8058926; Bild DE, 1996, ANN EPIDEMIOL, V6, P235, DOI 10.1016/1047-2797(96)00005-1; Bild DE, 1997, CAN J CARDIOL SB, V13, p241B; Blankenhorn DH, 1961, AM J MED SCI, V42, P1; Cook W, 1954, J APPL PSYCHOL, V386, P414; DEMBROSKI TM, 1985, PSYCHOSOM MED, V47, P219, DOI 10.1097/00006842-198505000-00001; DEMBROSKI TM, 1989, PSYCHOSOM MED, V51, P514, DOI 10.1097/00006842-198909000-00003; DIAMOND EL, 1982, PSYCHOL BULL, V92, P410, DOI 10.1037/0033-2909.92.2.410; DOUMA S, 1992, NOUV REV FR HEMATOL, V34, P73; DYER AR, 1990, J CLIN EPIDEMIOL, V43, P11; Everson SA, 1997, AM J EPIDEMIOL, V146, P142; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FRIEDMAN GD, 1988, J CLIN EPIDEMIOL, V41, P1105, DOI 10.1016/0895-4356(88)90080-7; FRIEDMAN M, 1986, AM HEART J, V112, P653, DOI 10.1016/0002-8703(86)90458-8; Goodman M, 1996, MAYO CLIN PROC, V71, P729; Guyll M, 1998, HEALTH PSYCHOL, V17, P30, DOI 10.1037/0278-6133.17.1.30; HEARN MD, 1989, J BEHAV MED, V12, P105, DOI 10.1007/BF00846545; HELMER DC, 1991, AM J EPIDEMIOL, V133, P112, DOI 10.1093/oxfordjournals.aje.a115850; HUGHES GH, 1987, CONTROL CLIN TRIA S4, V8, pSB68; Jacobs DR, 1989, J CARDIOPULM REHABIL, V9, p448B; JULKUNEN J, 1994, PSYCHOSOM MED, V56, P519, DOI 10.1097/00006842-199411000-00007; KAUFMANN RB, 1994, RADIOLOGY, V190, P347, DOI 10.1148/radiology.190.2.8284380; Kennedy J, 1998, AM HEART J, V135, P696, DOI 10.1016/S0002-8703(98)70288-1; KOSKENVUO M, 1988, PSYCHOSOM MED, V50, P330, DOI 10.1097/00006842-198807000-00002; Lahad A, 1997, J PSYCHOSOM RES, V43, P183, DOI 10.1016/S0022-3999(96)00369-8; LARSSON PT, 1989, BRIT J CLIN PHARMACO, V28, P663, DOI 10.1111/j.1365-2125.1989.tb03559.x; Lavie CJ, 1999, MAYO CLIN PROC, V74, P959; LEON GR, 1988, J CONSULT CLIN PSYCH, V56, P597, DOI 10.1037/0022-006X.56.4.597; Markovitz JH, 1998, PSYCHOSOM MED, V60, P586, DOI 10.1097/00006842-199809000-00013; Matthews KA, 1998, PSYCHOSOM MED, V60, P633, DOI 10.1097/00006842-199809000-00021; Pasic J, 1998, AM J HYPERTENS, V11, P245, DOI 10.1016/S0895-7061(97)00464-0; Rumberger JA, 1996, MAYO CLIN PROC, V71, P369, DOI 10.4065/71.4.369; SCHERWITZ L, 1991, PSYCHOSOM MED, V53, P36, DOI 10.1097/00006842-199101000-00004; SCHERWITZ LW, 1992, AM J EPIDEMIOL, V136, P136, DOI 10.1093/oxfordjournals.aje.a116480; SECCI A, 1997, CIRCULATION, V96, P112; SHEKELLE RB, 1983, PSYCHOSOM MED, V45, P109, DOI 10.1097/00006842-198305000-00003; SMITH TW, 1992, HEALTH PSYCHOL, V11, P139, DOI 10.1037/0278-6133.11.3.139; Suarez EC, 1997, PSYCHOSOM MED, V59, P481, DOI 10.1097/00006842-199709000-00004; Suarez EC, 1998, PSYCHOSOM MED, V60, P78, DOI 10.1097/00006842-199801000-00017; Suarez EC, 1998, J PSYCHOSOM RES, V44, P261, DOI 10.1016/S0022-3999(97)00201-8; Warnick G R, 1986, Methods Enzymol, V129, P101; WARNICK GR, 1982, CLIN CHEM, V28, P1379; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175	51	163	169	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2546	2551		10.1001/jama.283.19.2546	http://dx.doi.org/10.1001/jama.283.19.2546			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	312VL	10815118	Bronze			2022-12-28	WOS:000086964600035
J	Dahlback, B				Dahlback, B			Blood coagulation	LANCET			English	Article							ACTIVATED PROTEIN-C; TISSUE FACTOR PATHWAY; POOR ANTICOAGULANT RESPONSE; FACTOR-V-LEIDEN; VENOUS THROMBOSIS; INHERITED THROMBOPHILIA; PROTHROMBIN DEFICIENCY; TARGETED DISRUPTION; EMBRYONIC LETHALITY; BLEEDING EVENTS	Under normal circumstances, the coagulation system is balanced in favour of anticoagulation. Thrombin is the key effector enzyme of the clotting cascade. Antagonists of vitamin K inhibit a vitamin-K-dependent post-translational modification of several coagulation proteins, which is required for these proteins to attain a phospholipid-binding conformation. Heparin stimulates the activity of antithrombin, a serine-protease inhibitor. Analysis of knock-out mice has shown the relative importance of the coagulation factors in vivo. Gene therapy may soon be a therapeutic option for inherited deficiencies of factors VIII and IX.	Univ Lund Hosp, Dept Clin Chem, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Dahlback, B (corresponding author), Univ Lund Hosp, Dept Clin Chem, S-20502 Malmo, Sweden.	bjorn.dahlback@klkemi.mas.lu.se		Dahlback, Bjorn/0000-0003-1546-0328				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Brackmann HH, 1998, EUR J HAEMATOL, V61, P18; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Carmeliet P, 1998, CARDIOVASC RES, V39, P8, DOI 10.1016/S0008-6363(98)00108-4; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; Dahlback B, 1999, J LAB CLIN MED, V133, P415, DOI 10.1016/S0022-2143(99)90018-5; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1995, THROMB RES, V77, P1, DOI 10.1016/0049-3848(94)00138-4; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; DiMichele DM, 1998, HAEMOPHILIA, V4, P568; FURIE B, 1992, NEW ENGL J MED, V326, P800; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Hoffman M, 1996, HAEMOSTASIS, V26, P12; Huang ZF, 1997, BLOOD, V90, P944, DOI 10.1182/blood.V90.3.944.944_944_951; Jalbert LR, 1998, J CLIN INVEST, V102, P1481, DOI 10.1172/JCI3011; Kirchhofer D, 1996, CURR OPIN BIOTECH, V7, P386, DOI 10.1016/S0958-1669(96)80112-1; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; Kundu RK, 1998, BLOOD, V92, P168, DOI 10.1182/blood.V92.1.168.413k06_168_174; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P651; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P824; LINDAHL U, 1991, THROMB HAEMOSTASIS, V66, P44; Lindqvist PG, 1998, THROMB HAEMOSTASIS, V79, P69; Mann KG, 1998, BLOOD COAGUL FIBRIN, V9, pS3; MANN KG, 1993, METHOD ENZYMOL, V222, P1; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Rosen ED, 1997, NATURE, V390, P290, DOI 10.1038/36862; Rosenberg RD, 1997, THROMB HAEMOSTASIS, V78, P705; Rosendaal FR, 1997, SEMIN HEMATOL, V34, P171; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; Sun WY, 1998, P NATL ACAD SCI USA, V95, P7597, DOI 10.1073/pnas.95.13.7597; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; Thorelli E, 1999, BLOOD, V93, P2552, DOI 10.1182/blood.V93.8.2552.408k15_2552_2558; Toomey JR, 1996, BLOOD, V88, P1583; Triplett DA, 1996, HAEMOSTASIS, V26, P358; Xue JC, 1998, P NATL ACAD SCI USA, V95, P7603, DOI 10.1073/pnas.95.13.7603; Zivelin A, 1997, BLOOD, V89, P397; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	44	514	565	2	105	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 6	2000	355	9215					1627	1632		10.1016/S0140-6736(00)02225-X	http://dx.doi.org/10.1016/S0140-6736(00)02225-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821379				2022-12-28	WOS:000086981200037
J	El Goresy, A; Dubrovinsky, L; Sharp, TG; Saxena, SK; Chen, M				El Goresy, A; Dubrovinsky, L; Sharp, TG; Saxena, SK; Chen, M			A monoclinic post-stishovite polymorph of silica in the Shergotty meteorite	SCIENCE			English	Article							PEROVSKITE MGSIO3; PRESSURE; PHASE; MANTLE; TRANSITION; HISTORY	A post-stishovite phase of silica was identified in the Shergotty meteorite by x-ray diffraction and field emission scanning electron microscopy. The diffraction pattern revealed a monoclinic Lattice, similar to the baddeleyite-structured polymorph with the cell parameters a = 4.375(1) angstroms, b = 4.584(1) angstroms, c = 4.708(1) angstroms, beta = 99.97(3), rho = 4.30(2) grams per cubic centimeter, where the numbers in parentheses are the maximum deviations. Transmission electron microscopy investigations indicate the presence of the alpha-lead dioxide-like polymorph, stishovite, and secondary cristobalite in the same silica grain. The mixture of high-density polymorphs suggests that several post-stishovite phases were formed during the shock event on the Shergotty parent body.	Max Planck Inst Chem, D-55128 Mainz, Germany; Uppsala Univ, Inst Earth Sci, Theoret Geochem Program, S-75236 Uppsala, Sweden; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Acad Sinica, Guangzhou Inst Geochem, Guangzhou 510640, Peoples R China	Max Planck Society; Uppsala University; Arizona State University; Arizona State University-Tempe; Chinese Academy of Sciences; Guangzhou Institute of Geochemistry, CAS	El Goresy, A (corresponding author), Max Planck Inst Chem, J Becher Weg 27, D-55128 Mainz, Germany.			Dubrovinsky, Leonid/0000-0002-3717-7585				Belonoshko AB, 1996, AM MINERAL, V81, P785; CHAO ECT, 1962, J GEOPHYS RES, V67, P419, DOI 10.1029/JZ067i001p00419; CHAO ECT, 1967, SCIENCE, V156, P192, DOI 10.1126/science.156.3772.192; CHAO ECT, 1967, GEOCHEMISTRY-USSR, V2, P204; CHAO ETC, 1968, SHOCK METAMORPHISM N; Dubrovinsky LS, 1997, NATURE, V388, P362, DOI 10.1038/41066; DUBROVINSKY LS, UNPUB PHYS REV LETT; DUBROVINSKY LS, UNPUB PHYS CHEM MINE; DUBROVINSKY LS, 1996, HIGH PRESSURE SCI TE, P921; El Goresy A, 1998, METEORIT PLANET SCI, V33, pA45; ElGoresy A, 1997, METEORIT PLANET SCI, V32, pA38; ELGORESY A, 1998, LUNAR PLANET SCI C, V29, P1707; GILLET P, 1984, EARTH PLANET SC LETT, V70, P426, DOI 10.1016/0012-821X(84)90026-8; HEMLEY RJ, 1994, REV MINERAL, V29, P41; Karki BB, 1997, PHYS REV B, V55, P3465, DOI 10.1103/PhysRevB.55.3465; KINGMA KJ, 1995, NATURE, V374, P243, DOI 10.1038/374243a0; LEGER JM, 1994, J MATER SCI LETT, V13, P1688, DOI 10.1007/BF00451741; MCCULLOUGH JD, 1959, ACTA CRYSTALLOGR, V12, P507, DOI 10.1107/S0365110X59001530; MULLER WF, 1993, GEOCHIM COSMOCHIM AC, V57, P4311, DOI 10.1016/0016-7037(93)90325-Q; Olsen JS, 1999, J PHYS CHEM SOLIDS, V60, P229, DOI 10.1016/S0022-3697(98)00274-1; Saxena SK, 1998, EUR J MINERAL, V10, P1275; Saxena SK, 1996, SCIENCE, V274, P1357, DOI 10.1126/science.274.5291.1357; Sharma S, 1998, CAN J OPHTHALMOL, V33, P144; Sharp TG, 1999, SCIENCE, V284, P1511, DOI 10.1126/science.284.5419.1511; Stishov S., 1961, GEOCHEMISTRY-USSR, P837; STOFFLER D, 1986, GEOCHIM COSMOCHIM AC, V50, P889, DOI 10.1016/0016-7037(86)90371-6; STOFFLER D, 1974, FORTSCHR MINERAL, V51, P256; Teter DM, 1998, PHYS REV LETT, V80, P2145, DOI 10.1103/PhysRevLett.80.2145	28	94	96	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1632	1634						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834840				2022-12-28	WOS:000087382300038
J	Posey, JE; Gherardini, FC				Posey, JE; Gherardini, FC			Lack of a role for iron in the Lyme disease pathogen	SCIENCE			English	Article							BORRELIA-BURGDORFERI; LACTOBACILLUS-PLANTARUM; SUPEROXIDE-DISMUTASE; BACILLUS-SUBTILIS; SEQUENCE; IDENTIFICATION; ACQUISITION; SPIROCHETE; MANGANESE; INFECTION	A fundamental tenet of microbial pathogenesis is that bacterial pathogens must overcome host iron limitation to establish a successful infection. Surprisingly, the Lyme disease pathogen Borrelia burgdorferi has bypassed this host defense by eliminating the need for iron. B. burgdorferi grew normally and did not alter gene expression in the presence of iron chelators. Furthermore, typical bacterial iron-containing proteins were not detected in cell lysates, nor were the genes encoding such proteins identified in the genome sequence. The intracellular concentration of iron in B. burgdorferi was estimated to be less than 10 atoms per cell, well below a physiologically relevant concentration.	Univ Georgia, Dept Microbiol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Gherardini, FC (corresponding author), Univ Georgia, Dept Microbiol, Athens, GA 30602 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000905, ZIAAI000905, Z01AI000906, ZIAAI000906, R29AI033501] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33501, AI144911] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANO A, 1990, J BACTERIOL, V172, P1457, DOI 10.1128/jb.172.3.1457-1463.1990; ARCHIBALD F, 1983, FEMS MICROBIOL LETT, V19, P29, DOI 10.1111/j.1574-6968.1983.tb00504.x; ARCHIBALD FS, 1984, J BACTERIOL, V158, P1; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BLEDSOE HA, 1994, J BACTERIOL, V176, P7447, DOI 10.1128/JB.176.24.7447-7455.1994; Bsat N, 1998, MOL MICROBIOL, V29, P189, DOI 10.1046/j.1365-2958.1998.00921.x; BULLEN JJ, 1981, REV INFECT DIS, V3, P1127; CHEN L, 1993, J BACTERIOL, V175, P5428, DOI 10.1128/JB.175.17.5428-5437.1993; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GRAEFFWOHLLEBEN H, 1997, J BACTERIOL, V179, P21941; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549; Ma JF, 1999, J BACTERIOL, V181, P3730, DOI 10.1128/JB.181.12.3730-3742.1999; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTIN ME, 1986, J BIOL CHEM, V261, P9361; Payne Shelley M., 1993, Trends in Microbiology, V1, P66, DOI 10.1016/0966-842X(93)90036-Q; WEINBERG ED, 1978, MICROBIOL REV, V42, P45, DOI 10.1128/MMBR.42.1.45-66.1978; Whitehouse CA, 1997, INFECT IMMUN, V65, P4865, DOI 10.1128/IAI.65.11.4865-4868.1997; WOOLDRIDGE KG, 1993, FEMS MICROBIOL REV, V12, P325, DOI 10.1016/0168-6445(93)90011-W	20	374	384	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1651	1653		10.1126/science.288.5471.1651	http://dx.doi.org/10.1126/science.288.5471.1651			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834845				2022-12-28	WOS:000087382300043
J	Dumelow, C; Littlejohns, P; Griffiths, S				Dumelow, C; Littlejohns, P; Griffiths, S			Relation between a career and family life for English hospital consultants: qualitative, semistructured interview study	BRITISH MEDICAL JOURNAL			English	Article							WOMEN DOCTORS; STRESS	Objective To explore the relation between work and family life among hospital consultants and their attitude towards the choices and constraints that influence this relation. Design Qualitative study of consultants' experiences and views based on tape recorded semistructured interviews. Setting Former South Thames health region in southeast England. Participants 202 male and female NHS hospital consultants aged between 40 to 50 years representing all hospital medical specialties. Results Three types of relation between work and family life (career dominant, segregated, and accommodating) were identified among hospital consultants. Most consultants had a segregated relation, although female consultants were more likely than male consultants to have a career dominant or an accommodating relation. Many male consultants and some female consultants expressed considerable dissatisfaction with the balance between their career and family life. A factor influencing this dissatisfaction was the perceived lack of choice to spend time on their personal or family life, because of the working practices and attitudes within hospital culture, if they wanted a successful career. Conclusions Consultants are currently fitting in with the profession rather than the profession adapting to enable doctors to have fulfilling professional and personal lives. Current government policies to increase the medical workforce and promote family friendly policies in the NHS ought to take account of the need for a fundamental change in hospital culture to enable doctors to be more involved in their personal or family life without detriment to their career progress.	Univ London St Georges Hosp, Sch Med, Dept Publ Hlth, Hlth Care Evaluat Unit, London SW17 0RE, England; Oxfordshire Hlth Author, Dept Publ Hlth & Hlth Policy, Oxford OX3 7LG, England	St Georges University London	Dumelow, C (corresponding author), 92 Tennyson Ave, Rugby CV22 6JF, England.							Allen, 1988, DOCTORS THEIR CAREER; ALLEN L, 1994, DOCTORS THEIR CAREER; BYNOE G, 1994, BRIT J HOSP MED, V51, P267; *DEP HLTH, 1996, GUID SPEC REG TRAIN; *DEP HLTH, 1999, IMPR WORK LIV; ELLIOT FR, 1979, SOC SCI MED-MED SOC, VA13, P57, DOI 10.1016/0160-7979(79)90008-0; FIRTHCOZENS J, 1990, BRIT MED J, V301, P89, DOI 10.1136/bmj.301.6743.89; Lewis Susan., 1997, GENDER WORK ORGAN, V4, P13, DOI DOI 10.1111/1468-0432.00020; Liff Sonia., 1997, GENDER WORK ORGAN, V4, P35, DOI [10.1111/1468-0432.00022, DOI 10.1111/1468-0432.00022]; Newman J., 1995, GENDER CULTURE ORG C, P10; *NHS MAN EX, 1991, JUN DOCT NEW DEAL; RHODES PJ, 1989, MED EDUC, V23, P125, DOI 10.1111/j.1365-2923.1989.tb00876.x; Ritchie J, 2002, ANAL QUALITATIVE DAT, P187; SWERDLOW AJ, 1980, BRIT MED J, V281, P754, DOI 10.1136/bmj.281.6242.754; Tait A, 1995, MED EDUC, V29, P372, DOI 10.1111/j.1365-2923.1995.tb00028.x; WARD AWM, 1981, CAREERS MED WOMEN; Webb J., 1997, GENDER WORK ORGAN, V4, P159; White C, 1998, BRIT MED J, V317, P300, DOI 10.1136/bmj.317.7154.300; [No title captured]	19	51	54	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1437	1440		10.1136/bmj.320.7247.1437	http://dx.doi.org/10.1136/bmj.320.7247.1437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827044	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000087414700024
J	Dyer, G				Dyer, G			Tobacco firms fight ban on advertisements	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1427	1427						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827037	Green Published			2022-12-28	WOS:000087414700015
J	Du, YQ; Karniadakis, GE				Du, YQ; Karniadakis, GE			Suppressing wall turbulence by means of a transverse traveling wave	SCIENCE			English	Article							BOUNDARY-LAYER; FLOW; SURFACES	Direct numerical simulations of wall-bounded flow reveal that turbulence production can be suppressed by a transverse traveling wave. Flow visualizations show that the near-wall streaks are eliminated, in contrast to other turbulence-control techniques, leading to a large shear stress reduction. The traveling wave can be induced by a spanwise force that is confined within the viscous sublayer; it has its maximum at the wall and decays exponentially away from it. We demonstrate the application of this approach in salt water, using arrays of electromagnetic tiles that produce the required traveling wave excitation at a high efficiency.	Brown Univ, Div Appl Math, Providence, RI 02912 USA; MIT, Dept Mech Engn, Cambridge, MA 02139 USA	Brown University; Massachusetts Institute of Technology (MIT)	Karniadakis, GE (corresponding author), Brown Univ, Div Appl Math, Providence, RI 02912 USA.							BECHERT DW, 1989, J FLUID MECH, V206, P105, DOI 10.1017/S0022112089002247; CHOI KS, 1989, J FLUID MECH, V208, P417, DOI 10.1017/S0022112089002892; CHU DC, 1993, J FLUID MECH, V250, P1, DOI 10.1017/S0022112093001363; COUSTOLS E, 1992, TURB SKIN FRICT DRAG; Crawford CH, 1997, PHYS FLUIDS, V9, P788, DOI 10.1063/1.869210; DU Y, 1999, THESIS BROWN U PROVI; Gad-el-Hak M., 2000, CONTROL FLOW PASSIVE; HEAD MR, 1981, J FLUID MECH, V107, P297, DOI 10.1017/S0022112081001791; HENOCH C, 1995, PHYS FLUIDS, V7, P1371, DOI 10.1063/1.868525; Ho CM, 1996, J FLUID ENG-T ASME, V118, P437, DOI 10.1115/1.2817778; JUNG WJ, 1992, PHYS FLUIDS A-FLUID, V4, P1605, DOI 10.1063/1.858381; KARNIADAKIS GE, 1999, SPECTRAL HP ELEMENT, P276; KLINE SJ, 1967, J FLUID MECH, V30, P741, DOI 10.1017/S0022112067001740; Near CD, 1996, P SOC PHOTO-OPT INS, V2717, P246, DOI 10.1117/12.239027; NIEUWSTADT F, 2000, LECT NOTES COURSE TU; NOSENCHUCK D, 1996, P ASME FLUID ENG M, P1; NOSENCHUCK D, COMMUNICATION; NOSENCHUCK D, 1993, INT C NEAR WALL TURB, P689; PERRY AE, 1982, J FLUID MECH, V119, P173, DOI 10.1017/S0022112082001311; PHILLIPS RA, COMMUNICATION; REDINIOTIS OK, 2000, 20000522 AIAA; Schoppa W., 1997, P SELF SUST MECH WAL, P385; Sirovich L, 1997, NATURE, V388, P753, DOI 10.1038/41966; Townsend A. A., 1976, STRUCTURE TURBULENT; WALLACE JM, 1982, DEV THEORETICAL APPL, V11, P509; Wallis G, 1997, NEURAL COMPUT, V9, P883, DOI 10.1162/neco.1997.9.4.883	26	139	154	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1230	1234		10.1126/science.288.5469.1230	http://dx.doi.org/10.1126/science.288.5469.1230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817995				2022-12-28	WOS:000087112600047
J	Bianco, PR; Kowalczykowski, SC				Bianco, PR; Kowalczykowski, SC			Translocation step size and mechanism of theRecBC DNA helicase	NATURE			English	Article							COLI RECBCD ENZYME; ESCHERICHIA-COLI; ATP HYDROLYSIS; CRYSTAL-STRUCTURES; DUPLEX DNA; PROCESSIVITY; COMPLEXES; SEQUENCE; BINDING; STRAND	DNA helicases are ubiquitous enzymes that unwind double-stranded DNA(1-3). They are a diverse group of proteins that move in a linear fashion along a one-dimensional polymer lattice-DNA-by using a mechanism that couples nucleoside triphosphate hydrolysis to both translocation and double-stranded DNA unwinding to produce separate strands of DNA. The RecBC enzyme is a processive DNA helicase that functions in homologous recombination in Escherichia coli; it unwinds up to 6,250 base pairs per binding event and hydrolyses slightly more than one ATP molecule per base pair unwound. Here we show, by using a series of gapped oligonucleotide substrates, that this enzyme translocates along only one strand of duplex DNA in the 3' --> 5' direction. The translocating enzyme will traverse, or 'step' across, single-stranded DNA gaps in defined steps that are 23 (+/-2) nucleotides in length. This step is much larger than the amount of double-stranded DNA that can be unwound using the free energy derived from hydrolysis of one molecule of ATP, implying that translocation and DNA unwinding are separate events. We propose that the RecBC enzyme both translocates and unwinds by a quantized, two-step, inchworm-like mechanism that may have parallels for translocation by other linear motor proteins.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA.							Ali JA, 1997, SCIENCE, V276, P21; Bianco PR, 1997, P NATL ACAD SCI USA, V94, P6706, DOI 10.1073/pnas.94.13.6706; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Chamberlin M J, 1992, Harvey Lect, V88, P1; GANESAN S, 1993, J MOL BIOL, V229, P67, DOI 10.1006/jmbi.1993.1008; KORANGY F, 1992, J BIOL CHEM, V267, P3088; KORANGY F, 1994, BIOCHEMISTRY-US, V33, P9552, DOI 10.1021/bi00198a022; KORANGY F, 1993, BIOCHEMISTRY-US, V32, P4873, DOI 10.1021/bi00069a024; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TAYLOR AF, 1995, J BIOL CHEM, V270, P24451, DOI 10.1074/jbc.270.41.24451; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4	17	88	90	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					368	372		10.1038/35012652	http://dx.doi.org/10.1038/35012652			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830968				2022-12-28	WOS:000087085700052
J	Hostetler, SW; Bartlein, PJ; Clark, PU; Small, EE; Solomon, AM				Hostetler, SW; Bartlein, PJ; Clark, PU; Small, EE; Solomon, AM			Simulated influences of Lake Agassiz on the climate of central North America 11,000 years ago	NATURE			English	Article							LAURENTIDE ICE-SHEET; LAST DEGLACIATION; MODEL REGCM2; PLAINS	Eleven thousand years ago, large lakes existed in central and eastern North America along the margin of the Laurentide Ice Sheet. The large-scale North American climate at this time has been simulated with atmospheric general circulation models(1,2), but these relatively coarse global models do not resolve potentially important features of the mesoscale circulation that arise from interactions among the atmosphere, ice sheet, and proglacial lakes. Here we present simulations of the climate of central and eastern North America 11,000 years ago with a high-resolution, regional climate model nested within a general circulation model. The simulated climate is in general agreement with that inferred from palaeoecological evidence. Our experiments indicate that through mesoscale atmospheric feedbacks, the annual delivery of moisture to the Laurentide Ice Sheet was diminished at times of a large, cold Lake Agassiz relative to periods of lower lake stands. The resulting changes in the mass balance of the ice sheet may have contributed to fluctuations of the ice margin, thus affecting the routing of fresh water to the North Atlantic Ocean. A retreating ice margin during periods of high lake level may have opened an outlet for discharge of Lake Agassiz into the North Atlantic. A subsequent advance of the ice margin due to greater moisture delivery associated with a low lake level could have dammed the outlet, thereby reducing discharge to the North Atlantic. These variations may have been decisive in causing the Younger Dryas cold event(3,4).	US Geol Survey, Corvallis, OR 97333 USA; Univ Oregon, Dept Geog, Eugene, OR 97403 USA; Oregon State Univ, Dept Geosci, Corvallis, OR 97333 USA; New Mexico Tech, Dept Earth Sci, Socorro, NM 87801 USA; US EPA, Corvallis, OR 97333 USA	United States Department of the Interior; United States Geological Survey; University of Oregon; Oregon State University; United States Environmental Protection Agency	Hostetler, SW (corresponding author), US Geol Survey, Corvallis, OR 97333 USA.		Bartlein, Patrick J./E-4643-2011; small, eric/B-4939-2011	Bartlein, Patrick J./0000-0001-7657-5685; Small, ERIC/0000-0002-5010-4954				Bartlein PJ, 1998, QUATERNARY SCI REV, V17, P549, DOI 10.1016/S0277-3791(98)00012-2; BARTLEIN PJ, 1993, ELK LAKE MINNESOTA E, P275; BATES GT, 1995, MON WEATHER REV, V123, P1505, DOI 10.1175/1520-0493(1995)123<1505:TYSOTG>2.0.CO;2; BROECKER WS, 1989, NATURE, V341, P318, DOI 10.1038/341318a0; Clayton L., 1965, J GEOLOGY, V73, P652; Curry BB, 1997, CAN J EARTH SCI, V34, P699, DOI 10.1139/e17-056; DORMAN JL, 1989, J APPL METEOROL, V28, P833, DOI 10.1175/1520-0450(1989)028<0833:AGCOAR>2.0.CO;2; Giorgi F, 1998, CLIMATIC CHANGE, V40, P457, DOI 10.1023/A:1005384803949; Hostetler S. W., 1999, AGU MONOGRAPH SERIES, P313; HOSTETLER SW, 1994, SCIENCE, V263, P665, DOI 10.1126/science.263.5147.665; Hostetler SW, 1997, NATURE, V385, P393, DOI 10.1038/385393a0; Hu FS, 1997, GEOLOGY, V25, P207; Laird KR, 1996, LIMNOL OCEANOGR, V41, P890, DOI 10.4319/lo.1996.41.5.0890; Levesque AJ, 1997, NATURE, V385, P423, DOI 10.1038/385423a0; Licciardi JM, 1998, QUATERNARY SCI REV, V17, P427, DOI 10.1016/S0277-3791(97)00044-9; LICCIARDI JM, 1999, AGU MONOGRAPH SERIES, P177; Lowell TV, 1999, CAN J EARTH SCI, V36, P383, DOI 10.1139/e98-095; Mann JD, 1999, J PALEOLIMNOL, V22, P71, DOI 10.1023/A:1008090015161; MANN JD, 1997, GSA ANN M, V29, pA111; OVERPECK JT, 1992, GEOLOGY, V20, P1071, DOI 10.1130/0091-7613(1992)020<1071:MENAVC>2.3.CO;2; PELTIER WR, 1994, SCIENCE, V265, P195, DOI 10.1126/science.265.5169.195; POLLARD D, 1998, PALEOCLIMATES, V2, P183; Small EE, 1999, J GEOPHYS RES-ATMOS, V104, P6583, DOI 10.1029/98JD02348; Teller JT, 1990, PALEOCEANOGRAPHY, V5, P897, DOI 10.1029/PA005i006p00897; TELLER JT, 1986, N AM ADJACENT OCEANS, P39; THOMPSON SL, 1995, J CLIMATE, V8, P732, DOI 10.1175/1520-0442(1995)008<0732:AGCMWA>2.0.CO;2; Webb Thompson Iii, 1993, P415	29	60	61	2	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					334	337		10.1038/35012581	http://dx.doi.org/10.1038/35012581			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830959				2022-12-28	WOS:000087085700043
J	Temes, RT; Ketai, LH				Temes, RT; Ketai, LH			Mediastinal teratoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Temes, RT (corresponding author), Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2000	342	20					1492	1492		10.1056/NEJM200005183422005	http://dx.doi.org/10.1056/NEJM200005183422005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314QT	10816187				2022-12-28	WOS:000087068200005
J	Zheng, J; Shen, WX; He, DZZ; Kevin, BL; Madison, LD; Dallos, P				Zheng, J; Shen, WX; He, DZZ; Kevin, BL; Madison, LD; Dallos, P			Prestin is the motor protein of cochlear outer hair cells	NATURE			English	Article							GUINEA-PIG COCHLEA; ELECTROKINETIC SHAPE CHANGES; MOTILITY VOLTAGE SENSOR; MECHANICAL RESPONSES; MEMBRANE CAPACITANCE; FORCE GENERATION; ELECTROMOTILITY; SALICYLATE; IDENTIFICATION; TRANSPORTER	The outer and inner hair cells of the mammalian cochlea perform different functions. In response to changes in membrane potential, the cylindrical outer hair cell rapidly alters its length and stiffness. These mechanical changes, driven by putative molecular motors, are assumed to produce amplification of vibrations in the cochlea that are transduced by inner hair cells. Here we have identified an abundant complementary DNA from a gene, designated Prestin, which is specifically expressed in outer hair cells. Regions of the encoded protein show moderate sequence similarity to pendrin and related sulphate/anion transport proteins. Voltage-induced shape changes can be elicited in cultured human kidney cells that express prestin. The mechanical response of outer hair cells to voltage change is accompanied by a 'gating current', which is manifested as nonlinear capacitance. We also demonstrate this nonlinear capacitance in transfected kidney cells. We conclude that prestin is the motor protein of the cochlear outer hair cell.	Northwestern Univ, Auditory Physiol Lab, Hugh Knowles Ctr, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Auditory Physiol Lab, Hugh Knowles Ctr, Dept Commun Sci & Disorders, Evanston, IL 60208 USA; Northwestern Univ, Sch Med, Dept Med, Ctr Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University	Dallos, P (corresponding author), Northwestern Univ, Auditory Physiol Lab, Hugh Knowles Ctr, Dept Neurobiol & Physiol, Evanston, IL 60208 USA.	p-dallos@nwu.edu	Dallos, Peter/Q-9360-2019; Zheng, Jing/F-5273-2017	Dallos, Peter/0000-0002-9731-6591; Zheng, Jing/0000-0003-2790-1143; He (he zhi zhou), Zhi-Zhou/0000-0001-8383-9634				Adachi M, 1999, P NATL ACAD SCI USA, V96, P7244, DOI 10.1073/pnas.96.13.7244; ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASHMORE JF, 1992, SOC GEN PHY, V47, P395; ASHMORE JF, 1999, MECH HEARING, P107; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1995, SCIENCE, V267, P2006, DOI 10.1126/science.7701325; Dallos P., 1996, COCHLEA, P1; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Evans B.N., 1989, COCHLEAR MECHANISMS, P205; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Everett LA, 1999, HUM MOL GENET, V8, P1883, DOI 10.1093/hmg/8.10.1883; FORGE A, 1991, CELL TISSUE RES, V265, P473, DOI 10.1007/BF00340870; Frank G, 1999, P NATL ACAD SCI USA, V96, P4420, DOI 10.1073/pnas.96.8.4420; Geleoc GSG, 1999, NAT NEUROSCI, V2, P713, DOI 10.1038/11174; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Greinwald JH, 1998, AM J MED GENET, V78, P107, DOI 10.1002/(SICI)1096-8628(19980630)78:2<107::AID-AJMG2>3.3.CO;2-9; He DZZ, 1999, P NATL ACAD SCI USA, V96, P8223, DOI 10.1073/pnas.96.14.8223; He DZZ, 1997, J NEUROSCI, V17, P3634; HE DZZ, 1994, HEARING RES, V78, P77, DOI 10.1016/0378-5955(94)90046-9; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOLLEY MC, 1988, PROC R SOC SER B-BIO, V232, P413, DOI 10.1098/rspb.1988.0004; HOLLEY MC, 1992, J CELL SCI, V102, P569; HUANG GJ, 1994, P NATL ACAD SCI USA, V91, P12268, DOI 10.1073/pnas.91.25.12268; HUANG GJ, 1993, BIOPHYS J, V65, P2228, DOI 10.1016/S0006-3495(93)81248-7; Hudspeth AJ, 1997, CURR OPIN NEUROBIOL, V7, P480, DOI 10.1016/S0959-4388(97)80026-8; Iwasa KH, 1997, BIOPHYS J, V73, P546, DOI 10.1016/S0006-3495(97)78092-5; IWASA KH, 1993, BIOPHYS J, V65, P492, DOI 10.1016/S0006-3495(93)81053-1; KACHAR B, 1986, NATURE, V322, P365, DOI 10.1038/322365a0; Kakehata S, 1996, J NEUROSCI, V16, P4881; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; KALINEC F, 1993, NEUROSCI LETT, V157, P231, DOI 10.1016/0304-3940(93)90744-6; KNIPPER M, 1995, HEARING RES, V86, P100, DOI 10.1016/0378-5955(95)00060-H; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; Moseley RH, 1999, AM J PHYSIOL-GASTR L, V276, pG185, DOI 10.1152/ajpgi.1999.276.1.G185; Mustapha M, 1998, EUR J HUM GENET, V6, P548, DOI 10.1038/sj.ejhg.5200261; SANDAL NN, 1994, TRENDS BIOCHEM SCI, V19, P19, DOI 10.1016/0968-0004(94)90168-6; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; SHEHATA WE, 1991, ACTA OTO-LARYNGOL, V111, P707, DOI 10.3109/00016489109138403; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Souter M, 1995, HEARING RES, V91, P43, DOI 10.1016/0378-5955(95)00163-8; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TUNSTALL MJ, 1995, J PHYSIOL-LONDON, V485, P739, DOI 10.1113/jphysiol.1995.sp020765	47	918	967	0	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					149	155		10.1038/35012009	http://dx.doi.org/10.1038/35012009			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821263				2022-12-28	WOS:000087080100040
J	Fields, SA; Usatine, R; Steiner, E				Fields, SA; Usatine, R; Steiner, E			Teaching medical students in the ambulatory setting - Strategies for success	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMMUNITY PRECEPTORS; CARE; PARTICIPATION; EDUCATION		Oregon Hlth Sci Univ, Dept Family Med, Portland, OR 97201 USA; Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA	Oregon Health & Science University; University of California System; University of California Los Angeles	Fields, SA (corresponding author), 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							*ASS AM MED COLL, 1999, MED TEACH PHYS DOC I; BROOK RH, 1996, JAMA-J AM MED ASSOC, V276, P479; Devera-Sales A, 1999, ACAD MED, V74, P550, DOI 10.1097/00001888-199905000-00024; Ferenchick G, 1997, ACAD MED, V72, P277, DOI 10.1097/00001888-199704000-00011; Fields SA, 1998, ACAD MED, V73, P95, DOI 10.1097/00001888-199801000-00019; Fields SA, 1998, ACAD MED, V73, P25, DOI 10.1097/00001888-199801000-00008; Hunt CE, 1999, ARCH PEDIAT ADOL MED, V153, P297; KALET A, 1997, ACAD MED, V72, P766; Lawrence SL, 1999, ACAD MED, V74, P715, DOI 10.1097/00001888-199906000-00020; Ludmerer KM, 1999, TIME HEAL; Neher J O, 1992, J Am Board Fam Pract, V5, P419; Seifer SD, 1998, ACAD MED, V73, P273, DOI 10.1097/00001888-199803000-00015; SIMONS RJ, 1995, J GEN INTERN MED, V10, P251, DOI 10.1007/BF02599880; STANGL S, 1995, ACAD MED, V70, P459, DOI 10.1097/00001888-199505000-00066; USATINE R, IN PRESS ACAD MED; Usatine R P, 1995, Fam Med, V27, P566; Vinson DC, 1996, J FAM PRACTICE, V42, P243; Wilkes MS, 1998, ACAD MED, V73, P32, DOI 10.1097/00001888-199801000-00009	18	26	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2362	2364		10.1001/jama.283.18.2362	http://dx.doi.org/10.1001/jama.283.18.2362			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815060				2022-12-28	WOS:000086808200002
J	Kliewer, J; Berndt, R; Chulkov, EV; Silkin, VM; Echenique, PM; Crampin, S				Kliewer, J; Berndt, R; Chulkov, EV; Silkin, VM; Echenique, PM; Crampin, S			Dimensionality effects in the lifetime of surface states	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPE; ANGLE-RESOLVED PHOTOEMISSION; IMAGE-POTENTIAL STATES; FRIEDEL-OSCILLATIONS; METAL-SURFACES; SPECTROSCOPY; ELECTRONS	A long-standing discrepancy between experimental and theoretical values for the lifetimes of holes in the surface-state electron bands on noble metal surfaces is resolved; previous determinations of both are found to have been in error. The ability of the scanning tunneling microscope to verify surface quality before taking spectroscopic measurements is used to remove the effects of defect scattering on experimental lifetimes, found to have been a significant contribution to prior determinations. A theoretical treatment of inelastic electron-electron scattering is developed that explicitly includes intraband transitions within the surface state band. In our model, two-dimensional decay channels dominate the electron-electron interactions that contribute to the hole decay and are screened by the electron states of the underlying three-dimensional electron system.	Rhein Westfal TH Aachen, Inst Phys 2, D-52056 Aachen, Germany; Univ Kiel, Inst Expt & Angew Phys, D-24098 Kiel, Germany; Univ Basque Country, Fac Quim, Dept Fis Mat, E-20080 San Sebastian, Spain; Univ Basque Country, CSIC, Ctr Mixto, E-20080 San Sebastian, Spain; Donostia Int Phys Ctr, San Sebastian 20080, Spain; Univ Bath, Dept Phys, Bath BA2 7AY, Avon, England	RWTH Aachen University; University of Kiel; University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; University of Bath	Berndt, R (corresponding author), Rhein Westfal TH Aachen, Inst Phys 2, D-52056 Aachen, Germany.	berndt@physik.uni-kiel.de	Silkin, Vyacheslav M/T-8285-2019; Silkin, Vyacheslav/G-5446-2011; Chulkov, Eugeni V./J-5015-2017; Echenique, Pedro Miguel/AAB-3348-2019; Berndt, Richard/R-7908-2017	Silkin, Vyacheslav/0000-0002-7840-3868; Berndt, Richard/0000-0003-1165-9065; Kliewer, Joerg/0000-0003-0942-8006				Burgi L, 1999, PHYS REV LETT, V82, P4516, DOI 10.1103/PhysRevLett.82.4516; Campillo I, 1999, PHYS REV LETT, V83, P2230, DOI 10.1103/PhysRevLett.83.2230; Chen W, 1998, PHYS REV LETT, V80, P1469, DOI 10.1103/PhysRevLett.80.1469; Chulkov EV, 1999, SURF SCI, V437, P330, DOI 10.1016/S0039-6028(99)00668-8; Chulkov EV, 1998, PHYS REV LETT, V80, P4947, DOI 10.1103/PhysRevLett.80.4947; CRAMPIN S, 1994, PHYS REV LETT, V73, P1015, DOI 10.1103/PhysRevLett.73.1015; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; GAISCH R, 1992, ULTRAMICROSCOPY, V42, P1621, DOI 10.1016/0304-3991(92)90495-6; GIULIANI GF, 1982, PHYS REV B, V26, P4421, DOI 10.1103/PhysRevB.26.4421; Grimvall G., 1981, ELECT PHONON INTERAC; HASEGAWA Y, 1993, PHYS REV LETT, V71, P1071, DOI 10.1103/PhysRevLett.71.1071; Hedin L., 1969, SOLID STATE PHYS, V23, P1, DOI [10.1016/S0081-1947(08)60615-3, DOI 10.1016/S0081-1947(08)60615-3]; Himpsel FJ, 1998, ADV PHYS, V47, P511, DOI 10.1080/000187398243519; Hofmann P, 1997, PHYS REV LETT, V79, P265, DOI 10.1103/PhysRevLett.79.265; KEVAN SD, 1987, PHYS REV B, V36, P5809, DOI 10.1103/PhysRevB.36.5809; KOSTUR VN, 1993, PHYS REV B, V48, P16388, DOI 10.1103/PhysRevB.48.16388; LaShell S, 1996, PHYS REV LETT, V77, P3419, DOI 10.1103/PhysRevLett.77.3419; Li JT, 1998, PHYS REV LETT, V80, P2893, DOI 10.1103/PhysRevLett.80.2893; Matzdorf R, 1998, SURF SCI REP, V30, P153, DOI 10.1016/S0167-5729(97)00013-7; MCDOUGALL BA, 1995, PHYS REV B, V51, P13891, DOI 10.1103/PhysRevB.51.13891; Memmel N, 1998, SURF SCI REP, V32, P91, DOI 10.1016/S0167-5729(98)00006-5; Palik E D, 1985, HDB OPTICAL CONSTANT; PLUMMER EW, 1994, PROG SURF SCI, V46, P149, DOI 10.1016/0079-6816(94)90075-2; QUINN JJ, 1962, PHYS REV, V1, P1453, DOI 10.1103/PhysRev.126.1453; QUINN JJ, 1963, APPL PHYS LETT, V2, P167, DOI 10.1063/1.1753828; Smith N. V., 1992, Comments on Condensed Matter Physics, V15, P263; Sprunger PT, 1997, SCIENCE, V275, P1764, DOI 10.1126/science.275.5307.1764; Theilmann F, 1997, PHYS REV B, V56, P3632, DOI 10.1103/PhysRevB.56.3632	28	285	287	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1399	1402		10.1126/science.288.5470.1399	http://dx.doi.org/10.1126/science.288.5470.1399			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827945				2022-12-28	WOS:000087270900043
J	Jacobs, DG				Jacobs, DG			A 52-year-old suicidal man	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPRESSION; PROGRAM		Harvard Univ, Sch Med, Boston, MA USA; Screening Mental Hlth, Wellesley Hills, MA USA	Harvard University; Harvard Medical School	Jacobs, DG (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							Baer L, 2000, PSYCHOTHER PSYCHOSOM, V69, P35, DOI 10.1159/000012364; Baldessarini RJ, 1999, HARVARD MED SCH GUID, P355; Barber ME, 1998, AM J PSYCHIAT, V155, P385, DOI 10.1176/ajp.155.3.385; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BLUMENTHAL SJ, 1988, MED CLIN N AM, V72, P937, DOI 10.1016/S0025-7125(16)30754-4; DRAKE RE, 1989, SUICIDE UNDERSTANDIN, P183; FAVA M, 1991, J CLIN PSYCHIAT, V52, P108; FAWCETT JA, 1995, PSYCHIAT ANN, V23, P244; Greenfield SF, 1997, AM J PSYCHIAT, V154, P1391; HAVENS LL, 1999, HARVARD MED SCH GUID; JACOBS DG, 1995, HARVARD REV PSYCHIAT, V3, P156, DOI 10.3109/10673229509017181; Jacobs DG, 1999, HARVARD MED SCH GUID, P3; JACOBS DG, 1995, MIND BODY MED, V1, P17; JAMISON KR, 1999, NIGHT FALLS FAST UND; KLERMAN GL, 1987, J CLIN PSYCHIAT, V48, P33; MAGRUDER KM, 1995, AM J PSYCHIAT, V152, P1615; MELLEY B, 1997, NY TIMES        0425; MELTZER HY, 1995, AM J PSYCHIAT, V152, P183; MILLER MC, 1999, HARVARD MED SCH GUID, P520; MOSCICKI EK, 1999, HARVARD MED SCH GUID, P40; NARROW WE, 1993, ARCH GEN PSYCHIAT, V50, P95; Phillips DP, 1997, SUICIDE LIFE-THREAT, V27, P373; ROSENTHAL RJ, 1992, PSYCHIAT ANN, V22, P72, DOI 10.3928/0048-5713-19920201-09; Salzman C, 1999, HARVARD MED SCH GUID, P372; Shneidman E., 1977, DEFINITION SUICIDE; SIMON RI, 1992, CLIN PSYCHIAT LAW; TOLLEFSON GD, 1994, J CLIN PSYCHOPHARM, V14, P163; *US DEP HHS, 1993, AHCPR PUBL; 1999, SURG GEN CALL ACTION	29	7	7	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2693	2699		10.1001/jama.283.20.2693	http://dx.doi.org/10.1001/jama.283.20.2693			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	314FP	10819953				2022-12-28	WOS:000087046000038
J	Balter, S; Benin, A; Wyton, S; Pinto, L; Teixeira, LM; Alvim, GG; Luna, E; Jackson, D; LaClaire, L; Elliott, J; Facklam, R; Schuchat, A				Balter, S; Benin, A; Wyton, S; Pinto, L; Teixeira, LM; Alvim, GG; Luna, E; Jackson, D; LaClaire, L; Elliott, J; Facklam, R; Schuchat, A			Epidemic nephritis in Nova Serrana, Brazil	LANCET			English	Article							FOOD-BORNE OUTBREAK; STREPTOCOCCUS-ZOOEPIDEMICUS; GROUP-C; ACUTE GLOMERULONEPHRITIS; PHARYNGITIS; DYSGALACTIAE; INFECTION; CHILDREN	Background Outbreaks of nephritis have been rare since the 1970s. From December, 1997, to July, 1998, 253 cases of acute nephritis were identified in Nova Serrana, Brazil. Seven patients required dialysis, and three patients died. We did a case-control study to investigate the cause of the outbreak. Methods Using a matched cluster design, we examined seven recent patients, their family members (n=23), and members of neighbourhood-matched control households (n=22). We subsequently interviewed 50 patients and 50 matched controls about exposure to various dairy products. We also cultured daily foods and took udder-swab and milk samples from cows. Findings associated with group C Streptococcus equi subspecies zooepidemicus, a cause of bovine mastitis. S zooepidemicus was detected in four of seven case households (six of 30 people) and no control households (p=0.09). Patients were more likely than matched controls to have consumed a locally produced cheese called queijo fresco (matched odds ratio 2.1, p=0.05). The nephritis attach rate was 4.5 per 1000 in Nova Serrana but 18 per 1000 in the village Quilombo do Gaia (p=0.003). The largest supplier of unpasteurised queijo fresco was a farm in Quilombo do Gaia. S zooepidemicus was not detected in food samples or in swabs collected from cows in August, 1998, although mastitis was evident among cows on the suspected farm. Throat cultures of the two women who prepared cheese on this farm yielded the outbreak strain of S zooepidemicus. After the cheese was removed from the distribution system, no further cases were reported. Interpretation A large outbreak of glomerulonephritis was attributed to S zooepidemicus in unpasteurised cheese. This outbreak highlights the dangers of consuming unpasteurised daily products and need for global efforts to promote food safety.	Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA; Hosp Sao Joao de Deus, Dept Nephrol, Divinopolis, Brazil; Univ Fed Rio de Janeiro, Inst Microbiol, Rio De Janeiro, Brazil; Dept Hlth, Nova Serrana, Brazil; Ctr Nacl Epidemiol, Brasilia, DF, Brazil	Centers for Disease Control & Prevention - USA; Universidade Federal do Rio de Janeiro	Balter, S (corresponding author), Ctr Dis Control & Prevent, Resp Dis Branch, 1600 Clifton Rd,MS E-61, Atlanta, GA 30333 USA.		Teixeira, Lucia Martins/AAO-7988-2020; Balter, S/P-6211-2019; Luna, Expedito J A/B-7948-2012	Teixeira, Lucia Martins/0000-0002-4017-7076; Luna, Expedito J A/0000-0002-1145-9672				BarDayan Y, 1996, SCAND J INFECT DIS, V28, P563, DOI 10.3109/00365549609037961; Barham M, 1983, LANCET, V1, P945; BARHAM M, 1987, EPIDEMIOL INFECT, V98, P183; Bryans J. T., 1972, Streptococci and streptococcal diseases,, P327; *CDC, 1983, MMWR-MORBID MORTAL W, V32, P510; COLLAZOS J, 1992, CLIN INFECT DIS, V15, P744, DOI 10.1093/clind/15.4.744-a; DUCA E, 1969, J HYG-CAMB, V67, P691, DOI 10.1017/S0022172400042145; EDWARDS AT, 1988, EPIDEMIOL INFECT, V101, P43, DOI 10.1017/S0950268800029204; Elliott JA, 1998, J CLIN MICROBIOL, V36, P2115, DOI 10.1128/JCM.36.7.2115-2116.1998; Ferrandiere M, 1998, EUR J CLIN MICROBIOL, V17, P290, DOI 10.1007/BF01699990; FRANCIS AJ, 1993, J INFECTION, V27, P317, DOI 10.1016/0163-4453(93)92358-4; GALLO G, 1992, EUR J EPIDEMIOL, V8, P292; Headrick ML, 1998, AM J PUBLIC HEALTH, V88, P1219, DOI 10.2105/AJPH.88.8.1219; KLEINMAN H, 1954, Minn Med, V37, P479; KODAMA T, 1958, Yokohama Med Bull, V9, P105; LOSSOS IS, 1992, ARCH INTERN MED, V152, P853, DOI 10.1001/archinte.152.4.853; MARTINEZLUENGAS F, 1982, CAN MED ASSOC J, V127, P13; MCKEAGE MJ, 1990, AUST NZ J MED, V20, P177, DOI 10.1111/j.1445-5994.1990.tb01299.x; *NAT COMM CLIN LAB, 1998, M100S8 NAT COMM CLIN, P70; POONKING T, 1967, NEW ENGL J MED, V277, P728, DOI 10.1056/NEJM196710052771403; RAMMELKAMP CH, 1954, T ASSOC AM PHYSICIAN, V67, P276; ROSE HD, 1980, J CLIN MICROBIOL, V11, P76, DOI 10.1128/JCM.11.1.76-78.1980; ROY S, 1990, PEDIATR NEPHROL, V4, P585, DOI 10.1007/BF00858626; Ruoff Kathryn L., 1995, P299; Vandamme P, 1996, INT J SYST BACTERIOL, V46, P774, DOI 10.1099/00207713-46-3-774; Vieira VV, 1998, INT J SYST BACTERIOL, V48, P1231, DOI 10.1099/00207713-48-4-1231; WOOLCOCK JB, 1975, RES VET SCI, V18, P113, DOI 10.1016/S0034-5288(18)33642-7; YAP HK, 1990, PEDIATR NEPHROL, V4, P482, DOI 10.1007/BF00869825; 1994, CDR WKLY, V4, P241	29	64	68	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1776	1780						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832828				2022-12-28	WOS:000087126100012
J	Elsaleh, H; Joseph, D; Grieu, F; Zeps, N; Spry, N; Iacopetta, B				Elsaleh, H; Joseph, D; Grieu, F; Zeps, N; Spry, N; Iacopetta, B			Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer	LANCET			English	Article							REPLICATION ERROR PHENOTYPE; MICROSATELLITE INSTABILITY; MONONUCLEOTIDE REPEAT; COLON-CARCINOMA; CELL-LINES; METHYLATION; DNA; FLUOROURACIL; EXPRESSION; LEVAMISOLE	Background Adjuvant chemotherapy can improve 5-year survival in Dukes' C colorectal carcinoma. Improved selection of patients who will respond to adjuvant treatments is required. We investigated whether site of tumour origin, sex, and presence of microsatellite instability (MSI) phenotype were associated with a survival benefit from adjuvant chemotherapy. Methods We analysed data for 656 consecutive patients with Dukes' C colorectal carcinoma, with median follow-up of 54 months (range 7-104) and mean age 66.7 years (SD 12.9). We screened tumour samples by PCR for deletions in the BAT-26 mononucleotide repeat to establish MSI status. Details of chemotherapy and survival were obtained by review of hospital and health-department records. Adjuvant chemotherapy (fluorouracil and levamisole) was given with curative intent to 272 (42%) patients. Findings Striking survival benefits were seen for patients who had right-sided tumours and who received adjuvant chemotherapy compared with those who did not (48 vs 27% alive at end of study [95% CI 0.25-0.56], p<0.0001), for women (53 vs 33% [0.25-0.56], p<0.0001), and for patients with MSI tumours (90 vs 35% [0.01-0.53], p=0.0007). MSI-positive tumours were slightly more frequent in women than in men (10 vs 7%). Right-sided tumours were more frequently MSI positive than left-sided tumours (20 vs 1%). Men with right-sided tumours benefited from chemotherapy (37 vs 12% [0.24-0.69], p=0.0007) but men with left-sided tumours did not. Interpretation The survival benefits seen in patients treated with adjuvant chemotherapy suggest that data from previous trials of adjuvant chemotherapy should be reassessed and the predictive value of MSI status confirmed. Validation of our results will allow better selection of patients for chemotherapy.	Sir Charles Gairdner Hosp, Dept Radiat Oncol, Nedlands, WA 6009, Australia; Univ Western Australia, Dept Surg, Nedlands, WA, Australia	University of Western Australia; University of Western Australia	Elsaleh, H (corresponding author), Sir Charles Gairdner Hosp, Dept Radiat Oncol, Nedlands, WA 6009, Australia.		Zeps, Nikolajs/C-4180-2013; Zeps, Nikolajs/AAF-3186-2021	Zeps, Nikolajs/0000-0002-6404-6839; Zeps, Nikolajs/0000-0002-6404-6839; Spry, Nigel/0000-0001-8659-5065; Elsaleh, Hany/0000-0003-2083-4961				Ahuja N, 1997, CANCER RES, V57, P3370; Bubb VJ, 1996, ONCOGENE, V12, P2641; BUFILL JA, 1990, ANN INTERN MED, V113, P779, DOI 10.7326/0003-4819-113-10-779; DELATTRE O, 1989, LANCET, V2, P353; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; Feeley KM, 1999, J PATHOL, V188, P14, DOI 10.1002/(SICI)1096-9896(199905)188:1<14::AID-PATH323>3.0.CO;2-Q; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Halling KC, 1999, JNCI-J NATL CANCER I, V91, P1295, DOI 10.1093/jnci/91.15.1295; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hoang JM, 1997, CANCER RES, V57, P300; Iacopetta B, 1998, HUM MUTAT, V12, P355, DOI 10.1002/(SICI)1098-1004(1998)12:5<355::AID-HUMU9>3.0.CO;2-C; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jass JR, 1998, GUT, V42, P673, DOI 10.1136/gut.42.5.673; Kane MF, 1997, CANCER RES, V57, P808; KIM HG, 1994, AM J PATHOL, V145, P148; KUNE S, 1986, INT J EPIDEMIOL, V15, P483, DOI 10.1093/ije/15.4.483; Liu LU, 1999, GUT, V45, P45, DOI 10.1136/gut.45.1.45; LOTHE RA, 1993, CANCER RES, V53, P5849; Mamounas E, 1999, J CLIN ONCOL, V17, P1349, DOI 10.1200/JCO.1999.17.5.1349; MATHERS C, 1998, HLTH SYSTEM COSTS CA; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; Salahshor S, 1999, BRIT J CANCER, V81, P190, DOI 10.1038/sj.bjc.6690676; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS PRM, 1988, RADIOTHER ONCOL, V13, P245, DOI 10.1016/0167-8140(88)90219-8; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Wiencke JK, 1999, CANCER EPIDEM BIOMAR, V8, P501; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	28	462	474	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1745	1750		10.1016/S0140-6736(00)02261-3	http://dx.doi.org/10.1016/S0140-6736(00)02261-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832824				2022-12-28	WOS:000087126100008
J	Ferriman, A				Ferriman, A			Too early to introduce colorectal screening, say specialists	BRITISH MEDICAL JOURNAL			English	News Item																		1920, GUT, V46, P746	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	2000	320	7246					1361	1361		10.1136/bmj.320.7246.1361	http://dx.doi.org/10.1136/bmj.320.7246.1361			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818019	Green Published			2022-12-28	WOS:000087232500014
J	Gilligan, J				Gilligan, J			Violence in public health and preventive medicine	LANCET			English	Editorial Material											Gilligan, J (corresponding author), POB 385, W Stockbridge, MA 01286 USA.							CHINGCHI H, 1999, SOC POPULATION HLTH; FESHBACH S, 1971, AM PSYCHOL, V26, P281, DOI 10.1037/h0031219; GILLIGAN J, 1999, VIOLENCE REFLECTIONS; LUCKENBILL DF, 1977, SOC PROBL, V25, P176, DOI 10.1525/sp.1977.25.2.03a00050; Scheff TJ., 1991, EMOTIONS VIOLENCE SH	5	19	20	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1802	1804		10.1016/S0140-6736(00)02307-2	http://dx.doi.org/10.1016/S0140-6736(00)02307-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	315RE	10832843				2022-12-28	WOS:000087126100041
J	London, NJM; Nash, R				London, NJM; Nash, R			ABC of arterial and venous disease - Varicose veins	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Leicester, Leicester, Leics, England; Derbyshire Royal Infirm, Derby DE1 2QY, England	University of Leicester	London, NJM (corresponding author), Univ Leicester, Leicester, Leics, England.	sms16@leicester.ac.uk						Bradbury A, 1999, BRIT MED J, V318, P353, DOI 10.1136/bmj.318.7180.353; BRAND FN, 1988, AM J PREV MED, V4, P96, DOI 10.1016/S0749-3797(18)31203-0; Browse NL, 1999, DIS VEINS; Campbell B, 1996, BMJ-BRIT MED J, V312, P198; FRANKS PJ, 1992, EUR J SURG, V158, P143; *ROYAL COLL GEN PR, 1978, J R COLL GEN PRACT, V28, P393; RUCKLEY CV, 1998, VENOUS DIS; Tibbs D., 1992, VARICOSE VEINS RELAT; TIBBS DJ, 1997, VARICOSE VEINS VENOU; 1999, DRUG THER B, V37, P78	10	52	55	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2000	320	7246					1391	1394		10.1136/bmj.320.7246.1391	http://dx.doi.org/10.1136/bmj.320.7246.1391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818035	Green Published			2022-12-28	WOS:000087232500027
J	Bodenheimer, T				Bodenheimer, T			Uneasy alliance - Clinical investigators and the pharmaceutical industry	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONFLICT-OF-INTEREST; CARDIOVASCULAR-DISEASE; TRIALS; DRUG; QUALITY; SAFETY											Applegate WB, 1997, JAMA-J AM MED ASSOC, V277, P297; Bero LA, 1996, INT J TECHNOL ASSESS, V12, P209, DOI 10.1017/S0266462300009582; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; BRENNAN TA, 1994, NEW ENGL J MED, V331, P673, DOI 10.1056/NEJM199409083311012; *CENT, 1999, IND EV; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; Chow S.-C., 1998, DESIGN ANAL CLIN TRI; *COMM FUND, 1999, BENCH BEDS PRES RES; Davidson F, 1997, JAMA-J AM MED ASSOC, V277, P927; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; Flanagin A, 1998, JAMA-J AM MED ASSOC, V280, P222, DOI 10.1001/jama.280.3.222; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; Getz KA, 1999, AMCS REKINDLING CLIN; HENDERSON L, 1999, CENTERWATCH, V6, P4; *INT COMM MED J ED, 1998, JAMA-J AM MED ASSOC, V279, P510; Johansen HK, 1999, JAMA-J AM MED ASSOC, V282, P1752, DOI 10.1001/jama.282.18.1752; KUNIN CM, 1978, ANN INTERN MED, V89, P842, DOI 10.7326/0003-4819-89-5-842; Larkin M, 1999, LANCET, V354, P136, DOI 10.1016/S0140-6736(05)75272-7; LEVY D, 1996, US TODAY        0925; MATHIEU MP, 1999, PAREXELS PHARM R D S; Olivieri NF, 1998, NEW ENGL J MED, V339, P417, DOI 10.1056/NEJM199808133390701; Phillips RA, 1998, CAN MED ASSOC J, V159, P1244; Psaty BM, 1999, JAMA-J AM MED ASSOC, V282, P786, DOI 10.1001/jama.282.8.786; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P469, DOI 10.1001/jama.271.6.469; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Rochon PA, 1998, CAN MED ASSOC J, V159, P1373; Shine KI, 1997, JAMA-J AM MED ASSOC, V278, P245, DOI 10.1001/jama.278.3.245; SPILKER B, DRUG DEV APPROVAL PR; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; Temple R, 1999, JAMA-J AM MED ASSOC, V282, P790, DOI 10.1001/jama.282.8.790; Vogel J. R., 1999, APPL CLIN TRIALS, V8, P56; Wood AJJ, 1998, NEW ENGL J MED, V339, P1851, DOI 10.1056/NEJM199812173392512; Woodward B, 1999, JAMA-J AM MED ASSOC, V282, P1947, DOI 10.1001/jama.282.20.1947; 1997, CENTERWATCH, V4, P1; 1997, CENTERWATCH, V4, P9; 1993, LANCET, V342, P1498	38	523	541	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2000	342	20					1539	1544		10.1056/NEJM200005183422024	http://dx.doi.org/10.1056/NEJM200005183422024			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314QT	10816196				2022-12-28	WOS:000087068200031
J	Ochman, H; Lawrence, JG; Groisman, EA				Ochman, H; Lawrence, JG; Groisman, EA			Lateral gene transfer and the nature of bacterial innovation	NATURE			English	Review							ESCHERICHIA-COLI; PATHOGENICITY ISLANDS; SHIGELLA-FLEXNERI; SALMONELLA-TYPHIMURIUM; HORIZONTAL TRANSFER; EVOLUTION; DNA; VIRULENCE; GENOME; SEQUENCE	Unlike eukaryotes, which evolve principally through the modification of existing genetic information, bacteria have obtained a significant proportion of their genetic diversity through the acquisition of sequences from distantly related organisms. Horizontal gene transfer produces extremely dynamic genomes in which substantial amounts of DNA are introduced into and deleted from the chromosome. These lateral transfers have effectively changed the ecological and pathogenic character of bacterial species.	Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA	University of Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Howard Hughes Medical Institute; Washington University (WUSTL)	Ochman, H (corresponding author), Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA.							Andersson JO, 1999, CURR OPIN GENET DEV, V9, P664, DOI 10.1016/S0959-437X(99)00024-6; Andersson SGE, 1998, TRENDS MICROBIOL, V6, P263, DOI 10.1016/S0966-842X(98)01312-2; Aravind L, 1998, TRENDS GENET, V14, P442, DOI 10.1016/S0168-9525(98)01553-4; BERG DE, 1989, MOBILE DNA, P185; BlancPotard AB, 1997, EMBO J, V16, P5376, DOI 10.1093/emboj/16.17.5376; BLUM G, 1994, INFECT IMMUN, V62, P606, DOI 10.1128/IAI.62.2.606-614.1994; BUCHANANWOLLASTON V, 1987, NATURE, V328, P172, DOI 10.1038/328172a0; Casjens S, 1998, ANNU REV GENET, V32, P339, DOI 10.1146/annurev.genet.32.1.339; CHEETHAM BF, 1995, MOL MICROBIOL, V18, P201, DOI 10.1111/j.1365-2958.1995.mmi_18020201.x; Davidoff AJ, 1996, INT J TECHNOL ASSESS, V12, P9, DOI 10.1017/S026646230000934X; Davison J, 1999, PLASMID, V42, P73, DOI 10.1006/plas.1999.1421; Deiwick J, 1999, MOL MICROBIOL, V31, P1759, DOI 10.1046/j.1365-2958.1999.01312.x; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; Dubnau D, 1999, ANNU REV MICROBIOL, V53, P217, DOI 10.1146/annurev.micro.53.1.217; ELKINS C, 1991, J BACTERIOL, V173, P3911, DOI 10.1128/JB.173.12.3911-3913.1991; Gaasterland T, 1999, CURR OPIN MICROBIOL, V2, P542, DOI 10.1016/S1369-5274(99)00014-4; GEMSKI P, 1980, INFECT IMMUN, V28, P1044; GOODMAN SD, 1988, P NATL ACAD SCI USA, V85, P6982, DOI 10.1073/pnas.85.18.6982; GROISMAN EA, 1992, EMBO J, V11, P1309, DOI 10.1002/j.1460-2075.1992.tb05175.x; Groisman EA, 1997, TRENDS MICROBIOL, V5, P343, DOI 10.1016/S0966-842X(97)01099-8; Groisman EA, 1998, BIOESSAYS, V20, P96, DOI 10.1002/(SICI)1521-1878(199801)20:1<96::AID-BIES13>3.0.CO;2-3; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; Hacker J, 1997, MOL MICROBIOL, V23, P1089, DOI 10.1046/j.1365-2958.1997.3101672.x; Hall RM, 1997, CIBA F SYMP, V207, P192; HALL RM, 1995, MOL MICROBIOL, V15, P593, DOI 10.1111/j.1365-2958.1995.tb02368.x; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; JACKSON MP, 1987, FEMS MICROBIOL LETT, V44, P109, DOI 10.1016/0378-1097(87)90210-2; Jiang SC, 1998, APPL ENVIRON MICROB, V64, P2780; Karaolis DKR, 1999, NATURE, V399, P375, DOI 10.1038/20715; Karlin S, 1998, ANNU REV GENET, V32, P185, DOI 10.1146/annurev.genet.32.1.185; Lan RT, 1996, MOL BIOL EVOL, V13, P47, DOI 10.1093/oxfordjournals.molbev.a025569; Lawrence JG, 1996, GENETICS, V143, P1843; Lawrence JG, 1999, CURR OPIN MICROBIOL, V2, P519, DOI 10.1016/S1369-5274(99)00010-7; Lawrence JG, 1997, J MOL EVOL, V44, P383, DOI 10.1007/PL00006158; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; LAWRENCE JG, 1999, ORG PROKARYOTIC GENO, P263; Lindsay JA, 1998, MOL MICROBIOL, V29, P527, DOI 10.1046/j.1365-2958.1998.00947.x; Logsdon JM, 1999, CURR BIOL, V9, pR747, DOI 10.1016/S0960-9822(99)80474-6; Maurelli AT, 1998, P NATL ACAD SCI USA, V95, P3943, DOI 10.1073/pnas.95.7.3943; MAURELLI AT, 1985, INFECT IMMUN, V49, P164, DOI 10.1128/IAI.49.1.164-171.1985; Mazel D, 1998, SCIENCE, V280, P605, DOI 10.1126/science.280.5363.605; McDaniel TK, 1997, MOL MICROBIOL, V23, P399, DOI 10.1046/j.1365-2958.1997.2311591.x; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; Mirold S, 1999, P NATL ACAD SCI USA, V96, P9845, DOI 10.1073/pnas.96.17.9845; Moss JE, 1999, MOL MICROBIOL, V33, P74, DOI 10.1046/j.1365-2958.1999.01449.x; MUTO A, 1987, P NATL ACAD SCI USA, V84, P166, DOI 10.1073/pnas.84.1.166; NAKATA N, 1993, MOL MICROBIOL, V9, P459, DOI 10.1111/j.1365-2958.1993.tb01707.x; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; PORTNOY DA, 1981, INFECT IMMUN, V31, P775, DOI 10.1128/IAI.31.2.775-782.1981; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Ricchetti M, 1999, NATURE, V402, P96, DOI 10.1038/47076; RILEY M, 1978, ANNU REV MICROBIOL, V32, P519, DOI 10.1146/annurev.mi.32.100178.002511; RILEY M, 1990, BACTERIAL CHROMOSOME, P85; RITTER A, 1995, MOL MICROBIOL, V17, P109, DOI 10.1111/j.1365-2958.1995.mmi_17010109.x; Rowe-Magnus DA, 1999, CURR OPIN MICROBIOL, V2, P483, DOI 10.1016/S1369-5274(99)00004-1; SASAKAWA C, 1988, J BACTERIOL, V170, P2480, DOI 10.1128/jb.170.6.2480-2484.1988; SCHICKLMAIER P, 1995, APPL ENVIRON MICROB, V61, P1637, DOI 10.1128/AEM.61.4.1637-1640.1995; SMITH HO, 1995, SCIENCE, V269, P538, DOI 10.1126/science.7542802; Smith JM, 1999, GENETICS, V153, P1021; SUEOKA N, 1962, P NATL ACAD SCI USA, V48, P582, DOI 10.1073/pnas.48.4.582; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; Swofford David L., 1996, P407; Vokes SA, 1999, MOL MICROBIOL, V33, P63, DOI 10.1046/j.1365-2958.1999.01448.x; Vulic M, 1997, P NATL ACAD SCI USA, V94, P9763, DOI 10.1073/pnas.94.18.9763; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; WEEKS CR, 1984, INFECT IMMUN, V46, P531, DOI 10.1128/IAI.46.2.531-536.1984; WHITTAM TS, 1992, MECH MOL EVOLUTION, P223; Wolf YI, 1999, GENOME RES, V9, P689; [No title captured]	70	2533	2657	24	750	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 18	2000	405	6784					299	304		10.1038/35012500	http://dx.doi.org/10.1038/35012500			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830951				2022-12-28	WOS:000087085700035
J	Freigang, J; Proba, K; Leder, L; Diederichs, K; Sonderegger, P; Welte, W				Freigang, J; Proba, K; Leder, L; Diederichs, K; Sonderegger, P; Welte, W			The crystal structure of the ligand binding module of axonin-1/TAG-1 suggests a zipper mechanism for neural cell adhesion	CELL			English	Article							RAY-DIFFRACTION DATA; IMMUNOGLOBULIN SUPERFAMILY; NEURITE OUTGROWTH; NR-CAM; NG-CAM; MOLECULE; DOMAINS; FASCICULATION; NGCAM; FIBRONECTIN	We have determined the crystal structure of the ligand binding fragment of the neural cell adhesion molecule axonin-1/TAG-1 comprising the first four immunoglobulin (Ig) domains. The overall structure of axonin-1(Ig1-4) is U-shaped due to contacts between domains 1 and 4 and domains 2 and 3. In the crystals, these molecules are aligned in a string with adjacent molecules oriented in an anti-parallel fashion and their C termini perpendicular to the string. This arrangement suggests that cell adhesion by hemophilic axonin-1 interaction occurs by the formation of a linear zipper-like array in which the axonin-1 molecules are alternately provided by the two apposed membranes. In accordance with this model, mutations in a loop critical for the formation of the zipper resulted in the loss of the hemophilic binding capacity of axonin-1.	Univ Konstanz, Fac Biol, D-78457 Constance, Germany; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Konstanz; University of Zurich	Welte, W (corresponding author), Univ Konstanz, Fac Biol, Box M656, D-78457 Constance, Germany.							Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Brummendorf T, 1996, CURR OPIN NEUROBIOL, V6, P584, DOI 10.1016/S0959-4388(96)80089-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; Buchstaller A, 1996, J CELL BIOL, V135, P1593, DOI 10.1083/jcb.135.6.1593; BURGOON MP, 1995, J CELL BIOL, V130, P733, DOI 10.1083/jcb.130.3.733; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Denzinger T, 1997, EUR MASS SPECTROM, V3, P379, DOI 10.1255/ejms.170; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FITZLI D, 2000, IN PRESS J CELL BIOL; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; Janin J, 1997, NAT STRUCT BIOL, V4, P973, DOI 10.1038/nsb1297-973; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kunz S, 1996, J CELL BIOL, V135, P253, DOI 10.1083/jcb.135.1.253; Kunz S, 1998, J CELL BIOL, V143, P1673, DOI 10.1083/jcb.143.6.1673; Lustig M, 1999, DEV BIOL, V209, P340, DOI 10.1006/dbio.1999.9250; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; Rader C, 1996, EMBO J, V15, P2056, DOI 10.1002/j.1460-2075.1996.tb00559.x; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; Stoeckli ET, 1996, DEV BIOL, V177, P15, DOI 10.1006/dbio.1996.0141; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tsiotra PC, 1996, J BIOL CHEM, V271, P29216, DOI 10.1074/jbc.271.46.29216; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; ZUELLIG RA, 1992, EUR J BIOCHEM, V204, P453, DOI 10.1111/j.1432-1033.1992.tb16655.x	38	129	132	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 12	2000	101	4					425	433		10.1016/S0092-8674(00)80852-1	http://dx.doi.org/10.1016/S0092-8674(00)80852-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830169	Bronze, Green Submitted, Green Accepted			2022-12-28	WOS:000087010400010
J	Macilwain, C				Macilwain, C			Troubled US fusion project receives cash injection	NATURE			English	News Item																		GIOCONDA T, 2000, NATURE, V403, P469	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					110	110		10.1038/35012299	http://dx.doi.org/10.1038/35012299			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821243	Bronze			2022-12-28	WOS:000087080100011
J	Phillips, RL; Ernst, RE; Brunk, B; Ivanova, N; Mahan, MA; Deanehan, JK; Moore, KA; Overton, GC; Lemischka, IR				Phillips, RL; Ernst, RE; Brunk, B; Ivanova, N; Mahan, MA; Deanehan, JK; Moore, KA; Overton, GC; Lemischka, IR			The genetic program of hematopoietic stem cells	SCIENCE			English	Article							SUBTRACTIVE HYBRIDIZATION; HISTONE MACROH2A1; RECEPTOR; DNMT3B; MOUSE; CDNA	Blood cell production originates from a rare population of multipotent, self-renewing stem cells. A genome-wide gene expression analysis was performed in order to define regulatory pathways in stem cells as well as their global genetic program. Subtracted complementary DNA Libraries from highly purified murine fetal liver stem cells were analyzed with bioinformatic and array hybridization strategies. A large percentage of the several thousand gene products that have been characterized correspond to previously undescribed molecules with properties suggestive of regulatory functions. The complete data, available in a biological process-oriented database, represent the molecular phenotype of the hematopoietic stem cell.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Penn, Computat Biol & Informat Lab, Philadelphia, PA 19104 USA	Princeton University; University of Pennsylvania	Lemischka, IR (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	ilemischka@molbio.princeton.edu			NCRR NIH HHS [R01-RR04026] Funding Source: Medline; NIDDK NIH HHS [R01-DK42989] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR004026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042989] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; Choi K, 1998, DEVELOPMENT, V125, P725; Cong F, 1999, MOL CELL BIOL, V19, P8314; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Ema H, 2000, BLOOD, V95, P2284, DOI 10.1182/blood.V95.7.2284.007k14_2284_2288; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; Mermoud JE, 1999, J CELL BIOL, V147, P1399, DOI 10.1083/jcb.147.7.1399; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Moore KA, 1997, BLOOD, V89, P4337, DOI 10.1182/blood.V89.12.4337; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; Pehrson JR, 1997, J CELL BIOCHEM, V65, P107, DOI 10.1002/(SICI)1097-4644(199704)65:1<107::AID-JCB11>3.0.CO;2-H; RUBENSTEIN JLR, 1990, NUCLEIC ACIDS RES, V18, P4833, DOI 10.1093/nar/18.16.4833; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Voura EB, 1997, EXP HEMATOL, V25, P1172; Wiesmann A, 2000, IMMUNITY, V12, P193, DOI 10.1016/S1074-7613(00)80172-7; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6	28	316	337	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 2	2000	288	5471					1635	1640		10.1126/science.288.5471.1635	http://dx.doi.org/10.1126/science.288.5471.1635			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834841				2022-12-28	WOS:000087382300039
J	Jones, J				Jones, J			The secret life of the NHS	BRITISH MEDICAL JOURNAL			English	Article																		Beecham L, 2000, BRIT MED J, V320, P892; CRAFT N, 1994, BRIT MED J, V309, P1640, DOI 10.1136/bmj.309.6969.1640a; Ferriman A, 2000, BRIT MED J, V320, P205, DOI 10.1136/bmj.320.7229.205; MCENTEE J, 1999, EXPRESS         0930, P43; MILNE S, 2000, GUARDIAN        0930; MOORE W, 2000, BMJ NEWS        0504; *NHS EX, 1999, CLIN GOV LOND REG; *OFF COMM PUBL APP, 2000, PUBL APP NHS TRUSTS; *PARL COMM ADM, 1999, 2 PARL COMM ADM; RIDDELL M, 2000, NEW STATESMAN   0117; RIDDELL M, 2000, NEW STATESMAN   0124; SMITH R, 1987, BRIT MED J, V295, P1633, DOI 10.1136/bmj.295.6613.1633; TRAVIS A, 2000, GUARDIAN        0707; WHITFIELD L, 1999, HLTH SERVICE J  1209, P2; Wise J, 1999, BRIT MED J, V319, P939, DOI 10.1136/bmj.319.7215.939; YARNEY G, 2000, BRIT MED J, V320, P205	16	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1457	1459		10.1136/bmj.320.7247.1457	http://dx.doi.org/10.1136/bmj.320.7247.1457			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827056	Green Published			2022-12-28	WOS:000087414700031
J	Franz, WM; Muller, M; Muller, OJ; Herrmann, R; Rothmann, T; Cremer, M; Cohn, RD; Voit, T; Katus, HA				Franz, WM; Muller, M; Muller, OJ; Herrmann, R; Rothmann, T; Cremer, M; Cohn, RD; Voit, T; Katus, HA			Association of nonsense mutation of dystrophin gene with disruption of sarcoglycan complex in X-linked dilated cardiomyopathy	LANCET			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; GLYCOPROTEIN; IDENTIFICATION; ORGANIZATION; DEFICIENCY; COMPONENT; DELETION; LINKAGE; FAMILY; REGION	Background In a systematic analysis of inherited forms of cardiomyopathy, we previously identified a family with X-linked dilated cardiomyopathy characterised by a mutation in the rod region of dystrophin. We have now attempted to eludicate the genetic mechanism involved in this disease, as well as the role of dystrophin-associated glycoproteins. Methods The affected dystrophin epitope, which lacks binding to the dys-1 antibody, was analysed by single-strand conformation polymorphism analysis, reverse-transcription PCR, and DNA sequencing. Effects on dystrophin-associated glycoproteins were studied by immunohistochemistry and western blotting. Findings A translation-termination mutation (C4148T) in exon 29 of the dystrophin gene was found in all affected family members. Alternative splicing rescued the reading frame and led to the expression of a dystrophin molecule lacking 50 aminoacids both in cardiac and skeletal muscle. Immunohistochemical analysis of the dystrophin-associated proteins revealed a reduction of beta-sarcoglycan and delta-sarcoglycan in the sarcolemma of cardiac muscle but not skeletal muscle tissue. However, western blotting revealed similar amounts of sarcoglycan subunits in both tissues. Interpretation The molecular mechanism of this subtype of X-linked cardiomyopathy may be explained by a conformational change in exon-29-deleted dystrophin, resulting in disruption of the sarcoglycan assembly in heart muscle but not skeletal muscle.	Med Univ Lubeck, Med Klin 2, Lubeck, Germany; Univ Essen Gesamthsch, Kinderklin, Essen, Germany; Deutsch Krebsforschungszentrum, Heidelberg, Germany; Univ Heidelberg, Dept Human Genet, D-6900 Heidelberg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Franz, WM (corresponding author), Med Univ Lubeck, Med Klin 2, D-23538 Lubeck, Germany.		Cremer, Marion/P-8524-2014; Müller, Oliver J./H-4739-2016; Cohn, Ronald/AAC-5835-2021; Müller, Oliver/AAA-4399-2021	Cremer, Marion/0000-0002-1830-9589; Müller, Oliver/0000-0001-8223-2638; Muller, Mathias/0000-0002-7879-3552				Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Beggs AH, 1997, CIRCULATION, V95, P2344, DOI 10.1161/01.CIR.95.10.2344; Bies RD, 1997, J MOL CELL CARDIOL, V29, P3175, DOI 10.1006/jmcc.1997.0568; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chan YM, 1998, J CELL BIOL, V143, P2033, DOI 10.1083/jcb.143.7.2033; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; ENGLAND SB, 1992, NEW ENGL J MED, V326, P77; Fadic R, 1996, NEW ENGL J MED, V334, P362, DOI 10.1056/NEJM199602083340604; Ferlini A, 1998, AM J HUM GENET, V63, P436, DOI 10.1086/301952; FRANZ WM, 1995, ANN NY ACAD SCI, V752, P470, DOI 10.1111/j.1749-6632.1995.tb17457.x; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; HUNSAKER RH, 1982, AM J MED, V73, P235, DOI 10.1016/0002-9343(82)90184-X; Jung D, 1996, J BIOL CHEM, V271, P32321, DOI 10.1074/jbc.271.50.32321; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; Melacini P, 1996, CIRCULATION, V94, P3168, DOI 10.1161/01.CIR.94.12.3168; Meng HP, 1996, J BIOL CHEM, V271, P12364, DOI 10.1074/jbc.271.21.12364; MUNTONI F, 1995, J CLIN INVEST, V96, P693, DOI 10.1172/JCI118112; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; OrtizLopez R, 1997, CIRCULATION, V95, P2434, DOI 10.1161/01.CIR.95.10.2434; PALEK J, 1990, SEMIN HEMATOL, V27, P290; PRIOR TW, 1995, AM J HUM GENET, V57, P22; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Shiga N, 1997, J CLIN INVEST, V100, P2204, DOI 10.1172/JCI119757; Stevenson S, 1997, CIRC RES, V80, P269, DOI 10.1161/01.RES.80.2.269; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; VOIT T, 1989, J NEUROL SCI, V89, P199, DOI 10.1016/0022-510X(89)90022-1; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; YOSHIDA K, 1993, MUSCLE NERVE, V16, P1161, DOI 10.1002/mus.880161104	33	32	35	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1781	1785		10.1016/S0140-6736(00)02266-2	http://dx.doi.org/10.1016/S0140-6736(00)02266-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832829				2022-12-28	WOS:000087126100013
J	Terrones, M; Terrones, H; Banhart, F; Charlier, JC; Ajayan, PM				Terrones, M; Terrones, H; Banhart, F; Charlier, JC; Ajayan, PM			Coalescence of single-walled carbon nanotubes	SCIENCE			English	Article							FULLERENES; GROWTH	The coalescence of single-walled nanotubes is studied in situ under electron irradiation at high temperature in a transmission electron microscope. The merging process is investigated at the atomic level, using tight-binding molecular dynamics and Monte Carte simulations. Vacancies induce coalescence via a zipper-like mechanism, imposing a continuous reorganization of atoms on individual tube Lattices along adjacent tubes. Other topological defects induce the polymerization of tubes. Coalescence seems to be restricted to tubes with the same chirality, explaining the low frequency of occurrence of this event.	Univ Sussex, Sch Chem Phys & Environm Sci, Brighton BN1 9QJ, E Sussex, England; Univ Nacl Autonoma Mexico, Inst Fis, Lab Juriquilla, Queretaro 76000, Mexico; Max Planck Inst Met Res, D-70569 Stuttgart, Germany; Univ Catholique Louvain, Unite Physicochim & Phys Mat, B-1348 Louvain, Belgium; Rensselaer Polytech Inst, Dept Mat Sci & Engn, Troy, NY 12180 USA	University of Sussex; Universidad Nacional Autonoma de Mexico; Max Planck Society; Universite Catholique Louvain; Rensselaer Polytechnic Institute	Terrones, H (corresponding author), Univ Sussex, Sch Chem Phys & Environm Sci, Brighton BN1 9QJ, E Sussex, England.	terrones@fenix.ifisicacu.unam.mx	Terrones, Humberto/AAA-8454-2019; Dee, Chang Fu/G-4842-2010; Banhart, Florian/I-1118-2016; Terrones, Mauricio/B-3829-2014; Beguin, Francois/G-3079-2018	Dee, Chang Fu/0000-0003-1015-9181; Banhart, Florian/0000-0001-5911-9418; Terrones, Mauricio/0000-0003-0010-2851; Beguin, Francois/0000-0002-6189-1527; Terrones, Humberto/0000-0003-0515-0721				Ajayan PM, 1998, PHYS REV LETT, V81, P1437, DOI 10.1103/PhysRevLett.81.1437; AJAYAN PM, UNPUB; Banhart F, 1999, REP PROG PHYS, V62, P1181, DOI 10.1088/0034-4885/62/8/201; Banhart F, 1998, CHEM PHYS LETT, V292, P554, DOI 10.1016/S0009-2614(98)00705-2; Blase X, 1999, PHYS REV LETT, V83, P5078, DOI 10.1103/PhysRevLett.83.5078; BONNAMY S, IN PRESS GRAPHITE PR; Chernozatonskii LA, 1998, CHEM PHYS LETT, V297, P257, DOI 10.1016/S0009-2614(98)01100-2; Crespi VH, 1997, PHYS REV LETT, V79, P2093, DOI 10.1103/PhysRevLett.79.2093; Fang SL, 1998, J MATER RES, V13, P2405, DOI 10.1557/JMR.1998.0334; GOEDECKER S, 1994, PHYS REV LETT, V73, P122, DOI 10.1103/PhysRevLett.73.122; Journet C, 1997, NATURE, V388, P756, DOI 10.1038/41972; MAITI A, 1995, PHYS REV B, V52, P14850, DOI 10.1103/PhysRevB.52.14850; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Nardelli MB, 1998, PHYS REV B, V57, pR4277, DOI 10.1103/PhysRevB.57.R4277; Nikolaev P, 1997, CHEM PHYS LETT, V266, P422, DOI 10.1016/S0009-2614(97)00053-5; ROBERTSON DH, 1992, PHYS REV B, V45, P12592, DOI 10.1103/PhysRevB.45.12592; SAITO R, 1992, CHEM PHYS LETT, V195, P537, DOI 10.1016/0009-2614(92)85559-S; Sloan J, 2000, CHEM PHYS LETT, V316, P191, DOI 10.1016/S0009-2614(99)01250-6; Smith BW, 1998, NATURE, V396, P323, DOI 10.1038/24521; STONE AJ, 1986, CHEM PHYS LETT, V128, P501, DOI 10.1016/0009-2614(86)80661-3; Terrones H, 2000, PHYS REV LETT, V84, P1716, DOI 10.1103/PhysRevLett.84.1716; TERRONES H, 1995, FULLERENE SCI TECHN, V3, P107, DOI 10.1080/153638X9508543773; Terrones M, 1996, FULLERENE SCI TECHN, V4, P517, DOI 10.1080/10641229608001568; TERSOFF J, 1988, PHYS REV LETT, V61, P2879, DOI 10.1103/PhysRevLett.61.2879; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; XU CH, 1992, J PHYS-CONDENS MAT, V4, P6047, DOI 10.1088/0953-8984/4/28/006; YERETZIAN C, 1992, NATURE, V359, P44, DOI 10.1038/359044a0	27	433	453	5	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1226	1229		10.1126/science.288.5469.1226	http://dx.doi.org/10.1126/science.288.5469.1226			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817994				2022-12-28	WOS:000087112600046
J	Lee, MS; Kwon, YT; Li, MW; Peng, JM; Friedlander, RM; Tsai, LH				Lee, MS; Kwon, YT; Li, MW; Peng, JM; Friedlander, RM; Tsai, LH			Neurotoxicity induces cleavage of p35 to p25 by calpain	NATURE			English	Article							NEUTRAL PROTEINASE CALPAIN; CYCLIN-DEPENDENT KINASE-5; ALZHEIMERS-DISEASE; NEURONAL DEGENERATION; CDK5; ACTIVATOR; PATHOLOGY; DEATH; BRAIN	Cyclin-dependent kinase 5 (cdk5) and its neuron-specific activator p35 are required for neurite outgrowth and cortical lamination(1-3). Proteolytic cleavage of p35 produces p25, which accumulates in the brains of patients with Alzheimer's disease(4). Conversion of p35 to p25 causes prolonged activation and mislocalization of cdk5. Consequently, the p25/cdk5 kinase hyperphosphorylates tau, disrupts the cytoskeleton and promotes the death (apoptosis) of primary neurons. Here we describe the mechanism of conversion of p35 to p25. In cultured primary cortical neurons, excitotoxins, hypoxic stress and calcium influx induce the production of p25. In fresh brain lysates, addition of calcium can stimulate cleavage of p35 to p25. Specific inhibitors of calpain, a calcium-dependent cysteine protease, effectively inhibit the calcium-induced cleavage of p35. In vitro, calpain directly cleaves p35 to release a fragment with relative molecular mass 25,000. The sequence of the calpain cleavage product corresponds precisely to that of p25. Application of the amyloid beta-peptide A beta(1-42) induces the conversion of p35 to p25 in primary cortical neurons. Furthermore, inhibition of cdk5 or calpain activity reduces cell death in A beta-treated cortical neurons. These observations indicate that cleavage of p35 to p25 by calpain may be involved in the pathogenesis of Alzheimer's disease.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Neurapoptosis Lab,Neurosurg Serv,Dept Surg, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Tsai, LH (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 200 Longwood Ave, Boston, MA 02115 USA.		Friedlander, Robert M/A-2845-2016; Peng, Junmin/N-2614-2018	Friedlander, Robert M/0000-0003-4423-9219; Peng, Junmin/0000-0003-0472-7648				Alvarez A, 1999, FEBS LETT, V459, P421, DOI 10.1016/S0014-5793(99)01279-X; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3; HARTMANN H, 1993, BIOCHEM BIOPH RES CO, V194, P1216, DOI 10.1006/bbrc.1993.1952; IWAMOTO N, 1991, BRAIN RES, V561, P177, DOI 10.1016/0006-8993(91)90766-O; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Pascale A, 1999, PHARMACOL RES, V39, P81, DOI 10.1006/phrs.1998.0411; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SEISJO BK, 1978, BRAIN ENERGY METABOL, P454; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; WANG KKW, 1999, CALPAIN PHARM TOXICO, P77; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	20	872	924	0	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					360	364		10.1038/35012636	http://dx.doi.org/10.1038/35012636			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830966				2022-12-28	WOS:000087085700050
J	Gaston, KJ				Gaston, KJ			Global patterns in biodiversity	NATURE			English	Review							TREE SPECIES RICHNESS; NEW-WORLD BIRDS; LATITUDINAL GRADIENTS; MOIST FORESTS; ENERGY THEORY; CONSERVATION STRATEGIES; DIVERSITY GRADIENTS; SCALE DEPENDENCE; AREA; COMMUNITIES	To a first approximation, the distribution of biodiversity across the Earth can be described in terms of a relatively small number of broad-scale spatial patterns. Although these patterns are increasingly well documented, understanding why they exist constitutes one of the most significant intellectual challenges to ecologists and biogeographers. Theory is, however, developing rapidly, improving in its internal consistency, and more readily subjected to empirical challenge.	Univ Sheffield, Dept Anim & Plant Sci, Biodivers & Macroecol Grp, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Gaston, KJ (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Biodivers & Macroecol Grp, Sheffield S10 2TN, S Yorkshire, England.	k.j.gaston@sheffield.ac.uk						ADAMS JM, 1989, NATURE, V339, P699, DOI 10.1038/339699a0; Andersen Mark, 1997, P281; Blackburn Tim M., 1996, Biodiversity Letters, V3, P44, DOI 10.2307/2999768; Blackburn TM, 1997, EVOL ECOL, V11, P195, DOI 10.1023/A:1018451916734; Blackburn TM, 1996, ECOGRAPHY, V19, P369, DOI 10.1111/j.1600-0587.1996.tb00247.x; Brown J.H., 1995, MACROECOLOGY; Brown J. H., 1998, BIOGEOGRAPHY; Caley MJ, 1997, ECOLOGY, V78, P70; Chown SL, 1999, EVOL ECOL RES, V1, P365; Chown SL, 1998, ECOGRAPHY, V21, P342, DOI 10.1111/j.1600-0587.1998.tb00399.x; Clarke A, 1997, MARINE BIODIVERSITY-BOOK, P122, DOI 10.1017/CBO9780511752360.007; COLLAR NJ, 1994, BIRDS WATCH, V2; COLWELL RK, 1994, AM NAT, V144, P570, DOI 10.1086/285695; Cornell HV, 1999, ECOSCIENCE, V6, P303, DOI 10.1080/11956860.1999.11682532; CORNELL HV, 1992, J ANIM ECOL, V61, P1, DOI 10.2307/5503; COUSINS SH, 1989, NATURE, V340, P350, DOI 10.1038/340350b0; CRANE PR, 1989, SCIENCE, V246, P675, DOI 10.1126/science.246.4930.675; CURRIE DJ, 1991, AM NAT, V137, P27, DOI 10.1086/285144; CURRIE DJ, 1987, NATURE, V329, P326, DOI 10.1038/329326a0; Eeley Harriet A.C., 1999, P191, DOI 10.1017/CBO9780511542381.013; Flather CH, 1997, ECOL APPL, V7, P531, DOI 10.1890/1051-0761(1997)007[0531:IGICNO]2.0.CO;2; Francis AP, 1998, OIKOS, V81, P598, DOI 10.2307/3546780; Gaston Kevin J., 1996, P202; Gaston KJ, 1995, P ROY SOC B-BIOL SCI, V262, P335, DOI 10.1098/rspb.1995.0214; Gaston KJ, 1996, PROG PHYS GEOG, V20, P105, DOI 10.1177/030913339602000108; Gaston KJ, 1996, PROG PHYS GEOG, V20, P466, DOI 10.1177/030913339602000406; Gaston KJ, 1999, OIKOS, V84, P353, DOI 10.2307/3546417; Gaston KJ, 1997, J ANIM ECOL, V66, P579, DOI 10.2307/5951; GASTON KJ, IN PRESS PATTERN PRO; Gotelli N.J., 1996, NULL MODELS ECOLOGY; Griffiths D, 1997, J ANIM ECOL, V66, P49, DOI 10.2307/5963; HAWKINS BA, 1992, J ANIM ECOL, V61, P361, DOI 10.2307/5328; Hayden BP, 1998, PHILOS T ROY SOC B, V353, P5, DOI 10.1098/rstb.1998.0186; HOLMES RT, 1975, J ANIM ECOL, V44, P175, DOI 10.2307/3857; Huston MA, 1999, OIKOS, V86, P393, DOI 10.2307/3546645; JUDAS M, 1988, OECOLOGIA, V76, P579, DOI 10.1007/BF00397874; Kerr JT, 1999, BIODIVERS CONSERV, V8, P617, DOI 10.1023/A:1008846131749; Kerr JT, 1999, ECOSCIENCE, V6, P329, DOI 10.1080/11956860.1999.11682546; Kerr JT, 1998, ECOSCIENCE, V5, P448, DOI 10.1080/11956860.1998.11682483; LATHAM RE, 1993, OIKOS, V67, P325, DOI 10.2307/3545479; Lawton JH, 1999, OIKOS, V84, P177, DOI 10.2307/3546712; Lawton JH, 1996, OIKOS, V75, P145, DOI 10.2307/3546237; LENNON JJ, IN PRESS J ANIM ECOL; Lyons SK, 1999, ECOLOGY, V80, P2483, DOI 10.2307/177234; MacArthur R. H., 1966, BIOL POPULATIONS; MARTIN TE, 1981, AM NAT, V118, P823, DOI 10.1086/283873; OBRIEN EM, 1993, J BIOGEOGR, V20, P181, DOI 10.2307/2845670; OSMAN RW, 1978, PALEOBIOLOGY, V4, P41, DOI 10.1017/S0094837300005674; PALMER MW, 1994, AM NAT, V144, P717, DOI 10.1086/285704; Patterson BD, 1998, J BIOGEOGR, V25, P593, DOI 10.1046/j.1365-2699.1998.2530593.x; Pearson David L., 1993, P194; PIANKA ER, 1981, ECOLOGICAL BIOGEOGRA, V3, P1677; PLATNICK NI, 1991, J NAT HIST, V25, P1083, DOI 10.1080/00222939100770701; PRENDERGAST JR, 1993, NATURE, V365, P335, DOI 10.1038/365335a0; Ricklefs RE, 1999, OIKOS, V86, P369, DOI 10.2307/3546454; Ricklefs Robert E., 1993, P350; ROHDE K, 1992, OIKOS, V65, P514, DOI 10.2307/3545569; Rosenzweig Michael L., 1993, P52; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Rosenzweig ML, 1997, OIKOS, V80, P172, DOI 10.2307/3546528; ROSENZWEIG ML, 1992, J MAMMAL, V73, P715, DOI 10.2307/1382191; Roy K, 1998, P NATL ACAD SCI USA, V95, P3699, DOI 10.1073/pnas.95.7.3699; Rutherford S, 1999, NATURE, V400, P749, DOI 10.1038/23449; Schlapfer F, 1999, ECOL APPL, V9, P893, DOI 10.1890/1051-0761(1999)009[0893:EEOBAC]2.0.CO;2; Srivastava DS, 1998, AM NAT, V152, P510, DOI 10.1086/286187; Srivastava DS, 1999, J ANIM ECOL, V68, P1, DOI 10.1046/j.1365-2656.1999.00266.x; STEHLI FG, 1969, SCIENCE, V164, P947, DOI 10.1126/science.164.3882.947; STEVENS GC, 1989, AM NAT, V133, P240, DOI 10.1086/284913; Stork Nigel E., 1997, P41; TERBORGH J, 1973, AM NAT, V107, P481, DOI 10.1086/282852; Tilman D, 1999, ECOLOGY, V80, P1455, DOI 10.1890/0012-9658(1999)080[1455:TECOCI]2.0.CO;2; Tilman David, 1993, P13; TURNER JRG, 1988, NATURE, V335, P539, DOI 10.1038/335539a0; TURNER JRG, 1987, OIKOS, V48, P195, DOI 10.2307/3565855; van Jaarsveld AS, 1998, SCIENCE, V279, P2106, DOI 10.1126/science.279.5359.2106; WHITTAKER ROBERT H., 1960, ECOL MONOGR, V30, P279, DOI 10.2307/1943563; Wright David H., 1993, P66; WRIGHT DH, 1983, OIKOS, V41, P496, DOI 10.2307/3544109; Zheng XY, 1998, J CLIMATE, V11, P2078, DOI 10.1175/1520-0442-11.8.2078	79	2062	2355	128	1576	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					220	227		10.1038/35012228	http://dx.doi.org/10.1038/35012228			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821282				2022-12-28	WOS:000087080100059
J	Wittman, DM; Tyson, JA; Kirkman, D; Dell'Antonio, I; Bernstein, G				Wittman, DM; Tyson, JA; Kirkman, D; Dell'Antonio, I; Bernstein, G			Detection of weak gravitational lensing distortions of distant galaxies by cosmic dark matter at large scales	NATURE			English	Article							UNIVERSE; IMAGES; FLUCTUATIONS; TOMOGRAPHY; COSMOLOGY; SPECTRUM; CLUSTER	Most of the matter in the Universe is not luminous, and can be observed only through its gravitational influence on the appearance of luminous matter. Weak gravitational lensing is a technique that uses the distortions of the images of distant galaxies as a tracer of dark matter: such distortions are induced as the light passes through large-scale distributions of dark matter in the foreground. The patterns of the induced distortions reflect the density of mass along the line of sight and its distribution, and the resulting 'cosmic shear' can be used to distinguish between alternative cosmologies. But previous attempts to measure this effect have been inconclusive. Here we report the detection of cosmic shear on angular scales of up to half a degree using 145,000 galaxies and along three separate lines of sight. We find that the dark matter is distributed in a manner consistent with either an open universe, or a flat universe that is dominated by a cosmological constant. Our results are inconsistent with the standard cold-dark-matter model.	Bell Labs, Lucent Technol, Murray Hill, NJ 07574 USA; Natl Opt Astron Observ, Kitt Peak Natl Observ, Tucson, AZ 85726 USA; Univ Michigan, Dept Astron, Ann Arbor, MI 48109 USA	Alcatel-Lucent; Lucent Technologies; AT&T; National Optical Astronomy Observatory; University of Michigan System; University of Michigan	Wittman, DM (corresponding author), Bell Labs, Lucent Technol, Murray Hill, NJ 07574 USA.	wittman@physics.bell-labs.com	Tyson, J. Anthony/ABB-2612-2021	Tyson, J. Anthony/0000-0002-9242-8797; Wittman, David/0000-0002-0813-5888; Bernstein, Gary/0000-0002-8613-8259				Bahcall NA, 1999, SCIENCE, V284, P1481, DOI 10.1126/science.284.5419.1481; Bertin E, 1996, ASTRON ASTROPHYS SUP, V117, P393, DOI 10.1051/aas:1996164; CASTLEMAN KR, 1979, DIGITAL IMAGE PROCES, P214; Clowe D, 1998, ASTROPHYS J, V497, pL61, DOI 10.1086/311285; DYER CC, 1974, ASTROPHYS J, V189, P167, DOI 10.1086/152784; FAHLMAN G, 1994, ASTROPHYS J, V437, P56, DOI 10.1086/174974; Fischer P, 1997, ASTRON J, V114, P14, DOI 10.1086/118447; FRENK CS, 1990, ASTROPHYS J, V351, P10, DOI 10.1086/168439; GULLIXSON CA, 1995, ASTROPHYS J SUPPL S, V99, P281, DOI 10.1086/192187; GUNN JE, 1967, ASTROPHYS J, V147, P61, DOI 10.1086/148981; HAMILTON AJS, 1991, ASTROPHYS J, V374, pL1, DOI 10.1086/186057; Hoekstra H, 1998, ASTROPHYS J, V504, P636, DOI 10.1086/306102; Hu W, 1999, ASTROPHYS J, V522, pL21, DOI 10.1086/312210; Jain B, 1997, ASTROPHYS J, V484, P560, DOI 10.1086/304372; KAISER N, 1992, ASTROPHYS J, V388, P272, DOI 10.1086/171151; Kaiser N, 1998, ASTROPHYS J, V498, P26, DOI 10.1086/305515; KRISTIAN J, 1967, ASTROPHYS J, V147, P864, DOI 10.1086/149078; KRUSE G, 1999, ASTROPH9904192; Mellier Y, 1999, ANNU REV ASTRON ASTR, V37, P127, DOI 10.1146/annurev.astro.37.1.127; MIRALDAESCUDE J, 1991, ASTROPHYS J, V380, P1, DOI 10.1086/170555; MOULD J, 1994, MON NOT R ASTRON SOC, V271, P31, DOI 10.1093/mnras/271.1.31; OSTRIKER JP, 1995, NATURE, V377, P600, DOI 10.1038/377600a0; Page L, 1999, REV MOD PHYS, V71, pS173, DOI 10.1103/RevModPhys.71.S173; PEACOCK JA, 1996, MNRAS, V280, P19; Schneider P, 1998, ASTRON ASTROPHYS, V333, P767; Squires G, 1996, ASTROPHYS J, V469, P73, DOI 10.1086/177759; Tran KVH, 1999, ASTROPHYS J, V522, P39, DOI 10.1086/307624; Turner MS, 1999, REV MOD PHYS, V71, pS145, DOI 10.1103/RevModPhys.71.S145; TYSON JA, 1995, AIP CONF PROC, P287, DOI 10.1063/1.48339; TYSON JA, 1990, APJ, V349, P1; VALDES F, 1983, ASTROPHYS J, V271, P431, DOI 10.1086/161210; VALDES F, 1982, P SOC PHOTO-OPT INST, V331, P465; Villumsen JV, 1996, MON NOT R ASTRON SOC, V281, P369, DOI 10.1093/mnras/281.2.369; Wittman D, 1998, P SOC PHOTO-OPT INS, V3355, P626, DOI 10.1117/12.316787; WITTMAN D, ASP C SERIES ASTRONO	36	446	449	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					143	148		10.1038/35012001	http://dx.doi.org/10.1038/35012001			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821262	Green Published, Green Submitted			2022-12-28	WOS:000087080100039
J	Hirsch, MS; Brun-Vezinet, F; D'Aquila, RT; Hammer, SM; Johnson, VA; Kuritzkes, DR; Loveday, C; Mellors, JW; Clotet, B; Conway, B; Demeter, LM; Vella, S; Jacobsen, DM; Richman, DD				Hirsch, MS; Brun-Vezinet, F; D'Aquila, RT; Hammer, SM; Johnson, VA; Kuritzkes, DR; Loveday, C; Mellors, JW; Clotet, B; Conway, B; Demeter, LM; Vella, S; Jacobsen, DM; Richman, DD			Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society-USA panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE GENE; PROTEASE INHIBITORS; COMBINATION THERAPY; ZIDOVUDINE RESISTANCE; GENOTYPIC RESISTANCE; CONTROLLED TRIAL; DUAL RESISTANCE; VIRAL LOAD; IN-VIVO	Objective Assays for drug resistance testing in human immunodeficiency virus type 1 (HIV-1) infection are now available and clinical studies suggest that viral drug resistance is correlated with poor virologic response to new therapy. The International AIDS Society-USA sought to update prior recommendations to provide guidance for clinicians regarding indications for HIV-1 resistance testing. Participants An International AIDS Society-USA 13-member physician panel with expertise in basic science, clinical research, and patient care involving HIV resistance to antiretroviral drugs was reconvened to provide recommendations for the clinical use of drug resistance testing. Evidence and Consensus Process The full panel met regularly between January and October 1999. Resistance and resistance testing data appearing in the last decade th rough April 2000 and presentations at national and international research conferences were reviewed. Recommendations and considerations were developed by 100% group consensus, acknowledging that definitive data to support final recommendations are not yet available. Conclusions Emerging data indicate that despite limitations, resistance testing should be incorporated into patient management in some settings. Resistance testing is recommended to help guide the choice of new regimens after treatment failure and for guiding therapy for pregnant women. It should be considered in treatment-naive patients with established infection, but cannot be firmly recommended in this setting. Testing also should be considered prior to initiating therapy in patients with acute HIV infection, although therapy should not be delayed pending the results. Expert interpretation is recommended given the complexity of results and assay limitations.	Harvard Univ, Sch Med, Boston, MA USA; Hop Bichat Claude Bernard, F-75877 Paris 18, France; Columbia Univ, Coll Phys & Surg, New York, NY USA; Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; Birmingham Vet Affairs Med Ctr, Birmingham, AL USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Royal Free Hosp, Sch Med, London, England; Vet Affairs Med Ctr, Pittsburgh, PA USA; Univ Pittsburgh, Pittsburgh, PA USA; Fdn IrsaCAIXA, Barcelona, Spain; Hosp Badalona Germans Trias & Pujol, HIV Unit, Barcelona, Spain; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Rochester, Rochester, NY USA; Ist Super Sanita, I-00161 Rome, Italy; Univ Calif San Diego, San Diego, CA 92103 USA; San Diego Vet Affairs Med Ctr, San Diego, CA USA; Infect Dis Unit, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Columbia University; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hospital Germans Trias i Pujol; University of British Columbia; University of Rochester; Istituto Superiore di Sanita (ISS); University of California System; University of California San Diego	Hirsch, MS (corresponding author), Int AIDS Soc USA, Presidio San Francisco,1001 B OReilly Ave,Box 29, San Francisco, CA 94129 USA.	hirsch.martin@mgh.harvard.edu	VELLA, STEFANO/V-8440-2019; VELLA, STEFANO/ABI-3368-2020; Johnson, Victoria/GVU-7127-2022; Vella, Stefano/GZM-0519-2022	VELLA, STEFANO/0000-0003-2347-5984; 				ACOSTA EP, 2000, 7 C RETR OPP INF JAN; ALEXANDER C, 1999, 6 C RETR OPP INF JAN; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BACHELER LT, 1999, ANTIVIR THER S, V4, P63; Baxter J, 1999, ANTIVIR THER S, V4, P43; BECKERPERGOLA G, 2000, 7 C RETR OPP INF JAN; Boden D, 1999, JAMA-J AM MED ASSOC, V282, P1135, DOI 10.1001/jama.282.12.1135; Brodine SK, 1999, ANN INTERN MED, V131, P502, DOI 10.7326/0003-4819-131-7-199910050-00004; CALL S, 1999, 39 INT C ANT AG CHEM; CALVEZ V, 1999, ANTIVIR THER S, V4, P26; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CASADO JL, 1999, ANTIVIR THER S, V4, P78; CHAIX C, 1999, ANTIVIR THER S, V4, P69; Chandramohan D., 2011, INT J RECENT RES APP, V8, P194, DOI DOI 10.1089/AID.1996.12.1427; CLEVENBERGH P, 1999, ANTIVIR THER S, V4, P42; Coakley EP, 2000, AIDS, V14, pF9, DOI 10.1097/00002030-200001280-00002; COHEN C, 2000, 7 C RETR OPP INF JAN; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Conway B, 1999, CLIN INFECT DIS, V28, P910, DOI 10.1086/515225; CONWAY B, 1999, 39 INT C ANT AG CHEM; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DEBETHUNE MP, 1999, ANTIVIR THER S, V4, P33; DEEKS S, 2000, 7 C RETR OPP INF JAN; Deeks SG, 1999, J INFECT DIS, V179, P1375, DOI 10.1086/314775; Demeter LM, 2000, ANTIMICROB AGENTS CH, V44, P794, DOI 10.1128/AAC.44.3.794-797.2000; DEPASQUALE MP, 1998, ANTIVIR THER S, V3, P50; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fiscus SA, 1999, J INFECT DIS, V180, P99, DOI 10.1086/314840; FONTAINE E, 1998, 12 WORLD AIDS C JUN; GARRAFFO R, 1999, ANTIVIR THER S, V4, P75; Gomez-Cano M, 1998, AIDS, V12, P1015, DOI 10.1097/00002030-199809000-00007; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 1998, AIDS RES HUM RETROV, V14, P869, DOI 10.1089/aid.1998.14.869; HAMMER S, 1999, ANTIVIR THER S, V4, P45; HARRIGAN P, 1998, ANTIVIR THER S, V3, P38; HARRIGAN PR, 1999, ANTIVIR THER S, V4, P88; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hertogs K, 2000, ANTIMICROB AGENTS CH, V44, P568, DOI 10.1128/AAC.44.3.568-573.2000; HERTOGS K, 1999, ANTIVIR THER S, V4, P59; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; HOLDER DJ, 1999, 6 C RETR OPP INF JAN; JAPOUR AJ, 1995, J INFECT DIS, V171, P1172, DOI 10.1093/infdis/171.5.1172; JOHNSON VA, 1999, 6 C RETR OPP INF JAN; Kemp SD, 1998, J VIROL, V72, P5093, DOI 10.1128/JVI.72.6.5093-5098.1998; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Kuritzkes DR, 2000, J ACQ IMMUN DEF SYND, V23, P26; LANIER R, 1998, ANTIVIR THER S, V3, P36; LARDER B, 1999, ANTIVIR THER S, V4, P41; LARDER B, 1999, 6 C RETR OPP INF JAN; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; Larder BA, 1999, ANTIMICROB AGENTS CH, V43, P1961, DOI 10.1128/AAC.43.8.1961; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; LERMA JGG, 1998, ANTIVIR THER S, V3, P85; Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142; Lorenzi P, 1999, AIDS, V13, pF17, DOI 10.1097/00002030-199902040-00001; Martinez-Picado J, 1999, J VIROL, V73, P3744, DOI 10.1128/JVI.73.5.3744-3752.1999; Masquelier B, 1999, ANTIVIR THER, V4, P69; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; MONTANER JSG, 1995, ANN INTERN MED, V123, P561, DOI 10.7326/0003-4819-123-8-199510150-00001; Musey LK, 1999, J INFECT DIS, V180, P278, DOI 10.1086/314868; Nijhuis M, 1997, J INFECT DIS, V176, P398, DOI 10.1086/514056; PATICK A, 1998, ANTIVIR THER S, V3, P39; Pellegrin I, 1999, AIDS, V13, P1705, DOI 10.1097/00002030-199909100-00014; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; RIVA C, 1998, ANTIVIR THER S, V3, P81; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SABINO EC, 1998, 12 WORLD AIDS C JUN; Salomon H, 2000, AIDS, V14, pF17, DOI 10.1097/00002030-200001280-00003; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Schuurman R, 1999, J CLIN MICROBIOL, V37, P2291, DOI 10.1128/JCM.37.7.2291-2296.1999; SCHUURMAN R, 1999, ANTIVIRAL THERAPY S1, V4, P41; SKOWRON G, 1999, ANTIVIR THER S, V4, P55; SORIANO V, 1998, ANTIVIR THER S, V3, P24; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; *US DHHS HJ KAIS F, 2000, GUID US ANT AG HIV I; VERBIEST W, 1999, ANTIVIR THER S, V4, P86; VERHELST R, 1998, ANTIVIR THER S, V3, P78; Verhofstede C, 1999, AIDS, V13, P2541, DOI 10.1097/00002030-199912240-00007; VINGERHOETS J, 1999, ANTIVIRALT HER S1, V4, P53; Wainberg MA, 1999, ANTIVIR THER, V4, P87; WEGNER S, 1999, ANTIVIR THER S, V4, P85; WILLIAMS IG, 1998, ANTIVIR THER S, V3, P80; Winters MA, 1998, J CLIN INVEST, V102, P1769, DOI 10.1172/JCI4948; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YERLY S, 1998, ANTIVIR THER S, V3, P75; Zolopa AR, 1999, ANN INTERN MED, V131, P813, DOI 10.7326/0003-4819-131-11-199912070-00003	94	556	568	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2417	2426		10.1001/jama.283.18.2417	http://dx.doi.org/10.1001/jama.283.18.2417			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815085				2022-12-28	WOS:000086808200037
J	Vickers, A				Vickers, A			Use of hypericum as antidepressant - Use of placebo in depression trial was unethical	BRITISH MEDICAL JOURNAL			English	Letter									Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Vickers, A (corresponding author), Mem Sloan Kettering Canc Ctr, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.			Vickers, Andrew/0000-0003-1525-6503				Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1142	1142						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10836816				2022-12-28	WOS:000086782800029
J	Lee, DC; Halliday, AN				Lee, DC; Halliday, AN			Accretion of primitive planetesimals: Hf-W isotopic evidence from enstatite chondrites	SCIENCE			English	Article							EARLY SOLAR-SYSTEM; CORE FORMATION; DIFFERENTIATION; ASTEROIDS; OXYGEN	Enstatite chondrites have often been considered to be closely related to the material from which Earth accreted. However, tungsten isotopic data reveal clear differences. Moreover, the silicate and metal fractions define distinct initial H-182/Hf-180 corresponding to a 13.8 +/- 5.3 million year apparent age difference. Internal reequilibration does not provide a ready explanation for this result. Larger scale redistribution of tungsten is more likely, such as may have occurred during collisions between planetesimals.	Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA; ETH Zurich, Dept Earth Sci, Inst Isotope Geol & Mineral Resources, CH-8092 Zurich, Switzerland	University of Michigan System; University of Michigan; Swiss Federal Institutes of Technology Domain; ETH Zurich	Lee, DC (corresponding author), Univ Michigan, Dept Geol Sci, 1006 CC Little Bldg, Ann Arbor, MI 48109 USA.		Lee, Der-Chuen/N-9225-2013	Lee, Der-Chuen/0000-0001-8855-9594				Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; CLAYTON RN, 1984, P LUNAR PLANET SCI C, V15, P245; FAGAN TJ, 2000, LUNAR PLANET SCI, V31; GUAN Y, 1999, LUNAR PLANET SCI, V30; GUAN Y, 2000, LUNAR PLANET SCI, V31; Harper CL, 1996, GEOCHIM COSMOCHIM AC, V60, P1131, DOI 10.1016/0016-7037(96)00027-0; Horan MF, 1998, GEOCHIM COSMOCHIM AC, V62, P545, DOI 10.1016/S0016-7037(97)00368-2; Jacobsen SB, 1996, EARTH PROCESSES READ, P47; JAVOY M, 1995, GEOPHYS RES LETT, V22, P2219, DOI 10.1029/95GL02015; Javoy M, 1998, CHEM GEOL, V147, P11, DOI 10.1016/S0009-2541(97)00169-1; KALLEMEYN GW, 1986, GEOCHIM COSMOCHIM AC, V50, P2153, DOI 10.1016/0016-7037(86)90070-0; Kong P, 1997, GEOCHIM COSMOCHIM AC, V61, P4895, DOI 10.1016/S0016-7037(97)00278-0; LARIMER JW, 1979, GEOCHIM COSMOCHIM AC, V43, P1455, DOI 10.1016/0016-7037(79)90140-6; Lee DC, 1997, SCIENCE, V278, P1098, DOI 10.1126/science.278.5340.1098; Lee DC, 1997, NATURE, V388, P854, DOI 10.1038/42206; LEE DC, 1995, NATURE, V378, P771, DOI 10.1038/378771a0; LEE DC, 1995, INT J MASS SPECTROM, V146, P35, DOI 10.1016/0168-1176(95)04201-U; Lee DC, 1996, SCIENCE, V274, P1876, DOI 10.1126/science.274.5294.1876; LEE DC, IN PRESS CHEM GEOL; Lugmair GW, 1998, GEOCHIM COSMOCHIM AC, V62, P2863, DOI 10.1016/S0016-7037(98)00189-6; Polnau E, 1999, GEOCHIM COSMOCHIM AC, V63, P925, DOI 10.1016/S0016-7037(98)00316-0; QUITTE G, 2000, LUNAR PLANET SCI, V31; SAFRONOV VS, 1954, ASTRON ZH, V31, P499; SEARS DW, 1982, GEOCHIM COSMOCHIM AC, V46, P597, DOI 10.1016/0016-7037(82)90161-2; SHUKOLYUKOV A, 1998, LUNAR PLANET SCI, V29; SMITAL J, 1982, J MATH ANAL APPL, V90, P1, DOI 10.1086/628650; WASSON JT, 1988, PHILOS T R SOC A, V325, P535, DOI 10.1098/rsta.1988.0066; WEEKS KS, 1985, GEOCHIM COSMOCHIM AC, V49, P1525, DOI 10.1016/0016-7037(85)90257-1; Wetherill G. W, 1986, ORIGIN MOON, P519; WETHERILL GW, 1994, GEOCHIM COSMOCHIM AC, V58, P4513, DOI 10.1016/0016-7037(94)90352-2	30	36	37	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1629	1631		10.1126/science.288.5471.1629	http://dx.doi.org/10.1126/science.288.5471.1629			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834839				2022-12-28	WOS:000087382300037
J	Rowe, JB; Toni I; Josephs, O; Frackowiak, RSJ; Passingham, RE				Rowe, JB; Toni, I; Josephs, O; Frackowiak, RSJ; Passingham, RE			The prefrontal cortex: Response selection or maintenance within working memory?	SCIENCE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; LATERAL FRONTAL-CORTEX; FUNCTIONAL-ORGANIZATION; NEURONAL-ACTIVITY; DELAYED-RESPONSE; RHESUS-MONKEYS; UNIT-ACTIVITY; TASK; FMRI; DISSOCIATION	It is controversial whether the dorsolateral prefrontal cortex is involved in the maintenance of items in working memory or in the selection of responses. We used event-related functional magnetic resonance imaging to study the performance of a spatial working memory task by humans, We distinguished the maintenance of spatial items from the selection of an item from memory to guide a response. Selection, but not maintenance, was associated with activation of prefrontal area 46 of the dorsal lateral prefrontal cortex, In contrast, maintenance was associated with activation of prefrontal area 8 and the intraparietal cortex The results support a role for the dorsal prefrontal cortex in the selection of representations. ntis accounts for the fact that this area is activated both when subjects select between items on working memory tasks and when they freely select between movements on tasks of willed action.	Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; Forschungszentrum Julich, Inst Med, D-52425 Julich, Germany	University of London; University College London; Helmholtz Association; Research Center Julich	Rowe, JB (corresponding author), Inst Neurol, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England.	j.rowe@fil.ion.ucl.ac.uk	Frackowiak, Richard S/I-1809-2013; Frackowiak, Richard/H-4383-2011; Toni, Ivan/D-1980-2009; Tick, Beata/ABA-1728-2020; rowe, james B/C-3661-2013	Frackowiak, Richard/0000-0002-3151-822X; Toni, Ivan/0000-0003-0936-3601; rowe, james B/0000-0001-7216-8679	Wellcome Trust [077029] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguirre GK, 1998, NEUROIMAGE, V8, P360, DOI 10.1006/nimg.1998.0369; Aguirre GK, 1997, NEUROIMAGE, V5, P199, DOI 10.1006/nimg.1997.0264; Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Belger A, 1998, HUM BRAIN MAPP, V6, P14, DOI 10.1002/(SICI)1097-0193(1998)6:1<14::AID-HBM2>3.0.CO;2-O; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; D'Esposito M, 1999, BRAIN COGNITION, V41, P66, DOI 10.1006/brcg.1999.1096; D'Esposito M, 1998, NEUROIMAGE, V8, P274, DOI 10.1006/nimg.1998.0364; Desmond JE, 1998, NEUROIMAGE, V7, P368, DOI 10.1006/nimg.1998.0340; DIAMOND A, 1989, EXP BRAIN RES, V74, P24; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; FRITH C, IN PRESS CONTROL COG, V18; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; GoldmanRakic P. S., 1998, PREFRONTAL CORTEX EX, P87; GOLDMANRAKIC PS, 1987, CIBA F SYMP, V132, P187; Hadland K. A., 1999, Society for Neuroscience Abstracts, V25, P1893; Jueptner M, 1997, J NEUROPHYSIOL, V77, P1325, DOI 10.1152/jn.1997.77.3.1325; Jueptner M, 1997, J NEUROPHYSIOL, V77, P1313, DOI 10.1152/jn.1997.77.3.1313; KOJIMA S, 1984, BRAIN RES, V291, P229, DOI 10.1016/0006-8993(84)91255-1; Levy R, 1999, J NEUROSCI, V19, P5149; Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40; Miller EK, 1999, NEURON, V22, P15, DOI 10.1016/S0896-6273(00)80673-X; NIKI H, 1976, BRAIN RES, V105, P79, DOI 10.1016/0006-8993(76)90924-0; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; Owen AM, 1996, CEREB CORTEX, V6, P31, DOI 10.1093/cercor/6.1.31; Owen AM, 1999, EUR J NEUROSCI, V11, P567, DOI 10.1046/j.1460-9568.1999.00449.x; Owen AM, 1998, P NATL ACAD SCI USA, V95, P7721, DOI 10.1073/pnas.95.13.7721; Passingham RE., 1993, FRONTAL LOBES VOLUNT; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; Petrides M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; PETRIDES M, 1995, HDB NEUROPSYCHOLOGY, V9, P17; Postle BR, 1999, J COGNITIVE NEUROSCI, V11, P585, DOI 10.1162/089892999563652; Quintana J, 1999, CEREB CORTEX, V9, P213, DOI 10.1093/cercor/9.3.213; RAJKOWSKA G, 1995, CEREB CORTEX, V5, P307, DOI 10.1093/cercor/5.4.307; Sawaguchi T, 1999, J NEUROPHYSIOL, V82, P2070, DOI 10.1152/jn.1999.82.5.2070; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Spence SA, 1998, BRIT J PSYCHIAT, V172, P316, DOI 10.1192/bjp.172.4.316; TALALRACH J, 1988, COPLANAR STEREOTACTI; *WELLC DEP COGN NE, 1999, STAT PAR MAPP	45	667	679	4	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1656	1660		10.1126/science.288.5471.1656	http://dx.doi.org/10.1126/science.288.5471.1656			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	320BZ	10834847				2022-12-28	WOS:000087382300045
J	Baxter, EF; DePaolo, DJ				Baxter, EF; DePaolo, DJ			Field measurement of slow metamorphic reaction rates at temperatures of 500 degrees to 600 degrees C	SCIENCE			English	Article							FLUID-FLOW; REGIONAL METAMORPHISM; INFILTRATION; CONSTRAINTS; VERMONT; OXYGEN; ROCK; USA; SWITZERLAND; DIFFUSION	High-temperature metamorphic reaction rates were measured using strontium isotopic ratios of garnet and whole rock from a field site near Simplon Pass, Switzerland. For metamorphic conditions of cooling from 612 degrees +/- 17 degrees C to 505 degrees +/- 15 degrees C at pressures up to 9.1 kilobars, the inferred bulk fluid-rock exchange rate is 1.3(-0.4)(+1.1) x 10(-7) grams of solid reacted per gram of solid per year, several orders of magnitude lower than laboratory-based estimates. The inferred reaction rate suggests that mineral chemistry may lag the evolving conditions in Earth's crust during mountain building.	Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Baxter, EF (corresponding author), Univ Calif Berkeley, Dept Geol & Geophys, 301 McCone Hall, Berkeley, CA 94720 USA.		Baxter, Ethan/B-5606-2013	Baxter, Ethan/0000-0002-0077-2284				Ague JJ, 1998, CONTRIB MINERAL PETR, V132, P180, DOI 10.1007/s004100050415; Bickle MJ, 1997, J PETROL, V38, P1489, DOI 10.1093/petrology/38.11.1489; BRADY JB, 1983, AM J SCI A, V283, P181; DePaolo DJ, 1996, GEOCHIM COSMOCHIM AC, V60, P3933, DOI 10.1016/0016-7037(96)00215-3; Eppel H, 1997, AM J SCI, V297, P707, DOI 10.2475/ajs.297.7.707; FERRY JM, 1994, AM J SCI, V294, P905, DOI 10.2475/ajs.294.8.905; Graham CM, 1998, CONTRIB MINERAL PETR, V132, P371, DOI 10.1007/s004100050430; HACKER BR, 1992, SCIENCE, V258, P110, DOI 10.1126/science.258.5079.110; HELGESON HC, 1984, GEOCHIM COSMOCHIM AC, V48, P2405, DOI 10.1016/0016-7037(84)90294-1; Jove C, 1997, AM MINERAL, V82, P781; KOHN MJ, 1994, GEOCHIM COSMOCHIM AC, V58, P5551, DOI 10.1016/0016-7037(94)90249-6; KOTELNIKOV AR, 1998, GEOCHEM INT, V36, P846; LASAGA AC, 1993, AM J SCI, V293, P361, DOI 10.2475/ajs.293.5.361; MANCKTELOW NS, 1992, TECTONOPHYSICS, V215, P295, DOI 10.1016/0040-1951(92)90358-D; NICOLAYSEN LO, 1961, ANN NY ACAD SCI, V2, P198; OELKERS EH, 1988, GEOCHIM COSMOCHIM AC, V52, P63, DOI 10.1016/0016-7037(88)90057-9; PHILLIPS OM, 1991, FLOW REACTIONS PERME, P96; SCHRAMKE JA, 1987, AM J SCI, V287, P517, DOI 10.2475/ajs.287.6.517; Skelton ADL, 1997, EARTH PLANET SC LETT, V146, P527, DOI 10.1016/S0012-821X(96)00248-8; Spear F.S., 1993, MINERALOGICAL SOC AM; SPEAR FS, 1983, CONTRIB MINERAL PETR, V83, P348, DOI 10.1007/BF00371203; VANCE D, 1992, EARTH PLANET SC LETT, V114, P113, DOI 10.1016/0012-821X(92)90155-O; VanHaren JLM, 1996, GEOCHIM COSMOCHIM AC, V60, P3487, DOI 10.1016/0016-7037(96)00182-2; Vyhnal CR, 1996, AM J SCI, V296, P394, DOI 10.2475/ajs.296.4.394; WALTHER JV, 1994, J GEOL, V102, P559, DOI 10.1086/629698; WALTHER JV, 1986, FLUID ROCK INTERACTI, P195; YOUNG ED, 1993, GEOCHIM COSMOCHIM AC, V57, P2585, DOI 10.1016/0016-7037(93)90419-W	27	55	55	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 26	2000	288	5470					1411	1414		10.1126/science.288.5470.1411	http://dx.doi.org/10.1126/science.288.5470.1411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827949				2022-12-28	WOS:000087270900047
J	Chua, KB; Bellini, WJ; Rota, PA; Harcourt, BH; Tamin, A; Lam, SK; Ksiazek, TG; Rollin, PE; Zaki, SR; Shieh, WJ; Goldsmith, CS; Gubler, DJ; Roehrig, JT; Eaton, B; Gould, AR; Olson, J; Field, H; Daniels, P; Ling, AE; Peters, CJ; Anderson, LJ; Mahy, BWJ				Chua, KB; Bellini, WJ; Rota, PA; Harcourt, BH; Tamin, A; Lam, SK; Ksiazek, TG; Rollin, PE; Zaki, SR; Shieh, WJ; Goldsmith, CS; Gubler, DJ; Roehrig, JT; Eaton, B; Gould, AR; Olson, J; Field, H; Daniels, P; Ling, AE; Peters, CJ; Anderson, LJ; Mahy, BWJ			Nipah virus: A recently emergent deadly paramyxovirus	SCIENCE			English	Article							INFECTION; PROTEIN	A paramyxovirus virus termed Nipah virus has been identified as the etiologic agent of an outbreak of severe encephalitis in people with close contact exposure to pigs in Malaysia and Singapore. The outbreak was first noted in late September 1998 and by mid-June 1999, more than 265 encephalitis cases, including 105 deaths, had been reported in Malaysia, and 11 cases of encephalitis or respiratory illness with one death had been reported in Singapore. Electron microscopic, serologic, and genetic studies indicate that this virus belongs to the family Paramyxoviridae and is mast closely related to the recently discovered Hendra virus. We suggest that these two viruses are representative of a new genus within the family Paramyxoviridae. Like Hendra virus. Nipah virus is unusual among the paramyxoviruses in its ability to infect and cause potentially fatal disease in a number of host species, including humans.	Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Univ Malaya, Med Ctr, Dept Med Microbiol, Kuala Lumpur 50603, Malaysia; Ctr Dis Control, Div Vector Borne Dis, NCID, Ft Collins, CO 80522 USA; CSIRO, Australian Anim Hlth Lab, Geelong, Vic 3220, Australia; Queensland Dept Primary Ind, Anim Res Inst, Yeerongpilly, Qld 4105, Australia; Singapore Gen Hosp, Dept Pathol, Singapore 0316, Singapore	Centers for Disease Control & Prevention - USA; Universiti Malaya; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Queensland Department of Agriculture & Fisheries; Singapore General Hospital	Bellini, WJ (corresponding author), Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA.		LAM, SAI KIT/B-5231-2010; Eaton, Bryan Thomas/AAV-2103-2021; Daniels, Peter W/H-1966-2013	Rollin, Pierre/0000-0002-4608-2641				BRANDT WE, 1967, AM J TROP MED HYG, V16, P339, DOI 10.4269/ajtmh.1967.16.339; Centers for Disease Control and Prevention, 1999, MMWR MORB MORTAL WKL, V48, P265; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P335; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chua KB, 1999, LANCET, V354, P1257, DOI 10.1016/S0140-6736(99)04299-3; DUERMEYER W, 1979, J MED VIROL, V4, P25, DOI 10.1002/jmv.1890040104; Enserink M, 1999, SCIENCE, V284, P407, DOI 10.1126/science.284.5413.407; HALPIN K, 1998, COMMUN DIS INTELL, V20, P476; HARCOURT BH, IN PRESS; Hausmann S, 1999, J VIROL, V73, P5568, DOI 10.1128/JVI.73.7.5568-5576.1999; Ksiazek TG, 1999, J INFECT DIS, V179, pS177, DOI 10.1086/514321; MONATH TP, 1996, FIELDS VIROLOGY, P961; Murray K., 1998, EMERG INFECT DIS, V1, P43; Nordin MN, 1999, OIE DIS INF, V12, P20; PATERSON G, 1989, GENETICS PATHOGENICI, P232; Paton NI, 1999, LANCET, V354, P1253, DOI 10.1016/S0140-6736(99)04379-2; ROTA JS, 1994, VIRUS RES, V31, P317, DOI 10.1016/0168-1702(94)90025-6; SINNIAH M, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P581; THOMAS SM, 1988, CELL, V54, P891, DOI 10.1016/S0092-8674(88)91285-8; Tidona CA, 1999, VIROLOGY, V258, P425, DOI 10.1006/viro.1999.9693; Wang LF, 1998, J VIROL, V72, P1482, DOI 10.1128/JVI.72.2.1482-1490.1998; WANG LF, 1995, J IMMUNOL METHODS, V178, P1, DOI 10.1016/0022-1759(94)00235-O; Yu M, 1998, VIROLOGY, V251, P227, DOI 10.1006/viro.1998.9302	23	827	908	5	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1432	1435		10.1126/science.288.5470.1432	http://dx.doi.org/10.1126/science.288.5470.1432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827955				2022-12-28	WOS:000087270900053
J	Hartman, EE; Parker, RA				Hartman, EE; Parker, RA			A 26-year-old woman seeking an abortion, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		[Anonymous], 1999, PAT PERSP QUAL AB CA; Daley J, 1999, JAMA-J AM MED ASSOC, V282, P1169	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2700	2700		10.1001/jama.283.20.2700	http://dx.doi.org/10.1001/jama.283.20.2700			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819954				2022-12-28	WOS:000087046000039
J	Pless, B				Pless, B			The nonexistent role of injury prevention in medical practice	LANCET			English	Editorial Material							CHILDHOOD INJURY; PRIMARY-CARE		Montreal Childrens Hosp, Montreal, PQ H3H 1PE, Canada	McGill University	Pless, B (corresponding author), Montreal Childrens Hosp, Montreal, PQ H3H 1PE, Canada.							BASS JL, 1993, PEDIATRICS, V92, P544; Carnall D, 1999, BRIT MED J, V318, P1505, DOI 10.1136/bmj.318.7197.1505a; DiGuiseppi C, 2000, FUTURE CHILD, V10, P53, DOI 10.2307/1602825; FINCH CF, 1993, 54 MON U ACC RES CTR; Kendrick D, 1999, BRIT MED J, V318, P980, DOI 10.1136/bmj.318.7189.980; Roberts I, 1996, BRIT MED J, V312, P29, DOI 10.1136/bmj.312.7022.29; Robinson D, 1998, Inj Prev, V4, P170	7	1	2	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1807	1807		10.1016/S0140-6736(00)02311-4	http://dx.doi.org/10.1016/S0140-6736(00)02311-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832847				2022-12-28	WOS:000087126100045
J	Spencer, JR; Jessup, KL; McGrath, MA; Ballester, GE; Yelle, R				Spencer, JR; Jessup, KL; McGrath, MA; Ballester, GE; Yelle, R			Discovery of gaseous S-2 in Io's Pele plume	SCIENCE			English	Article							HUBBLE-SPACE-TELESCOPE; GLOBAL DISTRIBUTION; SO2; ATMOSPHERE; STABILITY; VOLCANISM; COLOR	Spectroscopy of Io's Pele plume against Jupiter by the Hubble Space Telescope in October 1999 revealed absorption due to S-2 gas, with a column density of 1.0 +/- 0.2 x 10(16) per square centimeter, and probably also SO2 gas with a column density of 7 +/- 3 x 10(16) per square centimeter. This SO2/S-2 ratio (3 to 12) is expected from equilibration with silicate magmas near the quartz-fayalite-magnetite or wustite-magnetite buffers. Condensed S-3 and S-4, probable coloring agents in Pele's red plume deposits, may form by polymerization of the S-2, which is unstable to ultraviolet photolysis. Diffuse red deposits near other to volcanoes suggest that venting and polymerization of S-2 gas is a widespread feature of Io volcanism.	Lowell Observ, Flagstaff, AZ 86001 USA; Univ Michigan, Space Res Lab, Ann Arbor, MI 48109 USA; Space Telescope Sci Inst, Baltimore, MD 21218 USA; No Arizona Univ, Dept Phys & Astron, Flagstaff, AZ 86011 USA	University of Michigan System; University of Michigan; Space Telescope Science Institute; Northern Arizona University	Spencer, JR (corresponding author), Lowell Observ, 1400 W Mars Hill Rd, Flagstaff, AZ 86001 USA.							AHEARN MF, 1983, ASTROPHYS J, V274, pL99, DOI 10.1086/184158; AHEARN MF, 1999, B AM ASTRON SOC, V31, P1124; BALLESTER GE, 1994, ICARUS, V111, P2, DOI 10.1006/icar.1994.1129; COLLINS SA, 1981, J GEOPHYS RES-SPACE, V86, P8621, DOI 10.1029/JA086iA10p08621; DAVIES AG, 1999, LUNAR PLANET SCI, V30, P1462; DOUTE S, IN PRESS ICARUS; Edgington SG, 1999, ICARUS, V142, P342, DOI 10.1006/icar.1999.6228; Geissler PE, 1999, ICARUS, V140, P265, DOI 10.1006/icar.1999.6128; HUBER KP, 1979, CONSTANTS ORGANIC MO; LELLOUCH E, 1992, ICARUS, V98, P271, DOI 10.1016/0019-1035(92)90095-O; MANNATT SL, 1993, J QUANT SPECTROSC RA, V50, P267; MCEWEN AB, COMMUNICATION; MCEWEN AS, 1983, ICARUS, V55, P191, DOI 10.1016/0019-1035(83)90075-1; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; McEwen AS, 1998, SCIENCE, V281, P87, DOI 10.1126/science.281.5373.87; MCEWEN AS, 1988, ICARUS, V73, P385, DOI 10.1016/0019-1035(88)90053-X; MCEWEN AS, 1988, ICARUS, V75, P450, DOI 10.1016/0019-1035(88)90157-1; MCEWEN AS, 1999, AM GEOPH UN FALL M S, V17; MCGRATH MA, IN PRESS ICARUS; MERCHANT VE, 1980, APPL OPTICS, V19, P3113, DOI 10.1364/AO.19.003113; MEYER KA, 1973, CAN J PHYS, V51, P2119, DOI 10.1139/p73-277; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; PEARL J, 1979, NATURE, V280, P755, DOI 10.1038/280755a0; Sartoretti P, 1996, ICARUS, V122, P273, DOI 10.1006/icar.1996.0125; SMITH AL, 1981, J CHEM PHYS, V75, P2080, DOI 10.1063/1.442328; Spencer JR, 1997, ICARUS, V127, P221, DOI 10.1006/icar.1996.5670; Spencer JR, 1997, GEOPHYS RES LETT, V24, P2471, DOI 10.1029/97GL02592; Stark G, 1999, J GEOPHYS RES-PLANET, V104, P16585, DOI 10.1029/1999JE001022; STROM RG, 1981, J GEOPHYS RES-SPACE, V86, P8593, DOI 10.1029/JA086iA10p08593; TATUM JB, 1971, CAN J PHYS, V49, P2693, DOI 10.1139/p71-325; Woods TN, 1996, J GEOPHYS RES-ATMOS, V101, P9541, DOI 10.1029/96JD00225; Zolotov MY, 1999, ICARUS, V141, P40, DOI 10.1006/icar.1999.6164; ZOLOTOV MY, 2000, LUNAR PLANET SCI, V31, P2098	33	148	148	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1208	1210		10.1126/science.288.5469.1208	http://dx.doi.org/10.1126/science.288.5469.1208			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817990				2022-12-28	WOS:000087112600042
J	A'Hearn, MF				A'Hearn, MF			Astronomy - The comet no one saw	NATURE			English	Editorial Material									Univ Maryland, Dept Astron, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	A'Hearn, MF (corresponding author), Univ Maryland, Dept Astron, College Pk, MD 20742 USA.	ma@astro.umd.edu						Bailey M. E., 1994, HAZARDS DUE COMETS A, P479; Brandt JC, 1996, EARTH MOON PLANETS, V72, P243, DOI 10.1007/BF00117524; Brandt JC, 1996, ASTR SOC P, V107, P289; Gehrels T., 1994, HAZARDS DUE COMETS A, V24; Grieve RAF, 1994, HAZARDS DUE COMETS A, P417; Makinen JTT, 2000, NATURE, V405, P321, DOI 10.1038/35012526; MARSDEN BG, 1999, CATALOGUE COMETARY O; MARSDEN BG, 1999 X07 MIN PLAN CT	8	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 18	2000	405	6784					285	287		10.1038/35012723	http://dx.doi.org/10.1038/35012723			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830942				2022-12-28	WOS:000087085700024
J	Sachdev, S; Starykh, OA				Sachdev, S; Starykh, OA			Thermally fluctuating superconductors in two dimensions	NATURE			English	Article							QUANTUM CRITICAL-POINTS; INSULATOR TRANSITION; CUPRATE SUPERCONDUCTORS; TEMPERATURE TRANSPORT; PHASE-TRANSITIONS; 2 DIMENSIONS; ANTIFERROMAGNETS; COHERENCE; DISSIPATION; CROSSOVERS	In many two-dimensional superconducting systems(1-4), such as Josephson-junction arrays, granular superconducting films, and the high-temperature superconductors, it appears that the electrons bind into Cooper pairs below a pairing temperature (T-P) that is well above the Kosterlitz-Thouless temperature (T-KT, the temperature below which there is long-range superconducting order(5-10)). The electron dynamics at temperatures between T-KT and TP involve a complex interplay of thermal and quantum fluctuations, for which no quantitative theory exists. Here we report numerical results for this region, by exploiting its proximity to a T = 0 superconductor-insulator quantum phase transition(11,12). This quantum critical point need not be experimentally accessible for our results to apply. We characterize the static, thermodynamic properties by a single dimensionless parameter, gamma(T). Quantitative and universal results are obtained for the frequency dependence of the conductivity, which are dependent only upon gamma(T) and fundamental constants of nature.	Yale Univ, Dept Phys, New Haven, CT 06520 USA	Yale University	Sachdev, S (corresponding author), Yale Univ, Dept Phys, POB 208120, New Haven, CT 06520 USA.		Sachdev, Subir/A-8781-2013; Sachdev, Subir/Y-3037-2019	Sachdev, Subir/0000-0002-2432-7070; Sachdev, Subir/0000-0002-2432-7070				AMBEGAOKAR V, 1978, PHYS REV LETT, V40, P783, DOI 10.1103/PhysRevLett.40.783; [Anonymous], 1983, FUNCTIONAL INTEGRALS; Chervenak JA, 1999, PHYS REV B, V59, P11209, DOI 10.1103/PhysRevB.59.11209; CHUBUKOV AV, 1994, PHYS REV B, V49, P11919, DOI 10.1103/PhysRevB.49.11919; Corson J, 1999, NATURE, V398, P221, DOI 10.1038/18402; Dalidovich D, 2000, PHYS REV LETT, V84, P737, DOI 10.1103/PhysRevLett.84.737; Damle K, 1997, PHYS REV B, V56, P8714, DOI 10.1103/PhysRevB.56.8714; DONIACH S, 1990, PHYS REV B, V41, P6668, DOI 10.1103/PhysRevB.41.6668; DONIACH S, 1981, PHYS REV B, V24, P5063, DOI 10.1103/PhysRevB.24.5063; Emery VJ, 1998, J PHYS CHEM SOLIDS, V59, P1705, DOI 10.1016/S0022-3697(98)00087-0; FISHER MPA, 1990, PHYS REV LETT, V65, P923, DOI 10.1103/PhysRevLett.65.923; FISHER MPA, 1990, PHYS REV LETT, V64, P587, DOI 10.1103/PhysRevLett.64.587; GREMPEL DR, 1988, PHYS REV LETT, V61, P1041, DOI 10.1103/PhysRevLett.61.1041; Herbut IF, 1998, PHYS REV LETT, V81, P3916, DOI 10.1103/PhysRevLett.81.3916; HOHENBERG PC, 1976, PHYS REV B, V14, P2865, DOI 10.1103/PhysRevB.14.2865; KAWASAKI K, 1970, ANN PHYS-NEW YORK, V61, P1, DOI 10.1016/0003-4916(70)90375-1; Khalatnikov I. M., 1965, INTRO THEORY SUPERFL; Markovic N, 1999, PHYS REV B, V60, P4320, DOI 10.1103/PhysRevB.60.4320; Rimberg AJ, 1997, PHYS REV LETT, V78, P2632, DOI 10.1103/PhysRevLett.78.2632; Sachdev S, 1999, PHYS REV B, V59, P14054, DOI 10.1103/PhysRevB.59.14054; Sachdev S, 1997, PHYS REV B, V55, P142, DOI 10.1103/PhysRevB.55.142; SACHDEV S, 1992, PHYS REV LETT, V69, P2411, DOI 10.1103/PhysRevLett.69.2411; Sachdev S., 1999, QUANTUM PHASE TRANSI; Sondhi SL, 1997, REV MOD PHYS, V69, P315, DOI 10.1103/RevModPhys.69.315; SUDBO A, 1999, CONDMAT9907386; TRIVEDI N, 1995, PHYS REV LETT, V75, P312, DOI 10.1103/PhysRevLett.75.312; UEMURA YJ, 1989, PHYS REV LETT, V62, P2317, DOI 10.1103/PhysRevLett.62.2317; Wagenblast KH, 1997, PHYS REV LETT, V79, P2730, DOI 10.1103/PhysRevLett.79.2730; Wagenblast KH, 1997, PHYS REV LETT, V78, P1779, DOI 10.1103/PhysRevLett.78.1779	30	10	10	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					322	325		10.1038/35012530	http://dx.doi.org/10.1038/35012530			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830955				2022-12-28	WOS:000087085700039
J	Raymondos, K; Panning, B; Leuwer, M; Brechelt, G; Korte, T; Niehaus, M; Tebbenjohanns, J; Piepenbrock, S				Raymondos, K; Panning, B; Leuwer, M; Brechelt, G; Korte, T; Niehaus, M; Tebbenjohanns, J; Piepenbrock, S			Absorption and hemodynamic effects of airway administration of adrenaline in patients with severe cardiac disease	ANNALS OF INTERNAL MEDICINE			English	Article							INTRAVENOUS ADRENALINE; ENDOTRACHEAL; EPINEPHRINE; DOGS; RESUSCITATION	Background: If intravenous access cannot be attained during resuscitation of adult patients, endotracheal application of at least 2 mg of adrenaline is recommended. However, the effects of this intervention have not yet been demonstrated in adults. Objective: To demonstrate the effects of adrenaline administered through the airways. Design: Prospective clinical trial. Setting: Operating theater at university hospital. Patients: 34 patients receiving implantable cardioverter defibrillators under general anesthesia. Intervention: When mean arterial pressure decreased below 80 mm Hg, 100 times the effective central intravenous dose of adrenaline (mean +/-SD, 1.3 +/- 0.6 mg [range, 0.7 to 3 mg]) was administered over 5 seconds into the endotracheal tube or through a bronchial catheter. Ten forced ventilations followed. Measurements: Hemodynamic variables were recorded with a polygraph recorder. Adrenaline levels were measured in 13 patients. Results: Plasma levels and arterial pressure increased in all patients (P < 0.002). Higher plasma levels (P < 0.039) and greater arterial pressure (P < 0.001) were achieved with this method than with intravenous injection. The effects of adrenaline did not differ between the two airway routes. Sustained ventricular arrhythmia did not occur. Conclusion: These substantial effects support the standard recommendation to consider the airways as an alternate route for at least 2 mg of adrenaline during resuscitation.	Hannover Med Sch, Dept Anesthesia, D-30625 Hannover, Germany	Hannover Medical School	Raymondos, K (corresponding author), Hannover Med Sch, Dept Anesthesia, Carl Neuberg Str 1, D-30625 Hannover, Germany.	KRaymondos@aol.com						GREENBERG MI, 1985, ANN EMERG MED, V14, P209, DOI 10.1016/S0196-0644(85)80441-8; Kloeck W, 1997, CIRCULATION, V95, P2180, DOI 10.1161/01.CIR.95.8.2180; KOLLER M, 1988, CLIN CHEM, V34, P947; Lindner KH, 1996, HEART, V75, P145, DOI 10.1136/hrt.75.2.145; MAZKERETH R, 1992, CRIT CARE MED, V20, P1582, DOI 10.1097/00003246-199211000-00017; MCCRIRRICK A, 1994, BRIT J ANAESTH, V72, P529, DOI 10.1093/bja/72.5.529; MCCRIRRICK A, 1992, LANCET, V340, P868, DOI 10.1016/0140-6736(92)93283-S; QUINTON DN, 1987, LANCET, V1, P828; RALSTON SH, 1985, ANN EMERG MED, V14, P1044, DOI 10.1016/S0196-0644(85)80916-1; ROBERTS JR, 1979, JACEP-J AM COLL EMER, V8, P53, DOI 10.1016/S0361-1124(79)80036-2	10	36	36	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2000	132	10					800	803		10.7326/0003-4819-132-10-200005160-00007	http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313XN	10819703				2022-12-28	WOS:000087025100005
J	Nimchuk, Z; Marois, E; Kjemtrup, S; Leister, RT; Katagiri, F; Dangl, JL				Nimchuk, Z; Marois, E; Kjemtrup, S; Leister, RT; Katagiri, F; Dangl, JL			Eukaryotic fatty acylation drives plasma membrane targeting and enhances function of several type III effector proteins from Pseudomonas syringae	CELL			English	Article							DISEASE RESISTANCE GENE; HYPERSENSITIVE CELL-DEATH; AVIRULENCE GENE; PLANT-CELLS; BACTERIAL PATHOGENS; SECRETION SYSTEM; ESCHERICHIA-COLI; PV PHASEOLICOLA; AVR PROTEINS; ARABIDOPSIS	Bacterial pathogens of plants and animals utilize conserved type III delivery systems to traffic effector proteins into host cells. Plant innate immune systems evolved disease resistance (R) genes to recognize some type III effecters, termed avirulence (Avr) proteins. On disease-susceptible (r) plants, Avr proteins can contribute to pathogen virulence. We demonstrate that several type III effecters from Pseudomonas syringae are targeted to the host plasma membrane and that efficient membrane association enhances function. Efficient localization of three Avr proteins requires consensus myristoylation sites, and Avr proteins can be myristoylated inside the host cell. These prokaryotic type III effecters thus utilize a eukaryote-specific posttranslational modification to access the subcellular compartment where they function.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Maryland, Dept Biol Sci, Baltimore, MD 21250 USA; Novartis Agr Discovery Inst Inc, San Diego, CA 92121 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University System of Maryland; University of Maryland Baltimore	Dangl, JL (corresponding author), Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA.	dangl@email.unc.edu	Marois, Eric/AAZ-5549-2021; Marois, Eric/H-9246-2016	Marois, Eric/0000-0003-4147-3747; Marois, Eric/0000-0003-4147-3747; Katagiri, Fumiaki/0000-0001-6893-3788	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017612] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32GM17612] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfano JR, 1997, J BACTERIOL, V179, P5655, DOI 10.1128/jb.179.18.5655-5662.1997; Anderson DM, 1999, P NATL ACAD SCI USA, V96, P12839, DOI 10.1073/pnas.96.22.12839; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Bendahmane A, 1999, PLANT CELL, V11, P781, DOI 10.1105/tpc.11.5.781; BERTHIAUME L, 1995, J BIOL CHEM, V38, P22039; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Boyes DC, 1998, P NATL ACAD SCI USA, V95, P15849, DOI 10.1073/pnas.95.26.15849; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; DANGL JL, 1992, PLANT CELL, V4, P1359, DOI 10.1105/tpc.4.11.1359; DANIELS MJ, 1994, PLANT PHYSIOL, V106, P1325, DOI 10.1104/pp.106.4.1325; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Ellard-Ivey M, 1999, PLANT MOL BIOL, V39, P199, DOI 10.1023/A:1006125918023; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Glover CJ, 1997, J BIOL CHEM, V272, P28680, DOI 10.1074/jbc.272.45.28680; Gopalan S, 1996, PLANT CELL, V8, P1095, DOI 10.1105/tpc.8.7.1095; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; Ham JH, 1998, P NATL ACAD SCI USA, V95, P10206, DOI 10.1073/pnas.95.17.10206; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; JENNER C, 1991, MOL PLANT MICROBE IN, V4, P553, DOI 10.1094/MPMI-4-553; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KEARNEY B, 1990, NATURE, V346, P385, DOI 10.1038/346385a0; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Leister RT, 1996, P NATL ACAD SCI USA, V93, P15497, DOI 10.1073/pnas.93.26.15497; Loh YT, 1998, MOL PLANT MICROBE IN, V11, P572, DOI 10.1094/MPMI.1998.11.6.572; LORANG JM, 1994, MOL PLANT MICROBE IN, V7, P508, DOI 10.1094/MPMI-7-0508; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; McNellis TW, 1998, PLANT J, V14, P247, DOI 10.1046/j.1365-313X.1998.00106.x; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; Mudgett MB, 1999, MOL MICROBIOL, V32, P927, DOI 10.1046/j.1365-2958.1999.01403.x; Mudgett MB, 1998, CURR OPIN MICROBIOL, V1, P109, DOI 10.1016/S1369-5274(98)80150-1; OLSON EN, 1986, J BIOL CHEM, V261, P2458; Puri N, 1997, MOL PLANT MICROBE IN, V10, P247, DOI 10.1094/MPMI.1997.10.2.247; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RITTER C, 1995, MOL PLANT MICROBE IN, V8, P444, DOI 10.1094/MPMI-8-0444; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; Rossier O, 1999, P NATL ACAD SCI USA, V96, P9368, DOI 10.1073/pnas.96.16.9368; SALMERON JM, 1993, MOL GEN GENET, V239, P6, DOI 10.1007/BF00281595; Scheel D, 1998, CURR OPIN PLANT BIOL, V1, P305, DOI 10.1016/1369-5266(88)80051-7; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; TAMAKI S, 1988, J BACTERIOL, V170, P4846, DOI 10.1128/jb.170.10.4846-4854.1988; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; VandenAckerveken G, 1996, CELL, V87, P1307, DOI 10.1016/S0092-8674(00)81825-5; Warren RF, 1998, PLANT CELL, V10, P1439, DOI 10.1105/tpc.10.9.1439; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; YANG YN, 1995, MOL PLANT MICROBE IN, V8, P627, DOI 10.1094/MPMI-8-0627; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621; Zhu WG, 1999, PLANT CELL, V11, P1665, DOI 10.1105/tpc.11.9.1665	54	264	271	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 12	2000	101	4					353	363		10.1016/S0092-8674(00)80846-6	http://dx.doi.org/10.1016/S0092-8674(00)80846-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830163	Bronze, Green Published			2022-12-28	WOS:000087010400004
J	Murtra, P; Sheasby, AM; Hunt, SP; De Felipe, C				Murtra, P; Sheasby, AM; Hunt, SP; De Felipe, C			Rewarding effects of opiates are absent in mice lacking the receptor for substance P	NATURE			English	Article							MU-OPIOID-RECEPTOR; IMMUNOHISTOCHEMICAL LOCALIZATION; CHOLINERGIC NEURONS; BRAIN; RAT; WITHDRAWAL; EXPRESSION; ADDICTION; ANALGESIA; STRIATUM	Modulation of substance P activity offers a radical new approach to the management of depression, anxiety and stress(1-3). The substance P receptor is highly expressed in areas of the brain that are implicated in these behaviours, but also in other areas such as the nucleus accumbens which mediate the motivational properties of both natural rewards such as food and of drugs of abuse such as opiates(4-7). Here we show a loss of the rewarding properties of morphine in mice with a genetic disruption of the substance P receptor. The loss was specific to morphine, as both groups of mice responded when cocaine or food were used as rewards. The physical response to opiate withdrawal was also reduced in substance P receptor knockout mice. We conclude that substance P has an important and specific role in mediating the motivational aspects of opiates and may represent a new pharmacological route for the control of drug abuse.	UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; Univ Miguel Hernandez, Inst Neurosci, Alicante 03550, Spain	University of London; University College London; Universidad Miguel Hernandez de Elche	Hunt, SP (corresponding author), UCL, Dept Anat & Dev Biol, Medawar Bldg,Gower St, London WC1E 6BT, England.	hunt@ucl.ac.uk	HUNT, STEPHEN P/C-1646-2008; de Felipe, Carmen/D-3813-2012	Hunt, Stephen/0000-0001-9453-5505				AUBRY JM, 1993, NEUROSCIENCE, V53, P417, DOI 10.1016/0306-4522(93)90205-T; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; BECHARA A, 1992, BEHAV NEUROSCI, V106, P351, DOI 10.1037/0735-7044.106.2.351; BOIX F, 1995, NEUROSCIENCE, V64, P1054; BOZARTH MA, 1994, NEUROSCI BIOBEHAV R, V18, P373, DOI 10.1016/0149-7634(94)90050-7; Culman J, 1997, J PHARMACOL EXP THER, V280, P238; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; ELLIOTT PJ, 1986, BRAIN RES, V381, P68, DOI 10.1016/0006-8993(86)90691-8; GERFEN CR, 1991, BRAIN RES, V556, P165, DOI 10.1016/0006-8993(91)90563-B; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; IZENWASSER S, 1993, J PHARMACOL EXP THER, V267, P145; Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; MALDONADO R, 1993, NEUROSCI LETT, V156, P135, DOI 10.1016/0304-3940(93)90457-V; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; MALDONADO R, 1992, J PHARMACOL EXP THER, V261, P669; MANSOUR A, 1995, J CHEM NEUROANAT, V8, P283, DOI 10.1016/0891-0618(95)00055-C; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; NAKAYA Y, 1994, J COMP NEUROL, V347, P249, DOI 10.1002/cne.903470208; Nye HE, 1996, MOL PHARMACOL, V49, P636; Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208; RUPNIAK NMJ, IN PRESS NEUROPHARMA; SHAHAM Y, 1995, PSYCHOPHARMACOLOGY, V119, P334, DOI 10.1007/BF02246300; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469	28	182	192	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					180	183		10.1038/35012069	http://dx.doi.org/10.1038/35012069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821273				2022-12-28	WOS:000087080100050
J	Shlesinger, MF				Shlesinger, MF			Statistical mechanics - Exploring phase space	NATURE			English	Editorial Material									Off Naval Res, Div Phys Sci, Arlington, VA 22217 USA	United States Department of Defense; United States Navy	Shlesinger, MF (corresponding author), Off Naval Res, Div Phys Sci, Code 331,800 N Quincy St, Arlington, VA 22217 USA.							Cox SG, 2000, PHYS REV LETT, V84, P2362, DOI 10.1103/PhysRevLett.84.2362	1	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					135	137		10.1038/35012197	http://dx.doi.org/10.1038/35012197			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821257				2022-12-28	WOS:000087080100032
J	Allen, I				Allen, I			Modernising the NHS - Challenges to the health services: the professions	BRITISH MEDICAL JOURNAL			English	Article																		ALLEN I, 1999, STRESS CONSULTANTS N; Allen I., 1994, DOCTORS THEIR CAREER; ALLEN I, 1997, COMMITTED CRITICAL E; *BRIT MED ASS, 1995, COR VAL MED PROF 21; CLAY B, 1998, BMJ S23, V316, P2; *DEP HLTH, 1999, HOSP PUBL HLTH MED C; *DEP HLTH, 1993, PART TIM CONS POSTS; *DEP HLTH, 2000, HLTH SERV TAL DEV NH; *DEP HLTH SOC SEC, 1969, REEMPL WOM DOCT; Goldberg I, 2000, HOSP MED, V61, P125, DOI 10.12968/hosp.2000.61.2.1278; Ham C, 1999, BRIT MED J, V319, P1490, DOI 10.1136/bmj.319.7223.1490; HAMILTON S, 2000, BMJ S1, V320, P2; *HIGH ED FUND COUN, 1999, MED RET FORM M2 1 RE; Kitson AL, 1996, BRIT MED J, V313, P1647, DOI 10.1136/bmj.313.7072.1647; Peters E, 2000, HOSP MED, V61, P129, DOI 10.12968/hosp.2000.61.2.1279	15	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1533	1535		10.1136/bmj.320.7248.1533	http://dx.doi.org/10.1136/bmj.320.7248.1533			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834906	Green Published			2022-12-28	WOS:000087471000036
J	Samach, A; Onouchi, H; Gold, SE; Ditta, GS; Schwarz-Sommer, Z; Yanofsky, MF; Coupland, G				Samach, A; Onouchi, H; Gold, SE; Ditta, GS; Schwarz-Sommer, Z; Yanofsky, MF; Coupland, G			Distinct roles of CONSTANS target genes in reproductive development of Arabidopsis	SCIENCE			English	Article							FLOWERING-TIME GENES; TRANSCRIPTION FACTORS; APICAL MERISTEM; LONG-DAY; PROTEIN; ACTIVATION; THALIANA; ENCODES; TRANSITION; REPRESSOR	In plants, flowering is triggered by endogenous and environmental signals, CONSTANS (CO) promotes flowering of Arabidopsis in response to day length. Four early target genes of CO were identified using a steroid-inducible version of the protein. Two of these genes, SUPPRESSOR OF OVEREXPRESSION OF CO 1 (SOC1) and FLOWERING LOCUS T (FT), are required for CO to promote flowering; the others are involved in proline or ethylene biosynthesis, The SOC1 and FT genes are also regulated by a second flowering-time pathway that acts independently of CO. Thus, early target genes of CO define common components of distinct flowering-time pathways.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Max Planck Inst Zuchtungsforsch, D-50829 Cologne, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of California System; University of California San Diego; Max Planck Society	Coupland, G (corresponding author), John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England.		Coupland, George/AAP-8609-2020	Coupland, George/0000-0001-6988-4172				AHN JM, UNPUB; BERNIER G, 1981, PHYSL FLOWERING, P135; Corbesier L, 1996, PLANT J, V9, P947, DOI 10.1046/j.1365-313X.1996.9060947.x; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; KOOMNEEF M, 1991, MOL GEN GENET, V229, P57; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; Koornneef M, 1998, GENETICS, V148, P885; Levy YY, 1998, PLANT CELL, V10, P1973, DOI 10.1105/tpc.10.12.1973; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Menzel G, 1996, PLANT J, V9, P399, DOI 10.1046/j.1365-313X.1996.09030399.x; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Nanjo T, 1999, PLANT J, V18, P185, DOI 10.1046/j.1365-313X.1999.00438.x; Nilsson O, 1998, GENETICS, V150, P403; ONOUCHI H, IN PRESS PLANT CELL; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; REDEI GP, 1962, GENETICS, V47, P443; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; Sablowski RWM, 1998, CELL, V92, P93, DOI 10.1016/S0092-8674(00)80902-2; Samach A, 2000, BIOESSAYS, V22, P38, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;38::AID-BIES8&gt;3.0.CO;2-L; Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Strizhov N, 1997, PLANT J, V12, P557, DOI 10.1046/j.1365-313X.1997.00557.x; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	30	1049	1165	14	203	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1613	1616		10.1126/science.288.5471.1613	http://dx.doi.org/10.1126/science.288.5471.1613			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834834				2022-12-28	WOS:000087382300032
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Statistics notes - The odds ratio	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Fund, Med Stat Grp, Oxford OX3 7LF, England	St Georges University London; University of Oxford	Bland, JM (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.							Bland JM, 1996, BRIT MED J, V312, P770; Sackett DL, 1996, EVIDENCE BASED MED, V1, P164, DOI DOI 10.1136/EBM.1996.1.164; Strachan DP, 1996, BRIT MED J, V312, P1195	3	873	907	0	58	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1468	1468		10.1136/bmj.320.7247.1468	http://dx.doi.org/10.1136/bmj.320.7247.1468			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827061	Green Submitted, Green Published			2022-12-28	WOS:000087414700035
J	Gorman, WP; Davis, KR; Donnelly, R				Gorman, WP; Davis, KR; Donnelly, R			ABC of arterial and venous disease - Swollen lower limb-1: General assessment and deep vein thrombosis	BMJ-BRITISH MEDICAL JOURNAL			English	Review									So Derbyshire Acute Hosp NHS Trust, Derby, England		Gorman, WP (corresponding author), So Derbyshire Acute Hosp NHS Trust, Derby, England.	sms16@leicester.ac.uk; richard.donnelly@nottingham.ac.uk						Anderson DR, 1999, THROMB HAEMOSTASIS, V82, P878; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; Lensing AWA, 1999, LANCET, V353, P479, DOI 10.1016/S0140-6736(98)04298-6; Levick JR, 1995, INTRO CARDIOVASCULAR; Prins MH, 1999, THROMB HAEMOSTASIS, V82, P892; Scurr J, 1998, PHLEBOLOGY, V13, P87	6	29	32	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 27	2000	320	7247					1453	1456		10.1136/bmj.320.7247.1453	http://dx.doi.org/10.1136/bmj.320.7247.1453			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827054	Green Published			2022-12-28	WOS:000087414700030
J	Morant, H				Morant, H			Milburn attacks doctors' private pay	BRITISH MEDICAL JOURNAL			English	News Item														Surana, Helen/0000-0002-1587-3918					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1426	1426						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827036				2022-12-28	WOS:000087414700014
J	Canto, JG; Every, NR; Magid, DJ; Rogers, WJ; Malmgren, JA; Frederick, PD; French, WJ; Tiefenbrunn, AJ; Misra, VK; Kiefe, CI; Barron, HV				Canto, JG; Every, NR; Magid, DJ; Rogers, WJ; Malmgren, JA; Frederick, PD; French, WJ; Tiefenbrunn, AJ; Misra, VK; Kiefe, CI; Barron, HV		Natl Registry Myocardial Infarctio	The volume of primary angioplasty procedures and survival after acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATIONAL REGISTRY; ASSOCIATION; HOSPITALS; CARDIOLOGY; MORTALITY; OUTCOMES; PROJECT; CARE	Background: There is an inverse relation between mortality from cardiovascular causes and the number of elective cardiac procedures (coronary angioplasty, stenting, or coronary bypass surgery) performed by individual practitioners or hospitals. However, it is not known whether patients with acute myocardial infarction fare better at centers where more patients undergo primary angioplasty or thrombolytic therapy than at centers with lower volumes. Methods: We analyzed data from the National Registry of Myocardial Infarction to determine the relation between the number of patients receiving reperfusion therapy (primary angioplasty or thrombolytic therapy) and subsequent in-hospital mortality. A total of 450 hospitals were divided into quartiles according to the volume of primary angioplasty. Multiple logistic-regression models were used to determine whether the volume of primary angioplasty procedures was an independent predictor of in-hospital mortality among patients undergoing this procedure. Similar analyses were performed for patients receiving thrombolytic therapy at 516 hospitals. Results: In-hospital mortality was 28 percent lower among patients who underwent primary angioplasty at hospitals with the highest volume than among those who underwent angioplasty at hospitals with the lowest volume (adjusted relative risk, 0.72; 95 percent confidence interval, 0.60 to 0.87; P<0.001). This lower rate, which represented 2.0 fewer deaths per 100 patients treated, was independent of the total volume of patients with myocardial infarction at each hospital, year of admission, and use or nonuse of adjunctive pharmacologic therapies. There was no significant relation between the volume of thrombolytic interventions and in-hospital mortality among patients who received thrombolytic therapy (7.0 percent for patients in the highest-volume hospitals vs. 6.9 percent for those in the lowest-volume hospitals, P=0.36). Conclusions: Among hospitals in the United States that have full interventional capabilities, a higher volume of angioplasty procedures is associated with a lower mortality rate among patients undergoing primary angioplasty, but there is no association between volume and mortality for thrombolytic therapy. (N Engl J Med 2000;342:1573-80.) (C) 2000, Massachusetts Medical Society.	Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA; Univ Alabama, Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL 35294 USA; Univ Washington, Cardiovasc Outcomes Res Ctr, Seattle, WA 98195 USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA; Colorado Permanente Med Grp, Clin Res Unit, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Div Emergency Med, Denver, CO USA; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Washington Univ, Sch Med, St Louis, MO USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Genentech Inc, S San Francisco, CA 94080 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Permanente Medical Groups; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Washington University (WUSTL); University of California System; University of California San Francisco; Roche Holding; Genentech	Canto, JG (corresponding author), Univ Alabama, Dept Med, Div Cardiovasc Dis, 363 BDB,1808 7th Ave S, Birmingham, AL 35294 USA.			Frederick, Paul/0000-0002-7936-5488	AHRQ HHS [HS08843] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008843] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bureau of the Census, 1996, STAT ABSTR US; Canto JG, 1997, J AM COLL CARDIOL, V29, P498, DOI 10.1016/S0735-1097(96)00532-3; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; Kastrati A, 1998, J AM COLL CARDIOL, V32, P970, DOI 10.1016/S0735-1097(98)00334-9; KIMMEL SE, 1995, JAMA-J AM MED ASSOC, V274, P1137, DOI 10.1001/jama.274.14.1137; Peterson ED, 1998, J AM COLL CARDIOL, V32, P993, DOI 10.1016/S0735-1097(98)00332-5; Ritchie JL, 1999, AM J CARDIOL, V83, P493, DOI 10.1016/S0002-9149(98)00901-1; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Ryan TJ, 1998, J AM COLL CARDIOL, V32, P977; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106	15	269	283	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2000	342	21					1573	1580		10.1056/NEJM200005253422106	http://dx.doi.org/10.1056/NEJM200005253422106			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316XJ	10824077				2022-12-28	WOS:000087193100006
J	Thomas, RDK; Shearman, RM; Stewart, CW				Thomas, RDK; Shearman, RM; Stewart, CW			Evolutionary exploitation of design options by the first animals with hard skeletons	SCIENCE			English	Article							ANOMALOCARIS; ARTHROPODS; PLATFORM; GENES	The set of viable design elements available for animals to use in building skeletons has been fully exploited. Analysis of animal skeletons in relation to the multivariate, theoretical "Skeleton Space" has shown that a Large proportion of these options are used in each phylum. Here, we show that structural elements deployed in the skeletons of Burgess Shale animals (Middle Cambrian) incorporate 146 of 182 character pairs defined in this morphospace. Within 15 million years of the appearance of crown groups of phyla with substantial hard parts, at least 80 percent of skeletal design elements recognized among Living and extinct marine metazoans were exploited.	Franklin & Marshall Coll, Dept Geosci, Lancaster, PA 17604 USA	Franklin & Marshall College	Thomas, RDK (corresponding author), Franklin & Marshall Coll, Dept Geosci, Lancaster, PA 17604 USA.							Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; BENGTSON S., 1994, EARLY LIFE EARTH, V84, P412; Bowring S.A., 1998, GSA TODAY, V8, P1; Briggs D.E.G., 1994, FOSSILS BURGESS SHAL; Budd GE, 1999, BIOESSAYS, V21, P326, DOI 10.1002/(SICI)1521-1878(199904)21:4<326::AID-BIES9>3.0.CO;2-0; Butterfield NJ, 1997, PALEOBIOLOGY, V23, P247, DOI 10.1017/S009483730001681X; CHEN J, 1997, B NAT MUS NAT SCI TA, V10; Collins D, 1996, J PALEONTOL, V70, P280, DOI 10.1017/S0022336000023362; Conway Morris S., 1998, CRUCIBLE CREATION BU; Foote M, 1997, ANNU REV ECOL SYST, V28, P129, DOI 10.1146/annurev.ecolsys.28.1.129; Gould S. J., 1989, WONDERFUL LIFE; HALANYCH KM, 1995, SCIENCE, V267, P1641, DOI 10.1126/science.7886451; Holland P. W. H., 1994, DEVELOPMENT S, P124; JACOBS DK, 1990, P NATL ACAD SCI USA, V87, P4406, DOI 10.1073/pnas.87.11.4406; KNOLL AH, 1999, SCIENCE, V284, P2129, DOI DOI 10.1126/SCIENCE.284.5423.2129; KRUSE PD, 1995, PALAIOS, V10, P291, DOI 10.2307/3515157; Niklas K.J., 1997, EVOLUTIONARY BIOL PL; ROSA R, 1999, NATURE, V399, P772; Shu DG, 1999, NATURE, V402, P42, DOI 10.1038/46965; SIGNOR PW, 1994, PALEOBIOLOGY, V20, P297, DOI 10.1017/S0094837300012793; Smith AB, 1999, EVOL DEV, V1, P138, DOI 10.1046/j.1525-142x.1999.99027.x; STEWART WD, 1993, GEOLOGY, V21, P687, DOI 10.1130/0091-7613(1993)021<0687:MCCPCS>2.3.CO;2; Thomas R.D.K., 1991, P283; THOMAS RDK, 1993, EVOLUTION, V47, P341, DOI 10.1111/j.1558-5646.1993.tb02098.x; Valentine JW, 1999, DEVELOPMENT, V126, P851; Valentine JW, 1997, P NATL ACAD SCI USA, V94, P8001, DOI 10.1073/pnas.94.15.8001; Valentine JW, 1996, DEV BIOL, V173, P373, DOI 10.1006/dbio.1996.0033; Whittington Harry B, 1985, BURGESS SHALE; WHITTINGTON HB, 1985, PHILOS T R SOC B, V309, P569, DOI 10.1098/rstb.1985.0096; WILLS MA, 1994, PALEOBIOLOGY, V20, P93, DOI 10.1017/S009483730001263X; [No title captured]	31	56	60	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1239	1242		10.1126/science.288.5469.1239	http://dx.doi.org/10.1126/science.288.5469.1239			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817998				2022-12-28	WOS:000087112600050
J	Espinal, MA; Kim, SJ; Suarez, PG; Kam, KM; Khomenko, AG; Migliori, GB; Baez, J; Kochi, A; Dye, C; Raviglione, MC				Espinal, MA; Kim, SJ; Suarez, PG; Kam, KM; Khomenko, AG; Migliori, GB; Baez, J; Kochi, A; Dye, C; Raviglione, MC			Standard short-course chemotherapy for drug-resistant tuberculosis - Treatment outcomes in 6 countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PULMONARY TUBERCULOSIS; RIFAMPIN	Context No large-scale study has investigated the impact of multidrug-resistant tuberculosis (TB) on the outcome of standard short-course chemotherapy under routine countrywide TB control program conditions in the World Health Organization's (WHO) directly observed treatment short-course strategy for TB control. Objective To assess the results of treatment with first-line drugs for patients enrolled in the WHO and the International Union Against Tuberculosis and Lung Disease's global project on drug-resistance surveillance. Design and Setting Retrospective cohort study of patients with TB in the Dominican Republic, Hong Kong Special Administrative Region (People's Republic of China), Italy, Ivanovo Oblast (Russian Federation), the Republic of Korea, and Peru. Patients New and retreatment TB cases who received short-course chemotherapy with isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin between 1994 and 1996. Main Outcome Measure Treatment response according to WHO treatment outcome categories (cured; died; completed, defaulted, or failed treatment; or transferred). Results Of the 6402 culture-positive TB cases evaluated, 5526 (86%) were new cases and 876 (14%) were retreatment cases. A total of 1148 (20.8%) new cases and 390 (44.5%) retreatment cases were drug resistant, including 184 and 169 cases of multidrug-resistant TB, respectively. Of the new cases 4585 (83%) were treated successfully, 138 (2%) died, and 151 (3%) experienced short-course chemotherapy failure. Overall, treatment failure (relative risk [RR], 15.4; 95% confidence interval [CI], 10.6-22.4; P<.001) and mortality (RR, 3.73; 95% CI, 2.13-6.53; P<.001) were higher among new multidrug-resistant TB cases than among new susceptible cases. Even in settings using 100% direct observation, cases with multidrug resistance had a significantly higher failure rate than those who were susceptible (9/94 [10%] vs 8/1410 [0.7%1; RR, 16.9; 95% CI, 6.6-42.7; P<.001). Treatment failure was also higher among patients with any rifampicin resistance (n = 115) other than multidrug resistance (RR, 5.48, 95% CI, 3.04-9.87; P<.001), any isoniazid resistance (n = 457) other than multidrug resistance (RR, 3.06; 95% CI, 1.85-5.05; P<.001), and among patients with TB resistant to rifampicin only (n = 76) (RR, 5.47; 95% CI, 2.68-11.2; P<,001). Of the retreatment cases, 497 (57%) were treated successfully, 51 (6%) died, and 124 (14%) failed short-course chemotherapy treatment. Failure rates among retreatment cases were higher in those with muitidrug-resistant TB, with any isoniazid resistance other than multidrug resistance, and in cases with TB resistant to isoniazid only. Conclusions These data suggest that standard short-course chemotherapy, based on first-line drugs, is an inadequate treatment for some patients with drug-resistant TB. Although the directly observed treatment short-course strategy is the basis of good TB control, the strategy should be modified in some settings to identify drug-resistant cases sooner, and to make use of second-line drugs in appropriate treatment regimens.	WHO, Commun Dis Programme, CH-1211 Geneva 27, Switzerland; Korean Inst TB, Seoul, South Korea; Natl TB Control Program, Lima, Peru; Hong Kong Dept Hlth, Pathol Serv, Hong Kong, Peoples R China; TB Res Ctr, Moscow, Russia; Fdn Salvatore Maugeri, Care & Res Inst, Tradate, Italy; Res Ctr Maternal & Child Hlth, Santo Domingo, Dominican Rep	World Health Organization; Istituti Clinici Scientifici Maugeri IRCCS	Espinal, MA (corresponding author), WHO, Commun Dis Programme, Ave Appla 20, CH-1211 Geneva 27, Switzerland.	espinalm@who.ch	Migliori, Giovanni Battista/AAB-8589-2020; Dye, Christopher/AIC-4659-2022; Suarez, Pedro G/AAD-2278-2019; KAM, Kai Man/K-4546-2012	Migliori, Giovanni Battista/0000-0002-2597-574X; Suarez, Pedro G/0000-0001-9825-1761; KAM, Kai Man/0000-0003-0579-0307; RAVIGLIONE, Mario/0000-0002-9331-2067; Dye, Christopher/0000-0002-2957-1793				CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; COLEBUNDERS R, 1994, ANN SOC BELG MED TR, V74, P263; Coninx R, 1999, LANCET, V353, P969, DOI 10.1016/S0140-6736(98)08341-X; DROLET G. J., 1938, American Review of Tuberculosis and Pulmonary Diseases, V37, P125; Espinal MA, 1998, INT J TUBERC LUNG D, V2, P490; Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Kumaresan JA, 1998, INT J TUBERC LUNG D, V2, P992; Laszlo A, 1997, INT J TUBERC LUNG D, V1, P231; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; NARAIN R, 1974, B WORLD HEALTH ORGAN, V51, P273; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Park SK, 1998, INT J TUBERC LUNG D, V2, P877; *PRPGR NAC CONTR T, 1998, MIN SAL PERU PUBL; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; Trebucq A, 1999, INT J TUBERC LUNG D, V3, P455; *WHO, 1997, T937012RUS WHO; WHO, 2000, WHO PUBL; WHO, 1997, OBESITY PREVENTING M; World Bank, 1993, INV HLTH WORLD DEV R; World Health Organization, 1998, WHO PUBL, VMSA/MDN/98.2, P55; Zhao FZ, 1997, INT J TUBERC LUNG D, V1, P570	24	454	474	0	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2537	2545		10.1001/jama.283.19.2537	http://dx.doi.org/10.1001/jama.283.19.2537			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312VL	10815117	Bronze			2022-12-28	WOS:000086964600034
J	Prosser, LA; Stinnett, AA; Goldman, PA; Williams, LW; Hunink, MGM; Goldman, L; Weinstein, MC				Prosser, LA; Stinnett, AA; Goldman, PA; Williams, LW; Hunink, MGM; Goldman, L; Weinstein, MC			Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; COA REDUCTASE INHIBITORS; ARTERY DISEASE; MODERATE HYPERCHOLESTEROLEMIA; SECONDARY PREVENTION; ECONOMIC-EVALUATION; CLINICAL-TRIALS; RISK FACTOR; PRAVASTATIN	Background: The National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) recommends treatment guidelines based on cholesterol level and number of risk factors. Objective: To evaluate how the cost-effectiveness ratios of cholesterol-lowering therapies vary according to different risk factors. Design: Cost-effectiveness analysis. Data Sources: Published data. Target Population: Women and men 35 to 84 years of age with low-density lipoprotein cholesterol levels of 4.1 mmol/L or greater (greater than or equal to 160 mg/dL), divided into 240 risk subgroups according to age, sex, and the presence or absence of four coronary heart disease risk factors (smoking status, blood pressure, low-density lipoprotein cholesterol level, and high-density lipoprotein cholesterol level). Time Horizon: 30 years. Perspective: Societal. Interventions: Step I diet, statin therapy, and no preventive treatment for primary and secondary prevention. Outcome Measures: Incremental cost-effectiveness ratios. Results of Base-Case Analysis: Incremental cost-effectiveness ratios for primary prevention with step I diet ranged from $1900 per quality-adjusted life-year (QALY) gained to $500 000 per QALY depending on risk subgroup characteristics. Primary prevention with a statin compared with diet therapy was $54 000 per QALY to $1 400 000 per QALY. Secondary prevention with a statin cost less than $50 000 per QALY for all risk subgroups. Results of Sensitivity Analysis: The inclusion of niacin as a primary prevention option resulted in much less favorable incremental cost-effectiveness ratios for primary prevention with a statin (>$500 000 per QALY). Conclusions: Cost-effectiveness of treatment strategies varies significantly when adjusted for age, sex, and the presence or absence of additional risk factors. Primary prevention with a step I diet seems to be cost-effective for most risk subgroups but may not be cost-effective for otherwise healthy young women. Primary prevention with a statin may not be cost-effective for younger men and women with few risk factors, given the option of secondary prevention and of primary prevention in older age ranges. Secondary prevention with a statin seems to be cost-effective for all risk subgroups and is cost-saving in some high-risk subgroups.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Univ Alabama Birmingham, Birmingham, AL 35294 USA; Erasmus MC, NL-3000 DR Rotterdam, Netherlands; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; Erasmus University Rotterdam; Erasmus MC; University of California System; University of California San Francisco	Weinstein, MC (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, 718 Huntington Ave, Boston, MA 02115 USA.		Hug, Balthasar L./G-1568-2010		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006258] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007092] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS 06258] Funding Source: Medline; NLM NIH HHS [5T15LM07092-08] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; [Anonymous], 1993, Am J Cardiol, V72, P1031; Ashraf T, 1996, AM J CARDIOL, V78, P409, DOI 10.1016/S0002-9149(96)00328-1; Avins AL, 1998, JAMA-J AM MED ASSOC, V279, P445, DOI 10.1001/jama.279.6.445; BROWN WV, 1995, POSTGRAD MED, V98, P185, DOI 10.1080/00325481.1995.11946037; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; DENKE MA, 1994, ARCH INTERN MED, V154, P1977, DOI 10.1001/archinte.154.17.1977; DENKE MA, 1994, ARCH INTERN MED, V154, P317, DOI 10.1001/archinte.154.3.317; DENKE MA, 1995, ARCH INTERN MED, V155, P393, DOI 10.1001/archinte.155.4.393; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gold MR, 1996, COST EFFECTIVENESS H; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; Graham JD, 1998, ANNU REV PUBL HEALTH, V19, P125, DOI 10.1146/annurev.publhealth.19.1.125; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; GUIBERT R, 1993, CAN J CARDIOL S, V9, pD28; HAMILTON VH, 1995, JAMA-J AM MED ASSOC, V273, P1032, DOI 10.1001/jama.273.13.1032; HAY JW, 1991, AM J CARDIOL, V67, P789, DOI 10.1016/0002-9149(91)90609-O; Hjalte K, 1992, Pharmacoeconomics, V1, P213; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; ILLINGWOUTH DR, 1994, ARCH INTERN MED, V154, P1586, DOI 10.1001/archinte.154.14.1586; Jacobson TA, 1996, AM J CARDIOL, V78, P32, DOI 10.1016/S0002-9149(96)00660-1; Johannesson M, 1997, NEW ENGL J MED, V336, P332, DOI 10.1056/NEJM199701303360503; JONES PH, 1991, CLIN CARDIOL, V14, P146, DOI 10.1002/clc.4960140211; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KEENAN JM, 1991, ARCH INTERN MED, V151, P1424, DOI 10.1001/archinte.151.7.1424; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957; MARTENS LL, 1989, AM J MED, V87, pS54, DOI 10.1016/S0002-9343(89)80600-X; MARTENS LL, 1994, CLIN THER, V16, P1052; Morris S, 1997, HEALTH ECON, V6, P589, DOI 10.1002/(SICI)1099-1050(199711)6:6<589::AID-HEC286>3.0.CO;2-D; MYERS RH, 1990, AM HEART J, V120, P963, DOI 10.1016/0002-8703(90)90216-K; PEDERSEN TR, 1994, LANCET, V344, P1383; Riviere M, 1997, CAN MED ASSOC J, V156, P991; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SCHULMAN KA, 1990, JAMA-J AM MED ASSOC, V264, P3025, DOI 10.1001/jama.264.23.3025; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STINNETT AA, 1996, COST EFFECTIVNESS HL; Tang JL, 1998, BMJ-BRIT MED J, V316, P1213, DOI 10.1136/bmj.316.7139.1213; TAYLOR WC, 1990, PREVENTING DIS RHETO, P437; TOBERT JA, 1990, AM J CARDIOL, V66, pB22; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tsalamandris C, 1994, J Cardiovasc Risk, V1, P231; VACEK JL, 1995, AM J CARDIOL, V76, P182, DOI 10.1016/S0002-9149(99)80056-3; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; Weinstein MC., 1995, VALUING HLTH CARE CO; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703; 1996, 1997 MED CLIN LAB FE; 1995, MCGRAWHILL COMPLETE; 1997, LABOUR FORCE STAT CU; 1996, FED REG, V61, P59717; 1997, DRUG TOPICS RED BOOK; 1991, AHCRP PUBLICATION RO	56	168	170	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2000	132	10					769	779		10.7326/0003-4819-132-10-200005160-00002	http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	313XN	10819699				2022-12-28	WOS:000087025100001
J	Donzeau, M; Kaldi, K; Adam, A; Paschen, S; Wanner, G; Guiard, B; Bauer, MF; Neupert, W; Brunner, M				Donzeau, M; Kaldi, K; Adam, A; Paschen, S; Wanner, G; Guiard, B; Bauer, MF; Neupert, W; Brunner, M			Tim23 links the inner and outer mitochondrial membranes	CELL			English	Article							PROTEIN IMPORT MACHINERY; INTERMEMBRANE SPACE; ELECTRON TOMOGRAPHY; DYNAMIC INTERACTION; YEAST MITOCHONDRIA; CARRIER PROTEINS; CONTACT SITES; TRANSLOCATION; COMPLEX; SYSTEM	Tim23, a key component of the mitochondrial preprotein translocase, is anchored in the inner membrane by its C-terminal domain and exposes an intermediate domain in the intermembrane space that functions as a presequence receptor. We show that the N-terminal domain of Tim23 is exposed on the surface of the outer membrane. The two-membrane-spanning topology of Tim23 is a novel characteristic in membrane biology. By the simultaneous integration into two membranes, Tim23 forms contacts between the outer and inner mitochondrial membranes. Tethering the inner membrane translocase to the outer membrane facilitates the transfer of precursor proteins from the TOM complex to the TIM23 complex and increases the efficiency of protein import.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany; Univ Munich, Inst Bot, D-30638 Munich, Germany; Univ Paris 06, CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France	University of Munich; University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Brunner, M (corresponding author), Univ Munich, Inst Physiol Chem, Goethestr 33, D-80336 Munich, Germany.		Káldi, Krisztina/X-4080-2019; Adam, Alexander/I-5713-2016	Brunner, Michael/0000-0001-9798-3047; Donzeau, Mariel/0000-0002-1145-9218; Kaldi, Krisztina/0000-0002-5724-0182				Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; FLYTLOVICH S, 1993, EMBO J, V12, P1209; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; HUGHSON FM, 1997, CURR BIOL, V7, P565; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; JASCUR T, 1992, J BIOL CHEM, V267, P13636; Kaldi K, 1998, EMBO J, V17, P1569, DOI 10.1093/emboj/17.6.1569; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; Mannella CA, 1997, J BIOENERG BIOMEMBR, V29, P525, DOI 10.1023/A:1022489832594; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Perkins G, 1997, J STRUCT BIOL, V119, P260, DOI 10.1006/jsbi.1997.3885; Perkins GA, 1998, J BIOENERG BIOMEMBR, V30, P431, DOI 10.1023/A:1020586012561; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Pfanner N, 1998, CURR BIOL, V8, pR262, DOI 10.1016/S0960-9822(98)70168-X; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Sirrenberg C, 1997, J BIOL CHEM, V272, P29963, DOI 10.1074/jbc.272.47.29963; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x	40	137	141	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 12	2000	101	4					401	412		10.1016/S0092-8674(00)80850-8	http://dx.doi.org/10.1016/S0092-8674(00)80850-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830167	Bronze			2022-12-28	WOS:000087010400008
J	Pondaven, P; Ragueneau, O; Treguer, P; Hauvespre, A; Dezileau, L; Reyss, JL				Pondaven, P; Ragueneau, O; Treguer, P; Hauvespre, A; Dezileau, L; Reyss, JL			Resolving the 'opal paradox' in the Southern Ocean	NATURE			English	Article							INTERGLACIAL CHANGES; INDIAN SECTOR; HIGH NUTRIENT; DIATOMS; WATERS; ATLANTIC; GROWTH; IRON; SEDIMENTATION; PRODUCTIVITY	In the Southern Ocean, high accumulation rates of opal-which forms by precipitation from silica-bearing solutions-have been found in the sediment in spite of low production rates of biogenic silica and carbon in the overlying surface waters. This so-called 'opal paradox' is generally attributed to a higher efficiency of opal preservation in the Southern Ocean than elsewhere(1,2). Here we report biogenic silica production rates, opal rain rates in the water column and opal sediment burial rates for the Indian Ocean sector of the Southern Ocean, which show that the assumed opal paradox is a result of underestimated opal production rates and overestimated opal accumulation rates. Our data thus demonstrate that the overall preservation efficiency of biogenic opal in this region is substantially lower than previously thought(2), and that it lies within a factor of two of the global mean(3). The comparison of our revised opal preservation efficiencies for the Southern Ocean with existing values from the equatorial Pacific Ocean and the North Atlantic Ocean shows that spatial differences in preservation efficiencies are not the primary reason for the differences in sedimentary opal accumulation. The reconciliation of surface production rates and sedimentary accumulation rates may enable the use of biogenic opal in the reconstruction of palaeo-productivity when the factors that affect the Si/C ratio are better understood.	Univ Bretagne Occidentale, CNRS, UMR 6539, Inst Univ Europeen Mer,Technopole Brest Iroise, F-29280 Plouzane, France; CEA, CNRS, Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Ifremer; Institut de Recherche pour le Developpement (IRD); Universite de Bretagne Occidentale; Institut Universitaire Europeen de la Mer (IUEM); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Pondaven, P (corresponding author), Univ Bretagne Occidentale, CNRS, UMR 6539, Inst Univ Europeen Mer,Technopole Brest Iroise, Pl Copernic, F-29280 Plouzane, France.		Ragueneau, Olivier/H-6021-2017; Treguer, Paul/H-6064-2012	Ragueneau, Olivier/0000-0001-8598-1730; Pondaven, Philippe/0000-0002-3427-7767				Arrigo KR, 1998, J GEOPHYS RES-OCEANS, V103, P15587, DOI 10.1029/98JC00930; BACON MP, 1984, ISOT GEOSCI, V2, P97; Berelson WM, 1997, DEEP-SEA RES PT II, V44, P2251, DOI 10.1016/S0967-0645(97)00030-1; Berger W.H., 1990, PALAEOGEOGR PALAEOCL, V89, P245, DOI DOI 10.1016/0031-0182(90)90065-F; Bianchi M, 1997, DEEP-SEA RES PT II, V44, P1017, DOI 10.1016/S0967-0645(96)00109-9; Blain S, 1997, DEEP-SEA RES PT I, V44, P1255, DOI 10.1016/S0967-0637(97)00014-9; Boyle E, 1998, NATURE, V393, P733, DOI 10.1038/31585; CAUBERT T, 1998, THESIS U BRETAGNE OC; Clowes A.J, 1938, DISCOVERY REP, V19, P1; DAVIS CO, 1976, J PHYCOL, V12, P291, DOI 10.1111/j.1529-8817.1976.tb02847.x; DEUSER WG, 1986, DEEP-SEA RES, V33, P225, DOI 10.1016/0198-0149(86)90120-2; FRANCOIS R, 1993, PALEOCEANOGRAPHY, V8, P611, DOI 10.1029/93PA00784; GORDON AL, 1984, J GEOPHYS RES-OCEANS, V89, P637, DOI 10.1029/JC089iC01p00637; HONJO S, 1995, DEEP-SEA RES PT II, V42, P831, DOI 10.1016/0967-0645(95)00034-N; JACQUES G, 1991, MAR CHEM, V35, P273, DOI 10.1016/S0304-4203(09)90022-6; JENNINGS JC, 1984, NATURE, V309, P51, DOI 10.1038/309051a0; KAMYKOWSKI D, 1989, MAR ECOL PROG SER, V58, P101, DOI 10.3354/meps058101; Lampitt RS, 1997, DEEP-SEA RES PT I, V44, P1377, DOI 10.1016/S0967-0637(97)00020-4; MINAS HJ, 1992, OCEANOL ACTA, V15, P145; Nelson DM, 1997, LIMNOL OCEANOGR, V42, P473, DOI 10.4319/lo.1997.42.3.0473; NELSON DM, 1995, GLOBAL BIOGEOCHEM CY, V9, P359, DOI 10.1029/95GB01070; Pondaven P, 1999, DEEP-SEA RES PT I, V46, P1923, DOI 10.1016/S0967-0637(99)00033-3; QUEGUINER B, 1997, DEEP SEA RES 2, V44, P68; Rabouille C, 1997, DEEP-SEA RES PT II, V44, P1151, DOI 10.1016/S0967-0645(96)00108-7; Sayles FL, 1996, DEEP-SEA RES PT I, V43, P383, DOI 10.1016/0967-0637(96)00027-1; SEMENEH M, 1998, POLAR BIOL, V20, P259; Takeda S, 1998, NATURE, V393, P774, DOI 10.1038/31674; TREGUER P, 1995, SCIENCE, V268, P375, DOI 10.1126/science.268.5209.375; TREGUER P, 1989, POLAR BIOL, V9, P397, DOI 10.1007/BF00442531; WEFER G, 1991, MAR CHEM, V35, P597, DOI 10.1016/S0304-4203(09)90045-7	30	184	192	0	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					168	172		10.1038/35012046	http://dx.doi.org/10.1038/35012046			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821269				2022-12-28	WOS:000087080100046
J	Saxton, JF; Blake, DA; Fox, JT; Johns, MME				Saxton, JF; Blake, DA; Fox, JT; Johns, MME			The evolving academic health center - Strategies and priorities at Emory University	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Emory Univ, Sch Med, Robert W Woodruff Hlth Sci Ctr, Atlanta, GA 30322 USA; Emory Univ, Emory Healthcare, Atlanta, GA 30322 USA	Emory University; Emory University	Johns, MME (corresponding author), Emory Univ, Sch Med, Robert W Woodruff Hlth Sci Ctr, 1440 Clifton Rd NE,Suite 408, Atlanta, GA 30322 USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2434	2436		10.1001/jama.283.18.2434	http://dx.doi.org/10.1001/jama.283.18.2434			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815089				2022-12-28	WOS:000086808200041
J	Pitt, B; Poole-Wilson, PA; Segal, R; Martinez, FA; Dickstein, K; Camm, AJ; Konstam, MA; Riegger, G; Klinger, GH; Neaton, J; Sharma, D; Thiyagarajan, B				Pitt, B; Poole-Wilson, PA; Segal, R; Martinez, FA; Dickstein, K; Camm, AJ; Konstam, MA; Riegger, G; Klinger, GH; Neaton, J; Sharma, D; Thiyagarajan, B		ELITE II Investigators	Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II	LANCET			English	Article							CONVERTING ENZYME-INHIBITORS; ANGIOTENSIN-II; MYOCARDIAL-INFARCTION; CLINICAL STATUS; ANTAGONIST; ENALAPRIL; DESIGN; TOLERABILITY; RATIONALE; MORBIDITY	Background The ELITE study showed an association between the angiotensin II antagonist losartan and an unexpected survival benefit in elderly heart-failure patients, compared with captopril, an angiotensin-converting-enzyme (ACE) inhibitor. We did the ELITE II Losartan Heart Failure Survival Study to confirm whether losartan is superior to captopril in improving survival and is better tolerated. Methods We undertook a double-blind, randomised, controlled trial of 3152 patients aged 60 years or older with New York Heart Association class II-IV heart failure and ejection fraction of 40% or less. Patients, stratified for beta-blocker use, were randomly assigned losartan (n=1578) titrated to 50 mg once daily or captopril (n=1574) titrated to 50 mg three times daily. The primary and secondary endpoints were all-cause mortality, and sudden death or resuscitated arrest. We assessed safety and tolerability. Analysis was by intention to treat. Findings Median follow-up was 555 days. There were no significant differences in all-cause mortality (11.7 vs 10.4% average annual mortality rate) or sudden death or resuscitated arrests (9.0 vs 7.3%) between the two treatment groups (hazard ratios 1.13 [95.7% CI 0.95-1.35], p=0.16and 1.5 [95% CI 0.98-1.60], p=0.08). Significantly fewer patients in the losartan group (excluding those who died) discontinued study treatment because of adverse effects (9.7 vs 14.7%, p<0.001), including cough (0.3 vs 2.7%). Interpretation Losartan was not superior to captopril in improving survival in elderly heart-failure patients, but was significantly better tolerated. We believe that ACE inhibitors should be the initial treatment for heart failure, although angiotensin II receptor antagonists may be useful to block the renin angiotensin aldosterone system when ACE inhibitors are not tolerated.	Univ Michigan, Sch Med, Div Cardiol, Ann Arbor, MI 48109 USA; Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London, England; Merck Res Labs, W Point, PA USA; Fdn Rusculleda, Cordoba, Argentina; Sentralsjukehuset Rogaland, Stavanger, Norway; Univ London St Georges Hosp, Sch Med, London SW17 0RE, England; New England Med Ctr, Boston, MA 02111 USA; Univ Regensburg Klinikum, Regensburg, Germany; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA	University of Michigan System; University of Michigan; Imperial College London; Merck & Company; St Georges University London; Tufts Medical Center; University of Regensburg; University of Minnesota System; University of Minnesota Twin Cities	Pitt, B (corresponding author), Univ Michigan, Sch Med, Div Cardiol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.							Adams KF, 1999, J CARD FAIL, V5, P357; Brooksby P, 1999, LANCET, V354, P395, DOI 10.1016/S0140-6736(99)01354-9; Brown NJ, 1998, CIRCULATION, V97, P1411, DOI 10.1161/01.CIR.97.14.1411; Burnier M, 2000, LANCET, V355, P637, DOI 10.1016/S0140-6736(99)10365-9; Cohn JN, 1999, J CARD FAIL, V5, P155, DOI 10.1016/S1071-9164(99)90038-6; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; CROZIER I, 1995, CIRCULATION, V91, P691, DOI 10.1161/01.CIR.91.3.691; Davies MK, 2000, BRIT MED J, V320, P428, DOI 10.1136/bmj.320.7232.428; DICKSTEIN K, 1995, J AM COLL CARDIOL, V26, P438, DOI 10.1016/0735-1097(95)80020-H; Dickstein K, 1999, AM J CARDIOL, V83, P477, DOI 10.1016/S0002-9149(98)00898-4; DZAU VJ, 1994, J HYPERTENS, V12, pS1; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GOLDBERG AI, 1995, AM J CARDIOL, V75, P793, DOI 10.1016/S0002-9149(99)80413-5; GOTTLIEB SS, 1993, CIRCULATION, V88, P1602, DOI 10.1161/01.CIR.88.4.1602; Hatta E, 1999, J PHARMACOL EXP THER, V288, P919; Hjalmarson A, 1999, LANCET, V353, P2001; Hobbs FDR, 1999, EUR J HEART FAIL, V1, P11, DOI 10.1016/S1388-9842(98)00006-3; Houghton AR, 1997, INT J CARDIOL, V59, P7, DOI 10.1016/S0167-5273(96)02904-X; Klinger G., 1997, Journal of the American College of Cardiology, V29, p205A; LACOURCIERE Y, 1994, J HYPERTENS, V12, P1387; Lang RM, 1997, J AM COLL CARDIOL, V30, P983, DOI 10.1016/S0735-1097(97)00253-2; Lechat P, 1999, LANCET, V353, P9; Lynch JJ, 1999, J AM COLL CARDIOL, V34, P876, DOI 10.1016/S0735-1097(99)00253-3; McDonald K M, 1998, J Card Fail, V4, P203, DOI 10.1016/S1071-9164(98)80007-9; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PAHOR M, 1994, CARDIOVASC RES, V28, P173, DOI 10.1093/cvr/28.2.173; Pitt B, 1999, J CARD FAIL, V5, P146, DOI 10.1016/S1071-9164(99)90037-4; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; PRATT CM, 1995, AM J CARDIOL, V75, P1244, DOI 10.1016/S0002-9149(99)80771-1; Remme WJ, 1997, EUR HEART J, V18, P736; Rump LC, 1998, LANCET, V351, P644, DOI 10.1016/S0140-6736(05)78427-0; Swedberg K, 1999, J Card Fail, V5, P276, DOI 10.1016/S1071-9164(99)90013-1; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Thomas GP, 1996, J PHARMACOL EXP THER, V278, P1090; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; URATA H, 1990, CIRC RES, V66, P883, DOI 10.1161/01.RES.66.4.883; WILLIAMS JF, 1995, CIRCULATION, V92, P2764; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	38	1307	1375	1	25	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 6	2000	355	9215					1582	1587		10.1016/S0140-6736(00)02213-3	http://dx.doi.org/10.1016/S0140-6736(00)02213-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821361				2022-12-28	WOS:000086981200008
J	Velazquez, EJ; Califf, RM				Velazquez, EJ; Califf, RM			All that glitters is not gold	LANCET			English	Editorial Material							CONGESTIVE-HEART-FAILURE; MORTALITY; TRIAL; DESIGN		Duke Clin Res Inst, Div Cardiol, Durham, NC 27705 USA	Duke University	Califf, RM (corresponding author), Duke Clin Res Inst, Div Cardiol, Durham, NC 27705 USA.							Bart BA, 1999, EUR HEART J, V20, P1182, DOI 10.1053/euhj.1998.1481; BART BA, 1997, AM J CARDIOL, V79, P118; Califf RM, 1997, AM HEART J, V134, P44, DOI 10.1016/S0002-8703(97)70105-4; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; Cohn JN, 1999, J CARD FAIL, V5, P155, DOI 10.1016/S1071-9164(99)90038-6; Dickstein K, 1999, AM J CARDIOL, V83, P477, DOI 10.1016/S0002-9149(98)00898-4; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PACKER M, 2000, COMMUNICATION; PFEFFER M, IN PRESS AM HEART J; PIRR B, 1997, LANCET, V349, P747; Swedberg K, 1999, J Card Fail, V5, P276, DOI 10.1016/S1071-9164(99)90013-1; YUUF S, 2000, AM HEART J, V139, pS136	12	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 6	2000	355	9215					1568	1569		10.1016/S0140-6736(00)02207-8	http://dx.doi.org/10.1016/S0140-6736(00)02207-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821355				2022-12-28	WOS:000086981200002
J	Baumgartner, I; Rauh, G; Pieczek, A; Wuensch, D; Magner, M; Kearney, M; Schainfeld, R; Isner, JM				Baumgartner, I; Rauh, G; Pieczek, A; Wuensch, D; Magner, M; Kearney, M; Schainfeld, R; Isner, JM			Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor	ANNALS OF INTERNAL MEDICINE			English	Article							PERMEABILITY FACTOR; THERAPEUTIC ANGIOGENESIS; COLLATERAL DEVELOPMENT; NITRIC-OXIDE; LIMB; PHVEGF(165); EXPRESSION; DISEASE; MITOGEN; RABBIT	Background: Vascular endothelial growth factor (VEGF) promotes angiogenesis and vascular permeability. The extent to which VEGF may cause tissue edema in humans has not been established. Objective: To evaluate patients undergoing VEGF gene transfer for evidence of lower-extremity edema. Design: Prospective consecutive case series. Setting: Hospital outpatient clinic. Patients: 62 patients with critical limb ischemia and 28 patients with claudication. Intervention: Gene transfer of VECF DNA. Measurements: Semiquantitative analysis of lower-extremity edema. Results: Lower-extremity edema was observed in 31 of 90 (34%) patients. Edema was less common in patients with claudication than in those with pain at rest (P = 0.016) or ischemic ulcers (P < 0.001), and it was less common in patients with pain at rest than in those with ischemic ulcers (P = 0.017). Treatment was typically limited to a brief course of oral diuretics. Conclusions: Vascular endothelial growth factor may enhance vascular permeability in humans. At the doses of plasmid DNA used in this study, lower-extremity edema responded to oral diuretic therapy and did not seem to be associated with serious sequelae.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Boston, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University	Isner, JM (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, 736 Cambridge St, Boston, MA 02135 USA.	jisner@opal.tufts.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053354, R01HL053354, R01HL057516] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57516, HL 02824, HL53354] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; BAUTERS C, 1995, J VASC SURG, V21, P314, DOI 10.1016/S0741-5214(95)70272-5; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Isner JM, 1998, ADV DRUG DELIVER REV, V30, P185, DOI 10.1016/S0169-409X(97)00115-4; Isner JM, 1996, HUM GENE THER, V7, P989, DOI 10.1089/hum.1996.7.8-989; Isner JM, 1996, HUM GENE THER, V7, P959, DOI 10.1089/hum.1996.7.8-959; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Isner JM, 1998, J VASC SURG, V28, P964, DOI 10.1016/S0741-5214(98)70022-9; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; ROBERTS WG, 1995, J CELL SCI, V108, P2369; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Takeshita S, 1996, LAB INVEST, V75, P487; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; Vale PR, 1998, CIRCULATION, V98, P66; vanderZee R, 1997, CIRCULATION, V95, P1030	19	152	165	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					880	884		10.7326/0003-4819-132-11-200006060-00005	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319HF	10836914				2022-12-28	WOS:000087334900004
J	Yamey, G				Yamey, G			Prisoners in England and Wales are at risk of bloodborne viruses	BRITISH MEDICAL JOURNAL			English	News Item																		2000, COMMUNICABLE DIS PUB, V3, P121	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1493	1493						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834881				2022-12-28	WOS:000087471000011
J	Appleby, J; Thomas, A				Appleby, J; Thomas, A			Measuring performance in the NHS: what really matters?	BRITISH MEDICAL JOURNAL			English	Article									Kings Fund, Hlth Syst Programme, London W1M 0AN, England; Royal Orthopaed Hosp NHS Trust, Birmingham B31 2AP, W Midlands, England	Royal Orthopaedic Hospital	Appleby, J (corresponding author), Kings Fund, Hlth Syst Programme, London W1M 0AN, England.							Appleby J, 1993, Health Serv J, V103, P20; Appleby J, 1993, Health Serv J, V103, P22; *BRIT MED ASS HLTH, 1998, Q B, V13, P4; CLARKE A, 1993, BRIT MED J, V307, P1436, DOI 10.1136/bmj.307.6917.1436; DAWSON D, 1999, 161 U YORK CTR HLTH; *DEP HLTH NHS EX, 1998, NEW NHS NAT FRAM ASS; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; *NHS EX, 1998, CLIN EFF IND CONS DO; *SECR STAT HLTH, 1997, CMND3807; SMITH P, 1990, J ROY STAT SOC A STA, V153, P53, DOI 10.2307/2983096; STREET A, 1999, 175 U YORK CTR HLTH; WILLIAMS MH, 1994, HLTH CARE ASSESSMENT, V1; 1998, BMJ, V317, P1604	14	9	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1464	1467		10.1136/bmj.320.7247.1464	http://dx.doi.org/10.1136/bmj.320.7247.1464			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827059	Green Published			2022-12-28	WOS:000087414700034
J	Mailand, N; Falck, J; Lukas, C; Syljuasen, RG; Welcker, M; Bartek, J; Lukas, L				Mailand, N; Falck, J; Lukas, C; Syljuasen, RG; Welcker, M; Bartek, J; Lukas, L			Rapid destruction of human Cdc25A in response to DNA damage	SCIENCE			English	Article							HAMSTER OVARY CELLS; S-PHASE CHECKPOINTS; G(1)/S TRANSITION; CYCLE CONTROL; P53; KINASE; PHOSPHORYLATION; PHOSPHATASE; PROTEIN; PATHWAY	To protect genome integrity and ensure survival, eukaryotic cells exposed to genotoxic stress cease proliferating to provide time for DNA repair. Human cells responded to ultraviolet light or ionizing radiation by rapid, ubiquitin- and proteasome-dependent protein degradation of Cdc25A, a phosphatase that is required for progression from G(1) to S phase of the cell cycle. This response involved activated Chk1 protein kinase but not the p53 pathway, and the persisting inhibitory tyrosine phosphorylation of Cdk2 blocked entry into S phase and DNA replication. Overexpression of Cdc25A bypassed this mechanism, leading to enhanced DNA damage and decreased cell survival. These results identify specific degradation of Cdc25A as part of the DNA damage checkpoint mechanism and suggest how Cdc25A overexpression in human cancers might contribute to tumorigenesis.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Claudia/0000-0001-7169-6883; Lukas, Jiri/0000-0001-9087-506X; Welcker, Markus/0000-0001-6723-4790				Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Freedman DA, 1999, CANCER RES, V59, P1; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUKAS J, 1994, ONCOGENE, V9, P2159; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; LUKAS J, 1992, EUR J BIOCHEM, V207, P169, DOI 10.1111/j.1432-1033.1992.tb17034.x; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; MAILAND N, UNPUB; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Poon RYC, 1997, CANCER RES, V57, P5168; POON RYC, 1996, J BIOL CHEM, V271; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sehested M, 1998, CANCER RES, V58, P1460; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Thullberg M, 2000, HYBRIDOMA, V19, P63, DOI 10.1089/027245700315806; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Wu WG, 1998, CANCER RES, V58, P4082; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793	45	632	655	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 26	2000	288	5470					1425	1429		10.1126/science.288.5470.1425	http://dx.doi.org/10.1126/science.288.5470.1425			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827953				2022-12-28	WOS:000087270900051
J	Lock, K				Lock, K			Health impact assessment	BRITISH MEDICAL JOURNAL			English	Article									E Sussex Brighton & Hove Hlth Author, Lewes BN7 2PB, E Sussex, England		Lock, K (corresponding author), E Sussex Brighton & Hove Hlth Author, Lewes BN7 2PB, E Sussex, England.							Acheson D., 1998, INDEPENDENT INQUIRY; [Anonymous], 1988, NEW PUBLIC HLTH; *AS DEV BANK, 1992, 11 AS DEV BANK; BIRLEY M, 1998, HLTH ENV IMPACT ASSE; Birley MH, 1995, HLTH IMPACT DEV PROJ; Dahlgren G, 1996, HLTH IMP ASS EU COMM; *DEP ENV, 1994, STRAT SUST DEV; *DEP HLTH, 1995, POL APPR HLTH GUID P; *DEP HLTH, 1999, HLTH IMP ASS; FLEEMAN N, 1999, OBSERVATORY REPORT S, V45; FLEEMAN N, 1997, OBSERVATORY REPORT S, V39; Konradsen F, 1997, IMPACT ASSESSMENT, V15, P55, DOI DOI 10.1080/07349165.1997.9726122; *POP HLTH RES BRAN, 1994, HLTH IMP ASS TOOLK R; Ratner PA, 1997, J PUBLIC HEALTH POL, V18, P67, DOI 10.2307/3343358; SAMUEL AS, 1998, J EPIDEMIOL COMMUNIT, V52, P704; SAMUEL AS, 1997, HEALTHLINES, V47, P15; SAMUEL AS, 1998, MORSEYSIDE GUIDELINE; *SECR STAT HLTH, 1999, SAV LIV OUR HLTH NAT; *SECR STAT NO IR, 1997, WELL 2000; *SECR STAT SCOTL, 1999, LTH SCOTL; Secretary of State for Wales, 1998, BETT HLTH BETT WAL; urdge R., 1995, ENV SOCIAL IMPACT AS, P31; WILL S, 1994, UNPUB INOSPECTIVE HL; WINTERS L, 1997, OBSERVATORY REPORT S, V38; WINTERS L, 1998, OBSERVATORY REPORT S, V43; *WORLD BANK, 1997, HLTH ASP ENV IMP ASS; World Health Organization, 1986, OTT CHART PRINC HLTH; 1992, UN C ENV DEV EARTH S	28	115	120	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	2000	320	7246					1395	1398		10.1136/bmj.320.7246.1395	http://dx.doi.org/10.1136/bmj.320.7246.1395			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818037	Green Published			2022-12-28	WOS:000087232500028
J	Craig, CM; Delay, D; Grealy, MA; Lee, DN				Craig, CM; Delay, D; Grealy, MA; Lee, DN			Guiding the swing in golf putting	NATURE			English	Article							COORDINATION; MOVEMENT		Univ Mediterranee, UMR Mouvement & Percept, F-13288 Marseille, France; Univ Grenoble 1, UFRAPS, F-38041 Grenoble, France; Univ Strathclyde, Dept Psychol, Glasgow G1 1XQ, Lanark, Scotland; Univ Edinburgh, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland	UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Strathclyde; University of Edinburgh	Craig, CM (corresponding author), Univ Mediterranee, UMR Mouvement & Percept, 163 Ave Luminy, F-13288 Marseille, France.		Craig, Cathy/D-9833-2014	Craig, Cathy/0000-0001-5509-1120; Grealy, Madeleine/0000-0002-2823-8841				Craig CM, 1999, EXP BRAIN RES, V124, P371, DOI 10.1007/s002210050634; GEORGOPOULOS AP, 1987, EXP BRAIN RES, V65, P361; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; HUDSON JL, 1986, MED SCI SPORT EXER, V18, P242; IVRY R, 1999, COGN NEUROSCI, V1, P136; JEANNEROD M, 1995, NEUROPSYCHOLOGIA, V33, P1419, DOI 10.1016/0028-3932(95)00073-C; JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026; KELSO JAS, 1991, HUM MOVEMENT SCI, V10, P93, DOI 10.1016/0167-9457(91)90034-U; Lee DN, 1998, ECOL PSYCHOL, V10, P221, DOI 10.1207/s15326969eco103&4_4; Lee DN, 1999, P ROY SOC B-BIOL SCI, V266, P2029, DOI 10.1098/rspb.1999.0882; Meck WH, 1996, COGNITIVE BRAIN RES, V3, P227, DOI 10.1016/0926-6410(96)00009-2; Nichelli P, 1996, NEUROPSYCHOLOGIA, V34, P863, DOI 10.1016/0028-3932(96)00001-2	12	77	77	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					295	296		10.1038/35012690	http://dx.doi.org/10.1038/35012690			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830947	Green Published			2022-12-28	WOS:000087085700030
J	Elderfield, H; Rickaby, REM				Elderfield, H; Rickaby, REM			Oceanic Cd/P ratio and nutrient utilization in the glacial Southern Ocean	NATURE			English	Article							ATMOSPHERIC CO2; SURFACE WATERS; CADMIUM; PRODUCTIVITY; DIATOM; MAXIMUM; PALEOCHEMISTRY; DISTRIBUTIONS; DELTA-C-13; DELTA-N-15	During glacial periods, low atmospheric carbon dioxide concentration has been associated with increased oceanic carbon uptake, particularly in the southern oceans. The mechanism involved remains unclear. Because ocean productivity is strongly influenced by nutrient levels, palaeo-oceanographic proxies have been applied to investigate nutrient utilization in surface water across glacial transitions. Here we show that present-day cadmium and phosphorus concentrations in the global oceans can be explained by a chemical fractionation during particle formation, whereby uptake of cadmium occurs in preference to uptake of phosphorus. This allows the reconstruction of past surface water phosphate concentrations from the cadmium/calcium ratio of planktonic foraminifera. Results from the Last Glacial Maximum show similar phosphate utilization in the subantarctic to that of today, but much smaller utilization in the polar Southern Ocean, in a model that is consistent with the expansion of glacial sea ice and which can reconcile all proxy records of polar nutrient utilization. By restricting communication between the ocean and atmosphere, sea ice expansion also provides a mechanism for reduced CO2 release by the Southern Ocean and lower glacial atmospheric CO2.	Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England	University of Cambridge	Elderfield, H (corresponding author), Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England.			Rickaby, Rosalind/0000-0002-6095-8419				ABE K, 1988, MAR CHEM, V23, P145, DOI 10.1016/0304-4203(88)90028-X; Anderson RF, 1998, J MARINE SYST, V17, P497, DOI 10.1016/S0924-7963(98)00060-8; Arrigo KR, 1999, SCIENCE, V283, P365, DOI 10.1126/science.283.5400.365; Bareille G, 1998, GEOLOGY, V26, P179, DOI 10.1130/0091-7613(1998)026<0179:ATOGSO>2.3.CO;2; BOYLE EA, 1981, J GEOPHYS RES-OCEANS, V86, P8048, DOI 10.1029/JC086iC09p08048; BOYLE EA, 1992, ANNU REV EARTH PL SC, V20, P245, DOI 10.1146/annurev.ea.20.050192.001333; BOYLE EA, 1988, J GEOPHYS RES-OCEANS, V93, P15701, DOI 10.1029/JC093iC12p15701; Boyle EA, 1988, PALEOCEANOGRAPHY, V3, P471, DOI 10.1029/PA003i004p00471; BROECKER WS, 1993, PALEOCEANOGRAPHY, V8, P137, DOI 10.1029/93PA00262; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P352, DOI 10.1029/98PA00920; BRULAND KW, 1978, LIMNOL OCEANOGR, V23, P618, DOI 10.4319/lo.1978.23.4.0618; Crosta X, 1998, PALEOCEANOGRAPHY, V13, P284, DOI 10.1029/98PA00339; Cullen JT, 1999, NATURE, V402, P165, DOI 10.1038/46007; De La Rocha CL, 1998, NATURE, V395, P680, DOI 10.1038/27174; DEBAAR HJW, 1994, MAR CHEM, V46, P261, DOI 10.1016/0304-4203(94)90082-5; FALKOWSKI P. G., 1997, NATURE, V342, P637; FRANCOIS R, 1993, PALEOCEANOGRAPHY, V8, P611, DOI 10.1029/93PA00784; Francois R, 1997, NATURE, V389, P929, DOI 10.1038/40073; Frew RD, 1995, MAR CHEM, V51, P223, DOI 10.1016/0304-4203(95)00057-7; GANESHRAM RS, 1995, NATURE, V376, P755, DOI 10.1038/376755a0; Hutchins DA, 1998, NATURE, V393, P561, DOI 10.1038/31203; JOUZEL J, 1993, NATURE, V364, P407, DOI 10.1038/364407a0; KEIGWIN LD, 1989, PALAEOGEOGR PALAEOCL, V73, P85, DOI 10.1016/0031-0182(89)90047-3; Kohfeld KE, 2000, PALEOCEANOGRAPHY, V15, P53, DOI 10.1029/1999PA900049; KUMAR N, 1995, NATURE, V378, P675, DOI 10.1038/378675a0; LEVITUS S, 1994, SATELLITE DATA INF S, V3; Loscher BM, 1997, MAR CHEM, V59, P87, DOI 10.1016/S0304-4203(97)00067-4; LUZ B, 1977, PALAEOGEOGR PALAEOCL, V22, P61, DOI 10.1016/0031-0182(77)90033-5; MARTIN JH, 1993, DEEP-SEA RES PT II, V40, P115, DOI 10.1016/0967-0645(93)90009-C; MORTLOCK RA, 1991, NATURE, V351, P220, DOI 10.1038/351220a0; Murnane RJ, 1988, PALEOCEANOGRAPHY, V3, P461, DOI 10.1029/PA003i004p00461; Pichon JJ, 1992, PALEOCEANOGRAPHY, V7, P289, DOI 10.1029/92PA00709; PRICE NM, 1990, NATURE, V344, P658, DOI 10.1038/344658a0; RAU GH, 1991, MAR CHEM, V35, P355, DOI 10.1016/S0304-4203(09)90028-7; Rickaby REM, 1999, PALEOCEANOGRAPHY, V14, P293, DOI 10.1029/1999PA900007; RICKABY REM, 1999, THESIS CAMBRIDGE U; Rosenthal Y, 1997, PALEOCEANOGRAPHY, V12, P787, DOI 10.1029/97PA02508; Rosenthal Y, 2000, PALEOCEANOGRAPHY, V15, P65, DOI 10.1029/1999PA000369; SAAGER PM, 1992, DEEP-SEA RES, V39, P9, DOI 10.1016/0198-0149(92)90017-N; SAAGER PM, 1994, THESIS FREE U; SHEMESH A, 1993, SCIENCE, V262, P407, DOI 10.1126/science.262.5132.407; Sherrell R. M., 1989, THESIS MIT; Sigman DM, 1999, PALEOCEANOGRAPHY, V14, P118, DOI 10.1029/1998PA900018; STEPHENS B, 1999, EOS, V80, pF79; Takeda S, 1998, NATURE, V393, P774, DOI 10.1038/31674; Toggweiler J.R., 1985, GEOPHYS MONOGR SER, V32, P163, DOI DOI 10.1029/GM032P0163; Toggweiler JR, 1999, PALEOCEANOGRAPHY, V14, P571, DOI 10.1029/1999PA900033; VanderLoeff MR, 1997, GEOCHIM COSMOCHIM AC, V61, P47, DOI 10.1016/S0016-7037(96)00333-X; Yeats PA, 1998, MAR CHEM, V61, P15, DOI 10.1016/S0304-4203(98)00004-8; Zielinski U, 1998, PALEOCEANOGRAPHY, V13, P365, DOI 10.1029/98PA01320	50	180	192	4	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 18	2000	405	6784					305	310		10.1038/35012507	http://dx.doi.org/10.1038/35012507			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830952				2022-12-28	WOS:000087085700036
J	Rapoport, J; Teres, D; Steingrub, J; Higgins, T; McGee, W; Lemeshow, S				Rapoport, J; Teres, D; Steingrub, J; Higgins, T; McGee, W; Lemeshow, S			Patient characteristics and ICU organizational factors that influence. Frequency of pulmonary artery catheterization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	39th Educational and Scientific Symposium of the Society-of-Critical-Care-Medicine	FEB 11-15, 2000	ORLANDO, FLORIDA	Soc Critical Care Med			INTENSIVE-CARE UNIT; RIGHT-HEART CATHETERIZATION; CRITICALLY ILL PATIENTS; RESOURCE UTILIZATION; FULL-TIME; PHYSICIANS; MORTALITY; OUTCOMES; IMPACT; MULTICENTER	Context Hemodynamic monitoring of patients with a pulmonary artery catheter is controversial because there are few data confirming its effectiveness, and patient and intensive care unit (ICU) organizational factors associated with its use are unknown. Objective To determine pulmonary artery catheter use in relationship to type of ICU organization and staffing, and patient characteristics, including severity of illness and insurance coverage. Design, Setting, and Patients Retrospective database study of 10 217 nonoperative patients who received treatment at 34 medical, mixed medical and surgical, and surgical ICUs at 27 hospitals during 1998 (patients were enrolled in Project IMPACT). Main Outcome Measures Pulmonary artery catheter use based on severity of illness measured by the Simplified Acute Physiology Score, resuscitation status at ICU admission, and ICU organizational variables, including type, size, and model. Results A pulmonary artery catheter was used for 831 patients (8.1%) in the ICU. In multivariate analysis adjusted for severity of illness, age, diagnosis, and do-not-resuscitate status, full-time ICU physician staffing was associated with a two-thirds reduction in the probability of catheter use (odds ratio [OR], 0.36; 95% confidence interval [CI], 0.28-0.45). Higher catheter use was associated with white race (OR, 1.38; 95% CI, 1.10-1.72) and private insurance coverage (OR, 1.33; 95% CI, 1.10-1.60). Admission to a surgical ICU was associated with a 2-fold increase in probability of catheter use (OR, 2.17; 95% CI, 1.70-2.76) compared with either medical or mixed medical and surgical ICUs. Conclusion Organizational characteristics of ICUs, insurance reimbursement, and race, as well as clinical variables, are associated with variation in practice patterns regarding pulmonary artery catheter use. Understanding such influences, combined with studies measuring clinical and economic outcomes, can contribute to the development of policies for the rational use of pulmonary artery catheters.	Tufts Univ, Sch Med, Primary Care Outcomes Res Inst, Boston, MA 02111 USA; Mt Holyoke Coll, Dept Econ, S Hadley, MA 01075 USA; Baystate Med Ctr, Ctr Hlth Serv Res, Springfield, MA USA; Baystate Med Ctr, Dept Med, Springfield, MA 01199 USA; Baystate Med Ctr, Dept Surg, Springfield, MA 01107 USA; Baystate Med Ctr, Dept Anesthesia, Springfield, MA USA; Ohio State Univ, Biostat Program, Columbus, OH 43210 USA	Tufts University; Mount Holyoke College; Baystate Medical Center; Baystate Medical Center; Baystate Medical Center; Baystate Medical Center; University System of Ohio; Ohio State University	Rapoport, J (corresponding author), Tufts Univ, Sch Med, Primary Care Outcomes Res Inst, 750 Washington St,POB 345, Boston, MA 02111 USA.		Higgins, Thomas L/I-9438-2019; Higgins, Thomas L/A-8385-2009	Higgins, Thomas L/0000-0002-9958-0767; 				Benjamin E, 1998, J CARDIOTHOR VASC AN, V12, P10, DOI 10.1016/S1053-0770(98)90048-9; BOYD KD, 1983, CHEST, V84, P245, DOI 10.1378/chest.84.3.245; BROWN JJ, 1989, CHEST, V96, P127, DOI 10.1378/chest.96.1.127; Carlson RW, 1996, CRIT CARE CLIN, V12, P525, DOI 10.1016/S0749-0704(05)70260-8; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; Chernow B, 1997, CHEST, V111, P261, DOI 10.1378/chest.111.2.261; CONNORS AF, 1985, CHEST, V88, P567, DOI 10.1378/chest.88.4.567; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Cook SF, 1999, CRIT CARE MED, V27, pA36, DOI 10.1097/00003246-199901001-00034; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; Gnaegi A, 1997, CRIT CARE MED, V25, P213, DOI 10.1097/00003246-199702000-00003; Gordon HS, 1996, MED CARE, V34, P295, DOI 10.1097/00005650-199604000-00002; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; IBERTI TJ, 1985, AM J MED, V78, P451, DOI 10.1016/0002-9343(85)90337-7; IBERTI TJ, 1990, JAMA-J AM MED ASSOC, V264, P2928, DOI 10.1001/jama.264.22.2928; KEARNEY TJ, 1995, CHEST, V108, P1349, DOI 10.1378/chest.108.5.1349; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; Manthous CA, 1997, MAYO CLIN PROC, V72, P391, DOI 10.4065/72.5.391; MIMOZ O, 1994, CRIT CARE MED, V22, P573, DOI 10.1097/00003246-199404000-00011; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; Pollack MM, 1997, CRIT CARE MED, V25, P1637, DOI 10.1097/00003246-199710000-00011; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Randolph AG, 1999, JAMA-J AM MED ASSOC, V281, P1330, DOI 10.1001/jama.281.14.1330; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; SHCULMAN KA, 1999, NEW ENGL J MED, V340, P1130; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1990, ARCH SURG-CHICAGO, V125, P1332; SHORTELL SM, 1991, MED CARE, V29, P709, DOI 10.1097/00005650-199108000-00004; STEINGRUB JS, 1991, CHEST, V99, P1451, DOI 10.1378/chest.99.6.1451; STROSBERG MA, 1990, HEART LUNG, V19, P452; SWAN HJC, 1970, NEW ENGL J MED, V283, P447, DOI 10.1056/NEJM197008272830902; Taylor RW, 1997, CRIT CARE MED, V25, P910; Teres D, 1994, Am J Crit Care, V3, P84; Zhu BP, 1996, CRIT CARE MED, V24, P57, DOI 10.1097/00003246-199601000-00011; Zimmerman J E, 1994, Am J Crit Care, V3, P129; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009; ZION MM, 1990, CHEST, V98, P1331, DOI 10.1378/chest.98.6.1331	45	76	88	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2559	2567		10.1001/jama.283.19.2559	http://dx.doi.org/10.1001/jama.283.19.2559			9	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312VL	10815120	Bronze			2022-12-28	WOS:000086964600037
J	Nanda, K; McCrory, DC; Myers, ER; Bastian, LA; Hasselblad, V; Hickey, JD; Matchar, DB				Nanda, K; McCrory, DC; Myers, ER; Bastian, LA; Hasselblad, V; Hickey, JD; Matchar, DB			Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ATYPICAL SQUAMOUS CELLS; HUMAN PAPILLOMAVIRUS INFECTIONS; PAP TEST ACCURACY; INTRAEPITHELIAL NEOPLASIA; UNDETERMINED SIGNIFICANCE; DIAGNOSTIC-TESTS; REPEAT CYTOLOGY; COST-EFFECTIVENESS; PREDICTIVE VALUE	Purpose: To evaluate the accuracy of conventional and new methods of Papanicolaou (Pap) testing when used to detect cervical cancer and its precursors. Data Sources: Systematic search of English-language literature through October 1999 using MEDLINE, EMBASE, other computerized databases, and hand searching. Study Selection: Ail studies that compared Pap testing (conventional methods, computer screening or rescreening, or monolayer cytology) with a concurrent reference standard (histologic examination, colposcopy, or cytology). Data Extraction: Two reviewers independently reviewed selection criteria and completed 2 x 2 tables for each study. Data Synthesis: 94 studies of the conventional Pap test and three studies of monolayer cytology met inclusion criteria. No studies of computerized screening were included. Data were organized by cytologic and histologic thresholds used to define disease. For conventional Pap tests, estimates of sensitivity and specificity varied greatly in individual studies. Methodologic quality and frequency of histologic abnormalities also varied greatly between studies. In the 12 studies with the least biased estimates, sensitivity ranged from 30% to 87% and specificity ranged from 86% to 100%. Conclusions: Insufficient high-quality data exist to estimate test operating characteristics of new cytologic methods for cervical screening. Future studies of these technologies should apply adequate reference standards. Most studies of the conventional Pap test are severely biased: The best estimates suggest that it is only moderately accurate and does not achieve concurrently high sensitivity and specificity. Cost-effectiveness models of cervical cancer screening should use more conservative estimates of Pap test sensitivity.	Duke Univ, Med Ctr, Ctr Clin Hlth Policy Res, Durham, NC 27705 USA; Durham Vet Affairs Med Ctr, Hlth Serv Res & Dev 152, Durham, NC 27705 USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Nanda, K (corresponding author), Family Hlth Int, Dept Clin Res, POB 13950, Res Triangle Pk, NC 27709 USA.	knanda@fhi.org	Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108; Nanda, Kavita/0000-0001-7650-2929	BHP HRSA HHS [AHRQ 290-97-0014] Funding Source: Medline	BHP HRSA HHS		Abulafia O, 1999, Obstet Gynecol Surv, V54, P469, DOI 10.1097/00006254-199907000-00027; Abulafia O, 1999, Obstet Gynecol Surv, V54, P253, DOI 10.1097/00006254-199904000-00022; ANDREWS S, 1989, OBSTET GYNECOL, V73, P747; [Anonymous], 1993, ACTA CYTOL, V37, P115; BALDAUF JJ, 1995, EUR J OBSTET GYN R B, V58, P33, DOI 10.1016/0028-2243(94)01970-I; BALDAUF JJ, 1995, EUR J OBSTET GYN R B, V62, P31, DOI 10.1016/0301-2115(95)02178-A; Bedrossian C, 1997, ACTA CYTOL, V41, P924; BEEBY AR, 1993, J OBSTET GYNAECOL, V13, P276; BIGRIGG MA, 1990, LANCET, V336, P229, DOI 10.1016/0140-6736(90)91746-W; Bolick DR, 1998, ACTA CYTOL, V42, P209, DOI 10.1159/000331548; Boyko EJ, 1996, AM J EPIDEMIOL, V143, P406; BROWN AD, 1998, COST EFFECTIVENESS 3; Buntinx F, 1996, BMJ-BRIT MED J, V313, P1285; Carta G., 1999, Clinical and Experimental Obstetrics and Gynecology, V26, P60; CECCHINI S, 1993, TUMORI, V79, P22, DOI 10.1177/030089169307900104; Chock C, 1997, J CLIN EPIDEMIOL, V50, P1211, DOI 10.1016/S0895-4356(97)00122-4; CHOMET J, 1987, BRIT MED J, V294, P1326, DOI 10.1136/bmj.294.6583.1326; COIBION M, 1994, BRIT J CANCER, V70, P125, DOI 10.1038/bjc.1994.260; COX JT, 1992, OBSTET GYNECOL, V80, P389; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; Cruickshank ME, 1999, BRIT J OBSTET GYNAEC, V106, P969, DOI 10.1111/j.1471-0528.1999.tb08439.x; DAVIS JR, 1981, ACTA CYTOL, V25, P533; DAVISON JM, 1994, J REPROD MED, V39, P388; DELPRIORE G, 1995, GYNECOL ONCOL, V56, P395, DOI 10.1006/gyno.1995.1069; DIBONITO L, 1993, CANCER-AM CANCER SOC, V72, P3002, DOI 10.1002/1097-0142(19931115)72:10<3002::AID-CNCR2820721023>3.0.CO;2-4; *DUK U, 1999, 5 DUK U AG HLTH CAR; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; Eskridge C, 1998, OBSTET GYNECOL, V92, P351, DOI 10.1016/S0029-7844(98)00199-9; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; Fahim H I, 1991, J Egypt Public Health Assoc, V66, P97; FAHS MC, 1992, ANN INTERN MED, V117, P520, DOI 10.7326/0003-4819-117-6-520; FEINSTEIN AR, 1985, ARCHIRECTURE CLIN RE, P434; Ferenczy A, 1996, ACTA CYTOL, V40, P1136; Ferris DG, 1998, J FAM PRACTICE, V46, P125; *FOOD DRUG AD, 1994, POINTS CONS CERV CYT; FRISCH LE, 1994, J FAM PRACTICE, V39, P457; Fung MFK, 1997, GYNECOL ONCOL, V66, P10, DOI 10.1006/gyno.1997.4724; Gaffikin L, 1999, LANCET, V353, P869; GARUTTI P, 1994, CERVIX LOWER FEMALE, V12, P31; GERMAIN M, 1994, OBSTET GYNECOL, V84, P168; GIARD RWM, 1993, CYTOPATHOLOGY, V4, P131, DOI 10.1111/j.1365-2303.1993.tb00078.x; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1067, DOI 10.1111/j.1471-0528.1989.tb03382.x; Giraud J, 1998, EUR J OBSTET GYN R B, V81, P51, DOI 10.1016/S0301-2115(98)00146-8; GLENTHOJ A, 1988, NEW FRONTIERS CYTOLO, P421; Gonzalez D, 1996, J REPROD MED, V41, P719; Guerra B, 1998, J REPROD MED, V43, P647; GUNDERSEN JH, 1988, J REPROD MED, V33, P46; HADDAD NG, 1988, BRIT MED J, V297, P1128, DOI 10.1136/bmj.297.6656.1128-a; HELLBERG D, 1987, ACTA OBSTET GYN SCAN, V66, P195, DOI 10.3109/00016348709020746; HERRINGTON CS, 1995, BRIT J CANCER, V71, P206, DOI 10.1038/bjc.1995.42; Hockstad R L, 1992, Fam Pract Res J, V12, P53; Hutchinson ML, 1999, CANCER CYTOPATHOL, V87, P48, DOI 10.1002/(SICI)1097-0142(19990425)87:2&lt;48::AID-CNCR2&gt;3.0.CO;2-D; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JOHANSEN P, 1979, ACTA OBSTET GYN SCAN, V58, P265, DOI 10.3109/00016347909154046; Jones BA, 1996, ARCH PATHOL LAB MED, V120, P523; JONES DED, 1987, AM J OBSTET GYNECOL, V157, P544; JONES MH, 1992, LANCET, V339, P1440, DOI 10.1016/0140-6736(92)92031-A; JOSEPH L, 1995, AM J EPIDEMIOL, V141, P263, DOI 10.1093/oxfordjournals.aje.a117428; Kaufman RH, 1997, AM J OBSTET GYNECOL, V177, P930, DOI 10.1016/S0002-9378(97)70296-5; KEALY WF, 1986, IRISH J MED SCI, V155, P381, DOI 10.1007/BF02940533; KESIC VI, 1993, INT J GYNECOL CANCER, V3, P395, DOI 10.1046/j.1525-1438.1993.03060395.x; KOONINGS PP, 1992, OBSTET GYNECOL, V80, P241; KORACH J, 1995, ISRAEL J MED SCI, V31, P352; KORN AP, 1994, OBSTET GYNECOL, V83, P401; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; KWIKKEL HJ, 1986, EUR J OBSTET GYN R B, V21, P101, DOI 10.1016/0028-2243(86)90048-1; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEDERER H, 1973, J OBSTET GYN BR COMM, V80, P67; Loiudice L, 1998, EUR J CANCER PREV, V7, P295, DOI 10.1097/00008469-199808000-00005; Londhe M., 1997, Indian Journal of Cancer, V34, P88; LOZOWSKI MS, 1982, ACTA CYTOL, V26, P285; MAGGI R, 1989, GYNECOL ONCOL, V35, P294, DOI 10.1016/0090-8258(89)90066-8; Maiman M, 1998, GYNECOL ONCOL, V68, P233, DOI 10.1006/gyno.1998.4938; MANN W, 1993, INT J GYNECOL OBSTET, V43, P289, DOI 10.1016/0020-7292(93)90518-2; Mannino J. Robert, 1998, Journal of the American Osteopathic Association, V98, P542; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; MAYEAUX EJ, 1995, J FAM PRACTICE, V40, P57; Miller WC, 1998, J CLIN EPIDEMIOL, V51, P219, DOI 10.1016/S0895-4356(97)00264-3; MORRISON BW, 1988, J REPROD MED, V33, P809; MORRISON EAB, 1992, AM J OBSTET GYNECOL, V167, P104, DOI 10.1016/S0002-9378(11)91637-8; NASLUND I, 1986, ACTA ONCOL, V25, P131; NYIRJESY I, 1972, J AMER MED ASSOC, V222, P691; OKAGAKI T, 1991, ACTA CYTOL, V35, P25; OYER R, 1986, GYNECOL ONCOL, V25, P204, DOI 10.1016/0090-8258(86)90100-9; PANG JCK, 1977, GYNECOL ONCOL, V5, P134, DOI 10.1016/0090-8258(77)90017-8; PARHAM DM, 1991, CYTOPATHOLOGY, V2, P285, DOI 10.1111/j.1365-2303.1991.tb00502.x; PARKER A, 1986, NEW ZEAL MED J, V99, P414; PHELPS CE, 1995, MED DECIS MAKING, V15, P44, DOI 10.1177/0272989X9501500108; RAMIREZ EJ, 1990, J REPROD MED, V35, P359; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; RASBRIDGE SA, 1995, ACTA CYTOL, V39, P648; REAGAN JW, 1979, INT J RADIAT ONCOL, V5, P1015, DOI 10.1016/0360-3016(79)90611-4; Recio FO, 1998, EUR J GYNAECOL ONCOL, V19, P203; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Richart R M, 1973, Pathol Annu, V8, P301; RITTER DB, 1988, AM J OBSTET GYNECOL, V159, P1517, DOI 10.1016/0002-9378(88)90587-X; Roberts JM, 1997, MED J AUSTRALIA, V167, P466, DOI 10.5694/j.1326-5377.1997.tb126672.x; Ronco G, 1996, CYTOPATHOLOGY, V7, P151, DOI 10.1046/j.1365-2303.1996.39382393.x; Sankaranarayanan R, 1998, CANCER-AM CANCER SOC, V83, P2150, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2150::AID-CNCR13>3.3.CO;2-S; SCHULZER M, 1991, J CLIN EPIDEMIOL, V44, P1167, DOI 10.1016/0895-4356(91)90149-4; SHEETS EE, 1995, J GYNECOL TECH, V1, P27; Shulman L P, 1999, J Pediatr Adolesc Gynecol, V12, P78, DOI 10.1016/S1083-3188(00)86631-0; SINGH P, 1985, SMJ Singapore Medical Journal, V26, P289; SKEHAN M, 1990, BRIT J OBSTET GYNAEC, V97, P811, DOI 10.1111/j.1471-0528.1990.tb02575.x; SLAWSON DC, 1994, J FAM PRACTICE, V38, P387; SMITH JJ, 1987, GYNECOL ONCOL, V28, P241, DOI 10.1016/0090-8258(87)90169-7; SOOST HJ, 1991, ACTA CYTOL, V35, P8; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; Spinillo A, 1998, GYNECOL ONCOL, V69, P109, DOI 10.1006/gyno.1998.4985; SPITZER M, 1987, OBSTET GYNECOL, V69, P731; STAFL A, 1981, AM J OBSTET GYNECOL, V139, P815, DOI 10.1016/0002-9378(81)90549-4; SYRJANEN KJ, 1987, ACTA CYTOL, V31, P855; TAIT IA, 1988, GENITOURIN MED, V64, P255; TAWA K, 1988, OBSTET GYNECOL, V71, P229; TAY SK, 1987, AUST NZ J OBSTET GYN, V27, P140; UPADHYAY SN, 1984, INDIAN J MED RES, V80, P457; WALKER EM, 1986, LANCET, V2, P672; WETRICH DW, 1986, AM J OBSTET GYNECOL, V154, P1339, DOI 10.1016/0002-9378(86)90722-2; WHEELOCK JB, 1989, J REPROD MED, V34, P815; WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591; WRIGHT TC, 1995, OBSTET GYNECOL, V85, P202, DOI 10.1016/0029-7844(94)00373-L; YOUNG NA, 1993, DIAGN CYTOPATHOL, V9, P646, DOI 10.1002/dc.2840090608; 1998, ACTA CYTOL, V42, P273	124	757	836	1	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2000	132	10					810	819		10.7326/0003-4819-132-10-200005160-00009	http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313XN	10819705				2022-12-28	WOS:000087025100007
J	Bull, ID; Parekh, NR; Hall, GH; Ineson, P; Evershed, RP				Bull, ID; Parekh, NR; Hall, GH; Ineson, P; Evershed, RP			Detection and classification of atmospheric methane oxidizing bacteria in soil	NATURE			English	Article							FATTY-ACIDS; CH4; GAS; MICROORGANISMS; OXIDATION; SEDIMENTS	Well-drained non-agricultural soils mediate the oxidation of methane directly from the atmosphere, contributing 5 to 10% towards the global methane sink(1,2). Studies of methane oxidation kinetics in soil infer the activity of two methanotrophic populations: one that is only active at high methane concentrations (low affinity) and another that tolerates atmospheric levels of methane (high affinity). The activity of the latter has not been demonstrated by cultured laboratory strains of methanotrophs, leaving the microbiology of methane oxidation at atmospheric concentrations unclear(3,4). Here we describe a new pulse-chase experiment using long-term enrichment with (CH4)-C-12 followed by shortterm exposure to (CH4)-C-13 to isotopically label methanotrophs in a soil from a temperate forest. Analysis of labelled phospholipid fatty acids (PLFAs) provided unambiguous evidence of methane assimilation at true atmospheric concentrations (1.8-3.6 p.p.m.v.). High proportions of C-13-labelled C-18 fatty acids and the co-occurrence of a labelled, branched C-17 fatty acid indicated that a new methanotroph, similar at the PLFA level to known type II methanotrophs, was the predominant soil micro-organism responsible for atmospheric methane oxidation.	Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England; Inst Terr Ecol, Merlewood Res Stn, Grange Sands LA11 6JU, Cumbria, England; Inst Freshwater Ecol, Ambleside LA22 0LP, Cumbria, England; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of Bristol; UK Centre for Ecology & Hydrology (UKCEH); UK Centre for Ecology & Hydrology (UKCEH); University of York - UK	Evershed, RP (corresponding author), Univ Bristol, Sch Chem, Cantocks Close, Bristol BS8 1TS, Avon, England.		Bull, Ian/AAV-1474-2020; Bull, Ian/G-7816-2012	Bull, Ian/0000-0002-5881-5654; 				Bender M, 1995, SOIL BIOL BIOCHEM, V27, P1517, DOI 10.1016/0038-0717(95)00104-M; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boschker HTS, 1998, NATURE, V392, P801, DOI 10.1038/33900; BOWMAN JP, 1991, FEMS MICROBIOL ECOL, V85, P15, DOI 10.1016/0378-1097(91)90627-M; Cicerone RJ, 1988, GLOBAL BIOGEOCHEM CY, V2, P299, DOI 10.1029/GB002i004p00299; Conrad R, 1996, MICROBIOL REV, V60, P609, DOI 10.1128/MMBR.60.4.609-640.1996; CRUTZEN PJ, 1991, NATURE, V350, P380, DOI 10.1038/350380a0; Dunfield PF, 1999, APPL ENVIRON MICROB, V65, P1009; GUCKERT JB, 1985, FEMS MICROBIOL ECOL, V31, P147, DOI 10.1111/j.1574-6968.1985.tb01143.x; GUCKERT JB, 1991, J GEN MICROBIOL, V137, P2631, DOI 10.1099/00221287-137-11-2631; Hall GH, 1996, SOIL BIOL BIOCHEM, V28, P9, DOI 10.1016/0038-0717(95)00122-0; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; Hinrichs KU, 1999, NATURE, V398, P802, DOI 10.1038/19751; JONES DM, 1991, BIOL MASS SPECTROM, V20, P641, DOI 10.1002/bms.1200201009; NICHOLS PD, 1987, ENVIRON TOXICOL CHEM, V6, P89, DOI [10.1897/1552-8618(1987)6[89:DOAMCI]2.0.CO;2, 10.1002/etc.5620060203]; NICHOLS PD, 1985, FEMS MICROBIOL ECOL, V31, P327, DOI 10.1016/0378-1097(85)90028-X; RIELEY G, 1994, ANALYST, V119, P915, DOI 10.1039/an9941900915; Roslev P, 1999, APPL ENVIRON MICROB, V65, P4064; ZELLES L, 1995, BIOL FERT SOILS, V19, P115, DOI 10.1007/BF00336146	19	181	200	9	113	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					175	178		10.1038/35012061	http://dx.doi.org/10.1038/35012061			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821271				2022-12-28	WOS:000087080100048
J	Cohen, P				Cohen, P			How to make diplomats scientifically literate	NATURE			English	Letter									Univ Michigan, Herbarium, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Cohen, P (corresponding author), Univ Michigan, Herbarium, Ann Arbor, MI 48109 USA.							ALBRIGHT M, 2000, NATURE, V404, P1	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					116	116		10.1038/35012167	http://dx.doi.org/10.1038/35012167			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821249	Bronze, Green Published			2022-12-28	WOS:000087080100020
J	Davis, JB; Gray, J; Gunthorpe, MJ; Hatcher, JP; Davey, PT; Overend, P; Harries, MH; Latcham, J; Clapham, C; Atkinson, K; Hughes, SA; Rance, K; Grau, E; Harper, AJ; Pugh, PL; Rogers, DC; Bingham, S; Randall, A; Sheardown, SA				Davis, JB; Gray, J; Gunthorpe, MJ; Hatcher, JP; Davey, PT; Overend, P; Harries, MH; Latcham, J; Clapham, C; Atkinson, K; Hughes, SA; Rance, K; Grau, E; Harper, AJ; Pugh, PL; Rogers, DC; Bingham, S; Randall, A; Sheardown, SA			Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia	NATURE			English	Article							ROOT GANGLION NEURONS; CAPSAICIN-RECEPTOR; RAT; HEAT; CAPSAZEPINE; ANTAGONIST; RESPONSES; PHENOTYPE; SHIRPA; CELLS	The vanilloid receptor-1 (VR1) is a ligand-gated, non-selective cation channel expressed predominantly by sensory neurons. VR1 responds to noxious stimuli including capsaicin, the pungent component of chilli peppers, heat and extracellular acidification, and it is able to integrate simultaneous exposure to these stimuli(1,2). These findings and research linking capsaicin with nociceptive behaviours (that is, responses to painful stimuli in animals(3) have led to VR1 being considered as important for pain sensation. Here we have disrupted the mouse VR1 gene using standard gene targeting techniques. Small diameter dorsal root ganglion neurons isolated from VR1-null mice lacked many of the capsaicin-, acid- and heat-gated responses that have been previously well characterized in small diameter dorsal root ganglion neurons from various species. Furthermore, although the VR1-null mice appeared normal in a wide range of behavioural tests, including responses to acute noxious thermal stimuli, their ability to develop carrageenan-induced thermal hyperalgesia was completely absent. We conclude that VR1 is required for inflammatory sensitization to noxious thermal stimuli but also that alternative mechanisms are sufficient for normal sensation of noxious heat.	SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Stat Sci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Lab Anim Sci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Biotechnol & Genet, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Davis, JB (corresponding author), SmithKline Beecham Pharmaceut, Dept Neurosci Res, 3rd Ave, Harlow CM19 5AW, Essex, England.			Randall, Andrew/0000-0001-8852-3671				BEVAN S, 1995, J NEUROSCI, V15, P4918; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Kwak JY, 1998, NEUROSCIENCE, V86, P619, DOI 10.1016/S0306-4522(98)00012-8; MILIKEN GA, 1992, ANAL MESSY DATA, P29; Nagy I, 1999, J NEUROSCI, V19, P10647, DOI 10.1523/JNEUROSCI.19-24-10647.1999; NAGY JI, 1983, J NEUROSCI, V3, P1145; Rogers DC, 1999, BEHAV BRAIN RES, V105, P207, DOI 10.1016/S0166-4328(99)00072-8; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Sasamura T, 1998, NEUROREPORT, V9, P2045, DOI 10.1097/00001756-199806220-00025; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Torres RM, 1997, LAB PROTOCOLS CONDIT; Ueno S, 1999, BRIT J PHARMACOL, V126, P429, DOI 10.1038/sj.bjp.0702319; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; WOOD JN, 1988, J NEUROSCI, V8, P3208; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	23	1338	1425	0	81	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					183	187		10.1038/35012076	http://dx.doi.org/10.1038/35012076			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821274				2022-12-28	WOS:000087080100051
J	Marples, D				Marples, D			Water channels: who needs them anyway?	LANCET			English	Editorial Material									Univ Leeds, Sch Biomed Sci, Leeds LS2 9NQ, W Yorkshire, England	University of Leeds	Marples, D (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9NQ, W Yorkshire, England.							DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marples D, 1999, AM J PHYSIOL-RENAL, V276, pF331, DOI 10.1152/ajprenal.1999.276.3.F331; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; Verkman AS, 2000, EXP PHYSIOL, V85, p233S, DOI 10.1111/j.1469-445X.2000.tb00028.x	9	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 6	2000	355	9215					1571	1572		10.1016/S0140-6736(00)02209-1	http://dx.doi.org/10.1016/S0140-6736(00)02209-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821357				2022-12-28	WOS:000086981200004
J	Ades, AE; Parker, S; Walker, J; Edginton, M; Taylor, GP; Weber, JN				Ades, AE; Parker, S; Walker, J; Edginton, M; Taylor, GP; Weber, JN			Human T cell leukaemia/lymphoma virus infection in pregnant women in the United Kingdom: population study	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS ANALYSIS; LEUKEMIA-LYMPHOMA VIRUS; HTLV-I INFECTION; BLOOD-DONORS; PREVALENCE; ANTIBODIES; SEROPREVALENCE; TRANSMISSION; LONDON; SWEDEN	Objective To assess the prevalence of human T cell leukaemia /lymphoma virus (HTLV) infection in pregnant women in the United Kingdom. Design Population study. Subjects Guthrie card samples from babies born in 1997-8. Samples were linked to data on mother's age and ethnic status and parents' country of birth and then anonymised. Setting North Thames Regional Health Authority Main outcome measures Presence of antibodies against HTLV in eluates tested by gelatin particle agglutination assay and results confirmed by immunoblot Results Of 126 010 samples tested, 67 had confirmed antibodies to HTLV (59 HTLV-I, 2 HTLV-II, 6 untyped) and six had indeterminate results. Seroprevalence was 17.0 per 1000 (95% confidence interval 9.2 to 28.3) in infants whose mothers were born in the Caribbean, 3.2/1000 (1.5 to 5.9) with mothers born in west and central Africa, and 6.8/1000 (3.1 to 12.9) in infants of black Caribbean mothers born in non-endemic regions. In infants with no known risk (both parents born in non-endemic regions and mother not black Caribbean) seroprevalence was 0.06-0.12 per 1000. Mother's country of birth, father's country of birth, and mother's ethnic status were all independently associated with neonatal seroprevalence. An estimated 223 (95% confidence interval 110 to 350) of the 720 000 pregnant women each year in the United Kingdom are infected with HTLV. Conclusions The prevalence of HTLV and HIV infections in pregnant women in the United Kingdom are comparable. The cost effectiveness of antenatal HTLV screening should be evaluated, and screening of blood donations should be considered.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; Great Ormond St Hosp Children NHS Trust, Dept Virol, London WC1N 3JH, England; Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Dept Genitourinary Med & Communicable Dis, London W2 1PG, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Imperial College London	Ades, AE (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.							Ades AE, 1999, AIDS, V13, P2437, DOI 10.1097/00002030-199912030-00016; Ades AE, 1999, BRIT MED J, V319, P1230, DOI 10.1136/bmj.319.7219.1230; Andersson S, 1999, TRANSFUSION, V39, P845, DOI 10.1046/j.1537-2995.1999.39080845.x; BANATVALA JE, 1990, LANCET, V335, P860; BHIGJEE AI, 1993, S AFR MED J, V83, P665; BRENNAN M, 1993, BRIT MED J, V307, P1235, DOI 10.1136/bmj.307.6914.1235; *DEP HLTH, 1999, PREV HIV ENGL WAL 19; Donati M, 2000, BMJ-BRIT MED J, V320, P92, DOI 10.1136/bmj.320.7227.92; DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x; FLANAGAN P, 1995, VOX SANG, V68, P220, DOI 10.1111/j.1423-0410.1995.tb02576.x; Foster K, 1997, INFANT FEEDING 1995; Gessain A, 1996, J ACQ IMMUN DEF SYND, V13, pS132, DOI 10.1097/00042560-199600001-00022; Goubau P, 1996, J ACQ IMMUN DEF SYND, V13, P68; Hale A, 1997, J MED VIROL, V52, P326, DOI 10.1002/(SICI)1096-9071(199707)52:3&lt;326::AID-JMV15&gt;3.0.CO;2-G; Hall WW, 1996, J ACQ IMMUN DEF SYND, V13, pS204, DOI 10.1097/00042560-199600001-00031; Hanchard B, 1996, J ACQ IMMUN DEF SYND, V13, pS20, DOI 10.1097/00042560-199600001-00005; Hino S, 1996, J ACQ IMMUN DEF SYND, V13, pS199, DOI 10.1097/00042560-199600001-00030; *INT AG RES CANC, 1996, MON EV CARC RISK HUM, V67; Kaplan JE, 1996, J ACQ IMMUN DEF SYND, V12, P193, DOI 10.1097/00042560-199606010-00014; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002/rmv.1980030304; KATAMINE S, 1999, J ACQ IMMUN DEF SYND, V20, pA23; LEE H, 1989, SCIENCE, V244, P472; MATHESON J, 1999, SOCIAL TRENDS, V29; MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114, DOI 10.1093/oxfordjournals.aje.a115824; NIGHTINGALE S, 1993, EPIDEMIOL INFECT, V110, P379, DOI 10.1017/S0950268800068321; *OFF NAT STAT, 1998, BIRTH STAT FM1, V25; *OFF NAT STAT, 1998, KEY POP VIT STA VS22, V18; OPCS/GRO(S), 1993, 1991 CENS ETHN GROUP; Otigbah C, 1997, BRIT J OBSTET GYNAEC, V104, P258, DOI 10.1111/j.1471-0528.1997.tb11057.x; OWEN D, 1996, ETHNICITY 1991 CENSU, V2; Parker SP, 1997, J VIROL METHODS, V68, P199, DOI 10.1016/S0166-0934(97)00127-4; PARKER SP, 1995, J CLIN PATHOL, V45, P904; Plancoulaine S, 1998, INT J CANCER, V76, P331, DOI 10.1002/(SICI)1097-0215(19980504)76:3&lt;331::AID-IJC8&gt;3.0.CO;2-W; Takezaki Toshiro, 1997, Leukemia (Basingstoke), V11, P60; Taylor GP, 1996, J ACQ IMMUN DEF SYND, V13, pS8, DOI 10.1097/00042560-199600001-00003; TAYLOR GP, 1998, VIRUSES HUMNAN CANC, P109; Tosswill JHC, 2000, BRIT MED J, V320, P611, DOI 10.1136/bmj.320.7235.611; TOSSWILL JHC, 1990, BRIT MED J, V301, P95, DOI 10.1136/bmj.301.6743.95; Tynell E, 1998, BRIT MED J, V316, P1417, DOI 10.1136/bmj.316.7142.1417; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; WEBER JN, 1996, BRIT MED J, V312, P702; WIKTOR SZ, 1997, J HUMAN VIROL, V1, P38; Yamashita M, 1996, J ACQ IMMUN DEF SYND, V13, pS124, DOI 10.1097/00042560-199600001-00021; 1999, COMM DIS REP, V9, P340	44	34	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1497	1501		10.1136/bmj.320.7248.1497	http://dx.doi.org/10.1136/bmj.320.7248.1497			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834889	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000087471000019
J	Adzick, NS; Nance, ML				Adzick, NS; Nance, ML			Pediatric surgery - part 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONGENITAL DIAPHRAGMATIC-HERNIA; MESSENGER-RNA EXPRESSION; NITRIC-OXIDE SYNTHASE; HIRSCHSPRUNGS-DISEASE; NECROTIZING ENTEROCOLITIS; ESOPHAGEAL ATRESIA; LIQUID VENTILATION; BIRTH-WEIGHT; INFANTS; HYPERINSULINISM		Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania	Adzick, NS (corresponding author), Childrens Hosp Philadelphia, Dept Surg, 34th St & Civ Ctr, Philadelphia, PA 19104 USA.							Adzick NS, 1999, J PEDIATR SURG, V34, P133, DOI 10.1016/S0022-3468(99)90243-9; Albanese CT, 1999, J PEDIATR SURG, V34, P834, DOI 10.1016/S0022-3468(99)90382-2; Azarow KS, 1997, PEDIATR SURG INT, V12, P137, DOI 10.1007/BF01349981; Azizkhan, 1997, GENEALOGY N AM PEDIA; BEALER JF, 1994, PEDIATRICS, V93, P647; Bullard KM, 1996, PEDIATR PULM, V22, P129, DOI 10.1002/(SICI)1099-0496(199608)22:2<129::AID-PPUL9>3.0.CO;2-L; Burke RP, 1999, PEDIATRICS, V104, P227, DOI 10.1542/peds.104.2.227; Choudhury SR, 1999, J PEDIATR SURG, V34, P70, DOI 10.1016/S0022-3468(99)90231-2; Clark RH, 1998, J PEDIATR SURG, V33, P1004, DOI 10.1016/S0022-3468(98)90522-X; Coran AG, 1999, ANN SURG, V230, P331, DOI 10.1097/00000658-199909000-00006; de Lonlay-Debeney P, 1999, NEW ENGL J MED, V340, P1169, DOI 10.1056/NEJM199904153401505; DEVRIES PA, 1982, J PEDIATR SURG, V17, P638, DOI 10.1016/S0022-3468(82)80126-7; Finer N, 1997, PEDIATRICS, V99, P838; Fortuna RS, 1996, ARCH SURG-CHICAGO, V131, P520; Georgeson KE, 1999, ANN SURG, V229, P678, DOI 10.1097/00000658-199905000-00010; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; Gross RE, 1939, J AMER MED ASSOC, V112, P729, DOI 10.1001/jama.1939.02800080049011; HENDREN WH, 1988, NEW ENGL J MED, V319, P86, DOI 10.1056/NEJM198807143190205; HENDREN WH, 1973, NEW ENGL J MED, V289, P507, DOI 10.1056/NEJM197309062891005; HENDREN WH, 1973, NEW ENGL J MED, V289, P456, DOI 10.1056/NEJM197308302890905; HENDREN WH, 1973, NEW ENGL J MED, V289, P562, DOI 10.1056/NEJM197309132891106; HENDREN WH, 1994, ARCH SURG-CHICAGO, V129, P345; HENDREN WH, 1988, NEW ENGL J MED, V319, P1732; HIRSCHL RB, 1995, ANN SURG, V221, P79, DOI 10.1097/00000658-199501000-00010; HORWITZ JR, 1995, J PEDIATR SURG, V30, P994, DOI 10.1016/0022-3468(95)90328-3; Jesudason EC, 2000, J PEDIATR SURG, V35, P124, DOI 10.1016/S0022-3468(00)80028-7; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Kays DW, 1999, ANN SURG, V230, P340, DOI 10.1097/00000658-199909000-00007; Koop CE, 1999, J PEDIATR SURG, V34, P38, DOI 10.1016/S0022-3468(99)90829-1; Kusafuka T, 1997, J PEDIATR SURG, V32, P1054, DOI 10.1016/S0022-3468(97)90398-5; Levitt MA, 1997, J PEDIATR SURG, V32, P462, DOI 10.1016/S0022-3468(97)90607-2; LOTZE A, 1994, J PEDIATR SURG, V29, P407, DOI 10.1016/0022-3468(94)90580-0; Lovvorn HN, 1999, J PEDIATR SURG, V34, P786, DOI 10.1016/S0022-3468(99)90374-3; LUND DP, 1994, J PEDIATR SURG, V29, P258, DOI 10.1016/0022-3468(94)90329-8; Merry CM, 1999, J PEDIATR SURG, V34, P178, DOI 10.1016/S0022-3468(99)90252-X; Miltenburg DW, 1998, J PEDIATR SURG, V33, P874, DOI 10.1016/S0022-3468(98)90664-9; Neu J, 1996, PEDIATR CLIN N AM, V43, P409, DOI 10.1016/S0031-3955(05)70413-2; Nuss D, 1998, J PEDIATR SURG, V33, P545, DOI 10.1016/S0022-3468(98)90314-1; ONEILL JA, 1995, J PEDIATR SURG, V30, P204, DOI 10.1016/0022-3468(95)90561-8; Oue T, 1999, J PEDIATR SURG, V34, P1257, DOI 10.1016/S0022-3468(99)90163-X; Pena A, 1995, Semin Pediatr Surg, V4, P35; Pranikoff T, 1996, J PEDIATR SURG, V31, P613, DOI 10.1016/S0022-3468(96)90659-4; Rescorla F J, 1998, Semin Pediatr Surg, V7, P207; RICH MA, 1988, PEDIATR SURG INT, V3, P110; Robertson K, 1997, GUT, V41, P436, DOI 10.1136/gut.41.4.436; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Rothenberg SS, 1998, J PEDIATR SURG, V33, P274, DOI 10.1016/S0022-3468(98)90446-8; Rothenberg SS, 1997, SURG ENDOSC-ULTRAS, V11, P93, DOI 10.1007/s004649900304; Sancandi M, 2000, J PEDIATR SURG, V35, P139, DOI 10.1016/S0022-3468(00)80094-9; Shew SB, 1999, J PEDIATR SURG, V34, P720; Spitz L, 1996, J PEDIATR SURG, V31, P19, DOI 10.1016/S0022-3468(96)90313-9; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; WUNG JT, 1995, J PEDIATR SURG, V30, P406, DOI 10.1016/0022-3468(95)90042-X	54	26	29	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2000	342	22					1651	1657		10.1056/NEJM200006013422207	http://dx.doi.org/10.1056/NEJM200006013422207			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319CE	10833212				2022-12-28	WOS:000087321600007
J	Mullon, J; Giacoppe, G; Clagett, C; McCune, D; Dillard, T				Mullon, J; Giacoppe, G; Clagett, C; McCune, D; Dillard, T			Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OXYGEN CARRIER; BLOOD SUBSTITUTES; TRANSPORT		Madigan Army Med Ctr, Dept Med, Tacoma, WA 98431 USA; Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA	Madigan Army Medical Center; Uniformed Services University of the Health Sciences - USA	Mullon, J (corresponding author), Madigan Army Med Ctr, Dept Med, Tacoma, WA 98431 USA.							Bone HG, 1998, J APPL PHYSIOL, V84, P1991, DOI 10.1152/jappl.1998.84.6.1991; BUNN HF, 1971, SCIENCE, V172, P1049, DOI 10.1126/science.172.3987.1049; Callas DD, 1997, CLIN CHEM, V43, P1744; Gonzalez P, 1997, J INVEST MED, V45, P258; GRIFFITHS E, 1995, LANCET, V345, P158, DOI 10.1016/S0140-6736(95)90168-X; HUGHES GS, 1995, J LAB CLIN MED, V126, P444; Hughes GS, 1996, CRIT CARE MED, V24, P756; Kasper SM, 1998, ANESTH ANALG, V87, P284, DOI 10.1097/00000539-199808000-00009; KAYE D, 1963, J IMMUNOL, V91, P65; LITWIN MS, 1963, ANN SURG, V157, P485, DOI 10.1097/00000658-196304000-00001; Ma ZM, 1997, CLIN CHEM, V43, P1732; MUDD S, 1942, BLOOD SUBSTITUTES BL, P156; OGDEN JE, 1995, VOX SANG, V69, P302, DOI 10.1111/j.1423-0410.1995.tb00365.x; Rapoport S, 1941, J BIOL CHEM, V138, P269; Scott MG, 1997, CLIN CHEM, V43, P1724; TEICHER BA, 1993, J CANCER RES CLIN, V120, P85, DOI 10.1007/BF01200729; VLAHAKES GJ, 1990, J THORAC CARDIOV SUR, V100, P379	17	78	80	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2000	342	22					1638	1643		10.1056/NEJM200006013422204	http://dx.doi.org/10.1056/NEJM200006013422204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319CE	10836875				2022-12-28	WOS:000087321600004
J	Lucking, CB; Durr, A; Bonifati, V; Vaughan, J; De Michele, G; Gasser, T; Harhangi, BS; Meco, G; Denefle, P; Wood, NW; Agid, Y; Brice, A				Lucking, CB; Durr, A; Bonifati, V; Vaughan, J; De Michele, G; Gasser, T; Harhangi, BS; Meco, G; Denefle, P; Wood, NW; Agid, Y; Brice, A		European Consortium Genetic Suscep; French Parkinsons Dis Genetics Stu	Association between early-onset Parkinson's disease and mutations in the parkin gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECESSIVE JUVENILE PARKINSONISM; HOMOZYGOUS DELETIONS; JAPANESE FAMILIES; EUROPE	Background: Mutations in the parkin gene have recently been identified in patients with early-onset Parkinson's disease, but the frequency of the mutations and the associated phenotype have not been assessed in a large series of patients. Methods: We studied 73 families in which at least one of the affected family members was affected at or before the age of 45 years and had parents who were not affected, as well as 100 patients with isolated Parkinson's disease that began at or before the age of 45 years. All subjects were screened for mutations in the parkin gene with use of a semiquantitative polymerase-chain-reaction assay that simultaneously amplified several exons. We sequenced the coding exons in a subgroup of patients. We also compared the clinical features of patients with parkin mutations and those without mutations. Results: Among the families with early-onset Parkinson's disease, 36 (49 percent) had parkin mutations. The age at onset ranged from 7 to 58 years. Among the patients with isolated Parkinson's disease, mutations were detected in 10 of 13 patients (77 percent) with an age at onset of 20 years or younger, but in only 2 of 64 patients (3 percent) with an age at onset of more than 30 years. The mean (+/-SD) age at onset in the patients with parkin mutations was younger than that in those without mutations (32+/-11 vs. 42+/-11 years, P<0.001), and they were more likely to have symmetric involvement and dystonia at onset, to have hyperreflexia at onset or later, to have a good response to levodopa therapy, and to have levodopa-induced dyskinesias during treatment. Nineteen different rearrangements of exons (deletions and multiplications) and 16 different point mutations were detected. Conclusions: Mutations in the parkin gene are a major cause of early-onset autosomal recessive familial Parkinson's disease and isolated juvenile-onset Parkinson's disease (at or before the age of 20 years). Accurate diagnosis of these cases cannot be based only on the clinical manifestations of the disease. (N Engl J Med 2000;342:1560-7.) (C) 2000, Massachusetts Medical Society.	Hop La Pitie Salpetriere, INSERM, U289, F-75651 Paris 13, France; Univ La Sapienza, Dipartimento Sci Neurol, Rome, Italy; Inst Neurol, London WC1N 3BG, England; Univ Naples Federico II, Dipartimento Sci Neurol, Naples, Italy; Univ Munich, Klinikum Grosshadern, Neurol Klin, D-8000 Munich, Germany; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Aventis Pharma France, Evry Genom Ctr, Evry, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Sapienza University Rome; University of London; University College London; University of Naples Federico II; University of Munich; Erasmus University Rotterdam; Sanofi-Aventis; Sanofi France	Brice, A (corresponding author), Hop La Pitie Salpetriere, INSERM, U289, 47 Blvd Hop, F-75651 Paris 13, France.		Breteler, Monique M.B./J-5058-2014; brice, alexis/AAE-8275-2019; Harhangi, Biswadjiet/P-7866-2018; Brice, Alexis/A-2170-2009; Wood, Nicholas W/C-2505-2009; Gasser, Thomas/GNH-5293-2022	Breteler, Monique M.B./0000-0002-0626-9305; brice, alexis/0000-0002-0941-3990; Wood, Nicholas W/0000-0002-9500-3348; Gasser, Thomas/0000-0002-1069-1146				Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; deRijk MC, 1997, J NEUROL NEUROSUR PS, V62, P10, DOI 10.1136/jnnp.62.1.10; Fahn S., 1987, RECENT DEV PARKINSON, VVol. 2, P153; Farrer M, 1999, HUM MOL GENET, V8, P81, DOI 10.1093/hmg/8.1.81; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; Gu WJ, 2000, J NEUROCHEM, V74, P1773, DOI 10.1046/j.1471-4159.2000.0741773.x; Hattori N, 1998, BIOCHEM BIOPH RES CO, V251, P666, DOI 10.1006/bbrc.1998.9504; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hattori N, 1998, BIOCHEM BIOPH RES CO, V249, P754, DOI 10.1006/bbrc.1998.9134; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Ishikawa A, 1996, NEUROLOGY, V47, P160, DOI 10.1212/WNL.47.1.160; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Leroy E, 1998, HUM GENET, V103, P424, DOI 10.1007/s004390050845; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lucking CB, 1998, LANCET, V352, P1355, DOI 10.1016/S0140-6736(05)60746-5; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Mori H, 1998, NEUROLOGY, V51, P890, DOI 10.1212/WNL.51.3.890; Piccini P, 1999, ANN NEUROL, V45, P577, DOI 10.1002/1531-8249(199905)45:5<577::AID-ANA5>3.0.CO;2-O; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; TAKAHASHI H, 1994, NEUROLOGY, V44, P437, DOI 10.1212/WNL.44.3_Part_1.437; Wood N, 1997, J NEUROL NEUROSUR PS, V62, P305, DOI 10.1136/jnnp.62.4.305	23	1106	1167	1	71	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2000	342	21					1560	1567		10.1056/NEJM200005253422103	http://dx.doi.org/10.1056/NEJM200005253422103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316XJ	10824074	Bronze			2022-12-28	WOS:000087193100003
J	Dyer, C				Dyer, C			Surgeon dies from hospital exposure to asbestos	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	2000	320	7246					1358	1358						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818013				2022-12-28	WOS:000087232500009
J	Ward, MD				Ward, MD			Materials science - Plastic sandwiches a la carte	NATURE			English	Editorial Material							POLYMERIZATION; INTERCALATION; DIACETYLENES; PHOSPHATE; CHEMISTRY				Ward, MD (corresponding author), Amundson Hall,421 Washington Ave SE, Minneapolis, MN 55455 USA.							CAI H, 1994, SCIENCE, V266, P1551, DOI 10.1126/science.266.5190.1551; CAO G, 1991, J SOLID STATE CHEM, V94, P59, DOI 10.1016/0022-4596(91)90221-3; CHENG K, 1977, J AM CHEM SOC, V99, P8102, DOI 10.1021/ja00466a080; COHEN MD, 1964, J CHEM SOC, P1996, DOI 10.1039/jr9640001996; DAY P, 1982, MOL CRYST LIQ CRYST, V86, P1903; Desiraju G. R., 1989, CRYSTAL ENG DESIGN O; ENKELMANN V, 1984, ADV POLYM SCI, V63, P91; Fogg AM, 1999, ADV MATER, V11, P1466, DOI 10.1002/(SICI)1521-4095(199912)11:17<1466::AID-ADMA1466>3.0.CO;2-1; Kagan CR, 1999, SCIENCE, V286, P945, DOI 10.1126/science.286.5441.945; KANE JJ, 1995, J AM CHEM SOC, V117, P12003, DOI 10.1021/ja00153a026; Kaschak DM, 1998, J AM CHEM SOC, V120, P10887, DOI 10.1021/ja9818710; Kovtyukhova NI, 1999, CHEM MATER, V11, P771, DOI 10.1021/cm981085u; Matsumoto A, 2000, NATURE, V405, P328, DOI 10.1038/35012550; Mitzi DB, 1999, INORG CHEM, V38, P6246, DOI 10.1021/ic991048k; Schmidt G.M.J., 1971, PURE APPL CHEM, V27, P687; TIEKE B, 1981, ANGEW CHEM INT EDIT, V20, P687, DOI 10.1002/anie.198106871	16	14	14	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					293	294		10.1038/35012741	http://dx.doi.org/10.1038/35012741			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830946				2022-12-28	WOS:000087085700029
J	Marx, SO; Reiken, S; Hisamatsu, Y; Jayaraman, T; Burkhoff, D; Rosemblit, N; Marks, AR				Marx, SO; Reiken, S; Hisamatsu, Y; Jayaraman, T; Burkhoff, D; Rosemblit, N; Marks, AR			PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts	CELL			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; DEPENDENT PROTEIN-KINASE; CARDIAC-MUSCLE; A-KINASE; SARCOPLASMIC-RETICULUM; FAILURE; MYOCYTES; NOREPINEPHRINE; PHOSPHOLAMBAN; PHOSPHATASES	The ryanodine receptor (RyR)/calcium release channel on the sarcoplasmic reticulum (SR) is the major source of calcium (Ca2+) required for cardiac muscle excitation-contraction (EC) coupling. The channel is a tetramer comprised of four type 2 RyR polypeptides (RyR2) and four FK506 binding proteins (FKBP12.6). We show that protein kinase A (PKA) phosphorylation of RyR2 dissociates FKBP12.6 and regulates the channel open probability (P-o). Using cosedimentation and coimmunoprecipitation we have defined a macromolecular complex comprised of RyR2, FKBP12.6, PKA, the protein phosphatases PP1 and PP2A, and an anchoring protein, mAKAP. In failing human hearts, RyR2 is PKA hyperphosphorylated, resulting in defective channel function due to increased sensitivity to Ca2+-induced activation.	Columbia Univ Coll Phys & Surg, Ctr Mol Cardiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Marks, AR (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Cardiol, 630 W 168th St, New York, NY 10032 USA.		Burkhoff, Daniel/D-7674-2011; Tuluc, Petronel/C-2527-2011; Lima, Thaísa/AAG-6483-2021		NHLBI NIH HHS [R01 HL56180, R01 HL61503] Funding Source: Medline; NIAID NIH HHS [R01 AI39794] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061503, R01HL056180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039794] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOHM M, 1994, CARDIOVASC RES, V28, P1713, DOI 10.1093/cvr/28.11.1713; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BRISTOW MR, 1992, J CLIN INVEST, V89, P803, DOI 10.1172/JCI115659; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; FOZZARD HA, 1992, BASIC RES CARDIOL, V87, P105; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; FRAZIER OH, 1994, CIRCULATION, V89, P2908, DOI 10.1161/01.CIR.89.6.2908; GO LO, 1995, J CLIN INVEST, V95, P888, DOI 10.1172/JCI117739; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; Hjalmarson A, 1999, LANCET, V353, P2001; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; Kapiloff MS, 1999, J CELL SCI, V112, P2725; Kirchhefer U, 1999, CARDIOVASC RES, V42, P254, DOI 10.1016/S0008-6363(98)00296-X; Laflamme MA, 1999, AM J PHYSIOL-HEART C, V277, pH1841, DOI 10.1152/ajpheart.1999.277.5.H1841; Lechat P, 1999, LANCET, V353, P9; LEVIN HR, 1995, CIRCULATION, V91, P2717, DOI 10.1161/01.CIR.91.11.2717; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; MORGAN JP, 1990, CIRCULATION, V81, P21; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; REGITZZAGROSEK V, 1994, EUR HEART J, V15, P7, DOI 10.1093/eurheartj/15.suppl_D.7; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Wang J, 1997, CIRCULATION, V96, P2683, DOI 10.1161/01.CIR.96.8.2683; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511	36	1540	1610	1	80	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 12	2000	101	4					365	376		10.1016/S0092-8674(00)80847-8	http://dx.doi.org/10.1016/S0092-8674(00)80847-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830164	Bronze			2022-12-28	WOS:000087010400005
J	Loeb, A; Waxman, E				Loeb, A; Waxman, E			Cosmic gamma-ray background from structure formation in the intergalactic medium	NATURE			English	Article							COMA-CLUSTER; HIGH-ENERGY; LUMINOSITY FUNCTION; ACCELERATION; DISCOVERY; SPECTRUM; EMISSION; ORIGIN; ABSORPTION; GALAXIES	The Universe is filled with a diffuse background of gamma-ray radiation(1), the origin of which remains one of the unsolved puzzles of cosmology. Less than one-quarter of the gamma-ray flux can be attributed to unresolved discrete sources(2,3), such as active galactic nuclei; the remainder appears to constitute a truly diffuse background. Here we show that the shock waves induced by gravity in the gas of the intergalactic medium, during the formation of large-scale structures like filaments and sheets of galaxies, produce a population of highly relativistic electrons. These electrons scatter a small fraction of the cosmic microwave background photons in the local Universe up to gamma-ray energies, thereby providing the gamma-ray background. The predicted diffuse flux agrees with the observed background across more than four orders of magnitude in photon energy, and the model predicts that the gamma-ray background, though generated locally, is isotropic to better than five per cent on angular scales larger than a degree. Moreover, the agreement between the predicted and observed background fluxes implies a mean cosmological density of baryons that is consistent with Big Bang nucleosynthesis.	Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Weizmann Institute of Science	Loeb, A (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.		WAXMAN, ELI/K-1557-2012					BELL AR, 1978, MON NOT R ASTRON SOC, V182, P147, DOI 10.1093/mnras/182.2.147; BLANDFORD R, 1987, PHYS REP, V154, P1, DOI 10.1016/0370-1573(87)90134-7; Cen RY, 1999, ASTROPHYS J, V514, P1, DOI 10.1086/306949; Chiang J, 1998, ASTROPHYS J, V496, P752, DOI 10.1086/305403; Coppi PS, 1997, ASTROPHYS J, V487, pL9, DOI 10.1086/310883; Deiss BM, 1997, ASTRON ASTROPHYS, V321, P55; FABIAN AC, 1992, ANNU REV ASTRON ASTR, V30, P429; FELTEN JE, 1966, ASTROPHYS J, V146, P686, DOI 10.1086/148946; Fixsen DJ, 1996, ASTROPHYS J, V473, P576, DOI 10.1086/178173; Fukugita M, 1998, ASTROPHYS J, V503, P518, DOI 10.1086/306025; Fusco-Femiano R, 1999, ASTROPHYS J, V513, pL21, DOI 10.1086/311902; Hasinger G, 1998, ASTRON ASTROPHYS, V329, P482; Kaastra JS, 1999, ASTROPHYS J, V519, pL119, DOI 10.1086/312112; KIM KT, 1989, NATURE, V341, P720, DOI 10.1038/341720a0; Konopelko AK, 1999, ASTROPHYS J, V518, pL13, DOI 10.1086/312062; Koyama K, 1997, PUBL ASTRON SOC JPN, V49, pL7, DOI 10.1093/pasj/49.3.L7; KOYAMA K, 1995, NATURE, V378, P255, DOI 10.1038/378255a0; KRONBERG PP, 1994, REP PROG PHYS, V57, P325, DOI 10.1088/0034-4885/57/4/001; LOEWENSTEIN M, 1999, ASTROPH9910276; LOEWENSTEIN M, IN PRESS ASTROPHYS J; METZLER CA, 1994, ASTROPHYS J, V437, P564, DOI 10.1086/175022; Mukherjee R, 1999, ASTROPART PHYS, V11, P213, DOI 10.1016/S0927-6505(99)00052-3; MURAISHI H, IN PRESS ASTRON ASTR; MURAISHI H, 2000, ASTROPH0001047; MUSHOTZKY RF, 2000, ASTROPH0002313; MUSHOTZKY RF, IN PRESS NATURE; NEVALAINEN J, IN PRESS ASTROPHYS J; NEVALAINEN J, 1999, ASTROPH9911369; Primack JR, 1999, ASTROPART PHYS, V11, P93, DOI 10.1016/S0927-6505(99)00031-6; Rephaeli Y, 1999, ASTROPHYS J, V511, pL21, DOI 10.1086/311828; Sreekumar P, 1998, ASTROPHYS J, V494, P523, DOI 10.1086/305222; Tanimori T, 1998, ASTROPHYS J, V497, pL25, DOI 10.1086/311267; TYTLER D, IN PRESS PHYS SCRIPT; TYTLER D, 2000, ASTROPH0001318; [No title captured]	35	168	168	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					156	158		10.1038/35012018	http://dx.doi.org/10.1038/35012018			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821264	Green Submitted			2022-12-28	WOS:000087080100041
J	Gray, RG; Kerr, DJ; McConkey, CC; Williams, NS; Hills, RK				Gray, RG; Kerr, DJ; McConkey, CC; Williams, NS; Hills, RK		QUASAR Collaborative Grp	Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial	LANCET			English	Article							COLON-CANCER; THERAPY; 5-FLUOROURACIL; LEUCOVORIN	Background Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved survival. Methods Patients with colorectal cancer, without evident residual disease, were randomly assigned fluorouracil (370 mg/m(2)) with high-dose (175 mg) or low-dose (15 mg) L-folinic acid and either active or placebo levamisole. The fluorouracil and folinic acid could be given either as six 5-day courses with 4 weeks between the start of the courses or as 30 once-weekly doses. Levamisole (50 mg) or placebo was given three times daily for 3 days repeated every 2 weeks for 12 courses. The primary endpoint was mortality from any cause. Analyses were by intention to treat. Findings Between 1994 and 1997, 4927 patients were enrolled. 1776 had recurrences and 1576 died. Survival was similar with high-dose and low-dose folinic acid (70.1% vs 71.0% at 3 years; p=0.43), as were 3-year recurrence rates (36.0% vs 35.8%; p=0.94). Survival was worse with levamisole than with placebo (69.4% vs 71.5% at 3 years; p=0.06). and there were more recurrences with the active drug (37.0% vs 34.9% at 3 years; p=0.16). Interpretation The inclusion of levamisole in chemotherapy regimens for colorectal cancer does not delay recurrence or improve survival. Higher-dose folinic acid produced no extra benefit in these regimens over that from low-dose folinic acid. Trials of chemotherapy versus no chemotherapy will show whether these four treatments are equally effective or equally ineffective.	Univ Birmingham, Clin Trials Unit, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Royal London Hosp, London E1 1BB, England	University of Birmingham; University of Birmingham; Barts Health NHS Trust; Royal London Hospital	Gray, RG (corresponding author), Sch Med, Inst Clin Res, CRC, Clin Trials Unit, Birmingham B15 2TT, W Midlands, England.			Gray, Richard/0000-0003-4440-574X; Steele, Robert JC/0000-0003-4248-6785; Hills, Robert/0000-0003-0166-0062				*7 KINGS FUND FOR, 1990, BRIT J SURG, V77, P1063; ARNAUD JP, 1989, BRIT J SURG, V76, P284, DOI 10.1002/bjs.1800760322; Bandealy MT, 1998, CLIN CANCER RES, V4, P935; FRANCINI G, 1994, GASTROENTEROLOGY, V106, P899, DOI 10.1016/0016-5085(94)90748-X; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; KERR DJ, 1989, BRIT J CANCER, V60, P807, DOI 10.1038/bjc.1989.370; LABIANCA R, 1995, LANCET, V345, P939; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; SLEVIN ML, 1991, BRIT MED J, V302, P1100, DOI 10.1136/bmj.302.6785.1100; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; Ychou M, 1998, AM J CLIN ONCOL-CANC, V21, P233, DOI 10.1097/00000421-199806000-00004	13	188	189	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 6	2000	355	9215					1588	1596						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821362				2022-12-28	WOS:000086981200009
J	Rabins, PV; Black, BS; Roca, R; German, P; McGuire, M; Robbins, B; Rye, R; Brant, L				Rabins, PV; Black, BS; Roca, R; German, P; McGuire, M; Robbins, B; Rye, R; Brant, L			Effectiveness of a nurse-based outreach program for identifying and treating psychiatric illness in the elderly	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED TRIAL; MENTAL-HEALTH SERVICES; PRIMARY-CARE; HOME VISITATION; DEPRESSION; INTERVENTION; QUESTIONNAIRE; DISABILITY; RESIDENTS; POLICY	Context Elderly persons with psychiatric disorders are less likely than younger adults to be diagnosed as having a mental disorder and receive needed mental health treatment. Lack of access to care is 1 possible cause of this disparity. Objective To determine whether a nurse-based mobile outreach program to seriously mentally ill elderly persons is more effective than usual care in diminishing levels of depression, psychiatric symptoms, and undesirable moves (eg, nursing home placement, eviction, board and care placement). Design Prospective randomized trial conducted between March 1993 and April 1996 to assess the effectiveness of the Psychogeriatric Assessment and Treatment in City Housing (PATCH) program. Setting Six urban public housing sites for elderly persons in Baltimore, Md. Participants A total of 945 (83 %) of 1195 residents in the 6 sites underwent screening for psychiatric illness, Among those screened, 342 screened positive and 603 screened negative. All screen-positive subjects aged 60 years and older (n=310) and a 10% random sample of screen-negative subjects aged 60 years and older (n=61) were selected for a structured psychiatric interview. Eleven subjects moved or died; 245 (82 %) of those who screened positive and 53 (88%) of those who screened negative were evaluated to determine who had a psychiatric disorder. Data were weighted to estimate the prevalence of psychiatric disorders at the 6 sites, Intervention Among the 6 sites, residents in 3 buildings were randomized to receive the PATCH model intervention, which included educating building staff to be case finders, performing assessment in residents' apartments, and providing care when indicated; and residents in the remaining 3 buildings were randomized to receive usual care (comparison group). Main Outcome Measures Number of undesirable moves and scores on the Montgomery-Asberg Depression Rating Scale (MADRS), a measure of depressive symptoms, and the Brief Psychiatric Rating Scale (BPRS), a measure of psychiatric symptoms and behavioral disorder, in intervention vs comparison sites, Results Based on weighted data, at 26 months of follow-up, psychiatric cases at the intervention sites had significantly lower (F-1=31.18; P<.001) MADRS scores (9.1 vs 15.2) and significantly lower (F-1=17.35; P<.001) BPRS scores (27.4 vs 33.9) than those at the nontreatment comparison sites. There was no significant difference between the groups in undesirable moves (relative risk, 0.97; 95% confidence interval, 0.44-2.17). Conclusions These results indicate that the PATCH intervention was more effective than usual care in reducing psychiatric symptoms in persons with psychiatric disorders and those with elevated levels of psychiatric symptoms.	Johns Hopkins Med Inst, Sheppard & Enoch Pratt Hosp, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Sheppard & Enoch Pratt Hosp, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Sheppard & Enoch Pratt Hosp, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Sheppard & Enoch Pratt Hosp, Sch Hyg & Publ Hlth, Dept Mental Hyg, Baltimore, MD 21205 USA; NIA, Gerontol Res Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Maryland Department of Health & Mental Hygiene; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Rabins, PV (corresponding author), Johns Hopkins Hosp, Meyer 279,600 N Wolfe St, Baltimore, MD 21287 USA.							Banerjee S, 1996, BRIT MED J, V313, P1058; BARKER JC, 1988, GERONTOLOGIST, V28, P610, DOI 10.1093/geront/28.5.610; Bayer R, 1998, AM J PUBLIC HEALTH, V88, P1052, DOI 10.2105/AJPH.88.7.1052; BELLER SA, 1984, J GERONTOL, V39, P194, DOI 10.1093/geronj/39.2.194; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; BERNSTEIN J, 1982, GERONTOLOGIST, V22, P305, DOI 10.1093/geront/22.3.305; Black B S, 1998, Int Psychogeriatr, V10, P309, DOI 10.1017/S1041610298005407; Black BS, 1997, GERONTOLOGIST, V37, P717, DOI 10.1093/geront/37.6.717; Black D, 1998, PERSPECT BIOL MED, V42, P1; BLANCHARD MR, 1995, INT J GERIATR PSYCH, V10, P289, DOI 10.1002/gps.930100405; BLAZER D, 1991, J GERONTOL, V46, pM210, DOI 10.1093/geronj/46.6.M210; BOJRAB SL, 1988, HOSP COMMUNITY PSYCH, V39, P304; BRADFRODHILL AB, 1963, BRIT MED J, V1, P1043; BUHLERWILKERSON K, 1993, AM J PUBLIC HEALTH, V83, P1778, DOI 10.2105/AJPH.83.12.1778; BURNS BJ, 1995, PSYCHIAT SERV, V46, P669; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fishbein M, 1996, AM J PUBLIC HEALTH, V86, P1075, DOI 10.2105/AJPH.86.8_Pt_1.1075; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FrasureSmith N, 1997, LANCET, V350, P473, DOI 10.1016/S0140-6736(97)02142-9; GERMAN PS, 1985, J AM GERIATR SOC, V33, P246, DOI 10.1111/j.1532-5415.1985.tb07111.x; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; Kitzman H, 1997, JAMA-J AM MED ASSOC, V278, P644, DOI 10.1001/jama.278.8.644; KRAEMER HC, 1997, AM J PUBLIC HEALTH, V87, P1717; McDowell I., 1996, MEASURING HLTH GUIDE; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Mrazek P., 1994, REDUCING RISKS MENTA; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; OVERALL JE, 1962, PSYCHOL REP, V10, P799; RABINS PV, 1992, J AM GERIATR SOC, V40, P727, DOI 10.1111/j.1532-5415.1992.tb01968.x; Rabins PV, 1996, J GERONTOL A-BIOL, V51, pM319, DOI 10.1093/gerona/51A.6.M319; Raschko R., 1990, PSYCHIAT TAKES STREE, P195; Ritchie K, 1998, INT J GERIATR PSYCH, V13, P459, DOI 10.1002/(SICI)1099-1166(199807)13:7<459::AID-GPS796>3.3.CO;2-N; ROCA RP, 1987, HOSP COMMUNITY PSYCH, V38, P741; ROCA RP, 1990, HOSP COMMUNITY PSYCH, V41, P916; Rosenheck RA, 1998, ARCH GEN PSYCHIAT, V55, P459, DOI 10.1001/archpsyc.55.5.459; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SHAPIRO S, 1985, MED CARE, V23, P1033, DOI 10.1097/00005650-198509000-00002; SPITZER RL, 1988, INSTRUCTION MANUAL S; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; Valenstein M, 1998, J AM GERIATR SOC, V46, P1499, DOI 10.1111/j.1532-5415.1998.tb01533.x; Waterreus A, 1994, J Clin Nurs, V3, P299, DOI 10.1111/j.1365-2702.1994.tb00403.x; Wells KB, 1996, J CONSULT CLIN PSYCH, V64, P638	44	54	54	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2000	283	21					2802	2809		10.1001/jama.283.21.2802	http://dx.doi.org/10.1001/jama.283.21.2802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	320BQ	10838648				2022-12-28	WOS:000087381500034
J	Seibold, JR; Korn, JH; Simms, R; Clements, PJ; Moreland, LW; Mayes, MD; Furst, DE; Rothfield, N; Steen, V; Weisman, M; Collier, D; Wigley, FM; Merkel, PA; Csuka, ME; Hsu, V; Rocco, S; Erikson, M; Hannigan, J; Harkonen, WS; Sanders, ME				Seibold, JR; Korn, JH; Simms, R; Clements, PJ; Moreland, LW; Mayes, MD; Furst, DE; Rothfield, N; Steen, V; Weisman, M; Collier, D; Wigley, FM; Merkel, PA; Csuka, ME; Hsu, V; Rocco, S; Erikson, M; Hannigan, J; Harkonen, WS; Sanders, ME			Recombinant human relaxin in the treatment of scleroderma - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						relaxin; recombinant proteins; scleroderma, systemic; skin diseases; fibrosis	SKIN THICKNESS SCORE; SYSTEMIC-SCLEROSIS; IN-VITRO; INVOLVEMENT; VARIABILITY; FIBROBLASTS; COLLAGEN; FIBROSIS; DISEASE; VIVO	Background: Relaxin is a pregnancy-related hormone that has tissue remodeling and antifibrotic effects. Systemic sclerosis (scleroderma) is characterized by fibrosis of the skin, vasculature, and internal organs. Objective: To assess the efficacy, safety, and dose-response effect of recombinant human relaxin in patients with scleroderma. Design: Multicenter, parallel-group, randomized, double-blind, placebo-controlled trial. Setting: Academic referral centers. Patients: 68 patients who had had stable, diffuse scleroderma (moderate to severe) for less than 5 years. Intervention: Recombinant human relaxin. 25 or 100 mu g/kg of body weight per day, or placebo administered by continuous subcutaneous infusion over 24 weeks. Measurements: Modified Rodnan skin score was the primary efficacy measure. Secondary measurements were pulmonary function, the Health Assessment Questionnaire, and other measures of scleroderma that reflected fibrosis. Results: Patients who received 25 mu g/kg of recombinant human relaxin per day had significantly lower skin scores than those who received placebo (mean change, -3.6 at 4 weeks [P = 0.021], -7.5 at 12 weeks [P < 0.001], and -8.7 at 24 weeks [P = 0.040]). Similar trends were noted in other outcome measures, including forced vital capacity, measures of oral aperture and hand extension, functional status, and global assessment. Patients who received 100 mu g/kg of relaxin per day did not differ from those who received placebo. Drug-related adverse events included menometrorrhagia, reversible anemia, and complications of the subcutaneous drug administration system (site irritation and local infection). Conclusions: Twenty-four weeks of recombinant human relaxin. 25 mu g/kg per day, is associated with reduced skin thickening, improved mobility, and improved function in patients with moderate to severe diffuse scleroderma.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Scleroderma Program, New Brunswick, NJ 08903 USA; Boston Univ, Med Ctr, Boston, MA 02118 USA; Univ Calif Los Angeles, Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA; Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Wayne State Univ, Detroit, MI 48201 USA; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA; Georgetown Univ, Med Ctr, Div Rheumatol Allergy & Immunol, Washington, DC 20007 USA; Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA; Med Coll Wisconsin, Div Rheumatol, Milwaukee, WI 53226 USA; Connet Corp, Palo Alto, CA 94303 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Calif San Diego, San Diego, CA 92103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Boston University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Alabama System; University of Alabama Birmingham; Wayne State University; Virginia Mason Medical Center; University of Connecticut; Georgetown University; Johns Hopkins University; Johns Hopkins Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Medical College of Wisconsin; Harvard University; Massachusetts General Hospital; University of California System; University of California San Diego	Seibold, JR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Scleroderma Program, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08903 USA.			Simms, Robert/0000-0002-0101-1807; Moreland, Larry/0000-0003-4483-0359				Akesson Anita, 1998, Current Opinion in Rheumatology, V10, P579; BLACK CM, 1995, J RHEUMATOL, V22, P1217; BRYANTGREENWOOD GD, 1994, ENDOCR REV, V15, P5, DOI 10.1210/er.15.1.5; CASTEN GG, 1958, JAMA-J AM MED ASSOC, V166, P319, DOI 10.1001/jama.1958.02990040005002; CLEMENTS P, 1995, J RHEUMATOL, V22, P1281; CLEMENTS PJ, 1993, J RHEUMATOL, V20, P1892; CLEMENTS PJ, 1990, ARTHRITIS RHEUM, V33, P1256, DOI 10.1002/art.1780330828; Clements PJ, 1999, ARTHRITIS RHEUM-US, V42, P1194, DOI 10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7; CLEMENTS PJ, 1995, SYSTEMIC SCLEROSIS, P515; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; EFRON B, 1980, BIOSTATISTICS CASEBO, P19; FRIES JF, 1982, J RHEUMATOL, V9, P789; Furst DE, 1998, J RHEUMATOL, V25, P84; POPE JE, 1995, J RHEUMATOL, V22, P1271; REMYJARDIN M, 1993, RADIOLOGY, V188, P499, DOI 10.1148/radiology.188.2.8327704; Seibold J. R., 1997, British Journal of Rheumatology, V36, P29; Seibold J. R, 1997, TXB RHEUMATOLOGY, P1133; Seibold James R., 1997, Current Opinion in Rheumatology, V9, P571, DOI 10.1097/00002281-199711000-00014; Seibold JR, 1998, J RHEUMATOL, V25, P302; SEIBOLD JR, 1992, J RHEUMATOL, V19, P673; SEIBOLD JR, 1996, SYSTEMIC SCLEROSIS, P535; Sherwood O.D., 1988, P585; STEEN VD, 1994, ARTHRITIS RHEUM, V37, P1283, DOI 10.1002/art.1780370903; STEINETZ BG, 1982, RELAXIN STRUCTURE FU, P1; UNEMORI EN, 1993, J INVEST DERMATOL, V101, P280, DOI 10.1111/1523-1747.ep12365206; UNEMORI EN, 1992, J INVEST DERMATOL, V99, P337, DOI 10.1111/1523-1747.ep12616665; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; Unemori EN, 1999, HUM REPROD, V14, P800, DOI 10.1093/humrep/14.3.800; Unemori EN, 1996, J CLIN INVEST, V98, P2739, DOI 10.1172/JCI119099; Vandlen R, 1995, PROGRESS IN RELAXIN RESEARCH, P59; WHITE B, 1995, ARTHRITIS RHEUM, V38, P351, DOI 10.1002/art.1780380309	31	200	211	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					871	+		10.7326/0003-4819-132-11-200006060-00004	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319HF	10836913				2022-12-28	WOS:000087334900003
J	DeAngelis, CD; Winker, MA				DeAngelis, CD; Winker, MA			Women's health - A call for papers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									JAMA, Chicago, IL 60610 USA		DeAngelis, CD (corresponding author), JAMA, 515 N State St, Chicago, IL 60610 USA.			Winker, Margaret/0000-0002-4708-5641				HEALY B, 1991, JAMA-J AM MED ASSOC, V266, P566, DOI 10.1001/jama.266.4.566; KIRSCHSTEIN RL, 1991, AM J PUBLIC HEALTH, V81, P291, DOI 10.2105/AJPH.81.3.291; PASKO T, 2000, PHYSICIAN CHARACTERI, P17; ROTER D, 1991, MED CARE, V29, P1083; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P1813; Woods N F, 1985, Health Care Women Int, V6, P193; 1992, J WOMENS HLTH, V1, P1; 2000, JAMA, V283, P128	8	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2714	2714		10.1001/jama.283.20.2714	http://dx.doi.org/10.1001/jama.283.20.2714			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819957				2022-12-28	WOS:000087046000042
J	Yokota, F; Thompson, KM				Yokota, F; Thompson, KM			Violence in G-rated animated films	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Children's exposure to violence in the media is a possible source of public health concern; however, violence in children's animated films has not been quantified. Objective To quantify and characterize violence in G-rated animated feature films, Design Violence content was reviewed for all 74 G-rated animated feature films released in theaters between 1937 and 1999, recorded in English, and available for review an videocassette in the United States before September 1999. Main Outcome Measures Duration of violent scenes, type of characters participating in violent acts (good, neutral, or bad), number of injuries/fatalities, and types of weapons used for each film. Results All 74 films reviewed contained at least 1 act of violence (mean duration, 9.5 minutes per film; range, 6 seconds-24 minutes). Analysis of time trends showed a statistically significant increase in the duration of violence in the films with time (P = .001), The study found a total of 125 injuries (including 62 fatal injuries) in 46 (62%) of the films. Characters portrayed as "bad" were much more likely to die of an injury than other characters (odds ratio, 23.2; 95% confidence interval, 8.5-63.4). A majority of the violence (55%) was associated with good or neutral characters dueling with bad characters (ie, using violence as a means of reaching resolution of conflict), and characters used a wide range of weapons in violent acts. Conclusions Our content analysis suggests that a significant amount of violence exists in animated G-rated feature films. Physicians and parents should not overlook videocassettes as a source of exposure to violence for children.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Thompson, KM (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, 718 Huntington Ave, Boston, MA 02115 USA.	kimt@hsph.harvard.edu		Thompson, Kimberly/0000-0002-0849-9147				*AM PSYCH ASS, 1999, VIOL TEL WHAT DO CHI; Cantor J, 1998, ANN AM ACAD POLIT SS, V557, P54, DOI 10.1177/0002716298557000005; HUSTON AC, 1992, BIG WORLD SMALL SCRE, P136; MALTIN L, 1998, 1999 L MALTINS MOVIE; *MOT PICT ASS AM, 2000, MOV RAT DAT; Pelletier AR, 2000, ARCH PEDIAT ADOL MED, V154, P283, DOI 10.1001/archpedi.154.3.283; Pelletier AR, 1999, JAMA-J AM MED ASSOC, V282, P428, DOI 10.1001/jama.282.5.428; PRANGE S, 1999, VIDEO STORE     0117, V21, P12; Roberts D. F., 1999, KIDS MEDIA NEW MILLE; SHELOV S, 1995, PEDIATRICS, V95, P949; STANGER J, 1997, TELEVISION HOME 1997; Strasburger VC, 1999, PEDIATRICS, V103, P129, DOI 10.1542/peds.103.1.129; ZAHED R, 1999, VARIETY         0118, pN20; 1999, SCREEN IT; 1999, LANCET, V354, P525; 1999, KIDS MIND	16	75	76	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2716	2720		10.1001/jama.283.20.2716	http://dx.doi.org/10.1001/jama.283.20.2716			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819958	Bronze			2022-12-28	WOS:000087046000043
J	Protheroe, J; Fahey, T; Montgomery, AA; Peters, TJ				Protheroe, J; Fahey, T; Montgomery, AA; Peters, TJ			The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL; COMMUNITY; WARFARIN; THERAPY; MEDICINE; HEALTH; AIDS	Objective To investigate the impact of patients' preferences for the treatment of atrial fibrillation, by using individualised decision analysis combining probability and utility assessments into a decision tree. Design Observational study based on interviews with patients. Setting Eight general practices in Avon. Participants 260 randomly selected patients aged 70-85 years with atrial fibrillation. Main outcome measures Patients' treatment preferences regarding anticoagulation treatment warfarin) after individualised decision analysis; comparison of these preferences with treatment guidelines on the basis of comorbidity and absolute risk and compared with current prescription. Results Of 195 eligible patients, 97 participated in decision making using decision analysis. Among these 97, the decision analysis indicated that 59 (61%; 95% 97, the decision analysis indicated that (61%; 95%, confidence interval 50% to 71%) would prefer anticoagulation treatment-considerably fewer than those who would be recommended treatment according to guidelines. There was marked disagreement between the decision analysis and guideline recommendations (kappa = 0.25 or less). Of 38 patients whose decision analysis indicated a preference for anticoagulation, 17 (45%) were being prescribed warfarin; on the other hand, 28 (47%) of 59 patients were not being prescribed warfarin although the results of their decision analysis suggested they wanted to be. Conclusions in the context of shared decision making, individualised decision analysis is valuable in a sizeable proportion of elderly patients with atrial fibrillation. Taking account of patients' preferences would lead to fewer prescriptions for warfarin than under published guideline recommendations. Decision analysis as a shared decision making tool should be evaluated in a randomised controlled trial.	Univ Bristol, Dept Social Med, Div Primary Hlth Care, Bristol BS8 2PR, Avon, England	University of Bristol	Fahey, T (corresponding author), Univ Bristol, Dept Social Med, Div Primary Hlth Care, Bristol BS8 2PR, Avon, England.		Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783; Montgomery, Alan/0000-0003-0450-1606; Peters, Tim/0000-0003-2881-4180	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altman D.G., 1991, PRACTICAL STAT MED R; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; CLANCY CM, 1988, AM J MED, V84, P283, DOI 10.1016/0002-9343(88)90426-3; Coulter A, 1997, J Health Serv Res Policy, V2, P112; Edwards A, 1999, JAMA-J AM MED ASSOC, V282, P779, DOI 10.1001/jama.282.8.779; English KM, 1999, BMJ-BRIT MED J, V318, P1088, DOI 10.1136/bmj.318.7191.1088; Ezekowitz M, 1998, ARCH INTERN MED, V158, P1316; Fahey T, 1999, BRIT J GEN PRACT, V49, P295; GLASS RL, 1995, J SYST SOFTWARE, V31, P1, DOI 10.1016/0164-1212(94)00083-Y; Gullov AL, 1999, ARCH INTERN MED, V159, P1322, DOI 10.1001/archinte.159.12.1322; HLATKY MA, 1995, JAMA-J AM MED ASSOC, V273, P1219, DOI 10.1001/jama.273.15.1219; Howitt A, 1999, BMJ-BRIT MED J, V318, P1324, DOI 10.1136/bmj.318.7194.1324; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LAUPACIS A, 1995, CHEST S, V108, P352; Lilford RJ, 1998, BMJ-BRIT MED J, V317, P405; Lip GYH, 1999, LANCET, V353, P4, DOI 10.1016/S0140-6736(05)74877-7; Man-Son-Hing M, 1999, JAMA-J AM MED ASSOC, V282, P737, DOI 10.1001/jama.282.8.737; Naglie G, 1997, MED DECIS MAKING, V17, P136, DOI 10.1177/0272989X9701700203; Nease RF, 1996, QUAL LIFE RES, V5, P175, DOI 10.1007/BF00435983; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; SWEENEY KG, 1995, BRIT J GEN PRACT, V45, P153; SWEENEY KG, 1995, BRIT MED J, V311, P560, DOI 10.1136/bmj.311.7004.560; Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6	27	185	188	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	2000	320	7246					1380	1384		10.1136/bmj.320.7246.1380	http://dx.doi.org/10.1136/bmj.320.7246.1380			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818030	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000087232500023
J	Adrogue, HJ; Madias, NE				Adrogue, HJ; Madias, NE			Primary care - Hypernatremia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SYSTEM; VOLUME		New England Med Ctr, Div Nephrol, Boston, MA 02111 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Dept Vet Affairs Med Ctr, Renal Sect, Houston, TX USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; New England Med Ctr, Tupper Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Tufts University; Tufts Medical Center	Madias, NE (corresponding author), New England Med Ctr, Div Nephrol, Box 172,750 Washington St, Boston, MA 02111 USA.							Adrogue HJ, 1997, INTENS CARE MED, V23, P309, DOI 10.1007/s001340050333; ADROGUE HJ, 1994, SALT WATER, P205; ARIEFF AI, 1976, KIDNEY INT, V10, P104, DOI 10.1038/ki.1976.82; BLUM D, 1986, J PEDIATR GASTR NUTR, V5, P232, DOI 10.1097/00005176-198605020-00012; BRUCK E, 1968, AM J DIS CHILD, V115, P122, DOI 10.1001/archpedi.1968.02100010124002; DEVILLOTA ED, 1973, AM J MED, V55, P116, DOI 10.1016/0002-9343(73)90158-7; EDELMAN IS, 1958, J CLIN INVEST, V37, P1236, DOI 10.1172/JCI103712; FEIG PU, 1977, NEW ENGL J MED, V297, P1444, DOI 10.1056/NEJM197712292972608; FINBERG L, 1955, PEDIATRICS, V16, P1; Gennari F.J., 1998, OXFORD TXB CLIN NEPH, V1, P175; GENNARI FJ, 1984, NEW ENGL J MED, V310, P102, DOI 10.1056/NEJM198401123100207; GENNARI FJ, 1974, NEW ENGL J MED, V291, P714, DOI 10.1056/NEJM197410032911408; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; HIROMATSU K, 1994, J NEUROL SCI, V122, P144, DOI 10.1016/0022-510X(94)90291-7; HOGAN GR, 1969, PEDIATRICS, V43, P54; KAHN A, 1979, INTENS CARE MED, V5, P27, DOI 10.1007/BF01738999; LIEN YHH, 1990, J CLIN INVEST, V85, P1427, DOI 10.1172/JCI114587; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MORRISJONES PH, 1967, LANCET, V2, P1385; Oh MS, 1995, FLUID ELECTROLYTE AC, P1; Palevsky PM, 1996, ANN INTERN MED, V124, P197, DOI 10.7326/0003-4819-124-2-199601150-00002; Palevsky PM, 1998, PRIMER KIDNEY DIS, V2nd, P64; PHILLIPS PA, 1991, AM J PHYSIOL, V261, pR166, DOI 10.1152/ajpregu.1991.261.1.R166; ROSE BD, 1986, AM J MED, V81, P1033, DOI 10.1016/0002-9343(86)90401-8; Rose BD, 1994, CLIN PHYSL ACID BASE, P695; ROSS EJ, 1969, MEDICINE, V48, P441, DOI 10.1097/00005792-196948060-00002; SILVER AJ, 1992, J AM GERIATR SOC, V40, P556, DOI 10.1111/j.1532-5415.1992.tb02102.x; SNYDER NA, 1987, ANN INTERN MED, V107, P309, DOI 10.7326/0003-4819-107-2-309	28	479	511	4	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2000	342	20					1493	1499		10.1056/NEJM200005183422006	http://dx.doi.org/10.1056/NEJM200005183422006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314QT	10816188				2022-12-28	WOS:000087068200006
J	Michaelis, J; Hettich, C; Mlynek, J; Sandoghdar, V				Michaelis, J; Hettich, C; Mlynek, J; Sandoghdar, V			Optical microscopy using a single-molecule light source	NATURE			English	Article							PARA-TERPHENYL CRYSTAL; P-TERPHENYL; FLUORESCENCE EXCITATION; PENTACENE MOLECULES; ROOM-TEMPERATURE; SPECTROSCOPY; TERRYLENE; FORCE; TIP	Rapid progress in science on nanoscopic scales has promoted increasing interest in techniques of ultrahigh-resolution optical microscopy. The diffraction limit can be surpassed by illuminating an object in the near field through a sub-wavelength aperture at the end of a sharp metallic probe(1,2). Proposed modifications(3,4) of this technique involve replacing the physical aperture by a nanoscopic active light source. Advances in the spatial(5) and spectral(6) detection of individual fluorescent molecules, using near-field and far-field methods(7), suggest the possibility of using a single molecule(8,9) as the illumination source. Here we present optical images taken with a single molecule as a point-like source of illumination, by combining fluorescence excitation spectroscopy(10) with shear-force microscopy(11). Our single-molecule probe has potential for achieving molecular resolution in optical microscopy; it should also facilitate controlled studies of nanometre-scale phenomena (such as resonant energy transfer) with improved lateral and axial spatial resolution.	Univ Konstanz, Fachbereich Phys, D-78457 Constance, Germany; Univ Konstanz, Opt Zentrum Konstanz, D-78457 Constance, Germany	University of Konstanz; University of Konstanz	Sandoghdar, V (corresponding author), Univ Konstanz, Fachbereich Phys, Fach M696, D-78457 Constance, Germany.		Michaelis, Jens/P-2873-2016; Sandoghdar, Vahid/AAT-8856-2020	Sandoghdar, Vahid/0000-0003-2594-4801; Michaelis, Jens/0000-0002-2739-4172				AMBROSE WP, 1991, J CHEM PHYS, V95, P7150, DOI 10.1063/1.461392; BARCHIESI D, 1995, P SOC PHOTO-OPT INS, V2384, P90, DOI 10.1117/12.205916; Basche T., 1997, SINGLE MOL OPTICAL D; BETZIG E, 1992, APPL PHYS LETT, V60, P2484, DOI 10.1063/1.106940; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; BETZIG E, 1992, APPL OPTICS, V31, P4563, DOI 10.1364/AO.31.004563; BINGGELI M, 1993, REV SCI INSTRUM, V64, P2888, DOI 10.1063/1.1144477; FISCHER UC, 1981, J VAC SCI TECHNOL, V19, P881, DOI 10.1116/1.571227; Fleury L, 1998, MOL PHYS, V95, P1333, DOI 10.1080/00268979809483263; HAROOTUNIAN A, 1986, APPL PHYS LETT, V49, P674, DOI 10.1063/1.97565; Henkel C, 1998, OPT COMMUN, V158, P250, DOI 10.1016/S0030-4018(98)00519-7; Huser T, 1999, J OPT SOC AM A, V16, P141, DOI 10.1364/JOSAA.16.000141; KARRAI K, 1995, APPL PHYS LETT, V66, P1842, DOI 10.1063/1.113340; KOPELMAN R, 1993, SCIENCE, V262, P1382, DOI 10.1126/science.262.5138.1382; Kulzer F, 1997, NATURE, V387, P688, DOI 10.1038/42674; Kulzer F, 1999, CHEM PHYS, V247, P23, DOI 10.1016/S0301-0104(99)00100-7; KUMMER S, 1994, CHEM PHYS LETT, V229, P309, DOI 10.1016/0009-2614(94)01043-9; Levi BG, 1999, PHYS TODAY, V52, P18, DOI 10.1063/1.882745; LEWIS A, 1991, NATURE, V354, P214, DOI 10.1038/354214a0; LEWIS A, 1983, BIOPHYS J, V41, P405; LIEBERMAN K, 1990, SCIENCE, V247, P59, DOI 10.1126/science.247.4938.59; MARTIN OJF, 1995, PHYS REV LETT, V74, P526, DOI 10.1103/PhysRevLett.74.526; Martin OJF, 1999, J MICROSC-OXFORD, V194, P235, DOI 10.1046/j.1365-2818.1999.00560.x; Michaelis J, 1999, OPT LETT, V24, P581, DOI 10.1364/OL.24.000581; MOERNER WE, 1989, PHYS REV LETT, V62, P2535, DOI 10.1103/PhysRevLett.62.2535; Novotny L, 1996, APPL PHYS LETT, V69, P3806, DOI 10.1063/1.117111; ORRIT M, 1990, PHYS REV LETT, V65, P2716, DOI 10.1103/PhysRevLett.65.2716; POHL DW, 1984, APPL PHYS LETT, V44, P651, DOI 10.1063/1.94865; Sekatskii SK, 1996, APPL PHYS B-LASERS O, V63, P525	29	245	252	4	93	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					325	328		10.1038/35012545	http://dx.doi.org/10.1038/35012545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830956				2022-12-28	WOS:000087085700040
J	Sulkowski, MS; Thomas, DL; Chaisson, RE; Moore, RD				Sulkowski, MS; Thomas, DL; Chaisson, RE; Moore, RD			Elevated liver enzymes following initiation of antiretroviral therapy - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Sulkowski, MS (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.							O'Sullivan CE, 1999, J INFECT DIS, V180, P847, DOI 10.1086/314943; Ragni MV, 1999, J INFECT DIS, V180, P2027, DOI 10.1086/315143; Renaud M, 1999, AIDS, V13, P669, DOI 10.1097/00002030-199904160-00007; Rutschmann OT, 1998, J INFECT DIS, V177, P783, DOI 10.1086/517808	4	37	38	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2526	2527						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312VL	10815113				2022-12-28	WOS:000086964600030
J	Steinhauser, KE; Clipp, EC; McNeilly, M; Christakis, NA; McIntyre, LM; Tulsky, JA				Steinhauser, KE; Clipp, EC; McNeilly, M; Christakis, NA; McIntyre, LM; Tulsky, JA			In search of a good death: Observations of patients, families, and providers	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							QUALITY-OF-LIFE; PATIENTS PERSPECTIVES; ADVANCE DIRECTIVES; CARE; END; PERSONNEL; DISEASE	Despite a recent increase in the attention given to improving end-of-life care, our understanding of what constitutes a good death is surprisingly lacking. The purpose of this study was to gather descriptions of the components of a good death from patients, families, and providers through focus group discussions and in-depth interviews. Seventy-five participants-including physicians, nurses. social workers, chaplains, hospice volunteers, patients, and recently bereaved family members-were recruited from a university medical center, a Veterans Affairs medical center, and a community hospice. Participants identified six major components of a good death: pain and symptom management, clear decision making, preparation for death, completion, contributing to others, and affirmation of the whole person. The six themes are process-oriented attributes of a good death, and each has biomedical, psychological, social, and spiritual components. Physicians' discussions of a good death differed greatly from those of other groups. Physicians offered the most biomedical perspective, and patients, families, and other health care professionals defined a broad range of attributes integral to the quality of dying. Although there is no "right" way to die, these six themes may be used as a framework for understanding what participants tend to value at the end of life. Biomedical care is critical, but it is only a point of departure toward total end-of-life care. For patients and families, psychosocial and spiritual issues are as important as physiologic concerns.	Duke Univ, Duke Vet Affairs Med Ctr 152, Durham, NC 27705 USA; Inst Multiculturalism, Durham, NC USA; Univ Chicago, Chicago, IL 60637 USA	Duke University; University of Chicago	Steinhauser, KE (corresponding author), Duke Univ, Duke Vet Affairs Med Ctr 152, 508 Fulton St, Durham, NC 27705 USA.	karensteinhauser@mindspring.com	McIntyre, Lauren/J-8414-2012; Christakis, Nicholas A/B-6690-2008; Christakis, Nicholas A/C-3205-2009	McIntyre, Lauren/0000-0002-0077-3359; 				Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; [Anonymous], 1999, DEATH FORETOLD PROPH; ARIES P, 1980, HOUR OUR DEATH; Armstrong K, 1998, SOC WORK HEALTH CARE, V27, P33, DOI 10.1300/J010v27n01_03; BYOCK I, 1997, DYING WELL PEACE POS, P4311; CLIPP EC, 1992, CANCER, V69, P1074, DOI 10.1002/1097-0142(19920215)69:4<1074::AID-CNCR2820690440>3.0.CO;2-L; Cohen S R, 1992, J Palliat Care, V8, P40; COHEN SR, 1995, PALLIATIVE MED, V9, P207, DOI 10.1177/026921639500900306; CORBIN J, 1990, BASICS QUALITIVE RES; Cudmore J, 1996, Nurs Crit Care, V1, P120; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Erikson E.H., 1982, LIFE CYCLE COMPLETED; Field MJ, 1997, APPROACHING DEATH IM; FOUCAULT M, 1973, BIRHT CLIN ARCHEOLOG; Fowler FJ, 1999, J PAIN SYMPTOM MANAG, V17, P114, DOI 10.1016/S0885-3924(98)00133-X; FOWLIE M, 1989, PALLIATIVE MED, V3, P55; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Kaufman SR, 1998, GERONTOLOGIST, V38, P715, DOI 10.1093/geront/38.6.715; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Krueger R.A., 1994, FOCUS GROUPS PRACTIC, V2nd; Lo B, 1999, ANN INTERN MED, V130, P772, DOI 10.7326/0003-4819-130-9-199905040-00018; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; MCCORMICK TR, 1995, WESTERN J MED, V163, P236; Rosebush PA, 1998, MIL MED, V163, P559, DOI 10.1093/milmed/163.8.559; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Solomon MZ, 1995, HASTINGS CENT REP, V25, pS28, DOI 10.2307/3527856; SPRANGERS MAG, 1992, J CLIN EPIDEMIOL, V45, P743, DOI 10.1016/0895-4356(92)90052-O; Starr P, 1982, SOCIAL TRANSFORMATIO; STERN P, 1985, QUALITATIVE RES METH; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; *VET HLTH AD, POLICY IMPLEMENTATIO	34	689	699	1	110	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2000	132	10					825	832		10.7326/0003-4819-132-10-200005160-00011	http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	313XN	10819707				2022-12-28	WOS:000087025100009
J	Steiner, JF; Earnest, MA				Steiner, JF; Earnest, MA			Lingua medica - The language of medication-taking	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; ADHERENCE; THERAPY; PATIENT; HYPERTENSION; INTERVENTIONS; PERSPECTIVES; GUIDELINES; EFFICACY		Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Steiner, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Box B-180,4200 E 9th Ave, Denver, CO 80262 USA.							Altice FL, 1998, ANN INTERN MED, V129, P503, DOI 10.7326/0003-4819-129-6-199809150-00015; ARLUKE A, 1980, HUM ORGAN, V39, P84, DOI 10.17730/humo.39.1.ln604545vgw68x32; Carleton RA, 1997, ANN INTERN MED, V126, P589, DOI 10.7326/0003-4819-126-7-199704010-00031; Chaulk CP, 1998, JAMA-J AM MED ASSOC, V279, P943, DOI 10.1001/jama.279.12.943; CONRAD P, 1985, SOC SCI MED, V20, P29, DOI 10.1016/0277-9536(85)90308-9; CRAMER JA, 1990, ARCH INTERN MED, V150, P1509, DOI 10.1001/archinte.150.7.1509; DIXON WM, 1957, LANCET, V2, P871; DONOVAN JL, 1995, INT J TECHNOL ASSESS, V11, P443, DOI 10.1017/S0266462300008667; Earnest M. A., 1999, JGIM, V14, P26; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P3077, DOI 10.1001/jama.263.22.3077; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; FEINSTEIN AR, 1990, ARCH INTERN MED, V150, P1377, DOI 10.1001/archinte.150.7.1377; GRAHAM DY, 1992, GASTROENTEROLOGY, V102, P493, DOI 10.1016/0016-5085(92)90095-G; Haynes RB, 1996, LANCET, V348, P383; HAYNES RB, 1976, COMPLIANCE THERAPEUT, P193; HORWITZ RI, 1993, ARCH INTERN MED, V153, P1863, DOI 10.1001/archinte.153.16.1863; INUI TS, 1981, MED CARE, V19, P1061, DOI 10.1097/00005650-198110000-00008; JENKINS B W, 1954, GP, V9, P66; KRAVITZ RL, 1993, ARCH INTERN MED, V153, P1869, DOI 10.1001/archinte.153.16.1869; KRUSE W, 1990, EUR J CLIN PHARMACOL, V38, P561, DOI 10.1007/BF00278582; KRUSE W, 1994, INT J CLIN PHARM TH, V32, P452; Lerner BH, 1998, ANN INTERN MED, V129, P573, DOI 10.7326/0003-4819-129-7-199810010-00012; Leslie Charles, 1976, HIST E AFRICA, P1, DOI DOI 10.1016/S0070-4571(08)71123-3; LEVENTHAL H, 1987, PATIENT EDUC COUNS, V10, P117, DOI 10.1016/0738-3991(87)90093-0; MARKOWITZ M, 1970, CIRCULATION, V41, P1077, DOI 10.1161/01.CIR.41.6.1077; MATERSON BJ, 1978, CLIN PHARMACOL THER, V24, P192; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; NIDES MA, 1993, CHEST, V104, P501, DOI 10.1378/chest.104.2.501; NORRBY SR, 1990, REV INFECT DIS, V12, P458; PATERSON D, 1999, 6 C RETR OPP INF FEB; PITMAN ER, 1959, DIS CHEST, V36, P1; PRICKMAN LE, 1958, JAMA-J AM MED ASSOC, V167, P1451, DOI 10.1001/jama.1958.02990290005002; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; SACKETT DL, 1975, LANCET, V1, P1205; Sackett DL, 1979, COMPLIANCE HLTH CARE; SHEINER LB, 1995, CLIN PHARMACOL THER, V57, P6, DOI 10.1016/0009-9236(95)90260-0; Smith MY, 1997, J GEN INTERN MED, V12, P216, DOI 10.1007/s11606-006-5043-3; STEELE DJ, 1990, J FAM PRACTICE, V30, P294; STEINER JF, 1991, J CLIN EPIDEMIOL, V44, P1361, DOI 10.1016/0895-4356(91)90097-S; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; Stone VE, 1998, J GEN INTERN MED, V13, P586, DOI 10.1046/j.1525-1497.1998.00180.x; TEMPLE R, 1989, INT CONGR SER, V808, P145; TROSTLE JA, 1988, SOC SCI MED, V27, P1299, DOI 10.1016/0277-9536(88)90194-3; Urquhart J, 1997, CLIN PHARMACOKINET, V32, P345, DOI 10.2165/00003088-199732050-00001; WAGNER EH, 1981, J CHRON DIS, V34, P519, DOI 10.1016/0021-9681(81)90014-X; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; WEINTRAUB M, 1984, DRUG TREATMENT ELDER, P43	49	94	96	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					926	930		10.7326/0003-4819-132-11-200006060-00026	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00026			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	319HF	10836931				2022-12-28	WOS:000087334900022
J	Wiese, JG; Shlipak, MG; Browner, WS				Wiese, JG; Shlipak, MG; Browner, WS			The alcohol hangover	ANNALS OF INTERNAL MEDICINE			English	Review							ETHANOL INTOXICATION; AIRCRAFT PILOTS; DRINKING; CONSUMPTION; PERFORMANCE; GLUCOSE; COSTS; PERSONALITY; ALDOSTERONE; SECRETION	Purpose: To review the cause, pathophysiologic characteristics, cost, and treatment of alcohol-induced hangover. Data Sources: A MEDLINE search of English-language reports (1966 to 1999) and a manual search of bibliographies of relevant papers. Study Selection: Related experimental, clinical, and basic research studies. Data Extraction: Data in relevant articles were reviewed, and relevant clinical information was extracted. Data Synthesis: The alcohol hangover is characterized by headache, tremulousness, nausea, diarrhea, and fatigue combined with decreased occupational, cognitive, or visual-spatial skill performance. In the United States, related absenteeism and poor job performance cost $148 billion annually (average annual cost per working adult, $2000). Although hangover is associated with alcoholism, most of its cost is incurred by the light-to-moderate drinker. Patients with hangover may pose substantial risk to themselves and others despite having a normal blood alcohol level. Hangover may also be an independent risk factor for cardiac death. Symptoms of hangover seem to be caused by dehydration, hormonal alterations, dysregulated cytokine pathways, and toxic effects of alcohol. Physiologic characteristics include increased cardiac work with normal peripheral resistance, diffuse slowing on electroencephalography, and increased levels of antidiuretic hormone. Effective interventions include rehydration, prostaglandin inhibitors, and Vitamin B-6. Screening for hangover severity and frequency may help early detection of alcohol dependency and substantially improve quality of life. Recommended interventions include discussion of potential therapies and reminders of the possibility for cognitive and visual-spatial impairment. No evidence suggests that alleviation of hangover symptoms leads to further alcohol consumption, and the discomfort caused by such symptoms may do so. Therefore, treatment seems warranted. Conclusions: Hangover, a common disorder, has substantial morbidity and societal cost. Appropriate management may relieve symptoms in many patients.	Vet Affairs Med Ctr, Gen Internal Med Sect 111, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Wiese, JG (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect 111, 4150 Clement St, San Francisco, CA 94121 USA.							ADE G, 1988, CHAMBERS DICT QUOTAT, P1538; BOGIN RM, 1987, AM J DRUG ALCOHOL AB, V13, P175, DOI 10.3109/00952998709001507; CHAPMAN LF, 1970, Q J STUD ALCOHOL S, V5, P67; CHAUHAN BL, 1991, EUR J CLIN PHARMACOL, V40, P187; Cherpitel CJ, 1998, J STUD ALCOHOL, V59, P216, DOI 10.15288/jsa.1998.59.216; COLLINS D, 1996, NATL CAMPAIGN DRUG A, V15; COLLINS WE, 1980, AVIAT SPACE ENVIR MD, V51, P327; COLLINS WE, 1980, HUM FACTORS, V22, P445, DOI 10.1177/001872088002200406; CROFTON J, 1987, ALCOHOL ALCOHOLISM, V22, P321; Damrau F, 1971, Southwest Med, V52, P179; DAMRAU F, 1960, J Natl Med Assoc, V52, P262; DELIN CR, 1992, ALCOHOL ALCOHOLISM, V27, P117; Devlin NJ, 1997, ADDICTION, V92, P1491; EARLEYWINE M, 1993, ADDICT BEHAV, V18, P291, DOI 10.1016/0306-4603(93)90030-D; EARLEYWINE M, 1993, ADDICT BEHAV, V18, P415, DOI 10.1016/0306-4603(93)90058-H; Ellingboe J, 1987, Alcohol Alcohol Suppl, V1, P109; Gauvin DV, 1997, PHARMACOL BIOCHEM BE, V57, P199, DOI 10.1016/S0091-3057(96)00310-3; GUNN RC, 1973, Q J STUD ALCOHOL, V34, P194; HARBURG E, 1994, ALCOHOL ALCOHOLISM, V29, P439; HARBURG E, 1993, J CLIN EPIDEMIOL, V46, P413, DOI 10.1016/0895-4356(93)90017-U; HARBURG E, 1981, J STUD ALCOHOL, V42, P998, DOI 10.15288/jsa.1981.42.998; Heikkonen E, 1996, ALCOHOL CLIN EXP RES, V20, P711, DOI 10.1111/j.1530-0277.1996.tb01676.x; Heikkonen E, 1998, ALCOHOL CLIN EXP RES, V22, P437, DOI 10.1097/00000374-199804000-00021; JARVILEHTO T, 1975, PSYCHOPHARMACOLOGIA, V42, P173, DOI 10.1007/BF00429549; KAIVOLA S, 1983, CEPHALALGIA, V3, P31, DOI 10.1046/j.1468-2982.1983.0301031.x; KANGASAHO M, 1982, THROMB HAEMOSTASIS, V48, P232; Kauhanen J, 1997, EPIDEMIOLOGY, V8, P310, DOI 10.1097/00001648-199705000-00014; KENTALA E, 1976, ANN CLIN RES, V8, P408; KHAN MA, 1973, Q J STUD ALCOHOL, V34, P1195; KREITMAN N, 1986, BRIT J ADDICT, V81, P353; KUPARI M, 1983, ACTA MED SCAND, V213, P84; LEMON J, 1993, ALCOHOL CLIN EXP RES, V17, P665, DOI 10.1111/j.1530-0277.1993.tb00816.x; LINKOLA J, 1978, ACTA PHYSIOL SCAND, V104, P180, DOI 10.1111/j.1748-1716.1978.tb06265.x; LINKOLA J, 1979, ACTA PHYSIOL SCAND, V106, P75, DOI 10.1111/j.1748-1716.1979.tb06372.x; LINKOLA J, 1976, EUR J CLIN INVEST, V6, P191, DOI 10.1111/j.1365-2362.1976.tb00511.x; MEILMAN PW, 1990, J STUD ALCOHOL, V51, P389, DOI 10.15288/jsa.1990.51.389; MYRSTEN AL, 1980, PSYCHOPHARMACOLOGY, V69, P117, DOI 10.1007/BF00427636; NEWLIN DB, 1990, ALCOHOL CLIN EXP RES, V14, P713, DOI 10.1111/j.1530-0277.1990.tb01231.x; PALMER JP, 1975, DIABETES, V24, P295, DOI 10.2337/diabetes.24.3.295; PAWAN GLS, 1973, P NUTR SOC, V32, pA15; PRISTACH CA, 1983, DRUG ALCOHOL DEPEN, V11, P177; RODIN AE, 1989, LIT EPONYMS ENCY MED; SAINIO K, 1976, ELECTROEN CLIN NEURO, V40, P535, DOI 10.1016/0013-4694(76)90084-5; SEPPALA T, 1976, ACTA PHARMACOL TOX, V38, P209; Single E, 1998, ADDICTION, V93, P991, DOI 10.1046/j.1360-0443.1998.9379914.x; Stockwell T, 1998, ALCOHOL CLIN EXP RES, V22, p63S, DOI 10.1111/j.1530-0277.1998.tb04375.x; STRECHER VJ, 1994, J FAM PRACTICE, V39, P26; STREUFERT S, 1995, ALCOHOL CLIN EXP RES, V19, P1141, DOI 10.1111/j.1530-0277.1995.tb01592.x; TORNROS J, 1991, Blutalkohol, V28, P24; Tsukamoto S, 1991, Arukoru Kenkyuto Yakubutsu Ison, V26, P500; VICTOR M, 1970, POSTGRAD MED, V47, P68, DOI 10.1080/00325481.1970.11697437; WATSON CG, 1990, J CLIN PSYCHOL, V46, P507, DOI 10.1002/1097-4679(199007)46:4<507::AID-JCLP2270460420>3.0.CO;2-L; WERMUT W, 1980, PSYCHIATRY, V1, P66; YESAVAGE JA, 1994, J AM GERIATR SOC, V42, P577, DOI 10.1111/j.1532-5415.1994.tb06852.x; YESAVAGE JA, 1986, AM J PSYCHIAT, V143, P1546; YLIKAHRI R, 1974, BMJ-BRIT MED J, V2, P445, DOI 10.1136/bmj.2.5916.445-a; YLIKAHRI RH, 1974, SCAND J CLIN LAB INV, V34, P327, DOI 10.3109/00365517409049888; YLIKAHRI RH, 1978, J CLIN ENDOCR METAB, V46, P715, DOI 10.1210/jcem-46-5-715; YLIKAHRI RH, 1976, EUR J CLIN INVEST, V6, P93, DOI 10.1111/j.1365-2362.1976.tb00498.x; YLIKAHRI RH, 1980, PHARMACOL BIOCHEM BE, V13, P131, DOI 10.1016/S0091-3057(80)80021-9; YLIKAHRI RH, 1974, EUR J CLIN INVEST, V4, P93, DOI 10.1111/j.1365-2362.1974.tb00378.x; 1998, PSYCHIAT SERV, V49, P1110	62	179	191	1	84	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					897	902		10.7326/0003-4819-132-11-200006060-00008	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	319HF	10836917				2022-12-28	WOS:000087334900007
J	Gatfield, J; Pieters, J				Gatfield, J; Pieters, J			Essential role for cholesterol in entry of mycobacteria into macrophages	SCIENCE			English	Article							GREEN FLUORESCENT PROTEIN; NONOPSONIC BINDING; TUBERCULOSIS; MEMBRANE; BIOLOGY	Mycobacteria are intracellular pathogens that can invade and survive within host macrophages, thereby creating a major health problem worldwide. The molecular mechanisms involved in mycobacterial entry are still poorly characterized. Here we report that cholesterol is essential for uptake of mycobacteria by macrophages. Cholesterol accumulated at the site of mycobacterial entry, and depleting plasma membrane cholesterol specifically inhibited mycobacterial uptake. Cholesterol also mediated the phagosomal association of TACO, a coat protein that prevents degradation of mycobacteria in lysosomes. Thus, by entering host cells at cholesterol-rich domains of the plasma membrane, mycobacteria may ensure their subsequent intracellular survival in TACO-coated phagosomes.	Basel Inst Immunol, CH-4005 Basel, Switzerland		Pieters, J (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.			Pieters, Jean/0000-0002-5284-9757				BLOOM BR, 1992, NATURE, V358, P538, DOI 10.1038/358538b0; BORNIG H, 1974, ACTA HISTOCHEM, V50, P110; BRAMHAM J, 1995, J INORG BIOCHEM, V57, P23, DOI 10.1016/0162-0134(94)00010-8; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cywes C, 1997, INFECT IMMUN, V65, P4258, DOI 10.1128/IAI.65.10.4258-4266.1997; DHANDAYUTHAPANI S, 1995, MOL MICROBIOL, V17, P901, DOI 10.1111/j.1365-2958.1995.mmi_17050901.x; DRABIKOWSKI W, 1973, BIOCHIM BIOPHYS ACTA, V291, P61, DOI 10.1016/0005-2736(73)90060-6; EFTHYMIOU C, 1962, J INFECT DIS, V110, P258, DOI 10.1093/infdis/110.3.258; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; GATFIELD J, UNPUB; Hasan Z, 1997, MOL MICROBIOL, V24, P545, DOI 10.1046/j.1365-2958.1997.3591731.x; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; RAY TK, 1983, J CELL BIOCHEM, V21, P141, DOI 10.1002/jcb.240210205; Russell DG, 1997, PHILOS T ROY SOC B, V352, P1303, DOI 10.1098/rstb.1997.0114; Schlesinger LS, 1996, CURR TOP MICROBIOL, V215, P71; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SPECTOR AA, 1985, J LIPID RES, V26, P1015; STOKES RW, 1993, J IMMUNOL, V151, P7067; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; Valdivia RH, 1996, GENE, V173, P47, DOI 10.1016/0378-1119(95)00706-7; Valdivia RH, 1997, SCIENCE, V277, P2007, DOI 10.1126/science.277.5334.2007; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; Young DB, 1998, NATURE, V393, P515, DOI 10.1038/31095	27	449	468	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1647	1650		10.1126/science.288.5471.1647	http://dx.doi.org/10.1126/science.288.5471.1647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834844				2022-12-28	WOS:000087382300042
J	Lewis, JD; Tollervey, D				Lewis, JD; Tollervey, D			Like attracts like: Getting RNA processing together in the nucleus	SCIENCE			English	Review							PRE-MESSENGER-RNA; SMALL NUCLEOLAR RNAS; CARBOXY-TERMINAL DOMAIN; DISEASE GENE-PRODUCT; TRANSCRIPTION ELONGATION-FACTOR; POLYMERASE-II TRANSCRIPTION; GREEN FLUORESCENT PROTEIN; U6 SPLICEOSOMAL RNA; COILED BODIES; SPLICING FACTORS	Structures visible within the eukaryotic nucleus have fascinated generations of biologists. Recent data show that these structures form in response to gene expression and are highly dynamic in Living cells. RNA processing and assembly require many factors but the nucleus apparently lacks any active transport system to deliver these to the RNAs. Instead, processing factors move by diffusion but are concentrated by transient association with functionally related components. At sites of high activity this gives rise to visible structures, with components in dynamic equilibrium with the surrounding nucleoplasm. Processing factors are recruited from this pool by cooperative binding to RNA substrates.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh	Tollervey, D (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.		Tollervey, David/AAR-6662-2020	Tollervey, David/0000-0003-2894-2772				Abbott J, 1999, MOL BIOL CELL, V10, P487, DOI 10.1091/mbc.10.2.487; Almeida F, 1998, J CELL BIOL, V142, P899, DOI 10.1083/jcb.142.4.899; Bellini M, 1998, MOL BIOL CELL, V9, P2987, DOI 10.1091/mbc.9.10.2987; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; Boudonck K, 1999, MOL BIOL CELL, V10, P2297, DOI 10.1091/mbc.10.7.2297; CAJAL SRY, 1908, TRAB LAB INVEST BIOL, V8, P27; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1993, J CELL BIOL, V120, P841, DOI 10.1083/jcb.120.4.841; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; CHABOT B, 1995, NUCLEIC ACIDS RES, V23, P3206, DOI 10.1093/nar/23.16.3206; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cooke C, 1996, MOL CELL BIOL, V16, P2579; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; CREMER T, 1993, COLD SPRING HARB SYM, V58, P777, DOI 10.1101/SQB.1993.058.01.085; Custodio N, 1999, EMBO J, V18, P2855, DOI 10.1093/emboj/18.10.2855; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Dundr M, 1998, MOL BIOL CELL, V9, P2407, DOI 10.1091/mbc.9.9.2407; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FREY MR, 1995, P NATL ACAD SCI USA, V92, P5915, DOI 10.1073/pnas.92.13.5915; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Ganot P, 1999, MOL CELL BIOL, V19, P6906; Gao LI, 1997, NUCLEIC ACIDS RES, V25, P4740, DOI 10.1093/nar/25.23.4740; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; HUANG S, 1994, J CELL BIOL, V126, P877, DOI 10.1083/jcb.126.4.877; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; Jacobs EY, 1999, MOL BIOL CELL, V10, P1653, DOI 10.1091/mbc.10.5.1653; Jacobson MR, 1998, P NATL ACAD SCI USA, V95, P7981, DOI 10.1073/pnas.95.14.7981; Jarrous N, 1999, J CELL BIOL, V146, P559, DOI 10.1083/jcb.146.3.559; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KARPEN GH, 1988, GENE DEV, V2, P1745, DOI 10.1101/gad.2.12b.1745; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KISS T, COMMUNICATION; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Knight SW, 1999, AM J HUM GENET, V65, P50, DOI 10.1086/302446; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lamond AI, 1999, NATURE, V397, P655, DOI 10.1038/17697; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LAMOND AI, COMMUNICATION; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lopato S, 1996, P NATL ACAD SCI USA, V93, P3074, DOI 10.1073/pnas.93.7.3074; Lyon CE, 1997, EXP CELL RES, V230, P84, DOI 10.1006/excr.1996.3380; Matera AG, 1998, J CELL BIOCHEM, V70, P181; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; Minvielle-Sebastia L, 1999, CURR OPIN CELL BIOL, V11, P352, DOI 10.1016/S0955-0674(99)80049-0; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Narayanan A, 1999, MOL BIOL CELL, V10, P2131, DOI 10.1091/mbc.10.7.2131; Narayanan A, 1999, EMBO J, V18, P5120, DOI 10.1093/emboj/18.18.5120; NEUGEBAUER K, COMMUNICATION; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; OAKES M, 1993, MOL CELL BIOL, V13, P2441, DOI 10.1128/MCB.13.4.2441; Oakes M, 1998, J CELL BIOL, V143, P23, DOI 10.1083/jcb.143.1.23; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; Pederson T, 1999, FASEB J, V13, pS238, DOI 10.1096/fasebj.13.9002.S238; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; Politz JC, 2000, P NATL ACAD SCI USA, V97, P55, DOI 10.1073/pnas.97.1.55; Politz JC, 1999, CURR BIOL, V9, P285, DOI 10.1016/S0960-9822(99)80136-5; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Puvion E, 1996, EXP CELL RES, V229, P217, DOI 10.1006/excr.1996.0363; PUVIONDUTILLEUL F, 1995, J CELL SCI, V108, P1143; Ramon y Cajal S., 1903, TRAD LAB INVEST BIOL, V2, P129; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; San-Segundo PA, 1999, CELL, V97, P313, DOI 10.1016/S0092-8674(00)80741-2; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; SCHULMEISTER T, 1993, BIOSENS BIOELECTRON, V8, P75, DOI 10.1016/0956-5663(93)80055-T; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; Singh OP, 1999, EXP CELL RES, V251, P135, DOI 10.1006/excr.1999.4490; Sleeman J, 1998, EXP CELL RES, V243, P290, DOI 10.1006/excr.1998.4135; Sleeman JE, 1999, CURR BIOL, V9, P1065, DOI 10.1016/S0960-9822(99)80475-8; SPECTOR D, 1993, ANN REV CELL BIOL, V9, P165; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Tuma RS, 1999, CHROMOSOMA, V108, P337, DOI 10.1007/s004120050385; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Verheggen C, 1998, J CELL BIOL, V142, P1167, DOI 10.1083/jcb.142.5.1167; Vincent M, 1996, NUCLEIC ACIDS RES, V24, P4649, DOI 10.1093/nar/24.23.4649; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Wu CHH, 1996, RNA, V2, P811; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zebarjadian Y, 1999, MOL CELL BIOL, V19, P7461; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	121	167	169	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 26	2000	288	5470					1385	1389		10.1126/science.288.5470.1385	http://dx.doi.org/10.1126/science.288.5470.1385			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827942				2022-12-28	WOS:000087270900040
J	Morrison, LJ; Verbeck, PR; McDonald, AC; Sawadsky, BV; Cook, DJ				Morrison, LJ; Verbeck, PR; McDonald, AC; Sawadsky, BV; Cook, DJ			Mortality and prehospital thrombolysis for acute myocardial infarction - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Royal-College-of-Physicians-and-Surgeons-of-Canada	SEP 16-27, 1998	TORONTO, CANADA	Royal Coll Physicians & Surgeons Canada			TISSUE PLASMINOGEN-ACTIVATOR; RANDOMIZED TRIALS; CLINICAL-TRIALS; THERAPY; MANAGEMENT; SURVIVAL; ELECTROCARDIOGRAM; METAANALYSIS; GUIDELINES; EMERGENCY	Context Early administration of thrombolysis for acute myocardial infarction (AMI) may improve survival if safely and appropriately delivered. No systematic reviews that have comprehensively examined this topic exist in the literature. Objective To perform a meta-analysis of randomized controlled trials of prehospital vs in-hospital thrombolysis for AMI measuring in-hospital mortality. Data Sources The Cochrane search strategy was used to search MEDLINE, EMBASE, and the Science Citation Index (1982-1999); Dissertation Abstracts (1987-1999); and Current Contents (1994-1999) for the terms thrombolysis, thrombolysis therapy, prehospital, and acute myocardial infarction. In addition, text and journal article bibliographies were hand searched, the National Institutes of Health Web site was reviewed, and primary authors and thrombolytic drug manufacturers were contacted for unpublished studies. Study Selection Randomized controlled trials of prehospital vs in-hospital thrombolysis for AMI measuring all-cause hospital mortality were included. Two authors independently reviewed 175 citations by title, abstract, or complete article. After exclusion of 30 duplicate citations, 145 studies remained, of which 6 studies and 3 follow-up studies met the inclusion criteria. Data Extraction Independent data abstraction by 2 reviewers blinded to the journal, title, and author was confirmed by consensus. Trial quality was independently assessed by 2 other coauthors, blinded to the author, title, journal, introduction, and discussion. Data Synthesis The results of the 6 randomized trials (n=6434) were pooled and indicated significantly decreased all-cause hospital mortality among patients treated with prehospital thrombolysis compared with in-hospital thrombolysis (odds ratio, 0.83; 95% confidence interval, 0.70-0.98). Results were similar regardless of trial quality or training and experience of the provider. Estimated (SE) time to thrombolysis was 104 (7) minutes for the prehospital group and 162 (16) minutes for the in-hospital thrombolysis group (P = .007). Conclusions Our meta-analysis suggests that prehospital thrombolysis for AMI significantly decreases the time to thrombolysis and all-cause hospital mortality.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Emergency Serv, Toronto, ON M4N 3M5, Canada; McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Morrison, LJ (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Emergency Serv, 2075 Bayview Ave,Suite BG-20, Toronto, ON M4N 3M5, Canada.	l.morrison@utoronto.ca	Morrison, Laurie Jean/A-6325-2012	Morrison, Laurie Jean/0000-0001-8369-9774				ANDERSON JL, 1992, J INTERV CARDIOL, V5, P127, DOI 10.1111/j.1540-8183.1992.tb00417.x; [Anonymous], 1990, LANCET, V336, P65; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BARBASH GI, 1990, AM J CARDIOL, V66, P261, DOI 10.1016/0002-9149(90)90832-L; BENSON NH, 1994, ANN EMERG MED, V23, P1047, DOI 10.1016/S0196-0644(94)70102-4; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; Boersma H, 1996, EUR HEART J, V17, P64; BOISSEL JP, 1995, INT J CARDIOL, V49, pS29, DOI 10.1016/0167-5273(95)02336-U; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P142; Brouwer MA, 1996, AM J CARDIOL, V78, P497, DOI 10.1016/S0002-9149(96)00352-9; Canto JG, 1997, J AM COLL CARDIOL, V29, P498, DOI 10.1016/S0735-1097(96)00532-3; Carlsson J, 1997, ANAESTHESIST, V46, P829, DOI 10.1007/s001010050476; CASTAIGNE AD, 1987, DRUGS, V33, P231, DOI 10.2165/00003495-198700333-00042; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; FathOrdoubadi F, 1996, HEART, V75, P169; *FIBR THER TRIAL C, 1994, LANCET, V343, P742; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GERSH BJ, 1993, CIRCULATION, V88, P296, DOI 10.1161/01.CIR.88.1.296; GOTSMAN M, 1996, KARDIOLOGIA POLSKA, V44, P6; GROVER A, 1995, CURR OPIN CARDIOL, V10, P361, DOI 10.1097/00001573-199507000-00004; GRUNEWALD M, 1994, FIBRINOLYSIS, V8, P67, DOI 10.1016/S0268-9499(05)80023-2; HUNT D, 1992, LANCET, V339, P753; Hunt DL, 1997, ANN INTERN MED, V126, P532, DOI 10.7326/0003-4819-126-7-199704010-00006; Julian DG, 1996, EUR HEART J, V17, P43; KENNEDY JW, 1987, HEART LUNG, V16, P740; KOWALENKO T, 1992, AM HEART J, V123, P181, DOI 10.1016/0002-8703(92)90764-M; LEFEUVRE C, 1993, AM J CARDIOL, V72, pG145, DOI 10.1016/0002-9149(93)90121-R; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; MCALEER B, 1992, CARDIOVASC DRUG THER, V6, P369, DOI 10.1007/BF00054183; MCNEILL AJ, 1989, BRIT HEART J, V61, P316; MULROW CD, 1997, COCHRANE COLLABORATI; Myers RBH, 1998, CAN J CARDIOL, V14, P1231; Nee PA, 1997, J ACCID EMERG MED, V14, P2; ORNATO JP, 1990, CLIN CARDIOL, V13, P27; ORNATO JP, 1995, AM J EMERG MED, V13, P58; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; Rawles JM, 1997, CLIN CARDIOL, V20, P6, DOI 10.1002/clc.4960201404; RISENFORS M, 1991, J INTERN MED, V229, P3; ROTH A, 1990, J AM COLL CARDIOL, V15, P932, DOI 10.1016/0735-1097(90)90219-F; ROZENMAN Y, 1995, INT J CARDIOL, V49, pS21, DOI 10.1016/0167-5273(95)02335-T; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; Selig MB, 1996, AM J EMERG MED, V14, P209, DOI 10.1016/S0735-6757(96)90135-7; Selker HP, 1997, ANN EMERG MED, V29, P310; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WEAVER WD, 1994, HOSP PRACT, V29, P77, DOI 10.1080/21548331.1994.11443004; WOO KS, 1994, CURR OPIN CARDIOL, V9, P471	50	385	411	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2686	2692		10.1001/jama.283.20.2686	http://dx.doi.org/10.1001/jama.283.20.2686			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	314FP	10819952				2022-12-28	WOS:000087046000037
J	Kurtz, JM				Kurtz, JM			Radiotherapy for early breast cancer: was a comprehensive overview of trials needed?	LANCET			English	Editorial Material							POSTOPERATIVE RADIOTHERAPY; RANDOMIZED TRIAL; MORTALITY; MORBIDITY		Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland	University of Geneva	Kurtz, JM (corresponding author), Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland.							ABE O, 1995, NEW ENGL J MED, V333, P1444; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; Gyenes G, 1998, RADIOTHER ONCOL, V48, P185, DOI 10.1016/S0167-8140(98)00062-0; Hojris I, 1999, LANCET, V354, P1425, DOI 10.1016/S0140-6736(99)02245-X; Overgaard M, 1999, LANCET, V353, P1641, DOI 10.1016/S0140-6736(98)09201-0; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Recht A, 1998, J CLIN ONCOL, V16, P2886, DOI 10.1200/JCO.1998.16.8.2886; Whelan TJ, 2000, J CLIN ONCOL, V18, P1220, DOI 10.1200/JCO.2000.18.6.1220	8	18	18	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1739	1740		10.1016/S0140-6736(00)02256-X	http://dx.doi.org/10.1016/S0140-6736(00)02256-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832819				2022-12-28	WOS:000087126100003
J	Bourges, P; Sidis, Y; Fong, HF; Regnault, LP; Bossy, J; Ivanov, A; Keimer, B				Bourges, P; Sidis, Y; Fong, HF; Regnault, LP; Bossy, J; Ivanov, A; Keimer, B			The spin excitation spectrum in superconducting YBa2Cu3O6.85	SCIENCE			English	Article							INELASTIC-NEUTRON-SCATTERING; MAGNETIC FLUCTUATIONS; T-C; DYNAMICS; LA2-XSRXCUO4; TEMPERATURE; DEPENDENCE; ENERGY; STATE; PHASE	A comprehensive inelastic neutron scattering study of magnetic excitations in the near optimally doped high-temperature superconductor YBa2Cu3O6.85 is presented. The spin correlations in the normal state are commensurate with the crystal Lattice, and the intensity is peaked around the wave vector characterizing the antiferromagnetic state of the insulating precursor, YBa2Cu3O6. Profound modifications of the spin excitation spectrum appear abruptly below the superconducting transition temperature T-c, where a commensurate resonant mode and a set of weaker incommensurate peaks develop. The data are consistent with models that are based on an underlying two-dimensional Fermi surface, predicting a continuous, downward dispersion relation connecting the resonant mode and the incommensurate excitations. The magnetic incommensurability in the YBa2Cu3O6+x system is thus not simply related to that of another high-temperature superconductor, La2-xSrxCuO4, where incommensurate peaks persist well above T-c. The temperature-dependent incommensurability is difficult to reconcile with interpretations based on charge stripe formation in YBa2Cu3O6+x near optimum doping.	CEA, CNRS, Leon Brillouin Lab, CE Saclay, F-91191 Gif Sur Yvette, France; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; CEA, Dept Rech Fondamentale Mat Condensee, F-38054 Grenoble 9, France; CNRS, Ctr Rech Tres Basses Temp, F-38042 Grenoble 9, France; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	CEA; Centre National de la Recherche Scientifique (CNRS); Princeton University; CEA; Centre National de la Recherche Scientifique (CNRS); Institut Laue-Langevin (ILL); Max Planck Society	Bourges, P (corresponding author), CEA, CNRS, Leon Brillouin Lab, CE Saclay, F-91191 Gif Sur Yvette, France.	bourges@bali.saclay.cea.fr	Regnault, Louis-Pierre/AAM-6840-2020	Regnault, Louis-Pierre/0000-0002-4786-299X; Bourges, Philippe/0000-0001-9494-0789; Keimer, Bernhard/0000-0001-5220-9023				Aeppli G, 1997, SCIENCE, V278, P1432, DOI 10.1126/science.278.5342.1432; Arai M, 1999, PHYS REV LETT, V83, P608, DOI 10.1103/PhysRevLett.83.608; Balatsky AV, 1999, PHYS REV LETT, V82, P5337, DOI 10.1103/PhysRevLett.82.5337; Bourges P, 1999, AIP CONF PROC, V483, P207; Bourges P, 1997, EUROPHYS LETT, V38, P313, DOI 10.1209/epl/i1997-00244-6; Bourges P, 1996, PHYS REV B, V53, P876, DOI 10.1103/PhysRevB.53.876; Bourges P, 1998, NATO ADV SCI I B-PHY, V371, P349; Bourges P, 1997, PHYS REV B, V56, P11439, DOI 10.1103/PhysRevB.56.R11439; Brinckmann J, 1999, PHYS REV LETT, V82, P2915, DOI 10.1103/PhysRevLett.82.2915; Dai PC, 1998, PHYS REV LETT, V80, P1738, DOI 10.1103/PhysRevLett.80.1738; Fong HF, 1996, PHYS REV B, V54, P6708, DOI 10.1103/PhysRevB.54.6708; FONG HF, 1995, PHYS REV LETT, V75, P316, DOI 10.1103/PhysRevLett.75.316; Fong HF, 1997, PHYS REV LETT, V78, P713, DOI 10.1103/PhysRevLett.78.713; FONG HF, IN PRESS PHYS REV B; MASON TE, 1992, PHYS REV LETT, V68, P1414, DOI 10.1103/PhysRevLett.68.1414; MOOK HA, 1993, PHYS REV LETT, V70, P3490, DOI 10.1103/PhysRevLett.70.3490; Mook HA, 1998, NATURE, V395, P580, DOI 10.1038/26931; Petit S, 1997, PHYSICA B, V234, P800, DOI 10.1016/S0921-4526(96)01100-3; Regnault LP, 1998, PH CH MAT L, V20, P85; ROSSATMIGNOD J, 1991, PHYSICA C, V185, P86, DOI 10.1016/0921-4534(91)91955-4; THURSTON TR, 1992, PHYS REV B, V46, P9128, DOI 10.1103/PhysRevB.46.9128; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; VANDERMAREL D, 1995, PHYS REV B, V51, P1147, DOI 10.1103/PhysRevB.51.1147; Yamada K, 1998, PHYS REV B, V57, P6165, DOI 10.1103/PhysRevB.57.6165	25	234	234	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	2000	288	5469					1234	1237		10.1126/science.288.5469.1234	http://dx.doi.org/10.1126/science.288.5469.1234			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817996				2022-12-28	WOS:000087112600048
J	Leitner, W				Leitner, W			Designed to dissolve	NATURE			English	Editorial Material							SUPERCRITICAL CARBON-DIOXIDE		Max Planck Inst Kohlenforsch, D-45470 Mulheim, Germany	Max Planck Society	Leitner, W (corresponding author), Max Planck Inst Kohlenforsch, Kaiser Wilhelm Pl 1, D-45470 Mulheim, Germany.		Leitner, Walter/D-3031-2015	Leitner, Walter/0000-0001-6100-9656				DESIMONE JM, 1994, SCIENCE, V265, P356, DOI 10.1126/science.265.5170.356; Hadida S, 1997, J AM CHEM SOC, V119, P7406, DOI 10.1021/ja971120i; JESSOP PG, 1999, CHEM SYNTHESIS USING; Johnston KP, 1996, SCIENCE, V271, P624, DOI 10.1126/science.271.5249.624; Kainz S, 1997, ANGEW CHEM INT EDIT, V36, P1628, DOI 10.1002/anie.199716281; LAINTZ KE, 1992, ANAL CHEM, V64, P2875, DOI 10.1021/ac00046a039; McHugh M., 1994, SUPERCRITICAL FLUID, Vsecond; NOYORI R, 1999, CHEM REV, V99; Sarbu T, 2000, NATURE, V405, P165, DOI 10.1038/35012040; ZOSEL K, 1978, ANGEW CHEM INT EDIT, V17, P702, DOI 10.1002/anie.197807021	10	115	119	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					129	130		10.1038/35012181	http://dx.doi.org/10.1038/35012181			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821253				2022-12-28	WOS:000087080100028
J	Herron, MJ; Nelson, CM; Larson, J; Snapp, KR; Kansas, GS; Goodman, JL				Herron, MJ; Nelson, CM; Larson, J; Snapp, KR; Kansas, GS; Goodman, JL			Intracellular parasitism by the human granulocytic ehrlichiosis bacterium through the P-selectin ligand, PSGL-1	SCIENCE			English	Article							MYELOID CELLS; GLYCOPROTEIN; AGENT; IDENTIFICATION; RECOGNITION; COMPLEMENT; EXPRESSION; RECEPTORS; INFECTION; BINDING	Human granulocytic ehrlichiosis (HGE) is a febrile tick-borne illness caused by a recently discovered intracellular bacterium remarkable for its tropism for professionally phagocytic neutrophils. Monoclonal antibodies against the P-selectin binding domain of the leukocyte P-selectin glycoprotein ligand, PSGL-1, prevented HGE cell binding and infection, as did enzymatic digestion of PSGL-1. Furthermore, simultaneous neoexpression in nonsusceptible cells of complementary DNAs for both PSGL-1 and its modifying alpha-(1,3) fucosyltransferase, Fuc-TVII, allowed binding and infection by HGE. Thus, the HGE bacterium specifically bound to fucosylated Leukocyte PSGL-1. Selectin mimicry is likely central to the organism's unique ability to target and infect neutrophils.	Univ Minnesota, Sch Med, Dept Med, Div Infect Dis, Minneapolis, MN 55455 USA; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	University of Minnesota System; University of Minnesota Twin Cities; Northwestern University	Goodman, JL (corresponding author), Univ Minnesota, Sch Med, Dept Med, Div Infect Dis, Minneapolis, MN 55455 USA.	goodmanj@cber.fda.gov			NIAID NIH HHS [R01AI40952] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040952] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Behl R, 2000, THROMB HAEMOSTASIS, V83, P114; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BLACKWELL JM, 1985, J EXP MED, V162, P324, DOI 10.1084/jem.162.1.324; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; Cossart P, 1996, SCIENCE, V271, P315, DOI 10.1126/science.271.5247.315; FURTADO GD, 1992, INFECT IMMUN, V60, P4925, DOI 10.1128/IAI.60.11.4925-4931.1992; Goodman JL, 1999, J CLIN INVEST, V103, P407, DOI 10.1172/JCI4230; Goodman JL, 1996, NEW ENGL J MED, V334, P209, DOI 10.1056/NEJM199601253340401; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Klein MB, 1997, J INFECT DIS, V176, P1405, DOI 10.1086/517332; KLEIN MB, IN PRESS J INFECT DI; LARSON J, 1998, INT C EM INF DIS ATL; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; Nadelman RB, 1997, NEW ENGL J MED, V337, P27, DOI 10.1056/NEJM199707033370105; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PAYNE NR, 1987, J EXP MED, V166, P1377, DOI 10.1084/jem.166.5.1377; Sinai AP, 1997, ANNU REV MICROBIOL, V51, P415, DOI 10.1146/annurev.micro.51.1.415; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; Snapp KR, 1998, J CELL BIOL, V142, P263, DOI 10.1083/jcb.142.1.263; SVEDMYR E, 1975, P NATL ACAD SCI USA, V72, P1622, DOI 10.1073/pnas.72.4.1622; Wagers AJ, 1997, J IMMUNOL, V159, P1917; Webster P, 1998, J CLIN INVEST, V101, P1932, DOI 10.1172/JCI1544; Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575	28	105	113	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 2	2000	288	5471					1653	1656		10.1126/science.288.5471.1653	http://dx.doi.org/10.1126/science.288.5471.1653			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834846				2022-12-28	WOS:000087382300044
J	Nasmyth, K; Peters, LM; Uhlmann, F				Nasmyth, K; Peters, LM; Uhlmann, F			Splitting the chromosome: Cutting the ties that bind sister chromatids	SCIENCE			English	Review							ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; FISSION YEAST; TOPOISOMERASE-II; MAMMALIAN-CELLS; BUDDING YEAST; DROSOPHILA-MELANOGASTER; CENTROMERE SEPARATION; PROTEIN COMPLEXES	In eukaryotic cells, sister DNA molecules remain physically connected from their production at S phase until their separation during anaphase. This cohesion is essential for the separation of sister chromatids to opposite poles of the cell at mitosis. It also permits chromosome segregation to take place long after duplication has been completed. Recent work has identified a multisubunit complex called cohesin that is essential for connecting sisters. Proteolytic cleavage of one of cohesin's subunits may trigger sister separation at the onset of anaphase,	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Nasmyth, Kim/0000-0001-7030-4403; Uhlmann, Frank/0000-0002-3527-6619				Akhmedov AT, 1999, J BIOL CHEM, V274, P38216, DOI 10.1074/jbc.274.53.38216; Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Belar Karl, 1929, Wilhelm Roux Arch Entwickl Mech Org, V118, P359, DOI 10.1007/BF02108879; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CLOSK R, 2000, MOL CELL, V5, P1; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; COMINGS DE, 1966, SCIENCE, V154, P1463, DOI 10.1126/science.154.3755.1463; Darlington CD, 1939, EVOLUTION GENETIC SY; DAVIS BK, 1971, MOL GEN GENET, V113, P251, DOI 10.1007/BF00339546; DENISON SH, 1993, GENETICS, V134, P1085; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1991, P NATL ACAD SCI USA, V88, P8895, DOI 10.1073/pnas.88.20.8895; FITZGERALD PH, 1975, ANN HUM GENET, V38, P417, DOI 10.1111/j.1469-1809.1975.tb00631.x; FLEMMING W, 1879, ARCH MIKROSK ANAT, V18, P151; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Furuya K, 1998, GENE DEV, V12, P3408, DOI 10.1101/gad.12.21.3408; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GORBSKY GJ, 1994, CANCER RES, V54, P1042; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; IZUTSU KOSAKU, 1959, MIE MED JOUR, V9, P15; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; Khodjakov A, 1996, J CELL BIOL, V132, P1093, DOI 10.1083/jcb.132.6.1093; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; LICA LM, 1986, J CELL BIOL, V103, P1145, DOI 10.1083/jcb.103.4.1145; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAGUIRE MP, 1991, GENOME, V34, P879, DOI 10.1139/g91-135; MAGUIRE MP, 1990, BIOCHEM CELL BIOL, V68, P1231, DOI 10.1139/o90-183; MAY GS, 1992, J BIOL CHEM, V267, P15737; MAZIA D, 1961, MITOSIS PHYSL CELL D, V3; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; MCNEILL PA, 1981, J CELL BIOL, V88, P543, DOI 10.1083/jcb.88.3.543; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MOLEBAJER J, 1958, CHROMOSOMA, V9, P332, DOI 10.1007/BF02568085; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; Nagao K, UNPUB; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; RATTNER JB, 1991, BIOESSAYS, V13, P51, DOI 10.1002/bies.950130202; RIEDER CL, 1992, J CELL SCI, V102, P387; Rieder CL, 1999, J CELL SCI, V112, P2607; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Schrader F., 1944, MITOSIS; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SUMARA I, COMMUNICATION; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka K, 2000, MOL CELL BIOL, V20, P3459, DOI 10.1128/MCB.20.10.3459-3469.2000; TANAKA T, COMMUNICATION; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; TIPPIT DH, 1980, J CELL BIOL, V86, P402, DOI 10.1083/jcb.86.2.402; TOMKINS D, 1979, AM J MED GENET, V4, P17, DOI 10.1002/ajmg.1320040104; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; van Heemst D, 1999, CELL, V98, P261, DOI 10.1016/S0092-8674(00)81020-X; VIG BK, 1981, HUM GENET, V57, P247; WAIZENEGGER I, COMMUNICATION; WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	95	362	373	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 26	2000	288	5470					1379	1384		10.1126/science.288.5470.1379	http://dx.doi.org/10.1126/science.288.5470.1379			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827941				2022-12-28	WOS:000087270900039
J	Lichtigfeld, F; Gillman, M				Lichtigfeld, F; Gillman, M			Violence and provision of community psychiatry	LANCET			English	Editorial Material									S African Brain Res Inst, ZA-2090 Waverly, South Africa		Gillman, M (corresponding author), S African Brain Res Inst, 6 Campbell St, ZA-2090 Waverly, South Africa.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1804	1804		10.1016/S0140-6736(00)02308-4	http://dx.doi.org/10.1016/S0140-6736(00)02308-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	315RE	10832844				2022-12-28	WOS:000087126100042
J	Shrewsbury, S; Pyke, S; Britton, M				Shrewsbury, S; Pyke, S; Britton, M			Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FLUTICASONE PROPIONATE; CORTICOSTEROIDS; TRIALS	Objective To examine the benefits of adding salmeterol compared with increasing dose of inhaled corticosteroids. Design Systematic review of randomised, double blind clinical trials. Independent data extraction and validation with summary data from study reports and manuscripts. Fixed and random effects analyses. Setting EMBASE, Medline, and GlaxoWellcome internal clinical study registers. Main outcome measures Efficacy and exacerbations. Results Among 2055 trials of treatment with salmeterol, there were nine parallel group trials of greater than or equal to 12 weeks with 3685 symptomatic patients aged greater than or equal to 12 years taking inhaled steroid in primary or secondary care. Compared with response to increased steroids: in patients receiving salmeterol morning peak expiratory flow was greater at thr ee months (difference 22.4 (95% confidence interval 15.0 to 30.0) litre/min. P< 0.001) and six months (27.7 (19.0 to 36.4) litre/min, P< 0.001). Forced expiratory volume in one second (FEV1,) was also increased at three months (0.10 (0.04 to 0.16) litres, P < 0.001) and six months (0.08 (0.02 to 0.14) litres, P <0.01) as were mean percentage of days and nights without symptoms (three months: days-12% (9% to 15%), nights-5% (3% to 7%); six months: days-15%(12% to 18%), nights-5% (3% to 7%); all P < 0.001) and mean percentage of days and nights without need for rescue treatment (three months: days-17% (14% to 20%), nights-9% (7% to 11%); six months: days-20% (17 to 23%), nights-8% (6% to 11%); all P< 0.001). Fewer patients experienced any exacerbation with salmeterol (difference 2.73% (0.43% to 5.04%), P = 0.02), and the proportion of patients with moderate or severe exacerbations was also lower (2.42% (0.24% to 4.60%), P = 0.03. Conclusions Addition of salmeterol in symptomatic patients aged 12 and over on low to moderate doses of inhaled steroid gives improved lung function and increased number of days aid nights without symptoms or need for rescue treatment with no increase in exacerbations of any severity.	Glaxo Wellcome UK, Uxbridge UB11 1BT, Middx, England; St Peters Hosp, Surrey KT16 0PZ, England	GlaxoSmithKline	Shrewsbury, S (corresponding author), Glaxo Wellcome UK, Stockley Pk W, Uxbridge UB11 1BT, Middx, England.	sbs40926@glaxowellcome.com			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Condemi JJ, 1999, ANN ALLERG ASTHMA IM, V82, P383, DOI 10.1016/S1081-1206(10)63288-7; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EGGER M, 1998, BRIT MED J, V16, P61; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; IND PW, 1998, AM J RESP CRIT CARE, V157, pA415; IND PW, 1998, AM J RESP CRIT CARE, V157, pA416; INNES JA, 1994, LANCET, V343, P599; Jenkins C, 1999, AM J RESP CRIT CARE, V159, pA638; Kalberg CJ, 1998, J ALLERGY CLIN IMMUN, V101, pS6; Kelsen SG, 1999, J ASTHMA, V36, P703, DOI 10.3109/02770909909055422; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Murray JJ, 1999, ALLERGY ASTHMA PROC, V20, P173, DOI 10.2500/108854199778553028; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; van Noord JA, 1999, THORAX, V54, P207, DOI 10.1136/thx.54.3.207; Vermetten FAAM, 1999, J ASTHMA, V36, P97, DOI 10.3109/02770909909065153; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	16	318	333	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2000	320	7246					1368	1373		10.1136/bmj.320.7246.1368	http://dx.doi.org/10.1136/bmj.320.7246.1368			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818025	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000087232500020
J	Huber, KM; Kayser, MS; Bear, MF				Huber, KM; Kayser, MS; Bear, MF			Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression	SCIENCE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; AREA CA1; CELL-BODIES; LATE-PHASE; INDUCTION; SYNAPSES; FACILITATION; TRANSLATION; EXPRESSION; ACTIVATION	A hippocampal pyramidal neuron receives more than 10(4) excitatory glutamatergic synapses. Many of these synapses contain the molecular machinery for messenger RNA translation, suggesting that the protein complement (and thus function) of each synapse can be regulated on the basis of activity. Here, Local postsynaptic protein synthesis, triggered by synaptic activation of metabotropic glutamate receptors, was found to modify synaptic transmission within minutes.	Brown Univ, Howard Hughes Med Inst, Providence, RI 02912 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Brown University; Howard Hughes Medical Institute; Brown University	Bear, MF (corresponding author), Brown Univ, Howard Hughes Med Inst, Providence, RI 02912 USA.		Huber, Kimberly/X-5534-2019	Kayser, Matthew/0000-0003-2359-4967; Bear, Mark/0000-0002-9903-2541				Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; CHU LY, 1980, BIOCHEMISTRY-US, V19, P184, DOI 10.1021/bi00542a028; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; Fitzjohn SM, 1999, NEUROPHARMACOLOGY, V38, P1577, DOI 10.1016/S0028-3908(99)00123-9; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Huber K. M., 1998, Society for Neuroscience Abstracts, V24, P512; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kemp N, 1999, NEUROPHARMACOLOGY, V38, P495, DOI 10.1016/S0028-3908(98)00222-6; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Linden DJ, 1996, NEURON, V17, P483, DOI 10.1016/S0896-6273(00)80180-4; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; Oliet SHR, 1997, NEURON, V18, P969, DOI 10.1016/S0896-6273(00)80336-0; Oliet SHR, 1996, SCIENCE, V271, P1294, DOI 10.1126/science.271.5253.1294; Ouyang Y, 1999, J NEUROSCI, V19, P7823; Raymond CR, 2000, J NEUROSCI, V20, P969, DOI 10.1523/JNEUROSCI.20-03-00969.2000; Sawtell NB, 1999, J NEUROPHYSIOL, V82, P3594, DOI 10.1152/jn.1999.82.6.3594; Sherff CM, 1999, SCIENCE, V285, P1911, DOI 10.1126/science.285.5435.1911; Steward O, 1996, J NEUROCYTOL, V25, P717, DOI 10.1007/BF02284837; TORRE ER, 1992, J NEUROSCI, V12, P762; WEILER IJ, 1993, P NATL ACAD SCI USA, V90, P7168, DOI 10.1073/pnas.90.15.7168; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395	24	732	747	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1254	1256		10.1126/science.288.5469.1254	http://dx.doi.org/10.1126/science.288.5469.1254			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10818003				2022-12-28	WOS:000087112600055
J	Petcherski, AG; Kimble, J				Petcherski, AG; Kimble, J			LAG-3 is a putative transcriptional activator in the C-elegans Notch pathway	NATURE			English	Article							OF-FUNCTION MUTATIONS; CAENORHABDITIS-ELEGANS; INTRACELLULAR DOMAIN; SIGNALING PATHWAY; ANKYRIN REPEATS; CELL FATE; GERM-LINE; GLP-1; GENE; PROTEIN	Notch signalling controls growth, differentiation and patterning during normal animal development(1,2); in humans, aberrant Notch signalling has been implicated in cancer and stroke(3,4). The mechanism of Notch signalling is thought to require cleavage of the receptor in response to ligand binding(5), movement of the receptor's intracellular domain to the nucleus(6,7), and binding of that intracellular domain to a CSL (for CBF1, Suppressor of Hairless, LAG-1)(8,9) protein. Here we identify LAG-3, a glutamine-rich protein that forms a ternary complex together with the LAG-1 DNA-binding protein(10) and the receptor's intracellular domain. Receptors with mutant ankyrin repeats that abrogate signal transduction are incapable of complex formation both in yeast and in vitro. Using RNA interference, we find that LAG-3 activity is crucial in Caenorhabditis elegans for both GLP-1 and LIN-12 signalling. LAG-3 is a potent transcriptional activator in yeast, and a Myc-tagged LAG-3 is predominantly nuclear in C. elegans. We propose that GLP-1 and LIN-12 promote signalling by recruiting LAG-3 to target promoters, where it functions as a transcriptional activator.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kimble, J (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, 433 Babcock Dr, Madison, WI 53706 USA.	jekimble@facstaff.wisc.edu						Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; Bartel P. L., 1997, YEAST 2 HYBRID SYSTE; Berry LW, 1997, DEVELOPMENT, V124, P925; *C EL SEQ CONS, 1998, SCIENCE, V283, P2103; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; C. elegans Sequencing Consortium, 1999, SCIENCE, V283, P35; Christensen S, 1996, DEVELOPMENT, V122, P1373; CRITTENDEN SL, 1998, CELL LAB MANUAL, V108, P101; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kato H, 1997, DEVELOPMENT, V124, P4133; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; KODOYIANNI V, 1992, MOL BIOL CELL, V3, P1199, DOI 10.1091/mbc.3.11.1199; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kraemer B, 1999, CURR BIOL, V9, P1009, DOI 10.1016/S0960-9822(99)80449-7; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; MANGO SE, 1991, NATURE, V352, P811, DOI 10.1038/352811a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Subramaniam K, 1999, DEVELOPMENT, V126, P4861; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X	32	148	162	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 18	2000	405	6784					364	368		10.1038/35012645	http://dx.doi.org/10.1038/35012645			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830967				2022-12-28	WOS:000087085700051
J	Walker, DW; McColl, G; Jenkins, NL; Harris, J; Lithgow, GJ				Walker, DW; McColl, G; Jenkins, NL; Harris, J; Lithgow, GJ			Natural selection - Evolution of lifespan in C-elegans	NATURE			English	Article							CAENORHABDITIS-ELEGANS; WILD-TYPE; MUTANT; THERMOTOLERANCE; LONGEVITY; AGE-1; LONG		Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Walker, DW (corresponding author), Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England.	Gordon.Lithgow@man.ac.uk	McColl, Gawain/Y-8959-2018	McColl, Gawain/0000-0002-6347-6722				DUHON SA, 1995, J GERONTOL A-BIOL, V50, pB254, DOI 10.1093/gerona/50A.5.B254; FRIEDMAN DB, 1988, J GERONTOL, V43, pB102, DOI 10.1093/geronj/43.4.B102; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; Malone EA, 1996, GENETICS, V143, P1193; Medawar P., 1952, UNSOLVED PROBLEM BIO; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Tissenbaum HA, 1998, GENETICS, V148, P703; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x	10	142	147	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 18	2000	405	6784					296	297		10.1038/35012693	http://dx.doi.org/10.1038/35012693			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830948				2022-12-28	WOS:000087085700031
J	Gapstur, SM; Gann, PH; Lowe, W; Liu, K; Colangelo, L; Dyer, A				Gapstur, SM; Gann, PH; Lowe, W; Liu, K; Colangelo, L; Dyer, A			Abnormal glucose metabolism and pancreatic cancer mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSOCIATION DETECTION PROJECT; POSTLOAD PLASMA-GLUCOSE; CORONARY HEART-DISEASE; SERUM URIC-ACID; MIDDLE-AGED MEN; GROWTH-FACTOR-I; NUTRITIONAL FACTORS; DIABETES-MELLITUS; UNITED-STATES; RISK-FACTORS	Context Previous studies reported an increased risk of pancreatic cancer among persons with diabetes. Few data exist, however, on the association of postload plasma glucose concentration with pancreatic cancer, which could provide insight into the role of abnormal glucose metabolism in the etiology of pancreatic cancer. Objective To determine the independent association between postload plasma glucose concentration and risk of pancreatic cancer mortality among persons without self-reported diabetes. Design Prospective cohort study. Setting and Participants Employees of 84 Chicago-area organizations, with an average age of 40 years at baseline, were screened from 1963 to 1973 and followed up for an average of 25 years. A total of 96 men and 43 women died of pancreatic cancer among 20475 men and 15 183 women, respectively. Main Outcome Measures Relationship of pancreatic cancer mortality with postload plasma glucose levels. Results Compared with a postload plasma glucose level of 6.6 mmol/L (119 mg/ dL) or less and after adjusting for age, race, cigarette smoking, and body mass index, the relative risks (95% confidence intervals) of pancreatic cancer mortality were 1.65 (1.05-2.60) for postload plasma glucose levels between 6.7 (120) and 8.8 (159) mmol/L (mg/dL); 1.60 (0.95-2.70) for levels between 8.9 (160) and 11.0 (199); and 2.15 (1.22-3.80) for levels of 11.1 (200) or more; P far trend = .01. An association appeared to be stronger for men than women. Estimates were only slightly lower after excluding 11 men and 2 women who died of pancreatic cancer during the first 5 years of followup. In men only, higher body mass index and serum uric acid concentration also were independently associated with an elevated risk of pancreatic cancer mortality. Conclusion These results suggest that factors associated with abnormal glucose metabolism may play an important role in the etiology of pancreatic cancer.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; Northwestern Univ, Sch Med, Dept Med, Ctr Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Chicago, IL USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University	Gapstur, SM (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.				NCI NIH HHS [R03 CA81617-01] Funding Source: Medline; NHLBI NIH HHS [R01 HL21010-21] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA081617] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Cancer Society, 1999, CANC FACTS FIG 1999; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; Anderson KE PJ, 1996, CANC EPIDEMIOLOGY PR, P725; BERGMANN U, 1995, CANCER RES, V55, P2007; Calle EE, 1998, CANCER CAUSE CONTROL, V9, P403, DOI 10.1023/A:1008819701485; CHOW WH, 1995, J NATL CANCER I, V87, P930, DOI 10.1093/jnci/87.12.930; COOPER R, 1984, AM HEART J, V108, P827, DOI 10.1016/0002-8703(84)90678-1; Criqui M H, 1991, Ann Epidemiol, V1, P385; DEMESQUITA HBB, 1990, INT J CANCER, V46, P435, DOI 10.1002/ijc.2910460319; FACCHINI F, 1991, JAMA-J AM MED ASSOC, V266, P3008, DOI 10.1001/jama.266.21.3008; Fisher WE, 1996, J SURG RES, V63, P310, DOI 10.1006/jsre.1996.0266; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FOSTER DW, 1994, HARRISONS PRINCIPLES, P1979; FRIEDMAN GD, 1993, INT J EPIDEMIOL, V22, P30, DOI 10.1093/ije/22.1.30; GHADIRIAN P, 1991, INT J CANCER, V47, P1, DOI 10.1002/ijc.2910470102; GULLO L, 1993, ITAL J GASTROENTEROL, V25, P487; HARRIS MI, 1995, DIABETES AM, P782; HIATT RA, 1988, CANCER RES, V48, P2916; Hoffman WS, 1937, J BIOL CHEM, V120, P51; HOWE GR, 1992, INT J CANCER, V51, P365, DOI 10.1002/ijc.2910510306; Ji BT, 1996, INT J CANCER, V66, P432; KOLONEL LN, 1994, CANCER EPIDEM BIOMAR, V3, P225; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; LEVINE W, 1990, AM J EPIDEMIOL, V131, P254, DOI 10.1093/oxfordjournals.aje.a115495; LEVINE W, 1989, J CLIN EPIDEMIOL, V42, P257, DOI 10.1016/0895-4356(89)90061-9; LIU K, 1982, J CHRON DIS, V35, P475, DOI 10.1016/0021-9681(82)90062-5; LYON JL, 1993, CANCER EPIDEM BIOMAR, V2, P513; MOLLER H, 1994, EUR J CANCER, V30A, P344, DOI 10.1016/0959-8049(94)90254-2; MOLLO F, 1986, PATHOL RES PRACT, V181, P442, DOI 10.1016/S0344-0338(86)80080-2; MUSEY VC, 1993, AM J MED SCI, V305, P131, DOI 10.1097/00000441-199303000-00001; *NAT CTR HLTH STAT, 1967, INT CLASS DIS; NOY A, 1994, J CLIN ENDOCR METAB, V79, P1223, DOI 10.1210/jc.79.5.1223; OHMURA E, 1990, CANCER RES, V50, P103; Orencia AJ, 1997, J CLIN EPIDEMIOL, V50, P1369, DOI 10.1016/S0895-4356(97)00201-1; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; PERMERT J, 1993, BRIT J SURG, V80, P1047, DOI 10.1002/bjs.1800800841; PERMERT J, 1993, EUR J SURG, V159, P101; PETERSSON B, 1983, BMJ-BRIT MED J, V287, P7, DOI 10.1136/bmj.287.6384.7; Silverman DT, 1998, JNCI-J NATL CANCER I, V90, P1710, DOI 10.1093/jnci/90.22.1710; SINDELAR WF, 1985, CANCER PRINCIPLES PR, P691; SMITH GD, 1992, AM J EPIDEMIOL, V136, P1110, DOI 10.1093/oxfordjournals.aje.a116576; SOKVERMAN DT, 1999, BRIT J CANCER, V80, P1830; STAMLER J, 1975, J CHRON DIS, V28, P499, DOI 10.1016/0021-9681(75)90059-4; SUIKKARI AM, 1988, J CLIN ENDOCR METAB, V66, P266, DOI 10.1210/jcem-66-2-266; TAKKUNEN H, 1984, BRIT MED J, V288, P1161, DOI 10.1136/bmj.288.6424.1161; Troiano RP, 1998, PEDIATRICS, V101, P497; VACCARO O, 1992, DIABETES CARE, V15, P1328, DOI 10.2337/diacare.15.10.1328; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; WILLIAMS JA, 1985, DIABETES, V34, P980, DOI 10.2337/diabetes.34.10.980	50	302	317	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2552	2558		10.1001/jama.283.19.2552	http://dx.doi.org/10.1001/jama.283.19.2552			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312VL	10815119	Bronze			2022-12-28	WOS:000086964600036
J	Smith, JE; Winkler, RL; Fryback, DG				Smith, JE; Winkler, RL; Fryback, DG			The first positive: Computing positive predictive value at the extremes	ANNALS OF INTERNAL MEDICINE			English	Article							DECISION-MAKING	Computing the positive predictive value (PPV) of a well-known test for a relatively common disease is a straightforward exercise. However, in the case of a new test for a rare disorder, the extreme numbers involved-the very low prevalence of the disorder and the lack of previous false-positive results-make it difficult to compute the PPV. As new genetic tests become available in the next decade, more and more clinicians will have to answer questions about PPVs in cases with extreme prevalence, sensitivity, and specificity. This paper presents some tools for thinking about these calculations. First, a standard PPV calculation with rough estimates of the prevalence, sensitivity, and specificity is reviewed. The "zero numerator" problem posed by not having seen any false-positive results is then discussed, and a Bayesian approach to this problem is described. The Bayesian approach requires specification of a prior distribution that describes the initial uncertainty about the false-positive rate. This prior distribution is updated as new evidence is obtained, and the updated expected false-positive rate is used to calculate PPVs. The Bayesian approach provides appropriate and defensible PPVs and can be used to estimate failure rates for other rare events as well.	Duke Univ, Fuqua Sch Business, Durham, NC 27708 USA; Univ Wisconsin, Madison, WI USA	Duke University; University of Wisconsin System; University of Wisconsin Madison	Smith, JE (corresponding author), Duke Univ, Fuqua Sch Business, Box 90120, Durham, NC 27708 USA.	jes9@mail.duke.edu						Berry D.A., 1996, STAT BAYESIAN PERSPE; BLYTH CR, 1986, J AM STAT ASSOC, V81, P843, DOI 10.2307/2289018; Clemen RT, 1999, RISK ANAL, V19, P187, DOI 10.1111/j.1539-6924.1999.tb00399.x; Davidoff F, 1999, ANN INTERN MED, V130, P1019, DOI 10.7326/0003-4819-130-12-199906150-00022; Eddy DM, 1982, JUDGMENT UNCERTAINTY, P249; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; *MICRO CORP, 1999, MICRO EXC 2000; Morgan M.G., 1990, UNCERTAINTY GUIDE DE; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; Smith JE, 1999, INTERFACES, V29, P63, DOI 10.1287/inte.29.3.63; Sox HC, 1988, MED DECISION MAKING; SPETZLER CS, 1975, MANAGE SCI, V39, P176; Winkler R., 1972, INTRO BAYESIAN INFER	15	27	29	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2000	132	10					804	809		10.7326/0003-4819-132-10-200005160-00008	http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	313XN	10819704				2022-12-28	WOS:000087025100006
J	Tsai, HM; Rice, L; Sarode, R; Chow, TW; Moake, JL				Tsai, HM; Rice, L; Sarode, R; Chow, TW; Moake, JL			Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura	ANNALS OF INTERNAL MEDICINE			English	Article							VONWILLEBRAND-FACTOR MULTIMERS; HEMOLYTIC-UREMIC SYNDROME; FACTOR-CLEAVING PROTEASE; FACTOR-VIII; ABNORMALITIES; CLEAVAGE	Background: Thrombotic thrombocytopenic purpura (TTP) affects 1 in 1600 to 1 in 5000 patients who receive ticlopidine, but little is known about the pathogenesis of this complication. Objective: To investigate whether von Willebrand factor (VWF), which has been associated with idiopathic TTP, is involved in the pathogenesis of ticlopidine-associated TTP. Design: Case series. Setting: Three tertiary care, university-affiliated medical centers. Patients: Seven patients who developed TTP 2 to 7 weeks after initiation of ticlopidine therapy. Controls were 7 consecutive patients without thrombocytopenia who had been receiving ticlopidine for 3 to 5 weeks and 10 randomly selected hospitalized patients. Measurements: Platelet-bound vWF in patients' EDTA-anticoagulated whole blood samples; vWF proteinase activity in patients' plasma samples; inhibitory activity of IgG isolated from patients' plasma samples against the proteinase from the controls' plasma samples; and vWF multimeric patterns in patients' EDTA-anticoagulated plasma samples. Results: Binding of vWF to single platelets was increased in the three patients tested during the most thrombocytopenic phase of TTP episodes. Initial plasma samples from al I seven patients lacked the largest vWF multimers and were severely deficient in vWF metalloproteinase. IgG molecules, isolated from plasma samples of five patients, inhibited metalloproteinase in plasma samples from the controls. In patients examined, these abnormalities resolved upon the remission that accompanied plasma exchange and discontinuation of ticlopidine therapy. Conclusion: In the patients who developed ticlopidine-associated TTP, autoantibodies to the vWF metalloproteinase were formed; this led to the same type of VWF abnormalities observed in patients with idiopathic acute TTP. The findings suggest that failure to process large and unusually large vWF multimers in vivo caused binding of vWF to platelets, systemic platelet thrombosis, and TTP.	Baylor Coll Med, Houston, TX 77030 USA; Rice Univ, Cox Lab Biomed Engn, Houston, TX 77005 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	Baylor College of Medicine; Rice University; Case Western Reserve University	Tsai, HM (corresponding author), Montefiore Med Ctr, Div Hematol, 111 East 210th St, Bronx, NY 10467 USA.				NHLBI NIH HHS [HL 54169, HL18584, HL62131, R01 HL062136-02, R01 HL062136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018584, R01HL062136, R01HL018584] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASADA Y, 1985, THROMB RES, V38, P469, DOI 10.1016/0049-3848(85)90180-X; Bennett CL, 1999, ARCH INTERN MED, V159, P2524, DOI 10.1001/archinte.159.21.2524; Bennett CL, 1998, ANN INTERN MED, V128, P541, DOI 10.7326/0003-4819-128-7-199804010-00004; Bennett CL, 1998, LANCET, V352, P1036, DOI 10.1016/S0140-6736(05)60079-7; CARSTAIRS KC, 1966, LANCET, V2, P133; Chow TW, 1998, AM J HEMATOL, V57, P293, DOI 10.1002/(SICI)1096-8652(199804)57:4<293::AID-AJH5>3.3.CO;2-R; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; MOAKE JL, 1989, AM J MED, V87, pN9; Moschcowitz E., 1924, P NY PATHOL SOC, V24, P21; PAGE Y, 1991, LANCET, V337, P774, DOI 10.1016/0140-6736(91)91383-6; Sharis PJ, 1998, ANN INTERN MED, V129, P394, DOI 10.7326/0003-4819-129-5-199809010-00009; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; Steinhubl SR, 1999, JAMA-J AM MED ASSOC, V281, P806, DOI 10.1001/jama.281.9.806; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Tsai HM, 1996, BLOOD, V88, P1292	19	146	153	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2000	132	10					794	799		10.7326/0003-4819-132-10-200005160-00005	http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313XN	10819702	Green Accepted			2022-12-28	WOS:000087025100004
J	Shulman, JM; Benton, R; St Johnston, D				Shulman, JM; Benton, R; St Johnston, D			The Drosophila homolog of C-elegans PAR-1 organizes the oocyte cytoskeleton and directs oskar mRNA localization to the posterior pole	CELL			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; CAENORHABDITIS-ELEGANS; ANTERIOR-POSTERIOR; MESSENGER-RNA; GERM-LINE; CYTOPLASMIC LOCALIZATION; PHOSPHORYLATION SITES; ANTEROPOSTERIOR AXIS; KINASE P110(MARK); PATTERN-FORMATION	In C. elegans, the PAR-1 kinase is localized to the posterior of the zygote and is required for anterior-posterior axis formation. Here, we report that a Drosophila PAR-1 homolog localizes to the posterior of the oocyte with oskar mRNA. Furthermore, par-1 mutants show a novel polarity phenotype in which bicoid mRNA accumulates normally at the anterior, but oskar mRNA is redirected to the center of the oocyte, resulting in embryonic patterning defects. These phenotypes arise from a disorganization of the oocyte microtubule cytoskeleton, consistent with reports that mammalian PAR-1 homologs regulate microtubule dynamics. Thus, Drosophila PAR-1 may remodel the oocyte microtubule network to define the posterior as the site for oskar localization. These results identify a molecular parallel between anterior-posterior polarization in Drosophila and C. elegans.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Genet, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge	St Johnston, D (corresponding author), Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England.	ds139@mole.bio.cam.ac.uk	St Johnston, Daniel/C-9568-2009	St Johnston, Daniel/0000-0001-5582-3301				Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; Bowerman B, 1997, DEVELOPMENT, V124, P3815; Boyd L, 1996, DEVELOPMENT, V122, P3075; Breitwieser W, 1996, GENE DEV, V10, P2179, DOI 10.1101/gad.10.17.2179; Chou TB, 1996, GENETICS, V144, P1673; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Clark IE, 1997, DEVELOPMENT, V124, P461; de Cuevas M, 1998, DEVELOPMENT, V125, P2781; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Ebneth A, 1999, CELL MOTIL CYTOSKEL, V44, P209, DOI 10.1002/(SICI)1097-0169(199911)44:3<209::AID-CM6>3.0.CO;2-4; EDDY EM, 1975, INT REV CYTOL, V43, P229; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; FASANO L, 1988, DEVELOPMENT, V104, P245; Goldstein B, 1996, DEVELOPMENT, V122, P1467; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Gruidl ME, 1996, P NATL ACAD SCI USA, V93, P13837, DOI 10.1073/pnas.93.24.13837; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; HARTL DL, 1994, P NATL ACAD SCI USA, V91, P6824, DOI 10.1073/pnas.91.15.6824; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; Hird SN, 1996, DEVELOPMENT, V122, P1303; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; Jordan P, 1997, J CELL BIOL, V139, P1805, DOI 10.1083/jcb.139.7.1805; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; Kimmerly W, 1996, GENOME RES, V6, P414, DOI 10.1101/gr.6.5.414; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KOMIYA T, 1994, DEV BIOL, V162, P354, DOI 10.1006/dbio.1994.1093; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; Manseau L, 1996, DEVELOPMENT, V122, P2109; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARKUSSEN FH, 1995, DEVELOPMENT, V121, P3723; McKim KS, 1998, GENE DEV, V12, P2932, DOI 10.1101/gad.12.18.2932; Micklem DR, 1997, CURR BIOL, V7, P468, DOI 10.1016/S0960-9822(06)00218-1; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; Rappleye CA, 1999, GENE DEV, V13, P2838, DOI 10.1101/gad.13.21.2838; Rongo C, 1997, COLD SPRING HARB SYM, V62, P1; Rose LS, 1998, ANNU REV GENET, V32, P521, DOI 10.1146/annurev.genet.32.1.521; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; ROUSSELL DL, 1993, P NATL ACAD SCI USA, V90, P9300, DOI 10.1073/pnas.90.20.9300; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; Seydoux G, 1999, DEVELOPMENT, V126, P3275; Shelton CA, 1999, J CELL BIOL, V146, P439, DOI 10.1083/jcb.146.2.439; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; Subramaniam K, 1999, DEVELOPMENT, V126, P4861; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; van Eeden F, 1999, CURR OPIN GENET DEV, V9, P396, DOI 10.1016/S0959-437X(99)80060-4; Wellington A, 1999, DEVELOPMENT, V126, P5267; XU T, 1993, DEVELOPMENT, V117, P1223	70	246	250	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 12	2000	101	4					377	388		10.1016/S0092-8674(00)80848-X	http://dx.doi.org/10.1016/S0092-8674(00)80848-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830165	Bronze			2022-12-28	WOS:000087010400006
J	Chapin, FS; Zavaleta, ES; Eviner, VT; Naylor, RL; Vitousek, PM; Reynolds, HL; Hooper, DU; Lavorel, S; Sala, OE; Hobbie, SE; Mack, MC; Diaz, S				Chapin, FS; Zavaleta, ES; Eviner, VT; Naylor, RL; Vitousek, PM; Reynolds, HL; Hooper, DU; Lavorel, S; Sala, OE; Hobbie, SE; Mack, MC; Diaz, S			Consequences of changing biodiversity	NATURE			English	Review							ECOSYSTEM FUNCTION; CLIMATE-CHANGE; GROWTH-RESPONSE; PLANT DIVERSITY; LYME-DISEASE; SEA OTTERS; COMMUNITIES; PRODUCTIVITY; STABILITY; GRASS	Human alteration of the global environment has triggered the sixth major extinction event in the history of life and caused widespread changes in the global distribution of organisms. These changes in biodiversity alter ecosystem processes and change the resilience of ecosystems to environmental change. This has profound consequences for services that humans derive from ecosystems. The large ecological and societal consequences of changing biodiversity should be minimized to preserve options for future solutions to global environmental problems.	Univ Alaska, Inst Arctic Biol, Fairbanks, AK 99775 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Inst Int Studies, Stanford, CA 94305 USA; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Kalamazoo Coll, Dept Biol, Kalamazoo, MI 49006 USA; Western Washington Univ, Dept Biol, Bellingham, WA 98225 USA; CNRS, UPR 9056, Ctr Ecol Fonct & Evolut, F-34293 Montpellier 05, France; Univ Buenos Aires, Fac Agron, Catedra Ecol, RA-4453 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Agron, Inst Fisiol & Ecol Vinculadas Agr, RA-4453 Buenos Aires, DF, Argentina; Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; Univ Nacl Cordoba, Fac Ciencias Exactas Fis & Nat, Inst Multidisciplinario Biol Vegetal, RA-5000 Cordoba, Argentina	University of Alaska System; University of Alaska Fairbanks; Stanford University; Stanford University; University of California System; University of California Berkeley; Kalamazoo College; Western Washington University; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut Agro; Montpellier SupAgro; CIRAD; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paul-Valery; Universite de Montpellier; University of Buenos Aires; University of Buenos Aires; University of Minnesota System; University of Minnesota Twin Cities; National University of Cordoba	Chapin, FS (corresponding author), Univ Alaska, Inst Arctic Biol, Fairbanks, AK 99775 USA.	fschapin@lter.uaf.edu	Chapin, F Stuart/AAZ-3931-2020; Díaz, Sandra/ABE-7349-2020; Diaz, Sandra/Q-9804-2018	Chapin, F Stuart/0000-0002-2558-9910; Díaz, Sandra/0000-0003-0012-4612; Hobbie, Sarah/0000-0001-5159-031X; Sala, Osvaldo/0000-0003-0142-9450; Eviner, Valerie/0000-0001-5530-9417				Altieri M. A., 1990, Agroecology., P551; BERRY W L, 1970, American Journal of Botany, V57, P1226; Bertness MD, 1997, ECOLOGY, V78, P1976, DOI 10.1890/0012-9658(1997)078[1976:TROPII]2.0.CO;2; Blockstein DE, 1998, SCIENCE, V279, P1831, DOI 10.1126/science.279.5358.1831c; Bryan JH, 1996, MED J AUSTRALIA, V164, P345, DOI 10.5694/j.1326-5377.1996.tb122051.x; BURDON JJ, 1993, ANNU REV PHYTOPATHOL, V31, P305, DOI 10.1146/annurev.py.31.090193.001513; Caraco NF, 1997, ECOLOGY, V78, P588, DOI 10.1890/0012-9658(1997)078[0588:ZMIIAL]2.0.CO;2; Channell R, 2000, NATURE, V403, P84, DOI 10.1038/47487; CHANWAY CP, 1991, ADV ECOL RES, V21, P121, DOI 10.1016/S0065-2504(08)60098-7; CHAPIN FS, 1985, ECOLOGY, V66, P564, DOI 10.2307/1940405; Christian JM, 1999, ECOLOGY, V80, P2397, DOI 10.1890/0012-9658(1999)080[2397:LTEIOA]2.0.CO;2; CLARHOLM M, 1985, SOIL BIOL BIOCHEM, V17, P181, DOI 10.1016/0038-0717(85)90113-0; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; Daily G. C., 1997, Nature's services: societal dependence on natural ecosystems., P113; DANTONIO CM, 1992, ANNU REV ECOL SYST, V23, P63, DOI 10.1146/annurev.es.23.110192.000431; DERUITER PC, 1995, SCIENCE, V269, P1257, DOI 10.1126/science.269.5228.1257; Diaz S, 1998, OECOLOGIA, V117, P177, DOI 10.1007/s004420050646; Elton C., 1958; Estes JA, 1998, SCIENCE, V282, P473, DOI 10.1126/science.282.5388.473; ESTES JA, 1974, SCIENCE, V185, P1058, DOI 10.1126/science.185.4156.1058; Fisher A. C., 1986, ADV APPL MICRO EC, V4, P169; FOLEY JA, 1994, NATURE, V371, P52, DOI 10.1038/371052a0; Garrity DP, 1996, AGROFOREST SYST, V36, P3, DOI 10.1007/BF00142865; GORDON DR, 1992, AM J BOT, V79, P967, DOI 10.2307/2444905; Goulder L. H., 1997, Nature's services: societal dependence on natural ecosystems., P23; Harrington R, 1999, TRENDS ECOL EVOL, V14, P146, DOI 10.1016/S0169-5347(99)01604-3; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; Holway DA, 1999, ECOLOGY, V80, P238, DOI 10.1890/0012-9658(1999)080[0238:CMUTDO]2.0.CO;2; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; JIFON JL, 1995, CAN J FOREST RES, V25, P824, DOI 10.1139/x95-300; Johnson KH, 1996, TRENDS ECOL EVOL, V11, P372, DOI 10.1016/0169-5347(96)10040-9; Jones CG, 1998, SCIENCE, V279, P1023, DOI 10.1126/science.279.5353.1023; Kattenberg A, 1996, SEVENTH SYMPOSIUM ON GLOBAL CHANGE STUDIES, P22; Lavelle P, 1997, EUR J SOIL BIOL, V33, P159; Lavorel S., 1999, Diversity and Distributions, V5, P41, DOI 10.1046/j.1472-4642.1999.00034.x; LAWLEY RA, 1982, SOIL BIOL BIOCHEM, V14, P237, DOI 10.1016/0038-0717(82)90032-3; Lawton J. H., 1995, EXTINCTION RATES; LAWTON JH, 1994, OIKOS, V71, P367, DOI 10.2307/3545824; Levine JM, 1999, OIKOS, V87, P15, DOI 10.2307/3546992; Lindroth Richard L., 1996, P105, DOI 10.1016/B978-012505295-5/50008-2; McGradySteed J, 1997, NATURE, V390, P162, DOI 10.1038/36561; MCNAUGHTON SJ, 1977, AM NAT, V111, P515, DOI 10.1086/283181; Mork M, 1996, SARSIA, V80, P323, DOI 10.1080/00364827.1996.10413607; Morrison J., 1996, SUSTAINABLE USE WATE; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; Naylor R, 1996, AMBIO, V25, P443; NAYLOR RL, IN PRESS INVASIVE SP; NITTA T, 1991, JARQ-JPN AGR RES Q, V25, P6; Orr MR, 1998, OECOLOGIA, V117, P420, DOI 10.1007/s004420050676; Paerl HW, 1996, MICROB ECOL, V31, P225; PECK SC, 1993, ASSESSING SURPRISES, P80; Pimentel D, 2000, BIOSCIENCE, V50, P53, DOI 10.1641/0006-3568(2000)050[0053:EAECON]2.3.CO;2; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; PORTER JH, 1991, AGR FOREST METEOROL, V57, P221, DOI 10.1016/0168-1923(91)90088-8; Postel SL, 1996, SCIENCE, V271, P785, DOI 10.1126/science.271.5250.785; Power ME, 1996, BIOSCIENCE, V46, P609, DOI 10.2307/1312990; POWER ME, 1985, ECOLOGY, V66, P1448, DOI 10.2307/1938007; READ DJ, 1991, EXPERIENTIA, V47, P376, DOI 10.1007/BF01972080; RICE KJ, 1987, ECOLOGY, V68, P1113, DOI 10.2307/1938386; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; SALONIUS PO, 1981, SOIL BIOL BIOCHEM, V13, P1, DOI 10.1016/0038-0717(81)90094-8; Schindler DE, 1997, SCIENCE, V277, P248, DOI 10.1126/science.277.5323.248; SCHLESINGER WH, 1990, SCIENCE, V247, P1043, DOI 10.1126/science.247.4946.1043; SHOCK CC, 1984, PLANT SOIL, V81, P311, DOI 10.1007/BF02323046; SHUKLA J, 1990, SCIENCE, V247, P1322, DOI 10.1126/science.247.4948.1322; Soluk DA, 1997, OIKOS, V80, P214, DOI 10.2307/3546588; STEWART G, 1949, ECOLOGY, V30, P58, DOI 10.2307/1932277; Stohlgren TJ, 1999, ECOL MONOGR, V69, P25, DOI 10.1890/0012-9615(1999)069[0025:EPSIHS]2.0.CO;2; THORP J, 1997, NATL WEEDS STRATEGY; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Tilman D, 1997, ECOLOGY, V78, P81, DOI 10.1890/0012-9658(1997)078[0081:CIRLAG]2.0.CO;2; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; Tomich TP, 1996, AGROFOREST SYST, V36, P233, DOI 10.1007/BF00142876; *USOT ASS, 1993, HARMF NONINDIGENOUS; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; VANCLEVE K, 1991, BIOSCIENCE, V41, P78, DOI 10.2307/1311560; vanWilgen BW, 1996, BIOSCIENCE, V46, P184, DOI 10.2307/1312739; VITOUSEK PM, 1987, SCIENCE, V238, P802, DOI 10.1126/science.238.4828.802; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; VITOUSEK PM, 1993, ECOL STU AN, V99, P3; Walker B, 1999, ECOSYSTEMS, V2, P95, DOI 10.1007/s100219900062; Wardle DA, 1997, OIKOS, V79, P247, DOI 10.2307/3546010; WARREN DM, 1998, LINKING SOCIAL ECOLO, P158; WASILEWSKA L, 1995, APPL SOIL ECOL, V2, P53, DOI 10.1016/0929-1393(94)00037-8; WHISENANT SG, 1990, USDA INTERM, V276, P4; Zavaleta E, 1999, HUM ECOL, V27, P231, DOI 10.1023/A:1018773211034; ZAVALETA ES, IN PRESS INVASIVE SP; ZIMOV SA, 1995, AM NAT, V146, P765, DOI 10.1086/285824	89	2569	2735	73	2445	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					234	242		10.1038/35012241	http://dx.doi.org/10.1038/35012241			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821284				2022-12-28	WOS:000087080100061
J	Ju, BG; Jeong, S; Bae, E; Hyun, S; Carroll, SB; Yim, J; Kim, J				Ju, BG; Jeong, S; Bae, E; Hyun, S; Carroll, SB; Yim, J; Kim, J			Fringe forms a complex with Notch	NATURE			English	Article							DROSOPHILA WING DEVELOPMENT; DORSAL-VENTRAL BOUNDARY; DORSOVENTRAL BOUNDARY; SIGNAL-TRANSDUCTION; EXPRESSION; ACTIVATION; RECEPTOR; SERRATE; GROWTH; DELTA	The Fringe protein of Drosophila and its vertebrate homologues function in boundary determination during pattern formation(1-9). Fringe has been proposed to inhibit Serrate-Notch signalling but to potentiate Delta-Notch signalling(10). Here we show that Fringe and Notch form a complex through both the Lin-Notch repeats and the epidermal growth factor repeats 22-36 (EGF22-36) of Notch when they are co-expressed. The Abruptex(59b) (Ax(59b)) and Ax(M1) mutations, which are caused by missense mutations in EGF repeats 24 and 25, respectively, abolish the Fringe-Notch interaction through EGF22-36, whereas the l(1)N-B mutation in the third Lin-Notch repeat of Notch abolishes the interaction through Lin-Notch repeats. Ax mutations also greatly affect the Notch response to ectopic Fringe in vivo. Results from in vitro protein mixing experiments and subcellular colocalization experiments indicate that the Fringe-Notch complex may form before their secretion. These findings explain how Fringe acts cell-autonomously to modulate the ligand preference of Notch and why the Fringe-Notch relationship is conserved between phyla and in the development of very diverse structures.	Seoul Natl Univ, Natl Creat Res Initiat Ctr Genet Reprogramming, Inst Mol Biol & Genet, Seoul 151742, South Korea; Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Seoul National University (SNU); Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Korea Advanced Institute of Science & Technology (KAIST)	Kim, J (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr Genet Reprogramming, Inst Mol Biol & Genet, Seoul 151742, South Korea.							Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brennan K, 1997, GENETICS, V147, P177; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; DECELIS JF, 1993, P NATL ACAD SCI USA, V90, P4037, DOI 10.1073/pnas.90.9.4037; deCelis JF, 1996, DEVELOPMENT, V122, P359; deCelis JF, 1997, DEVELOPMENT, V124, P3241; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; ESTEBAN CR, 1998, NATURE, V386, P360; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Han KH, 1996, NUCLEIC ACIDS RES, V24, P4362, DOI 10.1093/nar/24.21.4362; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; JOHANSEN H, 1989, GENE DEV, V3, P882, DOI 10.1101/gad.3.6.882; Johnston SH, 1997, DEVELOPMENT, V124, P2245; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; Kim J, 1997, COLD SPRING HARB SYM, V62, P283; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Klein T, 1998, DEVELOPMENT, V125, P2951; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; LYMAN D, 1993, P NATL ACAD SCI USA, V90, P10395, DOI 10.1073/pnas.90.21.10395; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	29	60	60	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					191	195		10.1038/35012090	http://dx.doi.org/10.1038/35012090			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821276				2022-12-28	WOS:000087080100053
J	Labib, K; Tercero, JA; Diffley, JFX				Labib, K; Tercero, JA; Diffley, JFX			Uninterrupted MCM2-7 function required for DNA replication fork progression	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; HELICASE ACTIVITY; PROTEINS; YEAST; CHROMATIN; MUTANTS; ORIGINS; PAUSE; CDC6P	Little is known about the DNA helicases required for the elongation phase of eukaryotic chromosome replication. Minichromosone maintenance (MCM) protein complexes have DNA helicase activity but have only been functionally implicated in initiating DNA replication. Using an improved method for constructing conditional degron mutants, we show that depletion of MCMs after initiation irreversibly blocks the progression of replication forks in Saccharomyces cerevisiae. Like the Escherichia coli dnaB and SV40 T antigen helicases, therefore, the MCM complex is loaded at origins before initiation and is essential for elongation. Restricting MCM Loading to the G(1) phase ensures that initiation and elongation occur just once per cell cycle.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		Diffley, JFX (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.		Tercero, José Antonio/D-7489-2016	Diffley, John/0000-0001-5184-7680; Tercero, Jose Antonio/0000-0003-4829-3570				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; LABIB K, 1998, GENE DEV, V12, P480; LABIB K, UNPUB; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; You ZY, 1999, MOL CELL BIOL, V19, P8003; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587	25	511	520	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1643	1647		10.1126/science.288.5471.1643	http://dx.doi.org/10.1126/science.288.5471.1643			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834843				2022-12-28	WOS:000087382300041
J	Gottlieb, S				Gottlieb, S			Thrombolytic agents no benefit to those over 75	BRITISH MEDICAL JOURNAL			English	News Item																		Ayanian JZ, 2000, CIRCULATION, V101, P2224, DOI 10.1161/01.CIR.101.19.2224	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1428	1428		10.1136/bmj.320.7247.1428	http://dx.doi.org/10.1136/bmj.320.7247.1428			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827040	Green Published			2022-12-28	WOS:000087414700018
J	Macleod, U; Ross, S; Twelves, C; George, WD; Gillis, C; Watt, GCM				Macleod, U; Ross, S; Twelves, C; George, WD; Gillis, C; Watt, GCM			Primary and secondary care management of women with early breast cancer from affluent and deprived areas: retrospective review of hospital and general practice records	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL-CLASS; SURVIVAL; DEPRIVATION; ENGLAND	Objectives To investigate whether poorer survival of breast cancer among deprived women compared with affluent women is related to their NHS care, Design Retrospective review of hospital and general practice case records. Setting Greater Glasgow Health Board area. Subjects Women diagnosed with breast cancer in 1992-3 who lived in die most affluent (deprivation categories 1 and 2) and the most deprived areas (deprivation categories 6 and 7) of Glasgow (Carstairs and Morris deprivation index). Main outcome measures Breast cancer treatment, time from general practice consultation to clinic visit and surgery, and details of hospital admissions and follow up in primary and secondary care. Results The access to care and surgical and oncological treatment of women from affluent and deprived areas were similar, Admissions to hospital for problems not related to breast cancer were more common in those living in deprived areas (number admitted once or more: 51 (24%) v 13 (10%), P = 0.001). Consultation patterns in general practice by the second year after diagnosis showed women in deprived areas consulting more frequently than women in affluent areas (median (interquartile range) number of consultations (5 (2-10) v 7 (4-13), P = 0.01). Conclusion Women living in affluent areas did not receive better NHS care for breast cancer than women in deprived areas. However, women from deprived areas seem to have greater comorbidity, and poorer outcomes from breast cancer among these women is probably due to factors which result in deprived communities having poorer health outcomes rather than to management of their breast cancer.	Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland; Univ Glasgow, Western Infirm, Beatson Oncol Ctr, CRC Dept Med Oncol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Surg, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, W Scotland Canc Surveillance Unit, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; Beatson Oncology Centre; University of Glasgow; University of Glasgow; University of Glasgow	Macleod, U (corresponding author), Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland.							BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; *BREAST SURG GROUP, 1995, EUR J SURG ONCOL SA, V21, P1; *BRIT BREAST GROUP, 1995, PROV BREAST SERV UK; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; CARSTAIRS V, 1988, DEPRIVATION HLTH SCO; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; Gillis CR, 1996, BRIT MED J, V312, P145, DOI 10.1136/bmj.312.7024.145; GORDON NH, 1992, AM J EPIDEMIOL, V135, P609, DOI 10.1093/oxfordjournals.aje.a116340; KARJALAINEN S, 1990, CANCER-AM CANCER SOC, V66, P819, DOI 10.1002/1097-0142(19900815)66:4<819::AID-CNCR2820660437>3.0.CO;2-E; Macleod U, 2000, ANN ONCOL, V11, P105, DOI 10.1023/A:1008385321476; Nichols S, 1981, Community Med, V3, P217, DOI 10.1007/BF02549119; Pollock AM, 1998, BMJ-BRIT MED J, V317, P245, DOI 10.1136/bmj.317.7153.245; Richards MA, 1996, BRIT J CANCER, V73, P751, DOI 10.1038/bjc.1996.131; SAINSBURY R, 1995, BRIT J CANCER, V71, P1275, DOI 10.1038/bjc.1995.246; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; SCHRIJVERS CTM, 1995, BRIT J CANCER, V72, P738, DOI 10.1038/bjc.1995.403; Scottish Intercollegiate Guideline Network, 1998, SIGN PUBL, V29; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; VAGERO D, 1987, J EPIDEMIOL COMMUN H, V41, P204, DOI 10.1136/jech.41.3.204	19	43	43	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1442	1445		10.1136/bmj.320.7247.1442	http://dx.doi.org/10.1136/bmj.320.7247.1442			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827047	Green Accepted, Green Published, Bronze, Green Submitted			2022-12-28	WOS:000087414700026
J	Zhang, CM; Clarke, PR				Zhang, CM; Clarke, PR			Chromatin-independent nuclear envelope assembly induced by Ran GTPase in Xenopus egg extracts	SCIENCE			English	Article							CHROMOSOME CONDENSATION; MICROTUBULE ASTERS; DNA-REPLICATION; RCC1 PROTEIN; BINDING; REGULATOR; MITOSIS; FUSION	The nuclear envelope (NE) forms a controlled boundary between the cytoplasm and the nucleus of eukaryotic cells. To facilitate investigation of mechanisms controlling NE assembly, we developed a cell-free system made from Xenopus laevis eggs to study the process in the absence of chromatin. NEs incorporating nuclear pores were assembled around beads coated with the guanosine triphosphatase Ran, forming pseudo-nuclei that actively imported nuclear proteins. NE assembly required the cycling of guanine nucleotides on Ran and was promoted by RCC1, a nucleotide exchange factor recruited to beads by Ran-guanosine diphosphate (Ran-GDP). Thus, concentration of Ran-GDP followed by generation of Ran-GTP is sufficient to induce NE assembly.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China	University of Dundee; Peking University	Zhang, CM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Level 5, Dundee DD1 9SY, Scotland.	c.zhang@icrf.icnet.uk; p.clarke@icrf.icnet.uk	Clarke, Paul R./AAA-6803-2020; Clarke, Paul/B-1684-2009	Clarke, Paul/0000-0003-3525-2622				BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; CLARKE PR, 1995, J CELL SCI, V108, P1217; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DEMETER J, 1995, P NATL ACAD SCI USA, V92, P1436, DOI 10.1073/pnas.92.5.1436; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hughes M, 1998, J CELL SCI, V111, P3017; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; LEE A, 1993, J CELL SCI, V106, P287; Macaulay C, 1996, J CELL BIOL, V132, P5, DOI 10.1083/jcb.132.1.5; Marshall ICB, 1997, TRENDS CELL BIOL, V7, P69, DOI 10.1016/S0962-8924(96)10047-7; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; Nicolas FJ, 1997, J CELL SCI, V110, P3019; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Pu RT, 1997, MOL BIOL CELL, V8, P1955, DOI 10.1091/mbc.8.10.1955; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SEINO H, 1992, J CELL SCI, V102, P393; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Zhang C., UNPUB; Zhang CM, 1999, J CELL SCI, V112, P2453	24	162	173	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1429	1432		10.1126/science.288.5470.1429	http://dx.doi.org/10.1126/science.288.5470.1429			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827954				2022-12-28	WOS:000087270900052
J	Bobak, M; Skodova, Z; Marmot, M				Bobak, M; Skodova, Z; Marmot, M			Effect of beer drinking on risk of myocardial infarction: population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ALCOHOL-CONSUMPTION		UCL, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, London WC1E 6BT, England; Inst Clin & Expt Med, Dept Prevent Cardiol, Prague 14000, Czech Republic	University of London; University College London; Institute for Clinical & Experimental Medicine (IKEM)	Bobak, M (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, Mortimer St, London WC1E 6BT, England.	martinb@public-health.ucl.ac.uk	Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419; Bobak, Martin/0000-0002-2633-6851	Medical Research Council [G19/35, G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bobak M, 2000, J EPIDEMIOL COMMUN H, V54, P91, DOI 10.1136/jech.54.2.91; Keil U, 1997, EPIDEMIOLOGY, V8, P150, DOI 10.1097/00001648-199703000-00005; Rehm J, 1999, INT J EPIDEMIOL, V28, P219, DOI 10.1093/ije/28.2.219; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; *WHO, 1987, MULT MON TRENDS DET	5	30	31	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2000	320	7246					1378	1379		10.1136/bmj.320.7246.1378	http://dx.doi.org/10.1136/bmj.320.7246.1378			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818027	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000087232500022
J	Boden, WE; van Gilst, WH; Scheldewaert, RG; Starkey, IR; Carlier, MF; Julian, DG; Whitehead, A; Bertrand, ME; Col, JJ; Pedersen, OL; Lie, KI; Santoni, JP; Fox, KM				Boden, WE; van Gilst, WH; Scheldewaert, RG; Starkey, IR; Carlier, MF; Julian, DG; Whitehead, A; Bertrand, ME; Col, JJ; Pedersen, OL; Lie, KI; Santoni, JP; Fox, KM		Incomplete Infarction Trial Europe	Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial	LANCET			English	Article							INTRAVENOUS DILTIAZEM; BETA-BLOCKADE; NIFEDIPINE; THERAPY; REINFARCTION; REPERFUSION; IMMEDIATE; RELEASE; ASPIRIN	Background Diltiazem reduces non-fatal reinfarction and refractory ischaemia after non-Q-wave myocardial infarction, an acute coronary syndrome similar to the incomplete infarction that occurs after successful reperfusion. We postulated that this agent would reduce cardiac events in patients after acute myocardial infarction treated initially with thrombolytic agents-a clinical application previously unexplored with heart-rate-lowering calcium antagonists. Methods A prospective, randomised, double-blind, sequential trial was done in 874 patients with acute myocardial infarction, but without congestive heart failure, who first received thrombolytic agents. Patients received either 300 mg oral diltiazem once daily, or placebo, initiated within 36-96 h of infarct onset, and given for up to 6 months. The trial primary endpoint was the cumulative first event rate of cardiac death, non-fatal reinfarction, or refractory ischaemia. Additional prespecified endpoints included several composites of non-fatal cardiac events (non-fatal reinfarction combined with refractory ischaemia, all recurrent ischaemia, or the need for myocardial revascularisation). The diagnosis of ischaemia, whether refractory or recurrent, and the need for myocardial revascularisation, was always based on objective electrocardiographical evidence of ischaemia, either at rest or on exertion. Results For the trial primary endpoint, 131 events occurred in the 444 placebo patients and 97 events in the 430 diltiazem patients (hazard ratio 0.79; 95% CI, 0.61-1.02; p=0.07). For non-fatal cardiac events, diltiazem treatment was associated with a relative decrease (0.76; 0.58-1.00) in the combined event rate of non-fatal reinfarction and refractory ischaemia. There was a similar decrease in the composite non-fatal endpoints of non-fatal reinfarction combined with all recurrent ischaemia (0.80; 0.64-1.00) and non-fatal reinfarction combined with the need for myocardial revascularisation (0.67; 0.46-0.96). The need for myocardial revascularisation alone was significantly reduced by 42% (0.61; 0.39-0.96). No major safety issues were encountered. Conclusions Diltiazem did not reduce the cumulative occurrence of cardiac death, non-fatal reinfarction, or refractory ischaemia during a 6-month follow-up, but did reduce all composite endpoints of non-fatal cardiac events, especially the need for myocardial revascularisation.	Vet Affairs Med Ctr, Syracuse, NY USA; Univ Groningen, Groningen, Netherlands; Sythelabo Grp, Bagneux, France; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; Clin St Joseph, Gilly, Belgium; Netherhall Gardens, London, England; Univ Reading, Reading RG6 2AH, Berks, England; Hop Cardiol, F-59037 Lille, France; Clin Univ St Luc, B-1200 Brussels, Belgium; Viborg Sygehus, Viborg, Denmark; Univ Amsterdam, NL-1012 WX Amsterdam, Netherlands; Synthelabo Grp, Le Plessis Robinson, France; Royal Brompton Hosp, London SW3 6LY, England	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Groningen; University of Edinburgh; University of Reading; Universite de Lille - ISITE; CHU Lille; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Amsterdam; Sanofi-Aventis; Sanofi France; Royal Brompton Hospital	Boden, WE (corresponding author), Hartford Hosp, 80 Seymour St, Hartford, CT 06102 USA.		van Gilst, Wiek H/C-3828-2008; van Gilst, Wiek/R-1806-2019	van Gilst, Wiek/0000-0003-2968-8585				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BIANCHETTI G, 1995, FUNDAM CLIN PHARM, V9, P197, DOI 10.1111/j.1472-8206.1995.tb00281.x; BODEN WE, 1991, AM J CARDIOL, V67, P335, DOI 10.1016/0002-9149(91)90038-M; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BODEN WE, 1991, AM J CARDIOL, V68, P520, DOI 10.1016/0002-9149(91)90789-N; BODEN WE, 1995, AM J CARDIOL, V75, P1120, DOI 10.1016/S0002-9149(99)80742-5; Boden William E., 1994, Drugs of Today, V30, P25; BRUNIER H, 1993, PEST 3 0 OPERATING M; BUCKLEY MMT, 1990, DRUGS, V39, P757, DOI 10.2165/00003495-199039050-00009; Cannon CP, 1997, CIRCULATION, V95, P351; Collett D., 1994, MODELING SURVIVAL DA; COLLINS R, 1991, BRIT HEART J, V66, P250; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GIBSON RS, 1986, NEW ENGL J MED, V315, P423, DOI 10.1056/NEJM198608143150704; Gobel EJAM, 1995, LANCET, V346, P1653, DOI 10.1016/S0140-6736(95)92837-5; Gobel EJAM, 1998, EUR HEART J, V19, P1208, DOI 10.1053/euhj.1998.0874; GOLDBOURT U, 1993, ARCH INTERN MED, V153, P345, DOI 10.1001/archinte.153.3.345; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Hanrath P, 1997, CIRCULATION, V96, P1445; HANSEN JF, 1990, AM J CARDIOL, V66, P779; LUBSEN J, 1986, BRIT HEART J, V56, P400; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; O'Connor SE, 1999, FUND CLIN PHARMACOL, V13, P145, DOI 10.1111/j.1472-8206.1999.tb00333.x; OHMAN EM, 1994, CIRCULATION S, V1, P56; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; Pizzetti G, 1998, J AM COLL CARDIOL, V31, p490A, DOI 10.1016/S0735-1097(97)88135-1; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; *SAS PROC LOGISTIC, 1990, SAS STAT US GUID, V2; Theroux P, 1998, J AM COLL CARDIOL, V32, P620, DOI 10.1016/S0735-1097(98)00281-2; Topol E, 1997, NEW ENGL J MED, V337, P1118; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Van de Werf F, 1993, J AM COLL CARDIOL, V22, P407, DOI 10.1016/0735-1097(93)90044-2; Wallentin L, 1999, LANCET, V354, P701; Whitehead J, 1997, DESIGN ANAL SEQUENTI; WILCOX RG, 1986, BRIT MED J, V293, P1204, DOI 10.1136/bmj.293.6556.1204; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZUCKER ML, 1993, THROMB HAEMOSTASIS, V70, P332	38	63	73	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1751	1756		10.1016/S0140-6736(00)02262-5	http://dx.doi.org/10.1016/S0140-6736(00)02262-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832825				2022-12-28	WOS:000087126100009
J	Macintyre, S				Macintyre, S			Modernising the NHS - Prevention and the reduction of health inequalities	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow	Macintyre, S (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.		Macintyre, Sally/P-6246-2014					Acheson D., 1998, INDEPENDENT INQUIRY; *DEP HLTH, 1998, OUR HLTH NAT CONTR H; *DEP HLTH, 1999, SAV LIV OUR HLTH NAT; *DEP HLTH, 1995, VAR HLTH DEP HLTH NA; *DEP HLTH, 1999, RED HLTH IN ACT REP; Enthoven AC, 2000, BRIT MED J, V320, P1329, DOI 10.1136/bmj.320.7245.1329; *NHS CTR REV DISS, 1995, REV RES EFF HLTH SER; *SCOTT OFF DEP HLT, 1999, HLTH SCOTL WHIT PAP; *SCOTT OFF DEP HLT, 1998, WORK HLTH SCOTL CONS; SHAW M, 1999, WIDENING GAP HLTH IN	10	15	15	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	2000	320	7246					1399	1400		10.1136/bmj.320.7246.1399	http://dx.doi.org/10.1136/bmj.320.7246.1399			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818038	Green Accepted, Green Published			2022-12-28	WOS:000087232500030
J	Menzies-Gow, A; Robinson, DS				Menzies-Gow, A; Robinson, DS			Eosinophil chemokines and their receptors: an attractive target in asthma?	LANCET			English	Editorial Material							ATOPIC ASTHMA; EOTAXIN; CCR3; CELLS; INFLAMMATION; EXPRESSION		Natl Heart & Lung Inst, Imperial Coll Sch Med, London SW3 6LY, England	Imperial College London	Menzies-Gow, A (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dovehouse St, London SW3 6LY, England.							Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Grimaldi JC, 1999, J LEUKOCYTE BIOL, V65, P846, DOI 10.1002/jlb.65.6.846; Hanazawa T, 2000, J ALLERGY CLIN IMMUN, V105, P58, DOI 10.1016/S0091-6749(00)90178-7; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Leckie MJ, 1999, AM J RESP CRIT CARE, V159, pA624; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; Sabroe I, 1999, J IMMUNOL, V162, P2946; Ying S, 1999, J IMMUNOL, V163, P6321; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zimmermann N, 1998, BBA-GENE STRUCT EXPR, V1442, P170, DOI 10.1016/S0167-4781(98)00162-6; Zingoni A, 1998, J IMMUNOL, V161, P547	17	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1741	1743		10.1016/S0140-6736(00)02258-3	http://dx.doi.org/10.1016/S0140-6736(00)02258-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832821				2022-12-28	WOS:000087126100005
J	Butler, D				Butler, D			Europe agrees to boost Internet networks used by researchers	NATURE			English	News Item																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					261	262		10.1038/35012748	http://dx.doi.org/10.1038/35012748			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830924	Bronze			2022-12-28	WOS:000087085700002
J	Schock, F; Reischl, J; Wimmer, E; Taubert, H; Purnell, BA; Jackle, H				Schock, F; Reischl, J; Wimmer, E; Taubert, H; Purnell, BA; Jackle, H			Phenotypic suppression of empty spiracles is prevented by buttonhead	NATURE			English	Article							DROSOPHILA HEAD DEVELOPMENT; FUNCTIONAL HIERARCHY; SEGMENT IDENTITY; HUMAN SP1; GENE; EXPRESSION; COMPLEX; EMBRYO	Unlike the trunk segments, the anterior head segments of Drosophila are formed in the absence of pair-rule(1,2) and HOX-cluster gene(3) expression, by the activities of the gap-like genes orthodenticle (otd), empty spiracles (ems) and buttonhead (btd)(4,5). The products of these genes are transcription factors(6,7), but only EMS has a HOX-like homeodomain(8,9). Indeed, ems can confer identity to trunk segments(10) when other HOX-cluster gene activities are absent(3,11). In trunk segments of wild-type embryos, however, ems activity is prevented by phenotypic suppression(10), in which more posterior HOX-cluster genes inactivate the more anterior without affecting transcription or translation(12). ems is suppressed by all other Hox-cluster genes and so is placed at the bottom of their hierarchy(10). Here we show that misexpression of EMS in the head transforms segment identity in a btd-dependent manner, that misexpression of BTD in the trunk causes ems-dependent structures to develop, and that EMS and BTD interact in vitro. The data indicate that this interaction may allow ems to escape from the bottom of the HOX-cluster gene hierarchy and cause a dominant switch of homeotic prevalence in the anterior-posterior direction.	Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, D-37077 Gottingen, Germany; Univ Bayreuth, Lehrstuhl Genet, D-95440 Bayreuth, Germany	Max Planck Society; University of Bayreuth	Jackle, H (corresponding author), Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, Fassberg 11, D-37077 Gottingen, Germany.		Schock, Frieder/A-9990-2009	Schock, Frieder/0000-0002-1351-0574; Wimmer, Ernst A./0000-0002-2480-2804				ARIAS AM, 1993, DEV DROSOPHILA MELAN, P517; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; Gallitano-Mendel A, 1998, DEV BIOL, V199, P125, DOI 10.1006/dbio.1998.8917; Janody F, 2000, DEVELOPMENT, V127, P1573; JONES B, 1993, GENE DEV, V7, P229, DOI 10.1101/gad.7.2.229; Jurgens G., 1993, DEV DROSOPHILA MELAN, P687; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Macias A, 1996, EMBO J, V15, P334, DOI 10.1002/j.1460-2075.1996.tb00363.x; MANAK JR, 1994, DEVELOPMENT, P61; Pankratz Michael J., 1993, P467; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Rogers BT, 1996, DEVELOPMENT, V122, P3419; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCHMIDTOTT U, 1994, P NATL ACAD SCI USA, V91, P8363, DOI 10.1073/pnas.91.18.8363; Schock F, 1999, P NATL ACAD SCI USA, V96, P5061, DOI 10.1073/pnas.96.9.5061; Thummel CS, 1992, DROS INF SERV, V71, P150; WALLDORF U, 1992, EMBO J, V11, P2247, DOI 10.1002/j.1460-2075.1992.tb05284.x; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0; Wimmer EA, 1996, MECH DEVELOP, V59, P53, DOI 10.1016/0925-4773(96)00575-8; Wimmer EA, 1997, DEVELOPMENT, V124, P1509; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	27	27	27	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					351	354		10.1038/35012620	http://dx.doi.org/10.1038/35012620			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830964				2022-12-28	WOS:000087085700048
J	Pelaz, S; Ditta, GS; Baumann, E; Wisman, E; Yanofsky, MF				Pelaz, S; Ditta, GS; Baumann, E; Wisman, E; Yanofsky, MF			B and C floral organ identity functions require SEPALLATA MADS-box genes	NATURE			English	Article							HOMEOTIC GENE; FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; ARABIDOPSIS; TRANSCRIPTION; FAMILY; EXPRESSION; PISTILLATA; DEFICIENS; PROTEINS	Abnormal flowers have been recognized for thousands of years, but only in the past decade have the mysteries of flower development begun to unfold. Among these mysteries is the differentiation of four distinct organ types (sepals, petals, stamens and carpels), each of which may be a modified leaf(1). A landmark accomplishment in plant developmental biology is the ABC model of flower organ identity(2,3). This simple model provides a conceptual framework for explaining how the individual and combined activities of the ABC genes produce the four organ types of the typical eudicot flower. Here we show that the activities of the B and C organ-identity genes require the activities of three closely related and functionally redundant MADS-box genes, SEPALLATA1/2/3 (SEP1/2/3). Triple mutant Arabidopsis plants lacking the activity of all three SEP genes produce flowers in which all organs develop as sepals. Thus SEP1/2/3 are a class of organ-identity genes that is required for development of petals, stamens and carpels.	Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Max Planck Inst Zuchtungsforsch, D-50829 Cologne, Germany	Max Planck Society	Yanofsky, MF (corresponding author), Sect Cell & Dev Biol, La Jolla, CA 92093 USA.		Pelaz, Soraya/F-3431-2015	Pelaz, Soraya/0000-0001-7699-9330				AMBROSE BA, IN PRESS MOL CELL; ANGENENT GC, 1994, PLANT J, V5, P33, DOI 10.1046/j.1365-313X.1994.5010033.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; Davies B, 1996, EMBO J, V15, P4330, DOI 10.1002/j.1460-2075.1996.tb00807.x; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Egea-Cortines M, 1999, EMBO J, V18, P5370, DOI 10.1093/emboj/18.19.5370; Fan HY, 1997, PLANT J, V12, P999, DOI 10.1046/j.1365-313X.1997.12050999.x; Ferrandiz C, 2000, DEVELOPMENT, V127, P725; FLANAGAN CA, 1994, PLANT MOL BIOL, V26, P581, DOI 10.1007/BF00013745; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; Kang HG, 1997, MOL CELLS, V7, P45; KEMPIN SA, 1995, SCIENCE, V267, P522, DOI 10.1126/science.7824951; Krizek BA, 1996, DEVELOPMENT, V122, P11; Liljegren SJ, 2000, NATURE, V404, P766, DOI 10.1038/35008089; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; Mandel MA, 1998, SEX PLANT REPROD, V11, P22, DOI 10.1007/s004970050116; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; Mouradov A, 1998, PLANT PHYSIOL, V117, P55, DOI 10.1104/pp.117.1.55; PNUELI L, 1994, PLANT CELL, V6, P175, DOI 10.1105/tpc.6.2.175; SAVIDGE B, 1995, PLANT CELL, V7, P721, DOI 10.1105/tpc.7.6.721; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; Wisman E, 1998, P NATL ACAD SCI USA, V95, P12432, DOI 10.1073/pnas.95.21.12432; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	30	1044	1200	17	278	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					200	203		10.1038/35012103	http://dx.doi.org/10.1038/35012103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821278				2022-12-28	WOS:000087080100055
J	Newman, DK; Kolter, R				Newman, DK; Kolter, R			A role for excreted quinones in extracellular electron transfer	NATURE			English	Article							SHEWANELLA-PUTREFACIENS MR-1; C-TYPE CYTOCHROME; GEOBACTER-SULFURREDUCENS; HUMIC SUBSTANCES; REDUCTION; BACTERIA; ACCEPTORS; FE(III); IRON; MANGANESE(IV)	Respiratory processes in bacteria are remarkable because of their ability to use a variety of compounds, including insoluble minerals, as terminal electron acceptors(1). Although much is known about microbial electron transport to soluble electron acceptors, little is understood about electron transport to insoluble compounds such as ferric oxides(2,3). In anaerobic environments, humic substances can serve as electron acceptors and also as electron shuttles to ferric oxides(4-6). To explore this process, we identified mutants in Shewanella putrefaciens that are unable to respire on humic substances. Here we show that these mutants contain disruptions in a gene that is involved in the biosynthesis of menaquinone. During growth, the wild type releases a menaquinone-related redox-active small molecule into the medium that complements the mutants. This finding raises the possibility that electron transfer to a variety of oxidants, including poorly soluble minerals, may be mediated by microbially excreted quinones that have yet to be identified.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Newman, DK (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.							ALEXEYEV MF, 1995, GENE, V160, P59, DOI 10.1016/0378-1119(95)00141-R; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARNOLD RG, 1988, BIOTECHNOL BIOENG, V32, P1081, DOI 10.1002/bit.260320902; Beliaev AS, 1998, J BACTERIOL, V180, P6292; Benz M, 1998, APPL ENVIRON MICROB, V64, P4507; Brock T.P., 1991, BIOL MICROORGANISMS, V340; Caccavo F, 1997, APPL ENVIRON MICROB, V63, P3837, DOI 10.1128/AEM.63.10.3837-3843.1997; Coates JD, 1998, APPL ENVIRON MICROB, V64, P1504; Collins MD, 1985, METHODS MICROBIOLOGY, P329, DOI 10.1016/S0580-9517(08)70480-X; GASPARD S, J BACTERIOL, V64, P3188; GENNIS RB, 1996, ESCHERICHIA COLI SAL, V1, P217; Lloyd JR, 1999, J BACTERIOL, V181, P7647, DOI 10.1128/JB.181.24.7647-7649.1999; LOVLEY DR, 1991, MICROBIOL REV, V55, P259, DOI 10.1128/MMBR.55.2.259-287.1991; LOVLEY DR, 1988, APPL ENVIRON MICROB, V54, P1472, DOI 10.1128/AEM.54.6.1472-1480.1988; Lovley DR, 1996, NATURE, V382, P445, DOI 10.1038/382445a0; Meganathan R., 1996, ESCHERICHIA COLI SAL, P642; MYERS CR, 1992, J BACTERIOL, V174, P3429, DOI 10.1128/JB.174.11.3429-3438.1992; MYERS CR, 1993, FEMS MICROBIOL LETT, V114, P215, DOI 10.1111/j.1574-6968.1993.tb06576.x; MYERS CR, 1990, J BACTERIOL, V172, P6232, DOI 10.1128/jb.172.11.6232-6238.1990; MYERS CR, 1988, SCIENCE, V240, P1319, DOI 10.1126/science.240.4857.1319; O'Toole GA, 1999, METHOD ENZYMOL, V310, P91; Scott DT, 1998, ENVIRON SCI TECHNOL, V32, P2984, DOI 10.1021/es980272q; Seeliger S, 1998, J BACTERIOL, V180, P3686, DOI 10.1128/JB.180.14.3686-3691.1998; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; TRATNYEK PG, 1989, J AGR FOOD CHEM, V37, P248, DOI 10.1021/jf00085a058	25	641	688	20	418	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					94	97		10.1038/35011098	http://dx.doi.org/10.1038/35011098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811225				2022-12-28	WOS:000086901600058
J	Astin, JA; Harkness, E; Ernst, E				Astin, JA; Harkness, E; Ernst, E			The efficacy of "distant healing": A systematic review of randomized trials	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY-CARE UNIT; THERAPEUTIC TOUCH; ALTERNATIVE MEDICINE; INTERCESSORY PRAYER; HEALTH-CARE; OUTCOMES; RELIGION; REMOTE; PAIN	Purpose: To conduct a systematic review of the available data on the efficacy of any form of "distant healing" (prayer, mental healing, Therapeutic Touch, or spiritual healing) as treatment for any medical condition. Data Sources: Studies were identified by an electronic search of the MEDLINE, PsychLIT, EMBASE, CISCOM, and Cochrane Library databases from their inception to the end of 1999 and by contact with researchers in the field. Study Selection: Studies with the following features were included: random assignment, placebo or other adequate control, publication in peer-reviewed journals, clinical (rather than experimental) investigations, and use of human participants. Data Extraction: Two investigators independently extracted data on study design, sample size, type of intervention, type of control, direction of effect (supporting or refuting the hypothesis), and nature of the outcomes. Data Synthesis: A total of 23 trials involving 2774 patients met the inclusion criteria and were analyzed. Heterogeneity of the studies precluded a formal meta-analysis. Of the trials, 5 examined prayer as the distant healing intervention, 11 assessed noncontact Therapeutic Touch, and 7 examined other forms of distant healing. Of the 23 studies, 13 (57%) yielded statistically significant treatment effects, 9 showed no effect over control interventions, and 1 showed a negative effect. Conclusions: The methodologic limitations of several studies make it difficult to draw definitive conclusions about the efficacy of distant healing. However, given that approximately 57% of trials showed a positive treatment effect, the evidence thus far merits further study.	Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Univ Exeter, Exeter, Devon, England	University System of Maryland; University of Maryland Baltimore; University of Exeter	Astin, JA (corresponding author), Kernan Hosp Mans, Complementary Med Program, 2200 Kernan Dr, Baltimore, MD 21207 USA.	jastin@compmed.ummc.umaryland.edu		Harkness, Elaine/0000-0001-6625-7739				Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; BENOR DJ, 1990, COMPLEMENT MED RES, V4, P9; BEUTLER JJ, 1988, BRIT MED J, V296, P1491, DOI 10.1136/bmj.296.6635.1491; BRAUD W, 1983, J PARAPSYCHOL, V47, P95; BROWN CK, 1995, COMPLEMENT THER MED, V3, P230; BYRD RC, 1988, SOUTHERN MED J, V81, P826, DOI 10.1097/00007611-198807000-00005; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Collipp P J, 1969, Med Times, V97, P201; Daley B, 1997, J ADV NURS, V25, P1123, DOI 10.1046/j.1365-2648.1997.19970251123.x; Dossey L, 1997, Altern Ther Health Med, V3, P10; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Gordon A, 1998, J FAM PRACTICE, V47, P271; GREYSON B, 1996, J SCI EXPLORATION, V10, P447; HARKNESS EF, IN PRESS AM J MED; Harris WS, 1999, ARCH INTERN MED, V159, P2273, DOI 10.1001/archinte.159.19.2273; HEDGES LV, 1982, PSYCHOL BULL, V92, P490, DOI 10.1037/0033-2909.92.2.490; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOYCE CRB, 1965, J CHRON DIS, V18, P367, DOI 10.1016/0021-9681(65)90040-8; KASS JD, 1991, J SCI STUD RELIG, V30, P203, DOI 10.2307/1387214; KELLER E, 1986, NURS RES, V35, P101; Krucoff MW, 1998, CIRCULATION, V98, P280; LEVIN JS, 1994, SOC SCI MED, V38, P1475, DOI 10.1016/0277-9536(94)90109-0; Luskin F, 2000, J Cardiopulm Rehabil, V20, P8, DOI 10.1097/00008483-200001000-00002; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; Matthews DA, 1998, ARCH FAM MED, V7, P118, DOI 10.1001/archfami.7.2.118; Meehan T C, 1993, Nurs Sci Q, V6, P69, DOI 10.1177/089431849300600206; Millar WJ, 1997, CAN J PUBLIC HEALTH, V88, P154, DOI 10.1007/BF03403879; MILLER RN, 1982, MED HYPOTHESES, V8, P481, DOI 10.1016/0306-9877(82)90009-3; OMATHUNA D, 1999, COCHRANE DATABASE SY, V2; OMATHUNA DP, 1998, SCI REV ALTERNATE ME, V2, P56; Quinn J F, 1984, ANS Adv Nurs Sci, V6, P42; Quinn J F, 1989, Nurs Sci Q, V2, P79, DOI 10.1177/089431848900200207; ROBERTS L, 1999, COCHRANE DATABASE SY, V2; Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005; Sicher F, 1998, WESTERN J MED, V169, P356; Simington J A, 1993, Clin Nurs Res, V2, P438, DOI 10.1177/105477389300200406; Sloan RP, 1999, LANCET, V353, P664, DOI 10.1016/S0140-6736(98)07376-0; Targ E, 1997, Altern Ther Health Med, V3, P92; Targ E, 1997, Altern Ther Health Med, V3, P74; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; Turner JG, 1998, J ADV NURS, V28, P10, DOI 10.1046/j.1365-2648.1998.00770.x; Walker S R, 1997, Altern Ther Health Med, V3, P79; Wallis C., 1996, TIME, P58; WARBER SL, IN PRESS FOCUS ALTER; Winstead-Fry P, 1999, ALTERN THER HEALTH M, V5, P58; WIRTH DP, 1995, SOC SCI MED, V41, P249, DOI 10.1016/0277-9536(94)00312-H; Wirth DP, 1993, COMPLEMENTARY THERAP, V1, P127; WIRTH DP, 1994, COMPLEMENTARY THERAP, V2, P187; Wirth DP, 1990, SUBTLE ENERGIES, V1, P1; WIRTH DP, 1996, COMPLEMENTARY THERAP, V4, P237; WIRTH DP, 1993, COMPLEMENT THER MED, V1, P133; Wiseman R, 1997, J PARAPSYCHOL, V61, P197	52	202	205	1	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					903	910		10.7326/0003-4819-132-11-200006060-00009	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	319HF	10836918				2022-12-28	WOS:000087334900008
J	Emanuel, EJ; Wendler, D; Grady, C				Emanuel, EJ; Wendler, D; Grady, C			What makes clinical research ethical?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CISPLATIN-INDUCED NAUSEA; DEVELOPING-COUNTRIES; INFORMED CONSENT; PROTECTING COMMUNITIES; ONDANSETRON GR-38032F; SEROTONIN ANTAGONIST; ROTAVIRUS VACCINE; CONTROLLED TRIALS; HUMAN-RIGHTS; PREVENTION	Many believe that informed consent makes clinical research ethical. However, informed consent is neither necessary nor sufficient for ethical clinical research. Drawing on the basic philosophies underlying major codes, declarations, and other documents relevant to research with human subjects, we propose 7 requirements that systematically elucidate a coherent framework for evaluating the ethics of clinical research studies: (1) value-enhancements of health or knowledge must be derived from the research; (2) scientific validity-the research must be methodologically rigorous; (3) fair subject selection-scientific objectives, not vulnerability or privilege, and the potential for and distribution of risks and benefits, should determine communities selected as study sites and the inclusion criteria for individual subjects; (4) favorable risk-benefit ratio-within the context of standard clinical practice and the research protocol, risks must be minimized, potential benefits enhanced, and the potential benefits to individuals and knowledge gained for society must outweigh the risks; (5) independent review-unaffiliated individuals must review the research and approve, amend, or terminate it; (6) informed consent-individuals should be informed about the research and provide their voluntary consent; and (7) respect for enrolled subjects-subjects should have their privacy protected, the opportunity to withdraw, and their well-being monitored. Fulfilling all 7 requirements is necessary and sufficient to make clinical research ethical. These requirements are universal, although they must be adapted to the health, economic, cultural, and technological conditions in which clinical research is conducted.	NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Grady, C (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.	cgradu@nih.gov						*ADV COMM HUM RAD, 1996, HUM RAD EXP; ANDERSON E, 1993, VALUE ETHICS EC, pCH9; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; ANGELL M, 1988, NEW ENGL J MED, V319, P1081, DOI 10.1056/NEJM198810203191608; Annas G J, 1992, Health Matrix Clevel, V2, P119; Annas GJ, 1998, AM J PUBLIC HEALTH, V88, P560, DOI 10.2105/AJPH.88.4.560; [Anonymous], 1996, JAMA-J AM MED ASSOC, V276, P1691; [Anonymous], 1996, Fed Regist, V61, P51498; [Anonymous], 1979, BELM REP; APPLEBAUM P, 1987, INFORMED CONSENT; BARRY M, 1992, J MED ETHICS, V18, P189, DOI 10.1136/jme.18.4.189; BEAUCHAMP TL, 1996, PRINCIPLES BIOMEDICA, pCH3; BECK TM, 1993, ANN INTERN MED, V118, P407, DOI 10.7326/0003-4819-118-6-199303150-00002; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; BIROS MH, 1995, JAMA-J AM MED ASSOC, V273, P1283, DOI 10.1001/jama.273.16.1283; Bresee JS, 1999, VACCINE, V17, P2207, DOI 10.1016/S0264-410X(98)00376-4; BRODY BS, 1998, ETHICS BIOMEDICAL RE, pCH9; BUCHANAN AE, 1990, DECIDING OTHERS, pCH2; Capron AM, 1999, NEW ENGL J MED, V340, P1430, DOI 10.1056/NEJM199905063401812; CHILDRESS JF, 1984, HASTINGS CENT REP, V14, P27, DOI 10.2307/3561094; Christakis N A, 1991, Law Med Health Care, V19, P214; CITRON ML, 1993, ANN INTERN MED, V118, P470, DOI 10.7326/0003-4819-118-6-199303150-00013; *COMM NIH RES PRIO, 1998, SCI OPP PUBL NEEDS; *COUNC ETH JUD AFF, 1997, 1A7 CEJA AM MED ASS; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; Council of Europe, 1996, CONV PROT HUM RIGHTS; Crouch RA, 1998, HASTINGS CENT REP, V28, P26, DOI 10.2307/3528266; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; Curran W.J, 1970, EXPT HUMAN SUBJECTS, P402; Debruin Debra A., 1994, Kennedy Institute of Ethics Journal, V4, P117; DECASTRO LD, 1995, BIOETHICS, V9, P259, DOI 10.1111/j.1467-8519.1995.tb00360.x; DONAGAN A, 1977, J MED PHILOS, V2, P307, DOI 10.1093/jmp/2.4.307; Dresser R, 1996, JAMA-J AM MED ASSOC, V276, P67, DOI 10.1001/jama.276.1.67; DRESSER R, 1992, HASTINGS CENT REP, V22, P24, DOI 10.2307/3562720; Dworkin Gerald, 1988, THEORY PRACTICE AUTO; EDGAR H, 1995, MILBANK Q, V73, P489, DOI 10.2307/3350283; *EUR FOR GOOD CLIN, 1997, GUID REC EUR ETH COM; FADEN RR, 1986, HIST THEORY INFORMED, pCH5; FLUSS S, 1998, INT GUIDELINES BIOET; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; FREEDMAN B, 1992, CLIN RES, V40, P653; FREEDMAN B, 1975, HASTINGS CENT REP, V5, P32, DOI 10.2307/3561421; FREEDMAN B, 1993, IRB, V15, P13; Freedman Benjamin, 1990, IRB, V12, P5, DOI 10.2307/3563682; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; Freedman Benjamin, 1987, IRB, V9, P7, DOI 10.2307/3563623; Fried C, 1974, MED EXPT; GANDARA DR, 1992, SEMIN ONCOL, V19, P67; Glantz LH, 1998, HASTINGS CENT REP, V28, P38, DOI 10.2307/3528268; Gold MR, 1996, COST EFFECTIVENESS H; Grady C, 1998, HASTINGS CENT REP, V28, P34, DOI 10.2307/3528267; GRISSO R, 1998, ASSESSING COMPETENCE; GRODIN MA, 1994, CHILDREN RES SUBJECT, P81; HAINSWORTH J, 1991, J CLIN ONCOL, V9, P721, DOI 10.1200/JCO.1991.9.5.721; HAIT WN, 1990, NEW ENGL J MED, V323, P1485; Harsanyi J.C., 1982, UTILITARIANISM; Hazard G.C., 1996, CONFLICTS INTEREST C, P85; IJSSELMUIDEN CB, 1992, NEW ENGL J MED, V326, P830, DOI 10.1056/NEJM199203193261212; Intussusception among recipients of rotavirus vaccine-United States, 1999, MMWR MORB MORTAL WKL, V48, P577; Joensuu J, 1997, LANCET, V350, P1205, DOI 10.1016/S0140-6736(97)05118-0; JONES J, 1992, BAD BLOOD; Juengst ET, 1998, KENNEDY INST ETHIC J, V8, P183, DOI 10.1353/ken.1998.0010; KAHN JP, 1998, CONSENT; Katz J., 1972, EXPT HUMAN BEINGS; KATZ J, 1993, ST LOUIS U LAW REV, V38, P1; KAUFFMAN RE, 1995, PEDIATRICS, V95, P286; KOPELMAN LM, 1989, CHILDREN HLTH CARE M, P73; KRUGMAN S, 1986, REV INFECT DIS, V8, P157; Kymlicka W., 1989, LIBERALISM COMMUNITY; LASAGNA L, 1995, J CLIN PSYCHOPHARM, V15, P96, DOI 10.1097/00004714-199504000-00002; Lehrman S, 1997, NATURE, V389, P322, DOI 10.1038/38579; Leikin Sanford, 1993, IRB, V15, P1, DOI 10.2307/3564579; Levine Carol, 1991, IRB, V13, P1; Levine R J, 1991, Law Med Health Care, V19, P207; Levine RJ, 1999, NEW ENGL J MED, V341, P531, DOI 10.1056/NEJM199908123410713; LEVINE RJ, 1995, JAMA-J AM MED ASSOC, V273, P1300, DOI 10.1001/jama.273.16.1300; Levine Robert J., 1994, Kennedy Institute of Ethics Journal, V4, P93; LEVINE ROBERT J., 1988, ETHICS REGULATION CL, V2nd; LIPSETT MB, 1982, JAMA-J AM MED ASSOC, V248, P941, DOI 10.1001/jama.248.8.941; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; MACKLIN A, 1999, RELATIVISM; MACLEAN D, 1985, VALUES RISK, P31; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; MASTRIANI AC, 1994, WOMEN HLTH RES; *MED RES COUNC CAN, 1998, TRI COUNC POL STAT; Medical Research Council, 1998, GUID GOOD CLIN PRACT; MERKATZ RB, 1993, NEW ENGL J MED, V329, P292, DOI 10.1056/NEJM199307223290429; MERTON V, 1993, AM J LAW MED, V19, P369; Michels R, 1999, NEW ENGL J MED, V340, P1427, DOI 10.1056/NEJM199905063401811; Moreno J, 1998, JAMA-J AM MED ASSOC, V280, P1951, DOI 10.1001/jama.280.22.1951; *NAT COMM PROT HUM, 1978, BELM REP, V1, pCH9; *NAT HLTH MED RES, 1999, NAT STAT ETH COND RE; National Bioethics Advisory Commission, 1998, RES INV PERS MENT DI; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1978, I REV BOARDS; National Institutes of Health, 1994, FED REGISTER, V59, P1408; PORTER RJ, 1992, BIOMEDICAL RES; *PRES COMM STUD ET, 1983, SUMM UP; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral research, 1982, MAK HLTH CAR DEC; RELMAN AS, 1989, NEW ENGL J MED, V320, P933, DOI 10.1056/NEJM198904063201410; Rennels MB, 1996, PEDIATRICS, V97, P7; ROTHMAN DJ, 1984, WILLOWBROOK WARS; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; RUTSTEIN DD, 1970, EXPT HUMAN SUBJECTS, P383; SCANLON TM, 1999, WHAT WE OWE EACH OTH, pCH1; Sen Amartya, 1982, CHOICE WELFARE MEASU, P264; SUGARMAN J, 1998, RES HUMAN SUBJECTS; TEMPLE R, 1982, DRUG INF J, P1610; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; Truog RD, 1999, NEW ENGL J MED, V340, P804, DOI 10.1056/NEJM199903113401013; *UG NAT COUNC SCI, 1998, GUID COND HLTH RES I; Vanderpool HY, 1996, ETHICS RES INVOLVING, P45; VANDERPOOL HY, 1996, ETHICS RES INVOLVING, P105; VANDERPOOL HY, 1996, ETHICS RES INVOLVING, P235; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; Weijer C, 1999, NAT GENET, V23, P275, DOI 10.1038/15455; Weijer C, 1999, CAMB Q HEALTHC ETHIC, V8, P501, DOI 10.1017/S0963180199004120; Weijer C, 1999, SCHIZOPHR RES, V35, P211, DOI 10.1016/S0920-9964(98)00127-3; Weijer C, 1996, CAMB Q HEALTHC ETHIC, V5, P334, DOI 10.1017/S0963180100007155; Weijer C, 1999, IRB, V21, P1, DOI 10.2307/3564450; WEIJER C, 1994, CLIN INVEST MED, V17, P115; WEIJER C, 1995, CAN MED ASSOC J, V152, P1973; WERTHEIMER A, 1996, EXPLOITATION, pCH1; WHITE LJ, 1989, ANN INTERN MED, V111, P843, DOI 10.7326/0003-4819-111-10-843; *WHO, 1995, USE ESS DRUGS; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038; 1997, FED REG, V62, P25692; 1990, N ENGL J MED, V323, P1486	128	1411	1469	6	231	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2701	2711		10.1001/jama.283.20.2701	http://dx.doi.org/10.1001/jama.283.20.2701			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	314FP	10819955				2022-12-28	WOS:000087046000040
J	Peipert, JF				Peipert, JF			Ambulatory gynecology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BACTERIAL VAGINOSIS; COST-EFFECTIVENESS; PRETERM BIRTH; HIV-INFECTION; VAGINAL FLORA; METRONIDAZOLE; TECHNOLOGIES; DISTURBANCES; PREGNANCY; WOMEN		Brown Univ, Sch Med, Women & Infants Hosp,Div Res Womens Hlth, Dept Obstet Gynecol & Community Hlth, Providence, RI 02912 USA	Brown University; Women & Infants Hospital Rhode Island	Peipert, JF (corresponding author), Women & Infants Hosp, Dept Obstet & Gynecol, 101 Dudley St, Providence, RI 02905 USA.							*AG HLTH CAR POL R, 1999, 5 AG HLTH CAR POL RE; Brown AD, 1999, JAMA-J AM MED ASSOC, V281, P347, DOI 10.1001/jama.281.4.347; Carey JC, 2000, NEW ENGL J MED, V342, P534, DOI 10.1056/NEJM200002243420802; Diaz-Rosario LA, 1999, ARCH PATHOL LAB MED, V123, P817; Grimes D, 1998, LANCET, V352, P428; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HILLIER S, 1999, SEXUALLY TRANSMITTED, P563; MARTIUS J, 1988, OBSTET GYNECOL, V71, P89; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8; Oleen-Burkey M A, 1995, Infect Dis Obstet Gynecol, V3, P149, DOI 10.1155/S1064744995000500; Raab SS, 1999, AM J CLIN PATHOL, V111, P259; Royce RA, 1999, J ACQ IMMUN DEF SYND, V20, P382, DOI 10.1097/00042560-199904010-00009; Sawaya GF, 1999, CLIN OBSTET GYNECOL, V42, P922, DOI 10.1097/00003081-199912000-00020; Sawaya GF, 1999, OBSTET GYNECOL, V94, P307, DOI 10.1016/S0029-7844(99)00289-6; Taha TE, 1999, J ACQ IMMUN DEF SYND, V20, P52, DOI 10.1097/00042560-199901010-00008; Taha TE, 1998, AIDS, V12, P1699, DOI 10.1097/00002030-199813000-00019; Trussell J, 2000, OBSTET GYNECOL, V95, P267, DOI 10.1016/S0029-7844(99)00518-9; *US PREV SERV TASK, 1995, GUID CLIN PREV SERV	18	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2630	2632		10.1001/jama.283.20.2630	http://dx.doi.org/10.1001/jama.283.20.2630			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819923				2022-12-28	WOS:000087046000002
J	Boot, BP; McGregor, LS; Hall, W				Boot, BP; McGregor, LS; Hall, W			MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks	LANCET			English	Editorial Material							POSITRON-EMISSION-TOMOGRAPHY; BRAIN-SEROTONIN NEURONS; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; (+/-)3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; COGNITIVE PERFORMANCE; RECREATIONAL USE; MEMORY DEFICITS; HUMANS; MOOD; DRUG		Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia; Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia	University of New South Wales Sydney; University of Sydney; University of Sydney	Hall, W (corresponding author), Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia.	w.hall@unsw.edu.au	Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				ALLEN RP, 1993, SLEEP, V16, P560, DOI 10.1093/sleep/16.6.560; Bolla KI, 1998, NEUROLOGY, V51, P1532, DOI 10.1212/WNL.51.6.1532; Brody S, 1998, PSYCHOPHARMACOLOGY, V136, P390, DOI 10.1007/s002130050582; CALAFAT A, 1998, CHARACTERISTICS SOCI; Chappell W, 1991, ADV DRUG RES; Cohen Richard, 1998, LOVE DRUG MARCHING B; Colado MI, 1999, BRIT J PHARMACOL, V126, P911, DOI 10.1038/sj.bjp.0702373; Curran HV, 1997, ADDICTION, V92, P821, DOI 10.1111/j.1360-0443.1997.tb02951.x; Dafters RI, 1998, PSYCHOPHARMACOLOGY, V138, P207, DOI 10.1007/s002130050664; Dafters RI, 1999, PSYCHOPHARMACOLOGY, V145, P82, DOI 10.1007/s002130051035; FEACHEM RGA, 1995, VALUING PAST INVESTI; FISCHER C, 1995, J NEUROSCI, V15, P5476; Frederick DL, 1997, NEUROSCI BIOBEHAV R, V21, P67, DOI 10.1016/0149-7634(95)00064-X; Gerra G, 1998, INT CLIN PSYCHOPHARM, V13, P1, DOI 10.1097/00004850-199801000-00001; Gerra G, 2000, BIOL PSYCHIAT, V47, P127, DOI 10.1016/S0006-3223(99)00180-8; Gijsman HJ, 1999, NEUROPSYCHOPHARMACOL, V21, P597; Hatzidimitriou G, 1999, J NEUROSCI, V19, P5096; Hegadoren KM, 1999, NEUROSCI BIOBEHAV R, V23, P539, DOI 10.1016/S0149-7634(98)00046-3; Malberg JE, 1998, J NEUROSCI, V18, P5086; Marston HM, 1999, PSYCHOPHARMACOLOGY, V144, P67, DOI 10.1007/s002130050978; MCCANN UD, 1993, J CLIN PSYCHOPHARM, V13, P214; McCann UD, 1999, PSYCHOPHARMACOLOGY, V147, P56, DOI 10.1007/s002130051142; McCann UD, 1997, JAMA-J AM MED ASSOC, V278, P666, DOI 10.1001/jama.278.8.666; McCann UD, 1999, PSYCHOPHARMACOLOGY, V143, P417, DOI 10.1007/s002130050967; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; MCCANN UD, 1994, NEUROPSYCHOPHARMACOL, V10, P129, DOI 10.1038/npp.1994.15; McElhatton PR, 1999, LANCET, V354, P1441, DOI 10.1016/S0140-6736(99)02423-X; Morgan MJ, 1998, NEUROPSYCHOPHARMACOL, V19, P252, DOI 10.1016/S0893-133X(98)00012-8; Morgan MJ, 1999, PSYCHOPHARMACOLOGY, V141, P30, DOI 10.1007/s002130050803; Obrocki J, 1999, BRIT J PSYCHIAT, V175, P186, DOI 10.1192/bjp.175.2.186; Parrott AC, 1998, J PSYCHOPHARMACOL, V12, P79, DOI 10.1177/026988119801200110; Parrott AC, 1998, PSYCHOPHARMACOLOGY, V139, P261, DOI 10.1007/s002130050714; PEROUTKA SJ, 1987, RES COMMUN SUBSTANCE, V8, P125; PRICE LH, 1989, ARCH GEN PSYCHIAT, V46, P20; Reed LJ, 1999, LANCET, V353, P1268, DOI 10.1016/S0140-6736(99)80066-X; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1; RICAURTE GA, 1990, ANN NY ACAD SCI, V600, P699; SAUNDERS N., 1996, ECSTASY DANCE TRANCE; Scheffel U, 1998, SYNAPSE, V29, P183, DOI 10.1002/(SICI)1098-2396(199806)29:2<183::AID-SYN9>3.0.CO;2-3; Schifano F, 1998, DRUG ALCOHOL DEPEN, V52, P85, DOI 10.1016/S0376-8716(98)00051-9; SEMLE DM, 1999, BRIT J PSYCHIAT, V175, P63; SOLOWIJ N, 1992, BRIT J ADDICT, V87, P1161; SOUBRIE P, 1986, BEHAV BRAIN SCI, V9, P319, DOI 10.1017/S0140525X00022871; Sprague JE, 1998, NEUROTOXICOLOGY, V19, P427; Staley JK, 1998, BIOL PSYCHIAT, V44, P534, DOI 10.1016/S0006-3223(98)00185-1; Topp L, 1999, DRUG ALCOHOL DEPEN, V55, P105, DOI 10.1016/S0376-8716(99)00002-2; Vollenweider FX, 1999, NEUROPSYCHOPHARMACOL, V21, P598	47	66	66	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 20	2000	355	9217					1818	1821		10.1016/S0140-6736(00)02276-5	http://dx.doi.org/10.1016/S0140-6736(00)02276-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	315RE	10832852				2022-12-28	WOS:000087126100049
J	Hotopf, M; David, A; Hull, L; Ismail, K; Unwin, C; Wessely, S				Hotopf, M; David, A; Hull, L; Ismail, K; Unwin, C; Wessely, S			Role of vaccinations as risk factors for ill health in veterans of the Gulf war: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article								Objectives To explore the relation between ill health after the Gulf war and vaccines received before or during the conflict To test the hypothesis that such ill health is limited to military personnel who received multiple vaccines during deployment and that pesticide use modifies any effect. Design Cross sectional study of Gulf war veterans followed for six to eight years after deployment Setting UK armed forces. Participants Military personnel who served in the Gulf and who still had their vaccine records. Main outcome measures Multisymptom illness as classified by the Centers for Disease Control and Prevention; fatigue; psychological distress; post-traumatic stress reaction; health perception; and physical functioning Results The response rate for the original survey was 70.4% (n = 3284). Of these, 28% (923) had vaccine records. Receipt of multiple vaccines before deployment was associated with only one of the six health outcomes (post-traumatic stress reaction). By contrast five of the six outcomes tall but post-traumatic stress reaction) were associated with multiple vaccines received during deployment. The strongest association was for the multisymptom illness (odds ratio 5.0; 95% confidence interval 2.5 to 9.8). Conclusion Among veterans of the Gulf war there is a specific relation between multiple vaccinations given during deployment and later ill health. Multiple vaccinations in themselves do not seem to be harmful but combined with the "stress" of deployment they may be associated with adverse health outcomes. These results imply that every effort should be made to maintain routine vaccines during peacetime.	Kings Coll London, Guys Kings Coll, Gulf War Res Unit, London SE5 8AZ, England; Kings Coll London, St Thomass Sch Med, London SE5 8AZ, England	University of London; King's College London; University of London; King's College London	Hotopf, M (corresponding author), Kings Coll London, Guys Kings Coll, Gulf War Res Unit, London SE5 8AZ, England.	m.hotopf@iop.kcl.ac.uk	David, Anthony/O-1750-2019; Wessely, Simon C/A-8713-2008; Hotopf, Matthew/E-4971-2010; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X; Wessely, Simon Charles/0000-0002-6743-9929; Hotopf, Matthew/0000-0002-3980-4466; Ismail, Khalida/0000-0001-6084-449X				CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Goldberg D.P, 1972, DETECTION PSYCHIAT I; GRIFFITHS GD, 1999, C FED SPONS GULF WAR; Rook GAW, 1997, LANCET, V349, P1831, DOI 10.1016/S0140-6736(97)01164-1; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Unwin C, 1999, LANCET, V353, P169, DOI 10.1016/S0140-6736(98)11338-7; Wessely S, 1998, CHRONIC FATIGUE ITS	8	122	124	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	2000	320	7246					1363	1367		10.1136/bmj.320.7246.1363	http://dx.doi.org/10.1136/bmj.320.7246.1363			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818024	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000087232500019
J	Gershon, D				Gershon, D			Are mega-mergers good medicine for the pharmaceutical industry?	NATURE			English	Editorial Material																			0	3	3	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					257	258		10.1038/35012205	http://dx.doi.org/10.1038/35012205			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821288				2022-12-28	WOS:000087080100066
J	Dong, C; Yang, DD; Tournier, C; Whitmarsh, AJ; Xu, J; Davis, RJ; Flavell, RA				Dong, C; Yang, DD; Tournier, C; Whitmarsh, AJ; Xu, J; Davis, RJ; Flavell, RA			JNK is required for effector T-cell function but not for T-cell activation	NATURE			English	Article							KINASE; DIFFERENTIATION	The hallmark of T-cell activation is the production of interleukin 2 (IL-2). c-Jun amino-terminal kinase (JNK), a MAP kinase that phosphorylates c-Jun and other components of the AP-1 group of transcription factors(1,2), has been implicated in the activation of IL-2 expression(3,4). Previously, we found that T cells from mice deficient in the Jnk1 or Jnk2 gene can be activated and produce IL-2 normally, but are deficient in functional differentiation into Th1 or Th2 subsets(5,6). However, studies of mice with compound mutations indicate that JNK1 and JNK2 are redundant during mouse development(7). Here we use three new mouse models in which peripheral T cells completely lack JNK proteins or signalling, to test whether the JNK signalling pathway is crucial for IL-2 expression and T-cell activation. Unexpectedly, these T cells made more IL-2 and proliferated better than wild-type cells. However, production of effector T-cell cytokines did require JNK. Thus, JNK is necessary for T-cell differentiation but not for naive T-cell activation.	Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, New Haven, CT 06520 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med,Howard Hughes Med Inst, Worcester, MA 01605 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Flavell, RA (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06520 USA.		dong, chen/B-3181-2009	dong, chen/0000-0002-0084-9130; Whitmarsh, Alan/0000-0003-1184-6610				CHOW CW, IN PRESS MOL CELL BI; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Gomez J, 1998, CRIT REV IMMUNOL, V18, P185, DOI 10.1615/CritRevImmunol.v18.i3.20; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; NISHINA H, 1997, J EXP MED, V186, P9541; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Swat W, 1998, IMMUNITY, V8, P625, DOI 10.1016/S1074-7613(00)80567-1; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8	16	276	291	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					91	94		10.1038/35011091	http://dx.doi.org/10.1038/35011091			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811224				2022-12-28	WOS:000086901600057
J	Dobson, R				Dobson, R			Geographical mobility is predictor of demand on psychiatric services	BRITISH MEDICAL JOURNAL			English	News Item																		2000, SOCIAL PSYCHIAT PSYC, V34, P164	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1496	1496		10.1136/bmj.320.7248.1496	http://dx.doi.org/10.1136/bmj.320.7248.1496			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834887	Green Published			2022-12-28	WOS:000087471000017
J	Stricker, T; Braegger, CP				Stricker, T; Braegger, CP			Oral manifestations of Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Zurich, Childrens Hosp, CH-8032 Zurich, Switzerland	University Children's Hospital Zurich; University of Zurich	Stricker, T (corresponding author), Univ Zurich, Childrens Hosp, CH-8032 Zurich, Switzerland.		Braegger, Christian Peter/ABC-9884-2021	Braegger, Christian/0000-0001-8069-9875					0	17	17	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2000	342	22					1644	1644		10.1056/NEJM200006013422205	http://dx.doi.org/10.1056/NEJM200006013422205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319CE	10833210				2022-12-28	WOS:000087321600005
J	Socas-Navarro, H; Trujillo Bueno, J; Cobo, BR				Socas-Navarro, H; Trujillo Bueno, J; Cobo, BR			Anomalous polarization profiles in sunspots: Possible origin of umbral flashes	SCIENCE			English	Article								We present time-series spectropolarimetric observations of sunspots in the Ca II infrared triplet Lines, which show a periodic occurrence of anomalous, asymmetric, circular polarization profiles in the umbral chromosphere. The profiles may be caused by the periodic development of an unresolved atmospheric component in a downward flowing magnetized environment. This active component with upward directed Velocities as high as 10 kilometers per second is connected to the umbral flash (UF) phenomenon. We can explain the observations with a semiempirical model of the chromospheric oscillation and of the sunspot magnetized atmospheric plasma during a UF event.	Inst Astrofis Canarias, E-38200 San Cristobal la Laguna, Tenerife, Spain; CSIC, Madrid, Spain; Univ La Laguna, Dept Astrofis, Tenerife, Spain	Instituto de Astrofisica de Canarias; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de la Laguna	Socas-Navarro, H (corresponding author), Inst Astrofis Canarias, E-38200 San Cristobal la Laguna, Tenerife, Spain.		Socas-Navarro, Hector/AAE-5090-2019; Bueno, Javier Trujillo/AAE-5264-2019; Ruiz Cobo, Basilio/K-9937-2014	Socas-Navarro, Hector/0000-0001-9896-4622; Ruiz Cobo, Basilio/0000-0001-9550-6749				ALMEIDA JS, 1994, ASTROPHYS J, V424, P1014, DOI 10.1086/173952; ALMEIDA JS, 1991, SOL PHYS, V134, P1, DOI 10.1007/BF00148738; BECKERS JM, 1969, SOL PHYS, V7, P351, DOI 10.1007/BF00146140; BUENO JT, 1993, ASTR SOC P, V46, P526; Chandrasekhar S., 1950, RAD TRANSFER; KNEER F, 1984, ASTROPHYS J, V102, P147; LITES BW, 1985, ASTROPHYS J, V294, P682, DOI 10.1086/163338; LITES BW, 1992, NATO ADV SCI I C-MAT, V375, P261; LITES BW, 1994, CHROMOSPHERIC DYNAMI, P1; Maltby P, 1997, ASTR SOC P, V118, P91; MOORE RL, 1981, SPACE SCI REV, V28, P387, DOI 10.1007/BF00212601; Schroter E. H., 1985, VISTAS ASTRON, V28, P519; SEMEL M, 1980, ASTRON ASTROPHYS, V91, P369; Socas-Navarro H, 2000, ASTROPHYS J, V530, P977, DOI 10.1086/308414; Socas-Navarro H, 1998, ASTROPHYS J, V507, P470, DOI 10.1086/306330; THOMAS JH, 1984, ASTROPHYS J, V285, P368, DOI 10.1086/162514; THOMAS JH, 1992, NATO ADV SCI I C-MAT, V375, P3; TUROVA IP, 1984, SOL PHYS, V91, P51, DOI 10.1007/BF00213610; WITTMANN A, 1969, SOL PHYS, V7, P366, DOI 10.1007/BF00146141	19	57	58	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1396	1398		10.1126/science.288.5470.1396	http://dx.doi.org/10.1126/science.288.5470.1396			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827944				2022-12-28	WOS:000087270900042
J	Byrne, JG; Aklog, L; Adams, DH				Byrne, JG; Aklog, L; Adams, DH			Assessment and management of functional or ischaemic mitral regurgitation	LANCET			English	Editorial Material							ECHOCARDIOGRAPHY; BYPASS		Brigham & Womens Hosp, Div Cardiac Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Byrne, JG (corresponding author), Brigham & Womens Hosp, Div Cardiac Surg, 75 Francis St, Boston, MA 02115 USA.							ADLER DS, 1986, AM J CARDIOL, V58, P195, DOI 10.1016/0002-9149(86)90046-9; Armstrong GP, 2000, CORONARY ARTERY DIS, V11, P23, DOI 10.1097/00019501-200002000-00005; BACH DS, 1995, AM J CARDIOL, V76, P508, DOI 10.1016/S0002-9149(99)80140-4; Bolling SF, 1998, J THORAC CARDIOV SUR, V115, P381, DOI 10.1016/S0022-5223(98)70282-X; Chen FY, 1998, CIRCULATION, V98, pII124; Christenson J T, 1995, J Heart Valve Dis, V4, P484; COHN LH, 1995, EUR J CARDIO-THORAC, V9, P568, DOI 10.1016/S1010-7940(05)80008-9; Czer LSC, 1996, TEX HEART I J, V23, P270; Dion R, 1995, J Heart Valve Dis, V4 Suppl 2, pS124; Duarte IG, 1999, ANN THORAC SURG, V68, P426, DOI 10.1016/S0003-4975(99)00516-0; Grewal KS, 2000, AM J CARDIOL, V85, P199, DOI 10.1016/S0002-9149(99)00644-X; Izhar U, 1999, CIRCULATION, V100, P84; Takuma S, 1998, Semin Thorac Cardiovasc Surg, V10, P247	13	29	29	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 20	2000	355	9217					1743	1744		10.1016/S0140-6736(00)02259-5	http://dx.doi.org/10.1016/S0140-6736(00)02259-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832822				2022-12-28	WOS:000087126100006
J	Colman, R				Colman, R			Failures of process at the GMC	BRITISH MEDICAL JOURNAL			English	Editorial Material																		1999, BRIT MED J, V318, P486	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	2000	320	7246					1415	1415		10.1136/bmj.320.7246.1415	http://dx.doi.org/10.1136/bmj.320.7246.1415			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818046	Green Published			2022-12-28	WOS:000087232500064
J	Taguchi, A; Blood, DC; del Toro, G; Canet, A; Lee, DC; Qu, W; Tanji, N; Lu, Y; Lalla, E; Fu, CF; Hofmann, MA; Kislinger, T; Ingram, M; Lu, A; Tanaka, H; Hori, O; Ogawa, S; Stern, DM; Schmidt, AM				Taguchi, A; Blood, DC; del Toro, G; Canet, A; Lee, DC; Qu, W; Tanji, N; Lu, Y; Lalla, E; Fu, CF; Hofmann, MA; Kislinger, T; Ingram, M; Lu, A; Tanaka, H; Hori, O; Ogawa, S; Stern, DM; Schmidt, AM			Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases	NATURE			English	Article							ACTIVATED-PROTEIN-KINASE; GLYCATION END-PRODUCTS; CELL-SURFACE RECEPTOR; NEURITE OUTGROWTH; PLASMINOGEN ACTIVATION; SIGNALING PATHWAYS; EPITHELIAL-CELLS; SOLUBLE RECEPTOR; BINDING-PROTEINS; OXIDANT STRESS	The receptor for advanced glycation end products (RAGE), a multi-ligand member of the immunoglobulin superfamily of cell surface molecules(1-2), interacts with distinct molecules implicated in homeostasis, development and inflammation, and certain diseases such as diabetes and Alzheimer's disease(3-8). Engagement of RAGE by a ligand triggers activation of key cell signalling pathways, such as p21(ras), MAP kinases, NF-kappa B and cdc42/rac, thereby reprogramming cellular properties(9-11). RAGE is a central cell surface receptor for amphoterin, a polypeptide linked to outgrowth of cultured cortical neurons derived from developing brain(3,12-15). Indeed, the co-localization of RAGE and amphoterin at the leading edge of advancing neurites indicated their potential contribution to cellular migration, and in pathologies such as tumour invasion. Here we demonstrate that blockade of RAGE-amphoterin decreased growth and metastases of both implanted tumours and tumours developing spontaneously in susceptible mice. Inhibition of the RAGE-amphoterin interaction suppressed activation of p44/p42, p38 and SAP/JNK MAP kinases; molecular effector mechanisms importantly linked to tumour proliferation, invasion and expression of matrix metalloproteinases(16-23).	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Osaka Univ, Sch Med, Osaka 5650871, Japan; Kanazawa Univ, Sch Med, Kanazawa, Ishikawa 9208640, Japan	Columbia University; Osaka University; Kanazawa University	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.		Kislinger, Thomas/A-5934-2008; li, tao/B-2402-2008	Kislinger, Thomas/0000-0003-3525-5540				Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; ALBINI A, 1987, CANCER RES, V47, P3239; BRETT J, 1993, AM J PATHOL, V143, P1699; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Montesano R, 1999, CELL GROWTH DIFFER, V10, P317; NEEPER M, 1992, J BIOL CHEM, V267, P14998; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; RAMAMURTHY NS, 1983, J PERIODONTAL RES, V18, P23, DOI 10.1111/j.1600-0765.1983.tb00331.x; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Tsang DK, 1999, INT J ONCOL, V15, P519; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	30	1041	1163	3	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					354	360		10.1038/35012626	http://dx.doi.org/10.1038/35012626			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830965				2022-12-28	WOS:000087085700049
J	Kawasaki, H; Schiltz, L; Chiu, R; Itakura, K; Taira, K; Nakatani, Y; Yokoyama, KK				Kawasaki, H; Schiltz, L; Chiu, R; Itakura, K; Taira, K; Nakatani, Y; Yokoyama, KK			ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation	NATURE			English	Article							AMP RESPONSE ELEMENT; COACTIVATORS P300; TRANSCRIPTIONAL ACTIVATION; GENOTOXIC AGENTS; RETINOIC-ACID; DNA-BINDING; ACETYLATION; PROTEIN; CBP; NUCLEAR	Transcription factors carry functional domains, which are often physically distinct, for sequence-specific DNA binding, transcriptional activation and regulatory functions. The transcription factor ATF-2 is a DNA-binding protein that binds to cyclic AMP-response elements (CREs), forms a homodimer or heterodimer with c-Jun, and stimulates CRE-dependent transcription(1-3). Here we report that ATF-2 is a histone acetyltransferase (HAT), which specifically acetylates histones H2B and H4 in vitro. Motif A, which is located in the HAT domain, is responsible for the stimulation of CRE-dependent transcription; moreover, in response to ultraviolet irradiation, phosphorylation of ATF-2 is accompanied by enhanced HAT activity of ATF-2 and CRE-dependent transcription. These results indicate that phosphorylation of ATF-2 controls its intrinsic HAT activity and its action on CRE-dependent transcription. ATF-2 may represent a new class of sequence-specific factors, which are able to activate transcription by direct effects on chromatin components.	RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan; AIST, Agcy Ind Sci & Technol, Natl Inst Adv Interdisciplianry Res, Tsukuba, Ibaraki 3050006, Japan; AIST, Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3050006, Japan; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Sch Med, Sch Dent Surg Oncol Oral Biol & Med, Los Angeles, CA 90095 USA; City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Genet, Duarte, CA 91010 USA; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan	RIKEN; National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; City of Hope; Beckman Research Institute of City of Hope; University of Tokyo	Yokoyama, KK (corresponding author), RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan.	kazunari@rtc.riken.go.jp						Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Herrlich P, 1997, BIOL CHEM, V378, P1217; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	29	213	220	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					195	200		10.1038/35012097	http://dx.doi.org/10.1038/35012097			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821277				2022-12-28	WOS:000087080100054
J	Margules, CR; Pressey, RL				Margules, CR; Pressey, RL			Systematic conservation planning	NATURE			English	Review							NEW-SOUTH-WALES; RESERVE SELECTION; BIODIVERSITY-ASSESSMENT; FOREST BIODIVERSITY; AREAS; DIVERSITY; HOTSPOTS; DESIGN; FRAGMENTATION; MANAGEMENT	The realization of conservation goals requires strategies for managing whole landscapes including areas allocated to both production and protection. Reserves alone are not adequate for nature conservation but they are the cornerstone on which regional strategies are built. Reserves have two main roles. They should sample or represent the biodiversity of each region and they should separate this biodiversity from processes that threaten its persistence. Existing reserve systems throughout the world contain a biased sample of biodiversity, usually that of remote places and other areas that are unsuitable for commercial activities. A more systematic approach to locating and designing reserves has been evolving and this approach will need to be implemented if a large proportion of today's biodiversity is to exist in a future of increasing numbers of people and their demands on natural resources.	CSIRO Wildlife & Ecol, Trop Forest Res Ctr, Atherton, Qld 4883, Australia; Rainforest Cooperat Res Ctr, Atherton, Qld 4883, Australia; NSW Natl Pk & Wildlife Serv, Armidale, NSW 2350, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Margules, CR (corresponding author), CSIRO Wildlife & Ecol, Trop Forest Res Ctr, POB 780, Atherton, Qld 4883, Australia.		Pressey, Bob/C-8370-2013; Wrbka, Thomas/A-5699-2010; Margules, Chris R/F-4605-2012	Pressey, Bob/0000-0003-2740-0330; Wrbka, Thomas/0000-0002-1451-9108; 				AIKEN SR, 1994, ENVIRON CONSERV, V21, P49, DOI 10.1017/S0376892900024073; [Anonymous], 1992, NATL FOREST POLICY S; Austin M.P., 1986, P45; AUSTIN MP, 1985, ANNU REV ECOL SYST, V16, P39, DOI 10.1146/annurev.es.16.110185.000351; Austin MP, 1996, FOREST ECOL MANAG, V85, P95, DOI 10.1016/S0378-1127(96)03753-X; AUSTIN MP, 1990, ECOL MONOGR, V60, P161, DOI 10.2307/1943043; BALMFORD A, 1994, NATURE, V372, P623, DOI 10.1038/372623a0; BALMFORD A, 1998, CONSERVATION CHANGIN, P1; BELBIN L, 1993, BIOL CONSERV, V66, P223, DOI 10.1016/0006-3207(93)90007-N; Bennett A.F., 1999, LINKAGES LANDSCAPE R; BRIATHWAITE LW, 1988, AUST WILDLIFE RES, V10, P231; Burgman MA, 1993, RISK ASSESSMENT CONS; CAUGHLEY G, 1994, WILDLIFE MANAGEMENT; Chandrashekara UM, 1998, FOREST ECOL MANAG, V112, P165, DOI 10.1016/S0378-1127(98)00326-0; Cochrane MA, 1999, SCIENCE, V284, P1832, DOI 10.1126/science.284.5421.1832; COLWELL RK, 1994, PHILOS T R SOC B, V345, P101, DOI 10.1098/rstb.1994.0091; *COMM AUSTR, 1997, NAT AGREED CRIT EST; Cowling R. M., 1999, Diversity and Distributions, V5, P51, DOI 10.1046/j.1472-4642.1999.00038.x; DAVIES KF, IN PRESS ECOLOGY, V81; Davis F.W., 1999, PARKS, V9, P31; Deadman PJ, 1997, AI APPLICATIONS, V11, P107; DIAMOND J M, 1975, Biological Conservation, V7, P129, DOI 10.1016/0006-3207(75)90052-X; Dias PC, 1996, TRENDS ECOL EVOL, V11, P326, DOI 10.1016/0169-5347(96)10037-9; Didham RK, 1998, ECOL MONOGR, V68, P295, DOI 10.1890/0012-9615(1998)068[0295:BSRTTF]2.0.CO;2; DINERSTEIN E, 1993, CONSERV BIOL, V7, P53, DOI 10.1046/j.1523-1739.1993.07010053.x; Dobson AP, 1997, SCIENCE, V275, P550, DOI 10.1126/science.275.5299.550; Faith DP, 1996, BIODIVERS CONSERV, V5, P399, DOI 10.1007/BF00056387; FAITH DP, 1989, BIOL CONSERV, V50, P77, DOI 10.1016/0006-3207(89)90006-2; FAITH DP, 1994, PHILOS T R SOC B, V345, P45, DOI 10.1098/rstb.1994.0085; Faith DP, 1996, BIODIVERS CONSERV, V5, P417, DOI 10.1007/BF00056388; FAITH DP, 1997, NATL PARKS PROTECTED, P297; FAITH DP, 1999, SCI PACIFIC POSTERIT, P153; FAITH DP, 1994, CONSERVING BIOL DIVE, P74; Faith DP, 1996, BIORAP, V3, P63; FERRIER S, IN PRESS BIOL CONSER; Ferrier S, 1997, EVALUATION EFFECTIVE; FJELDSA J, 1994, BIODIVERS CONSERV, V3, P207, DOI 10.1007/BF00055939; Frankel OH, 1981, CONSERVATION EVOLUTI; Gilpin ME, 1987, VIABLE POPULATIONS C, P126; Goldstein PZ, 1999, CONSERV BIOL, V13, P247, DOI 10.1046/j.1523-1739.1999.013002247.x; GROVE RH, 1992, SCI AM, V267, P42, DOI 10.1038/scientificamerican0792-42; HANKS J, 1997, PARKS, V7, P11; HANSEN AJ, 1993, ECOL APPL, V3, P481, DOI 10.2307/1941917; HIGGS AJ, 1981, J BIOGEOGR, V8, P117, DOI 10.2307/2844554; Hockings Marc, 1999, Parks (Newbury), V9, P5; Holling C.S., 1978, ADAPTIVE ENV ASSESSM; Holt Robert D., 1993, P77; Holt Robert D., 1993, Lecture Notes in Biomathematics, V96, P260; Howard PC, 1998, NATURE, V394, P472, DOI 10.1038/28843; Hutchinson M. F., 1996, BIORAP, V2; IUCN (The World Conservation Union), 1994, GUID PROT AR MAN CAT; James Alexander N., 1999, Parks (Newbury), V9, P15; Jennings MD, 2000, LANDSCAPE ECOL, V15, P5, DOI 10.1023/A:1008184408300; Kanowski P. J., 1999, INT FOREST CONSERVAT; KAPOS V, 1989, J TROP ECOL, V5, P173, DOI 10.1017/S0266467400003448; Kiester AR, 1996, CONSERV BIOL, V10, P1332, DOI 10.1046/j.1523-1739.1996.10051332.x; KIRKPATRICK JB, 1983, BIOL CONSERV, V25, P127, DOI 10.1016/0006-3207(83)90056-3; Lambeck RJ, 1997, CONSERV BIOL, V11, P849, DOI 10.1046/j.1523-1739.1997.96319.x; LAMBERSON RH, 1994, CONSERV BIOL, V8, P185, DOI 10.1046/j.1523-1739.1994.08010185.x; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; LINDENMAYER DB, 1995, ECOL MODEL, V82, P161, DOI 10.1016/0304-3800(94)00085-V; LINDENMAYER DB, 1995, RISK EXTINCTION RANK; MacArthur R, 1967, THEORY ISLAND BIOGEO; Margules C.R., 1987, NATURE CONSERVATION, P89; MARGULES CR, 1994, ECOLOGY, V75, P2033, DOI 10.2307/1941608; MARGULES CR, 1994, PHILOS T ROY SOC B, V344, P69, DOI 10.1098/rstb.1994.0053; MCKENZIE NL, 1989, BIOL CONSERV, V50, P239, DOI 10.1016/0006-3207(89)90012-8; Mittermeier RA, 1998, CONSERV BIOL, V12, P516, DOI 10.1046/j.1523-1739.1998.012003516.x; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Myers N, 1979, SINKING ARK NEW LOOK; NELSON BW, 1990, NATURE, V345, P714, DOI 10.1038/345714a0; Nix H, 1982, EVOLUTION FLORA FAUN, P47; Nix H. A., 1986, ATLAS ELAPID SNAKES, V7, P4; Nix H. A., 2000, BIORAP TOOLBOX NATL; Noss RF, 1999, NAT AREA J, V19, P392; Noss RF, 1999, FOREST ECOL MANAG, V115, P135, DOI 10.1016/S0378-1127(98)00394-6; NOSS RF, 1995, SCI CONSERVATION PLA; PERES CA, 1995, CONSERV BIOL, V9, P34, DOI 10.1046/j.1523-1739.1995.09010034.x; PICKETT STA, 1978, BIOL CONSERV, V13, P27, DOI 10.1016/0006-3207(78)90016-2; PRENDERGAST JR, 1993, NATURE, V365, P335, DOI 10.1038/365335a0; Pressey R.L., 1997, NATL PARKS PROTECTED, P337; Pressey RL, 1996, FOREST ECOL MANAG, V85, P311, DOI 10.1016/S0378-1127(96)03766-8; Pressey RL, 1998, BIOL CONSERV, V85, P305, DOI 10.1016/S0006-3207(97)00146-8; Pressey RL, 1998, ECOLOGY FOR EVERYONE, P73; PRESSEY RL, 1997, CONSERVATION OUTSIDE, P407; Ranta P, 1998, BIODIVERS CONSERV, V7, P385, DOI 10.1023/A:1008885813543; RICHARDS B.N., 1990, BIOL CONSERVATION SE; Ricketts T. H., 1999, TERRESTRIAL ECOREGIO; ROJAS M, 1992, CONSERV BIOL, V6, P170, DOI 10.1046/j.1523-1739.1992.620170.x; Sarkar S, 1999, BIOSCIENCE, V49, P405, DOI 10.2307/1313633; SAUER JD, 1969, GEOGR REV, V59, P582, DOI 10.2307/213863; SAUNDERS DA, 1991, CONSERV BIOL, V5, P18, DOI 10.1111/j.1523-1739.1991.tb00384.x; Shafer CL, 1999, LANDSCAPE URBAN PLAN, V44, P123, DOI 10.1016/S0169-2046(98)00115-7; SISK TD, 1994, BIOSCIENCE, V44, P592, DOI 10.2307/1312459; Soule M., 1987, VIABLE POPULATIONS C; Soule ME, 1998, SCIENCE, V279, P2060, DOI 10.1126/science.279.5359.2060; Stolton Sue, 1999, Parks (Newbury), V9, P27; Stoms DM, 2000, LANDSCAPE ECOL, V15, P21, DOI 10.1023/A:1008105026956; TERBORGH J, 1999, REQUIEM NATURE; Thomas C.D., 1998, CONSERVATION CHANGIN, P107; van Jaarsveld AS, 1998, SCIENCE, V279, P2106, DOI 10.1126/science.279.5359.2106; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; Wessels KJ, 1999, BIOL CONSERV, V89, P21, DOI 10.1016/S0006-3207(98)00133-5; Williams P, 1996, CONSERV BIOL, V10, P155, DOI 10.1046/j.1523-1739.1996.10010155.x; WILLIAMS PH, 1998, CONSERVATION CHANGIN, P211; Wilson E.O., 1975, P522; Yates CJ, 1997, AUST J BOT, V45, P949, DOI 10.1071/BT96091; 1992, GLOBAL BIODIVERSITY; [No title captured]	109	3661	3926	49	1382	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					243	253		10.1038/35012251	http://dx.doi.org/10.1038/35012251			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821285	Green Submitted			2022-12-28	WOS:000087080100062
J	Bulger, RJ				Bulger, RJ			The quest for the therapeutic organization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Assoc Acad Hlth Ctr, Washington, DC 20036 USA		Bulger, RJ (corresponding author), Assoc Acad Hlth Ctr, 1400 16th St NW,Suite 720, Washington, DC 20036 USA.							BERWICK D, 1999, GOOD IT SHOULD GET M; Bulger RJ, 1996, J PROF NURS, V12, P338, DOI 10.1016/S8755-7223(96)80081-0; BULGER RJ, 1999, U TEX ADM LEAD C MAR; BULGER RJ, 1998, QUEST MERCY; COHEN J, 1999, INTEGRATED HLTH DELI, P117; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; PELLIKAN J, 1992, IDEA U REEXAMINATION	8	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2431	2433		10.1001/jama.283.18.2431	http://dx.doi.org/10.1001/jama.283.18.2431			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815088				2022-12-28	WOS:000086808200040
J	Verdier, RI; Fitzgerald, DW; Johnson, WD; Pape, JW				Verdier, RI; Fitzgerald, DW; Johnson, WD; Pape, JW			Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; CLINICAL MANIFESTATIONS; HAITI	Background: In developing countries, Isospora belli and Cyclospora cayetanensis frequently cause chronic diarrhea in HIV-infected patients. Objective: To compare 1 week of trimethoprim-sulfamethoxazole treatment and 1 week of ciprofloxacin treatment in HIV-infected patients with chronic diarrhea caused by I. belli and C. cayetanensis. Design: Randomized, controlled trial. Setting: HIV clinic in Port-au-Prince, Haiti. Patients: 42 HIV-infected patients with chronic diarrhea due to I. belli (n = 22) or C. cayetanensis (n = 20). Interventions: Patients were randomly assigned to receive oral trimethoprim-sulfamethoxazole (160 mg or 800 mg) or ciprofloxacin (500 mg) twice daily for 7 days. Patients who responded clinically and microbiologically received prophylaxis for 10 weeks (1 tablet orally, three times per week). Measurements: Treatment success was measured by cessation of diarrhea and negative stool examination at day 7. Prophylaxis success was measured by recurrent disease rate. Results: Diarrhea ceased in all 19 patients treated with trimethoprim-sulfamethoxazole. Eighteen of 19 patients had negative results on stool examination at day 7 (95%). Among the 23 patients who received ciprofloxacin, diarrhea ceased in 20 (87% [Cl, 66% to 97%]) and 16 had negative results on stool examination at day 7 (70%). By survival analysis, diarrhea from isosporiasis and cyclosporiasis ceased more rapidly with trimethoprim-sulfamethoxazole than with ciprofloxacin. All patients receiving secondary prophylaxis with trimethoprim-sulfamethoxatole remained disease-free, and 15 of 16 patients receiving secondary prophylaxis with ciprofloxacin remained disease-free. Conclusions: A 1-week course of trimethoprim-sulfamethoxazole is effective in HIV-infected patients with cyclosporiasis or isosporiasis. Although ciprofloxacin is not as effective, it is acceptable for patients who cannot tolerate trimethoprim-suifamethoxazole.	Cornell Univ, Div Int Med & Infect Dis, Coll Med, New York, NY 10021 USA; Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti	Cornell University	Johnson, WD (corresponding author), Cornell Univ, Div Int Med & Infect Dis, Coll Med, Room A-421,1300 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007613, R37AI022624] Funding Source: NIH RePORTER; FIC NIH HHS [TW 00018] Funding Source: Medline; NIAID NIH HHS [T32 AI07613, R37 AI22624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAYARD PJ, 1992, J ACQ IMMUN DEF SYND, V5, P1237; DEHOVITZ JA, 1985, ANN INTERN MED, V103, P479, DOI 10.7326/0003-4819-103-3-479_2; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; DIVO AA, 1988, ANTIMICROB AGENTS CH, V32, P1182, DOI 10.1128/AAC.32.8.1182; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; HOGE CW, 1995, LANCET, V345, P691, DOI 10.1016/S0140-6736(95)90868-4; MALEBRANCHE R, 1983, LANCET, V2, P873; PAPE J, 1993, CLIN INFECT DIS, V17, pS341, DOI 10.1093/clinids/17.Supplement_2.S341; PAPE JW, 1985, ANN INTERN MED, V103, P674, DOI 10.7326/0003-4819-103-5-674; PAPE JW, 1994, ANN INTERN MED, V121, P654, DOI 10.7326/0003-4819-121-9-199411010-00004; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; PAPE JW, 1983, NEW ENGL J MED, V309, P945, DOI 10.1056/NEJM198310203091603; PAPE JW, 1988, AIDS, V2, pS161, DOI 10.1097/00002030-198800001-00024; SALMON D, 1990, ANTIMICROB AGENTS CH, V34, P2327, DOI 10.1128/AAC.34.12.2327	14	100	107	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					885	888		10.7326/0003-4819-132-11-200006060-00006	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319HF	10836915				2022-12-28	WOS:000087334900005
J	Quilis, V; Moore, B; Bower, R				Quilis, V; Moore, B; Bower, R			Gone with the wind: The origin of S0 galaxies in clusters	SCIENCE			English	Article							SPIRAL GALAXIES; DISTANT CLUSTERS; DISK GALAXIES; RAM PRESSURE; EVOLUTION; POPULATIONS; HYDROGEN; Z=0.31; MATTER	We present three-dimensional, high-resolution hydrodynamical simulations of the interaction between the hot ionized intracluster medium and the cold interstellar medium of spiral galaxies. Ram pressure and turbulent/viscous stripping remove 100% of the atomic hydrogen content of Luminous galaxies like the Milky Way within 100 million years. These mechanisms naturally account for the morphology of SO galaxies and the rapid truncation of star formation implied by spectroscopic observations, as well as a host of observational data on the neutral hydrogen (HI) morphology of galaxies in clusters.	Univ Durham, Dept Phys, Durham DH1 3LE, England	Durham University	Quilis, V (corresponding author), Univ Durham, Dept Phys, South Rd, Durham DH1 3LE, England.		Quilis, Vicent/E-8409-2016	Quilis, Vicent/0000-0002-2852-5031; Bower, Richard/0000-0002-5215-6010				Abadi MG, 1999, MON NOT R ASTRON SOC, V308, P947, DOI 10.1046/j.1365-8711.1999.02715.x; BALSARA D, 1994, ASTROPHYS J, V437, P83, DOI 10.1086/174977; Barnes JE, 1996, ASTROPHYS J, V471, P115, DOI 10.1086/177957; BLITZ L, 1980, ASTROPHYS J, V238, P148, DOI 10.1086/157968; Bravo-Alfaro H, 2000, ASTRON J, V119, P580, DOI 10.1086/301194; BRINKS E, 1986, ASTRON ASTROPHYS, V169, P14; BUTCHER H, 1984, ASTROPHYS J, V285, P426, DOI 10.1086/162519; CAYATTE V, 1990, ASTRON J, V100, P604, DOI 10.1086/115545; COUCH WJ, 1987, MON NOT R ASTRON SOC, V229, P423, DOI 10.1093/mnras/229.3.423; Couch WJ, 1998, ASTROPHYS J, V497, P188, DOI 10.1086/305462; Dressler A, 1997, ASTROPHYS J, V490, P577, DOI 10.1086/304890; DRESSLER A, 1983, ASTROPHYS J, V270, P7, DOI 10.1086/161093; DRESSLER A, 1980, ASTROPHYS J SUPPL S, V42, P565, DOI 10.1086/190663; Elmegreen BG, 1997, ASTROPHYS J, V480, P235, DOI 10.1086/303966; Fujita Y, 1999, ASTROPHYS J, V516, P619, DOI 10.1086/307139; GAETZ TJ, 1987, ASTROPHYS J, V316, P530, DOI 10.1086/165224; GAVAZZI G, 1995, ASTRON ASTROPHYS, V304, P325; Ghigna S, 1998, MON NOT R ASTRON SOC, V300, P146, DOI 10.1046/j.1365-8711.1998.01918.x; HERNQUIST L, 1993, ASTROPHYS J SUPPL S, V86, P389, DOI 10.1086/191784; Kenney JDP, 1999, ASTRON J, V117, P181, DOI 10.1086/300683; KENNEY JDP, 1989, ASTROPHYS J, V344, P171, DOI 10.1086/167787; Merrifield MR, 1998, MON NOT R ASTRON SOC, V294, P347, DOI 10.1046/j.1365-8711.1998.01265.x; Moore B, 1999, MON NOT R ASTRON SOC, V304, P465, DOI 10.1046/j.1365-8711.1999.02345.x; Moore B, 1996, NATURE, V379, P613, DOI 10.1038/379613a0; NULSEN PEJ, 1982, MON NOT R ASTRON SOC, V198, P1007, DOI 10.1093/mnras/198.4.1007; Poggianti BM, 1999, ASTROPHYS J, V518, P576, DOI 10.1086/307322; Quilis V, 1996, ASTROPHYS J, V469, P11, DOI 10.1086/177753; Raga AC, 1998, MON NOT R ASTRON SOC, V295, P738, DOI 10.1046/j.1365-8711.1998.01188.x; RYDER SD, 1997, PASP, V14, P1; SANDAGE A, 1970, ASTROPHYS J, V160, P831, DOI 10.1086/150475; Stevens IR, 1999, MON NOT R ASTRON SOC, V310, P663, DOI 10.1046/j.1365-8711.1999.02965.x; TOOMRE A, 1972, ASTROPHYS J, V178, P623, DOI 10.1086/151823; Vollmer B, 1999, ASTRON ASTROPHYS, V349, P411; WARMELS RH, 1988, ASTRON ASTROPHYS SUP, V72, P57	35	480	481	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1617	1620		10.1126/science.288.5471.1617	http://dx.doi.org/10.1126/science.288.5471.1617			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834835				2022-12-28	WOS:000087382300033
J	Zaccai, G				Zaccai, G			Biochemistry - How soft is a protein? A protein dynamics force constant measured by neutron scattering	SCIENCE			English	Review							X-RAY-DIFFRACTION; STRUCTURAL-CHANGES; MOLECULAR MOTIONS; PURPLE MEMBRANES; THERMAL MOTIONS; BACTERIORHODOPSIN; HYDRATION; TEMPERATURE; MYOGLOBIN; SPECTROSCOPY	An effective environmental force constant is introduced to quantify the molecular resilience (or its opposite, "softness") of a protein structure and relate it to biological function and activity. Specific resilience-function relations were found in neutron-scattering experiments on purple membranes containing bacteriorhodopsin, the light-activated proton pump of halobacteria; the connection between resilience and stability is illustrated by a study of myoglobin in different environments. Important advantages of the neutron method are that it can characterize the dynamics of any type of biological sample-which need not be crystalline or monodisperse-and that it enables researchers to focus on the dynamics of specific parts of a complex structure with deuterium labeling.	Inst Biol Struct, F-38027 Grenoble 1, France; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Institut Laue-Langevin (ILL)	Zaccai, G (corresponding author), Inst Biol Struct, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	zaccai@ibs.fr						ANDREANI C, 1995, BIOPHYS J, V68, P2519, DOI 10.1016/S0006-3495(95)80434-0; Bee M, 1988, QUASIELASTIC NEUTRON; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Brooks C. L., 1988, ADV CHEM PHYS, V71, P74; Cordone L, 1999, BIOPHYS J, V76, P1043, DOI 10.1016/S0006-3495(99)77269-3; Creighton TE, 1991, CURR OPIN STRUC BIOL, V1, P5, DOI 10.1016/0959-440X(91)90004-D; DIPACE A, 1992, BIOPHYS J, V62, P1; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; FERRAND M, 1993, P NATL ACAD SCI USA, V90, P9668, DOI 10.1073/pnas.90.20.9668; Fitter J, 1996, P NATL ACAD SCI USA, V93, P7600, DOI 10.1073/pnas.93.15.7600; Fitter J, 1998, FEBS LETT, V433, P321, DOI 10.1016/S0014-5793(98)00938-7; Fitter J, 1997, BIOPHYS J, V73, P2126, DOI 10.1016/S0006-3495(97)78243-2; Frauenfelder H, 1998, P NATL ACAD SCI USA, V95, P4795, DOI 10.1073/pnas.95.9.4795; Frauenfelder H., 1988, ANNU REV BIOPHYS BIO, V17, P569; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Hernandez G, 2000, P NATL ACAD SCI USA, V97, P3166, DOI 10.1073/pnas.040569697; Jaenicke R, 2000, P NATL ACAD SCI USA, V97, P2962, DOI 10.1073/pnas.97.7.2962; Lehnert U, 1998, BIOPHYS J, V75, P1945, DOI 10.1016/S0006-3495(98)77635-0; Linke WA, 1998, BIOPHYS J, V75, P2613, DOI 10.1016/S0006-3495(98)77706-9; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; PARAK F, 1982, J MOL BIOL, V161, P177, DOI 10.1016/0022-2836(82)90285-6; PETSKO GA, 1984, ANNU REV BIOPHYS BIO, V13, P331; Reat V, 1997, BIOLOGICAL MACROMOLECULAR DYNAMICS, P117; Reat V, 1998, P NATL ACAD SCI USA, V95, P4970, DOI 10.1073/pnas.95.9.4970; Sass HJ, 1997, EMBO J, V16, P1484, DOI 10.1093/emboj/16.7.1484; SMITH JC, 1991, Q REV BIOPHYS, V24, P227, DOI 10.1017/S0033583500003723; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Weik M, 1998, MOL CELL, V1, P411, DOI 10.1016/S1097-2765(00)80041-6; Weik M, 1998, J MOL BIOL, V275, P625, DOI 10.1006/jmbi.1997.1488; ZACCAI G, UNPUB; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	32	624	627	2	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 2	2000	288	5471					1604	1607		10.1126/science.288.5471.1604	http://dx.doi.org/10.1126/science.288.5471.1604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834833				2022-12-28	WOS:000087382300031
J	Slonim, AE; Bulone, L; Damore, MB; Goldberg, T; Wingertzahn, MA; McKinley, MJ				Slonim, AE; Bulone, L; Damore, MB; Goldberg, T; Wingertzahn, MA; McKinley, MJ			A preliminary study of growth hormone therapy for Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; SHORT-TERM; REPLACEMENT; PATHOGENESIS; ADAPTATION; GLUTAMINE; RESECTION; DIET	Background Crohn's disease is a chronic inflammatory disorder of the bowel. In a preliminary study, we evaluated whether the administration of growth hormone (somatropin) as well as a high-protein diet would ameliorate the symptoms of the disease. Methods We randomly assigned 37 adults with moderate-to-severe active Crohn's disease to four months of self-administered injections of growth hormone (loading dose, 5 mg per day subcutaneously for one week, followed by a maintenance dose of 1.5 mg per day) or placebo. We instructed all patients to increase their protein intake to at least 2 g per kilogram of body weight per day. Patients continued to be treated by their usual physicians and to receive other medications for Crohn's disease. The primary end point was the change in scores on the Crohn's Disease Activity Index from base line to month 4. Scores can range from 0 to 600, with higher scores indicating more disease activity. Results At base line, the mean (+/-SD) score on the Crohn's Disease Activity Index was somewhat higher among the 19 patients in the growth hormone group than among the 18 patients in the placebo group (287+/-134 vs. 213+/-120, P=0.09). Three patients in the placebo group withdrew before their first follow-up visit and were not included in the data analysis. At four months, the Crohn's Disease Activity Index score had decreased by a mean of 143+/-144 points in the growth hormone group, as compared with a decrease of 19+/-63 points in the placebo group (P=0.004). Side effects in the growth hormone group included edema (in 10 patients) and headache (in 5) and usually resolved within the first month of treatment. Conclusions Our preliminary study suggests that growth hormone may be a beneficial treatment for patients with Crohn's disease. (N Engl J Med 2000;342:1633-7.) (C)2000, Massachusetts Medical Society.	N Shore Univ Hosp, Dept Pediat, Manhasset, NY 11030 USA; N Shore Univ Hosp, Dept Med, Manhasset, NY 11030 USA; NYU, Sch Med, Manhasset, NY USA	Northwell Health; North Shore University Hospital; Northwell Health; North Shore University Hospital; New York University	Slonim, AE (corresponding author), N Shore Univ Hosp, Dept Pediat, 300 Community Dr, Manhasset, NY 11030 USA.	slonim@nshs.edu						BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BYRNE TA, 1995, ANN SURG, V222, P243, DOI 10.1097/00000658-199509000-00003; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Drake WM, 1998, J CLIN ENDOCR METAB, V83, P3913, DOI 10.1210/jc.83.11.3913; ELIA M, 1989, AM J CLIN NUTR, V49, P1203, DOI 10.1093/ajcn/49.6.1203; GUARINO A, 1995, PEDIATR RES, V37, P576, DOI 10.1203/00006450-199505000-00003; HOFMANN AF, 1972, GASTROENTEROLOGY, V62, P918; HOLLANDER D, 1986, ANN INTERN MED, V105, P883, DOI 10.7326/0003-4819-105-6-883; Iannoli P, 1997, SURGERY, V122, P721, DOI 10.1016/S0039-6060(97)90079-9; INOUE Y, 1994, ANN SURG, V219, P715, DOI 10.1097/00000658-199406000-00016; Lo HC, 1996, AM J PHYSIOL-ENDOC M, V271, pE872, DOI 10.1152/ajpendo.1996.271.5.E872; Lund PK, 1998, ANN NY ACAD SCI, V859, P18, DOI 10.1111/j.1749-6632.1998.tb11108.x; RUUSKA T, 1994, J PEDIATR GASTR NUTR, V19, P175, DOI 10.1097/00005176-199408000-00006; Sandborn WJ, 1999, INFLAMM BOWEL DIS, V5, P119, DOI 10.1097/00054725-199905000-00008; Sartor RB, 1997, AM J GASTROENTEROL, V92, pS5; SHULMAN DI, 1992, J PEDIATR GASTR NUTR, V14, P3, DOI 10.1097/00005176-199201000-00002; Strober W, 1998, ANN INTERN MED, V128, P848, DOI 10.7326/0003-4819-128-10-199805150-00009; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; ZAR JH, 1984, BIOSTAT ANAL, P162; ZHANG W, 1995, J SURG RES, V59, P6, DOI 10.1006/jsre.1995.1124	20	159	165	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2000	342	22					1633	1637		10.1056/NEJM200006013422203	http://dx.doi.org/10.1056/NEJM200006013422203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319CE	10833209				2022-12-28	WOS:000087321600003
J	Hallstrom, A; Cobb, L; Johnson, E; Copass, M				Hallstrom, A; Cobb, L; Johnson, E; Copass, M			Cardiopulmonary resuscitation by chest compression alone or with mouth-to-mouth ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMERGENCY CPR INSTRUCTION; VENTRICULAR-FIBRILLATION; CARDIAC-ARREST; TELEPHONE	Background: Despite extensive training of citizens of Seattle in cardiopulmonary resuscitation (CPR), bystanders do not perform CPR in almost half of witnessed cardiac arrests. Instructions in chest compression plus mouth-to-mouth ventilation given by dispatchers over the telephone can require 2.4 minutes. In experimental studies, chest compression alone is associated with survival rates similar to those with chest compression plus mouth-to-mouth ventilation. We conducted a randomized study to compare CPR by chest compression alone with CPR by chest compression plus mouth-to-mouth ventilation. Methods: The setting of the trial was an urban, fire-department-based, emergency-medical-care system with central dispatching. In a randomized manner, telephone dispatchers gave bystanders at the scene of apparent cardiac arrest instructions in either chest compression alone or chest compression plus mouth-to-mouth ventilation. The primary end point was survival to hospital discharge. Results: Data were analyzed for 241 patients randomly assigned to receive chest compression alone and 279 assigned to chest compression plus mouth-to-mouth ventilation. Complete instructions were delivered in 62 percent of episodes for the group receiving chest compression plus mouth-to-mouth ventilation and 81 percent of episodes for the group receiving chest compression alone (P=0.005). Instructions for compression required 1.4 minutes less to complete than instructions for compression plus mouth-to-mouth ventilation. Survival to hospital discharge was better among patients assigned to chest compression alone than among those assigned to chest compression plus mouth-to-mouth ventilation (14.6 percent vs. 10.4 percent), but the difference was not statistically significant (P=0.18). Conclusions: The outcome after CPR with chest compression alone is similar to that after chest compression with mouth-to-mouth ventilation, and chest compression alone may be the preferred approach for bystanders inexperienced in CPR. (N Engl J Med 2000;342:1546-53.) (C) 2000, Massachusetts Medical Society.	Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA; Medic I, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hallstrom, A (corresponding author), 1107 NE 45th St,Suite 505, Seattle, WA 98105 USA.		Ferreira, Daniel/E-9005-2010	Ferreira, Daniel/0000-0002-4683-0179	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008197] Funding Source: NIH RePORTER; AHRQ HHS [5 R01 HS08197-04] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Becker LB, 1997, CIRCULATION, V96, P2102, DOI 10.1161/01.CIR.96.6.2102; Berg RA, 1997, CIRCULATION, V96, P4364; CARTER WB, 1984, ANN EMERG MED, V13, P695, DOI 10.1016/S0196-0644(84)80730-1; COWIE MR, 1993, AM J PUBLIC HEALTH, V83, P955, DOI 10.2105/AJPH.83.7.955; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; EISENBERG MS, 1985, AM J PUBLIC HEALTH, V75, P47, DOI 10.2105/AJPH.75.1.47; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Hallstrom AP, 1996, CIRCULATION, V93, P2019, DOI 10.1161/01.CIR.93.11.2019; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; MEURSING BTJ, 1983, J AM COLL CARDIOL, V1, P610; THIES W, 1989, JAMA-J AM MED ASSOC, V262, P2714; THOMPSON RG, 1979, ANN INTERN MED, V90, P737, DOI 10.7326/0003-4819-90-5-737	12	386	412	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2000	342	21					1546	1553		10.1056/NEJM200005253422101	http://dx.doi.org/10.1056/NEJM200005253422101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316XJ	10824072	Bronze			2022-12-28	WOS:000087193100001
J	Wade, DT; de Jong, BA				Wade, DT; de Jong, BA			Recent advances - Recent advances in rehabilitation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED TRIAL; PROGRESSIVE MULTIPLE-SCLEROSIS; QUALITY-OF-LIFE; PHYSICAL THERAPY; BOTULINUM TOXIN; STROKE PATIENTS; DOUBLE-BLIND; IMPACT; INTERVENTIONS; RELIABILITY		Rivermead Rehabil Ctr, Oxford OX1 4XD, England; Univ Amsterdam, Acad Med Ctr, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Wade, DT (corresponding author), Rivermead Rehabil Ctr, Oxford OX1 4XD, England.	derick.wade@dial.pipex.com		Wade, Derick/0000-0002-1188-8442				Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Badley E M, 1993, Disabil Rehabil, V15, P161; BADLEY EM, 1997, REHABILITATION PHYSI; Bowling A., 1995, MEASURING DIS; BROWN RJ, 1993, BEHAV SOCIAL REHABIL; Burbaud P, 1996, J NEUROL NEUROSUR PS, V61, P265, DOI 10.1136/jnnp.61.3.265; Cardol M, 1999, DISABIL REHABIL, V21, P97, DOI 10.1080/096382899297819; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Collin C, 1988, Int Disabil Stud, V10, P61; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P576, DOI 10.1136/jnnp.53.7.576; Di Fabio RP, 1998, ARCH PHYS MED REHAB, V79, P141, DOI 10.1016/S0003-9993(98)90290-8; EKDAWI MY, 1994, PSYCHIATR REHABIL J, P16; Forlander DA, 1999, CLIN REHABIL, V13, P97, DOI 10.1191/026921599675502264; Freeman JA, 1997, ANN NEUROL, V42, P236, DOI 10.1002/ana.410420216; Indredavik B, 1998, STROKE, V29, P895, DOI 10.1161/01.STR.29.5.895; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Lew MF, 1997, NEUROLOGY, V49, P701, DOI 10.1212/WNL.49.3.701; Lin KC, 1997, OCCUP THER J RES, V17, P25, DOI 10.1177/153944929701700102; Lindroth Y, 1997, ARTHRIT CARE RES, V10, P325, DOI 10.1002/art.1790100507; Mann WC, 1999, ARCH FAM MED, V8, P210, DOI 10.1001/archfami.8.3.210; Mant J, 1998, CLIN REHABIL, V12, P465, DOI 10.1191/026921598668972226; MONTGOMERY EB, 1994, AM J MED, V97, P429, DOI 10.1016/0002-9343(94)90322-0; OLIVE RM, 1983, SOCIAL WORK DISABLED; Post MWM, 1999, CLIN REHABIL, V13, P5, DOI 10.1191/026921599701532072; RICHARDS CL, 1993, ARCH PHYS MED REHAB, V74, P612, DOI 10.1016/0003-9993(93)90159-8; Rudd AG, 1999, J ROY COLL PHYS LOND, V33, P460; VANTULDER MW, 1999, COCHRANE LIB; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Wade DT, 1998, CLIN REHABIL, V12, P273, DOI 10.1191/026921598678166365; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wade DT, 1996, J NEUROL NEUROSUR PS, V61, P242, DOI 10.1136/jnnp.61.3.242; Wade DT, 1998, CLIN REHABIL, V12, P183, DOI 10.1191/026921598677470232; Wade DT, 1999, CLIN REHABIL, V13, P164, DOI 10.1191/026921599673848768; Wade DT, 1998, CLIN REHABIL, V12, P363, DOI 10.1191/026921598666679396; WADE DT, 2000, NATL CLIN GUIDELINES; Wade DT., 1992, MEASUREMENT NEUROLOG; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Wood P., 1980, INT CLASSIFICATION I	39	189	190	3	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2000	320	7246					1385	1388		10.1136/bmj.320.7246.1385	http://dx.doi.org/10.1136/bmj.320.7246.1385			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	317NY	10818031	Green Published			2022-12-28	WOS:000087232500025
J	Devonshire, C				Devonshire, C			A simple observation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2498	2498		10.1001/jama.283.19.2498	http://dx.doi.org/10.1001/jama.283.19.2498			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312VL	10815095				2022-12-28	WOS:000086964600001
J	Croft, RP; Nicholls, PG; Steyerberg, EW; Richardus, JH; Smith, WCS				Croft, RP; Nicholls, PG; Steyerberg, EW; Richardus, JH; Smith, WCS			A clinical prediction rule for nerve-function impairment in leprosy patients	LANCET			English	Article							TYPE-1 REACTIONS; CONTROL PROGRAM; RISK-FACTORS; WEST NEPAL; DAMAGE; EXPERIENCE; MANAGEMENT; REGIMEN; MODELS	Background: Nerve-function impairment (NFI) commonly occurs during or after chemotherapy in leprosy and is the hey pathological process leading to disability and handicap. We describe the development of a simple clinical prediction rule for estimating the risk of NFI occurrence. Methods: New leprosy cases who presented to a centre in Bangladesh were recruited and followed up for 2 years in a field setting. We used multivariable regression analysis by Cox's proportional hazards model to identify predictive variables for NFI. Discriminative ability was measured by a concordance statistic. Internal validity was assessed with bootstrap resampling techniques. Findings: 2510 patients were followed up for 2 years, 166 developed NF. A simple model was developed with leprosy group (either paucibacillary leprosy [PB] or multibacillary leprosy [MB]) and the presence of any nerve-function loss at registration as predictive variables. Patients with PB leprosy and no nerve-function loss had a 1.3% (95% CI 0.8-1.8%) risk of developing NFI within 2 years of registration; patients with PB leprosy and nerve-function loss, or patients with MB leprosy and no nerve-function loss had a 16.0% (12-20%) risk; and patients with MB leprosy with nerve-function loss had a 65% (56-73%) risk. Interpretation: Our prediction rule can be used to plan surveillance of new leprosy patients. Patients at low risk of NFI may need no follow-up beyond their course of chemotherapy (6 months); patients with intermediate risk need a minimum of 1 year of surveillance; and patients with high risk should have at least 2 years of surveillance for new NFI. Current recommendations for surveillance of patients with leprosy (for the duration of chemotherapy only) exclude an important group of patients who are at risk of developing NFI after completion of treatment.	Danish Bangladesh Leprosy Mission, Nilphamari, Bangladesh; Univ Aberdeen, Dept Publ Hlth, Aberdeen AB9 1FX, Scotland	University of Aberdeen	Croft, RP (corresponding author), 56A St Peters Rd, Reading RG6 1PH, Berks, England.	richard@crofts32.freeserve.co.uk	Richardus, Jan Hendrik/AAE-1278-2021; Steyerberg, Ewout/C-1509-2018	Richardus, Jan Hendrik/0000-0003-0564-6313; Steyerberg, Ewout/0000-0002-7787-0122				Akaike H, 1973, P 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; [Anonymous], 1998, Wkly Epidemiol Rec, V73, P153; BECXBLEUMINK M, 1992, INT J LEPROSY, V60, P173; Croft RP, 1997, LEPROSY REV, V68, P316; Croft RP, 1999, LEPROSY REV, V70, P140; DUNCAN ME, 1982, INT J LEPROSY, V50, P31; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HOGEWEG M, 1991, LEPROSY REV, V62, P143; Jiang J, 1998, LEPROSY REV, V69, P367; JOB CK, 1989, INT J LEPROSY, V57, P532; KIRAN KU, 1985, LEPROSY REV, V56, P127; LIENHARDT C, 1994, LEPROSY REV, V65, P9; LOCKWOOD DNJ, 1993, INT J LEPROSY, V61, P8; NAAFS B, 1978, LEPROSY REV, V49, P153; NAAFS B, 1992, QUAD COOP SAN, V12, P67; ROCHE PW, 1991, LANCET, V338, P654, DOI 10.1016/0140-6736(91)91232-J; Roche PW, 1997, INT J LEPROSY, V65, P450; ROSE P, 1991, LEPROSY REV, V62, P113; Schreuder PAM, 1998, INT J LEPROSY, V66, P159; STEYERBERG EW, 1996, THESIS ERASMUS U ROT; van Brakel W H, 1997, Indian J Lepr, V69, P361; Van Brakel WH, 1999, LEPROSY REV, V70, P314; VANBRAKEL WH, 1994, LEPROSY REV, V65, P190; VANBRAKEL WH, 1994, LEPROSY REV, V65, P350; VANBRAKEL WH, 1994, LEPROSY REV, V65, P204; Watson JM., 1986, ESSENTIAL ACTION MIN	27	90	98	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 6	2000	355	9215					1603	1606		10.1016/S0140-6736(00)02216-9	http://dx.doi.org/10.1016/S0140-6736(00)02216-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821364				2022-12-28	WOS:000086981200011
J	Swales, JD				Swales, JD			Science and health care: an uneasy partnership	LANCET			English	Editorial Material							TECHNOLOGY-ASSESSMENT		Univ Leicester, Leicester Royal Infirm, Cardiovasc Res Inst, Leicester LE2 7LX, Leics, England	University of Leicester	Swales, JD (corresponding author), Univ Leicester, Leicester Royal Infirm, Cardiovasc Res Inst, Clin Sci Bldg, Leicester LE2 7LX, Leics, England.							AARON HJ, 1984, PAINFUL PRESCRIPTION; BLUMENTHAL D, 1997, NEW ENGL J MED, V337, P150; BROCK DW, 1999, BIOETHICS ANTHOLOGY; Campbell EG, 1997, JAMA-J AM MED ASSOC, V278, P222, DOI 10.1001/jama.278.3.222; FLORIN D, 1999, BMJ, V319; *HL SEL COMM SCI T, 1988, PRIOR MED RES, V1; Holohan TV, 1996, LANCET, V348, P1006; Huxley T., 1873, CRITIQUES ADDRESSES; Klein R, 1996, QJM-MON J ASSOC PHYS, V89, P85, DOI 10.1093/oxfordjournals.qjmed.a030142; Matthews JR., 1995, QUANTIFICATION QUEST, DOI 10.1515/9781400821808; Moy E, 1997, JAMA-J AM MED ASSOC, V278, P217, DOI 10.1001/jama.278.3.217; *NHS CTR REV DISS, 1997, EFF HLTH CAR B, V3; Peckham M, 1999, LANCET, V354, P1539, DOI 10.1016/S0140-6736(99)08417-2; Perry S, 1997, INT J TECHNOL ASSESS, V13, P81, DOI 10.1017/S0266462300010254; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; Swales JD, 1999, J HYPERTENS, V17, P1511, DOI 10.1097/00004872-199917110-00002; SWALES JD, 1995, GROWTH MED SCI LESSO; 1991, RES HLTH RES DEV STR; 1990, 19 ANN REPORT 1989 1, P23	19	9	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 6	2000	355	9215					1637	1640		10.1016/S0140-6736(00)02227-3	http://dx.doi.org/10.1016/S0140-6736(00)02227-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821381				2022-12-28	WOS:000086981200039
J	Coulehan, J				Coulehan, J			The tragic events of April 1996	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								In the early 19th century, Port Arthur, Tasmania, was the site of a notorious prison in a land at the end of the world. In 1996, Port Arthur was also the site of the worst mass murder in modern Australian history. A gunman with a semiautomatic weapon stepped into a tourist coffee shop and systematically shot dead 35 men, women, and children. Throughout Australia, an outpouring of grief, shame, and anger followed this tragic event and led quickly to more stringent gun control legislation. Several years later, Australians still remember the mass murder at Port Arthur with shame and horror as a personal affront, rather than simply a historical event. In the more violent society of the United States, many Americans perceive themselves as helpless victims or detached observers, rather than as persons who are responsible for promoting change.	SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Coulehan, J (corresponding author), SUNY Stony Brook, Dept Prevent Med, HSC L3-086, Stony Brook, NY 11794 USA.								0	7	7	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					911	913		10.7326/0003-4819-132-11-200006060-00010	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319HF	10836919				2022-12-28	WOS:000087334900009
J	Farquhar, CM				Farquhar, CM			Extracts from "Clinical evidence" - Endometriosis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PELVIC PAIN; LAPAROSCOPIC SURGERY; MILD ENDOMETRIOSIS; MEDICAL-TREATMENT; CONTROLLED TRIAL; HORMONE AGONIST; WOMEN; EPIDEMIOLOGY; PREVALENCE; INFERTILE		Natl Womens Hosp, Dept Obstet & Gynaecol, Auckland 3, New Zealand		Farquhar, CM (corresponding author), Natl Womens Hosp, Dept Obstet & Gynaecol, Private Bag 92 189, Auckland 3, New Zealand.	c.farquhar@auckland.ac.nz79		Farquhar, Cynthia/0000-0002-3685-3553				Ajossa S., 1994, Clinical and Experimental Obstetrics and Gynecology, V21, P195; [Anonymous], 1994, Hum Reprod, V9, P1158; Audebert A, 1998, EUR J OBSTET GYN R B, V79, P145, DOI 10.1016/S0301-2115(98)00028-1; Beretta P, 1998, FERTIL STERIL, V70, P1176, DOI 10.1016/S0015-0282(98)00385-9; Berube S, 1998, EPIDEMIOLOGY, V9, P504, DOI 10.1097/00001648-199809000-00006; COMPSTON JE, 1995, BONE, V16, P261, DOI 10.1016/8756-3282(94)00038-2; COOKE ID, 1989, ACTA OBSTET GYN SCAN, P27; Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8; Gregoriou O, 1997, INT J FERTIL WOMEN M, V42, P406; Hornstein MD, 1997, FERTIL STERIL, V68, P860, DOI 10.1016/S0015-0282(97)00360-9; HUGHES E, 1999, COCHRANE LIB; MAHMOOD TA, 1991, HUM REPROD, V6, P544, DOI 10.1093/oxfordjournals.humrep.a137377; Marcoux S, 1997, NEW ENGL J MED, V337, P217, DOI 10.1056/NEJM199707243370401; McLaren J, 1996, CURR OBSTET GYNAECOL, V6, P85; Moen MH, 1997, ACTA OBSTET GYN SCAN, V76, P559, DOI 10.3109/00016349709024584; MOORE J, 1997, COCHRANE LIB; PARAZZINI F, 1994, AM J OBSTET GYNECOL, V171, P1205, DOI 10.1016/0002-9378(94)90133-3; PRENTICE A, 1998, COCHRANE LIB; ROCK JA, 1992, LANCET, V340, P1264, DOI 10.1016/0140-6736(92)92959-J; SELAK V, 1997, COCHRANE LIB; Sutton CJG, 1997, FERTIL STERIL, V68, P1070, DOI 10.1016/S0015-0282(97)00403-2; SUTTON CJG, 1994, FERTIL STERIL, V62, P696; Taskin O, 1997, FERTIL STERIL, V67, P40, DOI 10.1016/S0015-0282(97)81853-5; Telimaa S, 1987, Gynecol Endocrinol, V1, P363, DOI 10.3109/09513598709082709; Vercellini P, 1996, FERTIL STERIL, V65, P299, DOI 10.1016/S0015-0282(16)58089-3; Vercellini P, 1999, BRIT J OBSTET GYNAEC, V106, P672, DOI 10.1111/j.1471-0528.1999.tb08366.x; VERCELLINI P, 1993, FERTIL STERIL, V60, P75; VESSEY MP, 1993, BRIT MED J, V306, P182, DOI 10.1136/bmj.306.6871.182; WALLER KG, 1993, EUR J OBSTET GYN R B, V48, P135, DOI 10.1016/0028-2243(93)90254-A; WILSON M, 1998, COCHRANE LIB	30	125	128	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 27	2000	320	7247					1449	1452		10.1136/bmj.320.7247.1449	http://dx.doi.org/10.1136/bmj.320.7247.1449			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827052	Green Published			2022-12-28	WOS:000087414700029
J	Steel, N				Steel, N			Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION; THERAPY		Univ E Anglia, Sch Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Steel, N (corresponding author), Univ E Anglia, Sch Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England.		Steel, Nicholas/K-1592-2014	Steel, Nicholas/0000-0003-1528-140X				Friedmann PD, 1996, ANN INTERN MED, V124, P414, DOI 10.7326/0003-4819-124-4-199602150-00005; Gueyffier F, 1996, J HUM HYPERTENS, V10, P1; MULROW C, 1998, COCHRANE LIB; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; REED WW, 1993, J GEN INTERN MED, V8, P591, DOI 10.1007/BF02599710	5	72	73	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1446	1447		10.1136/bmj.320.7247.1446	http://dx.doi.org/10.1136/bmj.320.7247.1446			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827049	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000087414700027
J	Watson, R				Watson, R			Juniors to wait 9 years for EU rules to bite	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1423	1423						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827028				2022-12-28	WOS:000087414700007
J	Rosendorff, C				Rosendorff, C			Calcium antagonists and secondary prevention of myocardial infarction	LANCET			English	Editorial Material							DOUBLE-BLIND; DILTIAZEM		Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Rosendorff, C (corresponding author), Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.							ANDREFOUET X, 1983, EUR HEART J, V4, P69; GIBSON RS, 1986, NEW ENGL J MED, V315, P423, DOI 10.1056/NEJM198608143150704; HANSEN JF, 1990, AM J CARDIOL, V66, P779; HUNG J, 1983, CIRCULATION, V68, P560, DOI 10.1161/01.CIR.68.3.560; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; PooleWilson PA, 1997, EUR HEART J, V18, P31; RENGO F, 1996, AM J CARDIOL, V77, P421	7	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1738	1739		10.1016/S0140-6736(00)02255-8	http://dx.doi.org/10.1016/S0140-6736(00)02255-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832818				2022-12-28	WOS:000087126100002
J	Dickler, R; Shaw, G				Dickler, R; Shaw, G			The Balanced Budget Act of 1997: Its impact on US teaching hospitals	ANNALS OF INTERNAL MEDICINE			English	Article								The Balanced Budget Act of 1997 had a profound impact on the financing and organization of many health care services. The Act disproportionately affected U.S. teaching hospitals, leading to substantial budget reductions in many institutions and the threat of cuts in major prog rams and services that teaching hospitals provide to communities. This paper examines the overall financial and organizational impact of the Balanced Budget Act on teaching hospitals and considers its effect on residency education. It also discusses to what degree the Balanced Budget Refinement Act of 1999 will mitigate these effects and posits other solutions to the serious financial issue facing teaching hospitals in the United States.	Assoc Amer Med Coll, Washington, DC 20037 USA	Association of American Medical Colleges	Shaw, G (corresponding author), Assoc Amer Med Coll, 2450 N St NW, Washington, DC 20037 USA.							ANDERSON B, 1999, RENO GAZETTE J  0511; BENDER P, 1999, TENNESEAN       0429, pA1; *MED PAYM ADV COMM, 1998, HLTH CAR SPEND MED P; POWELL JH, 1999, BOSTON HERALD   0720, P33; SOMASUNDARAM M, 1999, CRAINS CHICAGO  0619, P3; STARK K, 1999, PHILADELPHIA IN 1010; VANDERWERFT M, 1999, CHRONICLE HIGHE 0429; FED REG 35262, V64	8	31	31	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2000	132	10					820	824		10.7326/0003-4819-132-10-200005160-00010	http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313XN	10819706				2022-12-28	WOS:000087025100008
J	Ganz, DA; Kuntz, KM; Jacobson, GA; Avorn, J				Ganz, DA; Kuntz, KM; Jacobson, GA; Avorn, J			Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							AVERAGE CHOLESTEROL LEVELS; CORONARY HEART-DISEASE; LONG-TERM SURVIVAL; EVENTS CARE TRIAL; ELDERLY PATIENTS; CARDIOVASCULAR EVENTS; SECONDARY PREVENTION; STROKE PROJECT; PRAVASTATIN; AGE	Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy has proven efficacy in reducing the rate of coronary and cerebrovascular events in patients 75 years of age or younger with a history of myocardial infarction. However, in patients older than 75 years of age, the efficacy and potential cost-effectiveness of statins are unknown. Objective: To estimate the incremental cost-effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction. Design: Cost-effectiveness analysis. Data Sources: Published data from cohort studies. Target Population: Patients 75 to 84 years of age with a history of myocardial infarction. Time Horizon: Lifetime. Perspective: Societal. Intervention: Statin therapy. Outcome Measures: Life expectancy, quality-adjusted life expectancy, and incremental cost-effectiveness. Results of Base-Case Analysis: The incremental cost-effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction was $18 800 per quality-adjusted life-year (QALY). Results of Sensitivity Analysis: On the basis of a probabilistic sensitivity analysis, there is a 75% chance that statin therapy costs less than $39 800 per QALY compared with usual care. If the cost of statin therapy and efficacy of statin therapy at reducing myocardial infarction were set to their most favorable values, statin therapy cost $5400 per QALY; if cost and efficacy were set to their least favorable values, statin therapy cost $97 800 per QALY. Conclusions: The cost-effectiveness ratios of statin therapy in older patients with previous myocardial infarction are reasonable under a wide variety of assumptions about drug efficacy, drug cost, and rates of cardiac and cerebrovascular events. Pending results of randomized, controlled trials of secondary prevention in patients in this age group, statin therapy seems to be as cost-effective as many routinely accepted medical interventions in this setting.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Avorn, J (corresponding author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 221 Longwood Ave,Suite 341, Boston, MA 02115 USA.							BENHORIN J, 1990, J AM COLL CARDIOL, V15, P253, DOI 10.1016/S0735-1097(10)80043-9; Caro J, 1997, BRIT MED J, V315, P1577, DOI 10.1136/bmj.315.7122.1577; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Glasser SP, 1996, AM J CARDIOL, V77, P83, DOI 10.1016/S0002-9149(97)89140-0; GOLD MR, 1996, COST EFFECTIVENESS H, P198; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; Goldberg RJ, 1998, AM J CARDIOL, V82, P1311, DOI 10.1016/S0002-9149(98)00633-X; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; Graham JD, 1998, ANNU REV PUBL HEALTH, V19, P125, DOI 10.1146/annurev.publhealth.19.1.125; Grover SA, 1999, ARCH INTERN MED, V159, P593, DOI 10.1001/archinte.159.6.593; Grundy SM, 1998, ENDOCRIN METAB CLIN, V27, P655, DOI 10.1016/S0889-8529(05)70032-3; Health Care Investment Analysts Inc. Ernst and Young., 1998, DRG HDB COMP CLIN FI; Herlitz J, 1996, CARDIOLOGY, V87, P529, DOI 10.1159/000177150; Johannesson M, 1997, NEW ENGL J MED, V336, P332, DOI 10.1056/NEJM199701303360503; Kolominsky-Rabas PL, 1998, STROKE, V29, P2501, DOI 10.1161/01.STR.29.12.2501; KUNTZ KM, 1995, MED DECIS MAKING, V15, P158, DOI 10.1177/0272989X9501500209; LAVE JR, 1994, MED CARE, V32, pJS77; Lewis SJ, 1998, ANN INTERN MED, V129, P681, DOI 10.7326/0003-4819-129-9-199811010-00002; Manton KG, 1996, J GERONTOL A-BIOL, V51, pB362, DOI 10.1093/gerona/51A.5.B362; MARCUS FI, 1990, AM J CARDIOL, V65, P559, DOI 10.1016/0002-9149(90)91031-Z; Miettinen TA, 1997, CIRCULATION, V96, P4211; *NAT CTR HLTH STAT, 1995, DHHS PUBLICATION; PEDERSEN TR, 1994, LANCET, V344, P1383; Roberts WC, 1997, AM J CARDIOL, V80, P106, DOI 10.1016/S0002-9149(97)00298-1; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SANTINGA JT, 1994, AM J MED, V96, P509, DOI 10.1016/0002-9343(94)90090-6; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shepherd J, 1999, AM J CARDIOL, V84, P1192, DOI 10.1016/S0002-9149(99)00533-0; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tung CY, 1999, CIRCULATION, V99, P370, DOI 10.1161/01.CIR.99.3.370; Whisnant JP, 1996, NEUROLOGY, V47, P1420, DOI 10.1212/WNL.47.6.1420; 1998, CLIN DIAGNOSTIC LAB; 1998, DRUG TOPICS RED BOOK; 1998, NATL PHYSICIAN FEE S	40	73	73	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2000	132	10					780	787		10.7326/0003-4819-132-10-200005160-00003	http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313XN	10819700				2022-12-28	WOS:000087025100002
J	Purvis, A; Hector, A				Purvis, A; Hector, A			Getting the measure of biodiversity	NATURE			English	Review							SPECIES-RICHNESS; TAXONOMIC DIVERSITY; DIVERGENCE TIMES; BODY-SIZE; DIVERSIFICATION; EXTINCTION; EVOLUTIONARY; ECOSYSTEM; HISTORY; SPECIATION	The term 'biodiversity' is a simple contraction of 'biological diversity', and at first sight the concept is simple too: biodiversity is the sum total of all biotic variation from the level of genes to ecosystems. The challenge comes in measuring such a broad concept in ways that are useful. We show that, although biodiversity can never be fully captured by a single number, study of particular facets has led to rapid, exciting and sometimes alarming discoveries. Phylogenetic and temporal analyses are shedding light on the ecological and evolutionary processes that have shaped current biodiversity. There is no doubt that humans are now destroying this diversity at an alarming rate. A vital question now being tackled is how badly this loss affects ecosystem functioning. Although current research efforts are impressive, they are tiny in comparison to the amount of unknown diversity and the urgency and importance of the task.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, Ascot SL5 7PY, Berks, England; Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England	Imperial College London; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Purvis, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.		Purvis, Andy/A-7529-2008; Hector, Andrew/H-4199-2011	Purvis, Andy/0000-0002-8609-6204; Hector, Andrew/0000-0002-1309-7716				Abbott A, 1999, NATURE, V401, P105, DOI 10.1038/43525; Allison GW, 1999, AM NAT, V153, P26, DOI 10.1086/303144; Alroy J, 1996, PALAEOGEOGR PALAEOCL, V127, P285, DOI 10.1016/S0031-0182(96)00100-9; Alroy J, 1998, BIODIVERSITY DYNAMICS, P232; Avise JC, 1997, P NATL ACAD SCI USA, V94, P7748, DOI 10.1073/pnas.94.15.7748; Avise JC, 1999, P NATL ACAD SCI USA, V96, P7358, DOI 10.1073/pnas.96.13.7358; Avise JC, 1998, P ROY SOC B-BIOL SCI, V265, P1707, DOI 10.1098/rspb.1998.0492; Balmford A, 1996, P ROY SOC B-BIOL SCI, V263, P1267, DOI 10.1098/rspb.1996.0186; Barbault R., 1995, P193; Barraclough TG, 1998, PHILOS T R SOC B, V353, P241, DOI 10.1098/rstb.1998.0206; Barraclough TG, 1998, EVOL ECOL, V12, P751; BARRACLOUGH TG, 1995, P ROY SOC B-BIOL SCI, V259, P211, DOI 10.1098/rspb.1995.0031; Bennett PM, 1997, P ROY SOC B-BIOL SCI, V264, P401, DOI 10.1098/rspb.1997.0057; Benton MJ, 1997, TRENDS ECOL EVOL, V12, P490, DOI 10.1016/S0169-5347(97)84410-2; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; BENTON MJ, 1993, FOSSIL RECORD, V2; Bisby F.A., 1995, P21; Bromham L, 1999, TRENDS ECOL EVOL, V14, P113, DOI 10.1016/S0169-5347(98)01507-9; Cooper A, 1998, TRENDS ECOL EVOL, V13, P151, DOI 10.1016/S0169-5347(97)01277-9; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; CORBET GB, 1991, WORLD LIST MAMALIAN; Courtillot V, 1996, NATURE, V381, P146, DOI 10.1038/381146a0; Cowlishaw G, 1999, CONSERV BIOL, V13, P1183, DOI 10.1046/j.1523-1739.1999.98433.x; Cracraft J., 1983, Current Ornithology, V1, P159; Darwin C., 1858, J P LINNEAN SOC LOND, V3, P45, DOI DOI 10.1111/J.1096-3642.1858.TB02500.X; Darwin Charles, 1859, ORIGIN SPECIES MEANS; DIAL KP, 1989, SYST ZOOL, V38, P26, DOI 10.2307/2992433; Faith Daniel P., 1994, V50, P251; Foote M, 1999, SCIENCE, V283, P1310, DOI 10.1126/science.283.5406.1310; Foote Mike, 1996, P62; Fuhrman JA, 1998, NATURE, V393, P410, DOI 10.1038/30839; FUNCH P, 1995, NATURE, V378, P711, DOI 10.1038/378711a0; Gardezi T, 1999, AM NAT, V153, P110, DOI 10.1086/303150; Gittleman JL, 1998, P ROY SOC B-BIOL SCI, V265, P113, DOI 10.1098/rspb.1998.0271; Goddard MR, 1999, P NATL ACAD SCI USA, V96, P13880, DOI 10.1073/pnas.96.24.13880; Gould S. J., 1989, WONDERFUL LIFE BURGE; Grace James B., 1999, Perspectives in Plant Ecology Evolution and Systematics, V2, P1, DOI 10.1078/1433-8319-00063; Grelle CED, 1999, ANIM CONSERV, V2, P149, DOI 10.1111/j.1469-1795.1999.tb00060.x; Groombridge JJ, 2000, NATURE, V403, P616, DOI 10.1038/35001148; Gross M., 1998, LIFE EDGE; Hanken J, 1999, TRENDS ECOL EVOL, V14, P7, DOI 10.1016/S0169-5347(98)01534-1; Harvey P. H., 1996, NEW USES NEW PHYLOGE; Harvey PH, 1991, COMP METHODS EVOLUTI; Hawksworth D.L., 1995, P107; Heard SB, 2000, P ROY SOC B-BIOL SCI, V267, P613, DOI 10.1098/rspb.2000.1046; Heard Stephen B., 1995, Historical Biology, V10, P151; Hughes JB, 1997, SCIENCE, V278, P689, DOI 10.1126/science.278.5338.689; Jones CG, 1997, ECOLOGY, V78, P1946, DOI 10.1890/0012-9658(1997)078[1946:PANEOO]2.0.CO;2; Kauffman Erle G., 1993, P315; Kelley ST, 1998, EVOLUTION, V52, P1731, DOI [10.2307/2411346, 10.1111/j.1558-5646.1998.tb02253.x]; Kidwell MG, 1997, P NATL ACAD SCI USA, V94, P7704, DOI 10.1073/pnas.94.15.7704; Kirchner JW, 2000, NATURE, V404, P177, DOI 10.1038/35004564; Knops JMH, 1999, ECOL LETT, V2, P286, DOI 10.1046/j.1461-0248.1999.00083.x; Kunin William E., 1996, P283; Loreau M, 1998, P NATL ACAD SCI USA, V95, P5632, DOI 10.1073/pnas.95.10.5632; MACE GM, 1999, FUTURE PRIORITIES CO; MACGILLIVRAY CW, 1995, FUNCT ECOL, V9, P640, DOI 10.2307/2390156; Magurran A.E., 1988, ECOLOGICAL DIVERSITY; Mallidis C, 1996, J ASSIST REPROD GEN, V13, P53, DOI 10.1007/BF02068870; Marshall CR, 1998, ADEQUACY OF THE FOSSIL RECORD, P23; MARZLUFF JM, 1991, ECOLOGY, V72, P428, DOI 10.2307/2937185; May R.M., 1975, P81; May Robert M., 1995, P1; McKinney ML, 1998, ANIM CONSERV, V1, P159, DOI 10.1111/j.1469-1795.1998.tb00024.x; McKinney ML, 1997, ANNU REV ECOL SYST, V28, P495, DOI 10.1146/annurev.ecolsys.28.1.495; McKinney ML, 1998, BIODIVERSITY DYNAMICS, P1; MITTER C, 1988, AM NAT, V132, P107, DOI 10.1086/284840; Mooers AO, 1997, Q REV BIOL, V72, P31, DOI 10.1086/419657; MORITZ C, 1994, TRENDS ECOL EVOL, V9, P373, DOI 10.1016/0169-5347(94)90057-4; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Nee S, 1997, SCIENCE, V278, P692, DOI 10.1126/science.278.5338.692; Nee Sean, 1996, P230; OWENS IPF, 1909, P ROY SOC LOND B BIO, V266, P933; Pagel M, 1997, ZOOL SCR, V26, P331, DOI 10.1111/j.1463-6409.1997.tb00423.x; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Paxton CGM, 1998, J MAR BIOL ASSOC UK, V78, P1389, DOI 10.1017/S0025315400044611; Pimm Stuart L., 1998, P20, DOI 10.1002/9781444313499.ch2; PINE RH, 1994, NATURE, V368, P593, DOI 10.1038/368593a0; PRESSEY RL, 1994, BIODIVERS CONSERV, V3, P242, DOI 10.1007/BF00055941; Purvis A, 2000, SCIENCE, V288, P328, DOI 10.1126/science.288.5464.328; Purvis Andy, 1996, P153; Rosenzweig ML, 1996, EVOL ECOL, V10, P681, DOI 10.1007/BF01237714; Roy K, 1997, TRENDS ECOL EVOL, V12, P277, DOI 10.1016/S0169-5347(97)81026-9; Russell GJ, 1998, CONSERV BIOL, V12, P1365, DOI 10.1046/j.1523-1739.1998.96332.x; Russell GJ, 1998, BIODIVERSITY DYNAMICS, P377; Rylands Anthony B., 1995, Neotropical Primates, V3, P113; SANDERSON MJ, 1994, SCIENCE, V264, P1590, DOI 10.1126/science.264.5165.1590; Sanderson MJ, 1997, MOL BIOL EVOL, V14, P1218, DOI 10.1093/oxfordjournals.molbev.a025731; Schluter D, 1996, AM NAT, V148, pS40, DOI 10.1086/285901; Schwartz MW, 2000, OECOLOGIA, V122, P297, DOI 10.1007/s004420050035; Sepkoski J. J., 1982, MILWAUKEE PUBLIC MUS, V51, P1; Sepkoski JJ, 1998, PHILOS T R SOC B, V353, P315, DOI 10.1098/rstb.1998.0212; SPEHN EM, IN PRESS FUNCT ECOL, V14; Stachowicz JJ, 1999, SCIENCE, V286, P1577, DOI 10.1126/science.286.5444.1577; Tilman D, 1999, SCIENCE, V286, P1099, DOI 10.1126/science.286.5442.1099; Tilman D, 1997, ECOLOGY, V78, P81, DOI 10.1890/0012-9658(1997)078[0081:CIRLAG]2.0.CO;2; Tristem M, 2000, J VIROL, V74, P3715, DOI 10.1128/JVI.74.8.3715-3730.2000; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Van Valkenburgh Blaire, 1993, P330; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; Waide RB, 1999, ANNU REV ECOL SYST, V30, P257, DOI 10.1146/annurev.ecolsys.30.1.257; Wang DYC, 1999, P ROY SOC B-BIOL SCI, V266, P163, DOI 10.1098/rspb.1999.0617; Wardle DA, 1997, SCIENCE, V277, P1296, DOI 10.1126/science.277.5330.1296; WHITTAKER R H, 1972, Taxon, V21, P213, DOI 10.2307/1218190; Williams Paul H., 1996, P54; WILLIAMS PH, 1994, P ROY SOC B-BIOL SCI, V256, P67, DOI 10.1098/rspb.1994.0050; WILSON E O, 1992; ZINK RM, 1995, P NATL ACAD SCI USA, V92, P5832, DOI 10.1073/pnas.92.13.5832	108	733	813	18	382	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					212	219		10.1038/35012221	http://dx.doi.org/10.1038/35012221			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821281				2022-12-28	WOS:000087080100058
J	Smith, JT; Comans, RNJ; Beresford, NA; Wright, SM; Howard, BJ; Camplin, WC				Smith, JT; Comans, RNJ; Beresford, NA; Wright, SM; Howard, BJ; Camplin, WC			Pollution - Chernobyl's legacy in food and water	NATURE			English	Article							RADIOCESIUM; CS-137; LAKES; FISH		Winfrith Technol Ctr, Ctr Ecol & Hydrol, Dorchester DT2 8ZD, England; Netherlands Energy Res Fdn, NL-1755 ZG Petten, Netherlands; Ctr Ecol & Hydrol, Grange Sands LA11 6JU, Cumbria, England; Ctr Environm Fisheries & Aquaculture Sci, Lowestoft NR33 OHT, Suffolk, England	UK Centre for Ecology & Hydrology (UKCEH); UK Centre for Ecology & Hydrology (UKCEH); Centre for Environment Fisheries & Aquaculture Science	Smith, JT (corresponding author), Winfrith Technol Ctr, Ctr Ecol & Hydrol, Dorchester DT2 8ZD, England.		Howard, Brenda J/I-8279-2012; Beresford, Nicholas A/I-6188-2012; Smith, Jim T/G-7716-2011	Howard, Brenda J/0000-0002-9698-9524; Smith, Jim T/0000-0002-0808-2739				Beresford N. A., 1999, SELF HELP COUNTERMEA; Beresford NA, 1996, SCI TOTAL ENVIRON, V177, P85, DOI 10.1016/0048-9697(95)04863-4; COMANS RNJ, 1999, ACS SYM SER, V715, P179; ELLIOTT JM, 1992, J APPL ECOL, V29, P108, DOI 10.2307/2404354; Jonsson B, 1999, NATURE, V400, P417, DOI 10.1038/22675; Smith JT, 2000, J ENVIRON RADIOACTIV, V48, P359, DOI 10.1016/S0265-931X(99)00089-2; Smith JT, 1997, HEALTH PHYS, V72, P880, DOI 10.1097/00004032-199706000-00007; Smith JT, 1996, GEOCHIM COSMOCHIM AC, V60, P995, DOI 10.1016/0016-7037(96)00030-0; Smith JT, 1999, ENVIRON SCI TECHNOL, V33, P49, DOI 10.1021/es980670t; WATTERSON J, IN PRESS J ENV RADIO	10	77	79	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					141	141		10.1038/35012139	http://dx.doi.org/10.1038/35012139			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821261	Green Submitted, Green Accepted			2022-12-28	WOS:000087080100038
J	Weisse, AB				Weisse, AB			Naming names	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2357	2358		10.1001/jama.283.18.2357	http://dx.doi.org/10.1001/jama.283.18.2357			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815059				2022-12-28	WOS:000086808200001
J	Jacobson, RH; Ladurner, AG; King, DS; Tjian, R				Jacobson, RH; Ladurner, AG; King, DS; Tjian, R			Structure and function of a human TAF(II)250 double bromodomain module	SCIENCE			English	Article							HISTONE ACETYLTRANSFERASE; ACETYLATION SITES; H4 ACETYLATION; TRANSCRIPTION; COMPLEX; ACTIVATION; COACTIVATOR; CHROMATIN; GCN5P; CBP	TFIID is a large multiprotein complex that initiates assembly of the transcription machinery. It is unclear how TFIID recognizes promoters in vivo when templates are nucleosome-bound. Here, it is shown that TAF(II)250, the Largest subunit of TFIID, contains two tandem bromodomain modules that bind selectively to multiply acetylated histone H4 peptides. The 2.1 angstrom crystal structure of the double bromodomain reveals two side-by-side, four-helix bundles with a highly polarized surface charge distribution. Each bundle contains an N-epsilon-acetyllysine binding pocket at its center, which results in a structure ideally suited for recognition of diacetylated histone H4 tails. Thus, TFIID may be targeted to specific chromatin-bound promoters and may play a role in chromatin recognition.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Tjian, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, 401 Barker Hall, Berkeley, CA 94720 USA.	jmlim@uclink4.berkeley.edu		Ladurner, Andreas/0000-0003-3835-232X				ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; HOLTON J, UNPUB; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Matangkasombut O, 2000, GENE DEV, V14, P951; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; RODERICK SL, UNPUB; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	39	656	678	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1422	1425		10.1126/science.288.5470.1422	http://dx.doi.org/10.1126/science.288.5470.1422			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827952				2022-12-28	WOS:000087270900050
J	Gray, A; Raikou, M; McGuire, A; Fenn, P; Stevens, R; Cull, C; Stratton, I; Adler, A; Holman, R; Turner, R				Gray, A; Raikou, M; McGuire, A; Fenn, P; Stevens, R; Cull, C; Stratton, I; Adler, A; Holman, R; Turner, R		United Kingdom Prospective Diabet	Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONFIDENCE-INTERVALS; EFFECTIVENESS RATIOS; COMPLICATIONS; MODEL; NIDDM	Objective To estimate die cost effectiveness of conventional versus intensive blood glucose control in patients with type 2 diabetes. Design Incremental cost effectiveness analysis alongside randomised controlled trial. Setting 23 UK hospital clinic based study centres, Participants 3867 patients with newly diagnosed type 2 diabetes (mean age 53 years). Interventions Conventional (primarily diet) glucose control policy versus intensive control policy with a sulphonylurea or insulin. Main outcome measures Incremental cost per event-free year gained within the trial period. Results Intensive glucose control increased trial treatment casts by pound 695 (95% confidence interval pound 555 to pound 836) per patient but reduced the cost of complications by pound 957 (pound 233 to pound 1681) compared with conventional management If standard practice visit patterns were assumed rather than trial conditions, the incremental cost of intensive management was pound 478 (- pound 275 to pound 1232) per patient The within trial event-free time gained in the intensive group was 0.60 (0.12 to 1.10) years and the lifetime gain 1.14 (0.69 to 1.61) years. The incremental cost per event-free year gained was pound 1166 (costs and effects discounted at 6% a year) and pound 563 (costs discounted at 6% a year and effects not discounted). Conclusions Intensive blood glucose control in patients with type 2 diabetes significantly increased treatment costs but substantially reduced the cost of complications and increased the time free of complications.	Univ Oxford, Dept Publ Hlth, Hlth Econ Res Ctr, Inst Hlth Sci, Oxford OX3 7LF, England; City Univ London, Dept Econ, London EC1V 0HB, England; Univ Nottingham, Sch Business, Nottingham NG7 2RD, England; Univ Oxford, Nuffield Dept Clin Med, Diabet Res Labs, Oxford OX2 6HE, England; Univ Oxford, Nuffield Dept Clin Med, Diabet Trials Unit, Oxford OX2 6HE, England	University of Oxford; City University London; University of Nottingham; University of Oxford; University of Oxford	Gray, A (corresponding author), Univ Oxford, Dept Publ Hlth, Hlth Econ Res Ctr, Inst Hlth Sci, Oxford OX3 7LF, England.	alastair.gray@ihs.ox.ac.uk	stratton, irene/AAZ-3627-2020	stratton, irene/0000-0003-1172-7865; Stevens, Richard/0000-0002-9258-4060	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUXTON MJ, 1991, DIABETIC MED, V8, P371, DOI 10.1111/j.1464-5491.1991.tb01612.x; Chaudhary MA, 1996, STAT MED, V15, P1447; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; Nathan DM, 1996, JAMA-J AM MED ASSOC, V276, P1409; NETTEN A, 1998, UNIT COSTS COMMUNITY; Sculpher M J, 1992, Health Econ, V1, P39, DOI 10.1002/hec.4730010107; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UK Prospective Diabetes Study Grp, 1999, DIABETES CARE, V22, P1125; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; Willan AR, 1996, HEALTH ECON, V5, P297, DOI 10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T; 1997, APPR EV CENTR GOVT	12	229	238	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2000	320	7246					1373	1378		10.1136/bmj.320.7246.1373	http://dx.doi.org/10.1136/bmj.320.7246.1373			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818026	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000087232500021
J	McEwen, AS; Belton, MJS; Breneman, HH; Fagents, SA; Geissler, P; Greeley, R; Head, JW; Hoppa, G; Jaeger, WL; Johnson, TV; Keszthelyi, L; Klaasen, KP; Lopes-Gautier, R; Magee, KP; Milazzo, MP; Moore, JM; Pappalardo, RT; Phillips, CB; Radebaugh, J; Schubert, G; Schuster, P; Simonelli, DP; Sullivan, R; Thomas, PC; Turtle, EP; Williams, DA				McEwen, AS; Belton, MJS; Breneman, HH; Fagents, SA; Geissler, P; Greeley, R; Head, JW; Hoppa, G; Jaeger, WL; Johnson, TV; Keszthelyi, L; Klaasen, KP; Lopes-Gautier, R; Magee, KP; Milazzo, MP; Moore, JM; Pappalardo, RT; Phillips, CB; Radebaugh, J; Schubert, G; Schuster, P; Simonelli, DP; Sullivan, R; Thomas, PC; Turtle, EP; Williams, DA			Galileo at Io: Results from high-resolution imaging	SCIENCE			English	Article							SILICATE VOLCANISM; ACTIVE VOLCANISM; KILAUEA VOLCANO; MOUNTAINS; HAWAII; EARTH; FLOW; MOON	During late 1999/early 2000, the solid state imaging experiment on the Galileo spacecraft returned more than 100 high-resolution (5 to 500 meters per pixel) images of volcanically active lo. We observed an active Lava lake, an active curtain of lava, active Lava flows, calderas, mountains, plateaus, and plains. Several of the sulfur dioxide-rich plumes are erupting from distal flows, rather than from the source of silicate Lava (caldera or fissure, often with red pyroclastic deposits). Most of the active flows in equatorial regions are being emplaced slowly beneath insulated crust, but rapidly emplaced channelized flows are also found at all latitudes. There is no evidence for high-viscosity Lava, but some bright flows may consist of sulfur rather than mafic silicates. The mountains, plateaus, and calderas are strongly influenced by tectonics and gravitational collapse. Sapping channels and scarps suggest that many portions of the upper similar to 1 kilometer are rich in volatiles.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Natl Opt Astron Observ, Tucson, AZ 85719 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Brown Univ, Dept Geol Sci, Providence, RI 02913 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; DLR, Inst Weltraumsensorik & Planetenerkundung, D-12489 Berlin, Germany; Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA	University of Arizona; National Optical Astronomy Observatory; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Arizona State University; Arizona State University-Tempe; Brown University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of California System; University of California Los Angeles; Helmholtz Association; German Aerospace Centre (DLR); Cornell University	McEwen, AS (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.		Phillips, Cynthia B/ABE-4083-2021; Lopes, Rosaly M.C./D-1608-2016; Pappalardo, Robert/AAP-8953-2021; Fagents, Sarah/B-3983-2014; Turtle, Elizabeth/K-8673-2012	Phillips, Cynthia B/0000-0001-8914-9562; Lopes, Rosaly M.C./0000-0002-7928-3167; Pappalardo, Robert/0000-0003-2571-4627; Turtle, Elizabeth/0000-0003-1423-5751; Kestay, Laszlo/0000-0003-1879-4331				ACTON D, UNPUB; BRUNO BC, 1992, GEOPHYS RES LETT, V19, P305, DOI 10.1029/91GL03039; Carr MH, 1998, ICARUS, V135, P146, DOI 10.1006/icar.1998.5979; DAVIES AG, 1999, LUNAR PLANET SCI, V30; FAGENTS SA, 1999, EOS S, V80, pF625; Geissler PE, 1999, ICARUS, V140, P265, DOI 10.1006/icar.1999.6128; Geissler PE, 1999, SCIENCE, V285, P870, DOI 10.1126/science.285.5429.870; HEAD JW, 2000, LUNAR PLANET SCI, V31; HESLOP SE, 1989, B VOLCANOL, V51, P415, DOI 10.1007/BF01078809; HON K, 1994, GEOL SOC AM BULL, V106, P251; JOHNSON TV, 1982, SATELLITES JUPITER, P634; Kargel JS, 1999, ICARUS, V142, P249, DOI 10.1006/icar.1999.6183; Keszthelyi L, 1997, GEOPHYS RES LETT, V24, P2463, DOI 10.1029/97GL01368; Keszthelyi L, 1997, ICARUS, V130, P437, DOI 10.1006/icar.1997.5837; KESZTHELYI L, IN PRESS J GEOPHYS R; Kieffer SW, 2000, SCIENCE, V288, P1204, DOI 10.1126/science.288.5469.1204; KIEFFER SW, 1982, SATELLITES JUPITER, P647; Lopes-Gautier R, 2000, SCIENCE, V288, P1201, DOI 10.1126/science.288.5469.1201; Lopes-Gautier R, 1999, ICARUS, V140, P243, DOI 10.1006/icar.1999.6129; MATTOX TN, 1993, B VOLCANOL, V55, P407, DOI 10.1007/BF00302000; MCCAULEY JF, 1979, NATURE, V280, P736, DOI 10.1038/280736a0; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; McEwen AS, 1998, SCIENCE, V281, P87, DOI 10.1126/science.281.5373.87; MCEWEN AS, IN PRESS ENV EFFECTS; MOORE JM, 2000, LUNAR PLANET SCI, V31; ONEIL WJ, 1997, FLIGHT PROJECT GALIL; PHILLIPS CB, 2000, THESIS U ARIZONA TUC; Schenk PM, 1998, SCIENCE, V279, P1514, DOI 10.1126/science.279.5356.1514; Self S., 1997, LARGE IGNEOUS PROVIN, V100, P381, DOI [10.1029/gm100p0381, DOI 10.1029/GM100P0381]; Spencer JR, 1997, GEOPHYS RES LETT, V24, P2471, DOI 10.1029/97GL02592; Spencer JR, 2000, SCIENCE, V288, P1208, DOI 10.1126/science.288.5469.1208; Spencer JR, 2000, SCIENCE, V288, P1198, DOI 10.1126/science.288.5469.1198; Stansberry JA, 1997, GEOPHYS RES LETT, V24, P2455, DOI 10.1029/97GL02593; Thorarinsson S., 1953, B VOLCANOL, V2, P1; Williams DA, 2000, J GEOPHYS RES-PLANET, V105, P1671, DOI 10.1029/1999JE001157; WILLIAMS DA, IN PRESS EOS S; WILSON L, 1983, NATURE, V302, P663, DOI 10.1038/302663a0	37	106	107	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1193	1198		10.1126/science.288.5469.1193	http://dx.doi.org/10.1126/science.288.5469.1193			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817986				2022-12-28	WOS:000087112600038
J	Welch, DM; Meselson, M				Welch, DM; Meselson, M			Evidence for the evolution of bdelloid rotifers without sexual reproduction or genetic exchange	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; DROSOPHILA-MELANOGASTER; NATURAL-SELECTION; POPULATIONS; ERRORS	The Class Bdelloidea of the Phylum Rotifera is the largest metazoan taxon in which males, hermaphrodites, and meiosis are unknown. We conducted a molecular genetic test: of this indication that bdelloid rotifers may have evolved without sexual reproduction or genetic exchange. The test is based on the expectation that after millions of years without these processes, genomes will no Longer contain pairs of closely similar haplotypes and instead will contain highly divergent descendants of formerly allelic nucleotide sequences. We find that genomes of individual bdelloid rotifers, representing four different species, appear to Lack pairs of closely similar sequences and contain representatives of two ancient Lineages that began to diverge before the bdelloid radiation many millions of years ago when sexual reproduction and genetic exchange may have ceased.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Meselson, M (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.							BELL G, 1982, MASTERPIECE NATURE E; CROW JF, 1994, DEV GENET, V15, P205, DOI 10.1002/dvg.1020150303; Deng HW, 1996, GENETICS, V144, P349; DONNER J, 1965, ORDNUNG BDELLOIDEA; DUNNING AM, 1988, NUCLEIC ACIDS RES, V16, P10393, DOI 10.1093/nar/16.21.10393; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; Garey JR, 1998, HYDROBIOLOGIA, V387, P83, DOI 10.1023/A:1017060902909; Garey JR, 1996, J MOL EVOL, V43, P287, DOI 10.1007/BF02338837; GILBERT JJ, 1989, REPROD BIOL INVERTEB, V4, P179; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; Goddemeier ML, 1996, GENE, V174, P111, DOI 10.1016/0378-1119(96)00437-4; HOLMAN EW, 1987, SYST ZOOL, V36, P381, DOI 10.2307/2413402; HSU WS, 1956, BIOL BULL, V111, P364, DOI 10.2307/1539143; Hsu WS, 1956, CELLULE, V57, P283; Hudson C.T, 1886, ROTIFERA WHEEL ANIMA; Inomata N, 1997, MOL BIOL EVOL, V14, P942, DOI 10.1093/oxfordjournals.molbev.a025837; Judson Olivia P., 1996, Trends in Ecology and Evolution, V11, P41, DOI 10.1016/0169-5347(96)81040-8; KIMURA M, 1964, GENETICS, V49, P725; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; Li W. H, 1997, MOL EVOLUTION; LI WH, 1991, GENETICS, V129, P513; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; MAYNARDSMITH J, 1986, NATURE, V324, P300; Mayr E., 1963, ANIMAL SPECIES EVOLU; Melone G, 1998, HYDROBIOLOGIA, V387, P101, DOI 10.1023/A:1017057619574; Moriyama EN, 1996, MOL BIOL EVOL, V13, P261, DOI 10.1093/oxfordjournals.molbev.a025563; MUKAI T, 1972, GENETICS, V72, P335; PAGANI M, 1993, HYDROBIOLOGIA, V255, P225, DOI 10.1007/BF00025843; PALUMBI SR, 1991, MOL BIOL EVOL, V8, P227; RICCI CN, 1987, HYDROBIOLOGIA, V147, P117, DOI 10.1007/BF00025734; Richards A.J., 1986, PLANT BREEDING SYSTE; Robertson HM, 1998, GENOME RES, V8, P449, DOI 10.1101/gr.8.5.449; Shabalina SA, 1997, P NATL ACAD SCI USA, V94, P13034, DOI 10.1073/pnas.94.24.13034; WAGGONER BM, 1993, EXPERIENTIA, V49, P354, DOI 10.1007/BF01923421; Wallace R.L., 1991, P187; Wang RL, 1997, GENETICS, V147, P1091; Welch DBM, 1998, HYDROBIOLOGIA, V387, P395, DOI 10.1023/A:1017063201343; Welch DBM, 2000, INVERTEBR BIOL, V119, P17; WELCH DBM, 1999, THESIS HARVARD U CAM; Welch JLM, 1998, HYDROBIOLOGIA, V387, P403; White M.J.D., 1978, MODES SPECIATION	41	448	463	4	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1211	1215		10.1126/science.288.5469.1211	http://dx.doi.org/10.1126/science.288.5469.1211			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817991	Green Submitted			2022-12-28	WOS:000087112600043
J	Kemphues, K				Kemphues, K			PARsing embryonic polarity	CELL			English	Review							C-ELEGANS EMBRYO; DROSOPHILA		Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Kemphues, K (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.							BOWERMAN B, 1995, BIOESSAYS, V17, P405, DOI 10.1002/bies.950170508; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jan YN, 2000, CELL, V100, P599, DOI 10.1016/S0092-8674(00)80695-9; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; Schubert CM, 2000, MOL CELL, V5, P671, DOI 10.1016/S1097-2765(00)80246-4; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; STJOHNSTON D, 1992, CELL, V68, P201; van Eeden F, 1999, CURR OPIN GENET DEV, V9, P396, DOI 10.1016/S0959-437X(99)80060-4	10	195	219	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 12	2000	101	4					345	348		10.1016/S0092-8674(00)80844-2	http://dx.doi.org/10.1016/S0092-8674(00)80844-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830161	Bronze			2022-12-28	WOS:000087010400002
J	Plotnikov, AN; Hubbard, SR; Schlessinger, J; Mohammadi, M				Plotnikov, AN; Hubbard, SR; Schlessinger, J; Mohammadi, M			Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity	CELL			English	Article							FIBROBLAST-GROWTH-FACTOR; HIGH-AFFINITY RECEPTOR; BINDING SPECIFICITY; SIGNAL TRANSDUCTION; FACTOR FAMILY; HEPARIN; IDENTIFICATION; MOLECULES; DIMERIZATION; MUTAGENESIS	To elucidate the structural determinants governing specificity in fibroblast growth factor (FGF) signaling, we have determined the crystal structures of FGF1 and FGF2 complexed with the ligand binding domains (immunoglobulin-like domains 2 [D2] and 3 [D3]) of FGF receptor 1 (FGFR1) and FGFR2, respectively. Highly conserved FGF-D2 and FGF-linker (between D2-D3) interfaces define a general binding site for all FGF-FGFR complexes. Specificity is achieved through interactions between the N-terminal and central regions of FGFs and two loop regions in D3 that are subject to alternative splicing. These structures provide a molecular basis for FGF1 as a universal FGFR ligand and for modulation of FGF-FGFR specificity through primary sequence variations and alternative splicing.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA	New York University; New York University	Mohammadi, M (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.		Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Hubbard, Stevan/0000-0002-2707-9383				Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Chellaiah A, 1999, J BIOL CHEM, V274, P34785, DOI 10.1074/jbc.274.49.34785; DELL KR, 1992, J BIOL CHEM, V267, P21225; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Gray TE, 1996, BIOCHEMISTRY-US, V35, P15640, DOI 10.1021/bi961942c; GRAY TE, 1995, BIOCHEMISTRY-US, V34, P10325, DOI 10.1021/bi00033a002; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Naski M C, 1998, Front Biosci, V3, pd781; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; REICHSLOTKY R, 1995, J BIOL CHEM, V270, P29813; RON D, 1993, J BIOL CHEM, V268, P5388; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Wang F, 1999, BIOCHEMISTRY-US, V38, P160, DOI 10.1021/bi981758m; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhu HY, 1997, PROTEIN ENG, V10, P417, DOI 10.1093/protein/10.4.417; ZHU HY, 1995, J BIOL CHEM, V270, P21869, DOI 10.1074/jbc.270.37.21869; Zhu HY, 1998, PROTEIN ENG, V11, P937, DOI 10.1093/protein/11.10.937; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	44	320	374	2	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 12	2000	101	4					413	424		10.1016/S0092-8674(00)80851-X	http://dx.doi.org/10.1016/S0092-8674(00)80851-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	313QM	10830168	Bronze			2022-12-28	WOS:000087010400009
J	Jaime, M; Movshovich, R; Stewart, GR; Beyermann, WP; Berisso, MG; Hundley, MF; Canfield, PC; Sarrao, JL				Jaime, M; Movshovich, R; Stewart, GR; Beyermann, WP; Berisso, MG; Hundley, MF; Canfield, PC; Sarrao, JL			Closing the spin gap in the Kondo insulator Ce3Bi4Pt3 at high magnetic fields	NATURE			English	Article							YBB12; HEAT; STATE; SMB6	Kondo insulator materials(1)-such as CeRhAs, CeRhSb, YbB12, Ce3Bi4Pt3 and SmB6-are 3d, 4f and 5f intermetallic compounds that have attracted considerable interest in recent years(2-5). At high temperatures, they behave like metals. But as temperature is reduced, an energy gap opens in the conduction band at the Fermi energy and the materials become insulating. This contrasts with other f-electron compounds, which are metallic at all temperatures. The formation of the gap in Kondo insulators has been proposed to be a consequence of hybridization between the conduction band and the f-electron levels(6,7), giving a 'spin' gap. If this is indeed the case, metallic behaviour should be recovered when the gap is closed by changing external parameters, such as magnetic field or pressure. Some experimental evidence suggests that the gap can be closed in SmB6 (refs 5, 8) and YbB12 (ref. 9). Here we present specific-heat measurements of Ce3Bi4Pt3 in d.c. and pulsed magnetic fields up to 60 tesla. Numerical results and the analysis of our data using the Coqblin-Schrieffer model demonstrate unambiguously a field-induced insulator-to-metal transition.	Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Univ Florida, Gainesville, FL 32611 USA; Univ Calif Riverside, Riverside, CA 92521 USA; Ctr Atom Bariloche, RA-8400 Bariloche, Rio Negro, Argentina; Iowa State Univ, Ames Lab, Ames, IA 50011 USA; Iowa State Univ, Dept Phys & Astron, Ames, IA 50011 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; State University System of Florida; University of Florida; University of California System; University of California Riverside; Comision Nacional de Energia Atomica (CNEA); Centro Atomico Bariloche; Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University	Jaime, M (corresponding author), Univ Calif Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.		Canfield, Paul/H-2698-2014; Gómez Berisso, Mariano/GOJ-7746-2022; Jaime, Marcelo/F-3791-2015; stewart, greg/AAL-9267-2020; Gomez Berisso, Mariano/I-2931-2017	Jaime, Marcelo/0000-0001-5360-5220; Gomez Berisso, Mariano/0000-0001-5530-0180				Aeppli G., 1992, COMMENTS COND MAT PH, V16, P155; BACHMANN R, 1972, REV SCI INSTRUM, V43, P205, DOI 10.1063/1.1685596; BOEBINGER GS, 1995, PHYSICA B, V211, P227, DOI 10.1016/0921-4526(94)00992-5; Breuer K, 1998, EUROPHYS LETT, V41, P565, DOI 10.1209/epl/i1998-00192-1; Cooley JC, 1999, J SUPERCOND, V12, P171, DOI 10.1023/A:1007771030747; Degiorgi L, 1999, REV MOD PHYS, V71, P687, DOI 10.1103/RevModPhys.71.687; Hewson A C, 1993, KONDO PROBLEM HEAVY; HUNDLEY MF, 1993, PHYSICA B, V186-88, P425, DOI 10.1016/0921-4526(93)90593-U; HUNDLEY MF, 1990, PHYS REV B, V42, P6842, DOI 10.1103/PhysRevB.42.6842; HUNDLEY MF, 1991, PHYSICA B, V171, P254, DOI 10.1016/0921-4526(91)90525-J; IGA F, 1988, J MAGN MAGN MATER, V76-7, P156, DOI 10.1016/0304-8853(88)90349-6; Izawa K, 1999, PHYS REV B, V59, P2599, DOI 10.1103/PhysRevB.59.2599; JAIME M, 1999, PHYSICAL PHENOMENA H, V3, P148; Kumigashira H, 1999, PHYS REV LETT, V82, P1943, DOI 10.1103/PhysRevLett.82.1943; MANDRUS D, 1994, PHYS REV B, V49, P16809, DOI 10.1103/PhysRevB.49.16809; MODLER R, 1999, PHYSICAL PHENOMENA H, V3, P154; MOSHCHALKOV VV, 1985, J MAGN MAGN MATER, V47-8, P289, DOI 10.1016/0304-8853(85)90418-4; RAJAN VT, 1983, PHYS REV LETT, V51, P308, DOI 10.1103/PhysRevLett.51.308; REYES AP, 1994, PHYS REV B, V49, P16321, DOI 10.1103/PhysRevB.49.16321; SCHLOTTMANN P, 1992, PHYS REV B, V46, P998, DOI 10.1103/PhysRevB.46.998; SCHOTTE KD, 1975, PHYS LETT A, V55, P38, DOI 10.1016/0375-9601(75)90386-2; SEVERING A, 1991, PHYS REV B, V44, P6832, DOI 10.1103/PhysRevB.44.6832; SUGIYAMA K, 1988, J PHYS SOC JPN, V57, P3946, DOI 10.1143/JPSJ.57.3946; Susaki T, 1999, PHYS REV LETT, V82, P992, DOI 10.1103/PhysRevLett.82.992; THOMPSON JD, 1993, TRANSPORT AND THERMAL PROPERTIES OF F-ELECTRON SYSTEMS, P35	25	99	99	0	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					160	163		10.1038/35012027	http://dx.doi.org/10.1038/35012027			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821266				2022-12-28	WOS:000087080100043
J	McCann, KS				McCann, KS			The diversity-stability debate	NATURE			English	Review							CAPITA INTERACTION STRENGTH; FOOD-WEB COMPLEXITY; ECOLOGICAL COMMUNITIES; STATISTICAL INEVITABILITY; ECOSYSTEM RELIABILITY; TROPHIC INTERACTIONS; POPULATION-DYNAMICS; REAL ECOSYSTEMS; BIODIVERSITY; PRODUCTIVITY	There exists little doubt that the Earth's biodiversity is declining. The Nature Conservancy, for example, has documented that one-third of the plant and animal species in the United States are now at risk of extinction. The problem is a monumental one, and forces us to consider in depth how we expect ecosystems, which ultimately are our life-support systems, to respond to reductions in diversity. This issue - commonly referred to as the diversity-stability debate - is the subject of this review, which synthesizes historical ideas with recent advances. Both theory and empirical evidence agree that we should expect declines in diversity to accelerate the simplification of ecological communities.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University	McCann, KS (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.							Andersen T., 1997, PELAGIC NUTR CYCLES; ARMSTRONG RA, 1980, AM NAT, V115, P151, DOI 10.1086/283553; Berlow EL, 1999, NATURE, V398, P330, DOI 10.1038/18672; CHESSON J, 1983, ECOLOGY, V64, P1297, DOI 10.2307/1937838; Chesson P, 1997, AM NAT, V150, P519, DOI 10.1086/286080; Cohen AN, 1998, SCIENCE, V279, P555, DOI 10.1126/science.279.5350.555; DEANGELIS DL, 1987, ECOL MONOGR, V57, P1, DOI 10.2307/1942636; DEANGELIS DL, 1992, DYNAMICS NUTR RECYCL; DERUITER PC, 1995, SCIENCE, V269, P1257, DOI 10.1126/science.269.5228.1257; Doak DF, 1998, AM NAT, V151, P264, DOI 10.1086/286117; Elser JJ, 1999, ECOLOGY, V80, P735, DOI 10.2307/177013; Elton C. S., 1958, ECOLOGY INVASIONS AN; Fagan WF, 1997, AM NAT, V150, P554, DOI 10.1086/286081; FAGAN WF, 1994, ECOLOGY, V75, P2022, DOI 10.2307/1941607; FLAHERTY D L, 1969, Ecology (Washington D C), V50, P911, DOI 10.2307/1933710; Fritze RH, 1998, SIXTEENTH CENT J, V29, P113; GARDNER MR, 1970, NATURE, V228, P784, DOI 10.1038/228784a0; GOLDWASSER L, 1993, ECOLOGY, V74, P1216, DOI 10.2307/1940492; Harding SP, 1999, TELLUS B, V51, P815, DOI 10.1034/j.1600-0889.1999.t01-3-00006.x; HASTINGS A, 1994, SCIENCE, V263, P1133, DOI 10.1126/science.263.5150.1133; Holt RD, 1997, MULTITROPHIC INTERACTIONS IN TERRESTRIAL SYSTEMS, P333; Holyoak M, 1998, OECOLOGIA, V117, P413, DOI 10.1007/s004420050675; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; Huisman J, 1999, NATURE, V402, P407, DOI 10.1038/46540; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; Huxel GR, 1998, AM NAT, V152, P460, DOI 10.1086/286182; Kokkoris GD, 1999, ECOL LETT, V2, P70, DOI 10.1046/j.1461-0248.1999.22058.x; LAWTON JH, 1995, SCIENCE, V269, P328, DOI 10.1126/science.269.5222.328; LAWTON JH, 1993, ECOL STU AN, V99, P255; Levin S., 1999, FRAGILE DOMINION; LODGE DM, 1993, TRENDS ECOL EVOL, V8, P133, DOI 10.1016/0169-5347(93)90025-K; LUCKINBILL LS, 1979, ECOLOGY, V60, P1098, DOI 10.2307/1936956; MACARTHUR R, 1955, ECOLOGY, V36, P533, DOI 10.2307/1929601; May R.M., 1973, STABILITY COMPLEXITY; McCann K, 1997, P ROY SOC B-BIOL SCI, V264, P1249, DOI 10.1098/rspb.1997.0172; McCann K, 1998, NATURE, V395, P794, DOI 10.1038/27427; McGrady-Steed J, 2000, ECOLOGY, V81, P361; McGradySteed J, 1997, NATURE, V390, P162, DOI 10.1038/36561; MCNAUGHTON SJ, 1985, ECOL MONOGR, V55, P259, DOI 10.2307/1942578; MICHALSKI J, 1999, ADV ENV ECOLOGICAL M, P1; Morin P, 1999, ECOLOGY, V80, P752, DOI 10.2307/177014; MORIN PJ, 1995, ANNU REV ECOL SYST, V26, P505, DOI 10.1146/annurev.es.26.110195.002445; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; Naeem S, 1998, CONSERV BIOL, V12, P39, DOI 10.1046/j.1523-1739.1998.96379.x; Odum E. P., 1953, FUNDAMENTALS ECOLOGY; PAINE RT, 1984, ECOLOGY, V65, P1339, DOI 10.2307/1939114; PAINE RT, 1992, NATURE, V355, P73, DOI 10.1038/355073a0; PIMM SL, 1978, NATURE, V275, P542, DOI 10.1038/275542a0; POLIS GA, 1991, AM NAT, V138, P123, DOI 10.1086/285208; Polis GA, 1996, AM NAT, V147, P813, DOI 10.1086/285880; Post DM, 2000, ECOLOGY, V81, P8, DOI 10.2307/177129; Raffaelli David G., 1996, P185; Reid WV, 1997, ENVIRONMENT, V39, P16, DOI 10.1080/00139159709604751; REINTHAL PN, 1994, THEORY APPL FISH FEE, P296; Ricciardi A, 1999, CONSERV BIOL, V13, P1220, DOI 10.1046/j.1523-1739.1999.98380.x; Sankaran M, 1999, NATURE, V401, P691, DOI 10.1038/44368; Schapfer F., 1999, ECOL APPL, V9, P893; STRONG DR, 1992, ECOLOGY, V73, P747, DOI 10.2307/1940154; Tilman D, 1998, AM NAT, V151, P277, DOI 10.1086/286118; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; Tilman D, 1996, ECOLOGY, V77, P350, DOI 10.2307/2265614; TILMAN D, 1994, NATURE, V367, P363, DOI 10.1038/367363a0; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Vander Zanden MJ, 1999, NATURE, V401, P464, DOI 10.1038/46762; Wardle DA, 1999, ECOL MONOGR, V69, P535, DOI 10.1890/0012-9615(1999)069[0535:PRIPGV]2.0.CO;2; Williamson M, 1996, ECOLOGY, V77, P1661, DOI 10.2307/2265769; WINEMILLER KO, 1990, ECOL MONOGR, V60, P331, DOI 10.2307/1943061; Wootton JT, 1997, ECOL MONOGR, V67, P45, DOI 10.1890/0012-9615(1997)067[0045:EATOPC]2.0.CO;2; Yachi S, 1999, P NATL ACAD SCI USA, V96, P1463, DOI 10.1073/pnas.96.4.1463; YODZIS P, 1992, AM NAT, V139, P1151, DOI 10.1086/285380	73	1833	1979	36	954	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					228	233		10.1038/35012234	http://dx.doi.org/10.1038/35012234			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821283				2022-12-28	WOS:000087080100060
J	Sarbu, T; Styranec, T; Beckman, EJ				Sarbu, T; Styranec, T; Beckman, EJ			Non-fluorous polymers with very high solubility in supercritical CO2 down to low pressures	NATURE			English	Article							FLUOROETHER-FUNCTIONAL AMPHIPHILES; CARBON-DIOXIDE MICROEMULSIONS; DISPERSION POLYMERIZATION; METHYL-METHACRYLATE; EQUILIBRIUM; EXTRACTION; COPOLYMERS; FLUIDS; WATER	Liquid and supercritical carbon dioxide have attracted much interest as environmentally benign solvents(1), but their practical use has been limited by the need for high CO2 pressures to dissolve even small amounts of polar, amphiphilic, organometallic, or high-molecular-mass compounds(2-4). So-called 'CO2-philes' efficiently transport insoluble or poorly soluble materials into CO2 solvent, resulting in the development of a broad range of CO2 based processes, including homogeneous and heterogeneous polymerization, extraction of proteins and metals, and homogeneous catalysis(5-11). But as the most effective CO2-philes are expensive fluorocarbons, such as poly(perfluoroether), the commercialization of otherwise promising CO2-based processes has met with only limited success. Here we show that copolymers can act as efficient, non-fluorous CO2-philes if their constituent monomers are chosen to optimize the balance between the enthalpy and entropy of solute-copolymer and copolymer-copolymer interactions. Guided by heuristic rules regarding these interactions, we have used inexpensive propylene and CO2 to synthesize a series of poly(ether-carbonate) copolymers that readily dissolve in CO2 at low pressures. Even though non-fluorous polymers are generally assumed to be CO2-phobic, we expect that our design principles can be used to create a wide range of non-fluorous CO2-philes from low-cost raw materials, thus rendering a variety of CO2-based processes economically favourable, particularly in cases where recycling of CO2-philes is difficult.	Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Beckman, EJ (corresponding author), Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA.							BRNADRUP J, 1999, POLYM HDB, P47; Consani K.A., 1990, J SUPERCRIT FLUID, V3, P51, DOI DOI 10.1016/0896-8446(90)90008-A; DESIMONE JM, 1992, SCIENCE, V257, P945, DOI 10.1126/science.257.5072.945; Eckert CA, 1996, NATURE, V383, P313, DOI 10.1038/383313a0; Fink R, 1999, J PHYS CHEM B, V103, P6441, DOI 10.1021/jp990333m; Ghenciu EG, 1998, BIOTECHNOL BIOENG, V58, P572, DOI 10.1002/(SICI)1097-0290(19980620)58:6<572::AID-BIT2>3.0.CO;2-F; HARRISON K, 1994, LANGMUIR, V10, P3536, DOI 10.1021/la00022a028; HOEFLING TA, 1993, J SUPERCRIT FLUID, V6, P165, DOI 10.1016/0896-8446(93)90015-P; HOEFLING TA, 1991, J PHYS CHEM-US, V95, P7127, DOI 10.1021/j100172a006; HSIAO YL, 1995, MACROMOLECULES, V28, P8159, DOI 10.1021/ma00128a028; Jessop PG, 1999, CHEM REV, V99, P475, DOI 10.1021/cr970037a; Johnston K.P., 1996, ENCY CHEM PROCESSING, V56, P1; Johnston KP, 1996, SCIENCE, V271, P624, DOI 10.1126/science.271.5249.624; Kazarian SG, 1996, J AM CHEM SOC, V118, P1729, DOI 10.1021/ja950416q; Lepilleur C, 1997, MACROMOLECULES, V30, P745, DOI 10.1021/ma960764s; Li J, 1998, IND ENG CHEM RES, V37, P4768, DOI 10.1021/ie9802717; Meredith JC, 1996, J PHYS CHEM-US, V100, P10837, DOI 10.1021/jp953161b; NEWMAN DA, 1993, J SUPERCRIT FLUID, V6, P205, DOI 10.1016/0896-8446(93)90028-V; O'Neill ML, 1998, IND ENG CHEM RES, V37, P3067, DOI 10.1021/ie980010x; OSHEA KE, 1991, J PHYS CHEM-US, V95, P7863, DOI 10.1021/j100173a057; Rindfleisch F, 1996, J PHYS CHEM-US, V100, P15581, DOI 10.1021/jp9615823; Triolo F, 2000, LANGMUIR, V16, P416, DOI 10.1021/la990140q; Yazdi AV, 1997, IND ENG CHEM RES, V36, P2368, DOI 10.1021/ie960611t	23	390	428	0	166	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					165	168		10.1038/35012040	http://dx.doi.org/10.1038/35012040			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821268				2022-12-28	WOS:000087080100045
J	Berger, A				Berger, A			SLE is caused by cell debris	BRITISH MEDICAL JOURNAL			English	News Item																		Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1495	1495						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834886				2022-12-28	WOS:000087471000016
J	Clark, CE; Coote, JM; Silver, DAT; Halpin, DMG				Clark, CE; Coote, JM; Silver, DAT; Halpin, DMG			Asthma after childhood pneumonia: six year follow up study	BRITISH MEDICAL JOURNAL			English	Article							BRONCHIOLITIS	Objective To establish the long term cum cumulative prevalence of asthma in children admitted to hospital with pneumonia and to examine the hypothesis that some children admitted to hospital with pneumonia may be presenting with undiagnosed asthma Design Prospective study of a cohort of children previously admitted to hospital with pneumonia, followed up by postal questionnaires to their general practitioners and the children or their parents. Setting General practices in southwest England. Participants 78 children admitted to the Royal Devon and Exeter Hospital between 1989 and 1991 with a diagnosis of pneumonia confirmed on independent review of x ray films. Main outcome measures Any diagnosis of asthma, use of any treatment for asthma, and asthma symptom scores. Results On the basis of a 100% response rate from general practitioners and 86% from patients or parents, the cumulative prevalence of asthma was 45%. A diagnosis of asthma was associated with a family history of asthma (odds ratio 11.23; 95% confidence interval 2.57 to 56.36; P = 0.0002). Mean symptom scores were higher for all children with asthma (mean score 2.4; chi(2) = 14.88; P = 0.0001) and for children with asthma not being treated (mean 1.4; chi(2) = 6.2; P = 0.01) than for those without asthma (mean 0.2). Conclusions A considerable proportion of children presenting to a district general hospital with pneumonia either already have unrecognised asthma or subsequently develop asthma. The high cumulative prevalence of asthma suggests that careful follow up of such children is worth while. Asthma is undertreated in these children; a structured symptom questionnaire may help to identify and reduce morbidity due to undertreatment.	Mid Devon Med Practice, Witheridge EX16 8AH, Devon, England; Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England	University of Exeter	Clark, CE (corresponding author), Mid Devon Med Practice, Witheridge EX16 8AH, Devon, England.							Bodner C, 1997, BRIT MED J, V314, P792, DOI 10.1136/bmj.314.7083.792; CLARK CE, 1997, ASTHMA GEN PRACT, V5, P9; DEAN AG, 1990, EPIINFO VERSION 5 WO; KORPPI M, 1993, AM J DIS CHILD, V147, P628, DOI 10.1001/archpedi.1993.02160300034017; KORPPI M, 1994, ARCH PEDIAT ADOL MED, V148, P1079, DOI 10.1001/archpedi.1994.02170100077015; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MOK JYQ, 1984, ARCH DIS CHILD, V59, P306, DOI 10.1136/adc.59.4.306; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; Strachan DP, 1996, BRIT MED J, V312, P1195; VENABLES KM, 1993, THORAX, V48, P214, DOI 10.1136/thx.48.3.214; Wlson AG, 1995, IMAGING DIS CHEST; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	12	16	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1514	1516		10.1136/bmj.320.7248.1514	http://dx.doi.org/10.1136/bmj.320.7248.1514			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834897	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000087471000027
J	Dodds, JP; Nardone, L; Mercey, DE; Johnson, AM				Dodds, JP; Nardone, L; Mercey, DE; Johnson, AM			Increase in high risk sexual behaviour among homosexual men, London 1996-8: cross sectional, questionnaire study	BRITISH MEDICAL JOURNAL			English	Article									UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Dodds, JP (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England.	JDodds@gurn.ucl.ac.uk		Nardone, Anthony/0000-0003-1138-0937; Johnson, Anne/0000-0003-1330-7100				*COMM DIS SURV CTR, 1999, COMMUN DIS REP CDR W, V9, P121; Nardone A, 1998, Commun Dis Public Health, V1, P197; Nardone A, 1997, GENITOURIN MED, V73, P198; Page-Shafer KA, 1999, JAMA-J AM MED ASSOC, V281, P696; 1998, COMMUN DIS REP CDR W, V8, P194	5	156	156	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1510	1511		10.1136/bmj.320.7248.1510	http://dx.doi.org/10.1136/bmj.320.7248.1510			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834892	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000087471000024
J	Feagan, BG; Fedorak, RN; Irvine, EJ; Wild, G; Sutherland, L; Steinhart, AH; Greenberg, GR; Koval, J; Wong, CJ; Hopkins, M; Hanauer, SB; McDonald, JWD				Feagan, BG; Fedorak, RN; Irvine, EJ; Wild, G; Sutherland, L; Steinhart, AH; Greenberg, GR; Koval, J; Wong, CJ; Hopkins, M; Hanauer, SB; McDonald, JWD		N Amer Crohns Study Grp Investigat	A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; LOW-DOSE METHOTREXATE; RHEUMATOID-ARTHRITIS PATIENTS; LONG-TERM; DRUG-TREATMENT; LIVER-BIOPSY; 6-MERCAPTOPURINE; AZATHIOPRINE; BUDESONIDE; RHEUMATOLOGISTS	Background Patients with Crohn's disease often have relapses. Better treatments are needed for the maintenance of remission. Although methotrexate is an effective short-term treatment for Crohn's disease, its role in maintaining remissions is not known. Methods We conducted a double-blind, placebo-controlled, multicenter study of patients with chronically active Crohn's disease who had entered remission after 16 to 24 weeks of treatment with 25 mg of methotrexate given intramuscularly once weekly. Patients were randomly assigned to receive either methotrexate at a dose of 15 mg intramuscularly once weekly or placebo for 40 weeks. No other treatments for Crohn's disease were permitted. We compared the efficacy of treatment by analyzing the proportion of patients who remained in remission at week 40. Remission was defined as a score of 150 or less on the Crohn's Disease Activity Index. Results Forty patients received methotrexate, and 36 received placebo. At week 40, 26 patients (65 percent) were in remission in the methotrexate group, as compared with 14 (39 percent) in the placebo group (P=0.04; absolute reduction in the risk of relapse, 26.1 percent; 95 percent confidence interval, 4.4 percent to 47.8 percent). Fewer patients in the methotrexate group than in the placebo group required prednisone for relapse (11 of 40 [28 percent] vs. 21 of 36 [58 percent], P=0.01). None of the patients who received methotrexate had a severe adverse event; one patient in this group withdrew because of nausea. Conclusions In patients with Crohn's disease who enter remission after treatment with methotrexate, a low dose of methotrexate maintains remission. (N Engl J Med 2000;342:1627-32.) (C)2000, Massachusetts Medical Society.	John P Robarts Res Inst, London Clin Trials Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada; Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB, Canada; McMaster Univ, Dept Med, Div Gastroenterol, Hamilton, ON, Canada; Univ Calgary, Dept Med, Div Gastroenterol, Calgary, AB, Canada; Univ Toronto, Dept Med, Div Gastroenterol, Toronto, ON, Canada; Univ Chicago, Dept Med, Gastroenterol Sect, Chicago, IL 60637 USA; McGill Univ, Dept Med, Div Gastroenterol, Montreal, PQ, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Alberta; McMaster University; University of Calgary; University of Toronto; University of Chicago; McGill University	Feagan, BG (corresponding author), John P Robarts Res Inst, London Clin Trials Res Grp, 100 Perth Dr, London, ON N6A 5K8, Canada.	feagan@lctrg.com	Feagan, Brian G/M-4283-2015; Feagan, Brian/G-3292-2011; Greenberg, Gordon/C-4620-2015	Fedorak, Richard/0000-0002-7382-0080				ALAWADHI A, 1993, J RHEUMATOL, V20, P1121; Bawle EV, 1998, TERATOLOGY, V57, P51, DOI 10.1002/(SICI)1096-9926(199802)57:2<51::AID-TERA2>3.0.CO;2-9; BERGQUIST SR, 1995, ARTHRITIS RHEUM, V38, P326, DOI 10.1002/art.1780380306; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; CANDY S, 1995, GUT, V37, P674, DOI 10.1136/gut.37.5.674; Cron RQ, 1999, J RHEUMATOL, V26, P2036; ERICKSON AR, 1995, ARTHRITIS RHEUM, V38, P1115, DOI 10.1002/art.1780380814; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; Feeney M, 1997, LANCET, V350, P764, DOI 10.1016/S0140-6736(97)03192-9; Greenberg GR, 1996, GASTROENTEROLOGY, V110, P45, DOI 10.1053/gast.1996.v110.pm8536887; Haga Y, 1996, GUT, V38, P211, DOI 10.1136/gut.38.2.211; KOZAREK RA, 1989, ANN INTERN MED, V110, P353, DOI 10.7326/0003-4819-110-5-353; KOZLOWSKI RD, 1990, AM J MED, V88, P589, DOI 10.1016/0002-9343(90)90522-F; Kremer JM, 1996, J RHEUMATOL, V23, P459; Kremer JM, 1997, ARTHRITIS RHEUM, V40, P1829, DOI 10.1002/art.1780401016; KREMER JM, 1994, ARTHRITIS RHEUM-US, V37, P316, DOI 10.1002/art.1780370304; Lee JCW, 1996, GUT, V39, P231, DOI 10.1136/gut.39.2.231; Lofberg R, 1996, GUT, V39, P82, DOI 10.1136/gut.39.1.82; Maetzel A, 1998, J RHEUMATOL, V25, P2331; MALCHOW H, 1984, GASTROENTEROLOGY, V86, P249; MARKOWITZ J, 1990, GASTROENTEROLOGY, V99, P1347, DOI 10.1016/0016-5085(90)91160-8; MUNKHOLM P, 1994, GUT, V35, P360, DOI 10.1136/gut.35.3.360; ODONOGHUE DP, 1978, LANCET, V2, P955, DOI 10.1016/S0140-6736(78)92524-2; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; Rau R, 1997, J RHEUMATOL, V24, P1881; Ruderman EM, 1997, BRIT J RHEUMATOL, V36, P210; RUTGEERTS P, 1994, NEW ENGL J MED, V331, P842, DOI 10.1056/NEJM199409293311304; SARTOR RB, 1995, GASTROENTEROL CLIN N, V24, P475; SAS Institute, 1997, SAS STAT SOFTW CHANG; SILVENNOINEN JA, 1995, GUT, V37, P71, DOI 10.1136/gut.37.1.71; SINGLETON JW, 1979, GASTROENTEROLOGY, V77, P870; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; VAKIL N, 1989, GASTROENTEROLOGY, V96, P62, DOI 10.1016/0016-5085(89)90764-6; Ward MM, 1999, J RHEUMATOL, V26, P546; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; West SG, 1997, RHEUM DIS CLIN N AM, V23, P883, DOI 10.1016/S0889-857X(05)70365-3; Willkens RF, 1995, ARTHRITIS RHEUM, V38, P1799, DOI 10.1002/art.1780381213; Willkens RF, 1996, J RHEUMATOL, V23, P64; 1995, N ENGL J MED, V333, P600	40	570	592	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2000	342	22					1627	1632		10.1056/NEJM200006013422202	http://dx.doi.org/10.1056/NEJM200006013422202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319CE	10833208				2022-12-28	WOS:000087321600002
J	Ramers, C; Billman, G; Hartin, M; Ho, S; Sawyer, MH				Ramers, C; Billman, G; Hartin, M; Ho, S; Sawyer, MH			Impact of a diagnostic cerebrospinal fluid enterovirus polymerase chain reaction test on patient management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CENTRAL-NERVOUS-SYSTEM; ASEPTIC-MENINGITIS; CLINICAL UTILITY; INFECTION; OUTBREAK; INFANTS; PCR; CULTURE	Context Enterovirus (EV) infection. the most common cause of aseptic meningitis, can be rapidly diagnosed with an EV-specific reverse transcriptase polymerase chain reaction (EV-PCR) test. However, no studies have examined EV-PCR in a clinical context in which it is routinely used. Objective To determine the impact of EV-PCR testing on diagnosis and clinical management of suspected aseptic meningitis cases. Design and Setting Retrospective review of electronic medical records from a 220-bed tertiary care pediatric medical center in San Diego, Calif. Patients A total of 276 pediatric patients for whom a diagnostic EV-PCR test was performed during the calendar year 1998. Main Outcome Measures Clinical parameters such as length of stay, medication use, and ancillary test use. Results One hundred thirty-seven patients (49.6%) had a positive cerebrospinal fluid EV-PCR result, Enterovirus-positive patients with results available before hospital discharge (n=95) had significantly fewer ancillary tests performed (26% vs 72% with at least 1 test performed; P<.001), received intravenous antibiotics for less time (median, 2.0 vs 3.5 days; P<.001), and had shorter hospital stays (median, 42 vs 71.5 hours; P<.001) than EV-negative patients (n=92). A positive EV-PCR result was associated with more rapid hospital discharge (median EV-PCR-to-discharge time, 5.2 hours) compared with a negative result (median EV-PCR-to-discharge time, 27.4 hours; P<.001). Conclusions Our results suggest that a positive EV-PCR result may affect clinical decision making and can promote rapid discharge of patients, and that unnecessary diagnostic and therapeutic interventions can be reduced by use of EV-PCR testing.	Univ Calif San Diego, Sch Med, Div Pediat Infect Dis, La Jolla, CA 92093 USA; Childrens Hosp & Hlth Ctr, Dept Pathol, San Diego, CA USA; Childrens Hosp & Hlth Ctr, Dept Microbiol, San Diego, CA USA	University of California System; University of California San Diego	Sawyer, MH (corresponding author), Univ Calif San Diego, Sch Med, Div Pediat Infect Dis, 9500 Gilman Dr,0927, La Jolla, CA 92093 USA.							Ahmed A, 1997, J PEDIATR-US, V131, P393, DOI 10.1016/S0022-3476(97)80064-9; BERLIN LE, 1993, J INFECT DIS, V168, P888, DOI 10.1093/infdis/168.4.888; BONADIO WA, 1992, PEDIATR INFECT DIS J, V11, P589, DOI 10.1097/00006454-199207000-00015; BONADIO WA, 1992, PEDIATR INFECT DIS J, V11, P423, DOI 10.1097/00006454-199206000-00001; Byington CL, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.3.e27; CHERRY JD, 1997, TXB PEDIAT INFECT DI, P1729; CHONMAITREE T, 1982, JAMA-J AM MED ASSOC, V247, P1843, DOI 10.1001/jama.247.13.1843; DAGAN R, 1988, J PEDIATR-US, V113, P975, DOI 10.1016/S0022-3476(88)80566-3; Dagan R, 1996, PEDIATR INFECT DIS J, V15, P67, DOI 10.1097/00006454-199601000-00015; Gorgievski-Hrisoho M, 1998, J CLIN MICROBIOL, V36, P2408, DOI 10.1128/JCM.36.9.2408-2412.1998; Hamilton MS, 1999, PEDIATR INFECT DIS J, V18, P533, DOI 10.1097/00006454-199906000-00011; LIPSON SM, 1988, J CLIN MICROBIOL, V26, P1298, DOI 10.1128/JCM.26.7.1298-1303.1988; Marshall GS, 1997, PEDIATR INFECT DIS J, V16, P1086, DOI 10.1097/00006454-199711000-00015; Read SJ, 1997, J CLIN MICROBIOL, V35, P691, DOI 10.1128/JCM.35.3.691-696.1997; RICE SK, 1995, CLIN INFECT DIS, V20, P931, DOI 10.1093/clinids/20.4.931; Riding MH, 1996, J MED VIROL, V50, P204, DOI 10.1002/(SICI)1096-9071(199610)50:2&lt;204::AID-JMV16&gt;3.0.CO;2-L; Rotbart HA, 1997, PEDIATR INFECT DIS J, V16, P409, DOI 10.1097/00006454-199704000-00014; ROTBART HA, 1994, J CLIN MICROBIOL, V32, P2590, DOI 10.1128/JCM.32.10.2590-2592.1994; ROTBART HA, 1995, CLIN INFECT DIS, V20, P971, DOI 10.1093/clinids/20.4.971; SAWYER MH, 1994, PEDIATR INFECT DIS J, V13, P177, DOI 10.1097/00006454-199403000-00002; SCHLESINGER Y, 1994, PEDIATRICS, V94, P157; SINGER JI, 1980, J PEDIATR-US, V96, P559, DOI 10.1016/S0022-3476(80)80866-3; Tanel RE, 1996, ARCH PEDIAT ADOL MED, V150, P919, DOI 10.1001/archpedi.1996.02170340033006; WILFERT CM, 1983, PEDIATR INFECT DIS J, V2, P333, DOI 10.1097/00006454-198307000-00019; Yerly S, 1996, J CLIN MICROBIOL, V34, P199, DOI 10.1128/JCM.34.1.199-201.1996	25	184	194	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2680	2685		10.1001/jama.283.20.2680	http://dx.doi.org/10.1001/jama.283.20.2680			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819951	Bronze			2022-12-28	WOS:000087046000036
J	Bayston, R; de Louvois, J; Brown, EM; Johnston, RA; Lees, P; Pople, IK				Bayston, R; de Louvois, J; Brown, EM; Johnston, RA; Lees, P; Pople, IK		British Soc Antimicrobial Chemothe	Use of antibiotics in penetrating craniocerebral injuries	LANCET			English	Review							CIVILIAN GUNSHOT WOUNDS; LEBANESE CONFLICT; MISSILE INJURIES; BRAIN; HEAD; MANAGEMENT; MENINGITIS; TRAUMA; WOOD	The Working Party was instituted to investigate the rationale of prophylactic and therapeutic antibiotic use in penetrating craniocerebral injuries (PCCI), and to make recommendations for current practice. A systematic review of papers on civilian and military PCCI over the past 25 and 50 years, respectively, was done via electronic databases and secondary sources, and data were evaluated. Guidelines on the removal of indriven bone or metal fragments only if further neural damage can be avoided were supported. However, no publications were identified where the data on infection or its treatment and prevention were complete or satisfactorily derived, and no controlled trials have been published. All studies were retrospective or anecdotal. Working Party recommendations are based on the data available and the professional experience and knowledge of the members. Broad-spectrum antibiotic prophylaxis is recommended for both military and civilian PCCI, including those due to sports or recreational injuries.	Univ Nottingham, Fac Med & Hlth Sci, Div Microbiol & Infect Dis, Nottingham NG5 1PB, England; Frenchay Hosp, Dept Microbiol, Bristol BS16 1LE, Avon, England; Frenchay Hosp, Dept Neurosurg, Bristol BS16 1LE, Avon, England; So Gen Hosp, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland	University of Nottingham; University of Glasgow	Bayston, R (corresponding author), Univ Nottingham, Fac Med & Hlth Sci, Div Microbiol & Infect Dis, City Hosp, Clin Sci Bldg, Nottingham NG5 1PB, England.		Bayston, Roger/E-7699-2019; Bayston, Roger/AAD-5427-2019	Bayston, Roger/0000-0002-8312-3844				AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; Amirjamshidi A, 1997, SURG NEUROL, V47, P331, DOI 10.1016/S0090-3019(96)00357-6; ASCROFT PB, 1947, BR J SURG S, V1, P183; BANK DE, 1993, PEDIATR EMERG CARE, V9, P285; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; BURSICK DM, 1981, SURG NEUROL, V16, P427, DOI 10.1016/0090-3019(81)90235-4; Buxton N, 1997, J R Army Med Corps, V143, P112; BYRNES DP, 1974, BRIT J SURG, V61, P169, DOI 10.1002/bjs.1800610302; CAREY ME, 1972, SURG GYNECOL OBSTETR, V135, P386; CAREY ME, 1971, J NEUROSURG, V34, P145, DOI 10.3171/jns.1971.34.2part1.0145; CHAUDHRI KA, 1994, ACTA NEUROCHIR, V126, P120, DOI 10.1007/BF01476420; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; Cushing H, 1918, BRIT J SURG, V5, P558; DREW JH, 1954, J NEUROSURG, V11, P386, DOI 10.3171/jns.1954.11.4.0386; FOY P, 1980, LANCET, V2, P662; GORDON DS, 1975, BRIT MED J, V1, P614, DOI 10.1136/bmj.1.5958.614; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; GREEN BF, 1990, OPHTHALMOLOGY, V97, P608; GUTHKELCH AN, 1960, BRIT MED J, V202, P842; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HOPKINSON DA, 1967, BRIT J SURG, V54, P344, DOI 10.1002/bjs.1800540507; HORNER FA, 1964, NEW ENGL J MED, V271, P342, DOI 10.1056/NEJM196408132710703; ILDAN F, 1994, J TRAUMA, V36, P116, DOI 10.1097/00005373-199401000-00020; JOHNSTON RA, 1984, J NEUROSURG NEUROL P, V47, P102; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; LONG JG, 1987, PEDIATR INFECT DIS J, V6, P752, DOI 10.1097/00006454-198708000-00012; MUTLUKAN E, 1991, BRIT J OPHTHALMOL, V75, P374, DOI 10.1136/bjo.75.6.374; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; Neal G, 1996, J TRAUMA, V40, P476, DOI 10.1097/00005373-199603000-00030; PENCEK TL, 1986, J NEUROSURG, V64, P813, DOI 10.3171/jns.1986.64.5.0813; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; Salisbury DM, 1996, IMMUNISATION INFECT, P205; SOLOMON KD, 1993, J TRAUMA, V34, P285, DOI 10.1097/00005373-199302000-00020; STERN WE, 1994, SURG NEUROL, V41, P83, DOI 10.1016/0090-3019(94)90213-5; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; Viagappan GM, 1998, J INFECTION, V36, P130, DOI 10.1016/S0163-4453(98)93774-4; YAMASHITA T, 1988, ORBIT, V7, P59, DOI 10.3109/01676838809036127; YASHON D, 1972, American Surgeon, V38, P346	39	68	75	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1813	1817		10.1016/S0140-6736(00)02275-3	http://dx.doi.org/10.1016/S0140-6736(00)02275-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832851				2022-12-28	WOS:000087126100048
J	Kuras, L; Kosa, P; Mencia, M; Struhl, K				Kuras, L; Kosa, P; Mencia, M; Struhl, K			TAF-containing and TAF-independent forms of transcriptionally active TBP in vivo	SCIENCE			English	Article							TATA-BINDING PROTEIN; YEAST TFIIA/TBP/DNA COMPLEX; RNA-POLYMERASE-II; PROMOTER SELECTIVITY; CRYSTAL-STRUCTURE; IN-VIVO; TELOMERIC HETEROCHROMATIN; NUCLEOSOME ACETYLATION; SAGA COMPLEX; CORE	Transcriptional activity in yeast strongly correlates with promoter occupancy by general factors such as TATA binding protein (TBP), TFIIA, and TFIIB, but not with occupancy by TBP-associated factors (TAFs). Thus, TBP exists in at least two transcriptionally active forms in vivo. The TAF-containing form corresponds to the TFIID complex, whereas the form lacking TAFs corresponds to TBP itself or to some other TBP complex. Heat shock treatment altered the relative utilization of these TBP forms, with TFIID being favored. Promoter-specific variations in the association of these distinct forms of TBP may explain why only some yeast genes require TFIID for transcriptional activity in vivo.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	kevin@hms.harvard.edu	Mencia, Mario/AAS-4554-2020; Mencía, Mario/F-8197-2013	Mencia, Mario/0000-0003-3936-0655; Mencía, Mario/0000-0002-3151-929X; Kuras, Laurent/0000-0003-2932-0940	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R37GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dimova D, 1999, MOL CELL, V4, P75, DOI 10.1016/S1097-2765(00)80189-6; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Li BJ, 1999, MOL CELL BIOL, V19, P5393; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Sterner DE, 1999, MOL CELL BIOL, V19, P86; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X	32	144	145	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	2000	288	5469					1244	1248		10.1126/science.288.5469.1244	http://dx.doi.org/10.1126/science.288.5469.1244			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10818000				2022-12-28	WOS:000087112600052
J	Makinen, JTT; Bertaux, JL; Laakso, H; Pulkkinen, T; Summanen, T; Kyrola, E; Schmidt, W; Quemerais, E; Lallement, R				Makinen, JTT; Bertaux, JL; Laakso, H; Pulkkinen, T; Summanen, T; Kyrola, E; Schmidt, W; Quemerais, E; Lallement, R			Discovery of a comet by its Lyman-alpha emission	NATURE			English	Article							SWAN; SOHO	Several searches for near-Earth objects have recently been initiated, as a result of increased awareness of the hazard of impacts on the Earth. These programs mainly search for asteroids, so amateur astronomers can still contribute to the discovery of comets, especially out of the orbital plane of the Solar System. An ideal way to search for comets would be to use a spaceborne instrument capable of imaging the whole sky on a daily basis in a systematic and repeatable way. Such an instrument already exists on the solar observatory SOHO; it operates at the Lyman-alpha wavelength of neutral hydrogen, which is the main component of the emission cloud of a comet. Here we report the discovery, using archival data from this satellite, of a hitherto unnoticed comet which reached a perihelion of 1.546 a.u. on 26 June 1997. We derive the water production rate of the comet as a function of time and rnd that it increases after perihelion, like that of comet Halley.	Finnish Meteorol Inst, FIN-00101 Helsinki, Finland; CNRS, Serv Aeron, F-91371 Verrieres Buisson, France	Finnish Meteorological Institute; Centre National de la Recherche Scientifique (CNRS)	Makinen, JTT (corresponding author), Finnish Meteorol Inst, POB 503, FIN-00101 Helsinki, Finland.		Pulkkinen, Tuija I/D-8403-2012; Kyrölä, Erkki T/E-1835-2014	Pulkkinen, Tuija I/0000-0002-6317-381X; 				Bertaux JL, 1995, SOL PHYS, V162, P403, DOI 10.1007/BF00733435; Bertaux JL, 1998, PLANET SPACE SCI, V46, P555, DOI 10.1016/S0032-0633(97)00179-7; Combi MR, 2000, ICARUS, V144, P191, DOI 10.1006/icar.1999.6335; FELDMAN PD, 1991, COMETS POST HALLEY E, V1, P139; FESTOU MC, 1987, ASTRON ASTROPHYS, V187, P575; FESTOU MC, 1981, ASTRON ASTROPHYS, V95, P69; Hughes D.W., 1991, COMETS POSTHALLEY ER, Vsecond, P825; MAKINEN T, 1999, 7327 IAU; Meech K. J., 1991, COMETS POSTHALLEY ER, V1, P629; ROETTGER EE, 1990, ICARUS, V86, P100, DOI 10.1016/0019-1035(90)90202-K	10	11	11	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					321	322		10.1038/35012526	http://dx.doi.org/10.1038/35012526			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830954				2022-12-28	WOS:000087085700038
J	Fiscella, K; Franks, P; Gold, MR; Clancy, CM				Fiscella, K; Franks, P; Gold, MR; Clancy, CM			Inequality in quality - Addressing socioeconomic, racial, and ethnic disparities in health care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; OF-CARE; MEDICAL-CARE; PREVENTABLE HOSPITALIZATIONS; REVASCULARIZATION PROCEDURES; CARDIAC PROCEDURES; INSURANCE STATUS; SCREENING-TESTS; INNER-CITY; RACE	Socioeconomic and racial/ethnic disparities in health care quality have been extensively documented, Recently, the elimination of disparities in health care has become the focus of a national initiative, Yet, there is little effort to monitor and address disparities in health care through organizational quality improvement. After reviewing literature on disparities in health care, we discuss the limitations in existing quality assessment for identifying and addressing these disparities, We propose 5 principles to address these disparities through modifications in quality performance measures: disparities represent a significant quality problem; current data collection efforts are inadequate to identify and address disparities; clinical performance measures should be stratified by race/ethnicity and socioeconomic position for public reporting; population-wide monitoring should incorporate adjustment for race/ethnicity and socioeconomic position; and strategies to adjust payment for race/ethnicity and socioeconomic position should be considered to reflect the known effects of both on morbidity.	Univ Rochester, Sch Med & Dent, Dept Family Med, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY USA; CUNY, Sch Med, Dept Community Hlth & Social Med, New York, NY 10031 USA; Agcy Healthcare Res & Qual, Rockville, MD USA	University of Rochester; University of Rochester; City University of New York (CUNY) System; Agency for Healthcare Research & Quality	Fiscella, K (corresponding author), Family Med Ctr, 885 S Ave, Rochester, NY 14620 USA.	Kevin_Fiscella@urmc.rochester.edu	Fiscella, Kevin Anthony/AFO-3350-2022; Dalla Zuanna, Teresa/G-3133-2015	Fiscella, Kevin Anthony/0000-0003-3613-8012; 	PHS HHS [R01 09963-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Andrulis DP, 1998, ANN INTERN MED, V129, P412, DOI 10.7326/0003-4819-129-5-199809010-00012; Ayanian JZ, 1999, MED CARE, V37, P1260, DOI 10.1097/00005650-199912000-00009; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; Baker DW, 1996, ANN EMERG MED, V28, P677, DOI 10.1016/S0196-0644(96)70093-8; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; BIRCH S, 1993, INT J HEALTH SERV, V23, P629, DOI 10.2190/K18V-T33F-1VC4-14RM; Blustein J, 1998, HEALTH AFFAIR, V17, P177, DOI 10.1377/hlthaff.17.2.177; Blustein J, 1998, J HEALTH CARE POOR U, V9, P153; BOMBARDIER C, 1977, NEW ENGL J MED, V297, P699, DOI 10.1056/NEJM197709292971305; BRAWN PN, 1993, CANCER, V71, P2569, DOI 10.1002/1097-0142(19930415)71:8<2569::AID-CNCR2820710822>3.0.CO;2-R; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; BRIGHT RA, 1993, AM J PUBLIC HEALTH, V83, P1026, DOI 10.2105/AJPH.83.7.1026; BROOK RH, 1990, MED CARE, V28, P392, DOI 10.1097/00005650-199005000-00002; BROWN ML, 1990, PREV MED, V19, P562, DOI 10.1016/0091-7435(90)90054-N; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; Carlisle R, 1998, BRIT J GEN PRACT, V48, P1675; Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P57; Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P588; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; COLLINS SC, 1999, US MINORITY HLTH CHA; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; CRAWFORD SL, 1994, AM J PUBLIC HEALTH, V84, P957, DOI 10.2105/AJPH.84.6.957; DONABEDIAN A, 1990, ARCH PATHOL LAB MED, V114, P1115; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; Escarce JJ, 1997, RACIAL AND ETHNIC DIFFERENCES IN THE HEALTH OF OLDER AMERICANS, P183; Ferguson JA, 1997, J AM COLL CARDIOL, V30, P1707, DOI 10.1016/S0735-1097(97)00365-3; Fiscella K, 1998, MED CARE, V36, P180, DOI 10.1097/00005650-199802000-00007; Fiscella K, 1999, ANN INTERN MED, V131, P745, DOI 10.7326/0003-4819-131-10-199911160-00005; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; Geiger HJ, 1996, NEW ENGL J MED, V335, P815, DOI 10.1056/NEJM199609123351110; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; GUADAGNOLI E, 1995, ARCH SURG-CHICAGO, V130, P381; GUENDELMAN S, 1986, MED CARE, V24, P925, DOI 10.1097/00005650-198610000-00006; Hahn R A, 1998, J Am Med Womens Assoc (1972), V53, P96; Hahn R. A., 1998, J AM MED WOMEN ASSOC, V53, P107; HALL JA, 1993, MED CARE, V31, P84, DOI 10.1097/00005650-199301000-00007; Harris D. Robert, 1997, Ethnicity and Disease, V7, P91; Heckman TG, 1998, AIDS CARE, V10, P365, DOI 10.1080/713612410; Hemingway H, 1997, BMJ-BRIT MED J, V315, P1273, DOI 10.1136/bmj.315.7118.1273; *HJ KAIS FAM FDN, 1999, RAC ETHN FAM CAR SUR; Hoekstra EJ, 1998, JAMA-J AM MED ASSOC, V280, P1143, DOI 10.1001/jama.280.13.1143; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KELLER RB, 1990, J BONE JOINT SURG AM, V72A, P1286, DOI 10.2106/00004623-199072090-00002; Klabunde CN, 1998, MED CARE, V36, P1337, DOI 10.1097/00005650-199809000-00006; Kogan M D, 1993, J Perinatol, V13, P14; KOGAN MD, 1994, AM J PUBLIC HEALTH, V84, P82, DOI 10.2105/AJPH.84.1.82; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Kuttner R, 1999, NEW ENGL J MED, V340, P248, DOI 10.1056/NEJM199901213400324; Lannin DR, 1998, JAMA-J AM MED ASSOC, V279, P1801, DOI 10.1001/jama.279.22.1801; LANNON C, 1995, ARCH PEDIAT ADOL MED, V149, P1070, DOI 10.1001/archpedi.1995.02170230024003; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; Leape LL, 1999, ANN INTERN MED, V130, P183, DOI 10.7326/0003-4819-130-3-199902020-00003; LOPES AAS, 1995, AM J KIDNEY DIS, V25, P714, DOI 10.1016/0272-6386(95)90547-2; Lowry R, 1996, JAMA-J AM MED ASSOC, V276, P792, DOI 10.1001/jama.276.10.792; Marchand S, 1998, MILBANK Q, V76, P449, DOI 10.1111/1468-0009.00098; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MAYBERRY RM, 1995, J NATL CANCER I, V87, P1686, DOI 10.1093/jnci/87.22.1686; McBean A M, 1994, Health Care Financ Rev, V15, P77; MCDONALD TP, 1988, SOC SCI MED, V27, P167, DOI 10.1016/0277-9536(88)90325-5; MCQUILLAN GM, 1989, AM J MED, V87, pS5; Mitchell JM, 1997, J CLIN ONCOL, V15, P2644, DOI 10.1200/JCO.1997.15.7.2644; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; Mukamel DB, 1998, MED CARE, V36, P945, DOI 10.1097/00005650-199807000-00002; MUTCHLER JE, 1991, J HEALTH SOC BEHAV, V32, P342, DOI 10.2307/2137102; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; Newacheck PW, 1996, PEDIATRICS, V97, P26; *NY STAT DEP HLTH, 1998, QUAL ASS REP REQ 199; Oddone EZ, 1998, J NATL MED ASSOC, V90, P25; Pappas G, 1997, AM J PUBLIC HEALTH, V87, P811, DOI 10.2105/AJPH.87.5.811; Parker RM, 1999, JAMA-J AM MED ASSOC, V281, P552; Perloff JD, 1997, MED CARE, V35, P142, DOI 10.1097/00005650-199702000-00005; *PES ADV COMM CONS, 1998, QUAL 1 BETT HLTH CAR; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; *PHYS PAYM REV COM, 1997, IMPL RISK ADJ MED PR; PICKENS G, 1999, 16 ANN AHSR M JUN 28, P388; Pincus T, 1998, ANN INTERN MED, V129, P406, DOI 10.7326/0003-4819-129-5-199809010-00011; Potosky AL, 1998, MED CARE, V36, P257, DOI 10.1097/00005650-199803000-00004; Romano PS, 1997, SPINE, V22, P2677, DOI 10.1097/00007632-199711150-00018; Satcher D, 1999, PUBLIC HEALTH REP, V114, P283, DOI 10.1093/phr/114.3.283; Schneider EC, 1999, JAMA-J AM MED ASSOC, V282, P1184, DOI 10.1001/jama.282.12.1184; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Selby JV, 1997, ANN INTERN MED, V127, P719, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00056; Sellors J, 1997, CAN MED ASSOC J, V157, P143; SHAPIRO S, 1982, AM J PUBLIC HEALTH, V72, P1142, DOI 10.2105/AJPH.72.10.1142; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; Sirey JA, 1999, AM J PSYCHIAT, V156, P690; Smeeth L, 1999, BMJ-BRIT MED J, V318, P1020, DOI 10.1136/bmj.318.7190.1020; Smith DB, 1998, J HEALTH POLIT POLIC, V23, P75; Smith JP, 1997, DEMOGRAPHY, V34, P159, DOI 10.2307/2061665; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; STAFFORD RS, 1993, AM J OBSTET GYNECOL, V168, P1297, DOI 10.1016/0002-9378(93)90384-U; Stamler R, 1987, HYPERTENSION, V9, P641; Thomas LR, 1996, WOMEN HEALTH, V24, P77; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; WARREN JL, 1994, ARCH INTERN MED, V154, P1482, DOI 10.1001/archinte.154.13.1482; Weber BE, 1997, ARCH INTERN MED, V157, P2345, DOI 10.1001/archinte.157.20.2345; WEISSMAN JS, 1994, INQUIRY-J HEALTH CAR, V31, P163; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; Wennberg DE, 1998, ANN INTERN MED, V128, P866, DOI 10.7326/0003-4819-128-10-199805150-00012; Whittle J, 1997, J GEN INTERN MED, V12, P267, DOI 10.1046/j.1525-1497.1997.012005267.x; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wood D, 1998, JAMA-J AM MED ASSOC, V279, P29, DOI 10.1001/jama.279.1.29; WOOD DL, 1990, PEDIATRICS, V86, P666; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; ZASLAVSKY AM, 1999, 16 ANN AHSR M JUN 28, P327; [No title captured]	115	850	854	1	105	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2579	2584		10.1001/jama.283.19.2579	http://dx.doi.org/10.1001/jama.283.19.2579			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	312VL	10815125				2022-12-28	WOS:000086964600042
J	Amedeo, P; Habu, Y; Afsar, K; Scheid, OM; Paszkowski, J				Amedeo, P; Habu, Y; Afsar, K; Scheid, OM; Paszkowski, J			Disruption of the plant gene MOM releases transcriptional silencing of methylated genes	NATURE			English	Article							ARABIDOPSIS-THALIANA; DNA METHYLATION; HISTONE DEACETYLASE; PROTEIN; HELICASE; CLONING; DEMETHYLATION; MAINTENANCE; REPRESSION; CHROMATIN	Epigenetic modifications change transcription patterns in multicellular organisms to achieve tissue-specific gene expression and inactivate alien DNA such as transposons or transgenes(1,2). In plants and animals, DNA methylation is involved in heritability and flexibility of epigenetic states(3), although its function is far from clear. We have isolated an Arabidopsis gene, MOM, whose product is required for the maintenance of transcriptional gene silencing. Mutation of this gene or depletion of its transcript by expression of antisense RNA reactivates transcription from several previously silent, heavily methylated loci. Despite this, the dense methylation at these reactivated loci is maintained even after nine generations, indicating that transcriptional activity and methylation pattern are inherited independently. The predicted MOM gene product is a nuclear protein of 2,001 amino acids containing a region similar to part of the ATPase region of the SWI2/SNF2 family, members of which are involved in chromatin remodelling(4). MOM is the first known molecular component that is essential for transcriptional gene silencing and does not affect methylation pattern. Thus, it may act downstream of methylation in epigenetic regulation, or be part of a new pathway that does not require methylation marks.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Habu, Y (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	habu@fmi.ch						Adams R L, 1993, EXS, V64, P120; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; CHUANG JZ, 1995, J CELL BIOL, V128, P1095, DOI 10.1083/jcb.128.6.1095; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; Furner IJ, 1998, GENETICS, V149, P651; FURUKAWA K, 1995, EMBO J, V14, P1626, DOI 10.1002/j.1460-2075.1995.tb07151.x; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Jeddeloh JA, 1998, GENE DEV, V12, P1714, DOI 10.1101/gad.12.11.1714; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jiang YW, 1996, GENE DEV, V10, P604, DOI 10.1101/gad.10.5.604; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; Kakutani T, 1999, GENETICS, V151, P831; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Koonin EV, 1996, PROTEIN SCI, V5, P178; MARTIN L, 1995, J BIOL CHEM, V270, P8822, DOI 10.1074/jbc.270.15.8822; Matzke AJM, 1998, CURR OPIN PLANT BIOL, V1, P142, DOI 10.1016/S1369-5266(98)80016-2; Mengiste T, 1997, PLANT J, V12, P945, DOI 10.1046/j.1365-313X.1997.12040945.x; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Scheid OM, 1998, P NATL ACAD SCI USA, V95, P632, DOI 10.1073/pnas.95.2.632; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WORKMAN HJ, 1990, J CELL BIOL, V111, P1535; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	30	212	223	0	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 11	2000	405	6783					203	206		10.1038/35012108	http://dx.doi.org/10.1038/35012108			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821279				2022-12-28	WOS:000087080100056
J	Pardes, H				Pardes, H			The perilous state of academic medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		New York Presbyterian Hosp, New York, NY 10032 USA	NewYork-Presbyterian Hospital	Pardes, H (corresponding author), New York Presbyterian Hosp, 161 Ft Washington Ave,Room 1470, New York, NY 10032 USA.							*ASS AM MED COLL, 2000, MCAT SCOR GPAS APPL; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; KIRSCHNER MW, 1994, SCIENCE, V266, P49, DOI 10.1126/science.7939643; *LEW GROUP, 2000, IMP MED BAL BUDG REF; Moynihan DP, 1998, ACAD MED, V73, P453, DOI 10.1097/00001888-199805000-00007; Pardes H, 1997, ACAD MED, V72, P97, DOI 10.1097/00001888-199702000-00009; *TAYL GROUP INC, 1995, MED RES OP SURV SURV	7	40	41	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2427	2429		10.1001/jama.283.18.2427	http://dx.doi.org/10.1001/jama.283.18.2427			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815086				2022-12-28	WOS:000086808200038
J	MacLennan, JM; Shackley, F; Heath, PT; Deeks, JJ; Flamank, C; Herbert, M; Griffiths, H; Hatzmann, E; Goilav, C; Moxon, ER				MacLennan, JM; Shackley, F; Heath, PT; Deeks, JJ; Flamank, C; Herbert, M; Griffiths, H; Hatzmann, E; Goilav, C; Moxon, ER			Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIBODY-RESPONSE; POLYSACCHARIDE; IMMUNIZATION; CHILDREN; ADULTS	Context Neisseria meningitidis is a common cause of meningitis' and septicemia in infants worldwide. Whether a meningococcal C conjugate vaccine protects infants against the serogroup C strain is unknown. Objectives To determine whether a meningococcal C conjugate vaccine is safe and immunogenic and induces immunologic memory in infants. Design Single-center, double-blind, randomized controlled trial in 1995 and 1996. Setting Community, Oxfordshire, England. Participants One hundred eighty-two healthy infants. Interventions Participants were randomly assigned to receive vaccination with 0.5-mL doses of 1 of 2 lots of meningococcal C conjugate Vaccine (groups 1 and 2; n=60 in each group) or a hepatitis B control vaccine (group 3; n=62), administered with routine immunizations at 2, 3, and 4 months of age. Approximately half of each group received meningococcal C conjugate vaccine and half received plain meningococcal polysaccharide Vaccine (MPS) at 12 months of age. Main Outcome Measures Serum antibodies to meningococcal C polysaccharide, assayed by enzyme-linked immunosorbent assay, and serum bactericidal activity (SBA), at 2, 3, 4, 5, 12, and 13 months of age; local and systemic reactions, recorded for 6 days after each vaccination, compared by intervention group. Results Meningococcal C conjugate vaccine was well tolerated. After 3 doses, children in groups 1 and 2 achieved significantly higher meningococcal C IgG geometric mean concentrations (2 2 and 17 U/mL, respectively, vs 0.20 U/mL; P<.001) and SEA titers (629 and 420, respectively, vs 4.1; P<.001) than controls. At 12 months, antibody concentrations had decreased in all groups but remained significantly higher in children vaccinated with meningococcal C conjugate vaccine (SBA, 24 and 16 in groups 1 and 2, respectively, vs 4.2 in group 3; P<.001). Following vaccination with MPS at 12 months of age, SEA in the meningococcal C conjugate vaccine group was significantly higher than in controls (SBA, 789 vs 4.5; P<.001). Conclusions Our data indicate that meningococcal C conjugate vaccine is safe and immunogenic and results in immunologic memory when given with other routinely administered vaccines to infants at 2, 3, and 4 months of age.	St George Hosp, Sch Med, Dept Child Hlth, London SW17 0RE, England; John Radcliffe Hosp, Dept Paediat, Oxford Vaccine Grp, Oxford, England; Ctr Stat Med, Oxford, England; Chiron Vaccines, Amsterdam, Netherlands; Chiron Vaccines, Siena, Italy	St Georges University London; University of Oxford; University of Oxford; Novartis; Novartis	Heath, PT (corresponding author), St George Hosp, Sch Med, Dept Child Hlth, Cranmer Terr, London SW17 0RE, England.		Deeks, Jon/AAV-5745-2020	Deeks, Jon/0000-0002-8850-1971; Heath, Paul/0000-0002-7540-7433				ANDERSON PW, 1989, J IMMUNOL, V142, P2464; BOOY R, 1992, ARCH DIS CHILD, V67, P475, DOI 10.1136/adc.67.4.475; CEESAY SJ, 1993, J INFECT DIS, V167, P1212, DOI 10.1093/infdis/167.5.1212; Fairley CK, 1996, J INFECT DIS, V174, P1360, DOI 10.1093/infdis/174.6.1360; GOLD R, 1977, J INFECT DIS, V136, pS31, DOI 10.1093/infdis/136.Supplement.S31; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GOTSCHLICH EC, 1969, J EXP MED, V129, P1385, DOI 10.1084/jem.129.6.1385; Granoff DM, 1998, J INFECT DIS, V178, P870, DOI 10.1086/515346; Granoff DM, 1998, CLIN DIAGN LAB IMMUN, V5, P479, DOI 10.1128/CDLI.5.4.479-485.1998; GRIFFITHS H, 1992, CLIN EXP IMMUNOL, V89, P374; Kaczmarski E B, 1997, Commun Dis Rep CDR Rev, V7, pR55; Leach A, 1997, J INFECT DIS, V175, P200, DOI 10.1093/infdis/175.1.200; MacDonald NE, 1998, JAMA-J AM MED ASSOC, V280, P1685, DOI 10.1001/jama.280.19.1685; MILAGRES LG, 1995, BRAZ J MED BIOL RES, V28, P981; MILLER E, 1991, LANCET, V337, P70, DOI 10.1016/0140-6736(91)90735-8; Ramsay M, 1997, Commun Dis Rep CDR Rev, V7, pR49; REINGOLD AL, 1985, LANCET, V2, P114; SIBER GR, 1994, SCIENCE, V265, P1365; *STATA CORP, 1997, STATA STAT SOFTW; STEWARD MW, 1985, J IMMUNOL METHODS, V78, P173, DOI 10.1016/0022-1759(85)90074-2; TWUMASI PA, 1995, J INFECT DIS, V171, P632, DOI 10.1093/infdis/171.3.632; WOOD DJ, 1992, BIOLOGICALS, V20, P203, DOI 10.1016/S1045-1056(05)80039-9; 1994, COMMUN DIS REP CDR R, V4, P227	23	121	136	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2000	283	21					2795	2801		10.1001/jama.283.21.2795	http://dx.doi.org/10.1001/jama.283.21.2795			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320BQ	10838647	Bronze			2022-12-28	WOS:000087381500033
J	Chapman, S; Cornwall, J; Righetti, J; Sung, L				Chapman, S; Cornwall, J; Righetti, J; Sung, L			Preventing dog bites in children: randomised controlled trial of an educational intervention	BRITISH MEDICAL JOURNAL			English	Article									Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2000, Australia; Delta Soc Australia, Sydney, NSW 2000, Australia	University of Sydney	Chapman, S (corresponding author), Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2000, Australia.							Bandow JH, 1996, CAN VET J, V37, P478; Patrick GR, 1998, PUBLIC HEALTH REP, V113, P252; Sacks J J, 1996, Inj Prev, V2, P52, DOI 10.1136/ip.2.1.52; Thompson PG, 1997, MED J AUSTRALIA, V167, P129, DOI 10.5694/j.1326-5377.1997.tb138810.x; 1999, DELTA NEWS, P7	5	91	94	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1512	1513		10.1136/bmj.320.7248.1512	http://dx.doi.org/10.1136/bmj.320.7248.1512			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834894	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000087471000026
J	Gottlieb, S				Gottlieb, S			Mouth to mouth ventilation does not improve CPR	BRITISH MEDICAL JOURNAL			English	News Item																		Ewy GA, 2000, NEW ENGL J MED, V342, P1599, DOI 10.1056/NEJM200005253422109; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1493	1493		10.1136/bmj.320.7248.1493	http://dx.doi.org/10.1136/bmj.320.7248.1493			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834880	Green Published			2022-12-28	WOS:000087471000010
J	Lidzey, DG; Bradley, DDC; Armitage, A; Walker, S; Skolnick, MS				Lidzey, DG; Bradley, DDC; Armitage, A; Walker, S; Skolnick, MS			Photon-mediated hybridization of Frenkel excitons in organic semiconductor microcavities	SCIENCE			English	Article							QUANTUM MICROCAVITY; CONJUGATED-POLYMER; EMISSION; POLARITONS; DEVICES	Coherent excitations of intricate assemblies of molecules play an important role in natural photosynthesis. Microcavities are wavelength-dimension artificial structures in which excitations can be made to couple through their mutual interactions with confined photon modes, Results for microcavities containing two spatially separated cyanine dyes are presented here, where simultaneous strong coupling of the excitations of the individual dyes to a single cavity mode Leads to new eigenmodes, described as admixtures of ail three states. These "hybrid" exciton-photon structures are of potential interest as model systems in which to study energy capture, storage, and transfer among coherently coupled molecular excitations.	Univ Sheffield, Dept Phys & Astron, Sheffield S3 7RH, S Yorkshire, England; Univ Sheffield, Dept Elect & Elect Engn, Sheffield S1 3JD, S Yorkshire, England	University of Sheffield; University of Sheffield	Lidzey, DG (corresponding author), Univ Sheffield, Dept Phys & Astron, Hicks Bldg,Hounsfield Rd, Sheffield S3 7RH, S Yorkshire, England.		Skolnick, Maurice S/G-7250-2016; Bradley, Donal DC/F-6068-2011; Lidzey, David/AAB-8904-2019	Skolnick, Maurice S/0000-0002-3972-8344; Bradley, Donal DC/0000-0001-8713-5060; Lidzey, David/0000-0002-8558-1160				Agranovich V, 1997, SOLID STATE COMMUN, V102, P631, DOI 10.1016/S0038-1098(96)00433-4; Agranovich VM, 1997, PHYS STATUS SOLIDI A, V164, P39, DOI 10.1002/1521-396X(199711)164:1<39::AID-PSSA39>3.0.CO;2-M; Armitage A, 1998, PHYS REV B, V58, P15367, DOI 10.1103/PhysRevB.58.15367; Baxter D, 1997, PHYS REV B, V56, P10032, DOI 10.1103/PhysRevB.56.R10032; FLEMING GR, 1994, PHYS TODAY, V47, P48, DOI 10.1063/1.881413; Ho PKH, 1999, SCIENCE, V285, P233, DOI 10.1126/science.285.5425.233; Hu XC, 1997, PHYS TODAY, V50, P28, DOI 10.1063/1.881879; JEWELL J, 1990, PHYS WORLD       JUL, V28; Lidzey DG, 1998, IEEE J SEL TOP QUANT, V4, P113, DOI 10.1109/2944.669479; Lidzey DG, 1998, NATURE, V395, P53, DOI 10.1038/25692; Lidzey DG, 1997, APPL PHYS LETT, V71, P744, DOI 10.1063/1.119632; Lidzey DG, 1999, PHYS REV LETT, V82, P3316, DOI 10.1103/PhysRevLett.82.3316; MOBIUS D, 1995, ADV MATER, V7, P437, DOI 10.1002/adma.19950070503; NORRIS TB, 1995, CONFINED ELECT PHOTO; Potma EO, 1998, J CHEM PHYS, V108, P4894, DOI 10.1063/1.475898; Senellart P, 1999, PHYS REV LETT, V82, P1233, DOI 10.1103/PhysRevLett.82.1233; Skolnick MS, 1998, SEMICOND SCI TECH, V13, P645, DOI 10.1088/0268-1242/13/7/003; Tessler N, 1996, NATURE, V382, P695, DOI 10.1038/382695a0; UNLU MS, 1995, J APPL PHYS, V78, P607, DOI 10.1063/1.360322; Wainstain J, 1998, PHYS REV B, V58, P7269, DOI 10.1103/PhysRevB.58.7269; WEISBUCH C, 1992, PHYS REV LETT, V69, P3314, DOI 10.1103/PhysRevLett.69.3314; ZHU YF, 1990, PHYS REV LETT, V64, P2499, DOI 10.1103/PhysRevLett.64.2499	22	195	196	2	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1620	1623		10.1126/science.288.5471.1620	http://dx.doi.org/10.1126/science.288.5471.1620			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834836				2022-12-28	WOS:000087382300034
J	Kolbe, M; Besir, H; Essen, LO; Oesterhelt, D				Kolbe, M; Besir, H; Essen, LO; Oesterhelt, D			Structure of the light-driven chloride pump halorhodopsin at 1.8 angstrom resolution	SCIENCE			English	Article							ELECTROSTATIC CALCULATIONS; ION TRANSLOCATION; RETINAL PROTEINS; PALMITIC ACID; ANION-BINDING; CUBIC PHASES; BACTERIORHODOPSIN; RECONSTITUTION; MECHANISM; TRANSPORT	Halorhodopsin, an archaeal rhodopsin ubiquitous in Haloarchaea, uses Light energy to pump chloride through biological membranes. Halorhodopsin crystals were grown in a cubic Lipidic phase, which allowed the x-ray structure determination of this anion pump at 1.8 angstrom resolution. Halorhodopsin assembles to trimers around a central patch consisting of palmitic acid. Next to the protonated Schiff base between Lys(242) and the isomerizable retinal chromophore, a single chloride ion occupies the transport site. Energetic calculations on chloride binding reveal a combination of ion-ion and ion-dipole interactions for stabilizing the anion 18 angstroms below the membrane surface. ion dragging across the protonated Schiff base explains why chloride and proton translocation modes are mechanistically equivalent in archaeal rhodopsins.	Max Planck Inst Biochem, Dept Membrane Biochem, D-82152 Martinsried, Germany	Max Planck Society	Oesterhelt, D (corresponding author), Max Planck Inst Biochem, Dept Membrane Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	essen@biochem.mpg.de; oesterhe@biochem.mpg.de	Essen, Lars-Oliver/L-3862-2016	Essen, Lars-Oliver/0000-0003-4272-4026; Besir, Huseyin/0000-0002-7249-4762				ALSHUTH T, 1985, FEBS LETT, V179, P55, DOI 10.1016/0014-5793(85)80190-3; ARLT T, 1995, CHEM PHYS LETT, V241, P559, DOI 10.1016/0009-2614(95)00664-P; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAMBERG E, 1993, P NATL ACAD SCI USA, V90, P639, DOI 10.1073/pnas.90.2.639; Barauskas J, 1999, CHEM PHYS LIPIDS, V97, P167, DOI 10.1016/S0009-3084(98)00107-8; BASHFORD D, 1992, J MOL BIOL, V224, P473, DOI 10.1016/0022-2836(92)91009-E; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Beroza P, 1996, J PHYS CHEM-US, V100, P20156, DOI 10.1021/jp9623709; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRAIMAN MS, 1994, BIOCHEMISTRY-US, V33, P1629, DOI 10.1021/bi00173a003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chon YS, 1999, BIOCHEMISTRY-US, V38, P9449, DOI 10.1021/bi9903042; Colella M, 1998, BBA-BIOMEMBRANES, V1370, P273, DOI 10.1016/S0005-2736(97)00276-9; Corcelli A, 1996, BBA-BIOMEMBRANES, V1281, P173, DOI 10.1016/0005-2736(96)00007-7; DUSCHL A, 1988, J BIOL CHEM, V263, P17016; Edman K, 1999, NATURE, V401, P822, DOI 10.1038/44623; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; GUNNER MR, UNPUB; Haupts U, 1997, BIOCHEMISTRY-US, V36, P2, DOI 10.1021/bi962014g; HAVELKA WA, 1995, J MOL BIOL, V247, P726, DOI 10.1006/jmbi.1995.0176; HEYMANN JAW, 1993, MOL MICROBIOL, V7, P623, DOI 10.1111/j.1365-2958.1993.tb01153.x; Ihara K, 1999, J MOL BIOL, V285, P163, DOI 10.1006/jmbi.1998.2286; IKEDA M, 1990, BIOCHEMISTRY-US, V29, P2065, DOI 10.1021/bi00460a014; Kalaidzidis IV, 1998, FEBS LETT, V427, P59, DOI 10.1016/S0014-5793(98)00394-9; KOLBE M, UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, P44; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oesterhelt D, 1995, ISR J CHEM, V35, P475; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; Okuno D, 1999, BIOCHEMISTRY-US, V38, P5422, DOI 10.1021/bi9826456; OTOMO J, 1995, BIOPHYS CHEM, V56, P137, DOI 10.1016/0301-4622(95)00025-S; PASCHER I, 1992, BIOCHIM BIOPHYS ACTA, V1113, P339, DOI 10.1016/0304-4157(92)90006-V; Reat V, 1998, P NATL ACAD SCI USA, V95, P4970, DOI 10.1073/pnas.95.9.4970; ROSEN BP, 1990, BIOCHIM BIOPHYS ACTA, V1018, P203, DOI 10.1016/0005-2728(90)90249-4; RUDIGER M, 1995, EMBO J, V14, P1599, DOI 10.1002/j.1460-2075.1995.tb07148.x; Rudiger M, 1997, EMBO J, V16, P3813, DOI 10.1093/emboj/16.13.3813; SASAKI J, 1995, SCIENCE, V269, P73, DOI 10.1126/science.7604281; SCHOBERT B, 1986, J BIOL CHEM, V261, P2690; SCHOBERT B, 1982, J BIOL CHEM, V257, P306; TAVAN P, 1985, BIOPHYS J, V47, P415, DOI 10.1016/S0006-3495(85)83933-3; Tittor J, 1997, J MOL BIOL, V271, P405, DOI 10.1006/jmbi.1997.1204; VARO G, 1995, BIOPHYS J, V68, P2062, DOI 10.1016/S0006-3495(95)80385-1; WALTER TJ, 1994, BIOCHEMISTRY-US, V33, P1724, DOI 10.1021/bi00173a015	47	451	467	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1390	1396		10.1126/science.288.5470.1390	http://dx.doi.org/10.1126/science.288.5470.1390			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827943				2022-12-28	WOS:000087270900041
J	Tabazadeh, A; Santee, ML; Danilin, MY; Pumphrey, HC; Newman, PA; Hamill, PJ; Mergenthaler, JL				Tabazadeh, A; Santee, ML; Danilin, MY; Pumphrey, HC; Newman, PA; Hamill, PJ; Mergenthaler, JL			Quantifying denitrification and its effect on ozone recovery	SCIENCE			English	Article							MICROWAVE LIMB SOUNDER; WINTER POLAR STRATOSPHERES; ARCTIC OZONE; NITRIC-ACID; WATER-VAPOR; ANTARCTIC STRATOSPHERE; ATMOSPHERIC CHEMISTRY; HNO3 OBSERVATIONS; CLAES EXPERIMENT; CLOUD FORMATION	Upper Atmosphere Research Satellite observations indicate that extensive denitrification without significant dehydration currently occurs only in the Antarctic during mid to late June. The fact that denitrification occurs in a relatively warm month in the Antarctic raises concern about the likelihood of its occurrence and associated effects on ozone recovery in a colder and possibly more humid future Arctic lower stratosphere. Polar stratospheric cloud lifetimes required for Arctic denitrification to occur in the future are presented and contrasted against the current Antarctic cloud lifetimes. Model calculations show that widespread severe denitrification could enhance future Arctic ozone loss by up to 30%.	NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Atmospher & Environm Res Inc, Cambridge, MA 02139 USA; Univ Edinburgh, Dept Meteorol, Edinburgh EH9 3JZ, Midlothian, Scotland; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20904 USA; San Jose State Univ, Dept Phys, San Jose, CA 95192 USA; Lockheed Martin Adv Technol Ctr, Palo Alto, CA 94304 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Atmospheric & Environmental Research; University of Edinburgh; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; California State University System; San Jose State University; Lockheed Martin	Tabazadeh, A (corresponding author), NASA, Ames Res Ctr, MS 245-4, Moffett Field, CA 94035 USA.	atabazadeh@mail.arc.nasa.gov	Santee, MIchelle/R-5762-2019; Newman, Paul/D-6208-2012; Pumphrey, Hugh/S-2969-2019	Newman, Paul/0000-0003-1139-2508; Pumphrey, Hugh/0000-0003-0747-1457				ANDREWS DG, 1989, PURE APPL GEOPHYS, V130, P213, DOI 10.1007/BF00874456; Arnold F, 1998, J ATMOS CHEM, V30, P49, DOI 10.1023/A:1006014003391; Brasseur GP, 1997, J GEOPHYS RES-ATMOS, V102, P8909, DOI 10.1029/96JD03398; BRUNE WH, 1990, GEOPHYS RES LETT, V17, P505, DOI 10.1029/GL017i004p00505; BRUNE WH, 1991, SCIENCE, V252, P1260, DOI 10.1126/science.252.5010.1260; Carslaw KS, 1998, J GEOPHYS RES-ATMOS, V103, P5785, DOI 10.1029/97JD03626; Carslaw KS, 1998, NATURE, V391, P675, DOI 10.1038/35589; Chang HYA, 1999, J PHYS CHEM A, V103, P2673, DOI 10.1021/jp9841034; Chipperfield MP, 1998, J GEOPHYS RES-ATMOS, V103, P28389, DOI 10.1029/98JD01960; Chipperfield MP, 1999, NATURE, V400, P551, DOI 10.1038/22999; CRUTZEN PJ, 1986, NATURE, V324, P651, DOI 10.1038/324651a0; Danilin MY, 1998, GEOPHYS RES LETT, V25, P2141, DOI 10.1029/98GL01587; Danilin MY, 1996, GEOPHYS RES LETT, V23, P153, DOI 10.1029/95GL03783; DESHLER T, 1991, GEOPHYS RES LETT, V18, P1999, DOI 10.1029/91GL02311; Dessler AE, 1999, J GEOPHYS RES-ATMOS, V104, P13993, DOI 10.1029/1999JD900133; Evans SJ, 1998, J GEOPHYS RES-ATMOS, V103, P8715, DOI 10.1029/98JD00265; FAHEY DW, 1990, NATURE, V344, P321, DOI 10.1038/344321a0; Fischer H, 1997, J GEOPHYS RES-ATMOS, V102, P23559, DOI 10.1029/97JD02012; Forster PMD, 1999, GEOPHYS RES LETT, V26, P3309, DOI 10.1029/1999GL010487; HOFMANN DJ, 1991, J GEOPHYS RES-ATMOS, V96, P2897, DOI 10.1029/90JD02494; Kondo Y, 1999, J GEOPHYS RES-ATMOS, V104, P8215, DOI 10.1029/1999JD900020; LARSEN N, 1994, GEOPHYS RES LETT, V21, P1611, DOI 10.1029/94GL01394; Manney GL, 1996, GEOPHYS RES LETT, V23, P85, DOI 10.1029/95GL03591; MANNEY GL, 1994, NATURE, V370, P429, DOI 10.1038/370429a0; Manney GL, 1999, J GEOPHYS RES-ATMOS, V104, P18841, DOI 10.1029/1999JD900317; MANNEY GL, 1995, J ATMOS SCI, V52, P3069, DOI 10.1175/1520-0469(1995)052<3069:LTCUDP>2.0.CO;2; Manney GL, 1997, GEOPHYS RES LETT, V24, P2697, DOI 10.1029/97GL52827; Mergenthaler JL, 1997, J GEOPHYS RES-ATMOS, V102, P19161, DOI 10.1029/97JD01077; Michelsen HA, 1998, J GEOPHYS RES-ATMOS, V103, P28347, DOI 10.1029/98JD02850; Nedoluha GE, 1998, J GEOPHYS RES-ATMOS, V103, P3531, DOI 10.1029/97JD03282; OLTMANS SJ, 1995, NATURE, V374, P146, DOI 10.1038/374146a0; Pawson S, 1997, GEOPHYS RES LETT, V24, P575, DOI 10.1029/97GL00352; Plumb RA, 2000, J GEOPHYS RES-ATMOS, V105, P10047, DOI 10.1029/1999JD901023; Portmann RW, 1996, J GEOPHYS RES-ATMOS, V101, P22991, DOI 10.1029/96JD02608; Pumphrey HC, 1999, J GEOPHYS RES-ATMOS, V104, P9399, DOI 10.1029/1998JD200113; Ramaswamy V, 1996, NATURE, V382, P616, DOI 10.1038/382616a0; Rex M, 1999, J GEOPHYS RES-ATMOS, V104, P26611, DOI 10.1029/1999JD900463; Rex M, 1997, NATURE, V389, P835, DOI 10.1038/39849; ROCHE AE, 1994, J ATMOS SCI, V51, P2877, DOI 10.1175/1520-0469(1994)051<2877:OOLSCH>2.0.CO;2; SALAWITCH RJ, 1989, NATURE, V339, P525, DOI 10.1038/339525a0; SANTEE ML, 1995, SCIENCE, V267, P849, DOI 10.1126/science.267.5199.849; Santee ML, 1998, J GEOPHYS RES-ATMOS, V103, P13285, DOI 10.1029/98JD00365; Santee ML, 1999, J GEOPHYS RES-ATMOS, V104, P8225, DOI 10.1029/1998JD100089; SCHLAGER H, 1990, GEOPHYS RES LETT, V17, P433, DOI 10.1029/GL017i004p00433; SCHOEBERL MR, 1992, J GEOPHYS RES-ATMOS, V97, P7859, DOI 10.1029/91JD02168; Shindell DT, 1998, NATURE, V392, P589, DOI 10.1038/33385; Solomon S, 1999, REV GEOPHYS, V37, P275, DOI 10.1029/1999RG900008; Stolarski R, 1997, NATURE, V389, P788, DOI 10.1038/39737; Tabazadeh A, 2000, GEOPHYS RES LETT, V27, P1111, DOI 10.1029/1999GL010966; TABAZADEH A, 1994, GEOPHYS RES LETT, V21, P1619, DOI 10.1029/94GL01368; TOOHEY DW, 1993, SCIENCE, V261, P1134, DOI 10.1126/science.261.5125.1134; TOON OB, 1986, GEOPHYS RES LETT, V13, P1284, DOI 10.1029/GL013i012p01284; VOMEL H, 1995, J GEOPHYS RES-ATMOS, V100, P13919, DOI 10.1029/95JD01000; Waibel AE, 1999, SCIENCE, V283, P2064, DOI 10.1126/science.283.5410.2064; WATERS JW, 1993, NATURE, V362, P597, DOI 10.1038/362597a0; Waugh DW, 1999, J ATMOS SCI, V56, P1594, DOI 10.1175/1520-0469(1999)056<1594:COAAAP>2.0.CO;2; Waugh DW, 1997, J GEOPHYS RES-ATMOS, V102, P13119, DOI 10.1029/96JD03715; WEBSTER CR, 1993, SCIENCE, V261, P1130, DOI 10.1126/science.261.5125.1130; WMO, 1999, 44 WMO	59	117	119	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1407	1411		10.1126/science.288.5470.1407	http://dx.doi.org/10.1126/science.288.5470.1407			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827948				2022-12-28	WOS:000087270900046
J	Adrogue, HJ; Madias, NE				Adrogue, HJ; Madias, NE			Primary care: Hyponatremia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CENTRAL PONTINE MYELINOLYSIS; SEVERE SYMPTOMATIC HYPONATREMIA; ANTI-DIURETIC HORMONE; RAPID CORRECTION; INAPPROPRIATE SECRETION; MAGNETIC-RESONANCE; NEUROLOGIC COMPLICATIONS; ORGANIC OSMOLYTES; MANAGEMENT; VASOPRESSIN		Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA 02111 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Dept Vet Affairs Med Ctr, Renal Sect, Houston, TX USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Tupper Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Tufts University; Tufts Medical Center	Madias, NE (corresponding author), Tufts Univ New England Med Ctr, Div Nephrol, Box 172,750 Washington St, Boston, MA 02111 USA.	nmadias@infonet.tufts.edu						ADELMAN RD, 1996, NELSON TXB PEDIAT, P189; Adrogue HJ, 1997, INTENS CARE MED, V23, P309, DOI 10.1007/s001340050333; AGARWAL R, 1994, AM J KIDNEY DIS, V24, P108, DOI 10.1016/S0272-6386(12)80169-7; ANDERSON RJ, 1986, KIDNEY INT, V29, P1237, DOI 10.1038/ki.1986.134; ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; ANDROGUE HJ, 1994, SALT WATER, P205; ARIEFF AI, 1976, KIDNEY INT, V10, P104, DOI 10.1038/ki.1976.82; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; ASHRAF N, 1981, AM J MED, V70, P1163, DOI 10.1016/0002-9343(81)90822-6; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; BERL T, 1990, KIDNEY INT, V37, P1006, DOI 10.1038/ki.1990.78; BRUNNER JE, 1990, ANN NEUROL, V27, P61, DOI 10.1002/ana.410270110; BURROWS FA, 1983, CRIT CARE MED, V11, P527, DOI 10.1097/00003246-198307000-00009; CHENG JC, 1990, AM J MED, V88, P561, DOI 10.1016/0002-9343(90)90518-I; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; CLUITMANS FHM, 1990, AM J MED, V88, P161, DOI 10.1016/0002-9343(90)90467-R; DEWITT LD, 1984, NEUROLOGY, V34, P570, DOI 10.1212/WNL.34.5.570; EDELMAN IS, 1958, J CLIN INVEST, V37, P1236, DOI 10.1172/JCI103712; FICHMAN MP, 1971, ANN INTERN MED, V75, P853, DOI 10.7326/0003-4819-75-6-853; Fraser CL, 1997, AM J MED, V102, P67, DOI 10.1016/S0002-9343(96)00274-4; FRIZZELL RT, 1986, JAMA-J AM MED ASSOC, V255, P772, DOI 10.1001/jama.255.6.772; Gennari F.J., 1998, OXFORD TXB CLIN NEPH, V1, P175; GENNARI FJ, 1984, NEW ENGL J MED, V310, P102, DOI 10.1056/NEJM198401123100207; GENNARI FJ, 1974, NEW ENGL J MED, V291, P714, DOI 10.1056/NEJM197410032911408; GOLDMAN MB, 1988, NEW ENGL J MED, V318, P397, DOI 10.1056/NEJM198802183180702; GONZALES R, 1994, AM J KIDNEY DIS, V23, P735, DOI 10.1016/S0272-6386(12)70286-X; Gross P, 1998, KIDNEY INT, pS6; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; KARP BI, 1993, MEDICINE, V72, P359, DOI 10.1097/00005792-199311000-00001; KLEINSCHMIDTDEMASTERS BK, 1981, SCIENCE, V211, P1068, DOI 10.1126/science.7466381; KRAMER DS, 1983, AM J MED, V75, P712, DOI 10.1016/0002-9343(83)90462-X; KUMAR S, 1999, DISORDERS WATER EL 1, V1; LARAGH JH, 1954, J CLIN INVEST, V33, P807, DOI 10.1172/JCI102952; Laureno R, 1997, ANN INTERN MED, V126, P57, DOI 10.7326/0003-4819-126-1-199701010-00008; Lauriat SM, 1997, J AM SOC NEPHROL, V8, P1599; LIEN YHH, 1991, J CLIN INVEST, V88, P303, DOI 10.1172/JCI115292; MAAS AHJ, 1985, CLIN CHEM, V31, P482; OH MS, 1995, NEPHRON, V70, P143, DOI 10.1159/000188576; OH MS, 1989, AM J MED SCI, V298, P41, DOI 10.1097/00000441-198907000-00008; Oh MS, 1995, FLUID ELECTROLYTE AC, P1; ROSE BD, 1994, CLIN PHYSL ACID BASE, P651; Saito T, 1997, J CLIN ENDOCR METAB, V82, P1054, DOI 10.1210/jc.82.4.1054; SARNAIK AP, 1991, CRIT CARE MED, V19, P758, DOI 10.1097/00003246-199106000-00005; SerradeilLeGal C, 1996, J CLIN INVEST, V98, P2729, DOI 10.1172/JCI119098; SONNENBLICK M, 1993, CHEST, V103, P601, DOI 10.1378/chest.103.2.601; Soupart A, 1996, CLIN NEPHROL, V46, P149; Sterns R, 1996, FLUIDS ELECTROLYTES, P63; STERNS RH, 1987, ANN INTERN MED, V107, P656, DOI 10.7326/0003-4819-107-5-656; STERNS RH, 1989, KIDNEY INT, V35, P69, DOI 10.1038/ki.1989.9; STERNS RH, 1990, AM J MED, V88, P557, DOI 10.1016/0002-9343(90)90517-H; STERNS RH, 1994, J AM SOC NEPHROL, V4, P1522; STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402; STERNS RH, 1991, CONT MANAGEMENT CRIT, V1, P161; TANNEAU RS, 1994, J CLIN PSYCHIAT, V55, P349; Verbalis J G, 1993, Curr Opin Nephrol Hypertens, V2, P636, DOI 10.1097/00041552-199307000-00015; VERBALIS JG, 1991, BRAIN RES, V567, P274, DOI 10.1016/0006-8993(91)90806-7; Verbalis JG, 1998, PRIMER KIDNEY DIS, p57 ~63; VIDEEN JS, 1995, J CLIN INVEST, V95, P788, DOI 10.1172/JCI117728; WORTHLEY LIG, 1986, BRIT MED J, V292, P168, DOI 10.1136/bmj.292.6514.168	60	1082	1131	0	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2000	342	21					1581	1589		10.1056/NEJM200005253422107	http://dx.doi.org/10.1056/NEJM200005253422107			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316XJ	10824078				2022-12-28	WOS:000087193100007
J	Sakamoto, K; Gouzu, H; Komiya, K; Kiga, D; Yokoyama, S; Yokomori, T; Hagiya, M				Sakamoto, K; Gouzu, H; Komiya, K; Kiga, D; Yokoyama, S; Yokomori, T; Hagiya, M			Molecular computation by DNA hairpin formation	SCIENCE			English	Article							SEQUENCE; DESIGN	Hairpin formation by single-stranded DNA molecules was exploited in a DNA-based computation in order to explore the feasibility of autonomous molecular computing. An instance of the satisfiability problem, a famous hard combinatorial problem, was solved by using molecular biology techniques. The satisfiability of a given Boolean formula was examined autonomously, on the basis of hairpin formation by the molecules that represent the formula. This computation algorithm can test several clauses in the given formula simultaneously, which could reduce the number of Laboratory steps required for computation.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Sci, Dept Informat Sci, Bunkyo Ku, Tokyo 1130033, Japan; Waseda Univ, Sch Educ, Dept Math, Shinjuku Ku, Tokyo 1698050, Japan	University of Tokyo; University of Tokyo; Waseda University	Sakamoto, K (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Sakamoto, Kensaku/N-7496-2015; Yokoyama, Shigeyuki/N-6911-2015; Kiga, Daisuke/T-5361-2018; Komiya, Ken/V-8462-2017	Sakamoto, Kensaku/0000-0003-2866-5031; Yokoyama, Shigeyuki/0000-0003-3133-7338; Kiga, Daisuke/0000-0003-3778-5887; Komiya, Ken/0000-0001-7385-9738				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; BENNETT CH, 1982, INT J THEOR PHYS, V21, P905, DOI 10.1007/BF02084158; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; Faulhammer D, 2000, P NATL ACAD SCI USA, V97, P1385, DOI 10.1073/pnas.97.4.1385; Frutos AG, 1997, NUCLEIC ACIDS RES, V25, P4748, DOI 10.1093/nar/25.23.4748; Garzon MH, 1999, IEEE T EVOLUT COMPUT, V3, P236, DOI 10.1109/4235.788493; Guarnieri F, 1996, SCIENCE, V273, P220, DOI 10.1126/science.273.5272.220; Hagiya M, 1999, NEW GENERAT COMPUT, V17, P131, DOI 10.1007/BF03037433; Hopcroft J.E., 1979, INTRO AUTOMATA THEOR; JONES DH, 1992, NUCLEIC ACIDS RES, V20, P595, DOI 10.1093/nar/20.3.595; LABEAN TH, 1999, P 5 INT M DNA BAS CO, P121; LIPTON RJ, 1995, SCIENCE, V268, P542, DOI 10.1126/science.7725098; Liu QH, 2000, NATURE, V403, P175, DOI 10.1038/35003155; MITCHELL D, 1992, AAAI-92 PROCEEDINGS : TENTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, P459; MORIMOTO N, 1999, DIMACS SERIES DISCRE, V48, P193; OGIHARA M, 1999, DIMACS SERIES DISCRE, V48, P255; Ouyang Q, 1997, SCIENCE, V278, P446, DOI 10.1126/science.278.5337.446; Paun G., 1998, DNA COMPUTING NEW CO, DOI DOI 10.1007/978-3-662-03563-4; REIF JH, 1999, DIMACS, V48, P217; Sakamoto K, 1999, BIOSYSTEMS, V52, P81, DOI 10.1016/S0303-2647(99)00035-0; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998; Winfree E., 1999, DIMACS SER DISCRETE, V44, P191; Winfree Erik, 1996, DNA BASED COMPUTERS, V27, P199; Yokomori T., 1999, P 5 INT M DNA BAS CO, P153; YOSHIDA H, 1999, P 5 INT M DNA BAS CO, P9	26	289	333	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	2000	288	5469					1223	1226		10.1126/science.288.5469.1223	http://dx.doi.org/10.1126/science.288.5469.1223			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817993				2022-12-28	WOS:000087112600045
J	Dalton, R				Dalton, R			Los Alamos labs are safe from fire	NATURE			English	News Item																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					264	264		10.1038/35012768	http://dx.doi.org/10.1038/35012768			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830931	Bronze			2022-12-28	WOS:000087085700009
J	Fuster, JM; Bodner, M; Kroger, JK				Fuster, JM; Bodner, M; Kroger, JK			Cross-modal and cross-temporal association in neurons of frontal cortex	NATURE			English	Article							DORSOLATERAL PREFRONTAL CORTEX; MACAQUE MONKEY; MEMORY TASK; PERFORMANCE; OBJECT	The prefrontal cortex is essential for the temporal integration of sensory information in behavioural and linguistic sequences(1,2). Such information is commonly encoded in more than one sense modality, notably sight and sound. Connections from sensory cortices to the prefrontal cortex support its integrative function(3-5). Here we present the first evidence that prefrontal cortex cells associate visual and auditory stimuli across time. We gave monkeys the task of remembering a tone of a certain pitch for 10 s and then choosing the colour associated with it. In this task, prefrontal cortex cells responded selectively to tones, and most of them also responded to colours according to the task rule. Thus, their reaction to a tone was correlated with their subsequent reaction to the associated colour. This correlation faltered in trials ending in behavioural error. We conclude that prefrontal cortex neurons are part of integrative networks that represent behaviourally meaningful cross-modal associations. The orderly and timely activation of neurons in such networks is crucial for the temporal transfer of information in the structuring of behaviour, reasoning and language.	Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Fuster, JM (corresponding author), Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Los Angeles, CA 90095 USA.							Bodner M, 1996, NEUROREPORT, V7, P1905, DOI 10.1097/00001756-199608120-00006; COLOMBO M, 1994, BEHAV NEUROSCI, V108, P443, DOI 10.1037/0735-7044.108.3.443; DESIMONE R, 1984, J NEUROSCI, V4, P2051; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1982, J NEUROSCI, V2, P361; FUSTER JM, 1982, EXP NEUROL, V77, P679, DOI 10.1016/0014-4886(82)90238-2; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; FUSTER JM, 1985, BRAIN RES, V330, P299, DOI 10.1016/0006-8993(85)90689-4; FUSTER JM, 1997, PREFRONTAL CORTEX; Gibson JR, 1997, J NEUROPHYSIOL, V78, P1263, DOI 10.1152/jn.1997.78.3.1263; HIKOSAKA K, 1988, J NEUROPHYSIOL, V60, P1615, DOI 10.1152/jn.1988.60.5.1615; IWAMURA Y, 1993, EXP BRAIN RES, V92, P360; JONES E G, 1970, Brain Behavior and Evolution, V93, P793, DOI 10.1093/brain/93.4.793; Luria A.R., 1966, HIGHER CORTICAL FUNC, P3; MATELLI M, 1985, BEHAV BRAIN RES, V18, P125, DOI 10.1016/0166-4328(85)90068-3; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; NIKI H, 1974, BRAIN RES, V70, P346, DOI 10.1016/0006-8993(74)90324-2; Pandya DN., 1985, CEREB CORTEX, DOI [10.1007/978-1-4757-9619-3_1, DOI 10.1007/978-1-4757-9619-3_1]; PETRIDES M, 1986, J NEUROSCI, V6, P2054; Petrides M., 1994, HDB NEUROPSYCHOLOGY, V9, P17; Rainer G, 1998, NATURE, V393, P577, DOI 10.1038/31235; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; Romanski LM, 1999, NAT NEUROSCI, V2, P1131, DOI 10.1038/16056; Romo R, 1999, NATURE, V399, P470, DOI 10.1038/20939; TANAKA K, 1993, SCIENCE, V262, P685, DOI 10.1126/science.8235589; Tomita H, 1999, NATURE, V401, P699, DOI 10.1038/44372; Watanabe M, 1996, NATURE, V382, P629, DOI 10.1038/382629a0; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; Wise SP, 1997, ANNU REV NEUROSCI, V20, P25, DOI 10.1146/annurev.neuro.20.1.25; Zhou YD, 1997, EXP BRAIN RES, V116, P551, DOI 10.1007/PL00005783	30	339	344	1	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					347	351		10.1038/35012613	http://dx.doi.org/10.1038/35012613			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830963				2022-12-28	WOS:000087085700047
J	Goldenberg, RL; Hauth, JC; Andrews, WW				Goldenberg, RL; Hauth, JC; Andrews, WW			Mechanisms of disease - Intrauterine infection and preterm delivery	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOW-BIRTH-WEIGHT; AMNIOTIC-FLUID INTERLEUKIN-6; RANDOMIZED CONTROLLED TRIAL; TUMOR-NECROSIS-FACTOR; LOWER UTERINE SEGMENT; BACTERIAL VAGINOSIS; INTRAAMNIOTIC INFECTION; PREMATURE RUPTURE; UREAPLASMA-UREALYTICUM; FETAL FIBRONECTIN		Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35233 USA; Univ Alabama, Ctr Res Womens Hlth, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Goldenberg, RL (corresponding author), Univ Alabama, Dept Obstet & Gynecol, 618 S 20th St,OHB 560, Birmingham, AL 35233 USA.							AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9; ANDREWS WW, 1995, AM J OBSTET GYNECOL, V173, P606, DOI 10.1016/0002-9378(95)90290-2; Andrews WW, 1999, AM J OBSTET GYNECOL, V180, P1151, DOI 10.1016/S0002-9378(99)70609-5; Andrews WW, 1995, INFECT AGENT DIS, V4, P196; Arntzen KJ, 1998, J PERINAT MED, V26, P17, DOI 10.1515/jpme.1998.26.1.17; BOBITT JR, 1977, J REPROD MED, V19, P8; CAREY JC, 1991, AM J OBSTET GYNECOL, V164, P728; Carey JC, 2000, NEW ENGL J MED, V342, P534, DOI 10.1056/NEJM200002243420802; Cassell G., 1993, American Journal of Obstetrics and Gynecology, V168, P425; Cassell G., 1993, American Journal of Obstetrics and Gynecology, V168, P424; CASSELL G, 1999, SEXUALLY TRANSMITTED, P175; CASSELL GH, 1983, SEX TRANSM DIS, V10, P294; CHELLAM VG, 1985, BRIT J OBSTET GYNAEC, V92, P808, DOI 10.1111/j.1471-0528.1985.tb03050.x; DODDS WG, 1987, J REPROD MED, V32, P527; Domingue GJ, 1997, CLIN MICROBIOL REV, V10, P320, DOI 10.1128/CMR.10.2.320; Dudley DJ, 1997, J REPROD IMMUNOL, V36, P93, DOI 10.1016/S0165-0378(97)00065-X; ELDER HA, 1971, AM J OBSTET GYNECOL, V111, P441, DOI 10.1016/0002-9378(71)90793-9; Elimian A, 1998, OBSTET GYNECOL, V92, P72, DOI 10.1016/S0029-7844(98)00123-9; ERNEST JM, 1985, AM J OBSTET GYNECOL, V153, P648, DOI 10.1016/S0002-9378(85)80251-9; Eschenbach D A, 1984, Scand J Urol Nephrol Suppl, V86, P213; FEINBERG RF, 1991, AM J PATHOL, V138, P537; Fiscella K, 1996, PUBLIC HEALTH REP, V111, P104; FISCELLA K, 1995, OBSTET GYNECOL SURV, V51, P60; Ghidini A, 1997, AM J REPROD IMMUNOL, V37, P227; Gibbs RS, 1997, AM J OBSTET GYNECOL, V177, P375, DOI 10.1016/S0002-9378(97)70201-1; GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; Goepfert A. R., 1997, American Journal of Obstetrics and Gynecology, V176, pS6, DOI 10.1016/S0002-9378(97)80079-8; Goldenberg R. L., 2000, American Journal of Obstetrics and Gynecology, V182, pS32; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; GOLDENBERG RL, 1993, OBSTET GYNECOL, V81, P444; Goldenberg RL, 1996, AM J OBSTET GYNECOL, V174, P1618, DOI 10.1016/S0002-9378(96)70617-8; Goldenberg RL, 1996, AM J OBSTET GYNECOL, V175, P1317, DOI 10.1016/S0002-9378(96)70048-0; Goldenberg RL, 1996, OBSTET GYNECOL, V87, P643, DOI 10.1016/0029-7844(96)00035-X; Goldenberg RL, 1998, PRENAT NEONAT MED, V3, P43; Goldenberg RL, 2000, AM J OBSTET GYNECOL, V182, P625, DOI 10.1067/mob.2000.104210; Goldenberg RL, 1996, AM J OBSTET GYNECOL, V175, P1356, DOI 10.1016/S0002-9378(96)70054-6; Goldenberg RL, 1996, OBSTET GYNECOL, V87, P656, DOI 10.1016/0029-7844(96)00034-S; Goldenberg RL, 1998, AM J OBSTET GYNECOL, V179, P1599, DOI 10.1016/S0002-9378(98)70032-8; Gomez R, 1997, INFECT DIS CLIN N AM, V11, P135, DOI 10.1016/S0891-5520(05)70347-0; GRAVETT MG, 1986, OBSTET GYNECOL, V67, P229, DOI 10.1097/00006250-198602000-00013; GRAVETT MG, 1994, AM J OBSTET GYNECOL, V171, P1660, DOI 10.1016/0002-9378(94)90418-9; GRAY DJ, 1992, PRENATAL DIAG, V12, P111, DOI 10.1002/pd.1970120206; GUZICK DS, 1985, OBSTET GYNECOL, V65, P11; Guzman ER, 1999, AM J OBSTET GYNECOL, V181, P793, DOI 10.1016/S0002-9378(99)70303-0; HACK M, 1993, NEW ENGL J MED, V329, P1649, DOI 10.1056/NEJM199311253292210; Hauth JC, 1998, PRENAT NEONAT MED, V3, P86; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HILLIER SL, 1995, CLIN INFECT DIS, V20, pS276, DOI 10.1093/clinids/20.Supplement_2.S276; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; HOLST E, 1994, J CLIN MICROBIOL, V32, P176, DOI 10.1128/JCM.32.1.176-186.1994; HOROWITZ S, 1995, J REPROD MED, V40, P375; Iams JD, 1997, AM J OBSTET GYNECOL, V176, pS6; INGLIS SR, 1994, AM J OBSTET GYNECOL, V171, P5, DOI 10.1016/S0002-9378(94)70069-9; JOESOEF MR, 1995, AM J OBSTET GYNECOL, V173, P1527, DOI 10.1016/0002-9378(95)90644-4; KNOX IC, 1950, AM J OBSTET GYNECOL, V59, P190, DOI 10.1016/0002-9378(50)90370-X; KORN AP, 1995, OBSTET GYNECOL, V85, P387, DOI 10.1016/0029-7844(94)00400-8; KROHN MA, 1995, J INFECT DIS, V171, P1475, DOI 10.1093/infdis/171.6.1475; LOCKWOOD CJ, 1991, NEW ENGL J MED, V325, P669, DOI 10.1056/NEJM199109053251001; Lorenz JM, 1998, ARCH PEDIAT ADOL MED, V152, P425, DOI 10.1001/archpedi.152.5.425; Maeda K, 1997, GYNECOL OBSTET INVES, V43, P225, DOI 10.1159/000291862; MCCORMACK WM, 1987, OBSTET GYNECOL, V69, P202; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; McDonald HM, 1997, BRIT J OBSTET GYNAEC, V104, P1391, DOI 10.1111/j.1471-0528.1997.tb11009.x; MCGREGOR JA, 1994, AM J OBSTET GYNECOL, V170, P1048, DOI 10.1016/S0002-9378(94)70098-2; MEIS PJ, 1995, AM J OBSTET GYNECOL, V173, P1231, DOI 10.1016/0002-9378(95)91360-2; Mercer BM, 1997, JAMA-J AM MED ASSOC, V278, P989, DOI 10.1001/jama.278.12.989; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8; MUELLERHEUBACH E, 1990, OBSTET GYNECOL, V75, P622; Murtha AP, 1998, OBSTET GYNECOL, V91, P161, DOI 10.1016/S0029-7844(97)00602-9; NORMAN K, 1994, BRIT J OBSTET GYNAEC, V101, P404, DOI 10.1111/j.1471-0528.1994.tb11912.x; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; Offenbacher S, 1996, J PERIODONTOL, V67, P1103, DOI 10.1902/jop.1996.67.10s.1103; RAMSEY PS, 2000, J SOC GYNECOL INVE S, V7, pA190; Rizzo G., 1996, American Journal of Obstetrics and Gynecology, V174, P307; ROMERO R, 1992, AM J OBSTET GYNECOL, V166, P1576, DOI 10.1016/0002-9378(92)91636-O; Romero R, 1998, AM J OBSTET GYNECOL, V179, P186, DOI 10.1016/S0002-9378(98)70271-6; ROMERO R, 1993, AM J OBSTET GYNECOL, V169, P839, DOI 10.1016/0002-9378(93)90014-A; ROMERO R, 1988, CLIN OBSTET GYNECOL, V31, P553, DOI 10.1097/00003081-198809000-00006; ROMERO R, 1989, OBSTET GYNECOL, V73, P576; Russel P., 1979, AM J DIAG GYN OBSTET, V1, P127; SAITO S, 1993, CYTOKINE, V5, P81, DOI 10.1016/1043-4666(93)90027-3; SANGHA RK, 1994, J CLIN ENDOCR METAB, V78, P982, DOI 10.1210/jc.78.4.982; SILVER HM, 1989, AM J OBSTET GYNECOL, V161, P808, DOI 10.1016/0002-9378(89)90406-7; Stallmach T, 1995, REPROD FERT DEVELOP, V7, P1573, DOI 10.1071/RD9951573; Steinborn A, 1996, J PERINAT MED, V24, P381, DOI 10.1515/jpme.1996.24.4.381; STRAYPEDERSEN B, 1982, ACTA OBSTET GYN SCAN, V61, P21, DOI 10.3109/00016348209156945; Svare J, 1997, BRIT J OBSTET GYNAEC, V104, P892, DOI 10.1111/j.1471-0528.1997.tb14347.x; Tamura T, 1996, OBSTET GYNECOL, V87, P360, DOI 10.1016/0029-7844(95)00437-8; Tanaka Y, 1998, AM J OBSTET GYNECOL, V179, P644, DOI 10.1016/S0002-9378(98)70058-4; TUCKER JM, 1991, OBSTET GYNECOL, V77, P343; VanMeir CA, 1996, PLACENTA, V17, P291, DOI 10.1016/S0143-4004(96)90052-1; VanMeir CAV, 1997, PLACENTA, V18, P109, DOI 10.1016/S0143-4004(97)90081-3; Vermeulen GM, 1999, BRIT J OBSTET GYNAEC, V106, P652, DOI 10.1111/j.1471-0528.1999.tb08363.x; WATTS DH, 1992, OBSTET GYNECOL, V79, P351; Wenstrom KD, 1998, OBSTET GYNECOL, V92, P420, DOI 10.1016/S0029-7844(98)00210-5; Wenstrom KD, 1998, AM J OBSTET GYNECOL, V178, P546, DOI 10.1016/S0002-9378(98)70436-3; Winkler M, 1998, OBSTET GYNECOL, V91, P945, DOI 10.1016/S0029-7844(98)00098-2; Yoon BH, 1998, AM J OBSTET GYNECOL, V179, P1107, DOI 10.1016/S0002-9378(98)70114-0; 1996, MMWR MORB MORTAL WKL, V45, P1	100	1704	1752	1	93	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2000	342	20					1500	1507		10.1056/NEJM200005183422007	http://dx.doi.org/10.1056/NEJM200005183422007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314QT	10816189				2022-12-28	WOS:000087068200007
J	Matsumoto, A; Odani, T; Sada, K; Miyata, M; Tashiro, K				Matsumoto, A; Odani, T; Sada, K; Miyata, M; Tashiro, K			Intercalation of alkylamines into an organic polymer crystal	NATURE			English	Article							STEREOREGULAR POLYMER; STATE POLYMERIZATION; CLAY MIMICS	Organic solid-state synthesis allows formation of products that are difficult or impossible to produce by conventional methods. This feature, and the high degree of reaction selectivity that can be achieved, is a direct result of the control over the relative orientation of the reactants afforded by the solid state. But as the successful development of 'topochemical reactions' requires the careful design of suitable reactant crystals, the range of both reactions and products amenable to this approach has been limited(1,2). However, recent advances in organic crystal engineering, particularly the rational design of complex solid architectures through supramolecular preorganization(3-9), have renewed interest in topochemical reactions. Previously, we have orientated muconate monomers-diene moieties with a carboxylate group on each end-using long-chain n-alkylammonium ions, such that the topochemical photopolymerization of the solid-state reactants produces layered crystals of stereoregular and high-molecular-mass polymers(10-13). Here we show that these polymer crystals are capable of repeated, reversible intercalation(14) by conversion to the analogous poly(carboxylic acid), followed by transformation into a number of poly(alkylammonium muconate)s upon addition of the appropriate amine. Introduction of functional groups into these crystals may allow the design of organic solids for applications such as molecular recognition, separation and catalysis, thereby extending the range and practical utility of current intercalation compounds(15-20).	Osaka City Univ, Fac Engn, Dept Appl Chem, Sumiyoshi Ku, Osaka 5588585, Japan; Osaka Univ, Grad Sch Engn, Osaka 5650871, Japan; Osaka Univ, Grad Sch Sci, Dept Macromol Sci, Osaka 5600043, Japan	Osaka Metropolitan University; Osaka University; Osaka University	Matsumoto, A (corresponding author), Osaka City Univ, Fac Engn, Dept Appl Chem, Sumiyoshi Ku, Osaka 5588585, Japan.		TASHIRO, KOHJI/AAM-1198-2020	Matsumoto, Akikazu/0000-0002-4363-1393				AAKEROY CB, 1994, CHEM SOC REV, P283; [Anonymous], 1991, PHOTOCHEMISTRY ORG C; Biradha K, 1998, J AM CHEM SOC, V120, P11894, DOI 10.1021/ja973738y; COLEMAN AW, 1988, ANGEW CHEM INT EDIT, V27, P1361, DOI 10.1002/anie.198813611; Desiraju G. R., 1989, CRYSTAL ENG DESIGN O; ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005; Matsumoto A, 1999, POLYM J, V31, P717, DOI 10.1295/polymj.31.717; Matsumoto A, 1999, J AM CHEM SOC, V121, P11122, DOI 10.1021/ja992558g; Matsumoto A, 1998, MACROMOLECULES, V31, P2129, DOI 10.1021/ma9717348; Melendez RE, 1998, TOP CURR CHEM, V198, P97; MIYATA M, 1990, NATURE, V343, P446, DOI 10.1038/343446a0; OGAWA M, 1995, CHEM REV, V95, P399, DOI 10.1021/cr00034a005; Ogawa M, 1997, B CHEM SOC JPN, V70, P2593, DOI 10.1246/bcsj.70.2593; ROGERS RD, 1998, T AM CRYSTALLOGR ASS, V33, P1; Russell VA, 1997, SCIENCE, V276, P575, DOI 10.1126/science.276.5312.575; SCHMIDT G M J, 1971, Pure and Applied Chemistry, V27, P647; Swift JA, 1998, J AM CHEM SOC, V120, P5887, DOI 10.1021/ja980793d; Tashiro K, 1999, MACROMOLECULES, V32, P7946, DOI 10.1021/ma990876u; Whittingham MS, 1982, INTERCALATION CHEM; Zaworotko MJ, 1997, NATURE, V386, P220, DOI 10.1038/386220a0	20	115	118	1	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					328	330		10.1038/35012550	http://dx.doi.org/10.1038/35012550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830957				2022-12-28	WOS:000087085700041
J	Perez, JE; Bashirullah, AK				Perez, JE; Bashirullah, AK			Bureaucracy strangles Latin American research	NATURE			English	Letter									Univ Oriente, Inst Oceanog, Cumana 6101, Venezuela		Perez, JE (corresponding author), Univ Oriente, Inst Oceanog, Apartado Postal 138, Cumana 6101, Venezuela.							Finn R, 1997, SCIENTIST, V11, P13; Macilwain C, 1999, NATURE, V398, pA10; PENALVER LM, 1992, TEORIA PRAXIS U DIST	3	1	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					273	273		10.1038/35012788	http://dx.doi.org/10.1038/35012788			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830938	Bronze			2022-12-28	WOS:000087085700017
J	Mao, GM; Perea, RF; Howells, WS; Price, DL; Saboungi, ML				Mao, GM; Perea, RF; Howells, WS; Price, DL; Saboungi, ML			Relaxation in polymer electrolytes on the nanosecond timescale	NATURE			English	Article							POLY(ETHYLENE OXIDE); CONDUCTIVITY	The relation between mechanical and electrical relaxation in polymer/lithium-salt complexes is a fascinating and still unresolved problem in condensed-matter physics(1), yet has an important bearing on the viability of such materials for use as electrolytes in lithium batteries. At room temperature, these materials are biphasic: they consist of both fluid amorphous regions and salt-enriched crystalline regions. Ionic conduction is known to occur predominantly in the amorphous fluid regions. Although the conduction mechanisms are not yet fully understood(2), it is widely accepted that lithium ions, coordinated with groups of ether oxygen atoms on single or perhaps double polymer chains, move through re-coordination with other oxygen-bearing groups(3,4). The formation and disruption of these coordination bonds must be accompanied by strong relaxation of the local chain structure. Here we probe the relaxation on a nanosecond timescale using quasielastic neutron scattering, and we show that at least two processes are involved: a slow process with a translational character and one or two fast processes with a rotational character. Whereas the former reflects the slowing-down of the translational relaxation commonly observed in polyethylene oxide and other polymer melts, the latter appears to be unique to the polymer electrolytes and has not (to our knowledge) been observed before. A clear picture emerges of the lithium cations forming crosslinks between chain segments and thereby profoundly altering the dynamics of the polymer network.	Argonne Natl Lab, Argonne, IL 60439 USA; Rutherford Appleton Lab, Didcot OX11 0QX, Oxon, England	United States Department of Energy (DOE); Argonne National Laboratory; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory	Saboungi, ML (corresponding author), Argonne Natl Lab, 9700 S Cass Ave, Argonne, IL 60439 USA.		Price, David Long/A-8468-2013; Saboungi, Marie-Louise/C-5920-2013; Mao, Guomin/G-3933-2010; Fernandez-Perea, Ricardo/E-9118-2016	Saboungi, Marie-Louise/0000-0002-0607-4815; Fernandez-Perea, Ricardo/0000-0002-4011-2344				Arbe A, 1998, PHYS REV LETT, V81, P590, DOI 10.1103/PhysRevLett.81.590; ARMAND M, 1990, P 2 INT S POL EL, P91; Bee M, 1988, QUASIELASTIC NEUTRON; BERTHIER C, 1983, SOLID STATE IONICS, V11, P91, DOI 10.1016/0167-2738(83)90068-1; BRUCE PG, 1993, J CHEM SOC FARADAY T, V89, P3187, DOI 10.1039/ft9938903187; Carlsson P, 1998, SOLID STATE IONICS, V113, P139, DOI 10.1016/S0167-2738(98)00368-3; DONOSO JP, 1993, J CHEM PHYS, V98, P10026, DOI 10.1063/1.464435; GABRYS B, 1994, QUASIELASTIC NEUTRON, P221; GRAY FM, 1997, POLYM ELECT; MAO G, IN PRESS PHYS REV LE; MULLERPLATHE F, 1995, J CHEM PHYS, V103, P4745, DOI 10.1063/1.470611; Ratner M. A., 1987, POLYM ELECTROLYTE RE, V1, P173; Rey I, 1998, J PHYS CHEM A, V102, P3249, DOI 10.1021/jp980375v; STROBL GR, 1996, PHYSICS POLYM; TORRELL LM, 1992, SOLID STATE IONICS, V53, P1037; VALLEE A, 1992, ELECTROCHIM ACTA, V37, P1579, DOI 10.1016/0013-4686(92)80115-3	16	127	128	5	92	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					163	165		10.1038/35012032	http://dx.doi.org/10.1038/35012032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821267				2022-12-28	WOS:000087080100044
J	Roos-Serote, M; Vasavada, AR; Kamp, L; Drossart, P; Irwin, P; Nixon, C; Carlson, RW				Roos-Serote, M; Vasavada, AR; Kamp, L; Drossart, P; Irwin, P; Nixon, C; Carlson, RW			Proximate humid and dry regions in Jupiter's atmosphere indicate complex local meteorology	NATURE			English	Article							CLOUD STRUCTURE; WATER-VAPOR; ABUNDANCE; SPECTRA; 5-MU-M	Models of Jupiter's formation and structure predict that its atmosphere is enriched in oxygen, relative to the Sun, and that consequently water clouds should be present globally near the 5-bar pressure level(1,2). Past attempts to confirm these predictions have led to contradictory results(3-5); in particular, the Galileo probe revealed a very dry atmosphere at the entry site, with no significant clouds at depths exceeding the 2-bar level(6,7). Although the entry site was known to be relatively cloud-free, the contrast between the observed local dryness and the expected global wetness was surprising. Here we analyse near-infrared (around 5 mu m) observations of Jupiter, a spectral region that can reveal the water vapour abundance and vertical cloud structure in the troposphere(8). We find that humid and extremely dry regions exist in close proximity, and that some humid regions are spatially correlated with bright convective clouds extending from the deep water clouds to the visible atmosphere.	Observ Astron Lisboa, P-1349018 Lisbon, Portugal; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Observ Paris, CNRS, UMR 8632, Dept Spatial, F-92915 Meudon, France; Univ Oxford, Clarendon Lab, Atmospher Phys Dept, Oxford OX1 3PU, England	Universidade de Lisboa; University of California System; University of California Los Angeles; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; University of Oxford	Roos-Serote, M (corresponding author), Observ Astron Lisboa, P-1349018 Lisbon, Portugal.		Drossart, Pierre/H-8670-2013; Nixon, Conor A/A-8531-2009	Nixon, Conor A/0000-0001-9540-9121; Irwin, Patrick Gerard Joseph/0000-0002-6772-384X				Atreya SK, 1999, PLANET SPACE SCI, V47, P1243, DOI 10.1016/S0032-0633(99)00047-1; Banfield D, 1998, ICARUS, V135, P230, DOI 10.1006/icar.1998.5985; BJORAKER GL, 1986, ASTROPHYS J, V311, P1058, DOI 10.1086/164842; CARLSON BE, 1992, ASTROPHYS J, V388, P648, DOI 10.1086/171182; DROSSART P, 1982, ICARUS, V52, P483, DOI 10.1016/0019-1035(82)90008-2; GIERASCH P, 1999, B AM ASTRON SOC, V31, P115; Irwin PGJ, 1998, J GEOPHYS RES-PLANET, V103, P23001, DOI 10.1029/98JE00948; LARSON HP, 1975, ASTROPHYS J, V197, pL137, DOI 10.1086/181795; LIMAYE SS, 1986, ICARUS, V65, P335, DOI 10.1016/0019-1035(86)90142-9; Little B, 1999, ICARUS, V142, P306, DOI 10.1006/icar.1999.6195; Niemann HB, 1998, J GEOPHYS RES-PLANET, V103, P22831, DOI 10.1029/98JE01050; Ragent B, 1998, J GEOPHYS RES-PLANET, V103, P22891, DOI 10.1029/98JE00353; Roos-Serote M, 1999, ICARUS, V137, P315, DOI 10.1006/icar.1998.6043; Roos-Serote M, 1998, J GEOPHYS RES-PLANET, V103, P23023, DOI 10.1029/98JE01049; Seiff A, 1998, J GEOPHYS RES-PLANET, V103, P22857, DOI 10.1029/98JE01766; Vasavada AR, 1998, ICARUS, V135, P265, DOI 10.1006/icar.1998.5984; WEIDENSCHILLING SJ, 1973, ICARUS, V20, P465, DOI 10.1016/0019-1035(73)90019-5	19	32	32	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					158	160		10.1038/35012023	http://dx.doi.org/10.1038/35012023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821265				2022-12-28	WOS:000087080100042
J	Goraya, TY; Jacobsen, SJ; Pellikka, PA; Miller, TD; Khan, A; Weston, SA; Gersh, BJ; Roger, VL				Goraya, TY; Jacobsen, SJ; Pellikka, PA; Miller, TD; Khan, A; Weston, SA; Gersh, BJ; Roger, VL			Prognostic value of treadmill exercise testing in elderly persons	ANNALS OF INTERNAL MEDICINE			English	Article						prognostic value of tests; exercise test; age factors; workload; electrocardiography	CORONARY HEART-DISEASE; LOWER-EXTREMITY FUNCTION; ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; ARTERY DISEASE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RISK ASSESSMENT; OLMSTED COUNTY; UNITED-STATES	Background: Recent exercise testing guidelines recognized a gap in knowledge about the prognostic value of treadmill exercise testing in elderly persons. Objective: To test the hypothesis that treadmill exercise testing has equal prognostic value among elderly (greater than or equal to 65 years of age) and younger (greater than or equal to 65 years of age) persons and to examine the incremental value of this testing over clinical data. Design: Inception cohort with a median follow-up of 6 years. Setting: Olmsted County, Minnesota. Patients: All elderly (n = 514) and younger (n = 2593) residents of Olmsted County who underwent treadmill exercise testing between 1987 and 1989. Measurements: Overall mortality and cardiac events (cardiac death, nonfatal myocardial infarction, and congestive heart failure). Results: Compared with younger patients, elderly patients had more comorbid conditions, achieved a lower workload (6.0 and 10.7 metabolic equivalents; P < 0.001), and had a greater likelihood of a positive exercise electrocardiogram (28% and 9%; P < 0.001), With median follow-up of 6 years, overall survival (63% and 92%; Pt 0.001) and cardiac event-free survival (66% and 95%; P ( 0.001) were worse among elderly persons than among younger persons. Workload was the only treadmill exercise testing variable associated with all-cause mortality in both age groups, and the strength of association was similar. Workload and angina with exercise testing were associated with cardiac events in both age groups, whereas a positive exercise electrocardiogram was associated with cardiac events only in younger persons (P < 0.05 for all comparisons). After adjustment for clinical variables, workload was the only additional treadmill exercise testing variable that was predictive of death (P < 0.001) and cardiac events (P < 0.05); the strength of the association was similar in both age groups. Each 1-metabolic equivalent increase in exercise capacity was associated with a 14% and 18% reduction in cardiac events among younger and elderly persons, respectively. Conclusions: In elderly persons, treadmill exercise testing provided prognostic information that is incremental to clinical data. After adjustment for clinical factors, workload was the only treadmill exercise testing variable that was strongly associated with outcome, and its prognostic effect was of the same magnitude in elderly and younger persons.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Clin Epidemiol Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Goraya, TY (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1St St Sw, Rochester, MN 55905 USA.		Pellikka, Patricia A/N-5387-2014; Roger, Veronique/AAV-5951-2020	Pellikka, Patricia A/0000-0001-6800-3521; Jacobsen, Steven/0000-0002-8174-8533	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON RN, 1997, MONTHLY VITAL STAT R, V45; BISHOP E, 1996, WALL STREET J   1113, P86; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BRUCE RA, 1980, AM J CARDIOL, V46, P371, DOI 10.1016/0002-9149(80)90003-X; BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; BRUCE RA, 1983, J AM COLL CARDIOL, V2, P565, DOI 10.1016/S0735-1097(83)80286-1; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DAGENAIS GR, 1982, CIRCULATION, V65, P452, DOI 10.1161/01.CIR.65.3.452; Daida H, 1996, MAYO CLIN PROC, V71, P445, DOI 10.4065/71.5.445; DESTEFANO F, 1993, ARCH INTERN MED, V153, P2489, DOI 10.1001/archinte.153.21.2489; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; FLEG JL, 1990, CIRCULATION, V81, P428, DOI 10.1161/01.CIR.81.2.428; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; GLOVER DR, 1984, EUR HEART J, V5, P59, DOI 10.1093/eurheartj/5.suppl_E.59; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; Hakim AA, 1999, CIRCULATION, V100, P9, DOI 10.1161/01.CIR.100.1.9; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; KASSER IS, 1969, CIRCULATION, V39, P759, DOI 10.1161/01.CIR.39.6.759; Kushi LH, 1997, JAMA-J AM MED ASSOC, V277, P1287, DOI 10.1001/jama.277.16.1287; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; Leibson CL, 1998, NEUROLOGY, V51, P163, DOI 10.1212/WNL.51.1.163; Lindsted KD, 1996, J CLIN EPIDEMIOL, V49, P783, DOI 10.1016/0895-4356(96)00009-1; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MARK DB, 1989, J AM COLL CARDIOL, V14, P885, DOI 10.1016/0735-1097(89)90459-2; MARTINEZCARO D, 1984, EUR HEART J, V5, P63, DOI 10.1093/eurheartj/5.suppl_E.63; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MCNEER JF, 1978, CIRCULATION, V57, P64, DOI 10.1161/01.CIR.57.1.64; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MORROW K, 1993, ANN INTERN MED, V118, P689, DOI 10.7326/0003-4819-118-9-199305010-00005; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; RODEHEFFER RJ, 1984, CIRCULATION, V69, P203, DOI 10.1161/01.CIR.69.2.203; Roger VL, 1999, MAYO CLIN PROC, V74, P651, DOI 10.4065/74.7.651; Roger VL, 1998, CIRCULATION, V98, P2836, DOI 10.1161/01.CIR.98.25.2836; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SCHLANT RC, 1986, J AM COLL CARDIOL, V8, P725; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WEINER DA, 1995, AM J CARDIOL, V75, P865, DOI 10.1016/S0002-9149(99)80677-8; Woo J, 1999, J AM GERIATR SOC, V47, P1257, DOI 10.1111/j.1532-5415.1999.tb05209.x	47	157	167	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					862	+		10.7326/0003-4819-132-11-200006060-00003	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319HF	10836912				2022-12-28	WOS:000087334900002
J	Mortimer, PS				Mortimer, PS			ABC of arterial and venous disease - Swollen lower limb-2: Lymphoedema	BRITISH MEDICAL JOURNAL			English	Review									Univ London St Georges Hosp, London, England; Royal Marsden Hosp, London SW3 6JJ, England	St Georges University London; Royal Marsden NHS Foundation Trust	Mortimer, PS (corresponding author), Univ London St Georges Hosp, London, England.							Ko DSC, 1998, ARCH SURG-CHICAGO, V133, P452, DOI 10.1001/archsurg.133.4.452; Levick JR, 1995, INTRO CARDIOVASCULAR; MORTIMER PS, 1997, VARICOSE VEINS VENOU	3	38	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1527	1529		10.1136/bmj.320.7248.1527	http://dx.doi.org/10.1136/bmj.320.7248.1527			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834903	Green Published			2022-12-28	WOS:000087471000034
J	Toft, A				Toft, A			Has humanity disappeared from the NHS?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1483	1483		10.1136/bmj.320.7247.1483	http://dx.doi.org/10.1136/bmj.320.7247.1483			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827070	Green Published			2022-12-28	WOS:000087414700066
J	Gasser, SM				Gasser, SM			A sense of the end	SCIENCE			English	Editorial Material							DOUBLE-STRAND BREAKS; ASSEMBLY FACTOR-I; SACCHAROMYCES-CEREVISIAE; YEAST KU; TELOMERE LENGTH; DNA-REPAIR; CHROMOSOMAL DNA; PROTEIN; MAINTENANCE; CHROMATIN	How a cell distinguishes a double-strand break from the end of a chromosome has Long fascinated cell biologists. It was thought that the protection of chromosomal ends required either a telomere-specific complex or the Looping back of the 3' TG-rich overhang to anneal with a homologous double-stranded repeat. These models must now accommodate the findings that complexes involved in nonhomologous end joining play important roles in normal telomere Length maintenance, and that subtelomeric chromatin changes in response to the DNA damage checkpoint. A hypothetical chromatin assembly checkpoint may help to explain why telomeres and the double-strand break repair machinery share essential components.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Gasser, SM (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	sgasser@eliot.unil.ch		Gasser, Susan/0000-0003-3610-9123				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Burke DJ, 2000, CURR OPIN GENET DEV, V10, P26, DOI 10.1016/S0959-437X(99)00040-4; Corda Y, 1999, NAT GENET, V21, P204, DOI 10.1038/5991; DUBRANA K, UNPUB; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Lee SE, 1999, CURR BIOL, V9, P767, DOI 10.1016/S0960-9822(99)80339-X; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Matsuura A, 1999, GENETICS, V152, P1501; McAinsh AD, 1999, CURR BIOL, V9, P963, DOI 10.1016/S0960-9822(99)80424-2; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Mishra K, 1999, CURR BIOL, V9, P1123, DOI 10.1016/S0960-9822(99)80483-7; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Pryde FE, 1997, CURR OPIN GENET DEV, V7, P822, DOI 10.1016/S0959-437X(97)80046-9; Ramos W, 1998, NUCLEIC ACIDS RES, V26, P5676, DOI 10.1093/nar/26.24.5676; Ray A, 1999, P NATL ACAD SCI USA, V96, P15044, DOI 10.1073/pnas.96.26.15044; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; RUNGE KW, 1991, MOL CELL BIOL, V11, P2919, DOI 10.1128/MCB.11.6.2919; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	45	61	62	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2000	288	5470					1377	1379		10.1126/science.288.5470.1377	http://dx.doi.org/10.1126/science.288.5470.1377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827940				2022-12-28	WOS:000087270900038
J	Anderson, P				Anderson, P			Consequences - Perhaps the biotech sector should have employed more philosophers.	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					281	281		10.1038/35012720	http://dx.doi.org/10.1038/35012720			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830940	Bronze			2022-12-28	WOS:000087085700022
J	Delaney, P				Delaney, P			Palaeoceanography - Nutrients in the glacial balance	NATURE			English	Editorial Material									Univ Calif Santa Cruz, Dept Ocean Sci, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Inst Marine Sci, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Delaney, P (corresponding author), Univ Calif Santa Cruz, Dept Ocean Sci, Santa Cruz, CA 95064 USA.							BOYLE EA, 1985, EARTH PLANET SC LETT, V76, P135, DOI 10.1016/0012-821X(85)90154-2; Boyle EA, 1988, PALEOCEANOGRAPHY, V3, P471, DOI 10.1029/PA003i004p00471; Elderfield H, 2000, NATURE, V405, P305, DOI 10.1038/35012507; Rickaby REM, 1999, PALEOCEANOGRAPHY, V14, P293, DOI 10.1029/1999PA900007	4	1	1	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					288	291		10.1038/35012731	http://dx.doi.org/10.1038/35012731			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830944				2022-12-28	WOS:000087085700026
J	Fonseca, PJ; Munch, D; Hennig, RM				Fonseca, PJ; Munch, D; Hennig, RM			Auditory perception - How cicadas interpret acoustic signals	NATURE			English	Article							TONOTOPIC ORGANIZATION		Fac Ciencias Lisboa, Dept Zool, P-1700 Lisbon, Portugal; Fac Ciencias Lisboa, Ctr Biol Ambiental, P-1700 Lisbon, Portugal; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany	Universidade de Lisboa; Universidade de Lisboa; Humboldt University of Berlin	Fonseca, PJ (corresponding author), Fac Ciencias Lisboa, Dept Zool, Campo Grande, P-1700 Lisbon, Portugal.	matthias.hennig@rz.hu-berlin.de	Fonseca, Paulo/K-1537-2012	Fonseca, Paulo/0000-0002-2663-9385				Bradbury Jack W., 1998, pi; ENDLER JA, 1992, AM NAT, V139, pS125, DOI 10.1086/285308; FONSECA PJ, 1994, THESIS U LISBON; Gogala Matija, 1995, Bioacoustics, V6, P101; JOY RR, 1998, COMP HEARING INSECTS; OLDFIELD BP, 1988, TRENDS NEUROSCI, V11, P267, DOI 10.1016/0166-2236(88)90108-7; POPOV AV, 1990, ADV LIF SCI, P301; ROMER H, 1983, NATURE, V306, P60, DOI 10.1038/306060a0; Romer H., 1993, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, V340, P179, DOI 10.1098/rstb.1993.0056; Stumpner A, 1998, J NEUROPHYSIOL, V79, P2408, DOI 10.1152/jn.1998.79.5.2408	10	41	43	1	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 18	2000	405	6784					297	298		10.1038/35012696	http://dx.doi.org/10.1038/35012696			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830949				2022-12-28	WOS:000087085700032
J	Sherman, DG; Atkinson, RP; Chippendale, T; Levin, KA; Ng, K; Futrell, N; Hsu, CY; Levy, DE				Sherman, DG; Atkinson, RP; Chippendale, T; Levin, KA; Ng, K; Futrell, N; Hsu, CY; Levy, DE		STAT Participants	Intravenous ancrod for treatment of acute ischemic stroke - The STAT study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPARIN-INDUCED THROMBOCYTOPENIA; PLASMINOGEN-ACTIVATOR; THROMBOSIS; ALTEPLASE; ANTICOAGULATION; THROMBOLYSIS; THERAPY; ECASS	Context Approved treatment options for acute ischemic stroke in the United States and Canada are limited at present to intravenous tissue-type plasminogen activator, but bleeding corn plications, including intracranial hemorrhage, are a recognized complication. Objective To evaluate the efficacy and safety of the defibrinogenating agent ancrod in patients with acute ischemic stroke. Design The Stroke Treatment with Ancrod Trial (STAT), a randomized, parallel-group, double-blind, placebo-controlled trial conducted between August 1993 and January 1998. Setting Forty-eight centers, primarily community hospitals, in the United States and Canada. Patients A total of 500 patients with an acute or progressing ischemic neurological deficit were enrolled and included in the intent-to-treat analysis. Interventions Patients were randomly assigned to receive ancrod (n=248) or placebo (n=252) as a continuous 72-hour intravenous infusion beginning within 3 hours of stroke onset, followed by infusions lasting approximately 1 hour at 96 and 120 hours. The ancrod regimen was designed to decrease plasma fibrinogen levels to 1.18 to 2.03 mu mol/L. Main Outcome Measures The primary efficacy end point was functional status, with favorable functional status defined as survival to day 90 with a Barthel Index of 95 or more or at least the prestroke value, compared by treatment group. Primary safety variables included symptomatic intracranial hemorrhage and mortality. Results Favorable functional status was achieved by more patients in the ancrod group (42.2%) than in the placebo group (34.4%; P=.04) by the prespecified covariate-adjusted analysis. Mortality was not different between treatment groups (at 90 days, 25.4% for the ancrod group and 23% for the placebo group; P=.62), and the proportion of severely disabled patients was less in the ancrod group than in the placebo group (11.8% vs 19.8%; P=.01). The favorable functional status observed with ancrod vs placebo was consistent in all subgroups defined for age, stroke severity, sex, prestroke disability, and time to treatment (less than or equal to 3 or >3 hours after stroke onset). There was a trend toward more symptomatic intracranial hemorrhages in the ancrod group vs placebo (5.2% vs 2.0%; P=.06), as well as a significant increase in asymptomatic intracranial hemorrhages (19.0% vs 10.7%; P=.01). Conclusion In this study, ancrod had a favorable benefit-risk profile for patients with acute ischemic stroke.	Univ Texas, Hlth Sci Ctr, Div Neurol, San Antonio, TX 78284 USA; Mercy Gen Hosp, Sacramento, CA USA; Tri City Med Ctr, Oceanside, CA USA; Valley Hosp, Ridgewood, NJ USA; Munroe Reg Med Ctr, Ocala, FL USA; Intermt Stroke Ctr, Salt Lake City, UT USA; Washington Univ, Sch Med, St Louis, MO USA; Knoll Pharmaceut Co, Mt Olive, NJ USA	University of Texas System; University of Texas Health San Antonio; Washington University (WUSTL)	Sherman, DG (corresponding author), Univ Texas, Hlth Sci Ctr, Div Neurol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Masdeu, Joseph C/B-5052-2010	Hsu, Chung Y./0000-0002-5632-2733				ASPLUND K, 1985, STROKE, V16, P885; BARRIE WW, 1974, BMJ-BRIT MED J, V4, P130, DOI 10.1136/bmj.4.5937.130; Bath P, 1998, LANCET, V352, P1238, DOI 10.1016/S0140-6736(98)00039-7; BELL WR, 1968, LANCET, V1, P490; CANDELISE L, 1995, LANCET, V346, P1509; CHAN KE, 1965, BRIT J HAEMATOL, V11, P646, DOI 10.1111/j.1365-2141.1965.tb00113.x; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; COLE CW, 1990, CAN J SURG, V33, P207; Cole CW, 1998, CEREBROVASC DIS, V8, P29, DOI 10.1159/000047501; COLE CW, 1995, CAN J SURG, V38, P249; DAVIES JA, 1972, LANCET, V1, P113; DEMERS C, 1991, BLOOD, V78, P2194; DORMANDY JA, 1978, ANGIOLOGY, V29, P80, DOI 10.1177/000331977802900112; EHRLY A M, 1973, Biorheology, V10, P453; Fisher LD., 1997, BIOMETRICS, V53, P1182; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; GENT A, 1979, THROMB RES, V14, P61, DOI 10.1016/0049-3848(79)90024-0; GUBITZ GJ, 1999, ANTICOAGULANTS ACUTE; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hommel M, 1996, NEW ENGL J MED, V335, P145; HOSSMANN V, 1983, ARCH NEUROL-CHICAGO, V40, P803, DOI 10.1001/archneur.1983.04050120053007; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; LOWE GDO, 1978, THROMB HAEMOSTASIS, V40, P134; MAHONEY F I, 1965, Md State Med J, V14, P61; Marler JR, 1999, STROKE, V30, P244; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OLINGER CP, 1988, ANN EMERG MED, V17, P1208, DOI 10.1016/S0196-0644(88)80071-4; POLLAK VE, 1990, AM J MED SCI, V299, P319, DOI 10.1097/00000441-199005000-00006; REID HA, 1963, LANCET, V1, P621; Sacco RL, 1997, NEUROLOGY, V49, pS39, DOI 10.1212/WNL.49.5_Suppl_4.S39; SHARP AA, 1968, LANCET, V1, P493; SHERMAN DG, 1994, STROKE, V25, P1755; TEASDALE SJ, 1989, ANN THORAC SURG, V48, P712, DOI 10.1016/0003-4975(89)90800-X; TONNESEN KH, 1978, SCAND J CLIN LAB INV, V38, P431, DOI 10.3109/00365517809108447	36	212	226	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2395	2403		10.1001/jama.283.18.2395	http://dx.doi.org/10.1001/jama.283.18.2395			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815082				2022-12-28	WOS:000086808200034
J	Flather, MD; Yusuf, S; Kober, L; Pfeffer, M; Hall, A; Murray, G; Torp-Pedersen, C; Ball, S; Pogue, J; Moye, L; Braunwald, E				Flather, MD; Yusuf, S; Kober, L; Pfeffer, M; Hall, A; Murray, G; Torp-Pedersen, C; Ball, S; Pogue, J; Moye, L; Braunwald, E		ACE Inhibitor Myocardial Infarct C	Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients	LANCET			English	Article							MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; MORTALITY; SURVIVAL	Background We undertook a prospective systematic overview based on data from individual patients from five long-term randomised trials that assessed inhibitors of angiotensin-converting enzyme (ACE) in patients with left-ventricular dysfunction or heart failure. Methods Three of the trials enrolled patients within a week after acute myocardial infarction. Data were combined by use of the Peto-Yusuf method. Findings Overall 12 763 patients were randomly assigned treatment or placebo and followed up for an average of 35 months. In the three post-infarction trials (n=5966), mortality was lower with ACE inhibitors than with placebo (702/2995 [23.4%] Vs 866/2971 [29.1%]; odds ratio 0.74 [95% CI 0.66-0.83]), as were the rates of readmission for heart failure (355 [11.9%] vs 460 [15.55%]; 0.73 [0.63-0.85]), reinfarction (324 [10.8%] vs 391 [13.2%]; 0.80 [0.69-0.94]), or the composite of these events (1049 [35.0%] vs 1244 [41.9%]; 0.75 [0.67-0.83]; all p<0.001). For all five trials the ACE-inhibitor group had lower rates of death than the placebo group (1467/6391 [23.0%] vs 1710/6372 [26.8%]; 0.80 [0.74-0.87]) and lower rates of reinfarction (571 [8.9%] vs 703 [11.0%]; 0.79 [0.70-0.89]), readmission for heart failure (876 [13.7%] vs 1202 [18.9%]; 0.67 [0.61-0.74]), and the composite of these events (2161 [33.8%] vs 2610 [41.0%]; 0.72 [0.67-0.78]; all p<0.0001). The benefits were observed early after the start of therapy and persisted long term. The benefits of treatment on all outcomes were independent of age, sex, and baseline use of diuretics, aspirin, and beta-blockers. Although there was a trend towards greater reduction in risk of death or readmission for heart failure in patients with lower ejection fractions, benefit was apparent over the range examined. Interpretation This systematic overview shows that ACE inhibitors lower rates of mortality, myocardial infarction, and hospital admission for heart failure in patients with left-ventricular dysfunction or heart failure with or without a recent myocardial infarct. The use of ACE inhibitors should be part of routine practice in these patients.	Hamilton Hlth Sci Corp, Res Ctr, Prevent Cardiol & Therapeut Res Program, Hamilton, ON, Canada; McMaster Univ, Div Cardiol, Hamilton, ON, Canada; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; Royal Brompton Hosp, Clin Trials & Evaluat Unit, London, England; Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Yorkshire Heart Ctr, Cardiovasc Res Inst, Leeds, W Yorkshire, England; Univ Edinburgh, Edinburgh, Midlothian, Scotland; Univ Texas, Houston, TX USA	McMaster University; McMaster University; Imperial College London; Royal Brompton Hospital; University of Copenhagen; Herlev & Gentofte Hospital; Harvard University; Brigham & Women's Hospital; University of Leeds; University of Edinburgh; University of Texas System	Yusuf, S (corresponding author), Hamilton Gen Hosp, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@fhs.mcmaster.ca	Torp-Pedersen, Christian/E-5931-2013; Hall, Alistair/K-1953-2019	Yusuf, Salim/0000-0003-4776-5601; Murray, Gordon/0000-0001-9866-4734; Kober, Lars/0000-0002-6635-1466; Hall, Alistair/0000-0003-0306-7887				BALL SG, 1993, LANCET, V342, P821; Franzosi MG, 1998, CIRCULATION, V97, P2202, DOI 10.1161/01.CIR.97.22.2202; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCKELVIE RS, 1998, CIRCULATION, V98, P1; Nguyen KN, 1997, AM J CARDIOL, V79, P115, DOI 10.1016/S0002-9149(96)00696-0; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PITT B, 1992, J AM COLL CARDIOL, V19, P892, DOI 10.1016/0735-1097(92)90266-P; Yusuf S, 1998, EUR HEART J, V19, pJ36; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2000, NEW ENGL J MED, V342, P145	16	1058	1132	0	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 6	2000	355	9215					1575	1581		10.1016/S0140-6736(00)02212-1	http://dx.doi.org/10.1016/S0140-6736(00)02212-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821360				2022-12-28	WOS:000086981200007
J	Vico, L; Collet, P; Guignandon, A; Lafage-Proust, MH; Thomas, T; Rehailia, M; Alexandre, C				Vico, L; Collet, P; Guignandon, A; Lafage-Proust, MH; Thomas, T; Rehailia, M; Alexandre, C			Effects of long-term microgravity exposure on cancellous and cortical weight-bearing bones of cosmonauts	LANCET			English	Article							BED REST; SPACE-FLIGHT; SPACEFLIGHT; MASS; DENSITY; MARKERS; BODY	Background Microgravity has been thought to induce osteoporosis because of reduced weight-bearing. However, up to now, few data have been available about its precise nature and timecourse. Methods We measured bone mineral density (BMD) at the distal radius and tibia in 15 cosmonauts of the Russian MIR space station who sojourned in space either 1 (n=two), 2 (two), or 6 months (11). After recovery periods of similar duration to the space missions, BMD was measured for the 2-month and 6-month crews. Findings Neither cancellous nor cortical bone of the radius was significantly changed at any of the timepoints. On the contrary, in the weight-bearing tibial site, cancellous BMD loss was already present after the first month and deteriorated with mission duration. In tibial cortices, bone loss was noted after a 2-month flight. In the 6-month group, cortical bone loss was less pronounced than that for cancellous bone. In some individuals, tibial deterioration was great. Actual BMD did not depend on preceding cumulative periods spent in space. During recovery, tibial bone loss persisted, suggesting that the time needed to recover is longer than the mission duration. Interpretation in space, despite physical training, bone loss is an adaptive process that can become pathological after recovery on Earth. Striking interindividual variations in bone responses seem to suggest a need for adequate crew preselection. Targeted treatment or prevention strategies would be useful, not only for space purposes, but also for the increasing number of osteoporotic patients on Earth.	Fac Med St Etienne, Lab Biol & Biochim Tissu Osseux, INSERM E9901, GIP Exercice, F-42023 St Etienne 02, France; Univ St Etienne, Fac Sci, Dept Stat, St Etienne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Jean Monnet	Vico, L (corresponding author), Fac Med St Etienne, Lab Biol & Biochim Tissu Osseux, INSERM E9901, GIP Exercice, F-42023 St Etienne 02, France.	vico@univ-st-etienne.fr	Vico, Laurence/ABG-7239-2020; Vico, Laurence/O-1927-2018	Vico, Laurence/0000-0002-2110-287X; Vico, Laurence/0000-0002-2110-287X; GUIGNANDON, Alain/0000-0002-0745-5417; Lafage-Proust, Marie-Helene/0000-0002-2091-3961				Arden NK, 1997, J BONE MINER RES, V12, P2076, DOI 10.1359/jbmr.1997.12.12.2076; Caillot-Augusseau A, 1998, CLIN CHEM, V44, P578; Collet P, 1997, BONE, V20, P547, DOI 10.1016/S8756-3282(97)00052-5; JOUANNY P, 1995, ARTHRITIS RHEUM, V38, P61, DOI 10.1002/art.1780380110; Lafage-Proust MH, 1998, AM J PHYSIOL-REG I, V274, pR324, DOI 10.1152/ajpregu.1998.274.2.R324; LeBlanc A, 1998, BONE, V22, p113S, DOI 10.1016/S8756-3282(98)00013-1; LEBLANC A, 1996, J BONE MINER RES, V11, P323; LEBLANC AD, 1990, J BONE MINER RES, V5, P843; MINAIRE P, 1974, CALC TISS RES, V17, P57, DOI 10.1007/BF02547214; MULLER A, 1985, PHYS MED BIOL, V30, P401, DOI 10.1088/0031-9155/30/5/003; Mustalahti K, 1999, LANCET, V354, P744, DOI 10.1016/S0140-6736(99)01990-X; Oganov V. S., 1992, Aviakosmicheskaya i Ekologicheskaya Meditsina, V26, P20; OGANOV VS, 1990, KOSM BIOL AVIAK MED+, V24, P20; Ruegsegger P, 1991, Osteoporos Int, V1, P76, DOI 10.1007/BF01880447; Samaras K, 1999, ANN INTERN MED, V130, P873, DOI 10.7326/0003-4819-130-11-199906010-00002; SCHNEIDER V, 1992, J BONE MINER RES, V7, pS122; Smith SM, 1998, J CLIN ENDOCR METAB, V83, P3584, DOI 10.1210/jc.83.10.3584; STUPAKOV GP, 1984, SPACE BIOL MED, V18, P42; VOGEL JM, 1977, BIOMEDICAL RESULTS S, P183; White RJ, 1998, J APPL PHYSIOL, V85, P738, DOI 10.1152/jappl.1998.85.2.738; Zerath E, 1996, J APPL PHYSIOL, V81, P194, DOI 10.1152/jappl.1996.81.1.194; Zerwekh JE, 1998, J BONE MINER RES, V13, P1594, DOI 10.1359/jbmr.1998.13.10.1594	22	502	530	1	55	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 6	2000	355	9215					1607	1611		10.1016/S0140-6736(00)02217-0	http://dx.doi.org/10.1016/S0140-6736(00)02217-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CD	10821365				2022-12-28	WOS:000086981200012
J	Fadok, VA; Bratton, DL; Rose, DM; Pearson, A; Ezekewitz, RAB; Henson, PM				Fadok, VA; Bratton, DL; Rose, DM; Pearson, A; Ezekewitz, RAB; Henson, PM			A receptor for phosphatidylserine-specific clearance of apoptotic cells	NATURE			English	Article							VITRONECTIN RECEPTOR; C-ELEGANS; MEMBRANE PHOSPHATIDYLSERINE; MACROPHAGE RECOGNITION; SPERMATOGENIC CELLS; MURINE MACROPHAGES; SERTOLI CELLS; PHAGOCYTOSIS; PROTEIN; EXPOSURE	The culmination of apoptosis in vivo is phagocytosis of cellular corpses. During apoptosis, the asymmetry of plasma membrane phospholipids is lost, which exposes phosphatidylserine externally(1-4). The phagocytosis of apoptotic cells can be inhibited stereospecifically by phosphatidylserine and its structural analogues, but not by other anionic phospholipids, suggesting that phosphatidylserine is specifically recognized(1,5-10). Using phage display, we have cloned a gene that appears to recognize phosphatidylserine on apoptotic cells. Here we show that this gene, when transfected into B and T lymphocytes, enables them to recognize and engulf apoptotic cells in a phosphatidylserine-specific manner. Flow cytometric analysis using a monoclonal antibody suggested that the protein is expressed on the surface of macrophages, fibroblasts and epithelial cells; this antibody, like phosphatidylserine liposomes, inhibited the phagocytosis of apoptotic cells and, in macrophages, induced an anti-inflammatory state. This candidate phosphatidylserine receptor is highly homologous to genes of unknown function in Caenorhabditis elegans and Drosophila melanogaster, suggesting that phosphatidylserine recognition on apoptotic cells during their removal by phagocytes is highly conserved throughout phylogeny.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Massachusetts Gen Hosp, Boston, MA 02115 USA	National Jewish Health; Harvard University; Massachusetts General Hospital	Fadok, VA (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.							Aramaki Y, 1997, BIOCHEM BIOPH RES CO, V231, P827, DOI 10.1006/bbrc.1996.5999; Balasubramanian K, 1997, J BIOL CHEM, V272, P31113, DOI 10.1074/jbc.272.49.31113; BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1993, J IMMUNOL, V151, P4274; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 1998, J IMMUNOL, V161, P6250; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Heijne G. V, 1992, J MOL BIOL, V225, P487; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McDonald PP, 1999, J IMMUNOL, V163, P6164; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Ryeom SW, 1996, J CELL SCI, V109, P387; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; Shiratsuchi A, 1999, J BIOL CHEM, V274, P5901, DOI 10.1074/jbc.274.9.5901; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; van den Eijnde SM, 1998, APOPTOSIS, V3, P9, DOI 10.1023/A:1009650917818; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Wang PY, 1998, J BIOL CHEM, V273, P24309, DOI 10.1074/jbc.273.38.24309; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5	30	1181	1236	4	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					85	90		10.1038/35011084	http://dx.doi.org/10.1038/35011084			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811223				2022-12-28	WOS:000086901600056
J	Prose, NS				Prose, NS			Paying attention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2000	283	21					2763	2763		10.1001/jama.283.21.2763	http://dx.doi.org/10.1001/jama.283.21.2763			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320BQ	10838619				2022-12-28	WOS:000087381500001
J	Ramakrishnan, L; Federspiel, NA; Falkow, S				Ramakrishnan, L; Federspiel, NA; Falkow, S			Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family	SCIENCE			English	Article							HOST-CELLS; TUBERCULOSIS; MARINUM; GENE; DISRUPTION; INFECTION; SEQUENCE	Pathogenic mycobacteria, including the agent of tuberculosis, Mycobacterium tuberculosis, must replicate in macrophages for long-term persistence within their niche during chronic infection: organized collections of macrophages and lymphocytes called granulomas. We identified several genes preferentially expressed when Mycobacterium marinum, the cause of fish and amphibian tuberculosis. resides in host granulomas and/or macrophages. Two were homologs of M. tuberculosis PE/PE-PGRS genes, a family encoding numerous repetitive glycine-rich proteins of unknown function. Mutation of two PE-PGRS genes produced M. marinum strains incapable of replication in macrophages and with decreased persistence in granulomas. Our results establish a direct role in virulence for some PE-PGRS proteins.	Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA; Stanford Ctr DNA Sequence & Technol, Dept Biochem, Palo Alto, CA 94304 USA	Stanford University; Stanford University	Ramakrishnan, L (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA.			Ramakrishnan, Lalita/0000-0003-0692-5533	NIAID NIH HHS [K08 AI 01400, AI 32396] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001400] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barker LP, 1997, INFECT IMMUN, V65, P1497, DOI 10.1128/IAI.65.4.1497-1504.1997; Barker LP, 1998, MOL MICROBIOL, V29, P1167, DOI 10.1046/j.1365-2958.1998.00996.x; Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759; CLARK HF, 1963, J BACTERIOL, V86, P1057, DOI 10.1128/JB.86.5.1057-1069.1963; Clemens DL, 1996, TRENDS MICROBIOL, V4, P113, DOI 10.1016/0966-842X(96)81528-9; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COLLINS FM, 1975, INFECT IMMUN, V11, P1079, DOI 10.1128/IAI.11.5.1079-1087.1975; DAVIS NK, 1992, MOL GEN GENET, V232, P351, DOI 10.1007/BF00266237; FENNER F, 1956, AM REV TUBERC PULM, V73, P650; *GENB, AF201682 GENB; Paget E, 1996, J BACTERIOL, V178, P6357, DOI 10.1128/jb.178.21.6357-6360.1996; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; Ramakrishnan L, 1997, INFECT IMMUN, V65, P767, DOI 10.1128/IAI.65.2.767-773.1997; Ramakrishnan L, 1997, J BACTERIOL, V179, P5862, DOI 10.1128/jb.179.18.5862-5868.1997; RAMAKRISHNAN L, 1994, INFECT IMMUN, V62, P3222, DOI 10.1128/IAI.62.8.3222-3229.1994; ROBERTSON BD, 1992, TRENDS GENET, V8, P422, DOI 10.1016/0168-9525(92)90325-X; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SHEPARD CC, 1957, J EXP MED, V105, P39, DOI 10.1084/jem.105.1.39; SHEPARD CC, 1957, J EXP MED, V106, P722; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; Talaat AM, 1998, INFECT IMMUN, V66, P2938, DOI 10.1128/IAI.66.6.2938-2942.1998; Tonjum T, 1998, J CLIN MICROBIOL, V36, P918; TRAVIS WD, 1985, ARCH PATHOL LAB MED, V109, P1109; Triccas JA, 1999, MICROBIOL-SGM, V145, P2923, DOI 10.1099/00221287-145-10-2923; Valdivia RH, 1997, SCIENCE, V277, P2007, DOI 10.1126/science.277.5334.2007; VALDIVIA RH, IN PRESS METHODS ENZ; Via LE, 1996, J BACTERIOL, V178, P3314, DOI 10.1128/jb.178.11.3314-3321.1996; Young DB, 1998, NATURE, V393, P515, DOI 10.1038/31095	28	345	360	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 26	2000	288	5470					1436	1439		10.1126/science.288.5470.1436	http://dx.doi.org/10.1126/science.288.5470.1436			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318EL	10827956				2022-12-28	WOS:000087270900054
J	Buckley, DA; Fuller, LC; Higgins, EM; du Vivier, AWP				Buckley, DA; Fuller, LC; Higgins, EM; du Vivier, AWP			Lesson of the week - Tinea capitis in adults	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SOUTH-EAST LONDON; INFECTION		Kings Coll Hosp London, Dept Dermatol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Buckley, DA (corresponding author), Ealing Gen Hosp, Dept Dermatol, Southall UB1 3HW, Middx, England.	BillP@doctors.org.uk	Fuller, Lucinda Claire/AAB-1897-2021					BUCKLEY DA, 1996, BR J DERMATOL S47, V135, P21; Cremer G, 1997, DERMATOLOGY, V194, P8, DOI 10.1159/000246048; Fuller LC, 1997, BRIT J DERMATOL, V136, P139, DOI 10.1111/j.1365-2133.1997.tb08771.x; Hay RJ, 1996, BRIT J DERMATOL, V135, P955, DOI 10.1046/j.1365-2133.1996.d01-1101.x; PIPKIN JL, 1952, AMA ARCH DERM SYPH, V66, P9, DOI 10.1001/archderm.1952.01530260012002; ROTHMAN S, 1947, J INVEST DERMATOL, V8, P81, DOI 10.1038/jid.1947.15; SPERLING LC, 1991, INT J DERMATOL, V30, P190, DOI 10.1111/j.1365-4362.1991.tb03849.x; 1996, DRUG THERAP B, V34, P5	8	24	26	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2000	320	7246					1389	1390		10.1136/bmj.320.7246.1389	http://dx.doi.org/10.1136/bmj.320.7246.1389			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	317NY	10818032	Green Published			2022-12-28	WOS:000087232500026
J	Koketsu, K; Kikuchi, M				Koketsu, K; Kikuchi, M			Propagation of seismic ground motion in the Kanto basin, Japan	SCIENCE			English	Article							TOKYO METROPOLITAN-AREA; EARTHQUAKE; WAVES	The pattern of ground motion for a magnitude 5.7 earthquake near Tokyo was captured by 384 strong ground motion instruments across the Kanto sedimentary basin and its surroundings. The records allow the visualization of the propagation of long-period ground motion in the basin and show the refraction of surface waves at the basin edge. The refracted wave does not travel directly from the earthquake epicenter, but traverses the basin obliquely to the edge. The surface wave inside the basin propagates more slowly than that outside such that the wavefronts separate from each other, and the refracted wave heals the discrepancy in the speed of advance of the wavefronts inside and outside the basin. The refracted arrival is dominant near the edge of the Kanto basin.	Univ Tokyo, Earthquake Res Inst, Tokyo 1130033, Japan	University of Tokyo	Koketsu, K (corresponding author), Univ Tokyo, Earthquake Res Inst, 7-3-1 Hongo, Tokyo 1130033, Japan.							Cerveny V., 1977, RAY METHOD SEISMOLOG; Field EH, 1996, B SEISMOL SOC AM, V86, P991; HEATON TH, 1995, SCIENCE, V267, P206, DOI 10.1126/science.267.5195.206; *JAP MET AG, 1996, SEISM INT GYOS; KINOSHITA S, 1992, J PHYS EARTH, V40, P99, DOI 10.4294/jpe1952.40.99; Kinoshita S, 1998, SEISMOL RES LETT, V69, P309, DOI DOI 10.1785/GSSRL.69.4.309; KOKETSU K, 1992, B SEISMOL SOC AM, V82, P2328; OLSEN KB, 1995, SCIENCE, V270, P1628, DOI 10.1126/science.270.5242.1628; Sato T, 1999, B SEISMOL SOC AM, V89, P579; SUZUKI H, 1996, REP NATL RES I EARTH, V56, P77; WOODHOUSE JH, 1974, GEOPHYS J ROY ASTR S, V37, P461, DOI 10.1111/j.1365-246X.1974.tb04098.x; YOMOGIDA K, 1993, B SEISMOL SOC AM, V83, P1325; ZAMA S, 1992, P 10 WORLD C ENG 19	13	62	62	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	2000	288	5469					1237	1239		10.1126/science.288.5469.1237	http://dx.doi.org/10.1126/science.288.5469.1237			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315KH	10817997				2022-12-28	WOS:000087112600049
J	Hulot, FD; Lacroix, G; Lescher-Moutoue, FO; Loreau, M				Hulot, FD; Lacroix, G; Lescher-Moutoue, FO; Loreau, M			Functional diversity governs ecosystem response to nutrient enrichment	NATURE			English	Article							TROPHIC INTERACTIONS; RATIO-DEPENDENCE; BOTTOM-UP; FOOD WEBS; TOP-DOWN; PRODUCTIVITY; COMMUNITIES; STABILITY; PREDATORS; PATTERNS	The relationship between species diversity and ecosystem functioning is a central topic in ecology today(1,2). Classical approaches to studying ecosystem responses to nutrient enrichment have considered linear food chains(3,4). To what extent ecosystem structure, that is, the network of species interactions, affects such responses is currently unknown. This severely limits our ability to predict which species or functional groups will benefit or suffer from nutrient enrichment and to understand the underlying mechanisms(5-8). Here our approach takes ecosystem complexity into account(6,9,10) by considering functional diversity at each trophic level(11-14). We conducted a mesocosm experiment to test the effects of nutrient enrichment in a lake ecosystem. We developed a model of intermediate complexity, which separates trophic levels into functional groups according to size and diet. This model successfully predicted the experimental results, whereas linear food-chain models did not. Our model shows the importance of functional diversity and indirect interactions in the response of ecosystems to perturbations, and indicates that new approaches are needed for the management of freshwater ecosystems subject to eutrophication.	Ecole Normale Super, UMR 7625, Ecol Lab, F-75230 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Sorbonne Universite	Hulot, FD (corresponding author), Ecole Normale Super, UMR 7625, Ecol Lab, 46 Rue Ulm, F-75230 Paris 05, France.			Hulot, Florence D./0000-0002-8897-3987				ABRAMS PA, 1993, AM NAT, V141, P351, DOI 10.1086/285478; ARDITI R, 1989, J THEOR BIOL, V139, P311, DOI 10.1016/S0022-5193(89)80211-5; Chapin FS, 1997, SCIENCE, V277, P500, DOI 10.1126/science.277.5325.500; DEMELO R, 1992, LIMNOL OCEANOGR, V29, P941; GLEESON SK, 1994, ECOLOGY, V75, P1834, DOI 10.2307/1939642; Hamlaoui S, 1998, CR ACAD SCI III-VIE, V321, P39, DOI 10.1016/S0764-4469(97)89624-2; HUNTER MD, 1992, ECOLOGY, V73, P724; Johnson KH, 1996, TRENDS ECOL EVOL, V11, P372, DOI 10.1016/0169-5347(96)10040-9; Kaunzinger CMK, 1998, NATURE, V395, P495, DOI 10.1038/26741; Lacroix G., 1991, Memorie dell'Istituto Italiano di Idrobiologia Dott Marco de Marchi, V48, P53; Lacroix Gerard, 1996, P162; Leibold MA, 1997, ANNU REV ECOL SYST, V28, P467, DOI 10.1146/annurev.ecolsys.28.1.467; LEIBOLD MA, 1989, AM NAT, V134, P922, DOI 10.1086/285022; LEIBOLD MA, 1992, NATURE, V360, P341, DOI 10.1038/360341a0; LEVINS R, 1974, ANN NY ACAD SCI, V231, P123, DOI 10.1111/j.1749-6632.1974.tb20562.x; McCann K, 1998, NATURE, V395, P794, DOI 10.1038/27427; Menge BA, 1997, AM NAT, V149, P801, DOI 10.1086/286025; MENGE BA, 1995, ECOL MONOGR, V65, P21, DOI 10.2307/2937158; Mittelbach G. G., 1988, SIZE STRUCTURED POPU, P217; OKSANEN L, 1981, AM NAT, V118, P240, DOI 10.1086/283817; Persson Lennart, 1996, P396; PIMM SL, 1991, NATURE, V350, P669, DOI 10.1038/350669a0; Polis GA, 1998, NATURE, V395, P744, DOI 10.1038/27323; POLIS GA, 1994, AUST J ECOL, V19, P121; POWER ME, 1992, ECOLOGY, V73, P733, DOI 10.2307/1940153; Reynolds C.S, 1997, VEGETATION PROCESSES, V9, DOI 10.1017/S0025315400036432; SPILLER DA, 1990, NATURE, V347, P469, DOI 10.1038/347469a0; Yodzis Peter, 1996, P192; [No title captured]	30	197	213	8	186	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 18	2000	405	6784					340	344		10.1038/35012591	http://dx.doi.org/10.1038/35012591			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314YT	10830961				2022-12-28	WOS:000087085700045
J	Bergles, DE; Roberts, JDB; Somogyi, P; Jahr, CE				Bergles, DE; Roberts, JDB; Somogyi, P; Jahr, CE			Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus	NATURE			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; GLIAL-CELLS; PROGENITOR-CELL; RECEPTOR; ACTIVATION; LINEAGE; TRANSPORTER; ASTROCYTES; POPULATION; MEMBRANE	Fast excitatory neurotransmission in the central nervous system occurs at specialized synaptic junctions between neurons, where a high concentration of glutamate directly activates receptor channels. Low-affinity AMPA (alpha-amino-3-hydroxy-5-methyl isoxazole propionic acid) and kainate glutamate receptors are also expressed by some glial cells(1), including oligodendrocyte precursor cells (OPCs). However, the conditions that result in activation of glutamate receptors on these non-neuronal cells are not known. Here we report that stimulation of excitatory axons in the hippocampus elicits inward currents in OPCs that are mediated by AMPA receptors. The quantal nature of these responses and their rapid kinetics indicate that they are produced by the exocytosis of vesicles filled with glutamate directly opposite these receptors. Some of these AMPA receptors are permeable to calcium ions, providing a link between axonal activity and internal calcium levels in OPCs. Electron microscopic analysis revealed that vesicle-filled axon terminals make synaptic junctions with the processes of OPCs in both the young and adult hippocampus. These results demonstrate the existence of a rapid signalling pathway from pyramidal neurons to OPCs in the mammalian hippocampus that is mediated by excitatory, glutamatergic synapses.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England	Oregon Health & Science University; University of Oxford	Bergles, DE (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.		Messier, Claude/A-2322-2008; Bergles, Dwight/U-8343-2019	Messier, Claude/0000-0002-4791-1763; Bergles, Dwight/0000-0002-7133-7378				AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; Bergles DE, 1999, CURR OPIN NEUROBIOL, V9, P293, DOI 10.1016/S0959-4388(99)80043-9; Bergles DE, 1997, P NATL ACAD SCI USA, V94, P14821, DOI 10.1073/pnas.94.26.14821; Bergles DE, 1997, NEURON, V19, P1297, DOI 10.1016/S0896-6273(00)80420-1; Dingledine R, 1999, PHARMACOL REV, V51, P7; DUNWIDDIE TV, 1985, INT REV NEUROBIOL, V27, P63, DOI 10.1016/S0074-7742(08)60556-5; Dzubay JA, 1999, J NEUROSCI, V19, P5265; Gallo V, 1996, J NEUROSCI, V16, P2659, DOI 10.1523/jneurosci.16-08-02659.1996; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.3.CO;2-Z; KRIEGLER S, 1993, J NEUROSCI, V13, P4229, DOI 10.1523/jneurosci.13-10-04229.1993; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; McDonald JW, 1998, NEUROREPORT, V9, P2757, DOI 10.1097/00001756-199808240-00014; Miller RH, 1996, TRENDS NEUROSCI, V19, P92, DOI 10.1016/S0166-2236(96)80036-1; Ong WY, 1999, NEUROSCIENCE, V92, P83, DOI 10.1016/S0306-4522(98)00751-9; Palay S. L., 1974, CEREBELLAR CORTEX CY; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RENNER P, 1987, NEUROSCIENCE, V23, P319, DOI 10.1016/0306-4522(87)90292-2; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; Tillet E, 1997, J BIOL CHEM, V272, P10769; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Wolswijk G, 1998, J NEUROSCI, V18, P601; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	30	676	696	2	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					187	191		10.1038/35012083	http://dx.doi.org/10.1038/35012083			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821275				2022-12-28	WOS:000087080100052
J	Cramer, K				Cramer, K			Disextinction, Inc.	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					127	127		10.1038/35012178	http://dx.doi.org/10.1038/35012178			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821252	Bronze			2022-12-28	WOS:000087080100027
J	Etcoff, NL; Ekman, P; Magee, JJ; Frank, MG				Etcoff, NL; Ekman, P; Magee, JJ; Frank, MG			Lie detection and language comprehension	NATURE			English	Article							FACE		Massachusetts Gen Hosp East, Dept Psychiat, Charlestown, MA 02129 USA; Univ Calif San Francisco, Human Interact Lab, San Francisco, CA 94143 USA; Circle Com, Cambridge, MA 02138 USA; Rutgers State Univ, Sch Commun Informat & Lib Studies, New Brunswick, NJ 08901 USA	Harvard University; Massachusetts General Hospital; University of California System; University of California San Francisco; Rutgers State University New Brunswick	Etcoff, NL (corresponding author), Massachusetts Gen Hosp East, Dept Psychiat, Bldg 149,13th St, Charlestown, MA 02129 USA.							CAPLAN D, 1992, LANGUAGE; EKMAN P, 1991, J NONVERBAL BEHAV, V15, P125, DOI 10.1007/BF00998267; EKMAN P, 1991, AM PSYCHOL, V46, P913, DOI 10.1037/0003-066X.46.9.913; EKMAN P, 1988, J PERS SOC PSYCHOL, V54, P414, DOI 10.1037/0022-3514.54.3.414; Etcoff NL, 1986, ADV CLIN NEUROPSYCHO, V3, P127, DOI [10.1007/978-1-4613-2211-5_5, DOI 10.1007/978-1-4613-2211-5_5]; Harrington A, 1996, APHASIA KINDRED DISO; ROCHON E, 1994, BRAIN LANG, V46, P329, DOI 10.1006/brln.1994.1018; Sacks O., 1985, MAN WHO MISTOOK HIS; YOUNG AW, 1993, BRAIN, V116, P941, DOI 10.1093/brain/116.4.941	9	50	52	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					139	139		10.1038/35012129	http://dx.doi.org/10.1038/35012129			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	314WG	10821259	Bronze			2022-12-28	WOS:000087080100036
J	Schiermeier, Q				Schiermeier, Q			German Greens go cold on nuclear fusion	NATURE			English	News Item																		BRADSHAW, 1999, NATURE, V397, P375; Macilwain C, 1999, NATURE, V400, P394, DOI 10.1038/22615; 1999, NATURE, V402, P570	3	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					107	107		10.1038/35012285	http://dx.doi.org/10.1038/35012285			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821238	Bronze			2022-12-28	WOS:000087080100006
J	Fang, J; Alderman, MH				Fang, J; Alderman, MH			Sevum uric acid and cardiovascular mortality - The NHANES I epidemiologic follow-up study, 1971-1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; BLOOD-PRESSURE; HEART-DISEASE; HYPERURICEMIA; OBESITY; INSULIN; CHOLESTEROL; ASSOCIATION; INFORMATION; POPULATION	Context Although many epidemiological studies have suggested that increased serum uric acid levels are a risk factor for cardiovascular mortality, this relationship remains uncertain. Objective To determine the association of serum uric acid levels with cardiovascular mortality. Design and Setting Cross-sectional population-based study of epidemiological follow-up data from the First National Health and Nutrition Examination Survey (NHANES I) from 1971-1975 (baseline) and data from NHANES I Epidemiologic Follow-up Study (NHEFS). Participants A total of 5926 subjects who were aged 25 to 74 years and had serum uric acid level measurements at baseline. Main Outcome Measures Ischemic heart disease mortality, total cardiovascular mortality, and all-cause mortality, compared by quartiles of serum uric acid level. Results In an average of 16.4 years of follow-up, 1593 deaths occurred, of which 731 (45.9%) were ascribed to cardiovascular disease, Increased serum uric acid levels had a positive relationship to cardiovascular mortality in men and women and in black and white persons. Deaths due to ischemic heart disease in both men and women increased when serum uric acid levels were in the highest quartile compared with the lowest quartile (men, >416 vs <321 mu mol/L; risk ratio, 1.77 [95% confidence interval {CI}, 1.08-3.98]; women, >333 vs <238 mu mol/L; risk ratio, 3.00 [95% CI, 1.45-6.28]), Cox regression analysis showed that for each 59.48-mu mol/L increase in uric acid level, cardiovascular mortality and ischemic heart disease mortality increased. Hazard ratios for men were 1.09 (95% CI, 1.02-1.18) and 1.17 (95% CI, 1.06-1.28), and for women were 1.26 (95% CI, 1.16-1.36) and 1.30 (95% CI, 1.17-1.45), respectively, after adjustment for age, race, body mass index, smoking status, alcohol consumption, cholesterol level, history of hypertension and diabetes, and diuretic use. Further analysis, stratifying by cardiovascular risk status, diuretic use, and menopausal status, confirmed a significant association of uric acid and cardiovascular mortality in all subgroups except among men using diuretics (n=79) and men with 1 or more cardiovascular risk factors (n=1140). Conclusion Our data suggest that increased serum uric acid levels are independently and significantly associated with risk of cardiovascular mortality.	Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Alderman, MH (corresponding author), Albert Einstein Coll Med, Dept Epidemiol & Social Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							BENEDEK TG, 1967, ANN INTERN MED, V66, P851, DOI 10.7326/0003-4819-66-5-851; BENGTSSON C, 1988, ACTA MED SCAND, V224, P549; Bonora E, 1996, INT J OBESITY, V20, P975; BURACK RC, 1985, J CHRON DIS, V38, P865, DOI 10.1016/0021-9681(85)90111-0; Cox C S, 1997, Vital Health Stat 1, P1; Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003; Dzielak D J, 1998, Expert Opin Investig Drugs, V7, P85, DOI 10.1517/13543784.7.1.85; FACCHINI F, 1991, JAMA-J AM MED ASSOC, V266, P3008, DOI 10.1001/jama.266.21.3008; FESSEL WJ, 1980, AM J MED, V68, P401, DOI 10.1016/0002-9343(80)90111-4; FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P637, DOI 10.1093/oxfordjournals.aje.a117479; Grantham JJ, 1991, KIDNEY, P483; GUTMAN AB, 1952, ADV INTERNAL MED, V5, P227; KLEIN R, 1973, ARCH INTERN MED, V132, P401, DOI 10.1001/archinte.132.3.401; LELLOUCH J, 1969, J CHRON DIS, V22, P9, DOI 10.1016/0021-9681(69)90082-4; LEVINE W, 1989, J CLIN EPIDEMIOL, V42, P257, DOI 10.1016/0895-4356(89)90061-9; Low RK, 1997, UROL CLIN N AM, V24, P135, DOI 10.1016/S0094-0143(05)70359-1; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MACLACHLAN MJ, 1967, AM J MED, V42, P38, DOI 10.1016/0002-9343(67)90005-8; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MUSTARD JF, 1963, CAN MED ASSOC J, V89, P1207; *NAT CTR HLTH STAT, 1979, NAT CTR HLTH STAT PU; Newland H, 1975, Med Hypotheses, V1, P152, DOI 10.1016/0306-9877(75)90011-0; NICHOLLS A, 1973, BRIT MED J, V1, P449, DOI 10.1136/bmj.1.5851.449; Nishioka K, 1980, Adv Exp Med Biol, V122A, P155; ROUBENOFF R, 1990, RHEUM DIS CLIN N AM, V16, P539; SELBY JV, 1990, AM J EPIDEMIOL, V131, P1017, DOI 10.1093/oxfordjournals.aje.a115593; STAESSEN J, 1991, AM J MED, V90, pS50; STEELE TH, 1971, NEW ENGL J MED, V284, P1193, DOI 10.1056/NEJM197105272842106; STEELE TH, 1969, AM J MED, V47, P564, DOI 10.1016/0002-9343(69)90187-9; TWEEDDALE MG, 1979, NEPHRON, V23, P3, DOI 10.1159/000181660; VUORINENMARKKOLA H, 1994, J CLIN ENDOCR METAB, V78, P25, DOI 10.1210/jc.78.1.25; WOO J, 1994, POSTGRAD MED J, V70, P486, DOI 10.1136/pgmj.70.825.486; ZAVARONI I, 1993, J INTERN MED, V234, P25, DOI 10.1111/j.1365-2796.1993.tb00700.x	33	1202	1296	4	39	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2404	2410		10.1001/jama.283.18.2404	http://dx.doi.org/10.1001/jama.283.18.2404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815083				2022-12-28	WOS:000086808200035
J	Fein, R				Fein, R			The academic health center - Some policy reflections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Fein, R (corresponding author), Harvard Univ, Sch Med, Dept Social Med, 641 Huntington Ave, Boston, MA 02115 USA.								0	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2436	2437		10.1001/jama.283.18.2436	http://dx.doi.org/10.1001/jama.283.18.2436			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815090				2022-12-28	WOS:000086808200042
J	Iribarren, C; Sidney, S; Sternfeld, B; Browner, WS				Iribarren, C; Sidney, S; Sternfeld, B; Browner, WS			Calcification of the aortic arch - Risk factors and association with coronary heart disease, stroke, and peripheral vascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BEAM COMPUTED-TOMOGRAPHY; BONE-MINERAL DENSITY; CARDIOVASCULAR MORTALITY; ATHEROSCLEROTIC PLAQUE; ARTERY CALCIFICATION; FOLLOW-UP; OSTEOPOROSIS; CALCIUM; EVENTS; WOMEN	Context Calcium deposits in coronary and extracoronary arterial beds may indicate the extent of atherosclerosis, However, the incremental predictive value of vascular calcification, beyond traditional coronary risk factors, is not clearly established. Objective To evaluate risk factors for aortic arch calcification and its long-term association with cardiovascular diseases in a population-based sample. Design and Setting Cohort study conducted at a health maintenance organization in northern California. Participants A total of 60 393 women and 55 916 men, aged 30 to 89 years at baseline who attended multiphasic health checkups between 1964 and 1973 and for whom incidence of hospitalizations and/or mortality data were ascertained using discharge diagnosis codes and death records through December 31, 1997 (median follow-up, 28 years). Main Outcome Measure Hospitalization for or death due to coronary heart disease, ischemic stroke, hemorrhagic stroke, or peripheral vascular disease, as associated with aortic arch calcification found on chest radiograph at checkup from 1964-1973. Results Aortic arch calcification was present in 1.9% of men and 2.6% of women. It was independently associated with older age, no college education, current smoking, and hypertension in both sexes, but it was inversely related to body mass index and family history of myocardial infarction. In women, aortic arch calcification was also associated with black race and elevated serum cholesterol level. After adjustment for age, educational attainment, race/ethnicity, cigarette smelting, alcohol consumption, body mass index, serum cholesterol level, hypertension, diabetes, and family history of myocardial infarction, aortic arch calcification was associated with an increased risk of coronary heart disease (in men, relative risk [RR], 1.27; 95% confidence interval [CI], 1.11-1.45; in women, RR, 1.22; 95% CI, 1.07-1.38). Among women, it was also independently associated with a 1.46-fold increased risk of ischemic stroke (95% CI, 1.28-1.67). Conclusion In our population-based cohort, aortic arch calcification was independently related to coronary heart disease risk in both sexes as well as to ischemic stroke risk in women.	Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, Gen Internal Med Sect, San Francisco, CA 94143 USA; Dept Vet Affairs Med Ctr, San Francisco, CA USA	Kaiser Permanente; University of California System; University of California San Francisco	Iribarren, C (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3505 Broadway, Oakland, CA 94611 USA.							Arad Y, 1996, CIRCULATION, V93, P1951, DOI 10.1161/01.CIR.93.11.1951; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BANKS LM, 1994, EUR J CLIN INVEST, V24, P813, DOI 10.1111/j.1365-2362.1994.tb02024.x; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BLACKSHEAR JL, 1967, STROKE, V19, P86; Blankenhorn DH, 1961, AM J MED SCI, V42, P1; BOUKHRIS R, 1972, J AMER MED ASSOC, V219, P1307, DOI 10.1001/jama.219.10.1307; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; Cohen A, 1997, CIRCULATION, V96, P3838; Cohen MF, 1978, MULTIPHASIC HLTH TES; COLLEN MF, 1969, JOM-J OCCUP MED, V11, P355; COX DR, 1972, J R STAT SOC B, V34, P187; Danielsen R, 1996, J CLIN EPIDEMIOL, V49, P383, DOI 10.1016/0895-4356(95)00547-1; Detrano R, 1992, Int J Card Imaging, V8, P209, DOI 10.1007/BF01146839; Detrano RC, 1999, CIRCULATION, V99, P2633, DOI 10.1161/01.CIR.99.20.2633; Drinka P J, 1992, Wis Med J, V91, P299; FRYE MA, 1992, BONE MINER, V19, P185, DOI 10.1016/0169-6009(92)90925-4; Giachelli CM, 1999, AM J PATHOL, V154, P671, DOI 10.1016/S0002-9440(10)65313-8; GORICH J, 1989, RADIOLOGE, V29, P614; GORMSEN H, 1984, FORENSIC SCI INT, V24, P51, DOI 10.1016/0379-0738(84)90151-8; Iribarren C, 1997, ARCH INTERN MED, V157, P873, DOI 10.1001/archinte.157.8.873; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; MOON J, 1992, J AM COLL NUTR, V11, P567; NAKAO J, 1979, ATHEROSCLEROSIS, V34, P469, DOI 10.1016/0021-9150(79)90071-6; *PRACT MAN INF COR, 1989, CLIN MOD INT CLASS D; RUMBERGER JA, 1995, CIRCULATION, V92, P2157, DOI 10.1161/01.CIR.92.8.2157; Secci A, 1997, CIRCULATION, V96, P1122, DOI 10.1161/01.CIR.96.4.1122; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; Shemesh J, 1997, OBSTET GYNECOL, V89, P989, DOI 10.1016/S0029-7844(97)00143-9; SHIBATA H, 1976, JPN HEART J, V17, P452; SIMON A, 1995, CIRCULATION, V92, P1414, DOI 10.1161/01.CIR.92.6.1414; TEALE C, 1989, AGE AGEING, V18, P333, DOI 10.1093/ageing/18.5.333; Vogt MT, 1997, J AM GERIATR SOC, V45, P140, DOI 10.1111/j.1532-5415.1997.tb04498.x; von der Recke P, 1999, AM J MED, V106, P273, DOI 10.1016/S0002-9343(99)00028-5; Watson KE, 1998, ARTERIOSCL THROM VAS, V18, P1964, DOI 10.1161/01.ATV.18.12.1964; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175; WILSON PWF, 1999, 39 ANN C CARD DIS EP; WITTEMAN JCM, 1986, LANCET, V2, P1120; Zabalgoitia M, 1998, ANN INTERN MED, V128, P639, DOI 10.7326/0003-4819-128-8-199804150-00005; [No title captured]	40	368	386	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2000	283	21					2810	2815		10.1001/jama.283.21.2810	http://dx.doi.org/10.1001/jama.283.21.2810			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320BQ	10838649	Bronze			2022-12-28	WOS:000087381500035
J	Atkin, WS; Hart, A; Edwards, R; Cook, CF; Wardle, J; McIntyre, P; Aubrey, R; Baron, C; Sutton, S; Cuzick, J; Senapati, A; Northover, JMA				Atkin, WS; Hart, A; Edwards, R; Cook, CF; Wardle, J; McIntyre, P; Aubrey, R; Baron, C; Sutton, S; Cuzick, J; Senapati, A; Northover, JMA			Single blind, randomised trial of efficacy and acceptability of oral Picolax versus self administered phosphate enema in bowel preparation for flexible sigmoidoscopy screening	BRITISH MEDICAL JOURNAL			English	Article							YIELD	Objective To compare the acceptability and efficacy of two methods of self administered bowel preparation for flexible sigmoidoscopy screening: a single phosphate enema and a single sachet of Picolax. Design Single blind, randomised trial. Setting Endoscopy units of two general hospitals. Participants 1442 men and women aged 55-64 years who had agreed to be screened by flexible sigmoidoscopy. Main outcome measures Attendance rates, compliance with allocated preparations, adverse effects, quality of bowel preparation, procedure time, and yield of neoplasia. Results Compliance with the enema was higher than with the Picolax (608 (84%) v 566 (79%); difference 6%, 95% cofidence interval 2% to 10%). Almost half of those who refused Picolax; used an enema at home. Wind, incontinence, and sleep disturbance were more frequent in the Picolax group than the enema group; bottom soreness was more frequent in the enema group. Around 30% (187) found the diet restriction required by Picolax difficult; 78% (471) found the enema easy to administer. The quality of preparation was better with the enema; the proportion of procedures complete to the descending colon was greater and the mean duration of the procedure was shorter. There was no significant difference in polyp detection rates. Conclusion A single phosphate enema self administered around one hour before leaving home is a more acceptable and effective method of preparing the distal bowel for flexible sigmoidoscopy than Picolax.	St Marks Hosp, Imperial Canc Res Fund, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England; Leicester Gen Hosp, Leicester LE5 4PW, Leics, England; Imperial Canc Res Fund, Dept Math Stat & Epidemiol, London WC2A 3PX, England; UCL, Dept Epidemiol & Publ Hlth, Imperial Canc Res Fund, Hlth Behav Unit, London W1E 6BT, England; Queen Elizabeth II Hosp, Welwyn Garden City AL7 4HQ, Herts, England; Queen Alexandra Hosp, Portsmouth, Hants, England	Imperial College London; University Hospitals of Leicester NHS Trust; Leicester General Hospital; Cancer Research UK; Cancer Research UK; University of London; University College London; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	Atkin, WS (corresponding author), St Marks Hosp, Imperial Canc Res Fund, Colorectal Canc Unit, Northwick Pk, Harrow HA1 3UJ, Middx, England.	atkin@icrf.icnet.uk		Sutton, Stephen/0000-0003-1610-0404; Atkin, Wendy/0000-0001-9073-9658	MRC [G9615910] Funding Source: UKRI; Medical Research Council [G9615910] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; Atkin WS, 1998, GUT, V42, P560, DOI 10.1136/gut.42.4.560; DAKKAK M, 1992, ALIMENT PHARM THERAP, V6, P513; HIXSON LJ, 1995, GASTROINTEST ENDOSC, V42, P101, DOI 10.1016/S0016-5107(95)70260-1; Lund JN, 1998, BRIT MED J, V317, P1201, DOI 10.1136/bmj.317.7167.1201; MEISEL JL, 1977, GASTROENTEROLOGY, V72, P1274; Osgard E, 1998, AM J GASTROENTEROL, V93, P1126; PIETSCH JB, 1977, CAN MED ASSOC J, P1169; PRESTON KL, 1994, GASTROINTEST ENDOSC, V40, P474, DOI 10.1016/S0016-5107(94)70213-6; SENAPATI A, 1992, GUT, V33, pS53; THOMAS WM, 1990, BRIT J SURG, V77, P887, DOI 10.1002/bjs.1800770814; Verne JECW, 1998, BRIT MED J, V317, P182, DOI 10.1136/bmj.317.7152.182; WEISS BD, 1985, J FAM PRACTICE, V21, P285	13	36	37	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 3	2000	320	7248					1504	1508		10.1136/bmj.320.7248.1504	http://dx.doi.org/10.1136/bmj.320.7248.1504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321TP	10834891	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000087471000021
J	Peluso, P; Herschlag, D; Nock, S; Freymann, DM; Johnson, AE; Walter, P				Peluso, P; Herschlag, D; Nock, S; Freymann, DM; Johnson, AE; Walter, P			Role of 4.5S RNA in assembly of the bacterial signal recognition particle with its receptor	SCIENCE			English	Article							ESCHERICHIA-COLI; GTPASE DOMAIN; NG DOMAIN; PROTEIN; FTSY; SEQUENCE; RIBONUCLEOPROTEIN; NUCLEOTIDES; STIMULATION; CONTAINS	The mechanism by which a signal recognition particle (SRP) and its receptor mediate protein targeting to the endoplasmic reticulum or to the bacterial plasma membrane is evolutionarily conserved. in Escherichia coli, this reaction is mediated by the Ffh/4.5S RNA ribonucleoprotein complex (Ffh/4.5S RNP; the SRP) and the FtsY protein (the SRP receptor). We have quantified the effects of 4.5S RNA on Ffh-FtsY complex formation by monitoring changes in tryptophan fluorescence. Surprisingly, 4.5S RNA facilitates both assembly and disassembly of the Ffh-FtsY complex to a similar extent. These results provide an example of an RNA molecule facilitating protein-protein interactions in a catalytic fashion.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Texas A&M Univ, Syst Hlth Sci Ctr, College Stn, TX 77843 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Walter, P (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.		Johnson, Arthur E/G-3457-2012	Freymann, Douglas/0000-0002-5231-8841	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494, R01GM032384, R37GM032384] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32384, GM 26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; Fersht A., 1985, ENZYME STRUCTURE MEC; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; Jagath JR, 1998, BIOCHEMISTRY-US, V37, P15408, DOI 10.1021/bi981523a; Jagath JR, 2000, J MOL BIOL, V295, P745, DOI 10.1006/jmbi.1999.3427; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; Macao B, 1997, MOL MICROBIOL, V24, P523, DOI 10.1046/j.1365-2958.1997.3551729.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Moser C, 1997, P NATL ACAD SCI USA, V94, P11339, DOI 10.1073/pnas.94.21.11339; PELUSO P, UNPUB; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; Powers T, 1997, EMBO J, V16, P4880, DOI 10.1093/emboj/16.16.4880; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Walter P, 2000, SCIENCE, V287, P1212, DOI 10.1126/science.287.5456.1212; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	27	122	122	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 2	2000	288	5471					1640	1643		10.1126/science.288.5471.1640	http://dx.doi.org/10.1126/science.288.5471.1640			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	320BZ	10834842				2022-12-28	WOS:000087382300040
J	Loff, B				Loff, B			Violence in research	LANCET			English	Editorial Material									Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	Monash University	Loff, B (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.		Loff, Bebe/G-9241-2014	Loff, Bebe/0000-0003-1963-6503					0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2000	355	9217					1806	1806		10.1016/S0140-6736(00)02310-2	http://dx.doi.org/10.1016/S0140-6736(00)02310-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	315RE	10832846				2022-12-28	WOS:000087126100044
J	Watzman, H				Watzman, H			Israel debates raising commitment to CERN	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2000	405	6783					109	109		10.1038/35012296	http://dx.doi.org/10.1038/35012296			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WG	10821242	Bronze			2022-12-28	WOS:000087080100010
J	Koss, LG				Koss, LG			Human papillomavirus testing as a screening tool for cervical cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CARCINOMA; LESIONS		Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Koss, LG (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA.		Schiffman, Mark/B-9766-2015					Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Jones BA, 1995, ARCH PATHOL LAB MED, V119, P1097; KOSS LG, 1993, CANCER-AM CANCER SOC, V71, P1406, DOI 10.1002/cncr.2820710405; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; Schiffman M, 2000, JAMA-J AM MED ASSOC, V283, P87, DOI 10.1001/jama.283.1.87	6	23	24	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2525	2525		10.1001/jama.283.19.2525	http://dx.doi.org/10.1001/jama.283.19.2525			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312VL	10815111				2022-12-28	WOS:000086964600027
J	Schiffman, M; Hildesheim, A; Herrero, R; Bratti, C				Schiffman, M; Hildesheim, A; Herrero, R; Bratti, C			Human papillomavirus testing as a screening tool for cervical cancer - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									NCI, Bethesda, MD 20892 USA; Int Agcy Res Canc, F-69372 Lyon, France; Costa Rican Social Secur Adm, San Jose, Costa Rica	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); World Health Organization; International Agency for Research on Cancer (IARC)	Schiffman, M (corresponding author), NCI, Bethesda, MD 20892 USA.		Schiffman, Mark/B-9766-2015					Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; International Agency for Research on Cancer (I.A.R.C), 1995, IARC MON EV CARC RIS, V64, P277; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; SHERMAN ME, 1994, AM J CLIN PATHOL, V102, P182, DOI 10.1093/ajcp/102.2.182; Wise J, 2000, BRIT MED J, V320, P600	5	23	24	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2525	2526		10.1001/jama.283.19.2525	http://dx.doi.org/10.1001/jama.283.19.2525			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312VL	10815111				2022-12-28	WOS:000086964600028
J	Burgess, DS; Lewis, JS				Burgess, DS; Lewis, JS			A critical pathway for treatment of community-acquired pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Texas, Austin Coll Pharm, Austin, TX 78712 USA; Univ Hlth Syst, San Antonio, TX USA	University of Texas System; University of Texas Austin	Burgess, DS (corresponding author), Univ Texas, Austin Coll Pharm, Austin, TX 78712 USA.							BURGESS DR, 1999, PHARMACOTHERAPY, V19, P491; *HCIA INC, 1999, LENGTH STAY DIAGN OP; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; Niederman MS, 1998, CHEST, V113, p179S, DOI 10.1378/chest.113.3_Supplement.179S; RAMIREZ JA, 1995, DIAGN MICR INFEC DIS, V22, P219, DOI 10.1016/0732-8893(95)00088-R	5	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2654	2655		10.1001/jama.283.20.2654	http://dx.doi.org/10.1001/jama.283.20.2654			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819938				2022-12-28	WOS:000087046000021
J	Fox, E; Lynn, J				Fox, E; Lynn, J			Prognostic criteria for hospice eligibility - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Dept Vet Affairs, Washington, DC 20422 USA; Ctr Improve Care Dying, Washington, DC 20250 USA		Fox, E (corresponding author), Dept Vet Affairs, Washington, DC 20422 USA.								0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2527	2527		10.1001/jama.283.19.2527	http://dx.doi.org/10.1001/jama.283.19.2527			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312VL	10815115				2022-12-28	WOS:000086964600032
J	Simpson, DA				Simpson, DA			Prognostic criteria for hospice eligibility	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Natl Hospice Org, Alexandria, VA 22301 USA		Simpson, DA (corresponding author), Natl Hospice Org, Alexandria, VA 22301 USA.							Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; 1990, FED REG, V55, P50834	2	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2000	283	19					2527	2527		10.1001/jama.283.19.2527	http://dx.doi.org/10.1001/jama.283.19.2527			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312VL	10815115				2022-12-28	WOS:000086964600031
J	Fins, JJ; Schiff, ND				Fins, JJ; Schiff, ND			Diagnosis and treatment of traumatic brain injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Cornell University	Fins, JJ (corresponding author), Cornell Univ, Weill Med Coll, New York, NY 10021 USA.			Fins, Joseph/0000-0002-7221-0053				Bejjani BP, 1999, NEW ENGL J MED, V340, P1476, DOI 10.1056/NEJM199905133401905; Kennedy PR, 1998, NEUROREPORT, V9, P1707, DOI 10.1097/00001756-199806010-00007; Menon DK, 1999, TRENDS COGN SCI, V3, P44, DOI 10.1016/S1364-6613(98)01269-8; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rinaldi P. C., 1996, Society for Neuroscience Abstracts, V22, P904; Schiff ND, 1999, TRENDS COGN SCI, V3, P43, DOI 10.1016/S1364-6613(98)01268-6	6	5	5	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2392	2392		10.1001/jama.283.18.2392	http://dx.doi.org/10.1001/jama.283.18.2392			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815080				2022-12-28	WOS:000086808200030
J	Carter, ER				Carter, ER			William Osler at 150	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Madigan Army Med Ctr, Tacoma, WA 98431 USA	Madigan Army Medical Center	Carter, ER (corresponding author), Madigan Army Med Ctr, Tacoma, WA 98431 USA.							BLISS M, 1999, W OSLER LIFE MED, pR13; Golden RL, 1999, JAMA-J AM MED ASSOC, V282, P2252, DOI 10.1001/jama.282.23.2252; Osler W, 1901, J AMER MED ASSOC, V36, P1673; OSLER W, 1932, AEQUANIMITAS OTHER A	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2658	2658		10.1001/jama.283.20.2658	http://dx.doi.org/10.1001/jama.283.20.2658			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819946				2022-12-28	WOS:000087046000029
J	Golden, RL				Golden, RL			William Osler at 150 - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									SUNY Stony Brook, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Golden, RL (corresponding author), SUNY Stony Brook, Stony Brook, NY 11794 USA.							Bensley E H, 1976, Bull Hist Med, V50, P596; Harrell G T, 1973, Bull Hist Med, V47, P545	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2658	2658		10.1001/jama.283.20.2658	http://dx.doi.org/10.1001/jama.283.20.2658			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819946				2022-12-28	WOS:000087046000030
J	Ledergerber, B; Egger, M; Telenti, A				Ledergerber, B; Egger, M; Telenti, A			AIDS-related opportunistic illness and potent antiretroviral therapy - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Zurich Hosp, CH-8091 Zurich, Switzerland; Univ Lausanne Hosp, Lausanne, Switzerland; Univ Bristol, Bristol, Avon, England	University of Zurich; University Zurich Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Bristol	Ledergerber, B (corresponding author), Univ Zurich Hosp, CH-8091 Zurich, Switzerland.		Frisch, Morten/E-9206-2016; VALLET, Yannick/F-9979-2011; Seifert, Steven/J-4776-2019; Ledergerber, Bruno/B-5656-2009	Frisch, Morten/0000-0002-3864-8860; Seifert, Steven/0000-0002-3347-2050; Ledergerber, Bruno/0000-0002-6881-4401				Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Ledergerber B, 1999, BRIT MED J, V319, P23, DOI 10.1136/bmj.319.7201.23; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301	4	15	16	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2653	2654		10.1001/jama.283.20.2653	http://dx.doi.org/10.1001/jama.283.20.2653			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819935				2022-12-28	WOS:000087046000020
J	Reingold, AL				Reingold, AL			Protection for human subjects in medical research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Calif Berkeley, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Reingold, AL (corresponding author), Univ Calif Berkeley, Berkeley, CA 94720 USA.							Woodward B, 1999, JAMA-J AM MED ASSOC, V282, P1947, DOI 10.1001/jama.282.20.1947	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2388	2388						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815070				2022-12-28	WOS:000086808200021
J	Sackett, DL				Sackett, DL			Protection for human subjects in medical research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							TRIAL; NONPARTICIPANTS; PARTICIPANTS; OUTCOMES; SURVIVAL		Trout Res & Educ Ctr Irish Lake, Markdale, ON, Canada		Sackett, DL (corresponding author), Trout Res & Educ Ctr Irish Lake, Markdale, ON, Canada.							CHALMERS I, IN PRESS INFORMED CO; CLEMENS JD, 1992, AM J EPIDEMIOL, V135, P865, DOI 10.1093/oxfordjournals.aje.a116382; DAVIS S, 1985, CANCER-AM CANCER SOC, V56, P1710, DOI 10.1002/1097-0142(19851001)56:7<1710::AID-CNCR2820560741>3.0.CO;2-T; Jha P, 1996, J AM COLL CARDIOL, V27, P1335, DOI 10.1016/0735-1097(96)00018-6; Schmidt B, 1999, J PEDIATR-US, V134, P151, DOI 10.1016/S0022-3476(99)70428-2; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; Woodward B, 1999, JAMA-J AM MED ASSOC, V282, P1947, DOI 10.1001/jama.282.20.1947	7	5	5	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2388	2389						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10836967				2022-12-28	WOS:000086808200022
J	Howard, SM				Howard, SM			Gifts to physicians from the pharmaceutical industry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter																		Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	1	18	18	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2655	2656		10.1001/jama.283.20.2655	http://dx.doi.org/10.1001/jama.283.20.2655			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819943				2022-12-28	WOS:000087046000023
J	Ragnarsson, KT				Ragnarsson, KT		Consensus Dev Panel	Diagnosis and treatment of traumatic brain injury - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Mt Sinai Sch Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Ragnarsson, KT (corresponding author), Mt Sinai Sch Med, New York, NY 10029 USA.			Fins, Joseph/0000-0002-7221-0053					0	5	5	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2392	2392		10.1001/jama.283.18.2392	http://dx.doi.org/10.1001/jama.283.18.2392			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815080				2022-12-28	WOS:000086808200031
J	Engels, EA; Frisch, M; Biggar, RJ; Goedert, JJ				Engels, EA; Frisch, M; Biggar, RJ; Goedert, JJ			AIDS-related opportunistic illness and potent antiretroviral therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									NCI, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Engels, EA (corresponding author), NCI, Rockville, MD USA.		Frisch, Morten/E-9206-2016; VALLET, Yannick/F-9979-2011; Seifert, Steven/J-4776-2019; Ledergerber, Bruno/B-5656-2009	Frisch, Morten/0000-0002-3864-8860; Seifert, Steven/0000-0002-3347-2050; Ledergerber, Bruno/0000-0002-6881-4401				[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301	3	15	16	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2653	2653		10.1001/jama.283.20.2653	http://dx.doi.org/10.1001/jama.283.20.2653			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819935				2022-12-28	WOS:000087046000019
